Rationale, methods, and assays for identifying human and non-human primate taste specific genes and use thereof in taste modulator and therapeutic screening assays

ABSTRACT

This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salty, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Particularly, the genes identified herein and antibodies or oligos thereto can be used as markers to identify and/or purify specific taste cells e.g., from taste cell suspensions by use of FACS or magnetic bead cell selection or other known cell purification and isolation procedures.

RELATED AND PRIORITY PATENT APPLICATIONS

This application is a divisional of U.S. application Ser. No. 14/162,313 filed Jan. 23, 2014, which is a divisional of U.S. application Ser. No. 13/090,335, filed Apr. 20, 2011 (now U.S. Pat. No. 8,669,066), which is a divisional of U.S. application Ser. No. 12/134,302 filed Jun. 6, 2008 (now U.S. Pat. No. 7,932,058), which claims priority to earlier filed provisional applications by the present Assignee Senomyx Inc relating to a novel rationale for identifying primate taste specific genes and in particular for identification of the primate salt receptor gene or genes. These provisional applications are U.S. Application Ser. No. 60/929,017 filed Jun. 8, 2007; U.S. Application Ser. No. 60/929,007, filed Jun. 8, 2007; U.S. Application Ser. No. 60/947,052, filed Jun. 29, 2007; U.S. Application Ser. No. 60/935,297, filed Aug. 3, 2007; U.S. Application Ser. No. 60/987,611, filed Nov. 13, 2007; U.S. Application Ser. No. 60/988,938, filed Nov. 19, 2007; U.S. 60/991,274, filed Nov. 30, 2007; U.S. Application Ser. No. 60/991,289, filed Nov. 30, 2007; U.S. Application Ser. No. 60/992,502, filed Dec. 5, 2007; U.S. Application Ser. No. 60/992,517, filed Dec. 5, 2007; U.S. Application Ser. No. 61/017,244, filed Dec. 28, 2007; U.S. Application Ser. No. 61/021,437, filed Jan. 16, 2008; U.S. Application Ser. No. 61/043,257, filed Apr. 8, 2008; U.S. Application Ser. No. 61/053,310, filed May 15, 2008. In addition, this application relates to, and claims priority to U.S. Ser. No. 11/808,356, filed Jun. 8, 2007 and U.S. Ser. No. 12/134,390 filed on Jun. 6, 2008 and claiming priority to the same applications as this application. All of the afore-mentioned provisional and non-provisional applications are incorporated by reference in their entireties herein.

SEQUENCE LISTING

The sequence listing in the filed named “43268o2908.txt” having a size of 581,051 bytes that was created Aug. 11, 2015 is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

This application generally relates to novel protocols for identifying and functionalizing taste specific genes, especially taste specific genes of primates and non-human primates, which based on their structure, tissue specific expression, cells, where they are expressed in specific tissues and cells therein, and level of expression are predicted to elicit or be involved in one or more taste cell specific functions. As described and shown infra these methods have identified taste specific GPCRs, ion channels, and other transmembrane proteins likely to regulate taste specific cellular activities. In fact, as disclosed in a related application filed on even date claiming benefit of priority to the same provisional and utility applications as the subject application, these methods have already successfully identified a gene which encodes a salty taste receptor in primates including humans, rodents, and likely other vertebrates.

More specifically, the invention relates to novel rationales for identifying and functionalizing human and primate taste specific genes, the taste specific genes identified using these rationale, and specific novel taste cell subsets which express these taste specific genes and the functional characterization of these genes, gene products and novel taste cell subsets and their use as potential taste receptor or therapeutic targets, e.g., salt receptor targets. The genes and gene products identified using these protocols are useful targets in high-throughput screening efforts to identify human salty taste enhancers. These targets are initially identified using a combination of two different techniques, gene chips and a polymerase chain reaction (PCR) screen, resulting in a set of genes which are taste specific and potential taste, e.g., salt or fat taste receptor target genes. First, Affymetrix gene chips containing most all known macaque genes are used to determine which genes are specifically expressed in primate circumvallate at the back of the tongue and fungiform papilla taste cells at the front of the tongue and not lingual epithelial cells isolated by laser capture microdissection. Second, PCR is used to determine which ion channels, from channels we have cataloged in the human/macaque genomes, are specifically expressed in macaque fungiform and/or circumvallate (CV) papilla taste cells but not lingual epithelial cells isolated by laser capture microdissection. Taste-specific expression of genes identified by either approach, are confirmed using an independent histological method such as in situ hybridization or immunohistochemistry, to determine which genes are expressed in taste cells. Using double labeling histological methods, it is determined what novel taste-specific genes are expressed in sweet, bitter, and umami cells that express the taste-specific ion channel TRPM5, sour cells that express the taste-specific ion channel PKD2L1/PKD1L3, or a unique cell type that does not express TRPM5 or PKD2L1/PKD1L3. A taste-specific gene, preferably an ion channel, that is conductive or activated by sodium and is expressed in a TRPM5- and PKD2L1/PKD1L3-negative cell population is a probable candidate for screening efforts to identify the gene(s) that encode mammalian salty taste receptors, as well as specific cell types wherein these salty taste receptor genes are expressed such as in the oral cavity and urinary tract, and also for use in high throughput assays designed to identify enhancers of saltiness in humans. The invention further provides infra in vitro and in vivo strategies for functionalizing the identified taste specific genes, especially those genes identified in unique taste cell subsets also described infra. As described infra and in more detail in the related application cited above, these strategies have already successfully identified a human and non-human primate salty taste receptor and therefore should be effective for functionalizing other taste specific genes such as fat and metallic taste receptors or other taste specific genes involved in ancillary taste cell functions enumerated infra.

In addition, as further described infra, improvements of these methods are also provided which use the combination of real time polymerase chain reaction detection of gene expression and immunochemical assays using taste buds from human post-mortem samples and other methods have been utilized to successfully isolate and identify other unique human taste cell subsets and lineages which in all likelihood are involved in detecting other taste modalities or other taste cell functions.

More specifically, the improved method identifies human taste specific genes by quantitative polymerase chain reaction (PCR). Particularly, the inventors demonstrate taste specific gene expression in humans and primates and have validated the observed specificity of expression by a quantitative method (qPCR or “TaqMan”) The identified human taste specific genes (Table 8 infra) (most of which have known primate and other species counterparts) encode multi-span transmembrane proteins and therefore are predicted to include receptors involved in different taste modalities and other functions. (One of the identified human ion channels genes disclosed therein has been confirmed to encode a salty taste receptor.)

Also, in a related aspect this application identifies taste specific genes expressed in humans based on the identification of their counterparts (orthologs) in non-human primates using the disclosed rationales. The inventors predicted that as primates and humans are closely evolutionarily related that gene expression patterns seen in primate taste tissues would correlate to those observed for these genes in human taste tissues. Based on this assumption, taste specific genes shown to be taste specific in primates (including those recited in Tables 1-5 infra) were selected to be validated in human taste buds using non-microarray analysis (TaqMan qPCR).

In another related aspect the invention detects human taste specific genes in human LCM cDNA using LCM from post-mortem LC human tissues and a single cDNA amplification step, establishing that human postmortem LCM human tissue can be used to quantify the expression of taste specific genes sung qPCR.

In yet another related aspect the invention establishes that human taste specific genes can be measured by quantitative qPCR (taqMan) and that gene expression profiles of human taste specific genes can be directly measured by TaqMan and the results used to validate previous gene expression data obtained from microarrays and/or in situ hybridization (ISH) from non-human, e.g., macaque taste cell samples.

In an additional aspect the invention provides an improved method for the identification of a set of human and non-human primate taste specific genes which should identify all potential taste receptor and taste modulator genes based on a selection protocol which compares the expression of taste specific genes in cells in the top versus the bottom of the taste bud.

In another related aspect the invention identifies novel human taste-bud specific genes using the successive approaches of gene expression via microarray in primate LCM tongue tissue; top specific gene expression within the taste bud (akin to known taste receptors) and TaqMan quantification of gene expression in human postmortem tissues and have identified new human taste specific genes not described previously as being taste specific.

In another related aspect the invention identifies human taste specific genes expressed in human post-mortem tissues and provides methods for the functionalization of these genes and cells which express these genes or a combination thereof.

In another related aspect the invention provides a method for identifying and categorizing human taste specific genes which are involved in different functions of the taste buds based on measuring their expression by quantitative qPCR or based on where they are expressed in human taste buds.

In another related aspect the invention provides the specific primate and human taste specific genes identified using these methods which are involved in different taste cell functions including taste sensation, taste bud growth and development, control of the lifespan of mature taste bud cells, and the maintenance differentiation and proliferation of taste-bud committed taste stem cells.

Also, the invention provides the specific primate and human taste specific genes identified using these methods and the corresponding gene products as biomarkers of taste-bud committed stem cells.

Also, the invention provides the specific primate and human taste specific genes identified using these methods and the corresponding gene products as biomarkers of different mature taste cell subsets.

Also, the invention provides the specific primate and human taste specific genes identified using these methods and the corresponding gene products in methods which purify, enrich or ablate specific taste cell subsets and taste-bud committed stem cells.

More specifically, this application identifies novel categories of taste specific genes which are tabulated and enumerated infra derived from primates and human taste cell specific sources (See tables 1-8). These genes are expressed in chemosensory or taste cells, e.g. human and non-human primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as other non-human primates. These genes are referred to by the inventors as “taste-specific” genes because they are strongly expressed in taste cells. These taste-specific genes include genes which are directly or indirectly involved in taste detection and modulation, e.g., salty, umami, sweet, sour, fatty, metallic, or bitter taste transduction as well as including genes which are involved in biological functions not directly related to taste detection such as the modulation of digestion, taste cell turnover, regulation of the immune system, particularly of the oral cavity, and the regulation of metabolism e.g., carbohydrate metabolism, diabetes, obesity, cachexia, detection of food during digestion, et al.

Relating to the foregoing the present invention provides novel sets of genes that are expressed specifically in human and non-human primate (macaque) chemosensory, e.g., macaque fungiform or circumvallate papilla taste cells that are not expressed or are expressed at significantly lower levels in lingual epithelial cells that are useful in screening assays, preferably high throughput screening assays, for identifying compounds that directly or indirectly modulate different taste modalities, e.g., salty, sweet, umami, bitter, sour, fatty, or metallic.

While the identified taste-specific genes include genes which are directly or indirectly involved in taste detection and modulation, e.g., salty, umami, sweet, sour, fatty, metallic, or bitter taste transduction they also include genes which are involved in biological functions not directly related to taste detection such as the modulation of digestion, taste cell turnover, regulation of the immune system, particularly of the oral cavity, and the regulation of metabolism e.g., carbohydrate metabolism, diabetes, obesity, cachexia, detection of food during digestion, et al.

With particular respect to fat or lipid taste detection the present invention further identifies a subgenus of taste specific genes which are predicted to be involved in detecting fats or lipids based on the presence of characteristic lipid or fat binding motifs or based on the classification of these genes. These genes potentially may be used to screen for compounds that enhance or mimic or block fatty taste detection by the taste buds and potentially detection, binding or absorption by gastrointestinal tissues since it is likely that taste receptors which sense fats or lipids may be expressed in the gastrointestinal tissues as has been observed with other types of taste receptors (sweet, umami and bitter). These genes are referred to herein as “fat taste-specific” genes because they are expressed specifically in taste cells and because based on their structure or prior fictionalization as binding to fatty acids or lipids they are predicted to be involved in fat taste detection in human and non-human primates and likely other mammals. Also, these putative fat taste-specific genes include genes that may also play an ancillary role in other taste modalities and the detection or isolation of taste cells involved in other taste modalities such as, e.g., salty, umami, sweet, sour, metallic, or bitter taste transduction. In addition based on their structural characteristics such as characteristic motifs or prior functional characterization as fatty acid or lipid receptors these genes are predicted to possess other non-taste biological functions involving lipid transport and fat metabolism such as gastric motility and gastric peptide secretion.

Further relating to the foregoing the present invention identifies taste specific human and non-human primate (macaque) genes and the corresponding gene products or cells that express same that are useful in screening assays, preferably high throughput screening assays, for identifying compounds that are useful e.g., as therapeutics in the treatment of digestive system disorders such as cancers and autoimmune disorders, for modulating taste cell apoptosis or taste cell turnover, for inducing taste cell regeneration, for affecting the regulation of immunity in the oral cavity, and the regulation of metabolism, e.g., in the treatment of diabetes, obesity, eating disorders, and other metabolic disorders.

Also relating to the foregoing the invention provides a novel set of human and primate (macaque) and human genes which are useful in the identification and/or isolation and/or enrichment of specific types or lineages of taste or chemosensory cells, e.g., taste or chemosensory cells that are involved in specific taste modalities, immune system regulation in the oral cavity, taste cell apoptosis or taste cell turnover, taste cell regeneration, digestive system regulation, and the regulation of metabolism such as cells that aid in food detection, the secretion of hormones or enzymes involved in hunger and digestion, and the like.

Further, the invention relates to the use of these isolated chemosensory or taste cells in screening assays for identifying compounds that modulate taste, as well as in the identification of therapeutics for modulating the immune system, particularly the regulation of the immune homeostasis in the oral cavity, regulation of taste cell apoptosis, turnover or taste cell regeneration and proliferation, regulation of hormones or enzymes involved in digestion and other taste cell functions, treatment of digestive system disorders such as oral or digestive system cancers, autoimmune or inflammatory digestive disorders, treatment of diabetes, obesity, eating disorders, or other metabolic disorders, and the like.

Further relating to the foregoing the present invention provides a novel set of human and primate (macaque) genes and the corresponding gene products or cells that express same that are useful in screening assays, preferably high throughput screening assays, for identifying compounds that are useful e.g., as therapeutics in the treatment or prevention of digestive system disorders involving aberrant lipid and fat metabolism and the co morbidities associated with aberrant fat and lipid intake and metabolism such as obesity, hepatic steatosis, liver cirrhosis, atherosclerosis, hyperglycemia, insulin resistance and hepatic insulin resistance, type 1 and type 2 diabetes, abdominal obesity, cancers that are obesity or diet related, and the like.

Also, the invention relates to the use of such putative taste receptor genes and the corresponding polypeptides and cells which express same such as cancers and autoimmune disorders, in identifying compounds for modulating taste cell apoptosis or taste cell turnover, particularly compounds that modulate or inhibit fat taste cell regeneration and adipocyte differentiation, e.g., for affecting the regulation of metabolism, e.g., in the treatment of diabetes, obesity, fat accumulation, eating disorders, and other metabolic disorders.

Also relating to the foregoing the invention provides a novel set of human and primate (macaque) genes which are useful in identifying, isolating and/or enriching fat taste receptor expressing cells or cell lineages that upon maturation give rise to fat taste receptor cells using the subject genes or probes specific thereto such as nucleic acids or antibodies.

Also, the invention relates to the use of isolated chemosensory, e.g., taste or gastrointestinal, e.g., enteroendocrine cells which express one or more of the genes reported herein the identification and/or isolation and/or enrichment or ablation of specific types or lineages of taste or chemosensory cells, e.g., taste or chemosensory cells that are involved in specific taste modalities, immune system regulation in the oral cavity, taste cell apoptosis or taste cell turnover, taste cell regeneration, digestive system regulation, and the regulation of metabolism such as cells that aid in food detection, the secretion of hormones or enzymes involved in hunger and digestion, and the like.

Further, the invention relates to the use of these isolated chemosensory or taste cells in screening assays for identifying compounds that modulate taste, as well as in the identification of therapeutics for modulating the immune system, regulation of taste cell apoptosis, turnover or taste cell regeneration and proliferation, regulation of hormones or enzymes involved in digestion and other taste cell functions, treatment of digestive system disorders such as digestive system cancers, of diabetes, obesity, eating disorders, or other metabolic disorders, and the like.

The present invention further provides methods of isolating, purifying and marking desired taste cell types and taste cell lineages including e.g., umami, sweet, salty, bitter, fat, sour, metallic as well as taste stem cells and other immature and mature taste cell lineages including cells that differentiate into taste bud cells, taste cell neurons, taste immune cells et al. based on the expression or absence of expression of one or more of the taste specific genes provided herein. These isolation and purification methods include both positive and negative cell separation methods. For example desired taste cell lineages or types may be isolated by positive cell selection methods e.g., by the use of fluorescence activated cell sorting (FACS), magnetic bead cell selection e.g., by visual identification of desired cells such as individual transfected cells by electrophysiology using antibody coated beads. Alternatively, desired taste cell lineages or types may be recovered or purified by negative cell purification and isolation methods wherein the desired cell types are enriched or purified from a mixed cell population by the removal of one or several undesired cell lineages e.g., by contacting a mixed cell suspension containing the desired taste cells and undesired cells e.g., derived from the tongue, oral cavity or gastrointestinal tract and associated organs with cytotoxic antibodies specific to a target gene or genes expressed on the undesired taste cell type(s) which are to be removed.

Also the invention relates to the use of markers e.g., antibodies or oligonucleotides, that are specific to one or more of the subject taste specific genes provided herein in mapping regions of the tongue and oral cavity which are involved in specific taste and non-taste specific functions, mapping of cell comprised on specific regions of the gastrointestinal tract and associated organs such as the intestinal epithelium or urinary tract that express specific taste specific genes and which therefore are involved in one or more of the taste cell specific functions disclosed herein, and/or the use of the subject genes and markers specific thereto in taste cell differentiation studies, e.g. for identifying compounds that induce the differentiation or dedifferentiation of taste cells e.g., adult or embryonic stem cells and other pluripotent or immature cell types into desired taste cell lineages and taste cell types.

In yet another aspect, this invention relates to assays for identifying a compound having potential in vivo application for modulating human salty or other specific taste. This method comprises the steps of (i) contacting a cell that expresses a gene encoding an ion channel, receptor or transporter identified as a putative salty taste affecting gene according to any one of the methods above, or a gene encoding a polypeptide possessing at least 90% sequence identity to the polypeptide encoded thereby, with at least one putative enhancer compound; (ii) assaying sodium conductance, receptor activity or sodium transport in the presence and absence of said putative enhancer; and (iii) identifying the compound as a potential salty taste enhancer based on whether it increases sodium conductance, the activity of said receptor or sodium transport. In various embodiments, the gene encodes an ion channel or the gene encodes a GPCR. Preferably, the gene is a human gene. More preferably, the method further includes testing the effect of the compound or a derivative thereof in a human taste test. Preferably, the selected compound promotes sodium ion transport into taste bud cells. The putative salty taste affecting gene may be expressed in an amphibian oocyte, or in a mammalian cell, preferably a Xenopus oocyte or a mammalian cell selected from the group consisting of a HEK293, HEK293T, Swiss3T3, CHO, BHK, NIH3T3, monkey L cell, African green monkey kidney cell, Ltk-cell and COS cell. Preferably, the putative salty taste affecting gene is expressed under the control of a regulatable promoter. The putative salty taste affecting gene may be expressed stably or transiently. In a preferred mode, the putative salty taste affecting gene is selected from tables 1-8

In a preferred mode, the assay of step (ii) is an electrophysiological assay which uses a sodium sensitive dye, and preferred dyes include membrane potential dyes selected from the group consisting of Molecular Devices Membrane Potential Kit (Cat#R8034), Di-4-ANEPPS (pyridinium, 4-(2-(6-(dibutylamino)-2-naphthalen-yl)ethenyl)-1-(3-sulfopropyl)hydroxide, inner salt, DiSBACC4(2) (bis-(1,2-dibabituric acid)-triethine oxanol), Cc-2-DMPE (Pacific Blue 1,2-dietradecanoyl-sn-glycerol-3phosphoethanolamine, triethylammonium salt) and SBFI-AM (1,3-benzenedicarboxylic acid, 4,4-[1,4,10-trioxa-7,13-diazacyclopentadecane-7,13-diylbis(5-methoxy-6,1,2-benzofurandiyl)}bis-tetrakis{(acetyloxy)methyl}ester (Molecular Probes), more preferably, the sodium sensitive dye is sodium green tetraacetate (Molecular Probes) or Na-sensitive Dye Kit (Molecular Devices). In another preferred mode, the assay of step (ii) is a two electrode voltage clamping assay in Xenopus oocytes, or the assay is a patch clamp assay in mammalian cells. Preferably, the assay measures activity by an ion flux assay, including using atomic absorption spectroscopy to detect ion flux.

Alternatively, the assay may use a fluorescence plate reader (FLIPR), or a voltage imaging plate reader (VIPR), which is used to increase ion channel-dependent sodium or fluid absorption. In a preferred embodiment of this method, the activity of the putative salty taste affecting gene is assayed in a frog oocyte electrophysiologically by patch clamping or two electrode voltage clamping, preferably using an automatic imaging instrument, which may be a fluorescence plate reader (FLIPR) or a voltage imaging plate reader (VIPR).

In yet another mode, this invention relates to assays for identifying a compound having potential in vivo application for modulating human sweet, bitter, umami, or sour taste. This method comprises the steps of (i) contacting a cell that expresses a gene in Tables 1-8 with at least one putative enhancer or blocker compound; (ii) assaying sodium conductance, receptor activity or taste gene product function in the presence and absence of said putative enhancer or blocker; and (iii) identifying the compound as a potential enhancer or blocker for sweet, bitter or umami taste based on whether it modulates sodium conductance, the activity of said receptor or taste gene product function.

In a more specific embodiment the present invention relates to assays that screen for activators of TRPM5 or umami (T1R1/T1R3) and/or sweet (T1R2/T1R3) taste receptors preferably those which modulate insulin metabolism and/or the release of a satiety peptide such as GLP-1 (glucagon-like peptide 1), which may be used in treating or preventing metabolic and eating disorders such as in the treatment of one of obesity, diabetes, weight management, fat metabolism, glucose metabolism, insulin metabolism, satiety or other conditions wherein the release of satiety peptides or insulin metabolism is desirably controlled or reduced.

In another specific embodiment the present invention relates to assays using endogenous taste cells, e.g., gastrointestinal cells such as gastro-endocrine or gastro-epithelial cells or cells on the tongue or oral cavity, that screen for compounds which act as activators of TRPM5 or umami (T1R1/T1R3) and/or sweet (T1R2/T1R3) taste receptors, preferably those which modulate insulin metabolism and/or the release of a satiety peptide such as GLP-1 (glucagon-like peptide 1), which activators may be used in treating or preventing metabolic and eating disorders such as in the treatment of one of obesity, diabetes, weight management, fat metabolism, glucose metabolism, insulin metabolism, satiety or other conditions wherein the release of satiety peptides such as GLP-1 (glucagon-like peptide 1) is desirably controlled or reduced.

This invention in a more specific embodiment relates to specific taste specific genes identified infra, e.g., FAM26A, GPR113, MCTP1, TMEM16G, TMEM30B, TMEM44, and TUSC3 that are expressed in chemosensory or more specifically taste cells, e.g., human and primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates. and isolated taste cells expressing including cells wherein these genes are expressed as novel taste cells (do not correspond to prior taste modality) and that do not express TRPM5 or PKD2L1/PKD1L3.

Also, the invention relates to enriched, isolated or purified taste cell subsets which expresses at least one of FAM26A, MCTP1, TMEM30B, and/or TUSC3 and which further express at least one T1R or T2R or TRPM5 gene and/or which express T1R2/T1R3 or T1R1/T1R3 or T1R3 only. Particularly, the invention provides isolated taste cells that express GPR113 and/or TMEM16G and which isolated taste cells which further expresses at least one of T1R2/T1R3, T1R1/T1R3, T1R3 only, a T2R gene and/or TRPM5.

Also, the invention relates specifically to a method of using a probe specific to a gene or gene product corresponding to the genes to identify and/or isolate and or enrich taste specific cells from non-taste cells in a sample. For example, these methods include a method herein the gene is FAM26A, MCTP1, TMEM30B, and/or TUSC3 and the identified, isolated or enriched cell further expresses T1R1/T1R3, T1R2/T1R3, T1R3 only, a T2R, and/or TRPM5. Also, the invention includes methods wherein the gene is GPR113 and/or TMEM16G and the isolated, identified or enriched cell further expresses at least one of T1R2/T1R3, T1R1/T1R3, T1R3 only, a T2R or TRPM5 and/or wherein said taste cells are human or macaque taste cells. and wherein said isolated taste cells do not express PKD2L1, PKD1L3, or TRPM5 and/or wherein said cells do not express a T1R or a T2R and/or said taste cells express transducin or gustducin.

Also, the invention relates to the use of these identified taste specific genes or an ortholog or variant thereof encoding a protein at least 90% identical thereto in a cell isolation, purification, enrichment, or marking technique that isolates, purifies, enriches and/or marks at least one desired taste cell subtype or lineage contained in a mixed cell population or cell suspension comprising a desired taste cell type or lineage based on the expression or absence of expression of at least one gene contained in Tables 1-8 or an ortholog thereof, or a gene encoding a protein that is at least 90% identical to said gene or an ortholog thereof. Particularly, the invention includes methods wherein the taste cell subtype or taste cell lineage is isolated, purified, enriched, or marked by a method that includes the use of a fluorescence activated cell sorter (FACS) or by the use of labeled magnetic beads and wherein the cell suspension containing the cells may be produced by enzymatic digestion and/or tissue disaggregation of tissues containing taste cells. and methods wherein the desired taste cell subtype or taste cell lineage is isolated, purified, enriched or marked by a method that includes a negative cell selection technique that eliminates at least one non-target taste cell subtype or lineage based on the expression or absence of expression of at least one other taste cell specific gene identified herein. These methods may e.g., use cytotoxic antibodies to specifically kill at least one non-target cell type or lineage. These isolation methods may e.g., result in isolates containing sweet taste cells, umami taste cells, sour, salty, or fat taste cell subtype or lineages, taste stem cells taste cell neurons, or taste immune cells.

Also, the invention relates to methods of using a cell isolated, purified, enriched or marked according to these methods in screens for taste modulatory compounds, or in a method that screens for compounds that induce the differentiation of said enriched, isolated, purified or marked taste stem cells into one or more taste cell lineages or subtypes or taste buds or in a method wherein said taste cell lineages or subtypes are identified based on the expression or absence of expression of at least one the identified taste specific gene identified above. These cells may be used to screen for compounds that modulate at least one of sweet, umami, bitter, sour, fat, salty or metallic taste wherein the gene is GPR113 or TMEM16G or TMEM44 or to screen for compounds that modulate taste cell differentiation or turnover.

Also, the invention relates to these cells or the gene or gene product encoded thereby in assays that screen for compounds that modulate or treat the diseases and conditions involving taste cells previously identified. This in particular relates to GPR113 or the corresponding gene product or cells which express same or an ortholog or variant thereof in assays to identify compounds that modulate taste cell differentiation or taste cell turnover.

Also, the invention relates to isolated immature taste cells and/or taste stem cells that express TMEM44 or GPR113 and the use in an assay for identifying taste modulators, in particular which screens for sweet, umami, bitter, fat, salty, metallic and/or astringent taste modulators. Also, the invention relates to a recombinant cell engineered to co-express T1R3 and GPR113 and optionally TRPM5. Also, the invention embraces an assay for identifying compounds which modulate taste cell differentiation and/or maturation based on whether said compound specifically binds and/or modulates the activity of GPR113.

Also, the invention relates to the use of these cells in assays that screen for compounds that modulate the differentiation and/or maturation of sweet or umami taste cells. Also, the invention provides a method of using GPR113 as a marker to identify, enrich and/or isolate or ablate unique taste cells which express GPR113, TRPM5 and T1R3 wherein said taste cells do not express T1R1, T1R2 and/or a T2R or are immature, e.g., by FACS or magnetic bead cell separation or by use of cytotoxins.

In addition the invention relates to the discovery that TMEM44 and MFSD4 are expressed in unique taste cell type and that these gene are expressed in sensory taste cells that are not sweet, bitter, umami, or sour cells which further expresses another taste-specific gene disclosed herein. Also, the present invention relates to the discovery that expression of TMEM44 and MFSD4 are markers for a unique taste cell type that may correspond to a fat receptor. Further, the invention relates to the discovery that ATP8A1, FAM26B and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells.

This invention in a more specific embodiment identifies genes infra, e.g., FAM26A, GPR113, MCTP1, TMEM16G, TMEM30B, TMEM44, and TUSC3 that are expressed in chemosensory or more specifically taste cells, e.g., human or primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates. and isolated taste cells expressing including cells wherein these genes are expressed as novel taste cells (do not correspond to prior taste modality) and that do not express TRPM5 or PKD2L1/PKD1L3.

Also, the present invention relates to the discovery that MFSD4 is expressed in cells that do not express TRPM5 (bitter, sweet, umami) indicating that the expression of this gene is a marker for a unique taste cell type that could correspond to salt, fat, or another taste modality, and, furthermore, that this gene may encode the primary salt or fat receptor.

Also, the invention reveals that the expression pattern of MFSD4 is very similar to TMEM44, indicating that both genes are expressed in the same taste cell type and may be comprised in a heteromeric taste receptor.

Also, the invention relates to the discovery that ATP8A1, FAM26B, and SLC4A11 can be used as markers for sweet, bitter, and umami taste cells or cells expressing TRPM5.

Also, the invention relates to the discovery that ATP8A1, FAM26B, and SLC4A11 and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to tastants including sweet, bitter, and umami.

Also, the invention relates to the discovery based on in situ hybridization results that that TUSC3, ASCL1, FAM26A, FAM26C, IKBKAP, LOC285965, SCNN1D, SLC4A11, SLC26A7, and TMEM30B all are expressed by unique taste cell subsets comprised in primate taste buds and therefore can be used as biomarkers to isolate, enrich, mark or ablate these cells and thereby determine the taste related function of these taste bud cells.

Also, the present invention relates to the discovery that MFSD4 can be used as a marker for a unique, novel taste cell type that does not correspond to sweet, bitter, and umami taste cells. Moreover, the invention relates to the discovery that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, and umami, which include salt, fat, and other tastants. Based on the foregoing, the invention relates to the discovery that MFSD4 may correspond to the salt receptor or fat receptor. Also, MFSD4 may be a marker of immature taste cells or developing taste cells.

Related thereto, the present invention also relates to the discovery that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).

Also, the present invention relates to the discovery that MFSD4 and TMEM44 are expressed in the same unique taste cell type. Also, the present invention relates to the discovery that MFSD4 and TMEM44 may form a complex (heterodimer) to generate a taste receptor for a different taste than sweet, umami, sour or bitter, likely salt or fat. and may be used in screening assays.

Also, the present invention relates to the discovery that ATP8A1, FAM26B, and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells. and may regulate taste perception or other taste cell function. Moreover, the present invention reveals that ATP8A1, FAM26B, and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells.

In another embodiment the invention relates to the discovery that ASCL1 also known as MASH is a transcription factor that defines and is a useful marker of sour taste cells as it is selectively expressed in sour taste cells that express PKD1L3 but not in other taste cell types, i.e., it is not expressed in sweet, bitter, or umami cells which express TRPM5. Therefore, the ASCL1 transcription factor may bind to promoter elements in genes involved in sour taste perception. Thus, the invention provides the use thereof in screening the genome for ASCL1 motifs to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.

In another embodiment the invention establishes ASCL1 to be a marker of type III taste cells. Type III taste are defined by morphological criteria which include: staining with an intermediate density by electron microscopy and making synaptic contacts with nerve fibers. Thus, the invention reveals that type III taste cells, a cell type previously defined by morphological criteria, correspond to sour taste receptor cells defined by gene expression criteria.

In another embodiment the invention relates to the discovery that other taste receptor cells for sweet, bitter, umami, and salt are likely to express specific transcription factors related thereto that define those cell types. Therefore, the invention provides assays detecting the expression of all transcription factors in the genome in taste cells by PCR and/or histology to determine which taste cell types express which transcription factors.

In another embodiment the invention relaters to the discovery that the ASCL1 transcription factor binds to promoter elements in genes involved in sour taste perception. Thus, the invention encompasses such sequences found in the genome that comprise ASCL1 motifs and the use thereof to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.

In another embodiment the invention relates to the discovery that ASCL1 (aka MASH1) is a marker useful for identifying, purifying, and/or isolating or ablating sour taste cells in a mixed cell sample, e.g., derived from the tongue or gastrointestinal or urinary tract.

In a related embodiment the invention provides the use of ASCL1 as a marker of Type III taste cells that correspond to sour taste receptor cells

In another embodiment the invention establishes that because ASCL1 defines the sour taste cell lineage it may also control sour taste cell development.

In another embodiment the invention provides the use of ASCL1 transcription factor DNA binding sequences as a probe to identify sour cell genes and sour taste receptor genes that possess related structure such as ASCL1 motifs.

Also, the invention provides the use of these and other taste cell specific transcription factors to define, mark, and/or label taste cell types because each taste cell will express one or more transcription factors that define that taste modality.

The invention further provides the use of these transcription factors that define taste modalities in cell ablation studies to specifically eliminate a specific taste cell or taste modality.

Also, the invention provides ASCL1 or other taste transcriptional gene knockouts which result in transgenic animals possessing altered taste perception and other phenotypic effects, e.g., elimination of sour taste perception or altered urinary or digestive function since ASCL1 may be involved in the metabolic response to pH changes such as excess acidity.

Also, the invention provides the use of these transcription factors that define new taste cell types which can be used in cell ablation studies and in vitro assays to determine what taste modality is lacking as a result of this ablation (i.e. what taste modality is eliminated).

In another embodiment this invention identifies taste-specific genes NALCN, TRPML3 and NKAIN3 which when expressed separately or in combination are predicted to comprise a taste receptor, putatively a salty taste receptor, as these 3 genes are expressed in primate taste cells, are enriched in the top fraction of taste bud cells, and are known to encode sodium channels. In addition the invention relates to the discovery that NALCN is expressed in a unique taste cell subset and is predicted to encode a taste related function. (As noted, TRPML3 has been shown to encode a salty taste receptor).

In a related embodiment the present invention relates to the use of these taste specific ion channel genes as markers which can be used to enrich, identify or isolate salt receptor expressing cells.

In another embodiment the invention relates to assays that identify compounds that modulate the function of the use of NALCN, TRPML3 and/or NKAIN3 and the use of the identified compounds to modulate salty taste perception.

In another embodiment the invention relates to other taste specific genes, i.e., KIT, IKBKAP, LOC285965, and SV2B that are expressed in specific subsets of taste specific cells.

In another embodiment, this invention relates to the discovery that KIT is specifically expressed in TRPM5 and T1R3 taste cells and T1R1 taste cells indicating that the gene can be used as a marker to identify umami taste cells in a mixed cell population and/or may modulate the expression and activity of the umami taste receptor.

In another embodiment, this invention relates to the discovery that IKBKAP and SV2B are specifically expressed in PKD1L3 sour taste receptor cells indicating that these genes can be used as markers to identify sour taste cells and/or modulate taste, especially sour taste.

Also, in another embodiment this invention relates to the discovery that LOC285965 is specifically expressed in TRPM5 and T1R3 taste cell subsets and T1R3 cells lacking T1R1 and T1R2 suggesting that this gene can be used as a marker of these taste cell subsets and/or may associate with or modulate the T1R3 gene and/or encode a taste receptor distant from T1R1/T1R3 or T1R2/T1R3.

Further, in another embodiment the invention relates to the discovery that SV2B is specifically expressed in PKD1L3 cells indicating that this gene can be used as a marker of these specific cell subsets and/or may encode a polypeptide that modulates the activity or expression of the PKD1L3 sour taste receptor.

In addition, in another embodiment the invention relates to the discovery that MFSD4 is expressed in sensory taste cells that are not sweet, bitter, umami, or sour cells and that this gene is expressed in a similar taste cell population as TMEM44.

Also, in another embodiment the invention relates to primate taste specific genes identified in Table 4 found by gene chip analysis which encode transmembrane proteins for ion channels that can conduct sodium, ion transporters, G-protein coupled receptors, or may encode novel multi-transmembrane proteins with no known function which are candidate salty taste receptors.

In another embodiment, the invention relates to the use of compounds that enhance or inhibit IKBKAP and SV2B gene products to selectively modulate taste cell function and responses to sour tastants as well as other functions of the PKD1L3 taste cell population.

In another embodiment, since IKBKAP is mutated in the human disease familial dysautonomia, where taste buds are absent or atrophic and individuals exhibit deficiencies in detection of sweet, bitter, sour, and salty tastants (hypogeusia) the invention related to the discovery that IKBKAP expression in PKD1L3 cells may be important for taste cell development and/or maintenance.

In another embodiment since Botulinum neurotoxin (BoTox) enters neuronal-type cells by interacting with SV2B; the invention relates to the use of BoTox and derivatives to selectively modulate sour taste as well as other functions of the PKD1L3 taste cell population.

In another embodiment since KIT is expressed in umami taste cells the invention relates to the use thereof as a marker of this taste cell type.

In another embodiment the invention relates to the use of KIT and compounds that enhance or inhibit this gene product to selectively modulate taste cell function and responses to umami tastants.

In another embodiment the invention relates to the use of Gleevec (Imatinib), an inhibitor of the KIT tyrosine kinase activity, and other KIT tyrosine kinase inhibitors for selectively inhibiting umami taste.

In another embodiment the invention relates to the discovery that individuals with gain of function mutations in KIT, for example in gastrointestinal stromal tumors (GIST), may have altered umami taste perception.

In another embodiment since LOC285965 is expressed in T1R3 only taste cells similar to GPR113 the invention relates to the use as a marker for a unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells.

In another embodiment the invention relates to the discovery that LOC285965 may correspond to the salt receptor or fat receptor or a receptor for astringency or metallic taste by itself or in combination with GPR113, which is also expressed in T1R3 only cells.

In another embodiment the invention relates to the discovery that LOC285965 may be a coreceptor with T1R3 for specific sweet or umami tastants or other novel tastants such as astringent and metallic tastants.

In another aspect the invention relates to the discovery that compounds that enhance or inhibit LOC285965 can selectively modulate taste function and responses to tastants.

In another embodiment the invention relates to the discovery that LOC285965 may correspond to a marker of immature taste cells that are differentiating into sweet or umami cells.

In another embodiment the invention relates to the discovery that LOC285965 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. sweet or umami taste cells).

In another embodiment the invention relates to the discovery that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, umami, and sour which include salt, fat, and other tastants.

In another embodiment the invention relates to the discovery that MFSD4 may correspond to the salt receptor or fat receptor.

In another embodiment the invention relates to the discovery that MFSD4 may correspond to a marker of immature taste cells or developing taste cells or support cells.

In another embodiment the invention relates to the use of MFSD4 and compounds that enhance or inhibit this gene product to selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).

In another embodiment the invention relates to the discovery that MFSD4 and TMEM44 are expressed in the same unique taste cell population.

In another embodiment the invention relates to the discovery that MFSD4 and TMEM44 may form a complex (heterodimer) to generate a taste receptor for salt or fat.

In another embodiment the invention relates to the use of the genes listed in Tables 1-8 in assays for candidate salt or fat taste receptors.

BACKGROUND OF THE INVENTION

This invention and the specific rationales for identifying and functionalizing taste specific genes were developed with their initial objective being the identification and functionalization of a gene encoding a salty taste receptor. With respect thereto, epithelial sodium channels (ENaC) are members of the ENaC/degenerin family of ion channels that includes acid-sensing ion channels (ASIC) in mammals, mechanosensitive degenerin channels in worms, and FMRF-amide peptide-gated channels in mollusks (Kellenger, S. and Schild, L. (2002) Physiol. Rev. 82:735-767). ENaC mediates amiloride-sensitive apical membrane Na⁺ transport across high resistance epithelia in numerous tissues including kidney, colon, and lung and have been well studied and predicted to be involved in salty taste in primates and other species.

ENaC is known to be a heterotrimeric channel comprised of alpha, beta, and gamma subunits or delta, beta, and gamma subunits. Particularly, this heterotrimeric channel has been hypothesized to be involved in human salty taste perception. Previously, assays have been developed by the present assignee using ENaC sequences to identify compounds that modulate the delta beta gamma and alpha beta gamma human ENaC to examine if these compounds will potentially modulate human salty taste perception. Also, these compounds potentially may be used to treat human pathologies involving aberrant ENaC function.

Unlike other mammals, amiloride only slightly reduces the intensity of sodium chloride taste, i.e., by about 15-20% when used at concentrations that specifically modulate ENaC function (Halpern, B. P. (1998) Neuroscience and Behavioral Reviews. 23: 5-47). Experiments conducted by the inventors have shown that amiloride, or the more potent amiloride derivative phenamil did not elicit a significant effect on perceived human salt intensity when tested at levels 300-fold (for amiloride) and 3000-fold (for benzamil) above IC50 values for alpha beta gamma ENaC (equivalent to 10-fold for amiloride and 100-fold for benzamil over IC50 values for delta beta gamma ENaC). Thus, additional non-ENaC genes are likely involved in human salty taste.

In addition, it has been recently reported that taste receptors may be expressed in non-oral tissues, e.g., in the digestive system and potentially other organs such as the kidney. Particularly it has been reported that sweet, umami and bitter taste receptors are expressed in cells other than in the oral cavity such as gastrointestinal cells. (See, e.g., Sternini et al., Amer J Physiol. Gastrointestinal and Liver Physiology, 292:G457-G461, 2007; Mace, O. J. et al, J. Physiology. 10.1113/jphysiol.2007.130906. Published online May 10, 2007). Also, it has been reported by various groups (Margolskee et al., Bezencon et al., Rozengurt et al, and Sternini et al. (2007) (Id)) that bitter and umami taste receptors and other taste signaling molecules such as TRPM5 and gustducin are expressed in specialized cells in the gastrointestinal tract. (See e.g., Margolskee et al., Genes Brain Behavior 2007 (epub March 21); Rozengurt et al., Amer. J. Physiol. Gastroent. Liver Physiol. 291(2):G171-7 (2006); Bezencon et al., Chem Senses 32(1):41-47 (2007)). Margolskee et al. (Id) further reports that the loss of T1R3 or gustducin in rodents resulted in changes in insulin metabolism and the release of satiety peptides such as GLP-1 (glucagon-like peptide 1).

Based on the foregoing, it has been suggested that salty receptors may be expressed in the urinary tract. Taste receptors are purported to be involved in functions not directly related to taste such as digestive functions such as gastric motility, absorption, food detection, metabolism, and immune regulation of the oral or digestive tract and may also affect functions relating to sodium absorption, excretion and transport such as blood pressure and fluid retention.

Therefore, the identification of taste cell specific genes and identifying what specific cells these genes are specifically expressed (including unique taste cell subsets) should facilitate a better understanding of taste and non-taste functions of these taste receptors and should also facilitate the use of these genes, gene products and cells which express same in assays for identifying novel taste modulators and therapeutics, e.g., for treating digestive diseases such as autoimmune, inflammatory and cancers, metabolism, diabetes, eating disorders, obesity, taste cell turnover, hypertension, fluid retention, and immune regulation of the digestive system.

BRIEF DESCRIPTION AND OBJECTS OF THE INVENTION

The invention obviates the problems of the prior art in that it provides novel rationales for identifying and functionalizing primate and human taste specific genes and unique taste cell subsets and further provides novel uses of these taste specific genes, gene products, and modulators of these taste specific genes and cells containing.

This invention in one embodiment relates to the identification of genes that are expressed specifically in chemosensory or taste cells, particularly human and non-human primate (macaque) fungiform or circumvallate papilla cells, and in taste cells (fungiform, circumvallate, foliate, and palate) of other mammals such as humans and other non-human primates. These genes include genes which are directly or indirectly involved in detecting specific taste modalities such as salty, sweet, bitter, umami, sour, fatty and metallic taste and/or in modulating taste intensity and duration.

This invention in another embodiment relates to the identification of genes that are expressed specifically in chemosensory or taste cells, particularly primate (macaque) circumvallate cells and likely in other chemosensory or taste cells and similar cells derived from other mammals such as humans and non-human primates that are involved in other taste cell functions including by way of example taste cell apoptosis or taste cell turnover, taste cell regeneration, digestion, regulation of the immune system in the oral cavity, regulation of carbohydrate or other metabolic functions relating to digestion, food detection, taste cell trafficking, and the like.

The invention in another embodiment further relates to the identification of specific genes or gene products expressed specifically in human and primate (macaque) or other mammalian taste cells that can be used as markers for the identification, isolation, or enrichment of specific taste cell subtypes or taste cell lineages including by way of example sweet, umami, sour, bitter, salty, fatty and metallic taste cells and for isolating taste cells that are involved in non-taste functions such as regulation of immunity, e.g., in the oral cavity, regulation of digestion or metabolism, regulation of taste cell apoptosis, turnover, or taste cell differentiation and proliferation, and regulation of sodium excretion, transport and absorption.

The invention in another embodiment further relates to the use of these taste cell specific genes or gene products or said isolated or enriched taste cell lineages or taste cell types expressing said taste cell specific genes for use in screening assays, e.g. for identifying compounds that elicit of modulate sweet, sour, umami, salty, bitter, fatty or metallic taste as well as the use of these genes, gene products, or isolated or enriched taste cells for the identification of potential therapeutic compounds, e.g., therapeutics for treatment of various digestive system disorders such as ulcerative colitis, Crohn's disease, celiac disease, dyspepsia, cancers of the digestive system, compounds for modulating taste cell turnover or apoptosis or for regulating taste cell differentiation and regeneration e.g., in geriatric subjects or individuals with cancer, or undergoing chemotherapy, or radiation, compounds for modulating or enhancing the immune system of the oral cavity, compounds for the regulation of digestion and metabolism, e.g., compounds that affect the production of digestive fluids, hormones or enzymes such as saliva, stomach and intestinal fluids, GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotrophic polypeptide), secretin, amylase et al., compounds that affect digestive motility, compounds for treating diabetes, for modulating food detection, and compounds for treating obesity or eating disorders, cachexia, and the like.

This invention in its more specific embodiments relates to novel rationales and methods, and results to date using these rationale and methods for identification and characterization of novel taste-specific genes that based on various parameters constitute salt or other taste modality receptor targets. The targets using these protocols are useful targets in high-throughput screening efforts to identify human salty taste enhancers. These targets are initially identified using two different techniques, gene chips and a polymerase chain reaction (PCR) screen, to identify novel salt receptor target genes. First, Affymetrix gene chips containing most all known macaque genes are used to determine which genes are specifically expressed in primate circumvallate at the back of the tongue and fungiform papilla taste cells at the front of the tongue and not lingual epithelial cells isolated by laser capture microdissection. Second, PCR is used to determine which ion channels, from channels we have cataloged in the human/macaque genomes, are specifically expressed in macaque fungiform and/or circumvallate (CV) papilla taste cells but not lingual epithelial cells isolated by laser capture microdissection. Taste-specific expression of genes identified by either approach, are confirmed using an independent histological method such as in situ hybridization or immunohistochemistry, to determine which genes are expressed in taste cells. Using double labeling histological methods, it is determined what novel taste-specific genes are expressed in sweet, bitter, and umami cells that express the taste-specific ion channel TRPM5, sour cells that express the taste-specific ion channel PKD2L1/PKD1L3, or a unique cell type that does not express TRPM5 or PKD2L1/PKD1L3. A taste-specific gene, preferably an ion channel, that is conductive or activated by sodium and is expressed in a TRPM5- and PKD2L1/PKD1L3-negative cell population is a probable candidate for screening efforts to identify the gene(s) that encode mammalian salty taste receptors, as well as specific cell types wherein these salty taste receptor genes are expressed such as in the oral cavity and urinary tract, and also for use in high throughput assays designed to identify enhancers of saltiness in humans.

In another aspect we describe an improvement of the afore-described methods in the subject application by a method wherein genes expressed in primate taste buds are identified and functionalized using a specific protocol which hinges on where they are expressed and their level of expression in the taste bud. The inventors have developed a rationale wherein they are able to assign gene expression patterns within the primate taste bud (and likely human taste specific genes given the conservation of structure between primate (macaque) and human genes) for all taste bud-specific genes. Specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud, the inventors have found that they are able to classify genes into one of several functional classes that include taste receptor genes. A subset of genes in this classification is likely to encode taste receptors that include those for salty taste and other yet to be defined taste specificities.

The rationale for comparing gene expression between the top and bottom of the primate taste bud arose from the histological localization of mRNAs for a number of candidate taste receptor genes. Expression of a subset of these genes appeared to be localized at the bottom portion of the taste bud while other genes were predominantly expressed at the top of the taste bud. These patterns of expression are exemplified by the TMEM44 and TRPM5 genes which are expressed at the bottom and top of the taste bud respectively (see FIG. 38 and examples infra).

In a related embodiment the invention relates to these categorized taste specific genes. As disclosed infra, gene expression data obtained was queried to obtain three sets of genes. (Appendices 1-3 of this patent application). The first and second sets are genes that are expressed at a higher level in the top or bottom of the primate taste bud relative to the bottom or top respectively. Top-specific genes are listed in Appendix 1 and bottom specific genes are listed in Appendix 2. The third set of genes is expressed at a higher level in the top of the primate taste bud relative to surrounding lingual epithelium samples. These additional taste bud-specific genes are listed in Appendix 3.

Also, in another embodiment this invention describes rationales which are useful for and which have successfully identified human genes which are taste specific and which are predicted to be involved in one or more of the afore-described taste bud related functions. Specifically, these methods include methods which identify human taste specific genes by quantitative polymerase chain reaction (PCR) using taste buds from human postmortem samples. It is an improvement over the primate gene assays since this method provides direct results concerning human taste specific genes which may be functionalized using the described methods.

Also, in another embodiment this invention identifies taste specific genes which should be involved in specific taste cell functions based on where the gene is expressed and levels of expression in the taste bud. These methods are able to classify genes into one of several functional classes that include taste receptor genes. It is an improvement since it provides accurate predictions regarding the taste specific genes which may be functionalized using the described methods.

In another embodiment the invention provides the use of the afore-mentioned improved rationale to demonstrate taste specific gene expression in humans (in addition to primate) and validates the specificity of expression by a quantitative method (qPCR or “TaqMan”). These methods identify the genes contained in the Table 8 infra which all encode multi-span transmembrane proteins, and are predicted to include yet unidentified taste receptors as well as other genes involved in taste modulation including the fat and salt receptor and genes involved in ancillary functions afore-mentioned.

Also, in yet another embodiment the invention identifies unique taste cell subsets which themselves can be used in screens for taste modulatory and therapeutic compounds as described infra, and also further exploits the elucidation of these unique taste cell populations as part of its strategies for identifying salty and other types of taste sensing cells such as fat, metallic, astringent, CO2, et al.

In another embodiment the invention relates to the use of these identified taste specific genes in assays designed to identify therapeutics for the treatment of digestive system disorders such as digestive cancers, autoimmune and inflammatory digestive disorders such as ulcerative colitis, dyspepsia, Crohn's disease, celiac disease, inflammatory bowel syndrome, diverticulitis, et al., for regulating taste cell apoptosis or taste cell turnover, for inducing taste cell regeneration e.g. in geriatrics, cancer patients or individuals undergoing chemotherapy or radiation, for modulating the immune system of the oral cavity, for regulation of digestive mucous and fluids, enzymes or hormones such as GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotrophic polypeptide), amylase, saliva, stomach acids, intestinal fluids, pepsin, secretin, and the like; for treatment of diabetes, eating disorders, cachexia, and other metabolic disorders involving these genes and/or isolated or enriched taste cells.

In another embodiment the invention relates to the use taste-associated genes and polypeptides in assays to ascertain their role in taste cell development and apoptosis, taste cell regeneration, modulation of transcription factors that modulate taste cell receptor expression, e.g., bitter taste receptors, taste receptor trafficking to and from the apical membrane/taste pore region, regulation of taste cell action potential firing frequency/membrane potential to control the intensity of and/or to modulate specific tastes, neurotransmitter release to afferent nerves that regulate taste intensity or specific tastes, and taste cell signaling to nerve fibers.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and to identify compounds that specifically bind to or which modulate the activity of these genes which compounds may be used to treat or prevent pathological conditions involving digestive function. These conditions include by way of example functional dyspepsia (bad digestion) and other dyspepsias which may or may not be ulcer derived or related and may involve different areas of the digestive tract such as the upper abdominal tract, the mid-abdominal tract or the lower abdominal tract.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and to identify compounds that may be used to treat or prevent pathological conditions involving gastrointestinal fluids, mucous, enzymes or hormones involved with digestion or hunger such as gastrin, secretin, pepsin, cholecystokinin, glucose-dependent insulinotrophic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), amylase, ghrelin, leptin and the like. Also these compounds may enhance the production of saliva or other digestive mucous secretions and fluids. These compounds potentially may be used to suppress or induce hunger and/or to modulate digestion in subjects in need thereof.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and to the use of these genes, gene products, or cells that express same such as but not restricted to taste cells, e.g., gastrointestinal or oral cavity derived cells, in screening assays to identify compounds that bind to or modulate the activity or amount of these genes or gene products compounds which potentially may be used to treat or prevent pathological or chronic inflammatory or autoimmune gastrointestinal conditions such as Crohn's disease, inflammatory bowel syndrome (IBD), celiac disease, ulcerative colitis, diverticulitis, gastritis, reflux esophagitis, and the like. These compounds potentially may be used to treat or prevent autoimmune or inflammatory diseases affecting the digestive system.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or modulate the activity of these genes or gene products which compounds potentially may be used to modulate gastric reflux and diseases or conditions associated therewith such as gastroesophageal reflux disease, heartburn, Barrett's esophagus, and esophagitis.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or which modulate the activity of these genes or gene products and which therefore potentially may be used to treat or prevent cancers or malignancies associated with the digestive system such as by way of example cancers of the tongue, and oral cavity such as cancers of the taste buds and salivary gland cancers, stomach, esophagus, small or large intestine, anus or rectum, pancreas, gall bladder, liver, colorectal or colon.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or which modulate the activity of genes or gene products which compounds potentially my be use to treat or prevent appetite dysfunction and conditions associated therewith such as obesity, anorexia, bulimia, and cachexia associated therewith.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides for the isolation or enrichment of specific taste cell lineages or subtypes particularly taste cells derived e.g., from the tongue, oral cavity, or gastrointestinal system, which express one or several of these taste-cell associated genes.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in assays to identify compounds that bind to or which modulate the activity of these genes or gene products which may be used to treat or prevent pathological conditions involving digestive function. These conditions include by way of example functional dyspepsia (bad digestion) and other dyspepsias which may or may not be ulcer derived or related and may involve different areas of the digestive tract such as the upper abdominal tract, the mid-abdominal tract or the lower abdominal tract.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that may be used to treat or prevent pathological conditions involving gastrointestinal hormones, enzymes or fluids involved with digestion or hunger such as saliva, digestive fluids, gastrin, secretin, cholecystokinin, glucose-dependent insulinotrophic polypeptide, glucagon-like peptide 1, amylase, or ghrelin, leptin and the like. These compounds potentially may be used to suppress or induce hunger or to modulate digestion in subjects in need thereof.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or modulate the activity of these genes or gene products which compounds potentially may be used to treat or prevent pathological or chronic inflammatory or autoimmune gastrointestinal conditions such as Crohn's disease, inflammatory bowel syndrome (IBD), celiac disease, ulcerative colitis, diverticulitis, gastritis, reflux esophagitis, and the like. These compounds potentially may be used to treat or prevent autoimmune or inflammatory diseases affecting the digestive system.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or modulate the activity of these genes which compounds that potentially may be used to modulate gastric reflux and diseases or conditions associated therewith such as gastroesophageal reflux disease, heartburn, Barrett's esophagus, and esophagitis.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or which modulate the activity of these genes and which compounds therefore potentially may be used to treat or prevent cancers or malignancies associated with the digestive system such as by way of example cancers of the salivary glands and taste buds, tongue, oral cavity, stomach, esophagus, small or large intestine, anus, pancreas, gall bladder, liver, colorectal, or colon.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays for identifying compounds that regulate ion transport or ion flux, particularly sodium ions in order to identify therapeutic compounds that may be e.g., used to modulate blood pressure and fluid retention and conditions and diseases involving aberrant sodium absorption, excretion and transport.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays for identifying compounds that regulate selective apoptosis of taste cells, modulation of transcription factors that control taste receptor expression, autocrine/paracrine modulation of taste cell development, taste bud lifetime, screens using genes that result in supertaster phenotypes, compounds that activate taste stem cells, compounds that affect trafficking of taste cell receptors e.g., from the apical membrane/taste pore region, compounds that affect taste intensity by modulating regulation of taste cell action via potential firing frequency/membrane potential, compounds that regulate neurotransmitter release to afferent nerves that control general or specific taste intensity, and autocrine/paracrine modulation of taste receptor function.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays for identifying compounds that affect regeneration of taste cells or taste buds, e.g., in diseased or geriatric individuals or after injury or surgery, subjects undergoing chemotherapy or after injury, compounds for modulating drug-induced dysgeusia, ageusia, taste bud loss, dry mouth or xerostomia as for example found in Sjogren's syndrome, compounds that are useful in maintaining oral hygiene, treating or preventing halitosis, noxious oral microbia such as viruses and bacteria, and the like.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in methods of isolating, purifying and marking desired taste cell types and taste cell lineages including e.g., umami, sweet, salty, bitter, fat, sour, metallic as well as taste stem cells and other immature and mature taste cell lineages including cells that differentiate into taste bud cells, taste cell neurons, taste immune cells et al. based on the expression or absence of expression of one or more of the taste specific genes provided herein. These isolation and purification methods include both positive and negative cell separation methods. For example, desired taste cell lineages or types may be isolated by positive cell selection methods e.g., by the use of fluorescence activated cell sorting (FACS), magnetic bead cell selection e.g., by visual identification of desired cells such as individual transfected cells by electrophysiology using antibody coated beads. Alternatively, desired taste cell lineages or types may be recovered or purified by negative cell purification and isolation methods wherein the desired cell types are enriched or purified from a mixed cell population by the removal of one or several undesired cell lineages e.g., by contacting a mixed cell suspension containing the desired taste cells and undesired cells e.g., derived from the tongue, oral cavity or gastrointestinal tract and associated organs with cytotoxic antibodies specific to a target gene or genes expressed on the undesired taste cell type(s) which are to be removed.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to in taste cell differentiation studies, e.g. for identifying compounds that induce the differentiation or dedifferentiation of taste cells e.g., adult or embryonic stem cells and other pluripotent or immature cell types into desired taste cell lineages and taste cell types.

In another embodiment the invention relates to, as described in detail infra, a rationale and criteria for a candidate salty taste gene, preferably an ion channel which are:

a) Specific expression in primate (macaque) taste cells, particularly fungiform and/or circumvallate papilla derived taste cells, but also foliate and palate taste cells, and not lingual epithelial cells OR expression at higher levels in taste cells than lingual cells

b) Expression in a taste cell by histological methods. Specifically, expression in a unique taste cell type that does not express the sweet, bitter, and umami cell marker TRPM5 or the sour cell marker PKD2L1/PKD1L3. This unique cell type could be a dedicated salt sensing cell.

c) Functional expression as a sodium channel or a sodium-activated receptor with basal, constitutive function (i.e. a fraction of the channel population is open and passing sodium at rest) in heterologous expression systems (such as Xenopus oocytes and mammalian cells) or primary neurons (such as dorsal root ganglia neurons).

Genes fulfilling these criteria will be advanced into high-throughput screening efforts to identify compounds that enhance human salt perception. In addition the taste-specific genes reported herein, e.g., in Tables 1, 2, and 3 supra will be useful in the therapeutic screening assays as afore-mentioned.

Therefore in this patent application we describe screening assays to identify genes putatively involved in salty taste perception as well as taste and other taste-cell mediated activities in general.

In another embodiment the invention relates to a specific rationale that identifies taste-specific genes encoding membrane proteins expressed specifically in taste cells and not lingual cells at higher levels in taste cells than lingual epithelial cells using gene chip and/or PCR methodologies and use same as salt receptor targets in assays to identify salty taste modulators as well as compounds that affect other taste modalities and taste perception and taste-cell related biological and cellular functions and taste cell related phenotypes in general.

In another embodiment the invention relates to a rationale that determines which taste-specific genes are expressed in taste cells and especially in sweet, bitter, and/or umami cells (TRPM5 positive), sour cells (PKD2L1/PKD1L3 positive) or a unique cell type (TRPM5 negative). These unique cell types will likely comprise cells dedicated to salty taste perception.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to identify modulators (enhancers) of taste-specific ion channels or taste-specific genes as these compounds may modulate human salty taste perception.

In another embodiment the invention relates to a rationale wherein the inventors describe and are able to assign herein gene expression patterns within the primate taste bud for all taste bud-specific genes. Specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud, this invention classifies genes into one of several functional classes that include taste receptor genes. A subset of genes in this classification is likely to encode taste receptors that include those for salty taste and other yet to be defined taste specificities. (The rational for comparing gene expression between the top and bottom of the primate taste bud arose from the histological localization of mRNAs for a number of candidate taste receptor genes. Expression of a subset of these genes appeared to be localized at the bottom portion of the taste bud while other genes were predominantly expressed at the top of the taste bud. These patterns of expression are exemplified by the TMEM44 and TRPM5 genes which are expressed at the bottom and top of the taste bud respectively.)

In another embodiment the invention relates to novel methods for functional characterization of taste bud specific genes based on certain expression criteria. The invention provides three sets of genes which are contained in the Appendices 1-3 to this application identified using this rationale. The first and second sets are genes that are expressed at a higher level in the top or bottom of the primate taste bud relative to the bottom or top respectively. Top-specific genes are listed in Appendix 1 and bottom specific genes are listed in Appendix 2. (Accordingly, these lists contain top enriched and bottom enriched mRNAs). The third set of genes was identified as expressed at a higher level in the top of the primate taste bud relative to surrounding lingual epithelium. This set of taste bud-specific genes was obtained by the identification of taste bud-specific genes by comparing gene expression between whole (top+bottom) taste bud and lingual epithelium LCM samples. These additional taste bud-specific genes are listed in Appendix 3.

In another embodiment the invention relates to the discovery that taste-associated genes and polypeptides are expressed predominantly at the top of the taste buds. In contrast to prior knowledge, our new data clearly indicate that known taste receptor genes are expressed at a higher level in the top fraction of taste buds. It is reasonable to expect other yet to be identified taste receptor genes to be represented in the top-enriched gene list.

In another embodiment the invention relates to the functional characterization of particular “target” taste bud specific genes based on where they are expressed in the taste bud cells. The inventors have discovered based on gene expression profiles of the top and bottom fractions of the taste bud suggest that there are distinct functions for cells in each compartment. Functional classes of genes expressed in the top cells indicate these are mature sensory cells whereas those expressed in the bottom cells indicate these are immature progenitor cells associated with a basement membrane containing cellular environment. Examples of top-specific functional classes include taste receptors, taste-specific signal transduction components and receptors. Examples of bottom-specific functional classes include extracellular matrix components, growth factors and cell cycle-associated proteins.

In another embodiment the invention relates to a comprehensive listing of taste specific genes in the Tables and Appendices of this application. By fractionating the taste bud into top and bottom compartments the inventors have increased the sensitivity of mRNA detection in each compartment by a factor of approximately two and has identified virtually all taste bud specific genes.

In another embodiment the invention relates to a method for identifying genes involved in different functions of the taste bud based on measuring their expression in the top versus bottom of the taste bud.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to genes identified using the above method where genes involved in taste sensation would be over-expressed in the top part of the taste bud.

In another embodiment the invention relates to the set of genes identified using the above method where genes involved in modulation of taste sensation would be over-expressed in the top part of the taste bud.

In another embodiment the invention relates to a set of genes identified using the above method where genes involves in taste bud growth and development are over-expressed in the bottom part of the taste bud.

In another embodiment the invention relates to the genes identified using the above methods where the genes are involved in control of the lifespan of mature taste bud cells are over-expressed in the top part of the taste bud.

In another embodiment the invention relates to the genes identified using the above methods where genes involved in the maintenance, differentiation and proliferation of taste-bud committed stem cells will be over-expressed at the bottom of the taste bud.

In another embodiment the invention relates to the genes identified using the methods, where the genes represent biomarkers of taste-bud committed stem cells will be over-expressed at the bottom of the taste bud.

In another embodiment the invention relates to the genes identified using the above methods where genes representing biomarkers of different mature taste cell subsets will be over-expressed in the top of the taste bud.

In another embodiment the invention provides a set of genes identified as described above and the use thereof in order to purify, enrich, isolate or label specific taste cell subsets.

In another embodiment the invention provides electrophysiological assays that measure conductance of putative taste ion channels identified herein in the presence and absence of putative enhancers.

In another embodiment the invention identifies enhancers of the subject putative salty taste related ion channels and other taste affecting genes in an oocyte expression system.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in patch clamping or two electrode voltage clamping assays using oocytes that express a putative salty taste receptor ion channel for identifying compounds that modulate the activity of this channel and therefore modulate salty taste. These and other objects of the present invention are met by one or more of the embodiments described below.

In another embodiment the invention relates to methods of isolating, purifying and marking desired taste cell types and taste cell lineages including e.g., umami, sweet, salty, bitter, fat, sour, metallic as well as taste stem cells and other immature and mature taste cell lineages including cells that differentiate into taste bud cells, taste cell neurons, taste immune cells et al. based on the expression or absence of expression of one or more of the taste specific genes provided herein. These isolation and purification methods include both positive and negative cell separation methods. For example desired taste cell lineages or types may be isolated by positive cell selection methods e.g., by the use of fluorescence activated cell sorting (FACS), magnetic bead cell selection e.g., by visual identification of desired cells such as individual transfected cells by electrophysiology using antibody coated beads. Alternatively, desired taste cell lineages or types may be recovered or purified by negative cell purification and isolation methods wherein the desired cell types are enriched or purified from a mixed cell population by the removal of one or several undesired cell lineages e.g., by contacting a mixed cell suspension containing the desired taste cells and undesired cells e.g., derived from the tongue, oral cavity or gastrointestinal tract and associated organs with cytotoxic antibodies specific to a target gene or genes expressed on the undesired taste cell type(s) which are to be removed.

In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to methods of using these genes and gene products as markers e.g., using probes specific thereto such as antibodies or oligonucleotides, i.e., that are specific to one or more of the subject taste specific genes provided herein in mapping regions of the tongue and oral cavity which are involved in specific taste and non-taste specific functions, mapping of cell comprised on specific regions of the gastrointestinal tract and associated organs such as the intestinal epithelium or urinary tract that express specific taste specific genes and which therefore are involved in one or more of the taste cell specific functions disclosed herein, and/or the use of the subject genes and markers specific thereto in taste cell differentiation studies, e.g. for identifying compounds that induce the differentiation or dedifferentiation of taste cells e.g., adult or embryonic stem cells and other pluripotent or immature cell types into desired taste cell lineages and taste cell types.

In another specific embodiment the present invention relates to assays using endogenous taste cells, e.g., gastrointestinal cells such as gastro-endocrine or gastro-epithelial cells or cells on the tongue or oral cavity, that screen for compounds which act as activators of TRPM5 or umami (T1R1/T1R3) and/or sweet (T1R2/T1R3) taste receptors, preferably those which modulate insulin metabolism and/or the release of a satiety peptide such as GLP-1 (glucagon-like peptide 1), which activators may be used in treating or preventing metabolic and eating disorders such as in the treatment of one of obesity, diabetes, weight management, fat metabolism, glucose metabolism, insulin metabolism, satiety or other conditions wherein the release of satiety peptides such as GLP-1 (glucagon-like peptide 1) is desirably controlled or reduced.

This invention in a more specific embodiment relates to specific taste specific genes identified infra, e.g., FAM26A, GPR113, MCTP1, TMEM16G, TMEM30B, TMEM44, and TUSC3 that are expressed in chemosensory or more specifically taste cells, e.g., human and primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates. and isolated taste cells expressing including cells wherein these genes are expressed as novel taste cells (do not correspond to prior taste modality) and that do not express TRPM5 or PKD2L1/PKD1L3.

Also, the invention in another embodiment relates to enriched, isolated or purified taste cell subsets which expresses at least one of FAM26A, MCTP1, TMEM30B, and/or TUSC3 and which further express at least one T1R or T2R or TRPM5 gene and/or which express T1R2/T1R3 or T1R1/T1R3 or T1R3 only. Particularly, the invention provides isolated taste cells that express GPR113 and/or TMEM16G and which isolated taste cells which further expresses at least one of T1R2/T1R3, T1R1/T1R3, T1R3 only, a T2R gene and/or TRPM5.

Also, the invention in another embodiment relates specifically to a method of using a probe specific to a gene or gene product corresponding to the genes to identify and/or isolate and or enrich taste specific cells from non-taste cells in a sample. For example, these methods include a method herein the gene is FAM26A, MCTP1, TMEM30B, and/or TUSC3 and the identified, isolated or enriched cell further expresses T1R1/T1R3, T1R2/T1R3, T1R3 only, a T2R, and/or TRPM5. Also, the invention includes methods wherein the gene is GPR113 and/or TMEM16G and the isolated, identified or enriched cell further expresses at least one of T1R2/T1R3, T1R1/T1R3, T1R3 only, a T2R or TRPM5 and/or wherein said taste cells are human or macaque taste cells. and wherein said isolated taste cells do not express PKD2L1, PKD1L3, or TRPM5 and/or wherein said cells do not express a T1R or a T2R and/or said taste cells express transducin or gustducin.

Also, the invention relates to the use of TUSC3, ASCL1, FAM26A, FAM26C, IKBKAP, LOC285965, SCNN1D, SLC4A11, SLC26A7, and TMEM30B as a biomarker of specific taste cells and the isolated cells which express same as all of these genes are expressed by unique taste cell subsets comprised in primate taste buds and therefore can be used as biomarkers to isolate, enrich, mark or ablate these cells and thereby determine the taste related function of these taste bud cells.

Also, the invention in another embodiment relates to the use of these identified taste specific genes or an ortholog or variant thereof encoding a protein at least 90% identical thereto in a cell isolation, purification, enrichment, or marking technique that isolates, purifies, enriches and/or marks at least one desired taste cell subtype or lineage contained in a mixed cell population or cell suspension comprising a desired taste cell type or lineage based on the expression or absence of expression of at least one gene contained in Tables 1-8 or an ortholog thereof, or a gene encoding a protein that is at least 90% identical to said gene or an ortholog thereof. Particularly, the invention includes methods wherein the taste cell subtype or taste cell lineage is isolated, purified, enriched, or marked by a method that includes the use of a fluorescence activated cell sorter (FACS) or by the use of labeled magnetic beads and wherein the cell suspension containing the cells may be produced by enzymatic digestion and/or tissue disaggregation of tissues containing taste cells. and methods wherein the desired taste cell subtype or taste cell lineage is isolated, purified, enriched or marked by a method that includes a negative cell selection technique that eliminates at least one non-target taste cell subtype or lineage based on the expression or absence of expression of at least one other taste cell specific gene identified herein. These methods may e.g., use cytotoxic antibodies to specifically kill at least one non-target cell type or lineage. These isolation methods may e.g., result in isolates containing sweet taste cells, umami taste cells, sour, salty, or fat taste cell subtype or lineages, taste stem cells taste cell neurons, or taste immune cells.

Also, the invention in another embodiment relates to methods of using a cell isolated, purified, enriched or marked according to these methods in screens for taste modulatory compounds, or in a method that screens for compounds that induce the differentiation of said enriched, isolated, purified or marked taste stem cells into one or more taste cell lineages or subtypes or taste buds or in a method wherein said taste cell lineages or subtypes are identified based on the expression or absence of expression of at least one the identified taste specific gene identified above. These cells may be used to screen for compounds that modulate at least one of sweet, umami, bitter, sour, fat, salty or metallic taste wherein the gene is GPR113 or TMEM16G or TMEM44 or to screen for compounds that modulate taste cell differentiation or turnover.

Also, the invention in another embodiment relates to these cells or the gene or gene product encoded thereby in assays that screen for compounds that modulate or treat the diseases and conditions involving taste cells previously identified. This in particular relates to GPR113 or the corresponding gene product or cells which express same or an ortholog or variant thereof in assays to identify compounds that modulate taste cell differentiation or taste cell turnover.

Also, the invention in another embodiment relates to isolated immature taste cells and/or taste stem cells that express TMEM44 or GPR113 and the use in an assay for identifying taste modulators, in particular which screens for sweet, umami, bitter, fat, salty, metallic and/or astringent taste modulators. Also, the invention relates to a recombinant cell engineered to co-express T1R3 and GPR113 and optionally TRPM5. Also, the invention embraces an assay for identifying compounds which modulate taste cell differentiation and/or maturation based on whether said compound specifically binds and/or modulates the activity of GPR113.

Also, the invention in another embodiment relates to the use of these cells in assays that screen for compounds that modulate the differentiation and/or maturation of sweet or umami taste cells. Also, the invention provides a method of using GPR113 as a marker to identify, enrich and/or isolate or ablate unique taste cells which express GPR113, TRPM5 and T1R3 wherein said taste cells do not express T1R1, T1R2 and/or a T2R or are immature, e.g., by FACS or magnetic bead cell separation or by use of cytotoxins.

In addition the invention in another embodiment relates to the discovery that TMEM44 and MFSD4 are expressed in unique taste cell type and that these gene are expressed in sensory taste cells that are not sweet, bitter, umami, or sour cells which further expresses another taste-specific gene disclosed herein. Also, the present invention relates to the discovery that expression of TMEM44 and MFSD4 are markers for a unique taste cell type that may correspond to a fat receptor. Further, the invention relates to the discovery that ATP8A1, FAM26B and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells.

This invention in a more specific embodiment identifies genes infra, e.g., FAM26A, GPR113, MCTP1, TMEM16G, TMEM30B, TMEM44, and TUSC3 that are expressed in chemosensory or more specifically taste cells, e.g., human or primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates. and isolated taste cells expressing including cells wherein these genes are expressed as novel taste cells (do not correspond to prior taste modality) and that do not express TRPM5 or PKD2L1/PKD1L3.

Also, the present invention in another embodiment relates to the discovery that MFSD4 is expressed in cells that do not express TRPM5 (bitter, sweet, umami) indicating that the expression of this gene is a marker for a unique taste cell type e.g., a salt, fat, or another taste modality, and, furthermore, that this gene may encode the primary salt or fat receptor.

Also, the invention in another embodiment reveals that the expression pattern of MFSD4 is very similar to TMEM44, indicating that both genes are expressed in the same taste cell type and may be comprised in a heteromeric taste receptor.

Also, the invention in another embodiment relates to the discovery that ATP8A1, FAM26B, and SLC4A11 can be used as markers for sweet, bitter, and umami taste cells or cells expressing TRPM5.

Also, the invention in another embodiment relates to the discovery that ATP8A1, FAM26B, and SLC4A11 and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to tastants including sweet, bitter, and umami.

Also, the present invention in another embodiment relates to the discovery that MFSD4 can be used as a marker for a unique, novel taste cell type that does not correspond to sweet, bitter, and umami taste cells. Moreover, the invention relates to the discovery that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, and umami, which include salt, fat, and other tastants. Based on the foregoing, the invention relates to the discovery that MFSD4 may correspond to the salt receptor or fat receptor. Also, MFSD4 may be a marker of immature taste cells or developing taste cells.

Related thereto, in another embodiment the present invention also relates to the discovery that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).

Also, the present invention in another embodiment relates to the discovery that MFSD4 and TMEM44 are expressed in the same unique taste cell type. Also, the present invention relates to the discovery that MFSD4 and TMEM44 may form a complex (heterodimer) to generate a taste receptor for a different taste than sweet, umami, sour or bitter, likely salt or fat. and may be used in screening assays.

Also, in another embodiment the present invention relates to the discovery that ATP8A1, FAM26B, and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells. and may regulate taste perception or other taste cell function. Moreover, the present invention reveals that ATP8A1, FAM26B, and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells.

In another embodiment the invention relates to the discovery that ASCL1 also known as MASH is a transcription factor that defines and is a useful marker of sour taste cells as it is selectively expressed in sour taste cells that express PKD1L3 but not in other taste cell types, i.e., it is not expressed in sweet, bitter, or umami cells which express TRPM5. Therefore, the ASCL1 transcription factor may bind to promoter elements in genes involved in sour taste perception. Thus, the invention provides the use thereof in screening the genome for ASCL1 motifs to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.

In another embodiment the invention establishes ASCL1 to be a marker of type III taste cells. Type III taste are defined by morphological criteria which include: staining with an intermediate density by electron microscopy and making synaptic contacts with nerve fibers. Thus, the invention reveals that type III taste cells, a cell type previously defined by morphological criteria, correspond to sour taste receptor cells defined by gene expression criteria.

In another embodiment the invention relates to the discovery that other taste receptor cells for sweet, bitter, umami, and salt are likely to express specific transcription factors related thereto that define those cell types. Therefore, the invention provides assays detecting the expression of all transcription factors in the genome in taste cells by PCR and/or histology to determine which taste cell types express which transcription factors.

In another embodiment the invention relaters to the discovery that the ASCL1 transcription factor binds to promoter elements in genes involved in sour taste perception. Thus, the invention encompasses such sequences found in the genome that comprise ASCL1 motifs and the use thereof to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.

In another embodiment the invention relates to the discovery that ASCL1 (aka MASH1) is a marker useful for identifying, purifying, and/or isolating or ablating sour taste cells in a mixed cell sample, e.g., derived from the tongue or gastrointestinal or urinary tract.

In a related embodiment the invention provides the use of ASCL1 as a marker of Type III taste cells that correspond to sour taste receptor cells

In another embodiment the invention establishes that because ASCL1 defines the sour taste cell lineage it may also control sour taste cell development.

In another embodiment the invention provides the use of ASCL1 transcription factor DNA binding sequences as a probe to identify sour cell genes and sour taste receptor genes that possess related structure such as ASCL1 motifs.

Also, in another embodiment the invention provides the use of these and other taste cell specific transcription factors to define, mark, and/or label taste cell types because each taste cell will express one or more transcription factors that define that taste modality.

The invention further provides in another embodiment the use of these transcription factors that define taste modalities in cell ablation studies to specifically eliminate a specific taste cell or taste modality.

Also, in another embodiment the invention provides ASCL1 or other taste transcriptional gene knockouts which result in transgenic animals possessing altered taste perception and other phenotypic effects, e.g., elimination of sour taste perception or altered urinary or digestive function since ASCL1 may be involved in the metabolic response to pH changes such as excess acidity.

Also, t in another embodiment the invention provides the use of these transcription factors that define new taste cell types which can be used in cell ablation studies and in vitro assays to determine what taste modality is lacking as a result of this ablation (i.e. what taste modality is eliminated).

In another embodiment this invention identifies taste-specific genes NALCN, TRPML3 and NKAIN3 which when expressed separately or in combination are predicted to comprise a taste receptor, putatively a salty taste receptor, as these 3 genes are expressed in primate taste cells, are enriched in the top fraction of taste bud cells, and are known to encode sodium channels. In addition the invention relates to the discovery that NALCN is expressed in a unique taste cell subset and is predicted to encode a taste related function. (As noted, TRPML3 has been shown to encode a salty taste receptor).

In a related embodiment the present invention relates to the use of these taste specific ion channel genes as markers which can be used to enrich, identify or isolate salt receptor expressing cells.

In another embodiment the invention relates to assays that identify compounds that modulate the function of the use of NALCN, TRPML3 and/or NKAIN3 and the use of the identified compounds to modulate salty taste perception.

In another embodiment the invention relates to other taste specific genes, i.e., KIT, IKBKAP, LOC285965, and SV2B that are expressed in specific subsets of taste specific cells.

In another embodiment, this invention relates to the discovery that KIT is specifically expressed in TRPM5 and T1R3 taste cells and T1R1 taste cells indicating that the gene can be used as a marker to identify umami taste cells in a mixed cell population and/or may modulate the expression and activity of the umami taste receptor.

In another embodiment, this invention relates to the discovery that IKBKAP and SV2B are specifically expressed in PKD1L3 sour taste receptor cells indicating that these genes can be used as markers to identify sour taste cells and/or modulate taste, especially sour taste.

Also, in another embodiment this invention relates to the discovery that LOC285965 is specifically expressed in TRPM5 and T1R3 taste cell subsets and T1R3 cells lacking T1R1 and T1R2 suggesting that this gene can be used as a marker of these taste cell subsets and/or may associate with or modulate the T1R3 gene and/or encode a taste receptor distant from T1R1/T1R3 or T1R2/T1R3.

Further, in another embodiment the invention relates to the discovery that SV2B is specifically expressed in PKD1L3 cells indicating that this gene can be used as a marker of these specific cell subsets and/or may encode a polypeptide that modulates the activity or expression of the PKD1L3 sour taste receptor.

In addition, in another embodiment the invention relates to the discovery that MFSD4 is expressed in sensory taste cells that are not sweet, bitter, umami, or sour cells and that this gene is expressed in a similar taste cell population as TMEM44.

In another embodiment, the invention relates to the use of compounds that enhance or inhibit IKBKAP and SV2B gene products to selectively modulate taste cell function and responses to sour tastants as well as other functions of the PKD1L3 taste cell population.

In another embodiment, since IKBKAP is mutated in the human disease familial dysautonomia, where taste buds are absent or atrophic and individuals exhibit deficiencies in detection of sweet, bitter, sour, and salty tastants (hypogeusia) the invention relates to the discovery that IKBKAP expression in PKD1L3 cells may be important for taste cell development and/or maintenance.

In another embodiment since Botulinum neurotoxin (BoTox) enters neuronal-type cells by interacting with SV2B; the invention in another embodiment relates to the use of BoTox and derivatives to selectively modulate sour taste as well as other functions of the PKD1L3 taste cell population.

In another embodiment since KIT is expressed in umami taste cells the invention relates to the use thereof as a marker of this taste cell type.

In another embodiment the invention relates to the use of KIT and compounds that enhance or inhibit this gene product to selectively modulate taste cell function and responses to umami tastants.

In another embodiment the invention relates to the use of Gleevec (Imatinib), an inhibitor of the KIT tyrosine kinase activity, and other KIT tyrosine kinase inhibitors for selectively inhibiting umami taste.

In another embodiment the invention relates to the discovery that individuals with gain of function mutations in KIT, for example in gastrointestinal stromal tumors (GIST), may have altered umami taste perception.

In another embodiment since LOC285965 is expressed in T1R3 only taste cells similar to GPR113 the invention relates to the use as a marker for a unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells.

In another embodiment the invention relates to the discovery that LOC285965 may correspond to the salt receptor or fat receptor or a receptor for astringency or metallic taste by itself or in combination with GPR113, which is also expressed in T1R3 only cells.

Also, the invention relates to the discovery that TUSC3, ASCL1, FAM26A, FAM26C, IKBKAP, LOC285965, SCNN1D, SLC4A11, SLC26A7, and TMEM30B may be used as biomarkers of specific taste cells and the isolated cells which express same as all of these genes are expressed by unique taste cell subsets comprised in primate taste buds and therefore can be used as biomarkers to isolate, enrich, mark or ablate these cells and thereby determine the taste related function of these taste bud cells.

In another embodiment the invention relates to the discovery that LOC285965 may be a coreceptor with T1R3 for specific sweet or umami tastants or other novel tastants such as astringent and metallic tastants.

In another aspect the invention relates to the discovery that compounds that enhance or inhibit LOC285965 can selectively modulate taste function and responses to tastants.

In another embodiment the invention relates to the discovery that LOC285965 may correspond to a marker of immature taste cells that are differentiating into sweet or umami cells.

In another embodiment the invention relates to the discovery that LOC285965 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. sweet or umami taste cells).

Moreover, in a related embodiment this invention identifies a novel set of genes, i.e., FAM26A, GPR113, MCTP1, TMEM16G, TMEM30B, TMEM44, TUSC3, ATP8A1, FAM26B, SLC4A11, ASCL1 and MFSD4 and the afore-mentioned genes that are expressed in chemosensory or more specifically taste cells, e.g., primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates. In some embodiments these genes are expressed in novel taste cells that do not express TRPM5 or PKD2L1/PKD1L3. These genes are referred to herein as “taste-specific” genes because they are strongly expressed in taste cells, preferably a previously unidentified taste cell type that may be involved in fat or salty taste perception. These taste-specific genes include genes which are directly or indirectly involved in taste detection and modulation, e.g., salty, umami, sweet, sour, fatty, metallic, or bitter taste transduction as well as including genes which are involved in biological functions not directly related to taste detection such as the modulation of digestion, taste cell turnover, regulation of the immune system, particularly of the oral cavity, and the regulation of metabolism e.g., carbohydrate metabolism, diabetes, obesity, cachexia, detection of food during digestion, et al.

In another embodiment the invention relates to the discovery that taste cells in the bottom half of the taste bud are immature.

In another embodiment the invention reveals that taste cells in the top half of the taste bud are mature and express genes for sweet, bitter, umami, and sour taste receptors.

In another embodiment the invention reveals SHH to be a marker of immature and developing taste cells at the bottom of the taste bud.

In another embodiment the invention reveals TMEM44 and MFSD4 to be markers of immature and developing taste cells at the bottom of the taste bud.

In another embodiment the invention reveals a subpopulation of TMEM44 cells may be mature salty taste cells.

In another embodiment the invention suggests that a salt receptor will be expressed in the top taste bud cells, since all other known taste receptors are expressed in the top taste bud cells.

In a related embodiment the invention suggests that a salty taste cell will be present in the top half of the taste bud since all other known professional, mature taste cells are expressed in the top of the taste bud.

In a specific embodiment this invention reveals TMEM44 cells, which comprise about 40% of the taste bud cell population and are located towards the bottom of the taste bud, and have identified that other genes are expressed by these cells or in the bottom of the taste bud including MFSD4 and Sonic Hedgehog (SHH) (a cytokine involved in immature cell differentiation). Based thereon, this invention predicts that cells expressing TMEM44 represent an immature taste cell population that includes stem cells that replenish the taste bud cells every 2-3 weeks in the human and while immature, they may comprise a subset of mature cells that may be responsible for salt sensation.

Also in a specific embodiment this invention reveals that GPR113 cells which represent about 10% of the taste bud cell population, are distinct from sweet, bitter, and umami taste cells, are located in the top of the taste bud, and express T1R3 and TRPM5 but not the G protein alpha subunit gustducin (GNAT3), suggesting that these cells represent a novel taste cell population that detects a novel taste modality such as fat.

Also in a specific embodiment this invention reveals the existence of another cell subset which express TRPM5 and T1R3 and which include sweet cells (which also express TIR2) as well as umami cells (which also express T1R1).

Also in a specific embodiment this invention reveals that bitter (T2R expressing taste cells) express TRPM5 but not T1R3.

Also in a specific embodiment this invention reveals that sweet, bitter, and umami cells express GNAT3 indicating that this gene can be used as a marker of these types of taste cells.

Also in a specific embodiment this invention reveals that PKD2L1 and PKD1L3 cells: (which cells have been previously described to be responsible for sour taste sensation) comprise about 10% of the taste bud cell population located in the top of the taste bud, and are heterogeneous, i.e. there are distinct PKD2L1 and PKD1L3 ‘single positive’ cell populations in addition to a PKD2L1 and PKD1L3 ‘double positive’ cell population suggesting that one of these subsets may represent a salt sensing cell.

Also in a specific embodiment this invention reveals the existence of another subset of taste cells (˜8% of the taste bud cell population) that does not express any of the following markers: TMEM44, TRPM5, PKD2L1 or PKD1L3 which in addition or alternatively may represent a salt sensing cells.

More specifically, in a specific embodiment this invention provides a TMEM44 cell ablated non-human animal, e.g., a rodent.

Also, in a specific embodiment the invention provides taste cell suspensions consisting essentially of TMEM44 expressing taste cells.

Also, in a specific embodiment this invention provides a method of using the TMEM44 taste cell ablated animal (rodent) or the TMEM cell suspension for identifying the function of TMEM expressing cells in a taste modality, preferably salt or fat.

Also, in a specific embodiment the invention provides a GPR113 taste cell ablated animal, e.g., a rodent.

Also in a specific embodiment the invention provides taste cell suspensions consisting essentially of GPR113 expressing taste cells.

Also in a specific embodiment the invention provides a method of using the GPR113 taste cell ablated rodent or the GPR113 cell suspension for identifying the function of GPR113 expressing cells in a taste modality, preferably salt or fat.

Also, in a specific embodiment, the invention provides for PKD2L1 and/or PKD1L3 taste cell ablated animals, e.g., rodents.

Also, in a specific embodiment, the invention provides for taste cell suspensions consisting essentially of PKD2L1 and/or PKD1L3 expressing cells.

Also in a specific embodiment the invention reveals that the cells in the bottom half of taste buds are immature whereas taste cells in the top half of the taste bud are mature and express taste receptor genes. Cells in the bottom half of the taste bud express the gene sonic hedgehog (SHH), which is a marker of developing cells. TMEM44 taste cells are localized in the bottom half of the taste bud and the expression pattern of TMEM44 is similar to that of SHH. Thus, TMEM44 cells (which also express MFSD4) are immature and comprise, in part, developing taste cells. Supporting this finding, a small fraction of taste cells expressing TMEM44 also express either TRPM5 (a marker of mature sweet, bitter, and umami cells) or PKD1L3 (a marker of mature sour cells). Cells expressing both TMEM44 and TRPM5 (or PKD1L3) are, therefore, maturing into professional taste cells. By contrast, cells in the top half of the taste bud are mature taste cells, do not express SHH, and express taste receptor genes for the sweet, bitter, umami, and sour taste receptors. Since all mature, professional taste cells and taste receptors are localized to the top half of the taste bud, the salty taste cell and the salty taste receptor should also be present in the top half of the taste bud. Therefore, the invention demonstrates that taste cells in the bottom half of the taste bud are immature.

Also in a specific embodiment the invention demonstrates that taste cells in the top half of the taste bud are mature and express genes for sweet, bitter, umami, and sour taste receptors.

Also in a specific embodiment the invention demonstrates TMEM44 and MFSD4 are markers of immature and developing taste cells at the bottom of the taste bud.

Also the invention reveals a subpopulation of TMEM44 cells may comprise a mature salty taste cell.

SUMMARY OF THE INVENTION

This invention relates in general to novel and improved rationales for identifying (systematically and comprehensively) sets of primate genes which should encompass virtually all primate and human taste specific genes. Thereby, the invention provides a library of genes which will contain all primate and human taste receptors as well as taste specific genes involved in ancillary functions such as those relating to digestion, excretion and sodium ion related functions. These genes and gene products and cells expressing same are useful in screening assays for identifying taste modulators and therapeutics. A further advantage of the invention is that the invention provides methods for categorizing these genes into specific categories which should correlate to function thereby facilitating the number of genes to be functionalized by methods also provided in this application. More specifically, the invention has identified a subgenus of human and primate genes which will contain all taste receptors and taste modulators including those not yet identified. For example, this subgenus contained the salty taste receptor and in all likelihood other taste receptors involved in fat, metallic, CO2, astringent and the like.

Therefore, this invention in its more broad embodiments identifies genes that are expressed in chemosensory, e.g., human and non-human primate (macaque) fungiform and/or circumvallate papilla taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates (“taste specific”). These genes include genes which are directly or indirectly involved in taste detection and taste modulation, e.g., salty, umami, sweet, sour, fatty, metallic, or bitter taste transduction as well as functions not directly related to taste detection and taste modulation such as genes that are involved in the modulation of digestion and the production and composition of digestive fluids, mucous, enzymes and hormones such as saliva, stomach and intestinal fluids, GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotrophic polypeptide), secretin, pepsin, and the like; genes that are involved in regulation of blood pressure and fluid retention, genes that are involved in taste receptor trafficking, taste cell turnover and taste cell regeneration, genes that are involved in the regulation of the immune system of the oral cavity and gastrointestinal system, genes that are involved in the prevention or onset of gastrointestinal related diseases such as cancers, inflammatory and autoimmune diseases affecting the oral cavity and digestive system, genes that are involved in the regulation of metabolism e.g., carbohydrate metabolism, obesity, eating disorders, genes that are involved in the detection of food during digestion, et al.

Relating to the foregoing the present invention provides genes that are expressed in human and non-human primate (macaque) chemosensory, e.g., primate (macaque) circumvallate and/or fungiform papilla taste cells that are not expressed or are expressed at significantly lower levels in lingual epithelial cells that are useful in screening assays, preferably high throughput screening assays, for identifying compounds that directly or indirectly modulate different taste modalities, e.g., salty, sweet, umami, bitter, sour, fatty, or metallic.

Further relating to the foregoing the present invention provides genes that are useful in screening assays, preferably high throughput screening assays for identifying compounds that are useful as therapeutics in the treatment of digestive system disorders, for modulating taste cell apoptosis or taste cell turnover, for inducing taste cell regeneration, for effecting the regulation of immunity in the oral cavity or digestive system, and the treatment of diabetes, obesity, eating disorders, and other metabolic disorders.

Also relating to the foregoing the invention provides a novel set of genes which are useful in the identification and/or isolation and/or enrichment of specific types or lineages of taste or chemosensory cells, e.g., taste or chemosensory cells that are involved in specific taste modalities, immune system regulation in the oral cavity, taste cell apoptosis or taste cell turnover, taste cell regeneration, digestive system regulation, and the regulation of metabolism such as by aiding in food detection, the secretion of hormones or enzymes involved in hunger and digestion, and the like.

Further, the invention relates to the use of the isolated chemosensory or taste cells in screening assays for identifying compounds that modulate taste, as well as in the identification of therapeutics for modulating the immune system regulation of the oral cavity, taste cell apoptosis turnover, taste cell regeneration, regulation of hormones or enzymes or fluids and mucous involved in digestion and other taste cell functions, treatment of digestive system disorders, treatment of diabetes, obesity, eating disorders, or other metabolic disorders, and the like.

This invention more specifically relates to novel rationale, methods, and assays including electrophysiological assays that identify and characterize novel taste-specific genes, including those that function as salty taste receptors.

It was hypothesized by the inventors (in part based on properties of known taste receptors) that human salty taste may be mediated, in part, by a sodium or other ion channels as well as transporters and GPCRs expressed specifically in taste-cells. Based on this assumption and other criteria provided infra, the invention provides methods for identifying taste-specific genes, including genes that may regulate salty taste, as well as other taste modalities taste cell mediated functions and phenotypes using gene chip and PCR methodologies. The compounds identified and their derivatives that modulate the activity of these target genes potentially can be used as modulators of human salty taste in foods, beverages and medicinals for human consumption. Also, such compounds and their derivatives potentially may be used to treat diseases involving abet-rant ion channel function. Further the compounds identified using the genes identified herein and cells which express same are useful in therapeutic screening assays as discussed herein for identifying potential therapeutics that modulate other taste-cell related functions and phenotypes.

In one mode this invention identifies genes expressed in primate taste cells and use of these genes for screening for taste modulators and for identifying and isolating specific taste cell lineages and subtypes. These genes are identified based on their selective expression in primate fungiform papilla taste cells found at the front of the tongue and circumvallate papilla taste cells found at the back of the tongue using gene-chips microarrays from taste receptor cells as compared to non-taste lingual epithelial cells isolated by laser capture microdissection (LCM). Since salt perception is most prevalent at the front of the tongue, a salt receptor gene is likely contained within this set of identified genes.

In another mode, this invention provides a method for identifying a gene encoding a polypeptide involved in taste, preferably salty taste in a mammal. One embodiment of this method comprises the steps of (i) identifying a set of genes including genes which are expressed in macaque taste (fungiform and circumvallate papilla taste cells) but which are not expressed in lingual epithelial cells and/or genes which are expressed in taste cells at substantially higher levels than in lingual cells; (ii) identifying a subset of genes within the set of genes identified in (i) which are selected based on criteria which suggest that they are likely salt receptor candidates, i.e., putative ion channels and/or encode multidomain transmembrane proteins. These genes are then examined to determine whether these genes are expressed or not expressed in taste cells which express umami, sweet or bitter taste receptors (T1Rs or T2Rs) or sour taste receptors (PKD2L1/PKD1L3); and (iii) functionally expressing one or more genes in the subset identified according to (ii) and determining which of these genes function as a sodium responsive ion channel or sodium responsive receptor or transporter and thereby identifying this gene or genes as a putative gene that modulates salty taste. Typically, the taste tissues for this method are derived from human, primate, or rodent sources. In one preferred embodiment of the method, the genes in step (iii) function as sodium responsive ion channels, and more preferably, when the genes are expressed, a fraction of the channel population is open and passing sodium at rest.

In a preferred embodiment, step (i) comprises the use of laser capture microdissection (LCM) to dissect and purify taste tissues from non-taste tissues. In one mode of this embodiment, step (i) comprises RNA amplification of genes from taste cells and lingual cells and the amplified genes are screened against a gene chip containing a sample of genes specific to the particular mammal from which the taste and lingual tissues are obtained, and preferably, the gene chips include a set of annotated human genes. In an alternative mode of this embodiment, step (i) comprises high throughput PCR using primers for each ion channel in a mammalian genome.

In another preferred embodiment, step (ii) is effected by in situ hybridization using antisense RNA probes specific for the set of genes identified in step (i) to determine level of expression in taste versus lingual cells. In an alternative preferred embodiment, step (ii) is effected by use of immunochemical detection using a labeled antibody specific to the protein encoded by gene or genes identified in step (i).

In another embodiment of the method for identifying a gene encoding a polypeptide involved in salty taste perception in a mammal, the method of this invention comprises the steps of (i) identifying a set of macaque genes including genes which are expressed in taste cells but which are not expressed in lingual cells and/or genes which are expressed in taste cells at substantially higher levels than in macaque lingual cells; (ii) identifying a subset of genes within the set of genes identified in (i) which are not expressed in taste cells which express umami, sweet or bitter taste receptors (T1Rs or T2Rs) or sour taste receptors (PKD2L1/PKD1L3); and (iii) determining, in a primary neuron which expresses one or more genes in the subset identified according to (ii), which of said genes functions as a sodium responsive ion channel or sodium responsive receptor or transporter and thereby identifying this gene or genes as a putative gene that modulates salty taste. In one mode of this embodiment, step (iii) comprises contacting the neuron with an antibody which specifically binds the gene and inhibits its function.

Genes identified according to either of the methods described above may be characteristic of cells which do not express TRPM5 and PKD2L1/PKD1L3. In another mode, this invention provides a method to assist in selecting cells which do not express TRPM5 and PKD2L1/PKD1L3 by determining whether a cell expresses a gene identified according to the methods above. Preferably, the gene used in the method of this paragraph is one of the genes listed in Tables 1-3, listing taste-specific genes encoding transmembrane proteins in taste cells. Efforts were focused on transmembrane genes since all known taste receptor genes for sweet, bitter, umami, and sour taste encode transmembrane proteins.

In another aspect this application provides an improvement of the afore-described methods in which genes expressed in primate taste buds are identified and functionalized using the disclosed methods. The inventors have developed a rationale wherein they are able to assign gene expression patterns within the primate taste bud for all taste bud-specific genes. Specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud, the inventors have found that they are able to classify genes into one of several functional classes that include taste receptor genes. A subset of genes in this classification is likely to encode taste receptors that include those for salty taste and other yet to be defined taste specificities.

The rationale for comparing gene expression between the top and bottom of the primate taste bud arose from the histological localization of mRNAs for a number of candidate taste receptor genes. Expression of a subset of these genes appeared to be localized at the bottom portion of the taste bud while other genes were predominantly expressed at the top of the taste bud. These patterns of expression are exemplified by the TMEM44 and TRPM5 genes which are expressed at the bottom and top of the taste bud respectively, see FIG. 38.

In order to get more information on gene expression in both the top and bottom fractions of the taste bud the inventors isolate the corresponding fractions of primate taste buds using laser capture microdissection (LCM). This technique is described supra and briefly involves excision of specific groups of cells from tissue sections based on morphological distinctions. In the case of taste buds, the inventors are able to readily identify these structures in sections of primate tongue. As exemplified in the supporting experimental example infra, tissue collection was limited to taste buds in circumvallate papillae and then to only taste buds that were sectioned sagittally and at the taste pore. The inventors reasoned that only this type of section would reliably isolate top and bottom fractions. An example of sections used in sample collection is shown in FIG. 39.

The gene expression data obtained was queried to obtain three sets of genes. The first and second sets are genes that are expressed at a higher level in the top or bottom of the primate taste bud relative to the bottom or top respectively. Top-specific genes are listed in Appendix 1 and bottom specific genes are listed in Appendix 2. Accordingly, these lists contain top enriched and bottom enriched mRNAs. The third set of genes was identified as expressed at a higher level in the top of the primate taste bud relative to surrounding lingual epithelium. This set of taste bud-specific genes applications describing the identification of taste bud-specific genes by comparing gene expression between whole (top+bottom) taste bud and lingual epithelium LCM samples. These additional taste bud-specific genes are listed in Appendix 3.

This methodology achieves various advantages and makes certain discoveries including the following:

First, the inventors have found that taste receptor genes are expressed predominantly at the top of the taste bud. In contrast to prior knowledge, the data obtained using these methods clearly indicate that known taste receptor genes are expressed at a higher level in the top fraction of taste buds. It is reasonable to expect yet to be identified taste receptor genes are represented in the genes which are enriched at the top of the taste bud.

Second, the inventive top-versus-bottom gene classification methods allow for the functional classification of genes based on their expression in the cells in the top versus the bottom of the taste bud. Gene expression profiles at the top and bottom fractions of the taste bud suggest distinct functions for cell in each compartment. Functional classes of genes expressed in the top cells indicate that these are mature sensory cells whereas those expressed in the bottom cells indicate that these are immature progenitor cells associated with a basement membrane containing cellular environment. Examples of top-specific functional clauses include taste receptors, taste-specific signal transduction components and receptors. Examples of bottom-specific functional classes include matrix components, growth factors, and cell-cycle-associated proteins.

Third, this methodology allows for the identification of additional taste bud-specific genes. It has been found that by fractionating the taste bud into top and bottom compartments that the inventors have increased the sensitivity of mRNA detection in each compartment by a factor of about 2. This facilitates the identification of other taste specific genes not identified by the prior-described methods. These genes are contained in the Appendices to this patent application.

Therefore, these methods can be used to identify genes involved in different functions of the taste bud based on measuring their expression in the top versus bottom of the taste bud, e.g., where genes over-expressed in the top part of the taste bud. are predicted to be involved in one or more taste sensation, modulation of taste sensation, control of the lifespan of mature taste bud cells or they may be used as biomarkers of different mature taste cell subsets.

By contrast using the inventive rationale genes over-expressed at the bottom of the taste bud are predicted e.g., to be involved in one or more of the maintenance, differentiation and proliferation of taste-bud committed stem cells; or they will represent biomarkers of taste-bud committed stem cells.

In addition, genes expressed specifically in the top or bottom can be using to purify these functionally distinct taste bud cell subsets.

Also, in another aspect this invention describes rationales which are useful and have successfully identified human genes which are taste specific and which are predicted to be involved in one or more of the afore-described taste bud related functions. Specifically, these methods identify human taste specific genes by quantitative polymerase chain reaction (PCR). This also is an improvement of the afore-described methods for identifying taste specific genes, i.e., taste genes expressed in primate taste buds. and more optimally the previous described methods wherein the inventors assign gene expression patterns within the primate taste bud for all taste bud-specific genes; specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud. and thereby are e able to classify genes into one of several functional classes that include taste receptor genes.

By contrast, the third method demonstrates taste specific gene expression in humans (in addition to primate) and validates the specificity of expression by a quantitative method (qPCR or “TaqMan”). These methods have been used to identify genes contained in the Table 8 infra which all encode multi-span transmembrane proteins, and are predicted to include yet unidentified receptors and other genes involved in taste modulation including the fat and salt receptor and other taste receptors whose function has yet to be defined.

The previous methods which identify primate taste specific genes are useful as primates and humans are closely evolutionary related it is likely that gene expression pattern will also be closely related. Based on this reasonable assumption, taste specific genes identified by these methods (See Tables 1-4) were selected by the subject improved method to be validated in human taste buds using a technology distinct from microarray analysis—TaqMan qPCR.

As disclosed infra, these methods require a source of human taste buds. Human taste buds can be isolated by laser capture microdissection (LCM). This technique has been described supra and involves the excision and isolation of selected cells or groups of cells from tissue sections based on morphological distinctions. In the case of taste buds, these structures can be readily identified in sections of human tongue. In an exemplary embodiment (example 46 infra) tissue collection was limited to taste buds (TB) in circumvallate papillae and, as a control, cells from the adjacent lingual epithelium (LE). FIG. 47 which shows an example of sections used in sample collection, described in more detail in example 46). Essentially, multiple LCM preparations from different human donors are pooled (˜4500 cells per sample), RNA extracted and amplified (e.g., by WT-Ovation Pico RNA Amplification System) (NuGEN Technologies, Inc) and analyzed using TaqMan technology to determine specific levels of gene expression in the TB and LE pools.

Thereafter, the expression of the taste-specific genes is quantified by TaqMan in LCM derived cDNA from both LE and TB from the same donors. Exemplary results using this methodology are contained in Table 8 infra. More specifically, gene expression is measured in TaqMan as a CT (cycle threshold) value. Briefly the CT value for a given sample is determined by the PCR cycle at which the amount of gene-specific PCR product (as measured by fluorescence) reaches a set value. For highly expressed genes, the threshold will be reached early in the PCR run and the CT value will be relatively low (<35) while genes with very low or no expression will not reach the threshold before cycle 35. Expression of genes with CT values >40 are defined as not detectable.

As can be seen from the data in Table 8, for the majority of genes which were identified as being human taste specific genes when assayed using this methodology, expression was not detected in LE samples (CT>40) but was readily detectable in TB samples (CT<35). This is significant outcome as this group of human taste specific genes has not been described before as taste-specific in human tissue.

In contrast to the afore described gene chip and microarray methods, this technique provides yet additional benefits. and discoveries including the following:

Firstly, these methods allow for human taste specific genes to be detected in human LCM cDNA which were not previously known to be taste specific. Particularly, this approach that uses LCM from post-mortem human tissue samples and a single cDNA amplification step, the data obtained to date clearly indicate that postmortem LCM human tissue can be used to quantify the expression of taste specific genes using qPCR.

Secondly, this methodology allows for the expression of human taste specific genes to be reliably and accurately measured by quantitative PCR (TaqMan) providing for the gene expression profiles of taste specific genes as measured by TaqMan. This methodology further validated gene expression data obtained from the previously described methods which used microarrays and/or in situ hybridization (ISH).

Thirdly, these methods have shown to indeed identify human taste bud specific genes which are functional. Particularly, by using the successive approaches of gene expression via microarray in primate LCM tongue tissue; Top-specific gene expression within the taste bud (akin to known taste receptors) and now TaqMan quantification of gene expression in human postmortem tastes tissues, the inventors we identified new human taste specific genes that had not been described previously. (Table 8)

Therefore, these methods allow for identification of human taste specific genes in postmortem tissues, and the identifying of human genes involved in different functions of the taste bud based on measuring their expression by quantitative PCR.

It is anticipated that these human taste specific genes, based on the manner that they were identified, expressed, and categorized are involved in one or more of (i) taste sensation, modulation of taste sensation, regulation of taste bud growth and development, control of the lifespan of mature taste bud cells, and/or are involved in the maintenance, differentiation and proliferation of taste-bud committed stem cells. In addition, genes identified using these methods are biomarkers of taste-bud committed stem cells. or represent biomarkers of different mature taste cell subsets. Therefore, these genes and gene products can be used as a basis in methods which enrich or purify these cell subsets.

In addition, as well as its more generic embodiments this invention further describes certain information and characterization of taste specific genes identified by the rationales described in detail infra. These discoveries are enumerated as follows:

Particularly, the invention describes with respect to the genes infra which are expressed in primate and human taste cell subsets and also describe specific uses of these genes, cells and gene products in taste biology. These genes which are selectively expressed in primate fungiform papilla taste cells at the front of the tongue and circumvallate papilla taste cells at the back of the tongue were identified were identified using the afore-described gene chips/microarray methods by comparing expression in taste receptor cells compared to non-taste lingual epithelial cells isolated by laser capture micro-dissection (LCM). Since salty taste perception is most prevalent at the front of the tongue, taste receptor genes including the salty taste and other taste receptor should be present within this gene set. The genes in Table 6 are expressed in different subsets of primate taste cells and were identified by gene chip analysis and shown to be expressed in subsets of taste cells by in situ hybridization analysis.

The results obtained contained in the examples reveal that FAM26A, MCTP1, TMEM30B, and TUSC3 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells. Also, the results show that GPR113 and TMEM16G are expressed in a subset of TRPM5 cells, suggesting that these genes could be selectively expressed in sweet, umami, or bitter taste cells (or a combination thereof).

Also, these results show that TMEM44 is expressed in cells that do not express TRPM5 (bitter, sweet, umami) or PKD1L3 (sour), indicating that the expression of this gene is a marker for a unique taste cell type that could correspond to salt, fat, or another taste modality, and, furthermore, that this gene may encode the primary salt or fat receptor.

Based on the foregoing, the application teaches that FAM26A, MCTP1, TMEM30B, and TUSC3 can be used as markers for sweet, bitter, and umami taste cells or cells expressing TRPM5. In addition, FAM26A, MCTP1, TMEM30B, and TUSC3 and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to tastants including sweet, bitter, and umami.

In addition, these results indicate that GPR113 and TMEM16G can be used as a marker for sweet, bitter, or umami taste cells or subsets of TRPM5 cells. Also, the results indicate that GPR113 and TMEM16G and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to tastants including sweet, bitter, or umami.

Still further and based thereon this application teaches the use of these that TMEM44 can be used as a marker for a unique, novel taste cell type that does not correspond to sweet, bitter, and umami taste cells and that TMEM44 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, and umami, which include salt, fat, and other tastants.

Still further and based thereon this application teaches the use of these that TMEM44 may correspond to a salt receptor or fat receptor, or a marker of immature taste cells or stem cells. Also, TMEM44 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).

Still further and based thereon this application teaches the use of these gene products and compounds that enhance or inhibit gene products can affect: selective apoptosis of taste cells responding to aversive taste modalities such as bitter and sour cells; modulation of transcription factors that control taste receptor expression; modulation of specific bitter receptor expression to minimize off-tastes of vegetables, children's medicine, and coffee; autocrine/paracrine modulation of taste cell development; prolongation of taste bud lifetime; development of supertasters (rodent model systems) to screen for chemical and biological toxins (terrorism), rancid/spoiled/contaminated food and beverage products; and activation of stem cells to differentiate into defined taste cell types.

Still further this application teaches the use of these gene products as ancillary taste receptors or primary taste receptors including receptors for salt, fat, and other taste modalities including metallic.

Still further this application teaches the use of these gene products and compounds that enhance or inhibit gene products, can modulate the function of any cell expressing a taste receptor, including but not limited to cells in the gastrointestinal tract such as enteroendocrine cells that regulate gastric motility and peptide secretion (e.g. GLP-1: glucagon-like peptide 1; GIP: gastric inhibitory peptide) as well as the other therapeutic applications of taste specific genes and modulators afore-mentioned. These applications include trafficking of taste receptors to and from the apical membrane/taste pore region to enhance or repress general or specific tastes; regulation of taste cell action potential firing frequency/membrane potential to control the intensity of general or specific tastes; regulation of neurotransmitter release to afferent nerve to control the intensity of general or specific tastes; and autocrine/paracrine modulation of taste receptor function; regeneration of taste cells as well as prophylaxis/prevention of taste cell loss following injury, chemotherapy for cancer, radiation therapy for cancer, drug-induced dysgeusia, ageusia, and taste bud loss in the geriatric population; oral hygiene, halitosis, detoxification of noxious substances in oral cavity, and neutralization/elimination of bacteria, viruses, and other immunogens in the saliva/mouth; saliva composition and treatment of dry mouth in conditions of xerostomia and autoimmune disease (Sjogren's syndrome).

Also, this application teaches using double label in situ hybridization histology what specific TRPM5 cell type that GPR113 is expressed in. As disclosed infra in the examples and supporting figure we identify that GPR113 is not expressed in T1R1 umami cells, T1R2 sweet cells, or T2R bitter cells. GPR113 is expressed in a subset of T1R3 cells that do not express T1R1 or T1R2. Thus, GPR113 cells define a new taste cell type of T1R3 only cells.

Therefore, this application teaches the use of GPR113 as a marker for this unique taste cell type that because it is in a unique cell population, is a GPCR (many taste receptors are known to be GPCRs) likely corresponds to a specific taste modality or modulates a specific taste modality such as CO2 sensation, salt, fat, metallic or astringent. Also, GPR113 may associate with T1R3 to form a novel taste receptor for sweet, umami, or other tastants.

Further based on the foregoing, this application teaches the use of GPR113 as a marker to identify and isolate this unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells. and used to identify taste modulators and the aforementioned therapeutic applications of compounds modulating taste specific genes.

Also, the inseminators further identified using the same rationales (gene chip, in situ hybridization analysis) that the genes KIT, IKBKAP, LOC285965, and SV2B are taste specific taste cells and are expressed in the specific primate taste cell subsets (see Table 7 infra). In addition, we show infra that another gene, MFDS4, is expressed in sensory taste cells that are not sweet, umami, bitter or sour cells, suggesting that this gene is expressed in a similar taste cell subset as TMEM44.

Also, in Table 4 the application provides a listing of other primate taste-specific genes also identified by the same rationales. This listing of genes include genes encoding transmembrane proteins such as ion channels (sodium), GPCRs, ion transporters, as well as multi-transmembrane proteins with no function yet assigned. These genes and gene products are also useful in the same therapeutic and taste modulatory screening assays.

Based on the foregoing observations and the information in Table 7, the invention further teaches that since IKBKAP and SV2B are expressed in many PKD1L3 cells, that these genes are likely expressed in sour taste cells, since PKD1L3 is a marker of sour taste cells.

Also, based on the finding that KIT is expressed in cells that express the umami taste receptor component T1R1, the application teaches that KIT is likely expressed in cells responsible for umami taste perception.

Also, based on the finding (as determined by in situ hybridization of primate taste bud cells) that all of TUSC3, ASCL1, FAM26A, FAM26C, IKBKAP, LOC285965, SCNN1D, SLC4A11, SLC26A7, and TMEM30B are expressed by specific taste cell subsets that these genes may be used as biomarkers and that the genes and gene products may be used isolate, mark or ablate these cells and thereby determine the taste related function of these taste bud cells. Based on this same finding the invention further relates to these isolated cells and assays using these cells and genes to identify taste modulators.

Also, based on the finding that LOC285965 is expressed in cells that express TRPM5 and T1R3 but not in cells that express the umami taste receptor component T1R1, or the sweet taste receptor component T1R2; the application teaches that LOC285965 is expressed in the ‘T1R3 only’ population of taste cells (similar to GPR113).

Also, based on the experimental findings that IKBKAP and SV2B are expressed in PKD1L3 sour taste cells the application teaches that they can be used as markers of this taste cell population.

Also, based on these same experimental findings, the application further teaches that that IKBKAP and SV2B and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to sour tastants as well as other functions of the PKD1L3 taste cell population.

Also, based on these same findings and the fact that IKBKAP is mutated in the human disease familial dysautonomia, where taste buds are absent or atrophic and individuals exhibit deficiencies in detection of sweet, bitter, sour, and salty tastants (hypogeusia), this application teaches that IKBKAP expression in PKD1L3 cells may be important for taste cell development and/or maintenance.

Also, based on these same findings and the fact that Botulinum neurotoxin (BoTox) enters neuronal-type cells by interacting with SV2B; the application also teaches that BoTox may selectively modulate sour taste as well as other functions of the PKD1L3 taste cell population.

Also, based on the findings that KIT is expressed in umami taste cells, this application teaches its use as a marker of this taste cell type.

Also, based on these same findings, the application teaches that KIT and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to umami tastants.

Also, based on these findings and the fact that Gleevec (Imatinib), is an inhibitor of the KIT tyrosine kinase activity, this application teaches that this and other KIT tyrosine kinase inhibitors may selectively inhibit umami taste. Also, these findings suggest that individuals with gain of function mutations in KIT, for example in gastrointestinal stromal tumors (GIST), may have altered umami taste perception.

Also, based on the findings that LOC285965 is expressed in T1R3 only taste cells similar to GPR113, this application teaches that this gene can be used as a marker for a unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells.

Also, based on these findings, the application also teaches that LOC285965 may correspond to the salt receptor or fat receptor or a receptor for astringency or metallic taste by itself or in combination with GPR113.

Also, based on these findings the application teaches that LOC285965 may be a coreceptor with T1R3 for specific sweet or umami tastants or other novel tastants such as astringent and metallic tastants.

Still further, based on these findings the application teaches that compounds that enhance or inhibit LOC285965 can selectively modulate taste function and responses to tastants.

Also, based on these findings the application teaches that LOC285965 may correspond to a marker of immature taste cells that are differentiating into sweet or umami cells.

Also, based on these findings the application teaches that LOC285965 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. sweet or umami taste cells).

Also, based on experimental findings the application teaches suggest that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, umami, and sour which include salt, fat, and other tastants.

Also, based on experimental findings this application teaches that MFSD4 may correspond to the salt receptor or fat receptor. or may be used as a marker of immature taste cells or developing taste cells or support cells. Still further, these findings suggest that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).

Also, based on experimental findings that reveal that MFSD4 and TMEM44 are expressed in the same taste cell population the application teaches that this cell may respond to specific tastants and also that MFSD4 and TMEM44 may form a complex (heterodimer) to generate a taste receptor (such as fat, CO2, salt, metallic, or other taste modality).

Also, we describe experimental findings have demonstrated (see results infra in the examples) that the ASCL1 (aka MASH1) transcription factor defines sour taste cells. ASCL1 is expressed in sour taste cells expressing the sour taste receptor gene PKD1L3; ASCL1 is not expressed in sweet, bitter, and umami taste cells expressing TRPM5. ASCL1 was previously reported to be a marker of type III taste cells. Type III taste are defined by morphological criteria which include: staining with an intermediate density by electron microscopy and making synaptic contacts with nerve fibers. Thus, these results demonstrate that type III taste cells, a cell type previously defined by morphological criteria, correspond to sour taste receptor cells defined by gene expression criteria.

This application describes that an application of this finding is that the ASCL1 transcription factor may bind to promoter elements in genes involved in sour taste perception. Thus, the genome could be screened for ASCL1 motifs to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.

Analogously, other taste receptor cells for sweet, bitter, umami, and salt are likely to express specific transcription factors that define those cell types. Therefore, this application teaches that the expression of all transcription factors in the genome can be analyzed in taste cells by PCR and/or histology to determine which taste cell types express which transcription factors.

The application further describes various other practical applications of these discoveries. For example, the ASCL1 (aka MASH1) can be used as a marker of sour taste cells and further identify and allow for the isolation of Type III taste cells which correspond to sour taste receptor cells.

Moreover, it has been determined that ASCL1 defines the sour taste cell lineage and may control sour taste cell development. Therefore, the invention teaches that ASCL1 transcription factor DNA binding sequences can be used to identify sour cell genes and sour taste receptor genes. Also, such transcription factors can be used to define, mark, and/or label taste cell types. With respect thereto, each taste cell will express one or more transcription factors that define that taste modality.

Also, the application teaches the use of the identified transcription factors that define taste modalities such as ASCL1 in cell ablation studies to specifically eliminate a specific taste. Moreover, the application teaches the use of transcription factors that define new taste cell types in cell studies to determine what taste modality is lacking (i.e. what taste can an animal no longer perceive).

Also, as described and supported by data infra, the invention has determined that taste cells expressing the PKD2L1 and PKD1L3 genes, previously implicated in sour taste are heterogeneous and comprise multiple cell populations. In the front of the tongue, in fungiform (FG) papilla there are cells expressing PKD2L1 only, PKD1L3 only, and both PKD2L1 plus PKD1L3. In the back of the tongue, in circumvallate papilla (CV), most cells coexpress PKD2L1 plus PKD1L3, but in addition to this population there is a distinct group of taste cells that express PKD1L3 only and a smaller set of cells that express PKD2L1 only. Previous literature has suggested that cells expressing PKD2L1 (encompassing PKD2L1 and cells coexpressing PKD2L1 plus PKD1L3) responded to sour taste (Huang et al, Nature 2006 Aug. 24; 442(7105):934-8. However, PKD1L3 cells were not previously known and no function has yet been ascribed. Based thereon, the application teaches the use of PKD1L3 cells as candidate basic or salty taste responding cells and that PKD1L3 is involved in a different taste modality, e.g., basic taste perception since the related sour receptor, PKD2L1, responds to acidic taste.

In addition the invention provides experimental findings that the FAM26C gene is expressed in TRPM5 cells (see results infra) and teaches its use as a marker of sweet bitter and umami cells.

Also, based on the experimental findings herein the application teaches that PKD1L3 only taste cells are candidate taste cells, e.g., which modulate basic taste sensation or other taste modalities, and that PKD1L3 is a candidate taste receptor, e.g., basic taste sensation. Also, the application teaches that PKD1L3 may complex with one of the gene products identified herein to form a taste receptor.

Also, based on the experimental findings that FAM26C is expressed in TRPM5 cells, including sweet, bitter, and umami taste cells, the application describes its use as a marker of this taste cell population and FAM26C and use of compounds that enhance or inhibit FAM26C to selectively modulate taste cell function and responses to sweet, bitter, and umami tastants as well as other functions of the TRPM5 taste cell population, including functions of the GPR113 expressing taste cells that are candidate salty taste cells and that coexpress T1R3.

Also, This application provides data shown infra, indicating that taste cells in the bottom of the taste buds are immature whereas cells in the top half are mature and express taste receptor genes. Cells in the bottom half of the taste bud express the gene sonic hedgehog (SHH), which is a marker of developing cells. TMEM44 taste cells are localized in the bottom half of the taste bud and the expression pattern of TMEM44 is similar to SHH. Therefore, this application teaches that TMEM44 cells, (which also express MFSD4) are immature and comprise, in part, developing taste cells. Further supportive of this finding, a small fraction of taste cells expressing TMEM44 also express either TRPM5 (a marker of mature sweet, bitter and umami cells) or PKD1L3 (a marker of mature sour cells). Cells expressing both TMEM44 and TRPM5 (or PKD1L3) are Therefore maturing into professional taste cells. By contrast, cells in the top half of the taste bud are mature taste cells, do not express SHH, and express taste receptor genes for the sweet, bitter, umami, and sour taste receptors. Since all mature, professional taste cells and taste receptors are localized to the top half of the taste bud, the salty taste cell and the salty taste receptor should be found in the top half of the taste bud as well.

Also, this application teaches methods for identifying and assaying the expression of taste specific genes and identifying specific taste receptors and taste cell subsets which have shown that the taste cells in the bottom half of the taste bud are immature, that the taste cells in the top half of the taste bud are mature and express genes for sweet, bitter, umami, and sour taste receptors, that SHH is a marker of immature and developing taste cells at the bottom of the taste bud. and that TMEM44 and MFSD4 are markers of immature and developing taste cells at the bottom of the taste bud.

The application predicts based on these results that a subpopulation of TMEM44 cells may be mature salty taste cells. and that a salt receptor and a salty taste cell will be expressed or comprised in the top taste bud cells, since all other known taste receptors are expressed in the top taste bud cells. This is a reasonable assumption based on the results obtained by the inventors herein, especially since all other known professional, mature taste cells are expressed in the top of the taste bud.

Also, based on experimental findings herein, and further relating to the foregoing, the inventors have gleaned the following information relating to several subsets of taste bud cells we have identified discussed above, including:

With respect to TMEM44 cells, they have found that these cells comprise about 40% of the taste bud cell population and are located towards the bottom of the taste bud. Also, we have identified other genes expressed by these cells or in the bottom of the taste bud including MFSD4 and Sonic Hedgehog (SHH). The latter is a cytokine involved in immature cell differentiation. For this reason, they predict that TMEM44 represents an immature taste cell population that includes stem cells that replenish the taste bud cells every 2-3 weeks in the human. While these cells are immature, they may still contain a subset of mature cells that may be responsible for taste such as salt sensation.

Also, with respect to GPR113 cells, they have discovered that these cells represent about 10° A of the taste bud cell population, and are distinct from sweet, bitter, and umami taste cells, and are located in the top of the taste bud. They express T1R3 and TRPM5 but not the G protein alpha subunit gustudin (GNAT3), suggesting that they represent a novel taste cell population that detects a new taste modality such as fat. Other cells that express TRPM5 and T1R3 include sweet cells (also express TIR2) as well as umami cells (also express T1R1). Bitter cells (also express T2Rs) express TRPM5 but not T1R3. In contrast to GPR113 cells, sweet, bitter, and umami cells all express GNAT3.

Also, with respect to PKD2L1 and PKD1L3 cells, reportedly responsible for sour taste sensation, they are found to constitute about 10% of the taste bud cell population and are located in the top of the taste bud. As discussed below, we have observed that these cells are heterogeneous and that there are distinct PKD2L1 and PKD1L3 ‘single positive’ cell populations in addition to a PKD2L1 and PKD1L3 ‘double positive’ cell population. This heterogeneity suggests that one of these subsets could represent a salt sensing cell.

Also, the experimental findings herein suggest that there is another subset of taste cells (˜8% of the taste bud cell population) that does not express any of the following markers: TMEM44, TRPM5, PKD2L1 or PKD1L3, which may represent another taste e.g., CO2 or salt sensing cells. As disclosed a primary focus of this invention was the elucidation of the salty taste receptor. These results were successful as TRPML3 gene has been shown to be a salty taste receptor.

The invention further exploits the elucidation of these unique taste cell populations as part of its strategies for identifying salty and other types of taste sensing cells such as fat, metallic, astringent, CO2, et al.

The application provides different methods. For example, one way to identify the salt cell or other taste cell modality population is to use cell ablation. This technique employs diphtheria toxin under the control of a promoter of a gene expressed in one of the taste cell subsets described above to selectively eliminate this taste cell population, while leaving all other taste cell populations intact. Cell ablation has been used successfully in other laboratories to selectively eliminate sweet (T1R2) and sour (PKD2L1) taste cell populations (work of Charles Zuker). Therefore, ablation of the afore-identified taste cell subsets described above and then use nerve recoding and licking/behavior tests will enable evaluating whether the resulting mice still sense a particular type of tastant, e.g., salt, sour, basic, metallic et al. Based thereon, the inventors have made various predictions which will be confirmed or ruled out by the subject functional assays enumerated below:

(1) Assuming that TMEM44 ablated mice do not sense salt but still sense sweet, bitter, umami, and sour, this result would point this population, or a subset of cells within this population, as the salt sensing cell. Alternatively, the resulting mice may lack taste buds and the ability to detect all 5 taste qualities because TMEM44 is expressed in immature cells or may elicit no effect.

(2) Assuming that GPR113 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour, this result would point to GPR113 expressing cells as the salt sensing cells. (As noted TRPML3 cells have been shown to sense salt, therefore this outcome is not probable. More likely, another taste modality would be affected.)

(3) Assuming that PKD2L1 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour, this result would point to PKD2L1 expressing cells as the salt sensing cells. (Again, as TRPML3 cells have been shown to sense salt, this outcome is not probable. More likely, another taste modality would potentially be affected.)

(4) Assuming that PKD1L3 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour. This result would point to PKD1L3 expressing cells as the salt sensing cells. (Again, as TRPML3 cells have been shown to sense salt, this outcome is not probable. More likely, another taste modality would potentially be affected.)

(5) If none of these mice are deficient in salt perception, this suggests that the putative population of taste cells (8%) that do not express any of the aforementioned markers could be the salt sensing cell, or that all or multiple mature taste cell populations are capable of sensing salt.

Another means taught herein in order to identify the salt sensing cell involves generating a single cell suspension from taste buds and then performing single cell analyses with electrophysiology (patch clamping) or calcium imaging coupled with single cell PCR to identify which population(s) responds to sodium.

With respect to the foregoing assays, there are two main models to account for salt sensation in taste buds:

The first model is the labeled line model. In this model, a single cell type is responsible for sensing a given taste quality. This is true for sweet, bitter, umami and sour. In this model, there is a dedicated cell type responsible for salt sensation. As discussed above, and in the related utility application filed on even date, the inventors have narrowed down the list of candidate salt sensing cells and described techniques that have identified TRPML3 as a salt receptor and that TRPML3 expressing cells sense salty taste.

The second model is the across fibre model where there is not a single cell type responsible for salt sensation. Instead, all or multiple cell types sense salt. In this model, a cell surface molecule, such as a receptor or ion channel, expressed in all or multiple mature taste cells would constitute the salt sensor.

The way to distinguish between these two models is to perform cell ablation experiments such as are described above. Ablation experiments in Varitint mice depleted of TRPML3 taste cells indicate that these mice are deficient in their ability to taste salt. These results suggest TRPML3 expressing cells as being responsible for salty taste.

In yet another related aspect of the invention, the inventors teach three primate taste specific genes, TRPML3, NKAIN3 and NALCN, expressed in primate taste cells that were identified as taste specific genes by gene chip analysis, and shown to function as sodium channels in the literature. These genes were identified as being enriched in the top fraction of taste buds along with all other known taste receptor genes. Therefore, these genes were identified as probable candidates for encoding a salty taste receptor. As described in detail, and substantiated by extensive functional data in a related patent application filed on even date as this application, one of these genes, TRPML3 has been shown in functional assays and transgenic animals to be necessary for salty taste perception and to correspond to a salty taste receptor. These ion channel genes, are expressed as follows in the top versus the bottom of taste buds and in taste versus lingual epithelium tissues: NALCN, (aka VGCNL1), top vs. bottom ratio of 7.2, and TB vs. LE ratio of 11.2; TRPML3 (aka MCOLN3) top vs. bottom ratio of 1.6, and TB vs. LE ratio of 10.2; and NKAIN3 (aka FAM77D) which has a top vs. bottom ratio of 1.5, and TB vs. LE ratio of 3.3.

As reported in Cell. 2007 Apr. 20; 129(2):371-83, the neuronal channel NALCN contributes resting sodium permeability and is required for normal respiratory rhythm. Also, Lu et al. describe that NALCN as a sodium leak channel. Further, with respect to TRPML3, J. Biol. Chem. 2007 Oct. 25; [Epub ahead of print] teach that a gain-of-function mutation in TRPML3 causes the mouse varitint-waddler phenotype. Also, Kim et al., describes TRPML3 as a channel permeable to sodium after exposure of the channel to no/low sodium (as in saliva), consistent with a salt receptor. Also, with respect to the NKAIN 3 gene, in Gorokhova et al., Human Mol. Genet. 2007 Oct. 15; 16(20):3394-410. Epub 2007 Jul. 2, this gene is reported as a member of a novel family of transmembrane proteins interacting with {beta} subunits of the Na,K-ATPase. Also, Gorokhova et al., describes a Drosophila homologue of NKAIN3 as an amiloride-insensitive sodium channel, consistent with a salt receptor. Again, the TRPML3 gene and its functional properties and that it encodes a salty taste receptor and its therapeutic applications are discussed extensively in the utility and PCT patent applications filed on the same date as this application, incorporated by reference in their entireties herein

Based on these observations and the experimental data therein and in this application, it was predicted and later confirmed that these 3 genes would include an ion channel that is involved in salty taste (TRPML3) Also, based thereon, this application teaches that NALCN, and NKAIN3 may constitute other salty taste receptors expressed in taste bud cells or may modulate the function of TRPML3 and/or may associate with TRPML3 to produce a functional taste receptor. Based on the foregoing, the application teaches the use of NALCN, and NKAIN3 as markers to identify salty taste receptor cells.

In addition, the application provides additional information in the examples concerning the NALCN taste-specific gene. Particularly, as described in the examples infra, the inventors demonstrated that NALCN is a taste-specific gene by end-point PCR using purified taste buds and lingual epithelial cells isolated by laser capture microdissection. They also found that NALCN is expressed in a novel, unique taste cell type distinct from sweet, bitter, umami, and sour taste cells by immunohistochemistry with a NALCN antibody.

Therefore, since NALCN is a taste-specific gene, is expressed in a novel taste cell type, and has been reported to function as a sodium-channel, the application teaches that NALCN is a candidate salty taste receptor and/or a marker of the salty taste cell population. Since NALCN and TRPML3 are both expressed in novel taste cell types, the application teaches that NALCN and TRPML3 may be co expressed in the same taste cell population. Accordingly, NALCN and TRPML3 may function together in a complex; or NALCN may function independently of TRPML3 as another salty taste receptor. For example, the application teaches that NALCN may function downstream of TRPML3 akin to how TRPM5 functions downstream of sweet, bitter, and umami receptors. In this manner, NALCN would be involved in the signal transduction pathway for salty taste but not constitute the primary salty taste sensory receptor.

This can be determined in mice. Rodents have 3 distinct taste cell types:

Type III cells correspond to sour cells (PKD2L1 positive, SNAP-25 positive);

Type II cells correspond to sweet, bitter, and umami cells (TRPM5-positive, IP3R3 positive); and

Type I cells have no defined function.

As shown in the examples infra, the inventors have demonstrated that NALCN is not expressed in IP3R3 cells (Type II) or SNAP-25 cells (Type III) in rodent. Thus, NALCN expression is implicated in Type I cells, and Type I cells are candidate salty taste cells.

However, alternatively, the application teaches that Type I cells may correspond to immature taste cells and if so, would likely be coexpressed with TMEM44/MFSD4 in an immature taste cell population.

Based on the foregoing discoveries, the invention further teaches NALCN as an additional salty (or other taste such as metallic or fat) taste receptor candidate gene or accessory molecule and based thereon the use thereof as a marker to identify these taste cells.

In addition, since NALCN is a sodium ion channel, and is expressed in the top half of taste buds in cells that have an indeterminate taste function, the application teaches that NALCN may control the resting membrane potential and excitability of the taste cells it is expressed in. Related thereto, compounds that enhance or inhibit function of the NALCN channel may regulate the excitability of salty taste cells, i.e., TRPML3 cells.

Based on this modulatory property, the application teaches that compounds that enhance or inhibit function of the NALCN channel may increase and decrease salt perception respectively, e.g., alone or in combination with TRPML3.

In addition, this application teaches that NALCN may associate with TRPML3 to form a salty taste receptor. (Again, as shown in the related applications filed on even date the ablation of TRPML3 expressing taste cells in Varitint mice results in inhibition of salty taste perception in these rodents and in vitro electrophysiological assays using this ion channel have confirmed that it is a functional sodium channels and may be used to identify TRPML3 blockers and enhancers which should modulate salty taste).

Moreover, based on the experimental findings the application teaches that NALCN can be used as a marker of type I taste cells, which likely include salty taste cells. Alternatively, as type I taste cells may function as precursor cells for sweet, bitter, umami and sour taste cells, modulation of NALCN function may control taste cell differentiation and development into mature taste cell types.

In addition, because the application teaches that TMEM44 and MFSD4 are markers of immature taste cells, the application also teaches that NALCN may be expressed in the subset of immature taste cells expressing TMEM44/MFSD4.

Further, because type I taste cells may also function as glial (support) cells, the application teaches that modulation of NALCN function may indirectly control the activity of sweet, bitter, umami, and sour cells and, as a result, sweet, bitter, umami, and sour taste.

Also, the application teaches based on the experimental findings that compounds that enhance or inhibit function of NALCN may increase and decrease salt perception respectively.

In yet another aspect, this invention describes an assay for identifying a compound having potential in vivo application for modulating human salty taste. This method comprises the steps of (i) contacting a cell that expresses a gene encoding an ion channel, receptor or transporter identified as a putative salty taste affecting gene according to any one of the methods above, or a gene encoding a polypeptide possessing at least 90% sequence identity to the polypeptide encoded thereby, with at least one putative enhancer compound; (ii) assaying sodium conductance, receptor activity or sodium transport in the presence and absence of said putative enhancer; and (iii) identifying the compound as a potential salty taste enhancer based on whether it increases sodium conductance, the activity of said receptor or sodium transport. In various embodiments, the gene encodes an ion channel or the gene encodes a GPCR. Preferably, the gene is a human gene. More preferably, the method further includes testing the effect of the compound or a derivative thereof in a human taste test. Preferably, the selected compound promotes sodium ion transport into taste bud cells. The putative salty taste affecting gene may be expressed in an amphibian oocyte, or in a mammalian cell, preferably a Xenopus oocyte or a mammalian cell selected from the group consisting of a HEK293, HEK293T, Swiss3T3, CHO, BHK, NIH3T3, monkey L cell, African green monkey kidney cell, Ltk-cell and COS cell. Preferably, the putative salty taste affecting gene is expressed under the control of a regulatable promoter. The putative salty taste affecting gene may be expressed stably or transiently. In a preferred mode, the putative salty taste affecting gene is selected from tables 1-8.

In a preferred mode, the assay of step (ii) is an electrophysiological assay which uses a sodium sensitive dye, and preferred dyes include membrane potential dyes selected from the group consisting of Molecular Devices Membrane Potential Kit (Cat#R8034), Di-4-ANEPPS (pyridinium, 4-(2-(6-(dibutylamino)-2-naphthalen-yl)ethenyl)-1-(3-sulfopropyl)hydroxide, inner salt, DiSBACC4(2) (bis-(1,2-dibabituric acid)-triethine oxanol), Cc-2-DMPE (Pacific Blue 1,2-dietradecanoyl-sn-glycerol-3phosphoethanolamine, triethylammonium salt) and SBFI-AM (1,3-benzenedicarboxylic acid, 4,4-[1,4,10-trioxa-7,13-diazacyclopentadecane-7,13-diylbis(5-methoxy-6,1,2-benzofurandiyl)}bis-tetrakis{(acetyloxy)methyl}ester (Molecular Probes), more preferably, the sodium sensitive dye is sodium green tetraacetate (Molecular Probes) or Na-sensitive Dye Kit (Molecular Devices). In another preferred mode, the assay of step (ii) is a two electrode voltage clamping assay in Xenopus oocytes, or the assay is a patch clamp assay in mammalian cells. Preferably, the assay measures activity by an ion flux assay, including using atomic absorption spectroscopy to detect ion flux.

Alternatively, the assay may use a fluorescence plate reader (FLIPR), or a voltage imaging plate reader (VIPR), which is used to increase ion channel-dependent sodium or fluid absorption. In a preferred embodiment of this method, the activity of the putative salty taste affecting gene is assayed in a frog oocyte electrophysiologically by patch clamping or two electrode voltage clamping, preferably using an automatic imaging instrument, which may be a fluorescence plate reader (FLIPR) or a voltage imaging plate reader (VIPR).

In yet another mode, this invention describes an assay for identifying a compound having potential in vivo application for modulating human sweet, bitter, umami, or sour taste. This method comprises the steps of (i) contacting a cell that expresses a gene in Tables 1-8 with at least one putative enhancer or blocker compound; (ii) assaying sodium conductance, receptor activity or taste gene product function in the presence and absence of said putative enhancer or blocker; and (iii) identifying the compound as a potential enhancer or blocker for sweet, bitter or umami taste based on whether it modulates sodium conductance, the activity of said receptor or taste gene product function.

In yet another mode, this invention describes an assay for identifying a compound having potential in vivo application for as a potential therapeutic. This method comprises the steps of (i) contacting a cell that expresses a gene in Tables 1-3 with at least one putative enhancer or blocker compound; (ii) assaying sodium conductance, receptor activity or taste gene product function in the presence and absence of said putative enhancer or blocker; and (iii) identifying the compound as a potential therapeutic that may be used to modulate a taste cell related function or phenotype that does not directly involve taste such a digestive disorder or disease, taste cell or taste bud turnover or regeneration, immune regulation of the oral or digestive system, or treatment of a metabolic disorder such as diabetes, obesity, eating disorder et al., based on whether it modulates sodium conductance, the activity of said receptor or taste gene product function.

In yet another mode the present invention describes using the genes identified herein as markers to identify and/or purify specific taste cells including sweet, bitter, umami, sour, and other cells including stem cells. These methods include positive and negative cell isolation and selection methods and selection and are based on the expression or absence of expression of one or several of the genes contained in Tables 1-3, or an allelic variant or ortholog or gene that hybridizes thereto under stringent hybridization conditions and/or a gene encoding a polypeptide that is at least 80% identical to the polypeptides or orthologs thereof encoded by the genes contained in Table 1-3, moiré preferably at least 90% identical and still more preferably at least 95% identical. In one embodiment, antibodies directed against the proteins encoded by these genes produced by methods well known to those skilled in the art can be used to label cells in a suspension of taste bud cells produced by enzymatic digestion and tissue disaggregation (Herness, M. An exemplary dissociation procedure for mammalian taste buds. is reported in Neuroscience Letters. 106: 60-64, 1989). The separation can be achieved by using a fluorescence activated cell sorter (See e.g., Beavis, A. J. and K. J. Pennline. Biotechniques. 21: 498-503, 1996) or by magnetic beads (See e.g., Jurman, M. E., L. M. Boland, Y. Liu, and G. Yellen. Visual identification of individual transfected cells for electrophysiology using antibody coated beads. Biotechniques. 17: 876-881, 1994). Alternatively, cells belonging to a specific subset can also be purified by negative selection methods, e.g., by eliminating taste bud cells representing other subsets using cytotoxic antibodies against their specific markers produced using methods well known to those skilled in the art) from a cell suspension of taste bud cells.

DESCRIPTION OF THE FIGURES

FIG. 1 contains an example of laser capture microdissection (LCM) on primate fungiform (FG) taste tissue (top row) and lingual epithelium (LE) non-taste tissue (bottom row) Top row: Left image shows FG tissue before LCM with a single FG taste bud. Middle image shows FG tissue after LCM where single FG taste bud has been removed. Right image shows collected and isolated FG taste bud used for molecular biology experiments to discover taste-specific genes. Bottom row: Left image shows tissue before LCM with LE from anterior tongue surface. Middle image shows tissue after LCM where a region of LE has been removed. Right image shows collected and isolated LE region used for molecular biology experiments to discover taste-specific genes.

FIG. 2 contains an example of PCR quality control of primate taste and lingual cells collected by LCM. Taste bud cells (TB), but not lingual epithelial cells (LE), specifically express the known taste-specific genes T1R2 (a component of the sweet receptor), PLCbeta2 (an enzyme involved in sweet, bitter, and umami taste detection), and GNAT3 (i.e. gustducin, a G-protein alpha subunit involved in sweet, bitter, and umami taste detection). By contrast, both taste and lingual cells express the ubiquitous housekeeping genes GAPDH and beta-actin, indicating that taste and lingual cell RNA is intact and of high quality. ‘+’ indicates reverse transcription and ‘−’ indicates no reverse transcription was performed.

FIG. 3 contains an example of double labeling in situ hybridization illustrating expression of TRPM5 and PKD1L3 in different taste cells in primate circumvallate (CV) taste tissue. TRPM5 (top; green) is not detectable in cells expressing PKD1L3 (middle; red). Overlay of TRPM5 and PKD1L3 signals is depicted in the bottom image. Note that TRPM5 and PKD1L3 signals are present in different taste cells. TRPM5 is expressed in cells responsible for sweet, bitter, and umami taste, whereas PKD1L3 is expressed in cells responsible for sour taste.

FIG. 4 contains an example of double labeling in situ hybridization illustrating coexpression of PKD2L1 and PKD1L3 in the same taste cells in primate circumvallate (CV) taste tissue. PKD2L1 (top; green) is coexpressed in cells expressing PKD1L3 (middle; red). Overlay of PKD2L1 and PKD1L3 signals is depicted in the bottom image in yellow. Note that both PKD2L1 and PKD1L3 signals are present in the same taste cells. Both PKD2L1 and PKD1L3 are expressed in cells responsible for sour taste.

FIG. 5 contains an example of double labeling in situ hybridization illustrating expression of TRPM5 and PKD1L3 in different taste cells in primate fungiform (FG) taste tissue. TRPM5 (left; purple stain) is not detectable in cells expressing PKD1L3 (middle; red). Overlay of TRPM5 and PKD1L3 signals is depicted in the left image. Note that TRPM5 and PKD1L3 signals are present in different taste cells. TRPM5 is expressed in cells responsible for sweet, bitter, and umami taste, whereas PKD1L3 is expressed in cells responsible for sour taste tissue.

FIG. 6 contains an example of double labeling in situ hybridization illustrating coexpression of PKD2L1 and PKD1L3 in the same taste cells in primate fungiform (FG) taste tissue. PKD2L1 (left; purple stain) is coexpressed in cells expressing PKD1L3 (middle; red). Overlay of PKD2L1 and PKD1L3 signals is depicted in the right image. Note that both PKD2L1 and PKD1L3 signals are present in the same taste cells. Both PKD2L1 and PKD1L3 are expressed in cells responsible for sour taste.

FIG. 7 contains an example of a double labeling hybridization experiment using primate circumvallate papilla. The results in FIG. 7 reveal that FAM26A (purple color; left image) colocalizes with TRPM5 (red; middle image). The results contained in the figure also show that FAM26A cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).

FIG. 8 contains another double label in situ hybridization experiment. This hybridization experiment which again used primate circumvallate papilla revealed that the taste cell specific gene GPR113 (purple color; left image) colocalizes with a subset of TRPM5 cells (red; middle image). It can be seen from the figure that that only a fraction of cells expressing TRPM5, a marker of sweet, umami, and bitter taste cells, also express GPR113 (merged image on the right), but that all GPR113 cells express TRPM5. Two taste buds are shown.

FIG. 9 contains another double hybridization experiment using primate circumvallate papilla cells. The results contained in the Figure reveal that MCTP1 (purple color; left image), a taste cell specific gene, colocalizes with TRPM5 (red; middle image). It can be further seen that MCTP1 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown in the Figure.

FIG. 10 contains another double label in situ hybridization experiment using primate circumvallate papilla cells. The results in FIG. 10 show that TMEM16G (purple color; left image) colocalizes with a subset of TRPM5 cells (red; middle image). It can also be seen that only a fraction of cells expressing TRPM5, a marker of sweet, umami, and bitter taste cells, also express TMEM16G (merged image on the right), but that all TMEM16G cells express TRPM5.

FIG. 11 contains another double label in situ hybridization experiment using primate circumvallate papilla cells. The results contained in FIG. 11 show that TMEM44 (purple color; left image), a taste cell specific gene, does not colocalize with TRPM5 (red; middle image). It can be seen from the results in the figure that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown in the figure.

FIG. 12 contains another double label in situ hybridization experiment of primate circumvallate papilla cells. The results contained therein reveal that TMEM44 (purple color; left image) does not colocalize with PKD1L3 (red; middle image). It can also be seen therein that TMEM44 cells do not express PKD1L3, a marker of sour taste cells (merged image on the right). Two taste buds are shown.

FIG. 13 contains another double label in situ hybridization experiment using primate circumvallate papilla cells. The results which are contained in FIG. 13 show that TUSC3 (purple color; left image), a taste cell specific gene, colocalizes with TRPM5 (red; middle image). It can also be seen that TUSC3 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).

FIG. 14 shows that GPR113 is not expressed in T1R1 umami cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T1R1 (red; middle image). Note that GPR113 and T1R1, a marker of umami cells, are in different taste cells (merged image on the right).

FIG. 15 shows that GPR113 is not expressed in T1R2 sweet cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T1R2 (red; middle image). Note that GPR113 and T1R2, a marker of sweet cells, are in different taste cells (merged image on the right).

FIG. 16 shows that GPR113 is expressed in a subset of T1R3 cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does colocalize with a subset of T1R3 cells (red; middle image). Note that GPR113 is always expressed in cells with T1R3, but that there are T1R3 cells that do not express GPR113 (merged image on the right). These T1R3 cells that do not express GPR113 likely coexpress either T1R1 or T1R2. The T1R3 only cells are a new population of taste cells that coexpress GPR113.

FIG. 17 shows that GPR113 is not expressed in T2R bitter cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T2R (red; middle image). Note that GPR113 and T2R, a marker of bitter cells, are in different taste cells (merged image on the right).

FIG. 18 shows that TMEM44 is not expressed in TRPM5 or PKD1L3 cells in fungiform taste buds. Double label in situ hybridization of primate fungiform papilla from the front of the tongue showing that TMEM44 (blue/purple color; left images) does not colocalize with TRPM5 (red; middle top image) or PKD1L3 (red; middle bottom image). Note that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells, or PKD1L3, a marker of sour cells, in the merged images on the right.

FIG. 19 shows that TMEM44 is not expressed in TRPM5 cells in circumvallate papilla. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (green cells; top image) does not colocalize with TRPM5 (red cells; middle image). Note that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the bottom).

FIG. 20 shows that TMEM44 is not expressed in PKD1L3 cells in circumvallate papilla. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (green cells; top image) does not colocalize with PKD1L3 (red cells; middle image). Note that TMEM44 cells do not express PKD1L3, a marker of sour taste cells (merged image on the bottom).

FIG. 21 shows that TMEM44 cells extend processes to the taste pore. Double label histology experiment of primate circumvallate papilla at the back of the tongue. Cytokeratin 19 protein (green; left image) is present in cells expressing TMEM44 RNA (red; middle image). Note that TMEM44 cells extend processes to the taste pore facing the saliva. Asterisk denotes a TMEM44 cell nucleus and white arrows denote the apical process of this same cell extending to the taste pore (merged image on the right). Thus, TMEM44 cells are sensory taste cells that can sample the saliva for tastants. Cytokeratin 19 is a marker of all taste cells.

FIG. 22 shows that FAM26B is expressed in TRPM5 cells Double label in situ hybridization of primate circumvallate papilla showing that FAM26B (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that FAM26B cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).

FIG. 23 shows that SLC4A11 is expressed in TRPM5 cells. Double label in situ hybridization of primate circumvallate papilla showing that SLC4A11 (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that SLC4A11 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).

FIG. 24 reveals that MFSD4 is not expressed in TRPM5 cells. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 (blue/purple color; left image) does not colocalize with TRPM5 (red; middle image). Note that MFSD4 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown.

FIG. 25 shows that MFSD4 and TMEM44 are expressed in the same taste cells. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 and TMEM44 are expressed in the same taste cell population. TMEM44 (top blue/purple color) and MFSD4 (bottom blue/purple color) do not colocalize with TRPM5 (red color top and bottom images) and are expressed in taste cells in the bottom halves of taste buds. The equivalent localization, abundance, and morphology of TMEM44 and MFSD4 taste cells indicates that these cells are identical and that both TMEM44 and MFSD4 genes are expressed in the same taste cell type.

FIG. 26 shows that ASCL1 is expressed in sour taste cells but not sweet, bitter or umami taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that ASCL1 (blue/purple color; left images) does not colocalize with TRPM5 (red; middle top image) but does colocalize with PKD1L3 (red; middle bottom image). Note that ASCL1 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells, but do express PKD1L3, a marker of sour cells, in the merged images on the right.

FIG. 27 shows that KIT is expressed in T1R1 umami taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that KIT (blue/purple color; left images) colocalizes with T1R1 (red; middle image top row), does not colocalize with T1R2 (red; middle image 2^(nd) row), does colocalize with T1R3 (red; middle image 3^(rd)row), and does not colocalize with T2Rs (red; middle image bottom row). Note that KIT cells express T1R1 and T1R3, markers of umami taste cells, but not T1R2 or T2Rs, markers of sweet and bitter cells respectively, in the merged images on the right.

FIG. 28 shows that IKBKAP is expressed in PKD1L3 sour taste cells. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that IKBKAP (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) but does colocalize with PKD1L3 (red; middle image bottom). Note that IKBKAP cells express PKD1L3, a marker of sour taste cells (merge image bottom) but do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image top).

FIG. 29 shows that LOC285965 is expressed in T1R3 only taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that LOC285965 (blue/purple color; left images) does not colocalize with T1R1 (red; middle image top row), does not colocalize with T1R2 (red; middle image 2^(nd) row), does colocalize with T1R3 (red; middle image 3^(rd) row), and does not colocalize with T2Rs (red; middle image bottom row). Note that LOC285965 cells express T1R3, but not T1R1, T1R2 or T2Rs, markers of umami, sweet and bitter cells respectively, in the merged images on the right.

FIG. 30 shows that SV2B is expressed in PKD1L3 sour taste cells. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that SV2B (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) but does colocalize with PKD1L3 (red; middle image bottom). Note that SV2B cells express PKD1L3, a marker of sour taste cells (merge image bottom) but do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image top).

FIG. 31 shows that MFSD4 is expressed in a unique taste cell type. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 (blue/purple color; left image) does not colocalize with PKD1L3 or TRPM5 (red; middle images) but is expressed in a unique taste cell type. Note that MFSD4 cells do not express PKD1L3, a marker of sour taste cells or TRPM5, a marker of sweet, umami, and bitter taste cells (merged images on the right). Two taste buds each are shown for PKD1L3 & TRPM5 double labels.

FIG. 32 shows that MFSD4 and TMEM44 are expressed in the same taste cell population. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 and TMEM44 are expressed in the same taste cell population. MFSD4 (left; green) and TMEM44 (middle; red) signals are present in the same taste cells (right; merged image).

FIG. 33 contains an experiment showing that SHH is expressed in immature taste cells in the bottom of the taste bud. Double in situ hybridization of primate circumvallate papilla at the back of the tongue showing that SHH (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) or PKD1L3 (red; middle image bottom). Note that SHH cells do not express TRPM5, a marker of sweet, bitter, and umami taste cells (merge; right image top) or PKD1L3 (merge; right image bottom). Both TRPM5 and PKD1L3 genes are expressed in professional taste cells.

FIG. 34 contains an experiment showing that TMEM44 and SHH are expressed in immature taste cells at the bottom of the taste bud. In situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (blue/purple color; top 3 images) is expressed in cells towards the base of the taste bud. A similar expression pattern was observed with SHH (blue/purple color; bottom 3 images). Since SHH is marker of immature, developing taste cells, these data indicate that TMEM44 is expressed in and is a marker of immature taste cells

FIG. 35 contains a schematic model of taste cell development. In situ hybridization of primate circumvallate papilla at the back of the tongue showing SHH (blue/purple color) expression at the base of the taste bud and PKD1L3 (red color) expression towards the top of the taste bud. This model indicates a gradient of SHH expression from high levels at the base of the taste bud (immature cells) to low levels at the top of the taste bud (mature cells). As SHH expression levels decrease, expression of taste receptor genes such as TRPM5 and PKD1L3 increase. Thus, an opposite gradient of taste cell maturation exists where taste cells progressively mature and express taste receptor genes as they differentiate from the bottom to the top of the taste bud.

FIG. 36 shows that a small fraction of TMEM44 cells express TRPM5 or PKD1L3 as they differentiate into mature taste cells. Double label in situ hybridization of primate circumvallate papilla was performed using TRPM5 and TMEM44 riboprobes (left pie chart) or PKD1L3 and TMEM44 riboprobes (right pie chart). Taste cells expressing TRPM5 (blue graph region; left pie chart), TMEM44 (magenta graph region; left pie chart), or TRPM5 plus TMEM44 (labeled ‘both’ and yellow graph region; left pie chart) genes were counted and graphed in pie charts. Taste cells expressing PKD1L3 (blue graph region; right pie chart), TMEM44 (magenta graph region; right pie chart), or TRPM5 plus TMEM44 (labeled ‘both’ and yellow graph region; right pie chart) genes were counted and graphed in pie charts. Total number of counted cells is listed below each pie chart in parentheses. A small fraction of TMEM44 cells also express TRPM5 or PKD1L3, indicating that these cells are differentiating from an immature state (TMEM44 only) to a mature state (TRPM5 or PKD1L3 only). Inset shows example of CV taste bud labeled with TMEM44 (green) and TRPM5 (red). Note cell indicated with arrow that coexpresses both TMEM44 and TRPM5 (yellow).

FIG. 37 contains an experiment showing that mature taste cells do not coexpress markers for distinct taste modalities. Double label in situ hybridization of primate circumvallate papilla was performed using TRPM5 and PKD1L3. Taste cells expressing TRPM5 (blue graph region), PKD1L3 (magenta graph region), or TRPM5 plus PKD1L3 (labeled ‘both’ and yellow graph region which is too small to see any yellow segment due to the near absence of cells within this category) genes were counted and graphed in the pie chart. Total number of counted cells is listed below the pie chart in parentheses.

FIG. 38 contains an experiment showing that levels of gene expression define two compartments in primate taste buds. To create this overlay image sagittal sections of primate taste buds were initially stained with DAPI (4′,6-diamidino-2-phenylindole) to visualize cell nuclei; blue color. Double label in situ hybridization images of the same sections for TMEM44; green color and TRPM5+PKD1L3; pink color were then added. The overlay image shows that TMEM44 expression is restricted to the bottom third of each of the four taste buds shown and that TRPM5+PKD1L3 expression occurs predominantly in the upper regions of each of the taste buds.

FIG. 39 shows an exemplary experiment showing laser capture microdissection of top and bottom regions of primate taste buds. Panel) contains a methyl blue stained section A of macaque circumvallate taste buds. Panel B shows Section A following excision of bottom fraction of taste buds. Panel C contains the bottom fraction of taste buds. Panel D shows Section A following excision of bottom and top fractions of taste buds. Panel E shows the Top fraction of taste buds. Note, top and bottom fractions were only collected from taste buds exhibiting optimal morphology in section. In the example shown, the taste bud labeled with an arrow was excluded due to suboptimum sectioning or morphology.

FIG. 40 contains the results of an experiment establishing that distinct cell populations PKD2L1, PKD1L3 and PKD2L1 plus PKD1L3. Double label in situ hybridization of primate fungiform (FG; left) and circumvallate (CV; right) was performed using PKD2L1 and PKD1L3 riboprobes. Taste cells expressing PKD2L1 (blue graph regions), PKD1L3 (magenta graph regions), or PKD2L1 plus PKD1L3 (labeled ‘both’ and yellow graph regions) genes were counted and graphed in pie charts. Total number of counted cells is listed below each pie chart in parentheses.

FIG. 41 The experiment in FIG. 41 shows that FAM26C is expressed in TRPM5 taste cells. Therein double in situ hybridization of primate circumvallate papilla at the back of the tongue showing that FAM26C (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that FAM26C cells express TRPM5, a marker of sweet, bitter, and umami taste cells (merge; right image).

FIG. 42 The experiment in FIG. 42 shows that NALCN is a taste-specific gene. The figure shows end-point PCR experiments on circumvallate taste buds (taste) and lingual epithelial cells (lingual) of non-human primate (left) and mouse (right) isolated by laser-capture microdissection demonstrating that NALCN is a taste-specific gene. NALCN is only expressed in taste cells and is not detectable in lingual cells, similar to the known taste-specific genes gustducin, T1R2, and TRPM5. □-actin is detectable in both taste and lingual samples, indicating that high-quality RNA was present in both samples. ‘+’ indicates that reverse transcription was performed and ‘−’ indicates that no reverse transcription was performed. PCR bands were only observed with reverse transcriptase indicating that PCR products are derived from mRNA and not genomic DNA. PCR products were cloned and sequenced to verify that the bands corresponded to the expected gene products.

FIG. 43 The experiment in FIG. 43 shows that NALCN is expressed in a unique taste cell type effected at low magnification. Therein is shown a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel taste cell population. Numerous taste buds are shown.

FIG. 44 The experiment in FIG. 44 also shows that NALCN is expressed in a unique taste cell type but at high magnification. Therein is contained a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel taste cell population. One to two taste buds are shown.

FIG. 45 The experiment in FIG. 45 shows that NALCN is not expressed in TRPM5 cells. The figure contains a double label immunochemistry of circumvallate papilla from the back of the tongue showing that NALCN (red color, middle images( ) does not colocalize with TRPM5 in non-human primate (green, left image top row) or IP3R3 in rat (green; left image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since TRPM5 and IP3R3 mark sweet, bitter, and umami cells, equivalent to type II cells, NALCN is not expressed in type II cells in non-human primate and rat.

FIG. 46 The experiment in FIG. 46 shows that NALCN is expressed in a subset of fungiform taste cells. Therein single label immunochemistry of fungiform papilla from the front of the tongue of non-human primate showing that NALCN (red color) is expressed in a subset of taste cells. Top of the taste bud, facing saliva, if oriented towards the top in the image is shown (see arrow). unique taste cell type but at high magnification. Therein is contained a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel taste cell population. One to two taste buds are shown.

FIG. 47 shows the laser capture microdissection of human taste buds. Panel A shows methyl blue stained section of human circumvallate human taste buds. Panel B shows Section A following excision of taste buds. Panel C contains the captured taste buds.

DETAILS OF THE INVENTION

The invention relates to the identification of genes expressed in taste tissues of human and macaque, particularly fungiform and/or circumvallate papilla derived taste cells which are putatively involved in salty taste or other taste modalities or taste in general; or which are involved in taste cell related functions and phenotypes that do not directly involve taste such as taste cell or taste bud regeneration and turnover, immunoregulation of the oral cavity or digestive system, regulation of digestion or metabolism, onset or prevention of digestive system disorders such a cancers, autoimmune diseases, and inflammatory conditions such as IBD, ulcerative colitis, Sjogren's syndrome, celiac disease, Crohn's disease, and the like and the use thereof in screening assays to identify compounds that modulate salty taste perception or other taste modalities or taste in general or for identifying potential therapeutics for use in humans. In particular the invention includes use of the following methodologies, to identify novel taste-specific genes:

1) Laser Capture Microdissection (LCM) and RNA Amplification:

In laser capture microdissection, a fine laser beam is used to dissect and purify taste cells from histological sections. This method isolates taste cells, devoid of contaminating lingual epithelial cells and connective tissue, and allows one to perform molecular biology experiments on a highly enriched taste cell population. In parallel, lingual epithelial cells are isolated by LCM and used as a negative control devoid of taste cells. LCM is advantageous to manual or enzymatic dissection of taste papilla because these crude techniques yield a heterogeneous mixture of taste and lingual cells in which taste cells comprise 1-20% of collected material. RNA amplification amplifies total RNAs from taste cells and lingual cells isolated by LCM up to 1 million-fold in a non-biased fashion to generate sufficient genetic material to perform molecular biology studies (gene chips or PCR). We have found that 5,000 taste cells are sufficient for gene chip experiments with macaque taste tissue and greater than 10,000 taste cells are sufficient for PCR experiments with macaque taste tissue.

2) Gene Chips:

Gene chips contain most all annotated genes on a small chip. Hybridizing RNA, isolated and amplified from taste and lingual cells, to gene chips can be used to determine which specific genes are expressed in taste cells and not lingual cells and which specific genes are expressed at higher levels in taste cells compared to lingual cells. Gene chips experiments were conducted using paired macaque fungiform (FG) and circumvallate (CV) taste and lingual samples using Affymetrix rhesus macaque genome arrays and analyzed using GeneSpring GX v7.3 software (Agilent Technologies). 5000 fungiform and CV taste and lingual cells were separately isolated by LCM and total RNA was purified for each sample. RNA was then amplified and hybridized to gene chips. Data analyses are performed using two separate algorithms: Affymetrix Microarray Suite 5 (MAS5) which takes into account both perfect match and mismatch probes on gene chips, and robust multi-chip algorithm (RMA) which only takes into account perfect match probes on gene chips. Taste-specific genes encoding transmembrane proteins are identified in this analysis.

3) PCR:

High-throughput PCR is performed in 96 well plates using primers specific for ion channels in the human/macaque genome and amplified RNA from human/macaque taste and lingual cells isolated by LCM. Detection of products of the appropriate size in taste cells but not lingual cells and DNA sequencing of PCR products (to confirm gene identity) indicates the ion channel of interest is a taste-specific gene. Prior to high-throughput PCR using primers against ion channels identified in the macaque genome, quality-control PCR reactions are first performed on up to 4 known taste-specific genes and 2 housekeeping genes to ensure that taste and lingual RNAs are of high quality. Four taste-specific genes which may be examined are the G alpha protein gustducin (GNAT3), the sweet receptor components, the ion channel TRPM5 and the enzyme phospholipase beta 2; the two housekeeping genes examined are beta-actin and GAPDH. Specific expression of the taste genes by taste cells but not lingual cells plus expression of the ubiquitous housekeeping genes by both taste and lingual cells indicates high quality RNA material.

PCR products are analyzed on agarose gels to determine if bands of the appropriate size are present in taste cells but not lingual cells. Genes with this expression pattern are putative taste-specific genes. All taste-specific genes were cloned and sequenced to confirm the gene identities.

4) In Situ Hybridization:

Antisense RNA probes specific for an individual gene(s) (identified by gene chips or PCR) are hybridized to tissue sections containing taste cells to determine if the mRNA transcript for the gene of interest is expressed in taste cells, specifically in sour, sweet, bitter, and/or umami cells or in a unique cell type that may be involved in salty taste detection. In double labeling in situ hybridization, two different RNA probes are generated to label two different genes, specifically two different taste-specific genes identified by gene chip and/or PCR approaches. Alternatively, one probe can be generated to label a single gene to determine if the gene is expressed in taste cells. For double labeling studies, the first gene is labeled with a FITC probe that generates one color in a fluorescent microscope while the second gene is labeled with a digoxygenin (DIG) probe that generates a different color in a fluorescent microscope. Superimposition of probe 1 and probe 2 reveals if genes are expressed in the same or in different cell types. For example, if a unique ion channel identified by gene chip or PCR approaches colocalizes to cells expressing TRPM5, that unique ion channel is expressed in cells responsible for sweet, bitter, and/or umami taste. By contrast, if a unique ion channel identified by gene chip or PCR approaches does not colocalize to cells expressing TRPM5, that unique ion channel is expressed in a different cell type that may be responsible for salty taste (or another taste modality) and that unique ion channel may be directly involved in sodium detection.

5) Immunohistochemistry:

Antibodies specific for an individual protein (whose gene was identified by gene chips or PCR) are applied to tissue sections containing taste cells to determine if the protein of interest is expressed in taste cells, specifically in sour, sweet, bitter, and/or umami cells or in a unique cell type that may be involved in salty taste detection. In double labeling immunohistochemistry, two different antibody probes are used to label two different proteins, specifically two different taste-specific proteins whose genes were identified by gene chip and/or PCR approaches. Alternatively, one antibody probe can be used to label a single protein to determine if the protein is expressed in taste cells. For double labeling studies, the first protein is labeled with an antibody at a very dilute concentration that can only be detected with a sensitive detection method termed tyramide signal amplification (TSA). The second protein is then labeled with another antibody and detected using a non-TSA method. The dilute first antibody cannot be detected by the standard non-TSA method; therefore, two different antibodies from the same species (e.g. rabbit polyclonal antibodies) will not cross-react and, therefore, can be used in double labeling experiments. Superimposition of protein label 1 and protein label 2 reveals if proteins are expressed in the same or in different cell types. For example, if a unique ion channel identified by gene chip or PCR approaches colocalizes to cells expressing TRPM5, that unique ion channel is expressed in cells responsible for sweet, bitter, and/or umami taste. By contrast, if a unique ion channel identified by gene chip or PCR approaches does not colocalize to cells expressing TRPM5, that unique ion channel is expressed in a different cell type that may be responsible for salty taste (or another taste modality) and that unique ion channel may be directly involved in sodium detection.

In particular the present invention preferably uses the following rationale to select potential salty taste receptor or ion channel candidates. It is again emphasized that while this rationale is focused on isolating and functionalizing salty taste receptors because of its inclusive criteria discussed below it likely will identify non-salty taste receptors as well such as fat or metallic taste receptors and genes that encode other functions of taste cells such as discussed above.

First taste buds are isolated using LCM as described above from human or macaque (Macaca fascicularis). Macaque genes are on average 90-95% identical to human genes and the macaque is an excellent experimental model for study of human biology including taste. Thus taste genes identified in the macaque will be highly similar to their human orthologs and carry out similar functions to those seen in humans. Using LCM a fine laser beam is used to dissect and purify taste cells from histological sections. This method isolates taste cells devoid of contaminating lingual epithelial cells and connective tissue and allows molecular biology experiments to be effected on a highly enriched taste cell population. In parallel, lingual epithelial cells are isolated by LCM and used as a negative control devoid of taste cells. LCM is advantageous to manual or enzymatic dissection of taste papilla because these crude techniques tend to yield a heterogeneous mixture of taste and lingual cells in which taste cells only comprise about 1-20% of the collected material.

Secondly, RNA isolated from taste and non-taste cells is analyzed using gene chips/microarrays. Gene chips contain most all annotated genes on a small chip. Hybridizing RNA, isolated from taste and lingual cells, to gene chips can be used to determine which specific genes are expressed in taste cells and not lingual cells as well as which specific genes are expressed at higher levels in taste cells compared to lingual cells. In order to identify genes for which probe sets are not functional on gene chips, gene chips were performed on 21 macaque non-taste tissues. Probe sets for genes not yielding data above background levels include both probe sets that do not hybridize efficiently to gene targets as well as probe sets not represented within the panel of 21 macaque tissues. These genes, representing genes not covered by the gene chip approach, are analyzed separately by PCR and/or histology to identify genes, specifically genes encoding transmembrane proteins, which are expressed in taste cells and not lingual cells as well as genes expressed at higher levels in taste cells compared to lingual cells isolated by LCM.

Third, taste-specific genes identified by gene chips and/or PCR are examined by histology using double labeling approaches, With in situ hybridization antisense probes specific for individual genes are hybridized to tissue sections containing taste cells to determine if the mRNA transcript for the gene of interest is expressed in taste cells, specifically in sweet bitter, sour and/or umami taste cells or in a unique cell type that may be involved in salt or other taste modality, e.g., fat taste detection. Using immunohistochemistry antibodies specific for an individual protein (which gene was identified by gene chips) these antibodies are applied to tissue sections containing taste cells to determine if the protein of interest is expressed in taste cells, specifically in sweet, bitter, sour and/or umami cells or in a unique cell type that may be involved in salt or fat taste detection. Genes expressed in taste cells expressing TRPM5, a marker for sweet, bitter, and umami cells, would encode proteins that may modulate sweet, bitter and/or umami taste. Genes expressed in taste cells expressing PKD2L1 or PKD1L3, markers for sour cells, would encode proteins that may modulate sour taste. Genes expressed in taste cells expressing neither TRPM5 nor PKD2L1 or PKD1L3 would encode proteins expressed in a unique cell type that may correspond to a salt or fat cell. Therefore, genes expressed in a unique taste cell type may correspond to a salty taste receptor or a fat taste receptor and may modulate salty or fat taste detection.

Fourth, taste-specific genes expressed in a unique cell type are analyzed by use of functional assays including electrophysiology to determine of gene products expressed in heterologous systems such as HEK293 cells or Xenopus oocytes generate sodium-responsive receptors or sodium-conducting ion channels. A salt receptor target should respond to sodium ions at concentrations relevant for human taste (between 20-140 mM sodium).

Fifthly, to ultimately validate the role of a gene as a salt receptor, genes meeting the criteria set forth above are advanced into high-throughput screens to identify enhancers and blockers and these compounds are tested in salty taste tests to determine if they augment or repress salty taste perception. In parallel, mouse knockouts are generated lacking the gene of interest and physiological (nerve recordings) and behavioral (2-bottle preference tests and gustometer tests) experiments are performed to determine if the animals are deficient in or lack salty taste perception.

Therefore, salt receptor candidates will comprise the following criteria: 1) Genes expressed specifically in taste cells or at higher levels in taste cells than lingual cells in gene chip and/or PCR experiments (these are defined as taste-specific genes); 2) Genes expressed in a unique cell type, that does not correspond to sweet, bitter, sour, and/or umami cells by histology; 3) Gene products that generate sodium responsive receptors or sodium channels in electrophysiology or functional experiments; and 4) Enhancers or blockers of gene products modulate salty taste perception and/or mouse knockouts of genes of interest are deficient in or lack salty taste responsiveness.

In a preferred embodiment, step (i) comprises the use of laser capture microdissection (LCM) to dissect and purify taste tissues from non-taste tissues. In one mode of this embodiment, step (i) comprises RNA amplification of genes from taste cells and lingual cells and the amplified genes are screened against a gene chip containing a sample of genes specific to the particular mammal from which the taste and lingual tissues are obtained, and preferably, the gene chips include a set of annotated human genes. In an alternative mode of this embodiment, step (i) comprises high throughput PCR using primers for each ion channel in a mammalian genome.

In another preferred embodiment, step (ii) is effected by in situ hybridization using antisense RNA probes specific for the set of genes identified in step (i) to determine level of expression in taste versus lingual cells. In an alternative preferred embodiment, step (ii) is effected by use of immunochemical detection using a labeled antibody specific to the protein encoded by gene or genes identified in step (i).

In another embodiment of the method for identifying a gene encoding a polypeptide involved in salty taste perception in a mammal, the method of this invention comprises the steps of (i) identifying a set of macaque genes including genes which are expressed in taste cells but which are not expressed in lingual cells and/or genes which are expressed in taste cells at substantially higher levels than in macaque lingual cells; (ii) identifying a subset of genes within the set of genes identified in (i) which are not expressed in taste cells which express umami, sweet or bitter taste receptors (T1Rs or T2Rs) or sour taste receptors (PKD2L1/PKD1L3); and (iii) determining, in a primary neuron which expresses one or more genes in the subset identified according to (ii), which of said genes functions as a sodium responsive ion channel or sodium responsive receptor or transporter and thereby identifying this gene or genes as a putative gene that modulates salty taste. In one mode of this embodiment, step (iii) comprises contacting the neuron with an antibody which specifically binds the gene and inhibits its function.

Genes identified according to either of the methods described above may be characteristic of cells which do not express TRPM5 and PKD2L1/PKD1L3. In another mode, this invention provides a method to assist in selecting cells which do not express TRPM5 and PKD2L1/PKD1L3 by determining whether a cell expresses a gene identified according to the methods above. Preferably, the gene used in the method of this paragraph is one of the genes listed in Tables 1-3, listing taste-specific genes encoding transmembrane proteins in taste cells. Efforts were focused on transmembrane genes since all known taste receptor genes for sweet, bitter, umami, and sour taste encode transmembrane proteins.

In another aspect this application provides an improvement of the afore-described methods in which genes expressed in primate (e.g., macaque) taste buds are identified and functionalized using the disclosed methods. The inventors have developed a rationale wherein they are able to assign gene expression patterns within the primate taste bud for all taste bud-specific genes. Specifically, using a comparison of gene expression between the top and bottom sections of the human or primate taste bud, the inventors have found that they are able to classify genes into one of several functional classes that include taste receptor genes. A subset of genes in this classification is likely to encode all taste receptors and should include those for salty taste and other yet to be defined taste specificities.

The rationale for comparing gene expression between the top and bottom of the primate taste bud arose from the histological localization of mRNAs for a number of candidate taste receptor genes. Expression of a subset of these genes appeared to be localized at the bottom portion of the taste bud while other genes were predominantly expressed at the top of the taste bud. These patterns of expression are exemplified by the TMEM44 and TRPM5 genes which are expressed at the bottom and top of the taste bud respectively, see FIG. 38, described in the examples infra.

In order to get more information on gene expression in both the top and bottom fractions of the taste bud the inventors isolate the corresponding fractions of primate taste buds using laser capture microdissection (LCM). This technique is described supra and briefly involves excision of specific groups of cells from tissue sections based on morphological distinctions. In the case of taste buds, the inventors are able to readily identify these structures in sections of primate tongue. As exemplified in the supporting experimental example infra, tissue collection was limited to taste buds in circumvallate papillae and then to only taste buds that were sectioned sagittally and at the taste pore. The inventors reasoned that only this type of section would reliably isolate top and bottom fractions. An example of sections used in sample collection is shown in FIG. 39.

The gene expression data obtained is then queried to obtain three sets of genes. The first and second sets are genes that are expressed at a higher level in the top or bottom of the primate taste bud relative to the bottom or top respectively. A third set of genes is identified by comparing gene expression between whole (top+bottom) taste bud and lingual epithelium LCM samples.

This methodology achieves various advantages including the following:

Firstly, the inventors have found that taste receptor genes are expressed predominantly at the top of the taste bud. In contrast to prior knowledge, the data obtained using these methods clearly indicate that known taste receptor genes are expressed at a higher level in the top fraction of taste buds. It is reasonable to expect yet to be identified taste receptor genes are represented in the genes which are enriched at the top of the taste bud.

Secondly, the inventive top-versus-bottom gene classification methods allow for the functional classification of genes based on their expression in the cells in the top versus the bottom of the taste bud. Gene expression profiles at the top and bottom fractions of the taste bud suggest distinct functions for cell in each compartment. Functional classes of genes expressed in the top cells indicate that these are mature sensory cells whereas those expressed in the bottom cells indicate that these are immature progenitor cells associated with a basement membrane containing cellular environment. Examples of top-specific functional clauses include taste receptors, taste-specific signal transduction components and receptors. Examples of bottom-specific functional classes include matrix components, growth factors, and cell-cycle-associated proteins.

Thirdly, this methodology allows for the identification of additional taste bud-specific genes. It has been found that by fractionating the taste bud into top and bottom compartments that the inventors have increased the sensitivity of mRNA detection in each compartment by a factor of about 2. This facilitates the identification of other taste specific genes not identified by the prior-described methods.

Therefore, these methods can be used to identify genes involved in different functions of the taste bud based on measuring their expression in the top versus bottom of the taste bud, e.g., where genes over-expressed in the top part of the taste bud. are predicted to be involved in one or more taste sensation, modulation of taste sensation, control of the lifespan of mature taste bud cells or they may be used as biomarkers of different mature taste cell subsets.

By contrast using the inventive rationale genes over-expressed at the bottom of the taste bud are predicted e.g., to be involved in one or more of the maintenance, differentiation and proliferation of taste-bud committed stem cells; or they will represent biomarkers of taste-bud committed stem cells. In addition, genes expressed specifically in the top or bottom can be using to purify these functionally distinct taste bud cell subsets.

Also, in another aspect this invention describes rationales which are useful and have successfully identified human genes which are taste specific and which are predicted to be involved in one or more of the afore-described taste bud related functions. Specifically, these methods identify human taste specific genes (also identified by the afore-described macaque taste gene selection method) by quantitative polymerase chain reaction (PCR). This is an improvement of the afore-described methods for identifying primate taste specific genes, i.e., taste genes specifically expressed in primate taste buds and may be combined with these method and the previous described method wherein the inventors assign gene expression patterns for genes expressed within the primate taste bud for all taste bud-specific genes; specifically, by comparing taste specific gene expression between the top and bottom sections of the primate taste bud and thereby are able to classify genes into one of several functional classes that include taste receptor genes.

This third method is advantageous as it validates the results of the prior methods (since the identified human taste specific genes are present in those identified as taste specific in the macaque) and also demonstrates similar pattern of taste specific gene expression in humans (in addition to primate) and validates the specificity of expression by a quantitative method (qPCR or “TaqMan”).

However, it should be emphasized that the subject methods which identify primate taste specific genes are still very predictive as primates and humans are closely evolutionary related. Therefore, gene expression patterns should also be closely related. Based on this reasonable assumption, taste specific genes identified in the macaque are selected to be validated as being taste specific by assaying the expression thereof in human taste buds using a technology distinct from microarray analysis—TaqMan qPCR.

These methods similarly require a source of isolated (human) taste buds. Human taste buds can be isolated by laser capture microdissection (LCM). This technique has been described supra and involves the excision and isolation of selected cells or groups of cells from tissue sections based on morphological distinctions. In the case of human taste buds, these structures similarly can be readily identified in sections of human tongue. Essentially, multiple LCM preparations from different human donors are pooled (˜4500 cells per sample), RNA extracted and amplified (e.g., by WT-Ovation Pico RNA Amplification System) (NuGEN Technologies, Inc) and analyzed using TaqMan technology to determine specific levels of gene expression in the TB and LE pools.

Thereafter, the expression of the taste-specific genes is quantified by TaqMan in LCM derived cDNA from both LE and TB from the same donors. More specifically, gene expression is measured in TaqMan as a CT (cycle threshold) value. Briefly the CT value for a given sample is determined by the PCR cycle at which the amount of gene-specific PCR product (as measured by fluorescence) reaches a set value. For highly expressed genes, the threshold will be reached early in the PCR run and the CT value will be relatively low (<35) while genes with very low or no expression will not reach the threshold before cycle 35. Expression of genes with CT values >40 are defined as not detectable.

For the majority of genes which are identified as being human taste specific genes when assayed using this methodology, expression is not detected in LE samples (CT>40) but is readily detectable in TB samples (CT<35). This is significant outcome as this group of human taste specific genes has not been described before as taste-specific in human tissue.

In contrast to the afore described gene chip and microarray methods, this technique provides yet additional benefits. and discoveries including the following:

Firstly, these methods allow for human taste specific genes to be detected in human LCM cDNA which were not previously known to be taste specific. Particularly, this approach that uses LCM from post-mortem human tissue samples and a single cDNA amplification step, the data obtained to date clearly indicate that postmortem LCM human tissue can be used to quantify the expression of taste specific genes using qPCR.

Secondly, this methodology allows for the expression of human taste specific genes to be reliably and accurately measured by quantitative PCR (TaqMan) providing for the gene expression profiles of taste specific genes as measured by TaqMan. This methodology further validates gene expression data obtained from the previously described methods which used microarrays and/or in situ hybridization (ISH).

Thirdly, these methods have shown to indeed identify human taste bud specific genes which are functional. Particularly, by using the successive approaches of gene expression via microarray in primate LCM tongue tissue; Top-specific gene expression within the taste bud (akin to known taste receptors) and now TaqMan quantification of gene expression in human postmortem tastes tissues, the techniques identify human taste specific genes that had not been described previously.

Therefore, these methods allow for identification of human taste specific genes in postmortem tissues, and the identifying of human genes involved in different functions of the taste bud based on measuring their expression by quantitative PCR.

It is anticipated that these human taste specific genes, based on the manner that they were identified, expressed, and categorized are involved in one or more of (i) taste sensation, modulation of taste sensation, regulation of taste bud growth and development, control of the lifespan of mature taste bud cells, and/or are involved in the maintenance, differentiation and proliferation of taste-bud committed stem cells. In addition, genes identified using these methods are biomarkers of taste-bud committed stem cells. or represent biomarkers of different mature taste cell subsets. Therefore, these genes and gene products can be used as a basis in methods which enrich or purify these cell subsets.

Using these rationales, or a combination thereof, the genes contained in Tables 1-8 infra were identified. These Tables are briefly described as follows.

Table 1:

This table summarizes primate taste-bud expressed genes that were identified as multi plasma membrane proteins with little or no functional characterization. The set is consistent with this gene set including taste receptors and more particularly including salty taste receptors as the identified genes includes genes identified as sodium channels. This Table comprises the most probable candidates for salty receptor genes and genes responsible for other characterized and uncharacterized taste receptors and polypeptides that modulate taste intensity as well as genes encoding transmembrane proteins involved in other taste cell functions.

Table 2:

This table summarizes primate taste-bud expressed genes that were identified as multi plasma membrane proteins with have been functionally characterized but which are potential candidates for salty taste and other taste receptors. In addition this gene set includes genes encoding transmembrane polypeptides involved in other taste cell related functions.

Table 3:

This Table contains other fungiform expressed genes and potential taste receptor candidates. This Table of genes was derived after compiling a list of ion channel genes permeable to sodium that were systematically tested for expression in laser capture micro-dissected primate tongue tissue from lingual epithelium and taste buds by end point PCR. Genes that were expressed in fungiform taste buds but not circumvallate taste buds or lingual epithelium were included in this list. Moreover, this list of genes includes other genes which were selected that are likely to encode multi-domain transmembrane proteins included on the macaque oligo array that did not satisfy the inclusion criteria of the systematic array and are not included in the Gene Lists contained in Tables 1 and 2.

Table 4:

This table contains additional new taste-specific genes identified in macaque fungiform and/or circumvallate taste-buds by gene chip analysis. These genes all encode transmembrane proteins with no described function or that function as ion channels, ion transporters, or G-protein coupled receptors. Accession numbers, ratios of gene expression in taste cells (TB) to non-taste lingual epithelial cells (LE), and the p values calculated using a two-tailed Student's t-test are listed.

Table 5:

This table contains additional primate genes previously described as fatty acid receptors or which contain amino acid motifs that are associated with lipid binding. This list of genes includes genes that do not encode multi-transmembrane proteins but which are reported to participate in lipid transport or binding at close to the plasma membrane.

Table 6:

This table contains 11 taste-specific genes shown to be expressed in different subsets of primate taste cells. These genes were identified as taste-specific genes by gene chip analysis and shown to be expressed in subsets of taste cells by in situ hybridization analysis as described in the experimental examples and Figures.

Table 7:

This table lists 4 other primate taste specific genes identified by the inventive rationales and provides information as to the specific cell types in which these genes are expressed.

Table 8:

This table contains a listing of the human taste-specific genes which were quantified by TaqMan in LCM derived cDNA from both LE and TB from the same donors. As noted in Example 46, gene expression was measured in TaqMan as a CT (cycle threshold) value. Briefly the CT value for a given sample was determined by the PCR cycle at which the amount of gene-specific PCR product (as measured by fluorescence) reaches a set value. For highly expressed genes, the threshold is reached early in the PCR run and the CT value is relatively low (<35) while genes with very low or no expression do not reach the threshold before cycle 35. Expression of genes with CT values >40 are defined as not detectable. For the majority of genes listed in Table 8 expression was not detected in LE samples (CT>40) but was readily detectable in TB samples (CT<35).

Therefore, based on the foregoing, the subject invention provides methods for identifying human and other primate taste specific genes, including genes involved in salty taste perception or other taste perception modalities or modulation of taste modalities such as fat, metallic, CO2, sweet, bitter, sour, etc. and the use in screening assays for identifying human salty or other taste enhancers and other taste modulatory compounds and for identifying potential therapeutics that modulate other taste cell related functions and phenotypes including diseases and conditions not directly related to taste transduction.

Particularly, the present invention includes the use of cell-based assays to identify salty taste modulators (enhancers). These compounds have potential application in modulating human salty taste perception. Compounds identified for example in electrophysiological assays and their biologically acceptable derivatives are to be tested in human taste tests using human volunteers to confirm their effect on human salty taste perception. In addition compounds identified as potential therapeutics will be evaluated in appropriate in vitro and in vivo models depending on the nature of the intended application. For example compounds identified as potential therapeutics for diabetes may be evaluated in well known diabetic animal models such the NOD mouse model or BB rat model. Similarly, compounds identified as potential therapeutics for IBD or Crohn's disease may be tested in rodent animal models for IBD or Crohn's disease.

As discussed further infra, the cell-based assays used to identify taste, e.g., salty taste modulatory or therapeutic compounds will preferably comprise high throughput screening platforms to identify compounds that modulate (enhance) the activity of genes involved in salty taste perception using cells that express the genes disclosed herein or combinations thereof. Additionally, these sequences may be modified to introduce silent mutations or mutations having a functional effect such as defined mutations that affect ion (sodium) influx. As noted above, the assays will preferably comprise electrophysiological assays effected in amphibian oocytes or assays using mammalian cells that express a an ion channel according to the invention using fluorescent ion sensitive dyes or membrane potential dyes, e.g., sodium-sensitive dyes. Preferably, compounds that modulate such ion channels are identified by screening using electrophysiological assays effected with oocytes that express an ion channel identified herein (e.g., patch clamping or two electrode voltage clamping).

Still alternatively, compounds that modulate the subject ion channels putatively involved in salty taste may be detected by ion flux assays, e.g., radiolabeled-ion flux assays or atomic absorption spectroscopic coupled ion flux assays. As disclosed supra, these compounds have potential application in modulating human salty taste perception or for modulating other biological processes involving aberrant or normal ion channel function.

The subject cell-based assays use mutant nucleic acid sequences which are expressed in desired cells, preferably oocytes or human cells such as HEK-293 cells, or other human or mammalian cells conventionally used in screens for identifying ion channel or GPCR modulatory compounds. These cells may further be engineered to express other sequences, e.g., other taste GPCRs, i.e., T1Rs or T2Rs such as are described in other patent applications by the present Assignee Senomyx as well as appropriate G proteins. The oocyte system is advantageous as it allows for direct injection of multiple mRNA species, provides for high protein expression and can accommodate the deleterious effects inherent in the overexpression of ion channels. The drawbacks are however that electrophysiological screening using amphibian oocytes is not as amenable to high throughput screening of large numbers of compounds and is not a mammalian system. As noted, the present invention embraces assays using mammalian cells, preferably high throughput assays.

Some ion channels putatively involved in salty taste (ENaC) proteins are known to form heteromeric channels comprised of three subunits, an alpha, beta, and a gamma or delta subunit. The sequences of these respective ENaC subunits are disclosed in an earlier patent application by the present Assignee, U.S. Ser. No. 10/133,573 which is incorporated by reference in its entirety herein. Upon co-expression in a suitable cell these subunits result in a heterotrimeric channel having cation ion channel activity; in particular it responds to sodium and should similarly respond to lithium ions in cell-based assays such as those which are disclosed herein and in Senomyx's prior application referenced above.

The Senomyx application incorporated by reference provides high throughput screening assays using mammalian cells transfected or seeded into wells or culture plates wherein functional expression in the presence of test compounds is allowed to proceed.

The invention specifically provides methods of screening for modulators, e.g., activators, inhibitors, stimulators, enhancers, etc., of human salty taste or other taste modalities and potential therapeutics that target other taste cell functions or phenotypes using the nucleic acids and proteins, sequences provided herein. Such modulators can affect salty taste or other taste modalities or taste cell related functions and phenotypes, e.g., by modulating transcription, translation, mRNA or protein stability; by altering the interaction of the ion channel with the plasma membrane, or other molecules; or by affecting ion channel protein activity. Compounds are screened, e.g., using high throughput screening (HTS), to identify those compounds that can bind to and/or modulate the activity of a taste receptor or taste ion channel polypeptide or transporter or fragment thereof. In the present invention, proteins are recombinantly expressed in cells, e.g., human cells, or frog oocytes and the modulation of activity is assayed by using any measure of ion channel, receptor or transporter function, such as measurement of the membrane potential, or measures of changes in intracellular sodium or lithium levels. Methods of assaying ion, e.g., cation, channel function include, for example, patch clamp techniques, two electrode voltage clamping, measurement of whole cell currents, and fluorescent imaging techniques that use ion sensitive fluorescent dyes and ion flux assays, e.g., radiolabeled-ion flux assays or ion flux assays.

An enhancer of a gene identified as set forth in the current application can be used for a number of different purposes. For example, it can be included as a flavoring agent to modulate the salty taste of foods, beverages, soups, medicines, and other products for human consumption. Additionally, the invention provides kits for carrying out the herein-disclosed assays.

Definitions

“Putative taste receptor or ion channel gene” refers to a gene expressed in taste cells that is not expressed in lingual cells or is expressed substantially less in lingual cells that moreover preferably is not expressed in taste cells that express a T1R, T2R, TRPM5, or PKD2L1/PKD1L3 gene.

“Putative salty taste receptor or ion channel gene” refers to a gene specifically expressed in taste cells that is not expressed in lingual cells or is expressed substantially less in lingual cells that moreover preferably is not expressed in taste cells that express a T1R or T2R gene. Preferably this gene will also be an ion channel or a G protein coupled receptor.

“Putative fat or lipid taste receptor or ion channel gene” refers to a gene specifically expressed in taste cells that is not expressed in lingual cells or is expressed substantially less in lingual cells that moreover preferably is not expressed in taste cells that express a T1R or T2R gene. Preferably this gene will also comprise specific motifs characteristic of fatty acid or lipid binding or be predicted to be a fat or lipid associated taste receptor based on its prior identification as encoding a fatty acid binding protein or to possess a structure or homology to another fatty acid binding protein.

“Taste Cell” refers to a cell that when mature expresses at least one receptor, transporter, or ion channel that directly or indirectly regulates or modulates a specific taste modality such as sweet, sour, umami, salty, bitter, fatty, metallic or other taste perception or general taste perception such as taste intensity or the duration of a taste response. Taste cells express mRNA and/or a protein for the gene C6orf15 (chromosome reading frame 15)—also known as STG. This gene has been described as a taste-specific gene (M. Neira et al. Mammalian Genome 12: 60-66, 2001) and is among the macaque taste specific genes reported herein. In addition a mature taste receptor cell typically will express mRNA and/or protein for alpha ENaC. We have data (not shown herein) that reveals that alpha ENaC is expressed in at least sweet, bitter, umami, sour and most likely salty taste cells. Further, a mature taste receptor cell will typically express mRNA and/or protein for cytokeratin 19. This protein is only expressed in mature taste cells and is not found in basal or stem cells. (L. Wong et al. Chemical Senses 19(3): 251-264, 1994). Furthermore, taste cells can be identified by those skilled in the art base on their characteristic morphology. In particular mature taste receptor taste cells are elongated and spindle-shaped. Also, a mature taste receptor cell has the apex of the cell (apical membrane) penetrating into the taste pore thereby gaining access or exposure to saliva. By contrast, an immature taste cell, e.g., a basal cell or stem cell is rounded and is not exposed to the taste pore and saliva. Also, unlike mature taste cells, basal and stem cells tend to be localized towards the base of taste buds.

“Chemosensory cells” are cells that are involved in sensing of chemical stimulants such as tastants and other chemical sensory stimuli such as odorants. Chemosensory cells herein include in particular taste receptor cells and cells comprised in the digestive or urinary tract or other organs that when mature express one or more taste receptors. For example, gastrointestinal chemosensory cells are known which express T1Rs or T2Rs and which cells are likely involved in food sensing, metabolism, digestion, diabetes, food absorption, gastric motility, et al. In addition, cells found in the urinary tract likely express salty taste receptors and are involved in sodium transport, excretion and functions associated therewith such as blood pressure and fluid retention. Further, in the digestive system chemosensory cells that express taste receptors may also express chromogranin A, which is a marker of secretory granules. (C. Sternini, “Taste Receptors in the Gastrointestinal Tract. IV. Functional Implications of Bitter Taste Receptors in Gastrointestinal Chemosensing”. American Journal of Physiology, Gastrointestinal and Liver Physiology.”, 292:G457-G461, 2007).

“Taste-cell associated gene” or “taste specific gene” herein refers to a gene expressed by a taste cell that is not expressed by lingual cell that is involved in a taste or non-taste related taste cell function or phenotype. Taste cells include cells in the oral cavity that express taste receptors such as the tongue and taste cells in other areas of the body that express taste receptors such as the digestive system and urinary tract. Such genes are contained in Tables 1, 2, 3, 4, 5, 6, 7, and 8. With respect to putative taste receptor or taste modulatory genes, preferably, these genes are expressed more in cells comprised in the top half relative to the bottom half of the taste bud. These genes include genes involved in taste and non-taste related functions such a taste cell turnover, diseases affecting the digestive system or oral cavity, immunoregulation of the oral cavity and/or digestive system, digestive and metabolic functions involving taste cells such a diabetes, obesity, blood pressure, fluid retention et al. In referring to the particular taste specific genes identified herein these genes include the nucleic acid sequences corresponding the Accession Numbers contained in Tables 1, 2, 3, 4, 5, 6, 7, and 8 and contained in the Sequence Listing preceding the claims as well as orthologs thereof and chimeras and variants including allelic variants thereof. In particular such variants include sequences encoding polypeptides that are at least 80% identical, more preferably at least 90% or 95, 96, 97, 98 or 99% identical to the polypeptides encoded by the genes corresponding to the recited Accession numbers or to orthologs thereof, especially human and non-human primate orthologs. In addition, the genes include nucleic acid sequences that hybridize under stringent hybridization conditions to a nucleic acid sequence corresponding to one of the gene sequences corresponding to the gene Accession numbers recited in the Tables and sequence listing herein.

“Cation channels” are a diverse group of proteins that regulate the flow of cations across cellular membranes. The ability of a specific cation channel to transport particular cations typically varies with the valency of the cations, as well as the specificity of the given channel for a particular cation.

“Homomeric channel” refers to a cation channel composed of identical alpha subunits, whereas “heteromeric channel” refers to a cation channel composed of two or more different types of alpha subunits. Both homomeric and heteromeric channels can include auxiliary beta subunits.

A “beta subunit” is a polypeptide monomer that is an auxiliary subunit of a cation channel composed of alpha subunits; however, beta subunits alone cannot form a channel (see, e.g., U.S. Pat. No. 5,776,734). Beta subunits are known, for example, to increase the number of channels by helping the alpha subunits reach the cell surface, change activation kinetics, and change the sensitivity of natural ligands binding to the channels. Beta subunits can be outside of the pore region and associated with alpha subunits.

The term “authentic” or wild-type” or “native” nucleic acid sequences refer to the wild-type nucleic acid sequences contained in the Tables and sequence listing herein as well as splice variants and other nucleic acid sequences generally known in the art.

The term “authentic” or “wild-type” or “native” polypeptides refers to the polypeptide encoded by the genes and nucleic acid sequence contained in the Tables and Sequence Listing.

The term “modified enhance receptor nuclear acid sequence” or “optimized nucleic acid sequence” refers to a nucleic acid sequence which contains one or more mutations, particularly those that affect (inhibit or enhance) gene activity in recombinant host cells, and most especially oocytes or human cells such as HEK-293 cells. Particularly, these mutations include those that affect gating by the resultant ion channel containing the mutated subunit sequence. The ion channel may comprise such mutations in one or several of the three subunits that constitute the particular ion channel. The modified nucleic acid sequence for example may contain substitution mutations in one subunit that affect (impair) gating function or defective surface expression. The invention embraces the use of other mutated gene sequences, i.e., splice variants, those containing deletions or additions, chimeras of the subject sequences and the like. Further, the invention may use sequences which may be modified to introduce host cell preferred codons, particularly amphibian or human host cell preferred codons.

The term receptor or ion channel protein or transporter or fragment thereof, or a nucleic acid encoding a particular taste receptor or ion channel or transporter or a fragment thereof according to the invention refers to nucleic acids and polypeptide polymorphic variants, alleles, mutants, and interspecies homologs that: (1) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino acid sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acids, to an amino acid sequence encoded by the wild-type nucleic acid or amino acid sequence of the taste protein, e.g., proteins encoded by the gene nucleic acid sequences contained in the Tables and Sequence Listing herein as well as fragments thereof, and conservatively modified variants thereof; (3) polypeptides encoded by nucleic acid sequences which specifically hybridize under stringent hybridization conditions to an anti-sense strand corresponding to a nucleic acid sequence encoding a gene encoded by one of said genes, and conservatively modified variants thereof; (4) have a nucleic acid sequence that has greater than about 60% sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, or higher nucleotide sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleic acid, e.g., those disclosed herein.

A putative salty or other taste specific gene or polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or any mammal. The nucleic acids and proteins of the invention include both naturally occurring or recombinant molecules. Typically these genes will encode proteins that have ion channel activity, i.e., they are permeable to sodium or lithium.

By “determining the functional effect” or “determining the effect on the cell” is meant assaying the effect of a compound that increases or decreases a parameter that is indirectly or directly under the influence of a taste gene, preferably salty taste gene identified herein e.g., functional, physical, phenotypic, and chemical effects. Such functional effects include, but are not limited to, changes in ion flux, membrane potential, current amplitude, and voltage gating, a as well as other biological effects such as changes in gene expression of any marker genes, and the like. The ion flux can include any ion that passes through the channel, e.g., sodium or lithium, and analogs thereof such as radioisotopes. Such functional effects can be measured by any means known to those skilled in the art, e.g., patch clamping, using voltage-sensitive dyes, or by measuring changes in parameters such as spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties.

“Inhibitors,” “activators,” and “modulators” of the subject taste cell expressed polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules identified using in vitro and in vivo assays of these polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of these taste specific proteins, e.g., antagonists. “Activators” are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate protein activity. Inhibitors, activators, or modulators also include genetically modified versions of the subject taste cell specific proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, peptides, cyclic peptides, nucleic acids, antibodies, antisense molecules, siRNA, ribozymes, small organic molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the subject taste cell specific protein in vitro, in cells, cell extracts, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above.

Samples or assays comprising the proteins encoded by genes identified herein that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of activation or migration modulation. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of an ion channel is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of an ion channel is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% or higher.

The term “test compound” or “drug candidate” or “modulator” or grammatical equivalents as used herein describes any molecule, either naturally occurring or synthetic compound, preferably a small molecule, or a protein, oligopeptide (e.g., from about 5 to about 25 amino acids in length, preferably from about 10 to 20 or 12 to 18 amino acids in length, preferably 12, 15, or 18 amino acids in length), small organic molecule, polysaccharide, lipid, fatty acid, polynucleotide, siRNA, oligonucleotide, ribozyme, etc., to be tested for the capacity to modulate cold sensation. The test compound can be in the form of a library of test compounds, such as a combinatorial or randomized library that provides a sufficient range of diversity. Test compounds are optionally linked to a fusion partner, e.g., targeting compounds, rescue compounds, dimerization compounds, stabilizing compounds, addressable compounds, and other functional moieties. Conventionally, new chemical entities with useful properties are generated by identifying a test compound (called a “lead compound”) with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

A “small organic molecule” refers to an organic molecule, either naturally occurring or synthetic, that has a molecular weight of more than about 50 daltons and less than about 2500 daltons, preferably less than about 2000 daltons, preferably between about 100 to about 1000 daltons, more preferably between about 200 to about 500 daltons.

“Biological sample” include sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histologic purposes. Such samples include blood, sputum, tissue, cultured cells, e.g., primary cultures, explants, and transformed cells, stool, urine, etc. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region (e.g., a gene or sequence contained in the Tables and Sequence Listing herein), when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site or the like). Such sequences are then said to be “substantially identical.” This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).

A preferred example of algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nucl. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always>0) and N (penalty score for mismatching residues; always<0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=−4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci., USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparison of both strands.

“Nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). A particular nucleic acid sequence also implicitly encompasses “splice variants.” Similarly, a particular protein encoded by a nucleic acid implicitly encompasses any protein encoded by a splice variant of that nucleic acid. “Splice variants,” as the name suggests, are products of alternative splicing of a gene. After transcription, an initial nucleic acid transcript may be spliced such that different (alternate) nucleic acid splice products encode different polypeptides. Mechanisms for the production of splice variants vary, but include alternate splicing of exons. Alternate polypeptides derived from the same nucleic acid by read-through transcription are also encompassed by this definition. Any products of a splicing reaction, including recombinant forms of the splice products, are included in this definition. An example of potassium channel splice variants is discussed in Leicher, et al., J. Biol. Chem. 273(52):35095-35101 (1998).

The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

“Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence with respect to the expression product, but not with respect to actual probe sequences.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

The following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (_(3rd) ed., 1994) and Cantor and Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). “Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains, e.g., transmembrane domains, pore domains, and cytoplasmic tail domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 15 to 350 amino acids long. Exemplary domains include extracellular domains, transmembrane domains, and cytoplasmic domains. Typical domains are made up of sections of lesser organization such as stretches of .beta.-sheet and .alpha.-helices. “Tertiary structure” refers to the complete three dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three dimensional structure formed by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

A “label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include ^(32P), fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide.

The term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

The term “heterologous” when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

The phrase “stringent hybridization conditions” refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Probes, “Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent conditions are selected to be about 5-10° C. lower than the thermal melting point (T_(m)) for the specific sequence at a defined ionic strength pH. The T_(m) is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_(m), 50% of the probes are occupied at equilibrium). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5×SSC, and 1% SDS, incubating at 42° C., or, 5×SSC, 1% SDS, incubating at 65° C., with wash in 0.2×SSC, and 0.1% SDS at 65° C.

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary “moderately stringent hybridization conditions” include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 1×SSC at 45° C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al.

For PCR, a temperature of about 36° C. is typical for low stringency amplification, although annealing temperatures may vary between about 32° C. and 48° C. depending on primer length. For high stringency PCR amplification, a temperature of about 62° C. is typical, although high stringency annealing temperatures can range from about 50° C. to about 65° C., depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90° C.-95° C. for 30 sec-2 min., an annealing phase lasting 30 sec.-2 min., and an extension phase of about 72° C. for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).

“Antibody” refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody will be most critical in specificity and affinity of binding.

The term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv), chimeric, humanized or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554 (1990)) For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4: 72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988) and Harlow & Lane, Using Antibodies, A Laboratory Manual (1999); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)).

The phrase “specifically (or selectively) binds” to an antibody or “specifically (or selectively) immunoreactive with,” when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein, often in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times the background and more typically more than 10 to 100 times background. Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to a protein, polymorphic variants, alleles, orthologs, and conservatively modified variants, or splice variants, or portions thereof, can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with proteins and not with other proteins. This selection may be achieved by subtracting out antibodies that cross-react with other molecules. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).

By “therapeutically effective dose” herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999).

Therefore, based on the foregoing, this invention provides in its generic embodiments methods for identifying taste specific genes which may be functionalized using the methods disclosed herein. These techniques have identified all of the genes contained in Tables 1-8 too be taste specific. In addition, as disclosed in the experimental examples this invention further provides specific information and characterization of certain human and primate taste specific genes identified by the rationales described in detail infra and further practical applications of these genes, gene products, and cells which express same as well as modulators of these genes. The more specific aspects of the invention are described as follows and in the examples.

Particularly, the inventors provide lists of genes in Table 6 and 7 infra which are expressed in primate taste cell subsets and describe uses of these genes in taste biology. These genes which are selectively expressed in primate fungiform papilla taste cells at the front of the tongue and circumvallate papilla taste cells at the back of the tongue were identified were identified using the afore-described gene chips/microarray methods by comparing expression in taste receptor cells compared to non-taste lingual epithelial cells isolated by laser capture micro-dissection (LCM). Since salty taste perception is most prevalent at the front of the tongue, taste receptor genes potentially including the salty taste and other taste receptor could be present within this gene set. The genes in Table 6 and Table 7 as reported therein are expressed in different subsets of primate taste cells and were identified by gene chip analysis and shown to be expressed in subsets of taste cells by in situ hybridization analysis.

For example, results contained in the experimental examples and figures referred to therein reveal that FAM26A, MCTP1, TMEM30B, and TUSC3 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells. Also, the results show that GPR113 and TMEM16G are expressed in a subset of TRPM5 cells, suggesting that these genes could be selectively expressed in sweet, umami, or bitter taste cells (or a combination thereof).

Also, the results contained in the experimental examples and figures referred to therein show that TMEM44 is expressed in cells that do not express TRPM5 (bitter, sweet, umami) or PKD1L3 (sour), indicating that the expression of this gene is a marker for a unique taste cell type that could correspond to salt, fat, or another taste modality, and, furthermore, that this gene may encode the primary salt or fat receptor.

Based on the foregoing, this invention contemplates the use of FAM26A, MCTP1, TMEM30B, and TUSC3 as markers alone or in combination with other taste specific genes contained herein for marking, isolating, enriching or ablating sweet, bitter, and umami taste cells or cells expressing TRPM5. In addition, this invention includes the use FAM26A, MCTP1, TMEM30B, and TUSC3 and compounds that enhance or inhibit these gene products in order to selectively modulate taste cell function and responses to tastants including sweet, bitter, and umami.

In addition, the results contained in the experimental examples and figures referred to therein indicate that GPR113 and TMEM16G can be used as a marker for sweet, bitter, or umami taste cells or subsets of TRPM5 cells. Therefore, the invention further describes the use of the use of GPR113 and TMEM16G as markers alone or in combination with other taste specific genes contained herein for marking, isolating, enriching or ablating sweet, bitter, and umami taste cells or cells expressing TRPM5.

In addition, the results contained in the experimental examples and figures referred to therein indicate that GPR113 and TMEM16G and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to tastants including sweet, bitter, or umami. Therefore, the invention further embraces the use of these genes and corresponding polypeptides in assays for identifying sweet, bitter or umami taste modulators.

In addition, based on the finding (as determined by in situ hybridization of primate taste bud cells) that all of TUSC3, ASCL1, FAM26A, FAM26C, IKBKAP, LOC285965, SCNN1D, SLC4A11, SLC26A7, and TMEM30B are expressed by specific taste cell subsets that these genes may be used as biomarkers and that the genes and gene products may be used isolate, mark or ablate these cells and thereby determine the taste related function of these taste bud cells. Based on this same finding the invention further relates to these isolated cells and assays using these cells and genes to identify taste modulators

Still further, the results contained in the experimental examples and figures referred to therein indicate that TMEM44 can be used as a marker for a unique, novel taste cell type that does not correspond to sweet, bitter, and umami taste cells and that TMEM44 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, and umami, which include salt, fat, and other tastants. Therefore, the invention further includes the use of these genes and their corresponding polypeptides in screening assays for identifying taste modulators.

Still further, the results contained in the experimental examples and figures referred to therein indicate that TMEM44 may correspond to a salt receptor or fat receptor, or a marker of immature taste cells or stem cells. Also, this suggests that TMEM44 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells). Accordingly, the invention embraces the use of these genes and polypeptides in screening assays for identifying compounds that selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).

Still further, based on the experimental data, the invention embraces the use of these gene products and compounds that enhance or inhibit gene products can affect: selective apoptosis of taste cells responding to aversive taste modalities such as bitter and sour cells; modulation of transcription factors that control taste receptor expression; modulation of specific bitter receptor expression to minimize off-tastes of vegetables, children's medicine, and coffee; autocrine/paracrine modulation of taste cell development; prolongation of taste bud lifetime; development of supertasters (rodent model systems) to screen for chemical and biological toxins (terrorism), rancid/spoiled/contaminated food and beverage products; and activation of stem cells to differentiate into defined taste cell types.

In addition, the invention further encompasses the possibility that these gene products can also be ancillary taste receptors or primary taste receptors including receptors for salt, fat, and other taste modalities including metallic. This can be determined by the inventive methods.

Also, based on the experimental results, the invention includes the use of these gene products and compounds that enhance or inhibit gene products to modulate the function of any cell expressing a taste receptor, including but not limited to cells in the gastrointestinal tract such as enteroendocrine cells that regulate gastric motility and peptide secretion (e.g. GLP-1: glucagon-like peptide 1; GIP: gastric inhibitory peptide) as well as the other therapeutic applications of taste specific genes and modulators afore-mentioned. These applications include trafficking of taste receptors to and from the apical membrane/taste pore region to enhance or repress general or specific tastes; regulation of taste cell action potential firing frequency/membrane potential to control the intensity of general or specific tastes; regulation of neurotransmitter release to afferent nerve to control the intensity of general or specific tastes; and autocrine/paracrine modulation of taste receptor function; regeneration of taste cells as well as prophylaxis/prevention of taste cell loss following injury, chemotherapy for cancer, radiation therapy for cancer, drug-induced dysgeusia, ageusia, and taste bud loss in the geriatric population; oral hygiene, halitosis, detoxification of noxious substances in oral cavity, and neutralization/elimination of bacteria, viruses, and other immunogens in the saliva/mouth; saliva composition and treatment of dry mouth in conditions of xerostomia and autoimmune disease (Sjogren's syndrome).

Still further, the results contained in the experimental examples and figures referred to therein indicate by use of double label in situ hybridization histology what specific TRPM5 cell type that GPR113 is expressed in. As disclosed infra we identify that GPR113 is not expressed in T1R1 umami cells, T1R2 sweet cells, or T2R bitter cells. Also, it was found that GPR113 is expressed in a subset of T1R3 cells that do not express T1R1 or T1R2. Thus, GPR113 cells define a new taste cell type of T1R3 only cells. Accordingly, this invention embraces the use of this gene to mark, enrich, isolate or ablate these cells.

Also, based on this discovery the invention provides for the use of GPR113 as a marker for this unique taste cell type that because it is in a unique cell population, is a GPCR (many taste receptors are already known to be GPCRs) and therefore this cell likely corresponds to a specific taste modality for which taste cells have not yet been characterized or modulates a specific taste modality such as CO2 sensation, salt, fat, metallic or astringent. Also, the invention provides for the further possibility that GPR113 may associate with T1R3 to form a novel taste receptor for sweet, umami, or other tastants.

Further, based on the foregoing experimental evidence, this invention provides for the use of GPR113 or the corresponding polypeptide as a marker to identify and isolate this unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells and its use to identify taste modulators as well as the aforementioned therapeutic applications of compounds modulating taste specific polypeptides.

Still further, the results contained in the experimental examples and figures referred to therein indicate that the genes KIT, IKBKAP, LOC285965, and SV2B are taste specific taste genes and are expressed in the specific primate taste cell subsets (see Table 7 infra). In addition, the results contained in the experimental examples and figures referred to therein indicate that another gene, MFDS4 is expressed in sensory taste cells that are not sweet, umami, bitter or sour cells, suggesting that this gene is expressed in a similar taste cell subset as TMEM44. Therefore, the invention includes the use of these genes and corresponding polypeptides in screening assays for taste modulators and therapeutics and as biomarkers of specific, unique taste cell subsets.

Still further, in Tables 1-5 of this application the inventors provide a listing of primate taste-specific genes also identified by the inventive rationales that have been demonstrated to reliably include functional taste specific genes already known. These listing of genes include genes encoding transmembrane proteins such as ion channels (sodium), GPCRs, ion transporters, as well as multi-transmembrane proteins with no function yet assigned. Therefore, the invention further includes functionalizing these genes and assessing their function in taste detection or modulation or ancillary taste cell functions.

Still further, the results contained in the experimental examples and figures referred to therein indicate that IKBKAP and SV2B are expressed in many PKD1L3 cells, and that these genes are likely expressed in sour taste cells, since PKD1L3 is a marker of sour taste cells. Therefore, the invention embraces screening assays to assess the effect of modulators on specific taste modalities including sour, or basic taste or other tastes.

Still further, the results contained in the experimental examples and figures referred to therein indicate that KIT is expressed in cells that express the umami taste receptor component T1R1. This is predicted by the inventors to support a view that KIT is expressed in cells responsible for umami taste perception. Accordingly, KIT may modulate umami taste perception.

Still further, the results contained in the experimental examples and figures referred to therein indicate that LOC285965 is expressed in cells that express TRPM5 and T1R3 but not in cells that express the umami taste receptor component T1R1, or the sweet taste receptor component T1R2. These results suggest that LOC285965 is expressed in the ‘T1R3 only’ population of taste cells (similar to GPR113).

Still further, the results contained in the experimental examples and figures referred to therein indicate that IKBKAP and SV2B are expressed in PKD1L3 sour taste cells and indicate that they can be used as markers of this taste cell population. Therefore, the invention includes the use thereof to mark, enrich, isolate or ablate these taste cells so that their effect can be assessed in vitro or in vivo.

Still further, the results contained in the experimental examples and figures referred to therein indicate that IKBKAP and SV2B and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to sour tastants as well as other functions of the PKD1L3 taste cell population. Accordingly, this invention includes the use of these genes and gene products in sour taste modulatory or other taste assays.

Still further, the results contained in the experimental examples and figures referred to therein indicate further that since IKBKAP is mutated in the human disease familial dysautonomia, where taste buds are absent or atrophic and individuals exhibit deficiencies in detection of sweet, bitter, sour, and salty tastants (hypogeusia) that IKBKAP expression in PKD1L3 cells may be important for taste cell development and/or maintenance. Accordingly, the invention embraces the use of this gene and gene product in assays to identify compounds that modulate taste cell development and/or maintenance.

Also, these same findings that and the fact that Botulinum neurotoxin (BoTox) enters neuronal-type cells by interacting with SV2B; indicate that BoTox may selectively modulate sour taste as well as other functions of the PKD1L3 taste cell population. Therefore, SV2B modulators identified by the inventive methods may elicit neuronal effects and may be useful in cosmetic applications.

Also, the same aforementioned findings that KIT is expressed in umami taste cells indicate that it can be used as a marker of this taste cell type. Therefore, the invention embraces the use of KIT as a marker of umami cells. Also, because these findings that indicate that KIT and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to umami tastants the invention further embraces the compounds identified and their use in modulating umami gene functions including taste and food sensing.

Also, these same findings and the fact that Gleevec (Imatinib), is an inhibitor of the KIT tyrosine kinase activity, indicate that this and other KIT tyrosine kinase inhibitors may selectively inhibit umami taste. Also, these findings suggest that individuals with gain of function mutations in KIT, for example in gastrointestinal stromal tumors (GIST), may have altered umami taste perception. Therefore, the invention further embraces the use of KIT modulators in treating gastrointestinal cancers and for detecting these conditions.

Still further, the results contained in the experimental examples and figures referred to therein indicate that LOC285965 is expressed in T1R3 only taste cells similar to GPR113 and indicate that this gene is useful as a marker for a unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells.

Still further, the results contained in the experimental examples and figures referred to therein indicate that LOC285965 may correspond to a salt receptor or fat receptor or a receptor for astringency or metallic taste by itself or in combination with GPR113. Therefore, the invention further provides for this possibility.

Still further, the results contained in the experimental examples and figures referred to therein indicate that LOC285965 may be a coreceptor with T1R3 for specific sweet or umami tastants or other novel tastants such as astringent and metallic tastants.

Still further, these same findings suggest that compounds that enhance or inhibit LOC285965 can selectively modulate taste function and responses to tastants. Accordingly, the invention embraces the use of this gene and gene products in screening assays for taste modulators.

Also, these same findings suggest that LOC285965 may correspond to a marker of immature taste cells that are differentiating into sweet or umami cells. Therefore, the invention embraces the use of this gene or polypeptide as a marker of immature taste cells and/or to isolate, enrich or deplete these cells.

Also, these same findings suggest that LOC285965 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. sweet or umami taste cells). Therefore, the invention embraces the use of these compounds as sweet or umami or other taste modulators.

Still further, the results contained in the experimental examples and figures referred to therein indicate that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, umami, and sour which include salt, fat, and other tastants. Therefore, the invention includes the use of MFSD4 modulators to modulate taste.

Also, these same findings suggest that MFSD4 may correspond to the salt receptor or fat receptor or may be used as a marker of immature taste cells or developing taste cells or support cells. The invention Therefore includes the use of this gene in such usages.

Still further, these findings suggest that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells). Accordingly, the invention embraces the use of modulators of this gene for modulating taste cell development or differentiation.

Also, the data infra reveal that MFSD4 and TMEM44 are expressed in the same taste cell population which may respond to specific tastants. Therefore, the invention includes assays which coexpress these genes in order to identify taste modulators.

Also, the invention embraces the resultant taste receptor wherein MFSD4 and TMEM44 form a complex (heterodimer) to generate a taste receptor (such as fat, CO2, salt, metallic, or other taste modality).

Still further, the results contained in the experimental examples and figures referred to therein indicate that the ASCL1 (aka MASH1) transcription factor defines sour taste cells. ASCL1 is expressed in sour taste cells expressing the sour taste receptor gene PKD1L3; ASCL1 is not expressed in sweet, bitter, and umami taste cells expressing TRPM5. ASCL1 was previously reported to be a marker of type III taste cells. Type III taste are defined by morphological criteria which include: staining with an intermediate density by electron microscopy and making synaptic contacts with nerve fibers. Thus, our results demonstrate that type III taste cells, a cell type previously defined by morphological criteria, correspond to sour taste receptor cells defined by gene expression criteria.

Therefore, an application of this finding is that the ASCL1 transcription factor may bind to promoter elements in genes involved in sour taste perception. Thus, the genome could be screened for ASCL1 motifs to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.

Analogously, other taste receptor cells for sweet, bitter, umami, and salt are likely to express specific transcription factors that define those cell types. Therefore, the invention further embraces methods wherein the expression of all transcription factors in the genome is analyzed in taste cells by PCR and/or histology to determine which taste cell types express which transcription factors.

These finding further support other applications of this gene. For example, the invention includes the use of ASCL1 (aka MASH1) as a marker of sour taste cells and further for the isolation of Type III taste cells which correspond to sour taste receptor cells.

Moreover, because it has been determined that ASCL1 defines the sour taste cell lineage and may control sour taste cell development, the invention further provides for ASCL1 transcription factor DNA binding sequences to be used to identify sour cell genes and sour taste receptor genes. Also, the invention includes the use of such transcription factors can be used to define, mark, and/or label taste cell types. With respect thereto, each taste cell will express one or more transcription factors that define that taste modality.

Also, the invention further encompasses the use of the identified transcription factors to define taste modalities and in cell ablation studies to specifically eliminate a specific taste. Moreover, the invention includes the use of these identified transcription factors that define new taste cell types in cell studies to determine what taste modality is lacking (i.e. what taste can an animal no longer perceive).

Also, as described and supported by data infra, this invention also shows that taste cells expressing the PKD2L1 and PKD1L3 genes, previously implicated in sour taste are heterogeneous and comprise multiple cell populations. In the front of the tongue, in fungiform (FG) papilla there are cells expressing PKD2L1 only, PKD1L3 only, and both PKD2L1 plus PKD1L3. By contrast, in the back of the tongue, in circumvallate papilla (CV), most cells coexpress PKD2L1 plus PKD1L3.

Also, the invention reveals that in addition thereto there is a distinct group of taste cells that express PKD1L3 only and a smaller set of cells that express PKD2L1 only. Previous literature has suggested that cells expressing PKD2L1 (encompassing PKD2L1 and cells coexpressing PKD2L1 plus PKD1L3) respond to sour taste (Huang et al, Nature 2006 Aug. 24; 442(7105):934-8.) However, PKD1L3 cells were not previously known and no function has yet been ascribed.

Therefore, the invention further contemplates the use of PKD1L3 cells as candidate basic or salt responding cells and that PKD1L3 is involved in a different (other than sour) taste modality, e.g., basic taste perception since the related sour receptor, PKD2L1, responds to acidic taste.

Still further, the results contained in the experimental examples and figures referred to therein indicate that the FAM26C gene is expressed in TRPM5 cells (see results infra) and therefore can be used as a marker of sweet, bitter and umami cells. Therefore, the invention further includes the use of FAM26C as a marker or to isolate, enrich or purify or ablate specific taste cells including sweet, bitter and umami cells.

Also, based on these same findings the invention includes the possibility that PKD1L3 only taste cells are candidate taste cells, e.g., which modulate basic taste sensation or other taste modalities, and that PKD1L3 is a candidate taste receptor, e.g., basic taste sensation. Also, the invention provides for an embodiment wherein PKD1L3 may complex with one of the gene products identified herein to form a taste receptor.

Also, based on the findings that FAM26C is expressed in TRPM5 cells, including sweet, bitter, and umami taste cells, it can be used as a marker of this taste cell population and FAM26C and compounds that enhance or inhibit FAM26C can selectively modulate taste cell function and responses to sweet, bitter, and umami tastants as well as other functions of the TRPM5 taste cell population, including functions of the TRPM5 taste cells that are candidate salty taste cells and that coexpress T1R3.

Also, as shown infra, this invention reveals that taste cells in the bottom of the taste buds are immature whereas cells in the top half are mature and express taste receptor genes. Cells in the bottom half of the taste bud express the gene sonic hedgehog (SHH), which is a marker of developing cells. TMEM44 taste cells are localized in the bottom half of the taste bud and the expression pattern of TMEM44 is similar to SHH. Therefore, we have predicted that TMEM44 cells, (which also express MFSD4) are immature and comprise, in part, developing taste cells. Supportive of this finding, a small fraction of taste cells expressing TMEM44 also express either TRPM5 (a marker of mature sweet, bitter and umami cells) or PKD1L3 (a marker of mature sour cells). Cells expressing both TMEM44 and TRPM5 (or PKD1L3) are therefore maturing into professional taste cells. By contrast, cells s in the top half of the taste bud are mature taste cells, do not express SHH, and express taste receptor genes for the sweet, bitter, umami, and sour taste receptors. Since all mature, professional taste cells and taste receptors are localized to the top half of the taste bud, the invention further includes methods for recovery of a fraction of taste bud cells that should include virtually all the functional taste cells including the salty taste cells. Particularly, recovery of the cells in the top half of the taste buds should include cells expressing the salty taste receptor.

Therefore, the invention and methods for assaying taste specific genes and identifying specific taste receptors and taste cell subsets have shown that the taste cells in the bottom half of the taste bud are immature, that the taste cells in the top half of the taste bud are mature and express genes for sweet, bitter, umami, and sour taste receptors, and further that SHH can be used as a marker of immature and developing taste cells at the bottom of the taste bud and that TMEM44 and MFSD4 are markers of immature and developing taste cells at the bottom of the taste bud.

It is predicted based on these results that a subpopulation of TMEM44 cells may be mature taste cells corresponding to a yet unidentified taste cell, e.g., metallic, fat, astringent, CO2, and the like and that a corresponding taste receptor and taste cell will be expressed or comprised in the top taste bud cells, since all other known taste receptors are expressed in the top taste bud cells. This is a reasonable assumption based on the results obtained by the inventors herein, especially since all other known professional, mature taste cells are expressed in the top of the taste bud.

More specifically, and further relating to the foregoing, and the results and data in the experimental examples and supporting figures, the inventors have gleaned the following information relating to several subsets of taste bud cells we have identified discussed above, including:

(i) with particular respect to TMEM44 cells, the inventors have found that these cells comprise about 40% of the taste bud cell population and are located towards the bottom of the taste bud. Also, we have identified other genes expressed by these cells or in the bottom of the taste bud including MFSD4 and Sonic Hedgehog (SHH). The latter is a cytokine involved in immature cell differentiation. For this reason, we predict that TMEM44 represents an immature taste cell population that includes stem cells that replenish the taste bud cells every 2-3 weeks in the human. While these cells are immature, they may still contain a subset of mature cells that may be responsible for taste such as salt sensation.

(ii) with particular respect to GPR113 cells, the inventors have discovered that these cells represent about 10% of the taste bud cell population, and are distinct from sweet, bitter, and umami taste cells, and are located in the top of the taste bud. They express T1R3 and TRPM5 but not the G protein alpha subunit gustudin (GNAT3), suggesting that they represent a novel taste cell population that detects a new taste modality such as fat. Other cells that express TRPM5 and T1R3 include sweet cells (also express TIR2) as well as umami cells (also express T1R1). Bitter cells (also express T2Rs) express TRPM5 but not T1R3. In contrast to GPR113 cells, sweet, bitter, and umami cells all express GNAT3.

(iii) with particular respect to PKD2L1 and PKD1L3 cells, reportedly responsible for sour taste sensation, the inventors have found that they comprise about 10° A of the taste bud cell population and are located in the top of the taste bud. Also, they have observed that these cells are heterogeneous and that there are distinct PKD2L1 and PKD1L3 ‘single positive’ cell populations in addition to a PKD2L1 and PKD1L3 ‘double positive’ cell population. This heterogeneity suggests that one of these subsets could represent a salt or another type of taste sensing cell.

(iv) with particular respect to other markers, the inventors' results suggest that there is another subset of taste cells (˜8% of the taste bud cell population) that does not express any of the following markers: TMEM44, TRPM5, PKD2L1 or PKD1L3, which may represent another taste e.g., CO2 or salt sensing cells. As disclosed while a primary focus of this invention was the elucidation of the salty taste receptor and that these efforts have been successful as the TRPML3 gene has been shown to be a salty taste receptor there may be other salty taste receptors.

The invention further includes the use of these unique taste cell populations as part of its strategies for identifying salty and other types of taste sensing cells such as fat, metallic, astringent, CO2, et al.

Also, the invention further encompasses the use of the genes reported herein as a specific means for confirming the identity of salt and other types of taste cells. In particular, the invention includes the use of the specific taste genes reported herein in methods of cell ablation as a means to identify the specific effect of the selective removal of distinct cell subsets on taste and other ancillary taste related functions already mentioned.

One way to identify the salt cell or other taste cell modality population is to use cell ablation. This technique employs diphtheria toxin under the control of a promoter of a gene expressed in one of the taste cell subsets described above to selectively eliminate this taste cell population, while leaving all other taste cell populations intact. Cell ablation has been used successfully in other laboratories to selectively eliminate sweet (T1R2) and sour (PKD2L1) taste cell populations (work of Charles Zuker). Therefore, ablation of the afore-identified taste cell subsets described herein and others and these of the resultant ablated animals in assays of function (such as nerve recoding and licking/behavior tests will enable evaluating whether the resulting mice still sense a particular type of tastant, e.g., salt, sour, basic, metallic et al or possess an ancillary taste cell function such as taste cell differentiation, proliferation, et al.

For example, in the case of TMEM44, assuming that TMEM44 ablated mice do not sense salt but still sense sweet, bitter, umami, and sour, this result would point this population, or a subset of cells within this population, as the salt sensing cell. Alternatively, if the resulting mice lack taste buds this would suggest that the mice lose the ability to detect all 5 taste qualities because TMEM44 is expressed in immature cells or cell ablation may elicit no effect.

Alternatively, in the case of GPR113, assuming that GPR113 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour, this result would point to GPR113 expressing cells as the salt sensing cells. (As noted TRPML3 cells have been shown to sense salt, therefore this outcome is not probable. More likely, another taste modality would be affected.)

Alternatively, in the case of PKD2L1 assuming that PKD2L1 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour, this result would point to PKD2L1 expressing cells as the salt sensing cells. (Again, as TRPML3 cells have been shown to sense salt, this outcome is not probable. More likely, another taste modality would potentially be affected.)

Still alternatively in the case of PKD1L3, assuming that PKD1L3 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour, this result would point to PKD1L3 expressing cells as the salt sensing cells. (Again, as TRPML3 cells have been shown to sense salt, this outcome is not probable. More likely, another taste modality would potentially be affected.)

Yet alternatively, if none of these mice are deficient in salt or another taste perception, this suggests that the putative population of taste cells (8%) that do not express any of the aforementioned markers could be the salt or another desired taste cell subset, e.g., a fat or metallic taste sensing cell, or that all or multiple mature taste cell populations are capable of sensing salt.

Another means encompassed by the invention for the use in identifying salt or other types of taste cells and further based on the information provided herein relating to taste specific genes and the identified unique taste cell subsets, and the various genes they express or do not express involves generating a single cell suspension from taste buds and then performing single cell analyses with electrophysiology (patch clamping) or calcium imaging coupled with single cell PCR to identify which population(s) responds to sodium or other ions or molecules.

With respect to the foregoing, there are two main models to account for salt sensation in taste buds:

The first model is the labeled line model. In this model, a single cell type is responsible for sensing a given taste quality. This is true for sweet, bitter, umami and sour. In this model, there is a dedicated cell type responsible for salt sensation. As discussed above, we have narrowed down the list of candidate salt sensing cells and described techniques we would use to identify the salt cell.

The second model is the across fibre model where there is not a single cell type responsible for salt sensation. Instead, all or multiple cell types sense salt. In this model, a cell surface molecule, such as a receptor or ion channel, expressed in all or multiple mature taste cells would constitute the salt sensor.

The way to distinguish between these two models and to determine which is valid is to perform ell ablation experiments such as are described above.

In yet another aspect of the invention, this invention provides three primate taste specific genes expressed specifically in primate taste cells that were identified as taste specific genes by gene chip analysis, and shown to function as sodium channels in the literature. These genes, NALCN, NKAIN3 and TRPML3 were identified as being enriched in the top fraction of taste buds along with all other known taste receptor genes. Therefore, these genes are probable candidates for encoding a salty taste receptor. As described in detail, and substantiated by extensive functional data in a related patent application filed on even date as this application, cells expressing one of these genes, TRPML3 has been shown in functional assays and transgenic animals to be necessary for salty taste perception and to correspond to a salty taste receptor.

These ion channels were selected as probable candidates for the salty taste receptor based on a compilation of the rationales provide herein including the primate microarray/gene chip methods, the top versus bottom gene selection technique (these ion channels are all expressed in the top half of taste buds) and that they are identified in the qPCR methods as being expressed by isolated human taste bud cells. In addition all of these genes were selected as they correspond to previously reported putative sodium channels (but not known to be expressed specifically in taste cells much less to be expressed specifically in the top portion of the taste bud where a salty taste cell would be predicted to be present. The gene expression profiles for these 3 ion channels detected according to the inventive method is as follows:

NALCN, (aka VGCNL1), top vs. bottom ratio of 7.2, and TB vs. LE ratio of 11.2; TRPML3 (aka MCOLN3) top vs. bottom ratio of 1.6, and vs. LE ratio of 10.2; and NKAIN3 (aka FAM7D) which has a top vs. bottom ratio of 1.5, and TB vs. LE ratio of 3.3.

There has been information reported about all of these ion channels in the literature. For example, in Cell. 2007 Apr. 20; 129(2):371-83, the neuronal channel NALCN reportedly contributes resting sodium permeability and is required for normal respiratory rhythm. Also, Lu et al., describe that NALCN as a sodium leak channel. Further, in Kim et al., J. Biol. Chem. 2007 Oct. 25; [Epub ahead of print] the authors teach that a gain-of-function mutation in TRPML3 causes the mouse varitint-waddler phenotype. Also, Kim et al., (Id.) describes TRPML3 as a channel permeable to sodium after exposure of the channel to no/low sodium (consistent with saliva), and which was deemed by the inventors to potentially correlate with a putative salt receptor. Also, with respect to the NKAIN 3 gene, in Gorokhova et al., Human Mol. Genet. 2007 Oct. 15; 16(20):3394-410. Epub 2007 Jul. 2, this gene is reported as a member of a novel family of transmembrane proteins interacting with {beta} subunits of the Na,K-ATPase. Also, Gorokhova et al., (Id.) describe a Drosophila homologue of NKAIN3 as an amiloride-insensitive sodium channel, which the inventors also concluded would potentially be consistent with a putative salt receptor.

The identification of TRPML3 gene as encoding a polypeptide that is involved in salty taste and evidence that it functions as a salty taste receptor and the therapeutic applications of this gene are discussed extensively in the utility and PCT patent applications filed on the same date as this application, incorporated by reference in their entireties herein, and therefore is not discussed herein. However, this information is relevant as it substantiates the validity of the subject rationales for identifying and functionalizing the identified primate and human taste specific genes.

However, based thereon, NALCN, and NKAIN3 may still constitute other salty taste receptors expressed in taste bud cells and/or may modulate the function of TRPML3 and/or may associate with TRPML3 to produce a functional taste receptor. Based on the foregoing, NALCN, and NKAIN3 may constitute markers to identify salty taste receptor cells.

In addition, the inventors have obtained additional information concerning NALCN taste-specific gene identified by gene chip analysis and which gene was further found to be enriched in the top fraction of taste bud cells (along with all other known taste receptor genes).

Particularly, as described in the examples infra, it was demonstrated that NALCN is a taste-specific gene by end-point PCR using purified taste buds and lingual epithelial cells isolated by laser capture microdissection. It was found that NALCN is expressed in a novel, unique taste cell type distinct from sweet, bitter, umami, and sour taste cells by immunohistochemistry with a NALCN antibody.

Therefore, since NALCN is a taste-specific gene, is expressed in a novel taste cell type, (and has been reported to function as a sodium-channel), NALCN is a candidate salty taste receptor and/or a marker of the salty taste cell population. Since NALCN and TRPML3 are both expressed in novel taste cell types, NALCN and TRPML3 may be coexpressed in the same taste cell population. Accordingly, NALCN and TRPML3 may function together in a complex; or NALCN may function independently of TRPML3 as another salty taste receptor. For example, NALCN may function downstream of TRPML3 akin to how TRPM5 functions downstream of sweet, bitter, and umami receptors. In this manner, NALCN would be involved in the signal transduction pathway for salty taste but not constitute the primary salty taste sensory receptor.

This can be determined in mice. Rodents have 3 distinct taste cell types:

Type III cells correspond to sour cells (PKD2L1 positive, SNAP-25 positive);

Type II cells correspond to sweet, bitter, and umami cells (TRPM5-positive, IP3R3 positive); and

Type I cells have no defined function.

As shown in the examples infra, the inventors have demonstrated that NALCN is not expressed in IP3R3 cells (Type II) or SNAP-25 cells (Type III) in rodent. Thus, NALCN expression is implicated in Type I cells, and Type I cells are candidate salty taste cells.

However, alternatively, Type I cells may correspond to immature taste cells and if so, would likely be coexpressed with TMEM44/MFSD4 in an immature taste cell population.

Therefore, based on the foregoing information, the invention further encompasses NALCN as an additional salty (or other taste such as metallic or fat) taste receptor candidate gene and based thereon the use thereof as a marker to identify these taste cells.

In addition, since NALCN is a sodium ion channel, and is expressed in the top half of taste buds in cells that have an indeterminate taste function NALCN may control the resting membrane potential and excitability of the taste cells it is expressed in. Related thereto, compounds that enhance or inhibit function of the NALCN channel may regulate the excitability of salty taste cells, i.e., TRPML3 cells.

Based on this modulatory property, compounds that enhance or inhibit function of the NALCN channel may increase and decrease salt perception respectively, e.g., alone or in combination with TRPML3.

Also, NALCN may associate with TRPML3 to form a salty taste receptor. (As shown in the related application ablation of TRPML3 expressing taste cells in Varitint mice results in inhibition of salty taste perception in these rodents and in vitro electrophysiological assays using this ion channel have confirmed that it is a functional sodium channels and may be used to identify TRPML3 blockers and enhancers which should modulate salty taste).

Moreover, NALCN can be used as a marker of type I taste cells, which likely include salty taste cells. Alternatively, as type I taste cells may function as precursor cells for sweet, bitter, umami and sour taste cells, modulation of NALCN function may control taste cell differentiation and development into mature taste cell types.

In addition, because TMEM44 and MFSD4 are markers of immature taste cells, NALCN may be expressed in the subset of immature taste cells expressing TMEM44/MFSD4.

Further, because type I taste cells may also function as glial (support) cells, modulation of NALCN function may indirectly control the activity of sweet, bitter, umami, and sour cells and, as a result, sweet, bitter, umami, and sour taste.

Also, compounds that enhance or inhibit function of NALCN may increase and decrease salt perception respectively.

In yet another aspect, this invention provides specific assays for identifying a compound having potential in vivo application for modulating human salty taste. One method comprises the steps of (i) contacting a cell that expresses a gene encoding an ion channel, receptor or transporter identified as a putative salty taste affecting gene according to any one of the methods above, or a gene encoding a polypeptide possessing at least 90% sequence identity to the polypeptide encoded thereby, with at least one putative enhancer compound; (ii) assaying sodium conductance, receptor activity or sodium transport in the presence and absence of said putative enhancer; and (iii) identifying the compound as a potential salty taste enhancer based on whether it increases sodium conductance, the activity of said receptor or sodium transport. In various embodiments, the gene encodes an ion channel or the gene encodes a GPCR. Preferably, the gene is a human gene. More preferably, the method further includes testing the effect of the compound or a derivative thereof in a human taste test. Preferably, the selected compound promotes sodium ion transport into taste bud cells. The putative salty taste affecting gene may be expressed in an amphibian oocyte, or in a mammalian cell, preferably a Xenopus oocyte or a mammalian cell selected from the group consisting of a HEK293, HEK293T, Swiss3T3, CHO, BHK, NIH3T3, monkey L cell, African green monkey kidney cell, Ltk-cell and COS cell. Preferably, the putative salty taste affecting gene is expressed under the control of a regulatable promoter. The putative salty taste affecting gene may be expressed stably or transiently. In a preferred mode, the putative salty taste affecting gene is selected from tables 1-8 and in the Sequence Listing.

Recombinant Expression of Taste (Salty) Gene Identified Herein

To obtain high level expression of a cloned gene, such as those cDNAs encoding the subject genes, one typically subclones the gene into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. Suitable eukaryotic and prokaryotic promoters are well known in the art and described, e.g., in Sambrook et al., and Ausubel et al., supra. For example, bacterial expression systems for expressing the taste specific protein are available in, e.g., E. coli, Bacillus sp., and Salmonella (Palva et al., Gene 22:229-235 (1983); Mosbach et al., Nature 302:543-545 (1983). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available. For example, retroviral expression systems may be used in the present invention. As described infra, the subject putative salty taste affecting genes are preferably expressed in human cells such as HEK-293 cells which are widely used for high throughput screening.

Selection of the promoter used to direct expression of a heterologous nucleic acid depends on the particular application. The promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the nucleic acid in host cells. A typical expression cassette thus contains a promoter operably linked to the nucleic acid sequence encoding the identified gene and signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination. Additional elements of the cassette may include enhancers and, if genomic DNA is used as the structural gene, introns with functional splice donor and acceptor sites.

In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.

The particular expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells may be used. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and fusion expression systems such as MBP, GST, and LacZ. Epitope tags can also be added to recombinant proteins to provide convenient methods of isolation, e.g., c-myc. Sequence tags may be included in an expression cassette for nucleic acid rescue. Markers such as fluorescent proteins, green or red fluorescent protein, β-gal, CAT, and the like can be included in the vectors as markers for vector transduction.

Expression vectors containing regulatory elements from eukaryotic viruses are typically used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, retroviral vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A⁺, pMTO10/A⁻, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the CMV promoter, SV40 early promoter, SV40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.

Expression of proteins from eukaryotic vectors can also be regulated using inducible promoters. With inducible promoters, expression levels are tied to the concentration of inducing agents, such as tetracycline or ecdysone, by the incorporation of response elements for these agents into the promoter. Generally, high level expression is obtained from inducible promoters only in the presence of the inducing agent; basal expression levels are minimal.

The vectors used in the invention may include a regulatable promoter, e.g., tet-regulated systems and the RU-486 system (see, e.g., Gossen & Bujard, Proc. Nat'l Acad. Sci USA 89:5547 (1992); Oligino et al., Gene Ther. 5:491-496 (1998); Wang et al., Gene Ther. 4:432-441 (1997); Neering et al., Blood 88:1147-1155 (1996); and Rendahl et al., Nat. Biotechnol. 16:757-761 (1998)). These impart small molecule control on the expression of the candidate target nucleic acids. This beneficial feature can be used to determine that a desired phenotype is caused by a transfected cDNA rather than a somatic mutation.

Some expression systems have markers that provide gene amplification such as thymidine kinase and dihydrofolate reductase. Alternatively, high yield expression systems not involving gene amplification are also suitable, such as using a baculovirus vector in insect cells, with a gene sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.

The elements that are typically included in expression vectors also include a replicon that functions in the particular host cell. In the case of E. coli, the vector may contain a gene encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of eukaryotic sequences. The particular antibiotic resistance gene chosen is not critical, any of the many resistance genes known in the art are suitable. The prokaryotic sequences are preferably chosen such that they do not interfere with the replication of the DNA in eukaryotic cells, if necessary.

Standard transfection methods may be used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of the desired taste specific protein, which are then purified using standard techniques (see, e.g., Colley et al., J. Biol. Chem. 264:17619-17622 (1989); Guide to Protein Purification, in Methods in Enzymology, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (see, e.g., Morrison, J. Bact. 132:349-351 (1977); Clark-Curtiss & Curtiss, Methods in Enzymology 101:347-362 (Wu et al., eds, 1983). Any of the well-known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, biolistics, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook et al., supra). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the gene.

After the expression vector is introduced into the cells, the transfected cells are cultured under conditions favoring expression of the gene. In some instances, such polypeptides may be recovered from the culture using standard techniques identified below.

Assays for Modulators of Putative Taste Cell Specific Gene Products Identified Herein

Modulation of a putative taste cell specific protein, can be assessed using a variety of in vitro and in vivo assays, including cell-based models as described above. Such assays can be used to test for inhibitors and activators of the protein or fragments thereof, and, consequently, inhibitors and activators thereof. Such modulators are potentially useful in medications or as flavorings to modulate salty or other taste modalities or taste in general or for usage as potential therapeutics for modulating a taste cell related function or phenotype involving one or several of the identified taste cell specific genes reported herein.

Assays using cells expressing the subject taste specific proteins, either recombinant or naturally occurring, can be performed using a variety of assays, in vitro, in vivo, and ex vivo, as described herein. To identify molecules capable of modulating activity thereof, assays are performed to detect the effect of various candidate modulators on activity preferably expressed in a cell.

The channel activity of ion channel proteins in particular can be assayed using a variety of assays to measure changes in ion fluxes including patch clamp techniques, measurement of whole cell currents, radiolabeled ion flux assays or a flux assay coupled to atomic absorption spectroscopy, and fluorescence assays using voltage-sensitive dyes or lithium or sodium sensitive dyes (see, e.g., Vestergarrd-Bogind et al., J. Membrane Biol. 88:67-75 (1988); Daniel et al., J. Pharmacol. Meth. 25:185-193 (1991); Hoevinsky et al., J. Membrane Biol. 137:59-70 (1994)). For example, a nucleic acid encoding a protein or homolog thereof can be injected into Xenopus oocytes or transfected into mammalian cells, preferably human cells such as HEK-293 cells. Channel activity can then be assessed by measuring changes in membrane polarization, i.e., changes in membrane potential.

A preferred means to obtain electrophysiological measurements is by measuring currents using patch clamp techniques, e.g., the “cell-attached” mode, the “inside-out” mode, and the “whole cell” mode (see, e.g., Ackerman et al., New Engl. J. Med. 336:1575-1595, 1997). Whole cell currents can be determined using standard methodology such as that described by Hamil et al., Pflugers. Archiv. 391:185 (1981).

Channel activity is also conveniently assessed by measuring changes in intracellular ion levels, i.e., sodium or lithium. Such methods are exemplified herein. For example, sodium flux can be measured by assessment of the uptake of radiolabeled sodium or by using suitable fluorescent dyes. In a typical microfluorimetry assay, a dye which undergoes a change in fluorescence upon binding a single sodium ion, is loaded into the cytosol of taste cell specific ion channel-expressing cells. Upon exposure to an agonist, an increase in cytosolic sodium is reflected by a change in fluorescence that occurs when sodium is bound.

The activity of the subject taste cell specific polypeptides can in addition to these preferred methods also be assessed using a variety of other in vitro and in vivo assays to determine functional, chemical, and physical effects, e.g., measuring the binding thereof to other molecules, including peptides, small organic molecules, and lipids; measuring protein and/or RNA levels, or measuring other aspects of the subject polypeptides, e.g., transcription levels, or physiological changes that affects the taste cell specific protein's activity. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as changes in cell growth or pH changes or changes in intracellular second messengers such as IP3, cGMP, or cAMP, or components or regulators of the phospholipase C signaling pathway. Such assays can be used to test for both activators and inhibitors of KCNB proteins. Modulators thus identified are useful for, e.g., many diagnostic and therapeutic applications.

In Vitro Assays

Assays to identify compounds with modulating activity on the subject genes are preferably performed in vitro. The assays herein preferably use full length protein according to the invention or a variant thereof. This protein can optionally be fused to a heterologous protein to form a chimera. In the assays exemplified herein, cells which express the full-length polypeptide are preferably used in high throughput assays are used to identify compounds that modulate gene function. Alternatively, purified recombinant or naturally occurring protein can be used in the in vitro methods of the invention. In addition to purified protein or fragment thereof, the recombinant or naturally occurring taste cell protein can be part of a cellular lysate or a cell membrane. As described below, the binding assay can be either solid state or soluble. Preferably, the protein, fragment thereof or membrane is bound to a solid support, either covalently or non-covalently. Often, the in vitro assays of the invention are ligand binding or ligand affinity assays, either non-competitive or competitive (with known extracellular ligands such as menthol). These in vitro assays include measuring changes in spectroscopic (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein.

Preferably, a high throughput binding assay is performed in which the protein is contacted with a potential modulator and incubated for a suitable amount of time. A wide variety of modulators can be used, as described below, including small organic molecules, peptides, antibodies, and ligand analogs. A wide variety of assays can be used to identify modulator binding, including labeled protein-protein binding assays, electrophoretic mobility shifts, immunoassays, enzymatic assays such as phosphorylation assays, and the like. In some cases, the binding of the candidate modulator is determined through the use of competitive binding assays, where interference with binding of a known ligand is measured in the presence of a potential modulator. In such assays the known ligand is bound first, and then the desired compound i.e., putative enhancer is added. After the particular protein is washed, interference with binding, either of the potential modulator or of the known ligand, is determined. Often, either the potential modulator or the known ligand is labeled.

In addition, high throughput functional genomics assays can also be used to identify modulators of cold sensation by identifying compounds that disrupt protein interactions between the taste specific polypeptide and other proteins to which it binds. Such assays can, e.g., monitor changes in cell surface marker expression, changes in intracellular calcium, or changes in membrane currents using either cell lines or primary cells. Typically, the cells are contacted with a cDNA or a random peptide library (encoded by nucleic acids). The cDNA library can comprise sense, antisense, full length, and truncated cDNAs. The peptide library is encoded by nucleic acids. The effect of the cDNA or peptide library on the phenotype of the cells is then monitored, using an assay as described above. The effect of the cDNA or peptide can be validated and distinguished from somatic mutations, using, e.g., regulatable expression of the nucleic acid such as expression from a tetracycline promoter. cDNAs and nucleic acids encoding peptides can be rescued using techniques known to those of skill in the art, e.g., using a sequence tag.

Proteins interacting with the protein encoded by a cDNA according to the invention can be isolated using a yeast two-hybrid system, mammalian two hybrid system, or phage display screen, etc. Targets so identified can be further used as bait in these assays to identify additional components that may interact with the particular ion channel, receptor or transporter protein which members are also targets for drug development (see, e.g., Fields et al., Nature 340:245 (1989); Vasavada et al., Proc. Nat'l Acad. Sci. USA 88:10686 (1991); Fearon et al., Proc. Nat'l Acad. Sci. USA 89:7958 (1992); Dang et al., Mol. Cell. Biol. 11:954 (1991); Chien et al., Proc. Nat'l Acad. Sci. USA 9578 (1991); and U.S. Pat. Nos. 5,283,173, 5,667,973, 5,468,614, 5,525,490, and 5,637,463).

Cell-Based In Vivo Assays

In preferred embodiments, wild-type and mutant taste cell specific proteins are expressed in a cell, and functional, e.g., physical and chemical or phenotypic, changes are assayed to identify modulators that modulate function or which restore the function of mutant genes, e.g., those having impaired gating function. Cells expressing proteins can also be used in binding assays. Any suitable functional effect can be measured, as described herein. For example, changes in membrane potential, changes in intracellular lithium or sodium levels, and ligand binding are all suitable assays to identify potential modulators using a cell based system. Suitable cells for such cell based assays include both primary cells and recombinant cell lines engineered to express a protein. The subject taste cell specific proteins therefore can be naturally occurring or recombinant. Also, as described above, fragments of these proteins or chimeras with ion channel activity can be used in cell based assays. For example, a transmembrane domain of a ion channel or GPCR or transporter gene according to the invention can be fused to a cytoplasmic domain of a heterologous protein, preferably a heterologous ion channel protein. Such a chimeric protein would have ion channel activity and could be used in cell based assays of the invention. In another embodiment, a domain of the taste cell specific protein, such as the extracellular or cytoplasmic domain, is used in the cell-based assays of the invention.

In another embodiment, cellular polypeptide levels of the particular target taste polypeptide can be determined by measuring the level of protein or mRNA. The level of protein or proteins related to ion channel activation are measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatic ally labeled antibodies, and the like, as described herein.

Alternatively, protein expression can be measured using a reporter gene system. Such a system can be devised using a promoter of the target gene operably linked to a reporter gene such as chloramphenicol acetyltransferase, firefly luciferase, bacterial luciferase, beta-galactosidase and alkaline phosphatase. Furthermore, the protein of interest can be used as an indirect reporter via attachment to a second reporter such as red or green fluorescent protein (see, e.g., Mistili & Spector, Nature Biotechnology 15:961-964 (1997)). The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In another embodiment, a functional effect related to signal transduction can be measured. An activated or inhibited ion channel or GPCR or transporter will potentially alter the properties of target enzymes, second messengers, channels, and other effector proteins. The examples include the activation of phospholipase C and other signaling systems. Downstream consequences can also be examined such as generation of diacyl glycerol and IP3 by phospholipase C.

Assays for ion channel activity include cells that are loaded with ion or voltage sensitive dyes to report activity, e.g., by observing sodium influx or intracellular sodium release. Assays for determining activity of such receptors can also use known agonists and antagonists for these receptors as negative or positive controls to assess activity of tested compounds. In assays for identifying modulatory compounds (e.g., agonists, antagonists), changes in the level of ions in the cytoplasm or membrane voltage will be monitored using an ion sensitive or membrane voltage fluorescent indicator, respectively. Among the ion-sensitive indicators and voltage probes that may be employed are those disclosed in the Molecular Probes 1997 Catalog. Radiolabeled ion flux assays or a flux assay coupled to atomic absorption spectroscopy can also be used.

Animal Models

Animal models also find potential use in screening for modulators of gene activity. Transgenic animal technology results in gene overexpression, whereas siRNA and gene knockout technology results in absent or reduced gene expression following homologous recombination with an appropriate gene targeting vector. The same technology can also be applied to make knock-out cells. When desired, tissue-specific expression or knockout of the target gene may be necessary. Transgenic animals generated by such methods find use as animal models of responses related to the gene target. For example such animals expressing a gene or genes according to the invention may be used to derive supertaster phenotypes such as for use in screening of chemical and biological toxins, rancid/spoiled/contaminated foods, and beverages or for screening for therapeutic compounds that modulate taste stem cell differentiation.

Knock-out cells and transgenic mice can be made by insertion of a marker gene or other heterologous gene into an endogenous gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting an endogenous gene with a mutated version of the target gene, or by mutating an endogenous gene, e.g., by exposure to known mutagens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach (Robertson, ed., 1987).

Candidate Modulators

The compounds tested as modulators of the putative taste related proteins or other non-taste related functions and phenotypes involving taste cells can be any small organic molecule, or a biological entity, such as a protein, e.g., an antibody or peptide, a sugar, a nucleic acid, e.g., an antisense oligonucleotide or a ribozyme, or a lipid. Alternatively, modulators can be genetically altered versions of a protein. Typically, test compounds will be small organic molecules, peptides, lipids, and lipid analogs. In one embodiment, the compound is a menthol analog, either naturally occurring or synthetic.

Essentially any chemical compound can be used as a potential modulator or ligand in the assays of the invention, although most often compounds can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, Mo.), Aldrich (St. Louis, Mo.), Sigma-Aldrich (St. Louis, Mo.), Fluka Chemika-Biochemica Analytika (Buchs Switzerland) and the like.

In one preferred embodiment, high throughput screening methods involve providing a combinatorial small organic molecule or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such “combinatorial chemical libraries” or “ligand libraries” are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka, Int. J. Pept. Prot. Res. 37:487-493 (1991) and Houghton et al., Nature 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (e.g., PCT Publication No. WO 91/19735), encoded peptides (e.g., PCT Publication No. WO 93/20242), random bio-oligomers (e.g., PCT Publication No. WO 92/00091), benzodiazepines (e.g., U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)), nucleic acid libraries (see Ausubel, Berger and Sambrook, all supra), peptide nucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology, 14(3):309-314 (1996) and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science, 274:1520-1522 (1996) and U.S. Pat. No. 5,593,853), small organic molecule libraries (see, e.g., benzodiazepines, Baum C&EN, January 18, page 33 (1993); isoprenoids, U.S. Pat. No. 5,569,588; thiazolidinones and metathiazanones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S. Pat. No. 5,288,514, and the like).

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville Ky., Symphony, Rainin, Woburn, Mass., 433A Applied Biosystems, Foster City, Calif., 9050 Plus, Millipore, Bedford, Mass.). In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, Mo., ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, Pa., Martek Biosciences, Columbia, Md.). C. Solid State and Soluble High Throughput Assays.

Additionally soluble assays can be effected using a target taste specific protein, or a cell or tissue expressing a target taste protein disclosed herein, either naturally occurring or recombinant. Still alternatively, solid phase based in vitro assays in a high throughput format can be effected, where the protein or fragment thereof, such as the cytoplasmic domain, is attached to a solid phase substrate. Any one of the assays described herein can be adapted for high throughput screening, e.g., ligand binding, calcium flux, change in membrane potential, etc.

In the high throughput assays of the invention, either soluble or solid state, it is possible to screen several thousand different modulators or ligands in a single day. This methodology can be used for assaying proteins in vitro, or for cell-based or membrane-based assays comprising an protein. In particular, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (e.g., 96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 100-about 1500 different compounds. It is possible to assay many plates per day; assay screens for up to about 6,000, 20,000, 50,000, or more than 100,000 different compounds are possible using the integrated systems of the invention.

For a solid state reaction, the protein of interest or a fragment thereof, e.g., an extracellular domain, or a cell or membrane comprising the protein of interest or a fragment thereof as part of a fusion protein can be bound to the solid state component, directly or indirectly, via covalent or non covalent linkage e.g., via a tag. The tag can be any of a variety of components. In general, a molecule which binds the tag (a tag binder) is fixed to a solid support, and the tagged molecule of interest is attached to the solid support by interaction of the tag and the tag binder.

A number of tags and tag binders can be used, based upon known molecular interactions well described in the literature. For example, where a tag has a natural binder, for example, biotin, protein A, or protein G, it can be used in conjunction with appropriate tag binders (avidin, streptavidin, neutravidin, the Fc region of an immunoglobulin, etc.) Antibodies to molecules with natural binders such as biotin are also widely available and appropriate tag binders; see, SIGMA Immunochemicals 1998 catalogue SIGMA, St. Louis Mo.).

Similarly, any haptenic or antigenic compound can be used in combination with an appropriate antibody to form a tag/tag binder pair. Thousands of specific antibodies are commercially available and many additional antibodies are described in the literature. For example, in one common configuration, the tag is a first antibody and the tag binder is a second antibody which recognizes the first antibody. In addition to antibody-antigen interactions, receptor-ligand interactions are also appropriate as tag and tag-binder pairs. For example, agonists and antagonists of cell membrane receptors (e.g., cell receptor-ligand interactions such as transferrin, c-kit, viral receptor ligands, cytokine receptors, chemokine receptors, interleukin receptors, immunoglobulin receptors and antibodies, the cadherin family, the integrin family, the selectin family, and the like; see, e.g., Pigott & Power, The Adhesion Molecule Facts Book I (1993). Similarly, toxins and venoms, viral epitopes, hormones (e.g., opiates, steroids, etc.), intracellular receptors (e.g. which mediate the effects of various small ligands, including steroids, thyroid hormone, retinoids and vitamin D; peptides), drugs, lectins, sugars, nucleic acids (both linear and cyclic polymer configurations), oligosaccharides, proteins, phospholipids and antibodies can all interact with various cell receptors.

Synthetic polymers, such as polyurethanes, polyesters, polycarbonates, polyureas, polyamides, polyethyleneimines, polyarylene sulfides, polysiloxanes, polyimides, and polyacetates can also form an appropriate tag or tag binder. Many other tag/tag binder pairs are also useful in assay systems described herein, as would be apparent to one of skill upon review of this disclosure.

Common linkers such as peptides, polyethers, and the like can also serve as tags, and include polypeptide sequences, such as poly gly sequences of between about 5 and 200 amino acids. Such flexible linkers are known to persons of skill in the art. For example, poly(ethylene glycol) linkers are available from Shearwater Polymers, Inc. Huntsville, Ala. These linkers optionally have amide linkages, sulfhydryl linkages, or heterofunctional linkages.

Tag binders are fixed to solid substrates using any of a variety of methods currently available. Solid substrates are commonly derivatized or functionalized by exposing all or a portion of the substrate to a chemical reagent which fixes a chemical group to the surface which is reactive with a portion of the tag binder. For example, groups which are suitable for attachment to a longer chain portion would include amines, hydroxyl, thiol, and carboxyl groups. Aminoalkylsilanes and hydroxyalkylsilanes can be used to functionalize a variety of surfaces, such as glass surfaces. The construction of such solid phase biopolymer arrays is well described in the literature. See, e.g., Merrifield, J. Am. Chem. Soc. 85:2149-2154 (1963) (describing solid phase synthesis of e.g., peptides); Geysen et al., J. Immunol. Meth. 102:259-274 (1987) (describing synthesis of solid phase components on pins); Frank & Doring, Tetrahedron 44:6031-6040 (1988) (describing synthesis of various peptide sequences on cellulose disks); Fodor et al., Science, 251:767-777 (1991); Sheldon et al., Clinical Chemistry 39(4):718-719 (1993); and Kozal et al., Nature Medicine 2(7):753-759 (1996) (all describing arrays of biopolymers fixed to solid substrates). Non-chemical approaches for fixing tag binders to substrates include other common methods, such as heat, cross-linking by UV radiation, and the like.

Having described the invention supra, the examples provided infra further illustrate some preferred embodiments of the invention. These examples are provided only for purposes of illustration and should not be construed as limiting the subject invention.

Practical Applications of the Invention

Compounds which modulate, preferably enhance the activity of genes identified herein in the Tables have important implications in modulation of human salty taste and potentially other taste modalities or taste in general. In addition these compounds are potentially useful in therapeutic applications involving other taste cell related functions and phenotypes such as taste cell turnover, digestive diseases, digestive function, regulation of metabolism, regulation of immunity in the oral cavity and/or digestive system and the like.

Compounds which activate taste ion channels in taste papillae on the tongue can be used to enhance salt sensation by promoting Na⁺ transport into taste bud cells. This has obvious consumer applications in improving the taste and palatability of low salt foods and beverages.

In addition the genes and gene products herein can be used as markers for identifying, isolating or enriching specific taste cell types or lineages including sweet, bitter, umami, sour, salt, fat, metallic et al.

Further the genes and gene products specific to taste cells identified herein can be used to identify compounds that modulate apoptosis of taste cells, modulate transcription factors that control taste receptor expression, modulate bitter receptor expression e.g., to alleviate the off-taste of some vegetables, medicines, coffee, and the like; modulate autocrine/paracrine modulation of taste cell development, prolong taste bud lifetime, yield supertaster animal phenotypes for use in screening such as for bioterrorism or animals for use in screening for compounds that induce the activation and differentiation of stem cells into taste cells in vivo.

In addition the subject genes and gene products and cells which express may be used to identify ancillary taste receptors or primary taste receptors such as fat or metallic taste cells.

Also the subject genes, gene products and cells which express same can be used in screens to identify compounds that affect digestive function such s gastric motility, food detection, food absorption or the production of digestive fluids, peptides, hormones or enzymes such as Glucagon Like Peptide-1, Glucose Dependent Insulinotropic polypeptide, pepsin, secretin, amylase, saliva, et al.

Also the subject genes, gene products and cells which express same may be used to screen for compounds that affect trafficking of taste receptors to and from the apical membrane/taste pore region to enhance or repress general or specific tastes, regulation of taste cell action potential firing frequency/membrane potential to control the intensity of general or specific tastes, regulation of neurotransmitter release to afferent nerve to control the intensity of general or specific taste, and autocrine/paracrine modulation of taste receptor function.

Further the subject genes, gene products and cells which express same can be used to identify compounds that regenerate taste cells such as in geriatric individuals or patients with cancer, chemotherapy radiation, injury or surgery affecting taste, drug-induced dysgeusia, ageusia, and for alleviating taste bud loss.

Still further the subject genes and gene products and cells which express same can be used to screen for compounds that affect oral hygiene, halitosis, detoxification of noxious substances in the oral cavity, and neutralization/elimination of bacteria, viruses, and other immunogens in the saliva/mouth or digestive tract.

Yet additionally the subject genes, gene products and cells which express same can be used in screens to identify compounds that affect saliva production and composition and treatment of dry mouth in conditions such as xerostomia and Sjogren's disease, in autoimmune or inflammatory gastrointestinal diseases, IBD, ulcerative colitis, and diverticulitis and cancers affecting the oral cavity and digestive tract.

The following examples were effected using the materials and methods described supra. These examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention, and are not intended to limit the scope of what is regarded as the invention.

EXAMPLES Example 1

This experimental example the results of which are contained in FIG. 1 is exemplary of the results obtained with laser capture microdissection (LCM) on primate fungiform (FG) taste tissue (top row) and lingual epithelium (LE) non-taste tissue (bottom row). Shown in the top row, in the left image is FG tissue before LCM with a single FG taste bud. The middle image in FIG. 1 shows FG tissue after LCM where single FG taste bud has been removed. The right image in FIG. 1 shows collected and isolated FG taste bud used for molecular biology experiments to discover taste-specific genes. Shown in the bottom row, in the left image is tissue before LCM with LE from anterior tongue surface. The middle image in the same Figure shows tissue after LCM where a region of LE has been removed. Shown in the right image is the collected and isolated LE region used for molecular biology experiments to discover taste-specific genes.

Example 2

This experimental example the results of which are contained in FIG. 2 is exemplary of PCR quality control of primate taste and lingual cells collected by LCM. It can be seen therefrom that taste bud cells (TB), but not lingual epithelial cells (LE), specifically express the known taste-specific genes T1R2 (a component of the sweet receptor), PLCbeta2 (an enzyme involved in sweet, bitter, and umami taste detection), and GNAT3 (i.e. gustducin, a G-protein alpha subunit involved in sweet, bitter, and umami taste detection). By contrast, it can be seen that both taste and lingual cells express the ubiquitous housekeeping genes GAPDH and beta-actin, indicating that taste and lingual cell RNA is intact and of high quality. ‘+’ indicates reverse transcription and ‘−’ indicates no reverse transcription was performed.

Example 3

This example relates to the experiment contained in FIG. 3. Shown therein is an example of double labeling in situ hybridization illustrating expression of TRPM5 and PKD1L3 in different taste cells in primate circumvallate (CV) taste tissue. It can be seen that TRPM5 (top; green) is not detectable in cells expressing PKD1L3 (middle; red). The overlay of TRPM5 and PKD1L3 signals is depicted in the bottom image. It can further be seen that TRPM5 and PKD1L3 signals are present in different taste cells. Particularly, TRPM5 is expressed in cells responsible for sweet, bitter, and umami taste, whereas PKD1L3 is expressed in cells responsible for sour taste.

Example 4

This example which is contained in FIG. 4 shows a double labeling in situ hybridization illustrating coexpression of PKD2L1 and PKD1L3 in the same taste cells in primate circumvallate (CV) taste tissue. It can be seen therein that PKD2L1 (top; green) is coexpressed in cells expressing PKD1L3 (middle; red). The overlay of PKD2L1 and PKD1L3 signals is depicted in the bottom image in yellow. It can further be seen that both PKD2L1 and PKD1L3 signals are present in the same taste cells. Both PKD2L1 and PKD1L3 are expressed in cells responsible for sour taste.

Example 5

This example relates to the experiments contained in FIG. 5. This experiment is an example of double labeling in situ hybridization illustrating expression of TRPM5 and PKD1L3 in different taste cells in primate fungiform (FG) taste tissue. It can be seen therein that TRPM5 (left; purple stain) is not detectable in cells expressing PKD1L3 (middle; red). The overlay of TRPM5 and PKD1L3 signals is depicted in the left image. It can further be seen therein that TRPM5 and PKD1L3 signals are present in different taste cells. Particularly, the Figure shows that TRPM5 is expressed in cells responsible for sweet, bitter, and umami taste, whereas PKD1L3 is expressed in cells responsible for sour taste.

Example 6

This example relates to the results of a double labeling in situ hybridization experiment contained in FIG. 6. The Figure illustrates the coexpression of PKD2L1 and PKD1L3 in the same taste cells in primate fungiform (FG) taste tissue. It can further be seen that PKD2L1 (left; purple stain) is coexpressed in cells expressing PKD1L3 (middle; red). The overlay of PKD2L1 and PKD1L3 signals is depicted in the right image. The Figure further reveals that that both PKD2L1 and PKD1L3 signals are present in the same taste cells. Both PKD2L1 and PKD1L3 are expressed in cells responsible for sour taste.

Example 7

This example relates to the double labeling hybridization experiment contained in FIG. 7. This experiment which again involved double label in situ hybridization of primate circumvallate papilla revealed that FAM26A (purple color; left image) colocalizes with TRPM5 (red; middle image). The results contained in the figure also show that FAM26A cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).

Example 8

This example relates to the double label in situ hybridization experiment contained in FIG. 8. This hybridization experiment which again used primate circumvallate papilla revealed that the taste cell specific gene GPR113 (purple color; left image) colocalizes with a subset of TRPM5 cells (red; middle image). It can be seen from the figure that that only a fraction of cells expressing TRPM5, a marker of sweet, umami, and bitter taste cells, also express GPR113 (merged image on the right), but that all GPR113 cells express TRPM5. Two taste buds are shown.

Example 9

The experiment contained in FIG. 9 is another double hybridization experiment using primate circumvallate papilla cells. The results contained in the Figure reveal that MCTP1 (purple color; left image), a taste cell specific gene, colocalizes with TRPM5 (red; middle image). It can be seen that MCTP1 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown in the Figure.

Example 10

This example relates to another double label in situ hybridization of primate circumvallate papilla cells. The results in FIG. 10 show that TMEM16G (purple color; left image) colocalizes with a subset of TRPM5 cells (red; middle image). It can also be seen that only a fraction of cells expressing TRPM5, a marker of sweet, umami, and bitter taste cells, also express TMEM16G (merged image on the right), but that all TMEM16G cells express TRPM5.

Example 11

This example relates to another double label in situ hybridization of primate circumvallate papilla cells. The results contained in FIG. 11 show that TMEM44 (purple color; left image), a taste cell specific gene, does not colocalize with TRPM5 (red; middle image). It can be seen from the results in the figure that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown in the figure.

Example 12

This example relates to the double label in situ hybridization of primate circumvallate papilla cells contained in FIG. 12. The results contained therein reveal that TMEM44 (purple color; left image) does not colocalize with PKD1L3 (red; middle image). It can also be seen that TMEM44 cells do not express PKD1L3, a marker of sour taste cells (merged image on the right). Two taste buds are shown.

Example 13

This example relates to another double label in situ hybridization of primate circumvallate papilla cells. The results which are contained in FIG. 13 show that TUSC3 (purple color; left image), a taste cell specific gene, colocalizes with TRPM5 (red; middle image). It can also be seen that TUSC3 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).

Example 14

This example shows that GPR113 is not expressed in T1R1 umami cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T1R1 (red; middle image). Note that GPR113 and T1R1, a marker of umami cells, are in different taste cells (merged image on the right).

Example 15

This example shows that GPR113 is not expressed in T1R2 sweet cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T1R2 (red; middle image). Note that GPR113 and T1R2, a marker of sweet cells, are in different taste cells (merged image on the right).

Example 16

This example shows that GPR113 is expressed in a subset of T1R3 cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does colocalize with a subset of T1R3 cells (red; middle image). Note that GPR113 is always expressed in cells with T1R3, but that there are T1R3 cells that do not express GPR113 (merged image on the right). These T1R3 cells that do not express GPR113 likely coexpress either T1R1 or T1R2. The T1R3 only cells are a new population of taste cells that coexpress GPR113.

Example 17

This example shows that GPR113 is not expressed in T2R bitter cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T2R (red; middle image). Note that GPR113 and T2R, a marker of bitter cells, are in different taste cells (merged image on the right).

Example 18

This example contains an experiment that shows that TMEM44 is not expressed in TRPM5 or PKD1L3 cells in fungiform taste buds. Double label in situ hybridization experiments were conducted using primate fungiform papilla from the front of the tongue showing that TMEM44 (blue/purple color; left images) does not colocalize with TRPM5 (red; middle top image) or PKD1L3 (red; middle bottom image). Note that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells, or PKD1L3, a marker of sour cells, in the merged images on the right.

Example 19

This example contains an experiment that shows that TMEM44 is not expressed in TRPM5 cells in circumvallate papilla. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (green cells; top image) does not colocalize with TRPM5 (red cells; middle image). Note that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the bottom).

Example 20

This example contains experiments that show that TMEM44 is not expressed in PKD1L3 cells in circumvallate papilla. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (green cells; top image) does not colocalize with PKD1L3 (red cells; middle image). Note that TMEM44 cells do not express PKD1L3, a marker of sour taste cells (merged image on the bottom).

Example 21

This example contains experiments that reveal that TMEM44 cells extend processes to the taste pore. Double label histology experiment of primate circumvallate papilla at the back of the tongue. Cytokeratin 19 protein (green; left image) is present in cells expressing TMEM44 RNA (red; middle image). Note that TMEM44 cells extend processes to the taste pore facing the saliva. Asterisk denotes a TMEM44 cell nucleus and white arrows denote the apical process of this same cell extending to the taste pore (merged image on the right). Thus, TMEM44 cells are sensory taste cells that can sample the saliva for tastants. Cytokeratin 19 is a marker of all taste cells.

Example 22

This example shows that FAM26B is expressed in TRPM5 cells. Double label in situ hybridization of primate circumvallate papilla showing that FAM26B (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that FAM26B cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).

Example 23

This example shows that SLC4A11 is expressed in TRPM5 cells. Double label in situ hybridization of primate circumvallate papilla showing that SLC4A11 (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that SLC4A11 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).

Example 24

This example shows that MFSD4 is not expressed in TRPM5 cells. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 (blue/purple color; left image) does not colocalize with TRPM5 (red; middle image). Note that MFSD4 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown.

Example 25

This example shows that MFSD4 and TMEM44 are expressed in the same taste cells. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 and TMEM44 are expressed in the same taste cell population. TMEM44 (top blue/purple color) and MFSD4 (bottom blue/purple color) do not colocalize with TRPM5 (red color top and bottom images) and are expressed in taste cells in the bottom halves of taste buds. The equivalent localization, abundance, and morphology of TMEM44 and MFSD4 taste cells indicates that these cells are identical and that both TMEM44 and MFSD4 genes are expressed in the same taste cell type FIG. 26 shows that ASCL1 is expressed in sour taste cells but not sweet, bitter, or umami taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that ASCL1 (blue/purple color; left images) does not colocalize with TRPM5 (red; middle top image) but does colocalize with PKD1L3 (red; middle bottom image). Note that ASCL1 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells, but do express PKD1L3, a marker of sour cells, in the merged images on the right.

Example 26

Example 26 shows that ASCL1 is expressed in sour taste cells but not sweet, bitter, or umami taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that ASCL1 (blue/purple color; left images) does not colocalize with TRPM5 (red; middle top image) but does colocalize with PKD1L3 (red; middle bottom image). Note that ASCL1 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells, but do express PKD1L3, a marker of sour cells, in the merged images on the right.

Example 27

KIT is expressed in T1R1 umami taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that KIT (blue/purple color; left images) colocalizes with T1R1 (red; middle image top row), does not colocalize with T1R2 (red; middle image 2^(nd) row), does colocalize with T1R3 (red; middle image 3^(rd) row), and does not colocalize with T2Rs (red; middle image bottom row). Note that KIT cells express T1R1 and T1R3, markers of umami taste cells, but not T1R2 or T2Rs, markers of sweet and bitter cells respectively, in the merged images on the right.

Example 28

IKBKAP is expressed in PKD1L3 sour taste cells. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that IKBKAP (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) but does colocalize with PKD1L3 (red; middle image bottom). Note that IKBKAP cells express PKD1L3, a marker of sour taste cells (merge image bottom) but do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image top).

Example 29

This experiment revealed that the taste specific gene LOC285965 is expressed in T1R3 only taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that LOC285965 (blue/purple color; left images) does not colocalize with T1R1 (red; middle image top row), does not colocalize with T1R2 (red; middle image 2^(nd) row), does colocalize with T1R3 (red; middle image 3^(rd) row), and does not colocalize with T2Rs (red; middle image bottom row). Note that LOC285965 cells express T1R3, but not T1R1, T1R2 or T2Rs, markers of umami, sweet and bitter cells respectively, in the merged images on the right.

Example 30

This experiment revealed that the taste specific gene SV2B is expressed in PKD1L3 sour taste cells. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that SV2B (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) but does colocalize with PKD1L3 (red; middle image bottom). Note that SV2B cells express PKD1L3, a marker of sour taste cells (merge image bottom) but do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image top).

Example 31

This experiment revealed that the taste specific gene MFSD4 is expressed in a unique taste cell type. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 (blue/purple color; left image) does not colocalize with PKD1L3 or TRPM5 (red; middle images) but is expressed in a unique taste cell type. Note that MFSD4 cells do not express PKD1L3, a marker of sour taste cells or TRPM5, a marker of sweet, umami, and bitter taste cells (merged images on the right). Two taste buds each are shown for PKD1L3 & TRPM5 double labels.

Example 32

This experiment revealed that the taste specific genes MFSD4 and TMEM44 are expressed in the same taste cell population. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 and TMEM44 are expressed in the same taste cell population. MFSD4 (left; green) and TMEM44 (middle; red) signals are present in the same taste cells (right; merged image).

Example 33

This experiment the results of which are contained in FIG. 33 revealed that SHH is expressed in immature taste cells in the bottom of the taste bud. Double in situ hybridization of primate circumvallate papilla at the back of the tongue showing that SHH (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) or PKD1L3 (red; middle image bottom). Note that SHH cells do not express TRPM5, a marker of sweet, bitter, and umami taste cells (merge; right image top) or PKD1L3 (merge; right image bottom). Both TRPM5 and PKD1L3 genes are expressed in professional taste cells.

Example 34

This experiment the results of which are contained in FIG. 34 show that the taste specific genes TMEM44 and SHH are expressed in immature taste cells at the bottom of the taste bud. In situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (blue/purple color; top 3 images) is expressed in cells towards the base of the taste bud. A similar expression pattern was observed with SHH (blue/purple color; bottom 3 images). Since SHH is marker of immature, developing taste cells, these data indicate that TMEM44 is expressed in and is a marker of immature taste cells.

Example 35

This experiment relates to the experiment in FIG. 35. In situ hybridization of primate circumvallate papilla at the back of the tongue showing SHH (blue/purple color) expression at the base of the taste bud and PKD1L3 (red color) expression towards the top of the taste bud. This figure contains a schematic model of taste cell development which indicates that three is a gradient of SHH expression from high levels at the base of the taste bud (immature cells) to low levels at the top of the taste bud (mature cells). As SHH expression levels decrease, expression of taste receptor genes such as TRPM5 and PKD1L3 increase. Thus, an opposite gradient of taste cell maturation exists where taste cells progressively mature and express taste receptor genes as they differentiate from the bottom to the top of the taste bud.

Example 36

This experiment the results of which are contained in FIG. 36 show that a small fraction of TMEM44 cells express TRPM5 or PKD1L3 as they differentiate into mature taste cells. Double label in situ hybridization of primate circumvallate papilla was performed using TRPM5 and TMEM44 riboprobes (left pie chart) or PKD1L3 and TMEM44 riboprobes (right pie chart). Taste cells expressing TRPM5 (blue graph region; left pie chart), TMEM44 (magenta graph region; left pie chart), or TRPM5 plus TMEM44 (labeled ‘both’ and yellow graph region; left pie chart) genes were counted and graphed in pie charts. Taste cells expressing PKD1L3 (blue graph region; right pie chart), TMEM44 (magenta graph region; right pie chart), or TRPM5 plus TMEM44 (labeled ‘both’ and yellow graph region; right pie chart) genes were counted and graphed in pie charts. Total number of counted cells is listed below each pie chart in parentheses. A small fraction of TMEM44 cells also express TRPM5 or PKD1L3, indicating that these cells are differentiating from an immature state (TMEM44 only) to a mature state (TRPM5 or PKD1L3 only). Inset shows example of CV taste bud labeled with TMEM44 (green) and TRPM5 (red). Note cell indicated with arrow that coexpresses both TMEM44 and TRPM5 (yellow).

Example 37

This experiment the results of which are contained in FIG. 37 reveals that mature taste cells do not coexpress markers for distinct taste modalities. Double label in situ hybridization of primate circumvallate papilla was performed using TRPM5 and PKD1L3. Taste cells expressing TRPM5 (blue graph region), PKD1L3 (magenta graph region), or TRPM5 plus PKD1L3 (labeled ‘both’ and yellow graph region which is too small to see any yellow segment due to the near absence of cells within this category) genes were counted and graphed in the pie chart. Total number of counted cells is listed below the pie chart in parentheses.

Example 38

Top Versus Bottom Gene Expression in the Taste Buds

The experiments and results herein relate to a systematic method for assigning gene expression patterns within the primate taste bud for taste bud-specific genes. Specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud, the inventors were able to classify genes into one of several functional classes that include taste receptor genes. A subset of genes in this classification is likely to encode taste receptors that include those for salty taste and other yet to be defined taste specificities.

As explained previously, the rationale for comparing gene expression between the top and bottom of the primate taste bud arose from the histological localization of mRNAs for a number of candidate taste receptor genes. Expression of a subset of these genes appeared to be localized at the bottom portion of the taste bud while other genes were predominantly expressed at the top of the taste bud. These patterns of expression are exemplified by the TMEM44 and TRPM5 genes which are expressed at the bottom and top of the taste bud respectively, see FIG. 38.

In order to get more information on gene expression in both the top and bottom fractions of the taste bud we undertook an experiment to isolate the corresponding fractions of primate taste buds using laser capture microdissection (LCM). As described previously, LCM involves the excision and isolation of selected cells or groups of cells from tissue sections based on morphological distinctions. In the case of taste buds, we can readily identify these structures in sections of primate tongue. In this specific example tissue collection was limited to taste buds in circumvallate papillae and then to only taste buds that were sectioned sagittally and at the taste pore. We reasoned it was only from this type of section would we be able to reliably isolate top and bottom fractions. An example of sections used in sample collection is shown in FIG. 39.

Multiple LCM preparations from each of 4 animals were pooled (4 top samples, 4 bottom samples, ˜5000 cells per sample) RNA extracted and analyzed using Affymetrix whole genome macaque Gene Chips to obtain global mRNA expression profiles for the top and bottom fractions.

The gene expression data was queried to obtain three sets of genes. The first and second sets are genes that are expressed at a higher level in the top or bottom of the primate taste bud relative to the bottom or top respectively. Top-specific genes were listed in one group of genes, and bottom specific genes are listed in a second group. Accordingly, these lists contain top enriched and bottom enriched mRNAs. The third set of genes was also identified as being expressed at a higher level in the top of the primate taste bud relative to surrounding lingual epithelium.

An exemplary experiment validating this methodology is contained in FIG. 38. This experiment contains an experiment showing that levels of gene expression define two compartments in primate taste buds. To create this overlay image sagittal sections of primate taste buds were initially stained with DAPI (4′,6-diamidino-2-phenylindole) to visualize cell nuclei; blue color. Double label in situ hybridization images of the same sections for TMEM44; green color and TRPM5+PKD1L3; pink color were then added. The overlay image shows that TMEM44 expression is restricted to the bottom third of each of the four taste buds shown and that TRPM5+PKD1L3 expression occurs predominantly in the upper regions of each of the taste buds.

FIG. 39 shows an exemplary experiment showing laser capture microdissection of top and bottom regions of primate taste buds. Panel) contains a methyl blue stained section A of macaque circumvallate taste buds. Panel B shows Section A following excision of bottom fraction of taste buds. Panel C contains the bottom fraction of taste buds. Panel D shows Section A following excision of bottom and top fractions of taste buds. Panel E shows the Top fraction of taste buds. Note, top and bottom fractions were only collected from taste buds exhibiting optimal morphology in section. In the example shown, the taste bud labeled with an arrow was excluded due to suboptimum sectioning or morphology.

The results obtained by the inventors revealed that taste receptor genes are expressed predominantly at the top of the taste bud. In contrast to what has been reported, the data of the inventors suggests that known taste receptor genes are expressed at higher level in the top fraction of the taste buds. Therefore, this technique should allow for other yet to be identified taste receptor genes to be represented in the top-enriched set of genes.

In addition, there is an apparent functional classification that can be made based on top versus bottom taste bud cells. The gene expression profiles of the top and bottom fractions of the taste bud suggest distinct functions for cells in each compartment. Functional classes of genes represented in the top cells indicate that these are mature sensory cells whereas those expressed in the bottom cells indicate these are immature progenitor cells associated with a basement membrane containing cellular environment. Examples of top specific functional classes include taste receptors, taste-specific signal transduction components and receptors. Examples of bottom-specific functional classes include extracellular metric components, growth factors and cell-cycle associated proteins.

Also, based thereon, these techniques allow for the identification of additional taste bud-specific genes. By fractionating the taste buds into top and bottom compartments the inventors were able to increase the sensitivity of mRNA detection in each compartment by a factor of approximately two. This enables us to identify another set of taste bud specific genes

Example 39

This experiment the results of which are contained in FIG. 40 establish that distinct cell populations PKD2L1, PKD1L3 and PKD2L1 plus PKD1L3. Double label in situ hybridization of primate fungiform (FG; left) and circumvallate (CV; right) was performed using PKD2L1 and PKD1L3 riboprobes. Taste cells expressing PKD2L1 (blue graph regions), PKD1L3 (magenta graph regions), or PKD2L1 plus PKD1L3 (labeled ‘both’ and yellow graph regions) genes were counted and graphed in pie charts. Total number of counted cells is listed below each pie chart in parentheses.

Example 40

This experiment the results of which are contained in FIG. 41 shows that FAM26C is expressed in TRPM5 taste cells. Therein double in situ hybridization of primate circumvallate papilla at the back of the tongue showing that FAM26C (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that FAM26C cells express TRPM5, a marker of sweet, bitter, and umami taste cells (merge; right image).

Example 41

This experiment the results of which are contained in FIG. 42 shows that NALCN is a taste-specific gene. The figure shows end-point PCR experiments on circumvallate taste buds (taste) and lingual epithelial cells (lingual) of non-human primate (left) and mouse (right) isolated by laser-capture microdissection demonstrating that NALCN is a taste-specific gene. NALCN is only expressed in taste cells and is not detectable in lingual cells, similar to the known taste-specific genes gustducin, T1R2, and TRPM5. β-actin is detectable in both taste and lingual samples, indicating that high-quality RNA was present in both samples. ‘+’ indicates that reverse transcription was performed and ‘−’ indicates that no reverse transcription was performed. PCR bands were only observed with reverse transcriptase indicating that PCR products are derived from mRNA and not genomic DNA. PCR products were cloned and sequenced to verify that the bands corresponded to the expected gene products.

Example 42

This experiment the results of which are contained in FIG. 43 shows that NALCN is expressed in a unique taste cell type effected at low magnification. Therein is shown a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel taste cell population. Numerous taste buds are shown.

Example 43

This experiment the results of which are contained in FIG. 44 also shows that NALCN is expressed in a unique taste cell type but at high magnification. Therein is contained a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel taste cell population. One to two taste buds are shown.

Example 44

This experiment the results of which are contained in FIG. 45 shows that NALCN is not expressed in TRPM5 cells. The figure contains a double label immunochemistry of circumvallate papilla from the back of the tongue showing that NALCN (red color, middle images( ) does not colocalize with TRPM5 in non-human primate (green, left image top row) or IP3R3 in rat (green; left image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since TRPM5 and IP3R3 mark sweet, bitter, and umami cells, equivalent to type II cells, NALCN is not expressed in type II cells in non-human primate and rat.

Example 45

The experiment in FIG. 46 shows that NALCN is expressed in a subset of fungiform taste cells. Therein single label immunochemistry of fungiform papilla from the front of the tongue of non-human primate showing that NALCN (red color) is expressed in a subset of taste cells. Top of the taste bud, facing saliva, if oriented towards the top in the image is shown (see arrow). unique taste cell type but at high magnification. Therein is contained a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel. taste cell population. One to two taste buds are shown

Example 46 Identification of Human Taste Specific Genes by Quantitative PCR

Experiments enabling the identification of human taste specific genes by quantitative polymerase chain reaction (PCR) were also effected. In the previous examples we described genes expressed in primate taste buds and we assigned gene expression patterns within the primate taste bud for all taste bud-specific genes; specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud. By these methods the inventors were able to classify genes into one of several functional classes that include taste receptor genes. In this example we demonstrate taste specific gene expression in humans (in addition to primate) and have validated the specificity of expression by a quantitative method (qPCR or “TaqMan”). The genes described in Table below, identified by these methods all encode multi-span transmembrane proteins, and it is likely that they include the salt receptor and others taste receptors whose function has yet to be defined.

In these experiments the inventors used human taste bud samples. In order to isolate human taste buds we performed laser capture microdissection (LCM). This technique has been described in detail in the provisional patent applications and incorporated by reference and supra. Briefly, it involves the excision and isolation of selected cells or groups of cells from tissue sections based on morphological distinctions. In the case of taste buds, we can readily identify these structures in sections of human tongue. In this specific example tissue collection was limited to taste buds (TB) in circumvallate papillae and, as a control, cells from the adjacent lingual epithelium (LE). An example of sections used in sample collection is shown in FIG. 47. Multiple LCM preparations from each of 3 human donors were pooled (˜4500 cells per sample), RNA extracted and amplified by WT-Ovation Pico RNA Amplification System (NuGEN Technologies, Inc) and analyzed using TaqMan technology to determine specific levels of gene expression in the TB and LE pools.

The expression of the taste-specific genes was quantified by TaqMan in LCM derived cDNA from both LE and TB from the same donors. FIG. 47 shows the laser capture microdissection of human taste buds. Panel A shows methyl blue stained section of human circumvallate human taste buds. Panel B shows Section A following excision of taste buds. Panel C contains the captured taste buds.

A list of the analyzed human genes expressed are contained in Table 8 infra. Gene expression is measured in TaqMan as a CT (cycle threshold) value. Briefly the CT value for a given sample is determined by the PCR cycle at which the amount of gene-specific PCR product (as measured by fluorescence) reaches a set value. For highly expressed genes, the threshold will be reached early in the PCR run and the CT value will be relatively low (<35) while genes with very low or no expression will not reach the threshold before cycle 35. Expression of genes with CT values >40 are defined as not detectable. For the majority of genes listed in the Table, expression was not detected in LE samples (CT>40) but was readily detectable in TB samples (CT<35).

The group of human taste specific genes contained in Table 8 has not been described before as taste-specific in human tissue.

Therefore, these results show that by using this approach that uses LCM from post-mortem human tissue samples and a single cDNA amplification step, our data clearly indicate that postmortem LCM human tissue can be used to quantify the expression of taste specific genes using qPCR. and that human taste specific genes can be measured by quantitative PCR (TaqMan). Particularly, gene expression profiles of taste specific genes can be measured by TaqMan. This methodology validated gene expression data obtained from microarrays and/or in situ hybridization (ISH). Therefore, by using the successive approaches of gene expression via microarray in primate LCM tongue tissue; top-specific gene expression within the taste bud (akin to known taste receptors) and TaqMan quantification of gene expression in human postmortem tastes tissues, new human taste specific genes that had not been described previously were identified as contained in Table 8.

Additional Results and Tables Listing Taste Specific Genes (Human and Macaque)

The primate taste bud-specific gene list which resulted in the taste-specific genes contained in Tables 1-5 below were generated by the use of specific inclusion criteria. These inclusion criteria used Affymetrix MAS5 normalized data as follows:

Inclusion Criteria

Using Affymetrix MAS5 normalized data

FG taste bud mean expression value≧50

FG versus LE expression ratio≧2-fold up

FG versus LE expression ratio p value≦0.05

-   -   424 probe sets     -   Using Affymetrix GC-RMA normalized data         FG taste bud mean expression value≧20         FG versus LE expression ratio≧2-fold up         FG versus LE expression ratio p value≦0.05     -   504 probe sets     -   PLUS 3211 probe sets isolated from both data sets     -   [TOTAL Number of Primate Taste Bud Specific probe Sets Equals         4139}     -   TOTAL Number of Primate Taste Bud Specific Genes Equals 3455

TABLE 1 Representative MAS5 MAS5 MAS5 Representative Public ID: LE TB fold MAS5 Public ID Species mean mean change p value XM_001085855 Mm 168.1 825.8 4.9 0.0007 XM_001106014 Mm 50.9 113.9 2.2 0.0386 XM_001084081 Mm 17.1 174.9 10.2 0.0066 XM_001099138 Mm 126.8 547.4 4.3 0.0244 XM_001101439 Mm 30.3 102.6 3.4 0.0250 XM_001113252 Mm 5.0 702.3 139.3 0.0006 XM_001107314 Mm 12.3 74.2 6.0 0.0001 XR_014466 Mm 185.9 584.9 3.1 0.0056 XR_013101 Mm 63.8 405.3 6.4 0.0103 XM_001083619 Mm 16.5 155.4 9.4 0.0496 XM_001088479 Mm 344.9 1388.2 4.0 0.0043 XM_001088853 Mm 44.9 102.2 2.3 0.1992 XM_001085289 Mm 416.8 2226.5 5.3 0.0001 XM_001086036 Mm 34.3 88.7 2.6 0.0421 XM_001114058 Mm 404.5 3269.5 8.1 0.0007 XM_001112907 Mm 81.7 715.0 8.8 0.0223 BV165948 Mm 35.9 111.9 3.1 0.0172 BV166168 Mm 11.1 93.6 8.5 0.0026 BV166439 Mm 11.0 75.4 6.9 0.0016 BV209038 Mm 35.5 154.1 4.3 0.0139 BV209579 Mm 22.4 51.7 2.3 0.0393 BV209589 Mm 18.5 109.8 5.9 0.0340 BV209803 Mm 31.9 97.2 3.0 0.0775 BV209934 Mm 40.2 104.0 2.6 0.0606 BV210562 Mm 626.9 1473.7 2.4 0.0003 BV211039 Mm 164.1 439.3 2.7 0.0026 BV445286 Mm 51.7 493.2 9.5 0.0039 BV447952 Mm 36.9 454.5 12.3 0.0001 BV447979 Mm 22.4 123.1 5.5 0.0001 BV448453 Mm 36.7 184.8 5.0 0.0333 BV448619 Mm 32.7 90.3 2.8 0.0288 BV448731 Mm 374.3 769.4 2.1 0.0179 BV448735 Mm 20.6 1485.7 72.2 0.0010 BV448827 Mm 44.4 110.9 2.5 0.0441 AL833583 Hs 31.4 267.0 8.5 0.1140 CB550378 Mm 16.2 136.4 8.4 0.0164 CN804030 Mm 431.4 1060.7 2.5 0.0387 CO774248 Mm 22.4 70.6 3.1 0.0233 NM_000166 Hs 19.1 64.4 3.4 0.0466 NM_000335 Hs 4.5 381.4 85.4 0.0003 NM_001001666 Hs 13.0 139.7 10.7 0.0009 NM_001001994 Hs 40.0 1037.3 25.9 0.0003 NM_001002796 Hs 3.7 2066.5 558.9 0.0046 NM_001004746 Hs 35.3 102.1 2.9 0.0148 NM_001010898 Hs 26.8 106.7 4.0 0.0016 NM_001011655 Hs 8.2 1258.5 154.2 0.0035 NM_001012302 Hs 28.9 64.8 2.2 0.0090 NM_001017970 Hs 348.7 1779.2 5.1 0.0000 NM_001025356 Hs 43.1 175.0 4.1 0.0071 NM_001033026 Hs 90.2 180.8 2.0 0.0091 NM_001037984 Hs 134.6 263.8 2.0 0.0032 NM_001040456 Hs 46.2 155.1 3.4 0.0019 NM_001042680 Hs 28.4 59.3 2.1 0.0495 NM_001046 Hs 41.8 182.3 4.4 0.0002 NM_001076674 Hs 174.4 351.5 2.0 0.0666 NM_001077241 Hs 52.8 129.7 2.5 0.0175 NM_001079669 Hs 245.7 3971.8 16.2 0.0000 NM_001425 Hs 29.3 60.9 2.1 0.1000 NM_001606 Hs 700.5 3503.3 5.0 0.0000 NM_002211 Hs 7.1 42.6 6.0 0.0249 NM_003615 Hs 8.4 413.3 48.9 0.0034 NM_004099 Hs 66.5 174.0 2.6 0.0010 NM_005502 Hs 223.5 611.5 2.7 0.0264 NM_005724 Hs 321.1 666.4 2.1 0.0048 NM_007213 Hs 23.6 78.8 3.3 0.0336 NM_012329 Hs 43.0 209.1 4.9 0.0577 NM_014399 Hs 2718.3 5413.0 2.0 0.0013 NM_014858 Hs 62.8 176.7 2.8 0.0597 NM_014982 Hs 18.0 86.9 4.8 0.0493 NM_015205 Hs 177.2 389.7 2.2 0.0234 NM_015257 Hs 38.7 134.4 3.5 0.0269 NM_015292 Hs 986.6 2513.0 2.5 0.0004 NM_015916 Hs 5.2 152.3 29.5 0.0057 NM_016127 Hs 1915.3 3775.3 2.0 0.0003 NM_016235 Hs 27.7 584.2 21.1 0.0007 NM_016475 Hs 49.3 143.6 2.9 0.0400 NM_017586 Hs 266.0 1076.2 4.0 0.0140 NM_017672 Hs 68.9 231.9 3.4 0.0074 NM_017744 Hs 81.3 202.7 2.5 0.0061 NM_017799 Hs 42.0 191.1 4.6 0.0047 NM_017801 Hs 78.5 154.7 2.0 0.0110 NM_017814 Hs 33.0 100.7 3.1 0.0049 NM_017849 Hs 43.5 109.5 2.5 0.0092 NM_017905 Hs 32.5 91.7 2.8 0.0382 NM_017918 Hs 48.9 232.0 4.7 0.0012 NM_018056 Hs 25.7 63.3 2.5 0.0298 NM_018452 Hs 48.4 146.0 3.0 0.0090 NM_018487 Hs 8.9 924.9 103.6 0.0004 NM_018502 Hs 14.0 47.3 3.4 0.0234 NM_019118 Hs 37.5 451.0 12.0 0.0000 NM_020215 Hs 12.9 108.0 8.4 0.0112 NM_020448 Hs 34.7 93.3 2.7 0.0445 NM_020925 Hs 27.9 480.2 17.2 0.0069 NM_021194 Hs 132.0 329.5 2.5 0.0493 NM_021259 Hs 20.1 115.0 5.7 0.0178 NM_021637 Hs 6.9 64.5 9.3 0.0032 NM_021727 Hs 46.6 106.0 2.3 0.0132 NM_022369 Hs 8.6 131.0 15.3 0.0940 NM_022458 Hs 32.9 145.1 4.4 0.0203 NM_022495 Hs 33.1 154.8 4.7 0.0239 NM_023003 Hs 16.0 157.6 9.9 0.0175 NM_023943 Hs 7.7 57.2 7.4 0.0375 NM_024628 Hs 47.5 710.7 15.0 0.0018 NM_024630 Hs 71.6 386.9 5.4 0.0159 NM_024956 Hs 64.7 129.7 2.0 0.0211 NM_025257 Hs 9.7 275.1 28.2 0.0024 NM_030651 Hs 7.1 183.8 25.9 0.0053 NM_030923 Hs 6.5 1801.8 276.3 0.0004 NM_031442 Hs 8.7 73.8 8.5 0.0415 NM_031484 Hs 88.3 881.7 10.0 0.0001 NM_032012 Hs 390.0 1480.2 3.8 0.0006 NM_032016 Hs 135.4 961.3 7.1 0.0023 NM_032295 Hs 112.6 267.8 2.4 0.0152 NM_032483 Hs 87.0 224.8 2.6 0.0200 NM_032824 Hs 90.1 335.9 3.7 0.0563 NM_032826 Hs 17.5 62.2 3.6 0.0084 NM_032890 Hs 93.4 987.6 10.6 0.0000 NM_033102 Hs 7.8 125.6 16.1 0.0202 NM_138346 Hs 573.4 2006.8 3.5 0.0001 NM_139075 Hs 48.1 138.1 2.9 0.0046 NM_144638 Hs 19.8 92.2 4.6 0.0170 NM_144649 Hs 21.9 52.6 2.4 0.1617 NM_144686 Hs 18.0 406.4 22.6 0.0034 NM_145290 Hs 44.9 192.8 4.3 0.1919 NM_152288 Hs 353.5 1590.1 4.5 0.0006 NM_152522 Hs 357.2 514.3 1.4 0.0595 NM_152588 Hs 182.1 560.3 3.1 0.0148 NM_152778 Hs 43.7 208.5 4.8 0.0139 NM_153354 Hs 38.2 118.1 3.1 0.0523 NM_153365 Hs 600.9 1850.8 3.1 0.0027 NM_153704 Hs 8.9 46.9 5.3 0.0288 NM_153811 Hs 105.8 303.3 2.9 0.0433 NM_173512 Hs 10.3 77.0 7.5 0.0169 NM_173653 Hs 159.5 357.2 2.2 0.0187 NM_174926 Hs 8.2 211.1 25.9 0.0246 NM_175861 Hs 15.1 74.4 4.9 0.0146 NM_177964 Hs 27.7 267.4 9.7 0.0016 NM_178818 Hs 54.5 167.8 3.1 0.0145 NM_181644 Hs 63.9 520.8 8.2 0.0095 NM_181787 Hs 52.3 246.1 4.7 0.0109 NM_182494 Hs 5.4 1159.4 215.5 0.0010 NM_182504 Hs 8.4 53.3 6.4 0.0151 NM_182532 Hs 4.8 74.8 15.5 0.0180 NM_182547 Hs 1722.3 3135.0 1.8 0.0023 NM_198276 Hs 35.7 127.6 3.6 0.0226 NM_207351 Hs 116.0 890.6 7.7 0.0035 XM_001128552 Hs 4.7 292.8 62.8 0.0505 XM_370997 Hs 6.3 70.5 11.2 0.0057 XM_927351 Hs 5.3 1085.9 204.3 0.0027

-   -   This table summarizes primate taste-bud expressed genes that         were identified as multi-plasma membrane proteins with little or         no functional characterization. The set is consistent with this         gene set including taste receptors and more particularly         including salty taste receptors as the identified genes includes         genes identified as sodium channels. This Table comprises the         most probable candidates for salty receptor genes and genes         responsible for other characterized and uncharacterized taste         receptors and polypeptides that modulate taste intensity as well         as genes encoding transmembrane proteins involved in other taste         cell functions. Representative accession numbers are from         primate (i.e. Macaca mulatta abbreviated Mm) or humans (i.e.         Homo sapiens abbreviated Hs).

TABLE 2 Representative MAS5 MAS5 MAS5 Representative Public ID: LE TB fold MAS5 Public ID Species mean mean change p value XR_011926 Mm 11.4 213.4 18.7 0.0231 XM_001099450 Mm 10.2 57.8 5.7 0.0126 XM_001098390 Mm 12.8 93.4 7.3 0.0196 XM_001086764 Mm 12.5 58.0 4.6 0.0870 XM_001114476 Mm 5.3 122.9 23.1 0.0047 XM_001110867 Mm 16.0 245.0 15.3 0.0015 R58928 Mm 5.6 50.6 9.0 0.0126 XM_001093116 Mm 8.8 121.0 13.7 0.0095 XM_001099593 Mm 9.4 126.9 13.6 0.0008 XR_010972 Mm 9.2 547.5 59.6 0.0005 XM_001084620 Mm 4.4 1917.8 433.3 0.0001 XM_001090982 Mm 34.3 229.2 6.7 0.0060 XM_001098500 Mm 20.0 1366.9 68.2 0.0022 XM_001088661 Mm 12.7 70.0 5.5 0.0327 XM_001097918 Mm 367.0 1244.3 3.4 0.0059 XM_001089122 Mm 9.9 176.2 17.8 0.0307 XM_001106548 Mm 16.7 854.3 51.2 0.0001 BV166050 Mm 12.1 108.1 8.9 0.0043 BV166421 Mm 10.3 2141.3 207.1 0.0001 BV166428 Mm 90.1 1287.4 14.3 0.0010 BV166437 Mm 13.5 253.1 18.7 0.0871 BV166724 Mm 9.6 59.6 6.2 0.0304 BV166739 Mm 150.9 719.0 4.8 0.0002 BV166741 Mm 159.5 303.8 1.9 0.0297 BV166749 Mm 56.6 156.9 2.8 0.0055 BV166757 Mm 212.7 1221.6 5.7 0.0011 BV166818 Mm 23.3 157.6 6.8 0.0822 BV208636 Mm 25.4 584.3 23.0 0.0013 BV208853 Mm 23.0 225.5 9.8 0.0043 BV209086 Mm 22.9 85.6 3.7 0.0012 BV209237 Mm 26.3 1562.2 59.5 0.0000 BV209238 Mm 302.6 964.7 3.2 0.0073 BV209550 Mm 5.3 2121.2 398.1 0.0000 BV209574 Mm 20.8 111.0 5.3 0.0154 BV210515 Mm 100.4 202.2 2.0 0.0022 BV210859 Mm 46.9 140.8 3.0 0.0156 BV210983 Mm 181.8 563.9 3.1 0.0031 BV447592 Mm 12.8 1670.7 130.7 0.0003 BV447751 Mm 4.4 406.5 91.5 0.0010 BV448581 Mm 50.3 159.8 3.2 0.0422 BV448600 Mm 6.9 179.2 26.1 0.0071 AK057677 Hs 17.8 616.2 34.6 0.0017 AK095199 Hs 6.0 189.4 31.8 0.0313 NM_000068 Hs 20.9 379.4 18.1 0.0007 NM_000112 Hs 21.3 337.8 15.9 0.0182 NM_000238 Hs 8.8 427.4 48.5 0.0019 NM_000617 Hs 72.1 238.1 3.3 0.0359 NM_001001396 Hs 18.4 116.6 6.3 0.0081 NM_001001787 Hs 414.9 2580.5 6.2 0.0006 NM_001008783 Hs 1.0 114.5 117.2 0.0196 NM_001017403 Hs 4.6 265.1 57.2 0.0086 NM_001020818 Hs 484.8 1455.0 3.0 0.0006 NM_001023587 Hs 163.3 1680.5 10.3 0.0042 NM_001024938 Hs 35.3 114.7 3.2 0.0255 NM_001029858 Hs 4.3 2244.2 523.9 0.0033 NM_001076785 Hs 6.7 128.0 19.0 0.0178 NM_001106 Hs 12.5 65.6 5.2 0.0223 NM_002241 Hs 3.2 132.8 42.1 0.0018 NM_002980 Hs 35.9 156.4 4.4 0.0119 NM_003043 Hs 213.6 900.2 4.2 0.0147 NM_003304 Hs 144.8 663.9 4.6 0.0007 NM_003641 Hs 33.5 327.9 9.8 0.0086 NM_004616 Hs 13.2 795.8 60.4 0.0022 NM_004733 Hs 314.5 810.9 2.6 0.0187 NM_004770 Hs 1.8 305.6 173.7 0.0098 NM_004974 Hs 1.9 125.3 65.7 0.0017 NM_004996 Hs 923.5 4019.0 4.4 0.0000 NM_005173 Hs 29.8 3560.0 119.4 0.0000 NM_005415 Hs 468.3 1315.2 2.8 0.0035 NM_005669 Hs 2293.8 4587.3 2.0 0.0009 NM_006054 Hs 681.2 1701.5 2.5 0.0035 NM_006435 Hs 1431.8 4294.5 3.0 0.0198 NM_006598 Hs 71.4 673.6 9.4 0.0021 NM_006608 Hs 66.8 172.7 2.6 0.1044 NM_007001 Hs 10.3 80.3 7.8 0.0472 NM_012129 Hs 303.5 542.9 1.8 0.0154 NM_014220 Hs 81.6 306.2 3.8 0.0029 NM_015236 Hs 6.2 407.8 66.3 0.0041 NM_016395 Hs 25.6 100.9 3.9 0.0407 NM_018144 Hs 75.3 214.4 2.8 0.1049 NM_018155 Hs 84.9 411.3 4.8 0.0005 NM_020724 Hs 5.7 44.6 7.8 0.0120 NM_021095 Hs 41.5 203.3 4.9 0.0262 NM_022109 Hs 763.0 1828.3 2.4 0.0046 NM_022154 Hs 20.8 552.8 26.5 0.0087 NM_022754 Hs 65.5 213.6 3.3 0.1189 NM_024534 Hs 27.0 549.1 20.3 0.1113 NM_030571 Hs 373.9 735.4 2.0 0.0062 NM_031462 Hs 6.1 51.5 8.5 0.0173 NM_033272 Hs 7.0 677.5 97.3 0.0185 NM_052885 Hs 13.8 64.7 4.7 0.0270 NM_133329 Hs 7.6 160.7 21.3 0.0078 NM_138694 Hs 11.9 227.0 19.0 0.0066 NM_144673 Hs 19.6 288.7 14.7 0.0004 NM_152264 Hs 19.3 87.7 4.5 0.0088 NM_152686 Hs 17.7 392.4 22.2 0.0099 NM_153357 Hs 9.7 84.5 8.7 0.0578 NM_178276 Hs 1442.4 2921.0 2.0 0.0028 NM_178568 Hs 9.5 48.1 5.0 0.0462 XM_370711 Hs 17.4 91.9 5.3 0.0236 XM_931948 Hs 256.3 1010.3 3.9 0.0000 XM_001084141 Mm 65.3 229.1 3.5 0.0024 XM_001108664 Mm 21.1 79.8 3.8 0.0184 XM_001103706 Mm 82.6 232.7 2.8 0.0027 NM_207627 Hs 8.1 181.4 22.3 0.0499 XM_001083115 Mm 228.6 705.3 3.1 0.0040 XM_001103565 Mm 328.5 797.1 2.4 0.0015 BV166047 Mm 10.0 98.9 9.9 0.0445 BV166216 Mm 5.9 218.2 37.0 0.0000 BV166400 Mm 160.3 1036.6 6.5 0.0001 BV166539 Mm 111.9 1279.1 11.4 0.0036 BV166725 Mm 6.7 78.5 11.6 0.0192 BV208837 Mm 41.7 209.0 5.0 0.0010 BV209241 Mm 230.8 515.4 2.2 0.0041 BV209592 Mm 42.0 303.8 7.2 0.0004 BV445228 Mm 42.3 136.5 3.2 0.0530 BV447852 Mm 4.0 120.0 30.2 0.0205 NM_018398 Hs 5.8 273.7 46.9 0.0294 NM_001035 Hs 18.1 59.4 3.3 0.0342 NM_001736 Hs 168.9 1036.9 6.1 0.0013 NM_001992 Hs 7.0 73.7 10.6 0.0081 NM_004700 Hs 5.2 114.1 22.1 0.0005 NM_005845 Hs 35.4 616.0 17.4 0.0007 NM_006218 Hs 46.6 186.2 4.0 0.0460 NM_012072 Hs 12.7 110.8 8.7 0.0448 NM_012319 Hs 16.7 165.4 9.9 0.0586 NM_013384 Hs 19.1 187.2 9.8 0.0010 NM_013388 Hs 40.4 79.5 2.0 0.0281 NM_014331 Hs 90.2 544.5 6.0 0.0006 NM_015444 Hs 38.1 134.1 3.5 0.1685 NM_017746 Hs 24.5 54.3 2.2 0.0858 NM_017839 Hs 21.9 139.0 6.3 0.0280 NM_021814 Hs 126.4 686.9 5.4 0.0006 NM_022374 Hs 777.3 1714.3 2.2 0.0027 NM_022768 Hs 10.2 95.9 9.4 0.0320 NM_024809 Hs 40.6 87.9 2.2 0.0498 NM_025141 Hs 685.7 1708.0 2.5 0.0006 NM_025154 Hs 267.0 1000.7 3.7 0.0000 NM_031301 Hs 22.8 185.8 8.1 0.0629 NM_032027 Hs 288.0 667.2 2.3 0.0548 NM_144991 Hs 13.5 40.9 3.0 0.0153 NM_152261 Hs 38.0 262.7 6.9 0.0025 NM_152621 Hs 54.5 367.4 6.7 0.0128 NM_182589 Hs 6.2 214.2 34.5 0.0258 XM_290972 Hs 44.3 225.5 5.1 0.0000

-   -   Table 2 below summarizes primate taste-bud expressed genes that         were identified as multitransmembrane domain proteins that have         been functionally characterized and which are potential         candidates for salty taste and other taste receptors. In         addition this gene set includes genes encoding transmembrane         polypeptides involved in other taste cell related functions.         Representative accession numbers are from primate (i.e. Macaca         mulatta abbreviated Mm) or humans (i.e. Homo sapiens abbreviated         Hs).

TABLE 3 Fungiform Specific Genes and Other Potential Tate Receptor Candidates RefSeq Transcript ID NM_178826 NM_021625 NM_020199 NM_014386 NM_006765 NM_016113 NM_003305 NM_007369 NM_018202 NM_005725 NM_000334 NM_002976 NM_002977 NM_030782 CK232413 NM_005669 NM_001001188 XR_018915 NM_145239 NM_012264 NM_001040151 NM_005727 NM_004621 NM_002420 NM_019841 NM_153835 NM_018653 NM_152487 NM_018022 NM_001040142 NM_000297 NM_001040107 NM_032824 NM_031457 NM_018298 BV445354 XM_001111007 BV444941 AANU01224075; AANU01224076 (CLASS 2 Genes) Putative Fatty Taste Gene Receptors

-   -   This Table of genes was derived after compiling a list of ion         channel genes permeable to sodium that were systematically         tested for expression in laser capture micro-dissected primate         tongue tissue from lingual epithelium and taste buds by end         point PCR. Genes that were expressed in fungiform taste buds but         not circumvallate taste buds or lingual epithelium were included         in this list. Moreover, this list of genes includes other genes         which were selected that are likely to encode multi-domain         transmembrane proteins included on the macaque oligo array that         did not satisfy the inclusion criteria of the systematic array         and are not included in the Gene Lists contained in Tables 1 and         2 supra.

TABLE 4 Additional new taste-specific genes identified in macaque fungiform and/or circumvallate taste-buds by gene chip analysis. These genes all encode transmembrane proteins with no described function or that function as ion channels, ion transporters, or G-protein coupled receptors. Accession numbers, ratios of gene expression in taste cells (TB) to non-taste lingual epithelial cells (LE), and the p values calculated using a two-tailed Student's t-test are listed. Accession number or Unigene TB vs. LE TB vs. LE cluster ratio p value BC017041 4.93 0.3961 XM_001094702 4.36 0.0817 XM_001093133 6.08 0.3922 NM_020141 5.00 0.1647 XM_001101699 5.16 0.0204 XM_001084342 11.25 0.0894 XM_001097482 6.19 0.0498 Hs.98728 8.99 0.0141 Mmu.5446 16.62 0.1980 XM_001113863 18.35 0.1654 Hs.568078 13.28 0.3665 Hs.136017 4.93 0.0575 XM_001086597 6.50 0.0156 XM_001103527 15.02 0.3411 Hs.127196 10.66 0.2504 Hs.21606 11.47 0.3328 XM_001083605 13.09 0.1231 XM_001083934 25.63 0.3774 XM_001085321 5.89 0.2483 Hs.88972 5.01 0.1045 Hs.47068 14.48 0.0790 XR_010355 6.71 0.1362 XM_001088824 9.47 0.0968 NM_198503 56.03 0.0551 Hs.292453 5.45 0.2891 XM_001082226 1.33 0.2803 XM_001115408 5.84 0.2666 Hs.285976.2.S1 6.57 0.0156 Hs.306723 4.72 0.0762 XM_001117492 55.50 0.0903 XM_001114070 4.99 0.3147 XM_001083482 8.39 0.1759 XM_001085289 6.53 0.0358 XM_001090289 5.70 0.2157 XM_001099752 4.72 0.0333 XM_001103706 1.53 0.6021 XM_001108095 10.17 0.2344 XM_001099350 1.50 0.7839 XM_001092868 11.47 0.0594 XM_001082482 5.76 0.0990 XM_001087669 5.40 0.2955 XM_001085445 322.37 0.1177 XM_001095050 23.94 0.3918 XM_001090844 5.21 0.0776 XM_001118514 5.56 0.0704 XR_011068 11.49 0.3387 XM_001099407 10.13 0.1970 XM_001098987 226.16 0.0153 XR_012702 9.67 0.3743 XM_001090295 10.66 0.3814 XM_001101662 9.51 0.1324 XM_001113146 5.38 0.2783 XM_001103667 5.24 0.2633 XM_001106443 5.16 0.0742 XM_001103701 5.23 0.0055 Hs.76722 7.66 0.3632 NM_052832 199.81 0.0108 XM_001114769 13.77 0.0748 Mmu.9408 5.68 0.1025 NM_001032861 7.74 0.0691 Hs.199243 8.99 0.3158 XM_001111927 2.33 0.0255 Hs.255056 10.46 0.3185 XM_001084483 1.78 0.3006 XM_001108758 0.45 0.0553 XM_001084211 77.55 0.0168 Hs.8116 24.11 0.2107 Hs.18653 21.23 0.2566 Hs.35861 1.07 0.6589 XM_001118212 5.53 0.1690 XM_001090523 29.84 0.0230 XM_001099752 16.53 0.0181 XM_001108428 14.42 0.0212 XM_001103909 22.02 0.0309 Hs.211167 7.44 0.4008 XM_001083172 57.01 0.1186 XM_001112011 5.33 0.0137 Hs.166845 9.46 0.2667 XM_001111915 34.66 0.3156 XM_001117478 112.45 0.0068 Hs.45080 11.18 0.0012

TABLE 5 Public Transcript Public Transcript MAS5 LE MAS5 TB MAS5 fold MAS5 p ID ID: Species mean mean change value CO583226 Mm 8.5 48.0 5.7 0.0226 CB309123 Mm 17.1 130.1 7.6 0.0367 NM_001647 Hs 21.9 119.7 5.5 0.0235 NM_016619 Hs 22.1 1139.3 51.6 0.0018 NM_207352 Hs 91.3 405.4 4.4 0.0245 NM_000229 Hs 13.4 77.3 5.8 0.0036 NM_021105 Hs 20.6 203.8 9.9 0.0000 NM_004915 Hs 17.5 139.7 8.0 0.0811 NM_001017403 Hs 4.6 265.1 57.2 0.0086 NM_002899 Hs 631.1 3718.0 5.9 0.0001 NM_001153 Hs 1778.3 3990.5 2.2 0.0000 NM_017784 Hs 144.0 348.8 2.4 0.0002 NM_001077400 Hs 16.4 197.3 12.0 0.0050 NM_000253 Hs 7.1 493.9 69.4 0.0018 NM_002336 Hs 111.3 1452.8 13.0 0.0000 NM_032360 Hs 32.8 168.5 5.1 0.0180 NM_001004746 Hs 35.3 102.1 2.9 0.0148 NM_006551 Hs 10.0 78.1 7.8 0.0191 AB220498 Mm 81.7 715.0 8.8 0.0223 XM_001086422 Mm 48.4 262.8 5.4 0.0345 NM_014349 Hs 24.4 98.5 4.0 0.0054 XM_001100224 Mm 173.6 525.8 3.0 0.0411 NM_006684 Hs 7.5 107.1 14.4 0.0465 NM_006377 Hs 405.4 2498.0 6.2 0.0000 CO583346 Mm 160.3 1036.6 6.5 0.0001

-   -   Table 5 below contains primate genes previously described as         fatty acid receptors or which contain amino acid motifs that are         associated with lipid binding. This list of genes includes genes         that do not encode multi-transmembrane proteins but which are         reported to participate in lipid transport or binding at close         to the plasma membrane.

TABLE 6 Gene Name Cell type gene expressed in FAM26A Many TRPM5 cells GPR113 Subset TRPM5 cells MCTP1 Many TRPM5 cells TMEM16G Subset TRPM5 cells TMEM30B Many TRPM5 cells TMEM44 Many non-TRPM5 and non-PKD1L3 cells TUSC3 Many TRPM5 cells FAM26C MANY TRPM5 CELLS FAM26B Many TRPM5 cells MFSD4 Many Non-TRPM5 cells ATP8A1 Many TRPM5 and some non-TRPM5 cells SLC4A11 Many TRPM5 cells SLC4A7 Subset TRPM5 cells

-   -   The 11 taste-specific genes contained in Table 6 were shown to         be expressed in different subsets of primate taste cells. These         genes were identified as taste-specific genes by gene chip         analysis and shown to be expressed in subsets of taste cells by         in situ hybridization analysis as described in the experimental         examples and Figures.         Table 7 below lists 4 other primate taste specific genes         identified by the inventive rationales and provides information         as to the specific cell types in which these genes are         expressed.

TABLE 7 Gene Name Cell type gene expressed in KIT TRPM5 & T1R3 subset; T1R1 umami taste receptor cells IKBKAP PKD1L3 sour taste receptor cells LOC285965 TRPM5 & T1R3 subset; T1R3 only cells lacking T1R1 (umami) and T1R2 (sweet) SV2B PKD1L3 sour taste receptor cells

-   -   Table 8 contains a listing of the human taste-specific genes         which were quantified by TaqMan in LCM derived cDNA from both LE         and TB from the same donors. As noted in Example 46, gene         expression was measured in TaqMan as a CT (cycle threshold)         value. Briefly the CT value for a given sample was determined by         the PCR cycle at which the amount of gene-specific PCR product         (as measured by fluorescence) reaches a set value. For highly         expressed genes, the threshold is reached early in the PCR run         and the CT value is relatively low (<35) while genes with very         low or no expression do not reach the threshold before cycle 35.         Expression of genes with CT values >40 are defined as not         detectable. For the majority of genes listed in Table 8 below,         expression was not detected in LE samples (CT>40) but was         readily detectable in TB samples (CT<35).

TABLE 8 Gene TB CT LE CT Gene Title Symbol value value* solute carrier family 9 (sodium/hydrogen exchanger), member 2 SLC9A2 24.63 No Ct solute carrier family 44, member 4 SLC44A4 25.2 No Ct membrane-spanning 4-domains, subfamily A, member 8B MS4A8B 25.2 No Ct tetraspanin 2 TSPAN2 25.79 No Ct transmembrane protein 38B TMEM38B 26.44 No Ct family with sequence similarity 26, member C FAM26C 26.93 No Ct LR8 protein LR8 28.01 No Ct leucine-rich repeat-containing G protein-coupled receptor 6 LGR6 28.01 No Ct G protein-coupled receptor, family C, group 5, member B GPRC5B 28.51 38.69 solute carrier family 35, member E2 SLC35E2 28.58 39.46 G protein-coupled receptor 155 GPR155 28.64 No Ct LAG1 longevity assurance homolog 2 (S. cerevisiae) LASS2 29.12 No Ct major facilitator superfamily domain containing 4 MFSD4 29.23 No Ct transmembrane protein 108 TMEM108 29.28 No Ct tetraspanin 17 TSPAN17 29.37 No Ct G protein-coupled receptor 113 GPR113 29.44 No Ct transmembrane protein 163 TMEM163 29.61 No Ct Hypothetical protein LOC644139 LOC644139 29.93 No Ct transmembrane protein 16G TMEM16G 30 No Ct transient receptor potential cation channel, subfamily C, member 1 TRPC1 30.11 No Ct transmembrane 6 superfamily member 1 TM6SF1 30.13 36.8  leucine-rich repeat-containing G protein-coupled receptor 5 LGR5 30.15 No Ct transmembrane protein 44 TMEM44 30.26 No Ct family with sequence similarity 26, member A FAM26A 30.39 No Ct Transmembrane protein 118 TMEM118 30.91 No Ct chromosome 14 open reading frame 135 C14orf135 32.17 38.68 solute carrier family 8 (sodium/calcium exchanger), member 1 SLC8A1 32.72 No Ct brain-specific angiogenesis inhibitor 2 BAI2 32.97 No Ct hypothetical protein LOC130576 LOC130576 34.03 No Ct potassium voltage-gated channel, KQT-like subfamily, member 1 KCNQ1 34.26 No Ct ATPase, Class VI, type 11A ATP11A 34.33 No Ct ATPase, aminophospholipid transporter (APLT), Class I, type 8A, ATP8A1 34.54 No Ct member 1 chromosome 14 open reading frame 101 C14orf101 35.44 38.27 potassium channel, subfamily T, member 2 KCNT2 35.62 No Ct synaptic vesicle glycoprotein 2B SV2B 35.95 No Ct *No Ct = CT value > 40, or, not detectable. See text.

-   -   As afore mentioned the taste cell specific genes identified         herein and the corresponding gene products and cells which         express same e.g., endogenous taste or chemosensory cells and         recombinant cells including the taste specific genes recited in         Tables 1, 2, 3, 4, 5, 6, 7, and 8 and their orthologs, allelic         variants, variants possessing at least 90% sequence identity         thereto and/or genes which specifically hybridize thereto under         hybridization conditions denied supra may be used in assays to         identify taste modulatory compounds as well as in therapeutic         screening assays.     -   For example these taste specific genes, polypeptides and cells         expressing same can be used to screen for compounds for         treatment of digestive system disorders. These disorders include         by way of example conditions affecting digestion such as         dyspepsia, autoimmune and inflammatory diseases affecting the         digestive system such as ulcerative colitis, inflammatory bowel         syndrome, Crohn's syndrome, celiac disease, and precancers and         cancers that affect the digestive system such as cancers         affecting the salivary glands, taste buds, stomach, pancreas,         gall bladder, esophagus, small or large intestine, anus or         colon.     -   Also these taste specific genes may be used in screening assays         to identify compounds that affect taste cell turnover. It is         known that taste cells turnover rapidly (about every couple of         weeks). Moreover, many conditions including chemotherapy or         radiation treatment, as well as old age may negatively affect         the ability of taste cells to develop. The result is a         diminished sense of taste which may result in a decreased         quality of life in cancer patients or the elderly. This is         particularly pronounced in patients with head and neck cancer,         esophageal, stomach, lung, or pancreatic cancers. Additionally,         this may evolve along with another condition, cachexia or         wasting syndrome that combines to reduce the desire to eat. Lack         of proper nutrition is a serious cause of morbidity and         mortality in cancer patients. The subject taste specific genes         contain genes expressed in stem cells suggesting that they are         markers of stem cells that are the precursors of and which         evolve into taste cells. These genes or cells which express same         can be used to identify signals that accelerate taste cell         development. These signals which likely comprise cytokine-like         receptors present on taste cells likely mediate taste cell         development and can be used in screens to identify compounds         that induce taste cell differentiation or proliferation. The         ligands therefore potentially may be isolated from saliva and         may account for the ability of saliva to influence taste         function. For example, patients with Sjogren's syndrome (an         autoimmune disease that attacks the salivary glands) exhibit         altered taste functions. The subject genes and the study of gene         expression in the salivary glands by use of gene arrays will         facilitate an understanding of these differentiation mechanisms.     -   The subject taste cell specific genes and corresponding gene         products and cells which express these genes may also be used in         order to identify potential therapeutics for modulating the         immune system of the oral cavity. The oral cavity is populated         by normal flora as is the digestive tract. Alterations in normal         flora may give rise to conditions such as gingivitis, halitosis,         gastric problems and other infections that may result in tooth         decay or tooth loss. Included within the taste cell specific         genes identified herein are a number of immune system genes.         These genes and the corresponding polypeptides or cells which         express same can be used to identify therapeutics for         maintaining immune homeostasis in the oral cavity, preventing         overgrowth of pathogenic microbia, and for identification of the         cell types in the oral cavity that are the key players in         maintaining proper oral cavity immunity.     -   Moreover, the subject taste cell specific genes and the         corresponding gene products or cells which express same are         useful in screening assays for identifying compounds for         treatment of diabetes, eating disorders such as obesity,         anorexia, bulimia, and other metabolic disorders. The expression         of taste receptors in the digestive system likely represents a         comprehensive system that detects food and different types at         different places during digestion. Therefore, “sensing” the         presence of food or specific types such as carbohydrates, fats,         umami foods, salts, should trigger various signals that may         regulate the production of molecules that participate in the         regulation of digestion such as GIP (glucose-dependent         insulinotrophic polypeptide) and GLP-1 (glucagon-like peptide 1)         produced by the enteroendocrine cells in the intestine. It is         likely that taste receptors on these cells regulate the         production of other molecular signals in other cells of the         digestive system when triggered. These phenomena may be studied         by determining which cells express different receptors and then         using gene arrays to study the molecules that these cells         produce when activated.

REFERENCES

-   -   All the references cited in this application are incorporated by         reference in their entirety herein.

SEQUENCE LISTING

>gi|89886487|ref|NM_014848.3| Homo sapiens synaptic vesicle glycoprotein 2B (SV2B) (SEQ ID NO: 1) mRNAAGCATAACCTTCGGTGGCAGGACAAATCAGGCCAGCACGCAGTCTGCCAAGTC CTGCTCGCTCCCTGTCAAGAAAAACAGCTGGATCCATTTCTAATCAACACTTCCCAACG CAACACTTCTGAGTCTCTGAAGGAGACCAGAGCTTGAAACTTTCCAGACTTCCAACAG ACATCGAGTGCAAAAGGATATTTAGGTTGTCTTTGCACAAATCTGGTTGATTTGAGA GATAAAGGGGGGGGGAACCAGTGTGACTTTCACCTAAGAAGTCACATGAACATATTT CACATTTGAACTACATAATGAATGATGGTTATTGAAATAGCCCAAACCTCTACCACAG AGCGAGGGATATAGCTCAAGGGGCAACCAGGCAGTCGCAGAACCAAGGAATGGATG ACTACAAGTATCAGGACAATTATGGGGGCTATGCTCCCAGTGATGGCTATTACCGCG GCAATGAGTCCAACCCAGAAGAAGATGCACAGAGTGATGTCACCGAAGGCCATGAT GAGGAAGACGAGATCTATGAGGGCGAGTACCAGGGTATCCCTCACCCAGATGATGT CAAGGCCAAGCAGGCCAAGATGGCGCCCTCCAGAATGGACAGCCTTCGGGGCCAGA CAGACCTGATGGCTGAGAGGCTGGAAGATGAGGAGCAGTTGGCCCACCAGTACGAG ACCATCATGGATGAGTGTGGCCATGGCCGCTTCCAGTGGATCCTCTTTTTCGTCTTGG GTTTGGCCCTGATGGCCGATGGGGTGGAAGTGTTCGTGGTGAGTTTTGCCCTGCCC AGTGCAGAGAAGGACATGTGTCTGTCCAGTTCCAAAAAAGGAATGCTAGGGATGAT AGTCTACTTGGGAATGATGGCGGGCGCCTTCATCCTGGGAGGCCTGGCTGATAAGC TGGGAAGGAAGCGAGTCCTCAGCATGTCTCTGGCCGTCAATGCCTCCTTCGCCTCCCT CTCTTCCTTCGTGCAGGGATATGGAGCCTTCCTCTTCTGCCGACTCATCTCAGGCATC GGTATTGGGGGTGCTCTACCGATTGTTTTTGCCTATTTTTCTGAATTCTTGTCTCGGG AGAAGCGAGGAGAACACCTCAGTTGGCTGGGCATCTTCTGGATGACTGGGGGCCTG TACGCATCTGCCATGGCCTGGAGCATCATCCCACACTATGGCTGGGGCTTCAGCATG GGGACCAATTACCACTTCCATAGCTGGAGAGTGTTTGTCATCGTCTGTGCTCTGCCCT GCACCGTGTCCATGGTGGCCCTGAAGTTCATGCCAGAGAGCCCAAGGTTTCTGCTAG AGATGGGCAAACATGATGAAGCCTGGATGATTCTCAAGCAAGTCCATGACACCAACA TGAGAGCTAAGGGGACCCCAGAGAAAGTGTTCACGGTTTCCAACATCAAAACTCCCA AGCAAATGGATGAATTCATTGAGATCCAAAGTTCAACAGGAACCTGGTACCAGCGCT GGCTGGTCAGATTCAAGACCATTTTCAAGCAGGTCTGGGATAATGCCCTGTACTGTG TGATGGGGCCCTACAGAATGAATACACTGATTCTGGCCGTGGTTTGGTTTGCCATGG CATTCAGTTACTATGGACTGACAGTTTGGTTTCCTGATATGATCCGCTATTTTCAAGA TGAAGAATACAAGTCTAAAATGAAGGTGTTTTTTGGTGAGCATGTGTACGGCGCCAC AATCAACTTCACGATGGAAAATCAGATCCACCAACATGGGAAACTTGTGAATGATAA GTTCACAAGAATGTACTTTAAACATGTACTCTTTGAGGACACATTCTTTGACGAGTGC TATTTTGAAGACGTAACATCAACAGATACCTACTTCAAAAATTGTACCATTGAATCAAC CATCTTTTACAACACAGACCTCTACGAGCACAAGTTCATCAACTGTCGGTTTATCAACT CCACCTTCCTGGAGCAGAAGGAGGGCTGCCACATGGACTTGGAGCAAGATAATGACT TCCTGATTTACCTCGTCAGCTTCCTGGGCAGCCTGTCTGTCTTACCCGGGAACATCAT TTCTGCCCTGCTCATGGATAGAATTGGAAGGCTCAAGATGATTGGTGGCTCCATGCT AATCTCTGCAGTCTGCTGCTTCTTCCTGTTTTTTGGCAACAGTGAGTCTGCAATGATC GGCTGGCAGTGCCTGTTCTGTGGGACAAGCATTGCAGCCTGGAATGCTCTGGATGT GATCACAGTGGAGCTGTATCCCACCAACCAGAGAGCAACAGCCTTCGGCATTCTCAAT GGATTATGCAAATTTGGCGCCATCCTGGGAAACACCATCTTTGCTTCTTTTGTTGGGA TAACCAAAGTGGTCCCCATCCTTCTGGCTGCTGCTTCTCTGGTTGGGGGTGGCCTGA TTGCCCTTCGACTGCCAGAGACTCGAGAACAGGTCCTGATGTGAACAACCTATGGGA AAAGGAAAGGTCGAGAGAATCTTGTCCAGGACACTGAAATGCATCCACACTTCCTGC CTATCACGGTCCGGAGGACACCTTGGATAGCACGGGAGGAGAAGTTGACTTTGTGA CCCCTAGTTTAGGACCCACTTCAGCTGTCAATATGTTTGTAACTCAGGTGACTGATTT GGGGGTGCCCTGAGCCACCCTTAGAATCACAGAGCTGCGTGTTTAACTTCAAGTCTT CCCAGTCCAAGGCAGGGAGAGGATTCTCCAGTGAGTGCACACACTATGCGAGGAGC AAGCATTTCTCTAAGTCAAGTGCAAGGACTTAACTTGCGTTTGAAAAGGAATTAGAG GGTCAGAAACACCCAGGTTCCTCCAGAAAGCTCCTTGGAGCCCAACAACTTAACAAAT CAACTTGGCTGGAAGTTAGAGTCATTATATGAAGATTGGGCTTGAAGTATATATTTT TGCATTTAAAAGTATCACCTATCATATTTTCCACTCGAAAATTGACATAGTAGCATTGA GGATACTCTGATCTAGAAAGCCAAGTATTTGAGCAACATCTATAGAGATCTACTTTTC TCCTATGTCTCCTAGGCTTTCCATGATAATTAGGTAATACATTTAAGAAGGATATTTAT TTCTGTTTTGCTCTATTCAAAGAAACGGAATGGGATAGTTATTCTGTAAACTAAGTTT GTATATAACTTTATTTGGGTTTAATTTCCACAACTGGTATCTGCAAATATTGCCAGCAT TTTAGCCATATTTTGGGAGAACTTGGTGTTTGAGGTCCCAGGAAATGAGGTCTGATC AAATGAAATGCAAGCACAATTTCTTACAGCCATTTAACTTTCTGTTGGGAGGATGAAT TAACAAACTCACATTGTGCAGTCTGCTTAATCCAGGCACTTTTCTTTGTGCAGGTGTA GTGAGTAGTTACTTCTCTCCCTTACACAGATGACTTGTGAAACTCAAGCTCACCATCTT CAGTGCTGGCATTTTACTTTGCCACTACCCAAAAACAATGTGAGATGTGTTCAGTGGC CTCTGGTACTCTTTGCAGGCAAGAATCAAACAACATGGGGACTGAGGGAAGGATGG GGAAGTGTAGCCACAGTTCTTCCAAATGTAAATACTTTTTGTTTGTTCTAGTGGTAAA ATGCAAATGCAATCCATATTTGTTAGGATGGTCAGGTCTCATGAGAAATCTATGCTAT GTGTCCAGAGCTTTTGAAACAGAGTCCATTGGAGTGGGAGTTAGGGAGTGTAGTGG ATGCCAAATATGTTTTTCTTCAGTGCTTAAGAGAACTGTTTCCTGAAGTCCAGCTTTG AACATAAACAGGGGTGTGGGTTGGGGGAGGAGCTTAGGACAAACCTCTCTGATGAA GGTCAGCAATAGACTGAAGTCTTGACTGCATGGAAGAGGAAAAACATCAGAACTGTC TGACAATGGAGGGGACAGTGAGCTACGCACAACTGCCAGCGGAGGTGAACTTGCAC CTGCCCAGGCCGGATGAACATCAGCCTGCAAGAACTAGTTGTTTGAGTTGATTTGCA GTGCTCTCAATGGGCAAGTGCCACATTTTCCCTGGCAGAGATCTCCAAAAATTTAAAA CAGAATAATAATGGCTATATCGAGTGTTTTCTCAGTATTGGAGAAATGCTTAGGTCCT ATGATAGCTTCGGGACATCTTTCTGTAATTTTCCTCAATTAACGGGTTGGTAGGGGTA AATCTTATGACACCTTTCCACCGTCGATTTGAGATCAGTTTTAATGGTTAAAATGTTTA CTCTCCTTCTGTCAACCCTCACCTTTTTATTTACACCCCTCCCTTTTTTTCTGTACAGGG AGAGAAGACATATTGACTCTGACTGGACACCCTGATTCCTCCAAATATATATACCACT GTGTATTAATCTTTCTCTCAGTGTTTTATAGGAGTACTAACATTTATTGCTCTGTCAAT AATGAAAGGCTCGATGTAATATAGCTGTAATTTACTTTCCATATGAATACAGTGGCTA GGTTCATAAAAGAGAATTGTGTGAGTCTGGGATTACCACATCTAAAACATTATTCTTT AATGGGATAATACAATTCATTGAGCAGCTACCACTTAAAAAACTTGCAGGACAGTTA GAGCCTGCATTTCTAGTTAAGATGGATCTTGTAAATTTAAAATTGGATTAACATTGGA GTGCTGGGGTGGCTGCAATAATTTGGGGGCTAACTCCATTTGGTTTCCAAGATCTCA CTTCTGCATTATCTTTATGGCTCTTTAAACCAGCCACCTAGCCAATCAAGGGCAATTCC CATCTCATCCATCACTCAGGTCTTTGTAAAGGGTGCAGCCAAGCTCTGCAGACTTTTG CAGGATTGTCTAGCCTGAGTACCGGGCTACTTCTTAAATGCCGTCACTCCTGCTGAGA TAAATGCGTCTTTAAAAATAGTCTCTGTGGCAGGTCACTGGGGGACAATGTACAGCA TTCTGGCCATCCACTTCTTTTTCACTTCATGTTCTACCCCAAGAGACTCCCGATGTCGG CTGTGGAGGGTTAAAGGGATGAGGCTTTCCTTTGTTTAGCAAATCTGTTCACAGTTC TTGATGATGTATITTATGATGCCCAGCTTGGAAATAGTTGCTTTCCATAGTCTCAACT GTATTGTGTCATCTCCTGATGCTGATTTTTGATCTTTTGTTTTATTAAAAATAATTAGT GAAAGAGGTGTGCCTATCTGTGAAGTTTGTAGTACATCATCCTGAGGTCATGTAACA AGTAAACCCCAACCCAGCGTTCCCTCCTACGTTGTGTTAGTTCATTAAAACTAAATAAT AAAAATAACTGTAAGAAAACCTTAA >gi|55743093|ref|NM_004316.2| Homo sapiens achaete-scute complex homolog 1 (Drosophila) (ASCL1), mRNA (SEQ ID NO: 2) CTTCTGGCCAGGGAACGTGGAAGGCGCACCGACAGGGATCCGGCCAGGGAGGGCG AGTGAAAGAAGGAAATCAGAAAGGAAGGGAGTTAACAAAATAATAAAAACAGCCTG AGCCACGGCTGGAGAGACCGAGACCCGGCGCAAGAGAGCGCAGCCTTAGTAGGAG AGGAACGCGAGACGCGGCAGAGCGCGTTCAGCACTGACTTTTGCTGCTGCTTCTGCT TTTTTTTTTCTTAGAAACAAGAAGGCGCCAGCGGCAGCCTCACACGCGAGCGCCACG CGAGGCTCCCGAAGCCAACCCGCGAAGGGAGGAGGGGAGGGAGGAGGAGGCGGC GTGCAGGGAGGAGAAAAAGCATTTTCACTTTTTTTGCTCCCACTCTAAGAAGTCTCCC GGGGATTTTGTATATATTTTTTAACTTCCGTCAGGGCTCCCGCTTCATATTTCCTTTTC TTTCCCTCTCTGTTCCTGCACCCAAGTTCTCTCTGTGTCCCCCTCGCGGGCCCCGCACC TCGCGTCCCGGATCGCTCTGATTCCGCGACTCCTTGGCCGCCGCTGCGCATGGAAAG CTCTGCCAAGATGGAGAGCGGCGGCGCCGGCCAGCAGCCCCAGCCGCAGCCCCAGC AGCCCTTCCTGCCGCCCGCAGCCTGTTTCTTTGCCACGGCCGCAGCCGCGGCGGCCG CAGCCGCCGCAGCGGCAGCGCAGAGCGCGCAGCAGCAGCAGCAGCAGCAGCAGCA GCAGCAGCAGGCGCCGCAGCTGAGACCGGCGGCCGACGGCCAGCCCTCAGGGGGC GGTCACAAGTCAGCGCCCAAGCAAGTCAAGCGACAGCGCTCGTCTTCGCCCGAACTG ATGCGCTGCAAACGCCGGCTCAACTTCAGCGGCTTTGGCTACAGCCTGCCGCAGCAG CAGCCGGCCGCCGTGGCGCGCCGCAACGAGCGCGAGCGCAACCGCGTCAAGTTGGT CAACCTGGGCTTTGCCACCCTTCGGGAGCACGTCCCCAACGGCGCGGCCAACAAGAA GATGAGTAAGGTGGAGACACTGCGCTCGGCGGTCGAGTACATCCGCGCGCTGCAGC AGCTGCTGGACGAGCATGACGCGGTGAGCGCCGCCTTCCAGGCAGGCGTCCTGTCG CCCACCATCTCCCCCAACTACTCCAACGACTTGAACTCCATGGCCGGCTCGCCGGTCTC ATCCTACTCGTCGGACGAGGGCTCTTACGACCCGCTCAGCCCCGAGGAGCAGGAGCT TCTCGACTTCACCAACTGGTTCTGAGGGGCTCGGCCTGGTCAGGCCCTGGTGCGAAT GGACTTTGGAAGCAGGGTGATCGCACAACCTGCATCTTTAGTGCTTTCTTGTCAGTG GCGTTGGGAGGGGGAGAAAAGGAAAAGAAAAAAAAAAGAAGAAGAAGAAGAAAAG AGAAGAAGAAAAAAACGAAAACAGTCAACCAACCCCATCGCCAACTAAGCGAGGCAT GCCTGAGAGACATGGCTTTCAGAAAACGGGAAGCGCTCAGAACAGTATCTTTGCACT CCAATCATTCACGGAGATATGAAGAGCAACTGGGACCTGAGTCAATGCGCAAAATGC AGCTTGTGTGCAAAAGCAGTGGGCTCCTGGCAGAAGGGAGCAGCACACGCGTTATA GTAACTCCCATCACCTCTAACACGCACAGCTGAAAGTTCTTGCTCGGGTCCCTTCACCT CCCCGCCCTTTCTTAAAGTGCAGTTCTTAGCCCTCTAGAAACGAGTTGGTGTCTTTCG TCTCAGTAGCCCCCACCCCAATAAGCTGTAGACATTGGTTTACAGTGAAACTATGCTA TTCTCAGCCCTTTGAAACTCTGCTTCTCCTCCAGGGCCCGATTCCCAAACCCCATGGCT TCCCTCACACTGTCTTTTCTACCATTTTCATTATAGAATGCTTCCAATCTTTTGTGAATT TTTTATTATAAAAAATCTATTTGTATCTATCCTAACCAGTTCGGGGATATATTAAGATA TTTTTGTACATAAGAGAGAAAGAGAGAGAAAAATTTATAGAAGTTTTGTACAAATGG TTTAAAATGTGTATATCTTGATACTTTAACATGTAATGCTATTACCTCTGCATATTTTA GATGTGTAGTTCACCTTACAACTGCAATTTTCCCTATGTGGTTTTGTAAAGAACTCTCC TCATAGGTGAGATCAAGAGGCCACCAGTTGTACTTCAGCACCAATGTGTCTTACTTTA TAGAAATGTTGTTAATGTATTAATGATGTTATTAAATACTGTTCAAGAAGAACAAAGT TTATGCAGCTACTGTCCAAACTCAAAGTGGCAGCCAGTTGGTTTTGATAGGTTGCCTT TTGGAGATTTCTATTACTGCCTTTTTTTTCTTACTGTTTTATTACAAACTTACAAAAATA TGTATAACCCTGTTTTATACAAACTAGTTTCGTAATAAAACTTTTTCCTTTTTTTAAAAT GAAAAAAAAAAAAAAAAAA >gi|39725697|ref|NM_015916.3| Homo sapiens family with sequence similarity 26, member B (FAM26B), mRNA (SEQ ID NO: 3) GTTAGATTAGTCTGAAGCCGCCACCAGCCCCAGGCCCCCGTGCAGAAGAAAAGCGG GAGGGAACGGCGGAGGCCGCCGCTGCCCTGCACCGCCCTCCTGGAGGCCACTTGGA GAGTCCGGCCCCGAGGAGGCCATGGCCACAAGTGCCCACAGCTGGCCCCAGGTTGC CAGCGTCGCTACAGCCCAGACCAAGGCAGAATAATCTCCGGATGAGCTGGTGGCACC GCTGAGCCTTTGGTCTCACCAGGGCTTCCTGTTGCTGGCAGGCGGGGTGGAGCGGA GCTGCTGGGAGGCTGCTGGATAGGAGAGGGGTCACGGCTGCGGAAGAGGAGGTTC TTCGGGACACCCGTGGATGGACACGGCAAGGAAACACCAGGCCAACCACAGCTGGG GATAAAATAGCACAACCACACCCTGCCGTCCAGCGCCTCCCAGCCTGTGCCCCTTCCT AGTACCACCAGCAACCATCAATCCCGTCTCCTCCTGCCTCCTCTCCTGCAATCCACCCC GCCACGACTATCGCCATGGCAGCCCTGATCGCAGAGAACTTCCGCTTCCTGTCACTTT TCTTCAAGAGCAAGGATGTGATGATTTTCAACGGCCTGGTGGCACTGGGCACGGTG GGCAGCCAGGAGCTGTTCTCTGTGGTGGCCTTCCACTGCCCCTGCTCGCCGGCCCGG AACTACCTGTACGGGCTGGCGGCCATCGGCGTGCCCGCCCTGGTGCTCTTCATCATT GGCATCATCCTCAACAACCACACCTGGAACCTCGTGGCCGAGTGCCAGCACCGGAGG ACCAAGAACTGCTCCGCCGCCCCCACCTTCCTCCTTCTAAGCTCCATCCTGGGACGTG CGGCTGTGGCCCCTGTCACCTGGTCTGTCATCTCCCTGCTGCGTGGTGAGGCTTATG TCTGTGCTCTCAGTGAGTTCGTGGACCCTTCCTCACTCACGGCCAGGGAAGAGCACTT CCCATCAGCCCACGCCACTGAAATCCTGGCCAGGTTCCCCTGCAAGGAGAACCCTGAC AACCTGTCAGACTTCCGGGAGGAGGTCAGCCGCAGGCTCAGGTATGAGTCCCAGCTC TTTGGATGGCTGCTCATCGGCGTGGTGGCCATCCTGGTGTTCCTGACCAAGTGCCTC AAGCATTACTGCTCACCACTCAGCTACCGCCAGGAGGCCTACTGGGCGCAGTACCGC GCCAATGAGGACCAGCTGTTCCAGCGCACGGCCGAGGTGCACTCTCGGGTGCTCGCT GCCAACAATGTGCGCCGCTTCTTTGGCTTTGTGGCGCTCAACAAGGATGATGAGGAA CTGATTGCCAACTTCCCAGTGGAAGGCACGCAGCCACGGCCACAGTGGAATGCCATC ACCGGCGTCTACTTGTACCGTGAGAACCAGGGCCTCCCACTCTACAGCCGCCTGCACA AGTGGGCCCAGGGTCTGGCAGGCAACGGCGCGGCCCCTGACAACGTGGAGATGGCC CTGCTCCCCTCCTAAGGAGGTGCTTCCCATGCTCTTTGTAAATGGCACTACTTGGTCC CAAACTGAACCCCACTGCTTGCTCACATCCATATCAGAAGGGGATTTTTAAAAAACTG TTATCTTCTTGGCCAGGGGAAAGGACCACAAGGCAATCTGGGGTGTGGACAGACCC AGTAGACAATGGAAGCCCAGCCAGCAGGGCCAGGTGACAGTGAAGCTCACCAGTGG GCTCCTTTATGGTACTCTATGCAGTTAACATGTATCTAGCTGCATAGGGACACCCAGC GCAGCAGTGCACCACTGGGAAGTGGCCTCCAGTGCAGCCTCTGGCCTTATTTTATAT ATTTAAATTTTTGATAAAGTTTTTCTTACTAAAAAAAAAAAAAAAAAA >gi|47777332|ref|NM_001001412.1| Homo sapiens family with sequence similarity 26, member C (FAM26C), mRNA (SEQ ID NO: 4) CTCTGCTCTGAGCTCTGTTGGTCCCAGCCAGGAGAGCCCGAGTCATGAGGTGGGCAC CCAGTGGGCAGGGTGGGCAGCAGGGGCCCTCTTGGAGGCAGCAGTGAGTTGGGAA GAGGAGGCCGGGCCCCACAGCGGGCATGATGGACAAGTTCCGGATGATCTTCCAGT TCCTGCAGTCCAACCAGGAGTCCTTCATGAATGGCATCTGTGGCATCATGGCCCTGG CCAGTGCCCAGATGTACTCGGCCTTCGACTTCAACTGCCCCTGCCTGCCGGGCTACAA TGCGGCCTACAGCGCGGGCATCCTGCTGGCGCCACCCCTGGTGCTCTTTCTGCTTGG CCTGGTCATGAACAACAACGTGTCCATGCTGGCCGAAGAGTGGAAGCGGCCACCGG GCCGCCGGGCCAAGGACCCCGCTGTGTTGCGCTACATGTTCTGCTCCATGGCCCAGC GCGCCCTCATCGCGCCTGTCGTCTGGGTGGCCGTCACGCTACTCGACGGCAAATGCT TCCTCTGTGCCTTCTGCACTGCCGTGCCCGTGAGCGCACTGGGCAACGGCAGCCTGG CACCCGGCCTTCCTGCCCCCGAGCTCGCCCGCCTGCTGGCCCGGGTGCCCTGCCCTGA GATCTACGATGGCGACTGGCTGTTGGCCCGAGAGGTGGCCGTGCGTTACCTCCGCT GCATCTCCCAGGCGCTGGGCTGGTCCTTCGTGCTGCTGACCACTCTGCTGGCATTCG TGGTGCGCTCTGTGCGGCCCTGCTTCACGCAGGCCGCCTTCCTCAAGAGCAAGTACT GGTCCCACTATATCGACATCGAGCGCAAGCTCTTCGACGAGACGTGCACGGAGCACG CCAAAGCCTTTGCCAAGGTCTGCATCCAGCAGTTCTTCGAGGCCATGAACCATGACCT GGAGCTGGGTCACACCAACGGGACACTGGCCACGGCCCCTGCTTCCGCAGCTGCCCC CACGACCCCCGATGGTGCGGAGGAGGAAAGGGAGAAGCTGCGTGGCATCACGGAT CAAGGCACCATGAACAGGCTGCTCACGAGCTGGCACAAATGCAAACCGCCTCTGCGG CTGGGCCAGGAGGAGCCACCGCTGATGGGCAACGGCTGGGCTGGGGGTGGGCCCC GGCCTCCGCGTAAGGAGGTGGCCACCTACTTCAGCAAAGTGTGAGGCGTGGCCAGC TGAAGAGGCAGGAACGGGGATCTGAGCCCACAGCCCCTCCAACCCCCAAACCAGGTG GAAAAAGGAAGGGTTTCGGTGCTGGGCAGTACTCCCCTAGGCAGATCCACACTCCGT AGCACTCGCCTGCCCATTGGAGGCAGGAAATTTGGAGCTGGAAGGGGATCTGATGC CTTCAGGTGTGACACTGCCCTGGATGGCCCTAGGGCAGTGGGCCCATGAGCAGTATT AGTCTAAAGGGGTCGGAACTGTCATGGCAGGTACAGGGACCAATGGCTCCCCTCTGC CCAGCCCTTCCCAGGCTGATGTTCACTGTCTCCTCCCAGGTTCAACAGACATCCCTGC ACCAGGGTCCACCCTCGTCTGTGGCTGTTCAGTACCTCTCTTCCTTTATGCTCCGGGC TCGGGGAGTGGGAATCATCAGGCGTCTCATGAAGTGGGAGCCCTCTGATTTGGGCA AGCGTGTCGTAGGTGAGACTGGGTGTGCCGGGGCAGGTCCATAAGGACATGACACA CAGCCTACATGGTGTGACACACCTGGGGTGACAGGCGATGAGACAAGATGTCAGAA GCTAGGTTCACATGGAAGAGGTCAGAGTGTGTGGTCACCATGGGGGTCATGTGACA ATTGTCCAGGTGGACTGCATGTTTATTTAGCACAAACCAAGCACAAAAGTCCTCCTGT AGAGGGGTCTTTGAAAAACCACCTTAATACCCACGTCACATCCAGGTCTCCAGGGGA AATCAGACCATCCCCAAGGCTTGAGAAGTTAGACACAGAAGCTGAAGTCTCTCCATTT TTCTCAAAGACCCCACCTCTTGGGGATGGAGTTCTAAGAGGCTAAGAGGAGCTCCAA GGCTCTAGCCCAGGTGGGATGAGGGTGGAGGAGAGCAGTGTAAAGAGAAAGCAGC TCAGATTCCAGAGTGAGACAGAACTGGGTCAAATGGTGTCTCTACCACTCACAAACCC TGTCCCTGGGCCAGCTGCATCACTGCCTGTGCCTTCGTTTCTTCATCTATACAATGAG GATGAGGCCCCCCCGGCCCGCCATCATGGGGTTGCTGTGTGTAAAAGCACATGGCAC ATAGTAGGCACCCAGCACAGGGTGGCTAATGTATTTGTTGATTICTGAACCTAAGGA CTTCCTTCCTCCTCCCCTGGGCAGGGATGAGACAGCAACACAAACACTCGAGCTTCCA TCTTGTTGAGGAGGAAACAGAGGTACAGATAGGTTTCTCAGCACCGCCCTCAGCTCT GAGACATAAGTCCCAAGCATCTAAGGATICATTTTGATCTTGGCATGATTCCATCCTT TTTTATCCATCCTTCCCTCTATTCCCACTTCTGGGGTCCAGTTTCCCTCCTCTTAATTAT TTGGGAGGAGTTGCTCAGATCTTTGTGGGCCAAGGTGGGCTGGGAGGGCTCTTCCA GGAGGTAGGAGTTGGTATGGGCCCTGAAGTCAGGGAGGATTAGGATGAGCAAAAA ACAAGGTGTATGTTGGTGGGTGGCAGCACTTCCAGTGGGAAGAGAAGGCCCGGAG GTATCAGGAGGTACAAATGTGATGAAGAGCAAAGCTTTGGGTCAGGCACACCTGAG TTCAAATACCAGCACTGCAGGACTTGTGGCCAGTCACCCAGCCACTCTAAGCCTCAGT GTGTCTGTCTATAAAATGGATATTAGAAGACCTGCTTGGCCAGGCGGAGTGGCTCAT GCCTGTAATCCCAGCACTTGGGAGGCCAAGGAGGGAGGATCACTTGAGCCTGGGAG TTGGAGACCAGCCTGGGCAACATAGCAAGACTCTGTCTCTGTAAAGTAATAATAATA ATAATAAGAAGAAGAAGAAGAATAAAGAGAAGATTTATAATTTTAAAAAAAAAAAAA AAAAAAAAAAAAAGAAAAAAAAAAAAAAAA >gi|38569393|ref|NM_003640.2| Homo sapiens inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein (IKBKAP), mRNA (SEQ ID NO: 5) AGTGCTGCGGCTGCCTAGTTGACGCACCCATTGAGTCGCTGGCTTCTTTGCAGCGCT TCAGCGTTTTCCCCTGGAGGGCGCCTCCATCCTTGGAGGCCTAGTGCCGTCGGAGAG AGAGCGGGAGCCGCGGACAGAGACGCGTGCGCAATTCGGAGCCGACTCTGGGTGC GGACTGTGGGAGCTGACTCTGGGTAGCCGGCTGCGCGTGGCTGGGGAGGCGAGGC CGGACGCACCTCTGTTTGGGGGTCCTCAGAGATTAATGATTCATCAAGGGATAGTTG TACTTGTCTCGTGGGAATCACTTCATCATGCGAAATCTGAAATTATTTCGGACCCTGG AGTTCAGGGATATTCAAGGTCCAGGGAATCCTCAGTGCTTCTCTCTCCGAACTGAACA GGGGACGGTGCTCATTGGTTCAGAACATGGCCTGATAGAAGTAGACCCTGTCTCAAG AGAAGTGAAAAATGAAGTTTCTTTGGTGGCAGAAGGCTTTCTCCCAGAGGATGGAA GTGGCCGCATTGTTGGTGTTCAGGACTTGCTGGATCAGGAGTCTGTGTGTGTGGCC ACAGCCTCTGGAGACGTCATACTCTGCAGTCTCAGCACACAACAGCTGGAGTGTGTT GGGAGTGTAGCCAGTGGTATCTCTGTTATGAGTTGGAGTCCTGACCAAGAGCTGGT GCTTCTTGCCACAGGTCAACAGACCCTGATTATGATGACAAAAGATTTTGAGCCAATC CTGGAGCAGCAGATCCATCAGGATGATTTTGGTGAAAGCAAGTTTATCACTGTTGGA TGGGGTAGGAAGGAGACACAGTTCCATGGATCAGAAGGCAGACAAGCAGCTTTTCA GATGCAAATGCATGAGTCTGCTTTGCCCTGGGATGACCATAGACCACAAGTTACCTG GCGGGGGGATGGACAGTTTTTTGCTGTGAGTGTTGTTTGCCCAGAAACAGGGGCTC GGAAGGTCAGAGTGTGGAACCGAGAGTTTGCTTTGCAGTCAACCAGTGAGCCTGTG GCAGGACTGGGACCAGCCCTGGCTTGGAAACCCTCAGGCAGTTTGATTGCATCTACA CAAGATAAACCCAACCAGCAGGATATTGTGTTTTTTGAGAAAAATGGACTCCTTCATG GACACTTTACACTTCCCTTCCTTAAAGATGAGGTTAAGGTAAATGACTTGCTCTGGAA TGCAGATTCCTCTGTGCTTGCAGTCTGGCTGGAAGACCTTCAGAGAGAAGAAAGCTC CATTCCGAAAACCTGTGTTCAGCTCTGGACTGTTGGAAACTATCACTGGTATCTCAAG CAAAGTTTATCCTTCAGCACCTGTGGGAAGAGCAAGATTGTGTCTCTGATGTGGGAC CCTGTGACCCCATACCGGCTGCATGTTCTCTGTCAGGGCTGGCATTACCTCGCCTATG ATTGGCACTGGACGACTGACCGGAGCGTGGGAGATAATTCAAGTGACTTGTCCAAT GTGGCTGTCATTGATGGAAACAGGGTGTTGGTGACAGTCTTCCGGCAGACTGTGGT TCCGCCTCCCATGTGCACCTACCAACTGCTGTTCCCACACCCTGTGAATCAAGTCACAT TCTTAGCACACCCTCAAAAGAGTAATGACCTTGCTGTTCTAGATGCCAGTAACCAGAT TTCTGTTTATAAATGTGGTGATTGTCCAAGTGCTGACCCTACAGTGAAACTGGGAGC TGTGGGTGGAAGTGGATTTAAAGTTTGCCTTAGAACTCCTCATTTGGAAAAGAGATA CAAAATCCAGTTTGAGAATAATGAAGATCAAGATGTAAACCCGCTGAAACTAGGCCT TCTCACTTGGATTGAAGAAGACGTCTTCCTGGCTGTAAGCCACAGTGAGTTCAGCCCC CGGTCTGTCATTCACCATTTGACTGCAGCTTCTTCTGAGATGGATGAAGAGCATGGA CAGCTCAATGTCAGTTCATCTGCAGCGGTGGATGGGGTCATAATCAGTCTATGTTGC AATTCCAAGACCAAGTCAGTAGTATTACAGCTGGCTGATGGCCAGATATTTAAGTACC TTTGGGAGTCACCTTCTCTGGCTATTAAACCATGGAAGAACTCTGGTGGATTTCCTGT TCGGTTTCCTTATCCATGCACCCAGACCGAATTGGCCATGATTGGAGAAGAGGAATG TGTCCTTGGTCTGACTGACAGGTGTCGCTTTTTCATCAATGACATTGAGGTTGCGTCA AATATCACGTCATTTGCAGTATATGATGAGTTTTTATTGTTGACAACCCATTCCCATAC CTGCCAGTGTTTTTGCCTGAGGGATGCTTCATTTAAAACATTACAGGCCGGCCTGAG CAGCAATCATGTGTCCCATGGGGAAGTTCTGCGGAAAGTGGAGAGGGGTTCACGGA TTGTCACTGTTGTGCCCCAGGACACAAAGCTTGTATTACAGATGCCAAGGGGAAACT TAGAAGTTGTTCATCATCGAGCCCTGGTTTTAGCTCAGATTCGGAAGTGGTTGGACA AACTTATGTTTAAAGAGGCATTTGAATGCATGAGAAAGCTGAGAATCAATCTCAATCT GATTTATGATCATAACCCTAAGGTGTTTCTTGGAAATGTGGAAACCTTCATTAAACAG ATAGATTCTGTGAATCATATTAACTTGTTTTTTACAGAATTGAAAGAAGAAGATGTCA CGAAGACCATGTACCCTGCACCAGTTACCAGCAGTGTCTACCTGTCCAGGGATCCTGA CGGGAATAAAATAGACCTTGTCTGCGATGCTATGAGAGCAGTCATGGAGAGCATAAA TCCTCATAAATACTGCCTATCCATACTTACATCTCATGTAAAGAAGACAACCCCAGAAC TGGAAATTGTACTGCAAAAAGTACACGAGCTTCAAGGAAATGCTCCCTCTGATCCTGA TGCTGTGAGTGCTGAAGAGGCCTTGAAATATTTGCTGCATCTGGTAGATGTTAATGA ATTATATGATCATTCTCTTGGCACCTATGACTTTGATTTGGTCCTCATGGTAGCTGAG AAGTCACAGAAGGATCCCAAAGAATATCTTCCATTTCTTAATACACTTAAGAAAATGG AAACTAATTATCAGCGGTTTACTATAGACAAATACTTGAAACGATATGAAAAAGCCAT TGGCCACCTCAGCAAATGTGGACCTGAGTACTTCCCAGAATGCTTAAACTTGATAAAA GATAAAAACTTGTATAACGAAGCTCTGAAGTTATATTCACCAAGCTCACAACAGTACC AGGATATCAGCATTGCTTATGGGGAGCACCTGATGCAGGAGCACATGTATGAGCCA GCGGGGCTCATGTTTGCCCGTTGCGGTGCCCACGAGAAAGCTCTCTCAGCCTTTCTG ACATGTGGCAACTGGAAGCAAGCCCTCTGTGTGGCAGCCCAGCTTAACTTTACCAAA GACCAGCTGGTGGGCCTCGGCAGAACTCTGGCAGGAAAGCTGGTTGAGCAGAGGAA GCACATTGATGCGGCCATGGTTTTGGAAGAGTGTGCCCAGGATTATGAAGAAGCTG TGCTCTTGCTGTTAGAAGGAGCTGCCTGGGAAGAAGCTTTGAGGCTGGTATACAAAT ATAACAGACTGGATATTATAGAAACCAACGTAAAGCCTTCCATTTTAGAAGCCCAGAA AAATTATATGGCATTTCTGGACTCTCAGACAGCCACATTCAGTCGCCACAAGAAACGT TTATTGGTAGTTCGAGAGCTCAAGGAGCAAGCCCAGCAGGCAGGTCTGGATGATGA GGTACCCCACGGGCAAGAGTCAGACCTCTTCTCTGAAACTAGCAGTGTCGTGAGTGG CAGTGAGATGAGTGGCAAATACTCCCATAGTAACTCCAGGATATCAGCGAGATCATC CAAGAATCGCCGAAAAGCGGAGCGGAAGAAGCACAGCCTCAAAGAAGGCAGTCCGC TGGAGGACCTGGCCCTCCTGGAGGCACTGAGTGAAGTGGTGCAGAACACTGAAAAC CTGAAAGATGAAGTATACCATATTTTAAAGGTACTCTTTCTCTTTGAGTTTGATGAAC AAGGAAGGGAATTACAGAAGGCCTTTGAAGATACGCTGCAGTTGATGGAAAGGTCA CTTCCAGAAATTTGGACTCTTACTTACCAGCAGAATTCAGCTACCCCGGTTCTAGGTC CCAATTCTACTGCAAATAGTATCATGGCATCTTATCAGCAACAGAAGACTTCGGTTCC TGTTCTTGATGCTGAGCTTTTTATACCACCAAAGATCAACAGAAGAACCCAGTGGAAG CTGAGCCTGCTAGACTGAGTGACTGCAGTTAGGAGGGATCCGACAGAGAAGACCAT TTCCACTCATTCCTGTTGTCCTACCACCCCTTGCTCTTTGAGGGCTGGCTATTGAGAAC TGGAAAGAGTAAAATGATAACTTACCTTAGCATTGCCAAGAACTTCAGCAGACAACA AGCAATTCTATTTATTTTATGTTGTGTATACATCTTGATCATTAGCAAGACATTAAGCT TTAACCATTATGGCACCATTTTGTGAGAATGATTGTTCTTTCACTTGGGCTGTTTGAG AGCATAATTATGGTAATCATGAGATTAATGTTTCATGATTTCTACCTCCAAAGTGTGA AGACAAGTAAAACAATGTTTCTAAATTGTCTTATTTTGTTGGCGGAGAAGATTACAAT GGCTATTAGTGCTACATTTGGTCAAATGTAATCACTTAAATAGCTTCTTGTCACCTTAA ACTAAAGCAGAATAAAAAGTATCCTTTGAAATTATAAGCCCTCCTTTGCTGACAGCTA TTATTTTGTAACATCTTACCAGGTCATGTGCTTTCAGTTATAACTGGGCTGAGCCTCC TATAATTACAATGTCTATAGGGACTGTTTTACTGCCTGTGTATTTTCTGCTAGAGAGT TAGCAATGTTAGAGCTAGAACAGATTAGAATTTCTAAACAGTATCATGCACAGTTGG TGTGAGTGATCAGTGTGCATTGTATGGCATGCATGGTTGTGAATTATTCTCTGTTCTC CAAATACTGTTTCTTTAACTCAGATATTTTTGTTAGTGTCTAGGCCACTTCATTTATTT TTCGTCATGGTACTTTACTGACTTCTCTTTATTCAATTCTCCACGCCCTCACCAAAAAA AACTGTCTCAAAATGAGAATATTTTATTTTCATGGTGAGTCTAGAAAACGCCCACTTC ATTCTGATTAAAAATTCTTCCATGTTTTAAATATCAGAACCAGACCTTTCTTACTGTGT ATCTTAGCCCATTTGTGTCTCTATAACAACAACCAGCTTTCAAAGGAACTAATAGAGT GAAAACTCACTCATTACCACGAGGATGGCACAAGCGATTCACGTAGGATCTGCCCCT GTGACCAAAACACCTCCCATTGGGCCCCACTTCCAACACTGGTGATCACATTTCAACA TGAGGTTTAGGGAAACAAATGCCTAAACTACAGCACTGTACATAAACTAACAGGAAA TGCTGCTTTTGATCCTCAAAGAAGTGATATAGCCAAAATTGTAATTTAAGAAGCCTTT GTCAGTATAGCAAGATGTTAACTATAGAATCAATCTAGGAGTATTCACTGTAAAATTC AACTTTTCTGTATGTTTGAACATTTTCACAATCTCATAGGAGTTTTTAAAAAGAAGAG AAAGAAGATATACTTTGCTTTGGAGAAATCTACTTTTTGACTTACATGGGTTTGCTGT AATTAAGTGCCCAATATTGAAAGGCTGCAAGTACTTTGTAATCACTCTTTGGCATGGG TAAATAAGCATGGTAACTTATATTGAAATATAGTGCTCTTGCTTTGGATAACTGTAAA GGGACCCATGCTGATAGACTGGAAATAGAAGTAAATGTGTTTATTGAAAAAAAAAAA AAAAA >gi|21734229|emb|AL833583.1| Homo sapiens mRNA; cDNADKFZp686O0656 (from clone DKFZp686O0656 (LOC285965) (SEQ ID NO: 6) GGGAGAAAAAGGGCTCAGGACTGAGGAGTGAAGAGCTCCAGGGATTTCACTCTTCT TTGTGTGTGTGAAGGAAGGTTTATTTGCAAGATGGGTTTGAGGGAATTAAGGATAA AGTCTGCTGAAAGTAGCACCAGCCTCTGGATTAAAAGGGATGTTTGGATGAAGCTTC AATCTCAAGAAGAGGCAAGAGAAAACTAAAGAAAAAGAAGGCAGCAACTGCTTTCG GGAGCAGCTGAAGGCTGGAGATAACATGGACCTCCATGATGAGAGCTGGAATGAAG TACCAGGGCAAGGGAGCTGCCTGGATGAGGAAACCAAGGCTATCTCAGTACTGCCA AGGTGTTTTCATCATTCATCAAAATGCAAAAGTAAACACTGGTGAGAAAAACGATGTT GATCTCCCAGGCAAGCCACTTTCCAGGAGTGTGGCTGATTATTTTCAAATGCTGCATC GGAAAGTTGCAGGCCCCTTGGAAAATCTGTCACCCCTGAGAGTGATATTATTCTACA GAAACAACACATCACTGGATGCCTCTCACCATGCAATCCTCTGTGCACTTGAGAAGAA GACAAGACTCTCCTATTTTTAGATGGGAAAGCTGAGGCAAAACGGATGCACTTGGGC AAAATCATTTGATAAAAATGGAAGCTGAACCTCCAAGTCCTGGCATCGGTAGCTGCCT CATGTTCCTCCCGCCTCACTCCACCTCAGTGTACCCGCGACTGGAGGGTGCCACAGGC TGGAGCACACAAAACACTGTGTGCTTCGTGATTCTGATGTGGGGCGCCAGATCCGGT GGAAGGAGGGTGGCTGCGTGGGAACAGATGCTCGTGTCGCAAGGAGTTGTCTCTTG TGGGCAAAGCAAGCTGGAAAGTGTTTCGATTTCTTTATTTTCATGCTCTACTCTTGGT GCTTCCTTCTCCTTTGCCCACCAATCCCCCCAATGCCAGGCTTCTCCTTACCTGGGTGC AGAGAGAGGAACAACTTGGAGGTGGGCAGAGAGGGACTCAGTTCATGGTGCTTGG AGGTGGGAGAGCTCCCAGGCAAAATAGAGAGGAGACTGTGGAGATGCCGTGGGCA GGTGTGGAGGAGAGGGAGAGCTTGAACGGTGAAAAACAAGAGATGGAGAGTCTGG GAGAAGGGTGAGCAGCCAGAATGGGGATTTCCACAGTAGCTTCTGATGAGCTATGT CTGGTCAGAACTATAACCTTAGCTTCCTTTATTTCCCTGGAGGGGTGGGGAGATAGG AAGGAGAGGAGTATACTAGTCTCTTCCAAAGGGAGGGCCAGAGCAAAAGCGTCCTG TGATTAATTACTCACCACAAAAACCCTCTTCAAGGCTGGAGACCTAGGAGGGGCTTG GCACACAGACAACTCCTCTGCAGCTGTTCAGAGAAAAACAGCTCTTCCCATCTCAAGC CGCCCACCTGCCCAGTGTGCTGTCTGTCCCACTGGTCACACACTTTCCCTAGAGTGCT TCTTGCTTCTCTCACAGCAATTCCCACCTCCGCATGCTGGACCAGGCGGCCCCCTCTA GATCCCATGGTGAAGCATCAGGTGCCCACAGGTCTAAGATGTCTTCATTTGTTCAATG GCTAGAGCAGGCAGCTGGCTGTCCAGATGCATGAATGAATTCCCTAACTCTCACATG TCTGCAGGAAACTGCTGTAGGAAGCCTGCACCAGTGGATTGCCATTCGGGCAGATCC TCTCAACTTTGAGAGCTTAAGGCTTGCTTTTGAGTATGTGATTATGATCCTGCCTGTG TGTATGTATGTCAGAATCATAGAACTCTAGAGGTCATGTTTTAATTAATTTATTCATTC ATTGATTCATTAACAAATGCTTATTGAGTACCTACTATGTGTCAGGCTGTGATCTGGA TACTGAGGCACAGATCAGTGAGCAAAACAGACCAAAAGCTCTGTCATCATGAAGCTT ATATTCTAGAGAGAAGAGATATACTATCATCAAATTAAGTCAGTTATGTAGCATATTA GAAAGTGATAAGTCCAGTGGGGTAAAATAAAGGAGGATGATGGGGAATGTGAGGG GCGGCATGCAATTTTAAATAGAATGTTTGAGGAAGGCTTTCATGGGAAAGTGATATT TGGTGCAAAACGTGAAGGCGGTAAAGAGGTGAATTATGTGGCTATGTCGGGGATG GACATTACAGGCAGAAGAATTAGTTAGTCGGGGCTCTGAGCAGGGAGCAGGTCTGG CATGTTCCCATCCCAGCAAGTAGGCCAGTGTGGCTCTGGTGGAGTAAGCAAGGATG GAATTGCAGCAGGTGAGTCCAGAAGAGTGATAATGGACAGCCAGTTGGGGGTGCCT TCCAGGTGATTGTGGGAACTAGGCTTTATTCTGAGTGTGATGGGTAGCCACTTGGG GCTTTCAGGACAGGATGGTAAAAAAAGGATCATGCTGCCTGCTGTGTTGGGAACAG ACTGTATGGGACCAGGTGAAAGCAAAGCAGTCAGCCTCAAATAATTCAGGTGAGGG AAAACGTGACTTGAATAAGATTCACTGTAGAAGTGGTGAGATATAAGTGGATTCTGG ATATAATAAAAATATAGAGCCAGCAGGATTTTCTGATGGATTAGCTAAGGAGTGTAA AGAAATAGAGGAGTCAGAGTGACTTTTTTTTTTCCTTGAGCAACAGGAAGTGGAGAG GTATCATTACCTGAAAGGAGGAAAGCCTCAGGTAGAGAAAGTTTTAGAGGAGGTAA GATCAGAGGTTTAGTGCAAGACATGCTAAGTTTGAGATGTCTATTAGATACCCAAGT GGATCTGTCTAATGGGTATTTAGACAGATCCACTTGGATATCTGTCTCAATGGACATG TGATCTACATGTAGTTCACAGGATAAGTCCAGTTTAGAGTACCAATTTGAAGTCATCA AATGTAGGTGGCATTTAAAGTGGTAAAACTGGACTGAGCACAGTGGCTTATGCCTGT AACCCCTGCATTTTGGGAGGCTGAGGTGGGTGGATAACTTGAGGTCAGGAGTTCGA GACCAGCTTGGCCAACATGGTGAAACCCTATCTCTACTAAAAATACAAAAAATTAGCC AGGCATGGTGGCACATGCCTATAATCTGAGCCTCTCGGGAGGCTGAGGCAGGAGAA TTGCTTGAATCCAGGAGGCAGAGGTTGCAGTGAGCCAAGATCGTGCGACTGCACTCC AGCCTGGGTGACAGAGTGAGACTCCATCTCAAAAAAATAAATAAATAAATAAATAAA TAAAACAAAAATAAAAAATAAAGTGATAAAACTGGAGATCACTATGAGAATGAGGAT AGCTAGAGAAAAGAAGGGGTCCAGAAGGTTATCCTTGCTGTGCTCCAAGGTGCTTG AGTTTGGAAACATGAGACAAAACCAGAAACAGAGACCCTGGGAGAGTCTGTGGTCT CCATTTTTCCGCTGAGCAAACCACAGGCTTGTGTTCTGCCTATCTCCCACTTCGCACAT GTACAGCATTGTAGAATATTTACATGGAAAAGGATTCTATGATATAGTAGAGTGACT TCCCCTATTGATAACAAACAATTATGTCAGTCCCTACACAACTCTTATGCTAAAGGTAA TGGGGAGGGTTGAATGGTACTCATTTGGGCAGCTTTTTTTTTGGCTATGTATACTTT CAGAAAGAATTTACCTCACCTAGATCACATGACTAAATATAGGAATATTAATACCCAC TGTGTCTAATTGGCAGATTGTTTTGAGATTTTAAATGAGATCTATTCATGAAAACATT TTGTTAATCTTAAAGCACCACACCAATATCACCTATTATATTGTACAGCCATGATCAAC ACAATTTCCAATCTAGAAGTCCCTCTCAACTTTTCCTGGGACCGAGCTTTCAGGACTTA GAGTTCCTTCTCCTTCTCATTCTTTTTCTGCGCATAGTCTCCCGGTAAAGTGAAAACCA GCTGAGAAAAGATTCGGGCTGGACAGGCCTCCGTGGCGATTAAGAGTCACGAATGT GATGATATTATTCGCAAACAGCAGTGTAGTCATGGTTCAGAATTTTGGAAACAGTGC CAGGAGGATCTTGGACATAATTTTCAGGGTGTATAAGCCCTGCACTAAAGTAAAGTT TACCAGTGCCAAGAGTTTGACGTTTTCTTCTTCATGTTTTCTTTGGCTGGAGCCTGGC TTTAGTTGAAGAGTTCTGTCAACAAATGGAATTCTCTATTTGGGACTGGGATTCTTGA TTGGTGGTGCTTCTGTCTCCTCTTGCTGTGAGTTTCCTCAAACTTAGAGTCCTGTGGG ATCTGTGTTTGAACAGAGACTGGAAATGCTTACCTCATCTCCACATTTCTTAGCCATTT GTCACCAGACTGTAGATTGACTGGTGGGATGCCTGTTTCTAGAGAGAAAAGATACTG CTTTTCTCTGACTCCAGCTGAGAAGAGGTTGGTTAAATTACGAATCTGATGACTATCT ATGAACCTAAGGAGGAAAAGTTAATTTCTTTTGAGGGTTTGCATAATGTTTTAAAACA AATTTATAGAAATATAGATGATGGAAAAAAGCAATAGGGTAAACCTAAATTATTAAA AATAAATAATACATAGGAAATAAACAGCATAGAAAAGAAACAAAAAAGAGATTGTTA CCAAAAACCATAAGTTTTTTTTTTTTTGAAAATTCTAAGAAGGTGGATAAATTTCTGG AATTTTCAATGAGCAAAAAAGTGAAAAGATACAAATGAATAAAAAATGAAAAGGTAG AAATTAAAATAGGTCTAGTAGAGATTAAAAATAATAAAAGAATATTATTAAAAAGTAT TGGTGGATAAAATAGGCACATATCTGAAGATAAAAGCCGAATTGACCCCCTAAAAAG CAGAAAACTTACAATAACAATCATTAATGGCTTTGAATGGCTATGAAAAAATAATATC TCTGCCCTCTTCACTACTCCCATGTAAAATAATTTTACGGGTAGATTTTACCAACGTTT CAAGAGAGACATGATTCCCAAATATTATGTAAGTTTTTTCAGAAAAAAAAAAAAAAAA AAAA >gi|20336280|ref|NM_052832.2| Homo sapiens solute carrier family 26, member 7 (SLC26A7), transcript variant 1, mRNA (SEQ ID NO: 7) GAATATAAGGGGAATTACTGGCGAGAGAGCTGTAGACCAACTTAACACTGAACCCAT TACTTTTCCAAGACCAGAAAAAAATATTACATGAACAGGAACTACTTCTCCTTCAGATA AGAATTCAAGCTTTGACATTGTAAACCACAGACGAATTGGAGCTTGGCATTGAAAGG AGGTGTTCTGCAATGATTTTTTTTCTTGTTTAGAGAAGTTTACTTCTACAAGAAGAAA TCTGAAAAATGACAGGAGCAAAGAGGAAAAAGAAAAGCATGCTTTGGAGCAAGATG CATACCCCCCAGTGTGAAGACATTATACAGTGGTGTAGAAGGCGACTGCCCATTTTG GATTGGGCACCACATTACAATCTGAAAGAAAACTTGCTTCCAGACACTGTGTCTGGG ATAATGTTGGCAGTTCAACAGGTGACCCAAGGATTGGCCTTTGCTGTTCTCTCATCTG TGCACCCAGTGTTTGGTTTATATGGGTCTCTGTTTCCTGCCATAATTTATGCCATATTT GGAATGGGACATCATGTTGCCACAGGCACCTTTGCCTTGACATCCTTAATATCAGCCA ACGCCGTGGAACGGATTGTCCCTCAGAACATGCAGAATCTCACCACACAGAGTAACA CAAGCGTGCTGGGCTTATCCGACTTTGAAATGCAAAGGATCCACGTTGCTGCAGCAG TTTCCTTCTTGGGAGGTGTGATTCAGGTGGCCATGTTTGTGCTGCAACTGGGCAGTG CCACATTTGTGGTCACAGAGCCTGTGATCAGCGCAATGACAACTGGGGCTGCCACCC ATGTGGTGACTTCACAAGTCAAATATCTCTTGGGAATGAAAATGCCATATATATCCGG ACCACTTGGATTCTTTTATATTTATGCATATGTTTTTGAAAACATCAAGTCTGTGCGAC TGGAAGCATTGCTTTTATCCTTGCTGAGCATTGTGGTCCTTGTTCTTGTTAAAGAGCT GAATGAACAGTTTAAAAGGAAAATTAAAGTTGTTCTTCCTGTAGATTTAGTTTTGATT ATTGCTGCATCATTTGCTTGTTATTGCACCAATATGGAAAACACATATGGATTAGAAG TAGTTGGTCATATTCCACAAGGAATTCCCTCACCTAGAGCTCCCCCGATGAACATCCT CTCTGCGGTGATCACTGAAGCTTTCGGAGTGGCACTTGTAGGCTATGTGGCCTCACT GGCTCTTGCTCAAGGATCTGCCAAAAAATTCAAATATTCAATTGATGACAACCAGGAA TTTTTGGCCCATGGCCTCAGCAATATAGTTTCTTCATTTTTCTTCTGCATACCAAGTGC TGCTGCCATGGGAAGGACGGCTGGCCTGTACAGCACAGGAGCGAAGACACAGGTG GCTTGTCTAATATCTTGCATTTTCGTCCTTATAGTCATCTATGCAATAGGACCTTTGCT TTACTGGCTGCCCATGTGTGTCCTTGCAAGCATTATTGTTGTGGGACTGAAGGGAAT GCTAATACAGTTCCGAGATTTAAAAAAATATTGGAATGTGGATAAAATCGATTGGGG AATATGGGTCAGTACATATGTATTTACAATATGCTTTGCTGCCAATGTGGGACTGCTG TTTGGTGTTGTTTGTACCATAGCTATAGTGATAGGACGCTTCCCAAGAGCAATGACT GTAAGTATAAAAAATATGAAAGAAATGGAATTTAAAGTGAAGACAGAAATGGACAGT GAAACCCTGCAGCAGGTGAAAATTATCTCAATAAACAACCCGCTTGTTTTCCTGAATG CAAAAAAATTTTATACTGATTTAATGAACATGATCCAAAAGGAAAATGCCTGTAATCA GCCACTTGATGATATCAGCAAGTGTGAACAAAACACATTGCTTAATTCCCTATCCAAT GGCAACTGCAATGAAGAAGCTTCACAGTCCTGCCCTAATGAGAAGTGTTATTTAATCC TGGATTGCAGTGGATTTACCTTTTTTGACTATTCTGGAGTCTCCATGCTTGTTGAGGT TTACATGGACTGTAAAGGCAGGAGTGTGGATGTATTGTTAGCCCATTGTACAGCTTC CTTGATAAAAGCAATGACGTATTATGGAAACCTAGACTCAGAGAAACCAATTTTTTTT GAATCGGTATCTGCTGCAATAAGTCATATCCATTCAAATAAGAATTTGAGCAAACTCA GTGACCACAGTGAAGTCTGAGACCCTTTTGTCACAGTACAGCTCTTGTCTTTACCAAC TGCCTGAAGAGGCCATATGCTGGCATTTTGCACAACTTTTTGGTTGTTTAGATCCTAC AGATGACCTCTGCTACAATAAGTACGATGTGACTTAGTAACTGCATAGCAGTTGGAA AGAACTGCCAACTTTTTTTTCTCATTTTTGTTAGTAAGAAGATTCGCTTAGTTATTTTA TGTAAAAATCAGTATGTGTTTAGTTTTAGTGTACTGAAGGGTAAACATGGTTTTATTT TATTTTACCATATTATTTTGTGTTGTTTTATTTCTATTGTGCTGTAAGTTGATGTTTAA AATTGAGAAATACTTTTGTCATAGGTAATTTGGAACATTTACAAGCCATTTGTAAAAT TTTAAGATAATCTGTAACTAATACATAAAAACAACTTAGCAAATGTGCCATTTTCACAC AACTTCTCTCTGTATAGGCCTCTGAAATATCAATAAGGCTAAATATTACTTTACACAGT AAGATGTGAAATTCACAAAAAGTAAACCAAACAAAACGAATGAAAAACTGGAAATAA TTCGTTTCCATATCTTTCCATACATCCATTTCTGAAGTATTCAGGAATGTTTTCATAAT CGAAAGAAACGGGTATCCAAATAAAACCAAGTTCTTGACATTGGTCTGTTTTGCTGT GAATATTGGAAATGCTTAGGATCTTCAGACCCAATAGCTCTAATTTTAACATTTCTACC CAATAAGAGGCTCTGTTTTCCACTGAAGCTTTGTTGGAGAAAGAGAATATGAAAATT ACACATTTTATAATTTTTAGATGAGAAAATACCACTAGCAGAATAGCTTTGTGCTATT CCAGTATAAGATGAACTGTAATAATTTTTGACTTCCCTATTTCAGAGATAGTCAATAT AATATGTTTATCTATATCCATATGGATGGATAGGTAGGTAGATCTTCATAGATTTTTT TTTCTTTTGTTAGAGGAGAGCTTGATGTGATTATCTICAAACCCACCAAACCAACAGG ATAATTGACAAATAAACGCCATAGGCTAGGCTGAACTGTATGTTACTGTTTTCATGCT TATACATATATTTTCAATCACATACAAGTACATAGAATTTCACATTTTAATTTAGCAAA TTGATTTACCTAGGAAAAAATTATCACCTTCAAAGATAGGCATAGACACATAATTATG CTTAAGCTTTTAACAGCATTTTAACCGCTCTAAAAATTACCAGAGTAAGAAAAAGCTA GGTACTTTAAAGTGAGTTTGAGAAACAAGTTGAAACTAAAATTAAAATACCAGCCATT TAGGTGCTTTCTCTGGCATCTATAAAAGTAAATTCTAGTGCCTGCCAAGTGATGGATT ATAATGGTCTCTAGCAAATGTGTGGTAAACATTCATATGGCCATTAATTTTAACATTA AATCGTAGGTAGGGCAATGTAGTAAAATGAAAGAGAATTAAGAAAGGTTTTGAATTC TTATAACATATCCAGCCATTTCAATTTTGATTGAAATGAACTACAAAGAATAGTGTTT GTCCCTATGGTAGCCTCAGTCTCTTTATCACTAACTTGGATTGAAATGAGTGAGGCCA ACTCACATTCCCATCAAACACTCTTCCAAGGAAAAGCAGAAGTAATAATTGGAGGTAA AGTTTCCTTAGAGAAAATAATTTTATTCTGCTTTGTCCAATTAAATTATTCCAATGGCG GATGGTAATATTCACCATCTCTAATTCATTGGTCACTGGTAGGTAAGCATGAGTTAAG GAAAGTCAAAAATGAAAATATATTTTGCTGTGTATAAATTGATATTTTGCTATGCAAC TCCTGTAATTGAATTTGTATAATGCAGGCACTTTCTAATTTATTAGAGATTATGGATC AGTTCTGACATTAAAATCATAGTTAATTGATGGATGGTTTTTATAGTTTGTTGATAAA GTGGACACAGTATTGTCTGAGCAGTTATATTTTAATGCATTTCAGTGTTTATAGTAGA AGTTTAGTGGATAAAACTTTAAGTCCAATAACTTGGGGGTCAAATGCTAATGTTTTAT TCAATGTAAAGGAAGACCAAACCATGTACCTTATGAAGACCTTTGTTTTAAGACTTCC ACACACCAAGGCTACAATGACTGTTAACCTGGAGGAAGTCTCTGGTATGGAGTTCTG AGAGCTTAAGAGCTAAACATGAGTTTAGACACACAAGATTCTAAAATGCAAATGTTTA TTTTGAAGCAGGCATTGACAACACAAAAACTGTGTAGTGGTCTTGATGCTGGATTGT TTCTAGAGTCACAATGAATTATTTTTATGAGATTACCTTATTTTTATATATGACAAACT ACTTCTATAATGCTTATTATGGTAAAATAAAATTGGAAAAAATTAAAACTGACCTATA AGAGTGTTAAGGACCTAATAGAGTGACATATATAAATTAAGCATAAAATATGTAACC AGGAAAAGACTGTTAACATTACATTTATGCAAATTAAATGCCCTTAAATTTCACCATTT GTCTTTCATTTTAAAGGTTATTTGCTCCCGATTATATGATTCAAGTGTTATAAGTTTTA GCTTGAACTACTTTGCAGTAATTTATTTGACAGATCTCTATTCTATAAATGTGTAATGT GATGAAGAAAGAGATCTTTCTTTTTTAATGAAAACATTAATGTGTTAATACCCTGTAT GGATAATGCTTGACATTTAGTGGTTTCCAAAATATATTAGTATATTGTTGAACATACA TTATGCCTTAGAAATGCACATTCTGTATTTTGTGGGATGATAATCTAATTCAGTATAG AATATGCTGTTTGGCAATGAGTTTGTGGCCAGATTTCAAATAGGGAGTTAAGTGGTA CTTTCACAATCCAAAGATTTTTAGTTAAAAATCATGTAGTCTAATATGCTGCAGTTATT TTTTTATATTTTTCAATGCATTTAATTATCTTTTTTATAATTCTTTGTACTAACTCAGCA TGTAACAACCAATTTACATGGAAATAAATCGAAATATGATAACTATTATGCAAAAAAA AAAAAAAAAA >gi|116256456|ref|NM_032034.2| Homo sapiens solute carrier family 4, sodium borate transporter, member 11 (SLC4A11), mRNA (SEQ ID NO: 8) CTTTCTCCCTAGGGTGGCGTGGGTTGCATCCCTCGGAAGAGCGAAGGAATGAGCCA GGTCGGGGGGCGGGGAGACAGGTGCACACAGGAGGTCCAGGGCTTGGTCCATGGG GCTGGTGACCTTTCTGCTTCCCTTGCAGAAAACTCTCCCACCATGTCGCAGAATGGAT ACTTCGAGGATTCAAGCTACTACAAGTGTGACACAGATGACACCTTCGAAGCCCGAG AGGAGATCCTGGGGGATGAGGCCTTCGACACTGCCAACTCCTCCATCGTGTCTGGCG AGAGTATCCGTTTTTTTGTCAATGTCAACCTTGAGATGCAGGCCACCAACACTGAGAA TGAAGCGACTTCCGGTGGCTGTGTGCTCCTGCACACCTCCCGAAAGTACCTGAAGTT AAAGAACTTCAAGGAAGAGATCCGTGCGCACCGCGACCTAGATGGCTTCCTGGCGCA GGCCAGCATCGTCCTGAACGAGACGGCCACCTCCCTGGATAACGTGCTGCGGACCAT GCTTCGCCGCTTCGCCAGGGACCCTGACAACAATGAGCCCAACTGCAACCTGGACCT GCTCATGGCCATGCTCTTCACCGATGCCGGGGCACCCATGCGGGGTAAAGTCCACCT GCTGTCAGATACCATCCAAGGGGTCACCGCCACAGTGACAGGGGTGCGGTACCAGC AGTCGTGGCTCTGCATCATCTGTACCATGAAGGCCCTACAGAAGCGGCACGTGTGCA TCAGCCGCCTGGTTCGCCCACAGAACTGGGGGGAGAATTCCTGTGAGGTTCGGTTC GTCATCCTGGTGCTGGCCCCACCCAAGATGAAAAGCACTAAGACTGCGATGGAGGTG GCGCGCACGTTTGCCACCATGTTCTCGGATATCGCCTTCCGCCAGAAGCTCCTGGAG ACCCGCACAGAGGAGGAATTCAAGGAGGCCTTGGTGCATCAGAGACAGCTGCTCAC CATGGTGAGCCACGGTCCAGTGGCGCCGAGAACGAAGGAACGCAGCACAGTCTCCC TCCCTGCCCACAGACACCCAGAGCCCCCAAAGTGCAAGGACTTTGTCCCTTTTGGGAA GGGCATCCGGGAGGACATCGCACGCAGGTTCCCCTTGTACCCCTTGGACTTCACTGA TGGCATTATTGGGAAAAACAAGGCTGTGGGCAAATACATCACCACCACCCTGTTCCTC TACTTCGCCTGCCTCCTGCCCACCATCGCTTTCGGGTCTCTCAATGACGAGAACACAG ACGGGGCCATCGACGTGCAGAAGACCATAGCCGGGCAGAGCATCGGGGGCCTGCTC TACGCGCTCTTCTCTGGGCAGCCATTGGTGATTCTGCTGACCACCGCGCCCCTGGCGC TCTACATCCAGGTGATTCGTGTCATCTGTGATGACTATGACCTGGACTTCAACTCCTT CTACGCATGGACGGGCCTGTGGAATAGTTTCTTCCTTGCGCTTTATGCCTTTTTCAAC CTCAGCCTGGTCATGAGTCTCTTCAAGAGGTCGACGGAGGAGATCATCGCCCTCTTC ATTTCCATCACGTTTGTGCTGGATGCCGTCAAGGGCACGGTTAAAATCTTCTGGAAG TACTACTATGGGCATTACTTGGACGACTATCACACAAAAAGGACTTCATCCCTTGTCA GCCTGTCAGGCCTCGGCGCCAGCCTCAACGCCAGCCTCCACACTGCCCTCAACGCCAG CTTCCTCGCCAGCCCCACGGAGCTGCCCTCGGCCACACACTCAGGCCAGGCGACCGCC GTGCTCAGCCTCCTCATCATGCTGGGCACGCTCTGGCTGGGCTACACCCTCTACCAAT TCAAGAAGAGCCCCTACCTGCACCCCTGCGTGCGAGAGATCCTGTCCGACTGCGCCC TGCCCATCGCGGTGCTCGCCTTCTCCCTCATCAGCTCCCATGGCTTCCGGGAAATCGA GATGAGCAAGTTCCGCTACAACCCCAGCGAGAGCCCCTTTGCGATGGCGCAGATCCA GTCGCTGTCCCTGAGGGCCGTCAGCGGTGCCATGGGCCTCGGCTTCCTGCTGTCCAT GCTCTTCTTCATCGAGCAGAACTTGGTGGCCGCCTTGGTGAATGCACCGGAGAACAG GCTGGTGAAGGGCACTGCCTACCACTGGGACCTCCTGCTCCTCGCCATCATCAACACA GGGCTGTCTCTGTTTGGGCTGCCTTGGATCCATGCCGCCTACCCCCACTCCCCGCTGC ACGTGCGAGCCCTGGCCTTAGTGGAGGAGCGTGTGGAGAACGGACACATCTATGAC ACGATTGTGAACGTGAAGGAGACGCGGCTGACCTCGCTGGGCGCCAGCGTCCTGGT GGGCCTGTCCCTGTTGCTGCTGCCGGTCCCGCTTCAGTGGATCCCCAAGCCCGTGCT CTATGGCCTCTTCCTCTACATCGCGCTCACCTCCCTCGATGGCAACCAGCTCGTCCAGC GCGTGGCCCTGCTGCTCAAGGAGCAGACTGCGTACCCCCCGACACACTACATCCGGA GGGTGCCCCAGAGGAAGATCCACTACTTCACGGGCCTGCAGGTGCTTCAGCTGCTGC TGCTGTGTGCCTTCGGCATGAGCTCCCTGCCCTACATGAAGATGATCTTTCCCCTCAT CATGATCGCCATGATCCCCATCCGCTATATCCTGCTGCCCCGAATCATTGAAGCCAAG TACTTGGATGTCATGGACGCTGAGCACAGGCCTTGACTGGCAGACCCTGCCCACGCC CCATTCGCCAGCCCTCCACGTCCTCCCAGGCTGGCTCTGGAGCTGTGAGGGGAGGTG TAGGTGTGTGGGTGACTGCTCTGTGCTGCGCCTTCTCATGGCTGACTCAGGCCTGGG GCATCTGGGCATTGTAGGGGTGCAGTGGTATGTGCCCACCCCTCTCCCATTATCCTTT AGCTTTAGGCCAAGAGCGTTGCTCAGGGCAGCTTCTGCCCAGGGTGGGTGGGACTG AGCAGGATGGATTTTCTTTTGATAAAAGAGTCGATGCCTGAAAGAGAAACCATTTCC TTGATTGTGTAAGGAACTTGCTGGACGCACATTAGAGAATAAAGCTCCTGTTTCTAG GCTCCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA >gi|121949782|ref|NM_001017970.2| Homo sapiens transmembrane protein 30B (TMEM30B), mRNA (SEQ ID NO: 9) GGACACTCCCAACTTGAGACTGAAAGCTGGGCGAAAGCGGTTTGTGAAGCTAACCTA AAAGACAAAATGGTCTAGAGCCACCTTTTCCCCGCAAATAACAGAGGATTAAGGATC TGAAATCTTCAAGCCTCCAGGACCACGGTGCAAGCCCTCAGCAAAAATTTCTGCTGGA GGCCGGAGCGCCTTTTGATTTCGGGAGACTGGCCCAGGAACTCTAGTCACTTGGAAG GCGGAAGAGAAGGTGGTACCTGAGCCAGGTAGGAGCCACTCAGAGGCAGCCCGGG GCCGCCACTCACCTAGGAGAGGAGGTGGAGTCCGATGACCTGGACTGAGAGGAAAC GCGAGACTGAGTCTACCAGGTGAGGTAAAAAACACCCACCTGCTCACCTCGGAAGGG GCGGGCGAGGTGCGGCTCCCGGTGACCCGCGGGGGTGCAGCGCACCTGGGCGGAG GCGGAACTGGGAGGGTGTGGGCACTGCTCGTAGGGCCTGGAACTAAACTCACCTGT GACGGAGGCAGAGGAGGGGCCCGGGCAAAAACCCACCTGAGCTGGCGGGAAACCC GACCCGCGAGCAGTCCCCGGGCTTGCGCGGCGCGGAGAGGGAGGCGCCCCGCGGC GGGGCCCCCACTCGGTCAGCCCGCGCGTCGGTCCCCGCGCGGCCGCCATGACCTGG AGCGCCACGGCCCGGGGCGCCCACCAGCCCGACAACACCGCCTTCACTCAGCAGCGC CTCCCCGCCTGGCAGCCGCTGCTGTCGGCCAGCATCGCGCTGCCGCTCTTCTTCTGCG CGGGCCTGGCCTTCATCGGCCTGGGCCTGGGCCTCTACTACTCCTCCAACGGCATCAA GGAGCTGGAGTACGACTATACAGGCGACCCGGGCACCGGTAACTGCTCGGTGTGCG CCGCGGCTGGCCAGGGCCGGGCGCTGCCGCCCCCCTGCTCGTGCGCCTGGTACTTCT CGCTGCCCGAGCTCTTCCAGGGCCCAGTGTACCTCTACTACGAGCTGACCAACTTCTA CCAGAACAACCGGCGCTACGGCGTGTCCCGCGACGACGCGCAGCTGAGCGGACTCC CCAGCGCGCTGCGCCACCCTGTCAACGAGTGCGCCCCCTACCAGCGCAGCGCGGCCG GCCTGCCCATCGCGCCCTGCGGCGCCATCGCCAACAGCCTCTTCAACGACTCCTTCTC GCTTTGGCACCAGCGCCAGCCCGGCGGGCCCTACGTCGAGGTGCCGCTCGACCGCTC CGGCATCGCCTGGTGGACCGACTACCACGTCAAGTTCCGCAACCCGCCGCTGGTCAA CGGCAGCCTGGCGTTGGCCITCCAGGGCACGGCGCCCCCGCCCAACTGGCGCCGGC CAGTCTACGAGCTCAGCCCCGACCCCAACAACACCGGCTTCATCAATCAGGACTTCGT GGTGTGGATGCGCACGGCGGCGCTGCCCACGTTCCGCAAACTGTACGCGCGCATCC GCCAGGGCAACTACTCGGCCGGGCTGCCGCGGGGCGCCTACCGCGTCAACATCACCT ACAACTACCCGGTGCGCGCGTTCGGCGGCCACAAGCTCCTCATCTTCAGCAGCATCTC GTGGATGGGTGGCAAGAACCCCTTCCTGGGCATCGCCTACCTGGTCGTCGGCTCCCT CTGCATCCTCACCGGCTTTGTCATGCTGGTCGTCTACATTCGCTACCAGGACCAGGAC GACGACGACGAGGAGTGATTCCGGCTTTCCAGGGATCCCTCCTGCTTCTTGCCAAAA CTCTTGCAAGGTGCTTTTGGCATCTCCTCCTCGCCCGTCACCCAATTCCAACCTCGCCT AGCTTTTCCTCCCTTTGTGAATGAGGGGACCAGATAAGGGAATTACCCCCCTTGCTCT TGGGGGGCTGCTAGACTGTCTTGCCGCGGGGAGGGATGTTGACTGCAGAGTGAAA CATCCTTGCAAACTCTTCCCACCTCCTTCACGACACTGAGTTGCCATGTGAGGTTCTTC AAGTCTGAGAGTGGAAGGGATCCCTATGGAGACTCCTATTAAACCCCTATTAGAGGA AGAGATTGAGAGACCTAGCAATGTGAAGTAACAAAGATCAGGCAGCTGCAAGTGAC TCCTGAATCTTGAGTCCAGGGCTTTCGCCACTACAGTACAGTGGTTTTCTTTTCTTTG GTCGGGGAGAGTGGGCTGGAATGGAGAGTGAGGCCCACAAATTACCTGCAGAGAC GTGGAGGCGTGAGGGAGAACATGCTTGTTAAATATGCAGGTAGATTAGGAGACACC AAACAGAGATTCAGACACAGTAAGGCTGGGATGAGATCCTCGAAGCTGTGTTTTAAC AAACTCCACTGGAGAGTCCCATATTCCCTCAAATTTGGGAATCACGACCCTGAACCAG GTTGGGCCTGAAGCAGTCAACTGAATTCACTTTTTCGGATAGTAATTTGTTCCCAGG GGCAGTGACAACCATGATGTTCCAGGTTTGGTCTGGCACTCTGCCTTGAACGTAGGA AGCTCTTGATGATTTGTGGAATGAATTTTTAAAAAATTACTATCTGGGGAAAACTAGT TGGCATACAGAGTTGTAGGACAGGGTTTATGTGATTCATTTGATATTTTAGTATTTTG GTGTAAAAGCCAACAGGCAAACTTTGCCAGGTACTGTGTAGAAACTCGAAAATGTGA GGCCAGTTTGTACAGTTCAGAGGAAATGCTTTAACGTAGAATCAGATAGCTGGAAGA GATCTTCGAGGGAAAGTAAGTTCCCTAAAGTCACATCTATGTCTCCTAGCTCAGTGTT CTTTGTCATTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGATTAGAAAG GGCTTCATTCATACCTTTTCCCTTGGACCTGGAAAAAAAATTTTTTTTATCTTTTCAAA TGAAATCTATTGATTTCTAGTAATCATATTTGAATCAATGTTAAAGCATATATAGTCTT ATATGTAAACTAGATTCTTAAGATTATTTGAACCTTTGAGATGAAGTTTACACTCAACT AAAATCATTCCATTGATTTTATTGATTAACATCAATCAGTATGTTTAAAGTTATTCTAA GAAGCAATAGTTTATTTTTAAAAACCTTGTATAGCAAAATAACTTAAAACCCTTTGTG ATATCATCTTACCAGTTTATTTGGTAAAAACAAACAGTTATTTGGTATTTGTCAGAATT CTTCAGTGCCTGCTATTACAGCTATTTTCCAATTACTAACTTGATTATACTCACTCAAG GCAGTGCAAGATCTTGAAGTACTTTTTAGCAGTTAAGTAATATTGAATTGTATTGAAT AGTTTACATAGTTTATTCTAGTCTTTGAAAATTACTGAACATGGACAATGTGCATGTC ATTGACATCTGCCTTAGAACTICTGGGACAATCCTGATTCGAGAGATTCTATCCCATT ATTTACATATACCAAAAATACTTTGTTAATTTAATGTGTTGGCTTCCCAACTCCTGAAC ACGACACAATTTTATTATTAGATTTTGTATGGTGATTTTAGGCTATGAAAACATGATC ATTATATGTATATAGATACATITTTATTTGTTACAAATGTTTGAGCAGCTCACTAGCCC ACCCCTCCTCTATTTTGGGTAAGAGAATTTACTACCTTTTTTAACTATGTAGTTGAGAG CAACATGTATTTTGTTATTTTTAGAATGGTCAGTATATTGCTATAAAATTTTAAATGA GACTATGAAAGTTAAAGTATTCTGATTCTGGTTAAATTAACGAATATGGTTCCAGGCC CTGTTCTCTGGGTTTTTGAGAGAGAATAAAGGTTATGTTTGTCTTACCTTTGTTATCG AGTTTGCTGAATTCTTTTGAACGATGATCTTAAAGGCACAAACACCACCAGCCACTTT GCTAATTTCTTAATAGCAGATTTACATTGCAGCAAGAAAACCATCTTTTATAGTAACAT TCAGTTAAAATGAACTCAATTCATTGTTAACTTCCTAAAACAGAATTTGAACTTTATCA ACCTCAACGTGTATATAAACTAGATAGTCCTCAATACTTTATCAACCTCAACATGTATA TAAACTAGATAGTCCTCAAATACTGTTTGAATTTAATAAATGTCAATTTAAAAATTTTT GTAGTAGTCTTCTGCATTTTACTTCAATTATAAATTGCAATTATTTATTGGATATTTTG GACTTCAAAGCAGCAGAAACTTTAAAACTGAAATGGGAAACGTTTTCCTGCAATGATC CCTGTGCTGTAACATTTTGTCTGGTGTCTCAGGCTTCCAGGTTCTTGTTGGCCTGAAT TCCCTTGTTGCCCAGTAAATGTTCACTAGCTAGAAGTATCTTCAGGAAGTGAGATAGA AAAGAGTGAACCTCAACAATTGGACTGGAAATGAGCTTTGACCTAACTTTGTAAAATA AAAGCATAAAAGAGAAA >gi|30410787|ref|NM_006765.2| Homo sapiens tumor suppressor candidate 3 (TUSC3), transcript variant 1, mRNA (SEQ ID NO: 10) GCGCCTTTCCAGGTCTTCTCCCGGTGAACCGGATGCTCTGTCAGTCTCCTCCTCTGCG TCCTCGGCCGCGGCCCGGGTCCCTCGCAAAGCCGCTGCCATCCCGGAGGGCCCAGCC AGCGGGCTCCCGGAGGCTGGCCGGGCAGGCGTGGTGCGCGGTAGGAGCTGGGCGC GCACGGCTACCGCGCGTGGAGGAGACACTGCCCTGCCGCGATGGGGGCCCGGGGC GCTCCTTCACGCCGTAGGCAAGCGGGGCGGCGGCTGCGGTACCTGCCCACCGGGAG CTTTCCCTTCCTTCTCCTGCTGCTGCTGCTCTGCATCCAGCTCGGGGGAGGACAGAAG AAAAAGGAGAATCTTTTAGCTGAAAAAGTAGAGCAGCTGATGGAATGGAGTTCCAG ACGCTCAATCTTCCGAATGAATGGTGATAAATTCCGAAAATTTATAAAGGCACCACCT CGAAACTATTCCATGATTGTTATGTTCACTGCTCTTCAGCCTCAGCGGCAGTGTTCTG TGTGCAGGCAAGCTAATGAAGAATATCAAATACTGGCGAACTCCTGGCGCTATTCAT CTGCTTTTTGTAACAAGCTCTTCTTCAGTATGGTGGACTATGATGAGGGGACAGACG TTTTTCAGCAGCTCAACATGAACTCTGCTCCTACATTCATGCATTTTCCTCCAAAAGGC AGACCTAAGAGAGCTGATACTTTTGACCTCCAAAGAATTGGATTTGCAGCTGAGCAA CTAGCAAAGTGGATTGCTGACAGAACGGATGTTCATATTCGGGTTTTCAGACCACCC AACTACTCTGGTACCATTGCTTTGGCCCTGTTAGTGTCGCTTGTTGGAGGTTTGCTTT ATTTGAGAAGGAACAACTTGGAGTTCATCTATAACAAGACTGGTTGGGCCATGGTGT CTCTGTGTATAGTCTTTGCTATGACTTCTGGCCAGATGTGGAACCATATCCGTGGACC TCCATATGCTCATAAGAACCCACACAATGGACAAGTGAGCTACATTCATGGGAGCAG CCAGGCTCAGTTTGTGGCAGAATCACACATTATTCTGGTACTGAATGCCGCTATCACC ATGGGGATGGTTCTTCTAAATGAAGCAGCAACTTCGAAAGGCGATGTTGGAAAAAG ACGGATAATTTGCCTAGTGGGATTGGGCCTGGTGGTCTTCTTCTTCAGTTTTCTACTT TCAATATTTCGTTCCAAGTACCACGGCTATCCTTATAGTGATCTGGACTTTGAGTGAG AAGATGTGATTTGGACCATGGCACTTAAAAACTCTATAACCTCAGCTTTTTAATTAAA TGAAGCCAAGTGGGATTTGCATAAAGTGAATGTTTACCATGAAGATAAACTGTTCCT GACTTTATACTATTTTGAATTCATTCATTTCATTGTGATCAGCTAGCTTATTCTTGTGT ACTTTTTTTAAACTGTGGGTTTTCCTAGTAAATTTAATTTACAGAAATCAATGGTAGC ATTTAGTAATCTACAAAGGAAATATCAAAGTGTTTTTCAAGCCTGTTATATTCAGTGT GTGCCACAGGATTGAAATAAATGACAATGTAATTATGAAAAAAAAAAAAAAAAAAAA AAAAAAAA [>gi|157649067|ref|NM_006095.2| Homo sapiens ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 (ATP8A1), transcript variant 1, mRNA (SEQ ID NO: 11) AAGAGCTCGCCCAGCTCTGCGGGCGCCGCCACCTTCGCCGCCACCGCTGCCTTTCTCCTCCTCCTGTCGGCGTGCGG GGGCCGCGCCCGGCGGCAGCTCTGCCCTAGGTGGGCGGCGGCGCGGCCCAGGCTGCAGCTGAGCGCTCTGCGCGGCG CAGCCGGGTCTCCCGCGTGTACCACGCCGTGACAGGTGCAGAGTCCGGGCTGAGGACCCACCTGCAGCCGCCGCCGC GATGCCCACCATGCGGAGGACCGTGTCGGAGATCCGCTCGCGCGCCGAAGGTTATGAGAAGACAGATGATGTTTCAG AGAAGACCTCACTGGCTGACCAGGAGGAAGTAAGGACTATTTTCATCAACCAGCCCCAGCTGACAAAATTCTGCAAT AACCATGTCAGCACTGCAAAATACAACATAATCACATTCCTTCCAAGATTTCTCTACTCTCAGTTCAGAAGAGCTGC TAATTCATTTTTTCTCTTTATTGCACTGCTGCAGCAAATACCTGATGTGTCACCAACAGGTCGTTATACAACACTGG TTCCTCTCTTATTTATTTTAGCTGTGGCAGCTATCAAAGAGATAATAGAAGATATTAAACGACATAAAGCTGATAAT GCAGTGAACAAGAAACAAACGCAAGTTTTGAGAAATGGTGCTTGGGAAATTGTCCACTGGGAAAAGGTGGCAGTAGG GGAGATAGTGAAAGTGACCAATGGGGAACATCTCCCAGCAGATCTCATCAGTCTGTCCTCAAGTGAGCCCCAAGCCA TGTGCTACATTGAAACATCCAACTTAGATGGTGAAACAAACTTGAAAATTAGACAGGGCTTACCAGCAACATCAGAT ATCAAAGACGTTGACAGTTTGATGAGGATTTCTGGCAGAATTGAGTGTGAAAGTCCAAACAGACATCTCTACGATTT TGTTGGAAACATAAGGCTTGATGGACATGGCACCGTTCCACTGGGAGCAGATCAGATTCTTCTTCGAGGAGCTCAGT TGAGAAATACACAGTGGGTTCATGGAATAGTTGTCTACACTGGACATGACACCAAGCTGATGCAGAATTCAACAAGT CCACCACTTAAGCTCTCAAATGTGGAACGGATTACAAATGTACAAATTTTGATTTTATTTTGTATCTTAATTGCCAT GTCTCTTGTCTGTTCTGTGGGCTCAGCCATTTGGAATCGAAGGCATTCTGGAAAAGACTGGTATCTCAATCTAAACT ATGGTGGCGCTAGTAATTTTGGACTGAATTTCTTGACCTTCATCATCCTTTTCAACAATCTCATTCCTATCAGCTTA TTGGTTACATTAGAAGTTGTGAAATTTACCCAGGCATACTTCATAAATTGGGATCTTGACATGCACTATGAACCCAC AGACACTGCTGCTATGGCTCGAACATCTAATCTGAATGAGGAACTTGGCCAGGTTAAATACATATTTTCTGACAAAA CTGGTACTCTGACATGCAATGTAATGCAGTTTAAGAAGTGCACCATAGCGGGAGTTGCTTATGGCCATGTCCCTGAA CCTGAGGATTATGGCTGCTCTCCTGATGAATGGCAGAACTCACAGTTTGGAGATGAAAAAACATTTAGTGATTCATC ATTGCTGGAAAATCTCCAAAATAATCATCCAACTGCACCTATAATATGTGAATTTCTTACAATGATGGCAGTCTGTC ACACAGCAGTGCCAGAGCGAGAAGGTGACAAGATTATTTATCAAGCAGCATCTCCAGATGAGGGAGCATTGGTCAGA GCAGCCAAGCAATTGAATTTTGTTTTCACTGGAAGAACACCCGACTCGGTGATTATAGATTCACTGGGGCAGGAAGA AAGATATGAATTGCTCAATGTCTTGGAGTTTACCAGTGCTAGGAAAAGAATGTCAGTGATTGTTCGCACTCCATCTG GAAAGTTACGACTCTACTGCAAAGGAGCTGACACTGTAATTTATGATCGACTGGCAGAGACGTCAAAATACAAAGAA ATTACCCTAAAACATTTAGAGCAGTTTGCTACAGAAGGGTTAAGAACTTTATGTTTTGCTGTGGCTGAGATTTCAGA GAGCGACTTTCAGGAGTGGCGAGCAGTCTATCAGCGAGCATCTACATCTGTGCAGAACAGGCTACTCAAACTCGAAG AGAGTTATGAGTTGATTGAAAAGAATCTTCAGCTACTTGGAGCAACAGCCATTGAGGATAAATTACAAGATCAAGTG CCTGAAACCATAGAAACGCTAATGAAAGCAGACATCAAAATCTGGATCCTTACAGGGGACAAGCAAGAAACTGCCAT TAACATCGGACACTCCTGCAAACTGTTGAAGAAGAACATGGGAATGATTGTTATAAATGAAGGCTCTCTTGATGGAA CAAGGGAAACTCTCAGTCGTCACTGTACTACCCTTGGTGATGCTCTCCGGAAAGAGAATGATTTTGCTCTTATAATT GATGGGAAAACCCTCAAATATGCCTTAACCTTTGGAGTACGACAGTATTTCCTGGACTTAGCTTTGTCATGCAAAGC TGTCATTTGCTGTCGGGTTTCTCCTCTTCAAAAATCTGAAGTTGTTGAGATGGTTAAGAAACAAGTCAAAGTCGTAA CGCTTGCAATCGGTGATGGAGCAAATGATGTCAGCATGATACAGACAGCGCACGTTGGTGTTGGTATCAGTGGCAAT GAAGGCCTGCAGGCAGCTAATTCCTCTGACTACTCCATAGCTCAGTTCAAATATTTGAAGAATTTACTGATGATTCA TGGTGCCTGGAACTATAACAGAGTCTCCAAGTGCATCTTATACTGCTTCTACAAGAATATAGTGCTCTATATTATCG AGATCTGGTTTGCCTTTGTTAATGGCTTTTCTGGACAGATCCTCTTTGAAAGATGGTGTATAGGTCTCTATAACGTG ATGTTTACAGCAATGCCTCCTTTAACTCTTGGAATATTTGAGAGATCATGCAGAAAAGAGAACATGTTGAAGTACCC TGAATTATACAAAACATCTCAGAATGCCCTGGACTTCAACACCAAGGTTTTCTGGGTTCATTGTTTAAATGGCCTCT TCCACTCAGTTATTCTGTTTTGGTTTCCACTAAAAGCCCTTCAGTATGGTACTGCATTTGGAAATGGGAAAACCTCG GATTATCTGCTACTGGGAAACTTTGTGTACACTTTTGTGGTGATAACTGTGTGTTTGAAAGCTGGATTGGAGACATC ATATTGGACATGGTTCAGCCACATAGCGATATGGGGGAGCATCGCACTCTGGGTGGTGTTTTTTGGAATCTACTCAT CTCTGTGGCCTGCCATTCCGATGGCCCCTGATATGTCAGGAGAGGCAGCCATGTTGTTCAGTTCTGGAGTCTTTTGG ATGGGCTTGTTATTCATCCCTGTGGCATCTCTGCTCCTTGATGTGGTGTACAAGGTTATCAAGAGGACTGCTTTTAA AACATTGGTCGATGAAGTTCAGGAGCTGGAGGCAAAATCTCAAGACCCAGGAGCAGTTGTACTTGGAAAAAGCCTGA CCGAGAGGGCGCAACTGCTCAAGAACGTCTTTAAGAAGAACCACGTGAACTTGTACCGCTCTGAATCCTTGCAACAA AATCTGCTCCATGGGTATGCGTTCTCTCAAGATGAAAATGGAATCGTTTCACAGTCTGAAGTGATAAGAGCATATGA TACCACGAAACAGAGGCCCGACGAATGGTGATGGGGAGAGCCTGAAAGGCAGGCTCTGTTACCTCTCTAAGGAGAGC TACCAGGTTGTCACCGCAGTCTGCTAACCAATTCCAGTCTGGTCCATGAAGAGGAAAGGTAGATCTGAGCTCATCTC GCTGATGGACATTCAGATTCATGTATATTATAGACATAAGCACTGTGCAACTGTACTGTAACACCATCTCTTTTGGA TTTTTTTAAGGTATTTGCTAAGTCTTTGTAAACGGAAATTGAAAATGACCTGGTATCTTGCCAGAGGGCTTTCTTAA ACGGAGAATAAGTCAGTATTCTTATGCCATTACTGTGGGGCTGTAACTGACTGTCAGTTTATTGGCTGTACCACAAG GTAACCAACCATTAAAAAACTCTAAATGATATTTAGTTAAAGGGACTCTTGGTATCCAGACTTAGATTTCAGGATAT GCTGAAACAAACCAGCATTCTTAAGGAACTGACTCACCTTCCTGAGCAAAATTTCTAAACAAGCATTTGTGTCCAAA ATTGTCTTGATAAATGTTTGCCAAAGAGGTTCAGTAAGTGTTTTTCTAGTTCAGTAGTCATATGCCCAGAAATGTAA GAGAAAGTTTACTTCCAGTTCCGCTGTAAGATCTGCATGCCTGACTTTCCAAATGTAAGAGTGATTTACAAAAATGA ATATTTCAAGGCATTTGCTACTAAAATCGGTGATGTTGCACCTTTGGCCTTACAAATGCTTCTTTGTTGTTTGTCGT GTTTATTTGTTAGAGGACACACGTGTTAATGTGACTCTGTTGTTATGACACTGATTTTTCAAACTATGTATGTTTCA GGTATTTCTGATGAAGTTTCATCATCATTTAGATTTTTCTAAAAATCTGGCTAATGCAGTAGATTGAGTGATGTCAT TTTGTCTTAAAGTTTTTCCTCTTAAGAAACATATGCTACGTATTTACGTGGGATTTCCAAAGCTTCTGTTGCAATAT TTGGAATAACATGTCAGATAAATGCATGGGCTTTTGTCCTGTGTTCCAGTTCCCACTAGAGATGCCTGTGTCTTGTG TAGCACACCCAGTGTTATGGTGACTGCCCCCTATACTGAAGACTGAAAATTATTTCACAGTTCACTCATCAAATAGT TCCCAAAATTCGTCACATGCTGCTTATTGGGACAAATAGGTAGTACATTTTCCCCATTTAAAAAATGCGGATTTTAC TCAGGCCGGTAACTTTACAGTCAGAGGACACGTTCATCATGAGTAGCTTTTGTTAGTATGTTTTAAAATGTATCTTC AGTTCAATTATTTTCAGCATTTACAAGACATCTGAAAATGGCTATTTTGCTACCAACAGTAAATGAAGGGGCTGTTT AAAAACCACAACCAGTTTTCTACACTATTTTTTAAATAATACTTTCATTTGAAAAAAAGGAATTAGTTTTCAGATAC ACTTCAGAGATTGAAGCAAACTATTTGCCTTTTACTCAAAAGCCTGCTTGCCTTTACATGGACTTACCAGCAAAATA GGTAGAACTTTCTCTTTTAAAAAAAGTCAACTAGAATTGAGAAGAGGTGATTTTTTTTCAGATCGCTTCTCGAGTTT AATATTTTCACATTCTTTTCACCCTTTTTCTCAATCTAGATTTAAAATTAGGATATATGTCATTTCCTTGTCTGTAT TTGTAGCTCCTTAGTTACCAGTATGCCTCTCCATTTTCTACAAATAAGAGGTTATAACACATATACATAATTCTAAC CTTAAGGGAACACACGTTTACATACTTTACTTCCCAAGCCCTTCCTGTTTGGGGTACAGATTGAGAGAGTCATGAAT CAACACATCTAGCAAGACCACAGGTGTAAGAGTCTAAGATCGTCTTCAAAATTCTGAAGTCCCAGTCTTTACCTGTC CAGTGAATGAATATTCAGAGCAGCTTTTCCTGGGCTTCCCAGTGGTGATAGCTGAGGTCAAACCACAAAAAATAAGA AAGCAAGAGTGAAATGCACCCCTCCAGAGAAACACTTTGTAGTGTTTAATTCTGTTAATAGAGAAGAGCTGCTTCTG TTTGCGCTCACTTCATCAGTGGCACCCTTCTGCAGAATTTTAATATAAAAACATTATGGATATAATAGAACTGGATT TTCTGACTTAAAAATGTAAGTTTTATTTTAATCTTGAAACGTGGATTGTTTCTGTGGAGCTCTTAAACATGAGAAGA ATACTTACGGTTGATAATGTGTAACATGATCTGAAATGTGACTAATTTGAGCCTCTTTGTCCCATCGTCCTGTTTTT GAATTATTGACATTGTCAGTCTCTTTGCTTCCTGGGTGAGACTTGGGGTTTGAGGGACAGGGAATGACCTTCTTGGT GAAACTTAAAATATAACATTGCAATTGCAGTGACTTTACAGTGTTAAATTAGAGAAAATAGTCTGATTTTTTAAACC TTCCTTAACTGGAAAAAAGTCACATGGTTTTACCAGGATTGAAATAAACAGTCAATGTGACTTTTAACATGTGTTTT TTTGAAATAAAGGGCACGTACTCTTCAATTAAAAAGTTCCTTATAGGGACTCTGGCAAATGCTAACACAGTTGCTTT ACAATGTTTACAATTCAGACAATACGACTTATAATAGAAAATCCTCATTCATTTAGCATTGAAAAGCTGGAAGTTGC TTCTTTAATGTTGAATAGTATACAGTGGTATTGAGCATGGACTTTCTAAATGTTTTATATATACATATAAAAATATA TTGGTGTCTCACACCCAGAAAGATGTTATATTGTAGATATTATTAGGAAAACAGTGTTTCTCAGGAACGTTGTAAAT TTTAAATGATATATGTACTTCCCGTCCTCCCACCTCCACTCTGTGCTCTAATGTGAGACTGCTTCAGCAGTGTTGCT AAGTTAATGGAAAACTTTTTCTAATCAAGTCAGGTGAATGTGTATTCTGCTAAATAATGTTAGCCATTTACATGAAT TGTATGGTCATTAAATGGAATCAGTGATTCCTCTTTAATTTCCAGAGGGGAAATGAATTATGGAAATCAGTCAGCAT TCTGATCATTAAATTTTATACTTTAATTTTGCCGTTCAGCATTCTAAATATCCAATGTGAAAGTCACATGATAATTT GTTTTGCATTGCGTGCACTGTACAACACTTACAACTTGTCATTTAAAATGTTTTCTCGGGAAATGAATGCTAGTCAG AAAGTAATAGATTGTATTATTCATAGTTTTAAAATTATGACAATGTCATAATTACTACAAAGCTAAATAATCGTGTT TATTTTTGTGCAGTTGCCCTTTGATAGTTCCTGGTTTTAAAACCTATTAAGTGTATAATCTTACAAATAGTCATCTA CAAAATTTATGGAGAAAGTGCCCAGCCCATTCACATCACATGGACCAGGAATTCTTTTGTAAATGACTTAAGGTAAC ATCATGCAGTTCAGTGCCTAATAAATGCTTTTTAATGATGAACATTTCTATAATGACTCGTAAGATACCATAGTCTG ATTTTTCTCACATTAAAATAACTGAAGTCACTTGTGTAACGTAGTTATACTTTGCTGCATTTTAATTAACCTTCAAC AGCTATTAAAGTGGAATGTAAGTTAAATTTTGAAGGAAAGGAAATAAATGTTTTCCATATTTCGTCTTGATTTACTT TCTGTATGAGAACAGCTGTGTTTTTGATAGGTTTATGGTTTGCATGAGTTCATATTTAAAGTGATCCAGGCCAATGC ATGGCTATTGCTGTAAATCTTGATGTTTATTTCTGCCTTGTAAAGTTCTATCACGGCCTACCTGGAATTTAAAATTC AGTAGACAAATTAATTGGTCCTCTGCACAACTTTTTTAATAAGTAGATTATTTTACAAAGAAATTTGAACAAATTTA ATTGAATCTTTTGTTTAGCTTGCCTCTAAGAACTTTTCTTAATAAAGCTCCCAAAACTTCTCAGCAAATAAATCTCC CTTAAGTAGGAAAGCTAGATTTCATATTTGCTTACTTTGAATTAACAGCAACTTTCCACAGGTAAATCTGTTCTTGC AAAGATGTGAGCAGAATAGTTAAAAATAATATTTTTATGTTTCATGGTTCTAAATGGAAGCCATAAATGCAGTAAAT ACTATCTGTTGTTTAACTACTTTAATCGTCATTTTTTACATTTTCAAGTTTATTAGGTTAAGAAAAACAGGGCAGCC TTGGAAGGCAGCTACTACAGAAAACTGCAGTTTTGCGTTAAAGATAAAGTAGTATTTTCAGCTCCCTGAAAAACCAT TCCTGCTGAAACTGCTGTAGAAATTGTGAAGCTGCATGAGTGGAGAGTATTGAATCTGTGGTTATAGTAGTTTTCTC AGGTTTGTTTATCTTGATGTTTGATGCACTGTGTTTTATAGTTATTAAAATTGAGTAATATTATTTCTATGCAGTGT TATGTGTCATTGGCCTTTTGTGAATGTGCATGTTTTAAACTGCAAATTTTAAACATTTTGTCCTCTAATTGTTATTA AAAATGAAATAAACTTTACCATTACTTAAAA >gi|115387098|ref|NM_001703.2| Homo sapiens brain-specific angiogenesis inhibitor 2 (BAI2), mRNA (SEQ ID NO: 12) TTTTCTGCACCCGCCGCCCGGGAGAGCGGGAGCCTCGGCCCTCCGCGCGGCTGCAGCTACCTACCCTGCGCCCGGCC CGGTCCCCGACTTAGGGATGGCAAACTTGCGCCCCGTGGCCGCCCCCGCCAGCGCCGGCCCCCGCTCCTGCTGCTGA CGGCGCCCAGGAAATCCACAGCAGTGATACATGTGACGTCCACACTGACAGTGCCCTCCTGTGGGCATGGCTCAGGT TGTGCGCAGTTCCTGGCACACTGGCTGTAACTCCGCCCCTTTCTCTCCCTCTCAGTAAAGCAAGATTACGCGGTGAC ATGCCTCACAGCTGATCACGACACACGGGGATGGAGAGCAAGAGTTATGGAGAATACAGGTTGGATGGGCAAGGGAC ATAGGATGACCCCAGCCTGTCCCCTCTTACTGTCTGTGATTCTGTCCCTGCGCCTGGCCACCGCCTTCGACCCCGCC CCCAGTGCCTGCTCTGCCCTGGCCTCGGGTGTGCTCTACGGGGCCTTCTCGCTGCAGGACCTCTTTCCTACCATCGC CTCGGGCTGCTCCTGGACCCTGGAGAACCCTGACCCCACCAAGTACTCCCTCTACCTGCGCTTCAACCGCCAGGAGC AGGTGTGCGCACACTTTGCCCCCCGCCTGCTGCCCCTGGACCACTACCTGGTCAACTTTACCTGCCTGCGGCCTAGC CCCGAGGAGGCGGTGGCCCAGGCGGAGTCAGAGGTGGGGCGGCCAGAAGAGGAGGAGGCAGAGGCGGCAGCGGGGTT GGAGCTGTGCAGCGGCTCAGGCCCCTTTACCTTCCTGCACTTCGACAAGAACTTCGTGCAGCTGTGCCTGTCGGCTG AGCCCTCCGAGGCCCCGCGCCTGCTGGCGCCCGCTGCCCTAGCCTTCCGCTTTGTCGAGGTCTTGCTCATCAACAAC AACAACTCTAGCCAATTCACCTGTGGTGTGCTCTGCCGCTGGAGTGAGGAGTGTGGCCGCGCTGCCGGCAGGGCCTG CGGCTTTGCTCAGCCAGGCTGCAGCTGCCCTGGAGAGGCGGGGGCCGGCTCCACCACCACCACATCTCCAGGCCCTC CTGCTGCCCACACCCTGTCCAATGCCCTGGTGCCCGGGGGCCCAGCCCCACCTGCTGAGGCCGATTTGCACTCGGGG AGCAGCAATGATCTGTTCACAACCGAGATGAGATATGGTGAGGAGCCGGAAGAGGAACCGAAAGTGAAAACCCAGTG GCCGAGGTCTGCAGATGAGCCTGGGCTATACATGGCGCAGACAGGCGACCCGGCGGCTGAGGAGTGGTCCCCGTGGA GCGTGTGTTCCCTGACGTGTGGGCAGGGTCTGCAGGTGCGGACCCGCTCCTGTGTGTCCTCCCCCTATGGGACCCTG TGCAGCGGGCCCCTGCGGGAGACCAGGCCCTGCAACAATTCAGCCACCTGCCCAGTGCACGGCGTGTGGGAGGAGTG GGGGTCCTGGAGCCTGTGCTCCCGCAGCTGCGGGCGGGGGTCCCGGAGCCGGATGCGGACCTGCGTGCCCCCCCAGC ACGGCGGCAAGGCCTGCGAGGGTCCTGAGCTGCAGACTAAGCTCTGCAGTATGGCTGCCTGCCCGGTGGAAGGCCAG TGGTTAGAATGGGGTCCCTGGGGCCCATGCTCCACGTCCTGTGCCAATGGGACCCAACAGCGCAGCCGGAAGTGCAG CGTGGCGGGCCCAGCCTGGGCCACATGCACGGGTGCCCTCACTGACACCCGGGAGTGCAGCAACCTCGAGTGCCCGG CCACTGATAGCAAGTGGGGGCCATGGAATGCGTGGAGCCTGTGCTCTAAGACGTGTGACACAGGCTGGCAGCGCCGC TTCCGCATGTGCCAGGCCACGGGCACGCAGGGCTACCCCTGCGAGGGCACCGGAGAGGAGGTGAAGCCTTGTAGTGA GAAGAGGTGTCCAGCCTTCCATGAGATGTGCAGGGATGAGTACGTGATGCTGATGACGTGGAAGAAGGCAGCTGCTG GCGAGATCATCTACAACAAGTGCCCCCCGAATGCCTCAGGGTCTGCCAGCCGCCGCTGTCTCCTCAGTGCCCAAGGC GTGGCGTACTGGGGGCTGCCCAGCTTTGCTCGCTGCATCTCCCATGAGTACCGCTACCTGTATCTGTCACTTAGGGA GCACCTGGCCAAGGGGCAGCGCATGCTGGCAGGCGAGGGCATGTCGCAGGTGGTGCGCAGCCTGCAGGAGCTACTGG CCCGGCGCACCTACTATAGTGGGGACCTGCTCTTCTCTGTGGACATTCTGAGGAATGTCACTGACACCTTTAAGAGG GCCACCTACGTGCCCTCGGCTGATGATGTGCAGCGCTTCTTCCAGGTGGTGAGCTTCATGGTGGATGCGGAAAACAA GGAGAAGTGGGACGATGCTCAGCAGGTGTCCCCTGGCTCTGTGCACCTGCTCCGTGTCGTGGAGGACTTCATTCACC TGGTGGGCGATGCTCTCAAGGCCTTCCAGAGCTCTCTGATTGTCACAGATAATCTAGTGATCAGCATTCAGCGAGAG CCCGTCTCAGCTGTGTCCAGTGACATCACGTTCCCCATGCGGGGCCGCCGGGGCATGAAGGACTGGGTGCGGCACTC AGAGGACCGCCTCTTCCTGCCCAAGGAGGTGCTCAGCCTCTCCTCCCCAGGGAAGCCAGCCACATCTGGGGCAGCAG GCAGCCCTGGCAGGGGGAGGGGCCCAGGAACGGTGCCTCCTGGCCCAGGCCACTCCCACCAGCGCCTCCTCCCAGCA GACCCTGATGAGTCCTCCTACTTTGTGATCGGTGCTGTACTCTACCGCACCCTTGGCCTCATCCTGCCGCCTCCCAG GCCCCCGCTGGCCGTCACATCCCGGGTGATGACAGTGACTGTGCGCCCCCCTACCCAGCCTCCAGCTGAGCCCCTCA TCACTGTGGAGCTCTCCTACATCATCAATGGGACCACGGATCCCCATTGCGCCAGCTGGGACTACTCCAGAGCAGAT GCCAGCTCAGGAGACTGGGACACTGAAAATTGCCAGACCCTGGAGACCCAGGCAGCTCACACCCGCTGCCAGTGCCA GCACCTGTCCACCTTTGCTGTACTAGCCCAGCCGCCCAAGGACCTGACCCTGGAGCTGGCGGGCTCCCCCTCGGTCC CCCTGGTGATCGGCTGTGCAGTGTCGTGCATGGCGCTGCTCACCCTGCTCGCCATCTATGCCGCCTTTTGGAGGTTC ATAAAATCTGAACGCTCCATCATCTTGCTGAACTTCTGCCTGTCCATCTTGGCATCCAACATCCTGATCCTCGTGGG CCAGTCCCGGGTGCTGAGCAAGGGCGTGTGCACCATGACGGCTGCCTTCCTGCACTTCTTCTTTCTCTCCTCCTTTT GCTGGGTGCTTACCGAGGCCTGGCAGTCCTACCTGGCTGTCATTGGGCGGATGCGCACCCGCCTCGTTCGCAAGCGC TTCCTCTGCCTGGGCTGGGGTCTGCCTGCCCTGGTGGTGGCCGTGTCTGTTGGCTTTACCCGAACGAAAGGATACGG TACATCCAGCTACTGCTGGCTCTCCCTGGAGGGCGGCCTGCTCTACGCCTTTGTGGGCCCTGCAGCCGTCATTGTCC TGGTGAACATGCTCATCGGAATCATCGTCTTCAACAAGCTCATGGCACGTGATGGCATCTCCGACAAATCCAAGAAG CAGAGGGCCGGGTCGGAGCGGTGCCCCTGGGCCAGCCTGCTCCTCCCCTGCTCAGCGTGTGGAGCGGTCCCCAGCCC CCTGCTCAGCTCAGCCTCGGCCAGGAACGCCATGGCCTCACTCTGGAGCTCCTGCGTGGTGCTGCCCCTGCTGGCGC TCACCTGGATGTCTGCCGTCCTGGCTATGACAGACCGCCGTTCCGTCCTCTTCCAGGCCCTCTTTGCTGTCTTCAAC TCCGCGCAGGGCTTTGTCATCACTGCTGTGCACTGCTTCCTGCGCCGAGAGGTCCAGGATGTGGTGAAGTGCCAGAT GGGGGTGTGCCGGGCTGATGAGAGCGAAGACTCCCCTGACTCGTGTAAGAACGGGCAGCTGCAGATCCTGTCAGACT TTGAAAAGGATGTGGATCTGGCTTGTCAAACAGTGCTGTTCAAGGAGGTCAACACTTGCAACCCGTCCACCATCACG GGCACACTATCCCGCCTGTCCCTGGATGAGGATGAGGAGCCCAAGTCCTGCCTCGTGGGCCCTGAGGGCAGCCTCAG CTTCTCACCACTGCCTGGGAATATCCTGGTGCCCATGGCAGCCTCACCAGGGCTGGGGGAGCCTCCGCCCCCACAGG AGGCCAACCCTGTTTACATGTGTGGGGAGGGTGGCCTGCGGCAGCTGGACCTCACATGGCTGCGGCCCACTGAGCCA GGCTCTGAGGGAGACTACATGGTGCTGCCCCGGCGGACTTTGAGCCTGCAGCCTGGCGGTGGGGGTGGAGGTGGTGA GGATGCCCCCAGGGCCCGGCCGGAGGGGACCCCCCGGCGAGCTGCCAAGACAGTGGCCCACACTGAAGGCTACCCCA GCTTCCTGTCCGTGGACCACTCGGGCCTGGGGCTGGGCCCTGCCTATGGATCTCTCCAGAATCCCTATGGAATGACC TTCCAACCGCCACCGCCGACACCCAGCGCCCGCCAAGTGCCCGAGCCAGGGGAGCGCAGCCGGACCATGCCTCGCAC CGTGCCCGGCTCTACCATGAAGATGGGCTCCCTGGAGCGAAAGAAATTACGGTATTCAGACCTGGACTTTGAGAAGG TGATGCACACCCGGAAACGGCATTCAGAACTCTACCACGAGCTCAACCAGAAGTTCCACACTTTCGACCGCTACCGC AGCCAGTCCACGGCCAAGAGGGAGAAGCGGTGGAGTGTGTCCTCGGGTGGGGCAGCCGAGCGGAGCGTGTGCACCGA TAAGCCCAGCCCTGGGGAGCGCCCCAGCTTGTCCCAACATCGGCGCCATCAGAGCTGGAGCACCTTCAAATCTATGA CACTGGGCTCGCTGCCCCCCAAGCCCCGAGAACGGCTGACTCTGCACCGGGCAGCAGCCTGGGAGCCCACAGAACCA CCGGATGGTGACTTCCAGACAGAGGTGTGAGTGCCACGCTGGACTGCCCACTGCATATAAATATATATATCTCTCTA TTTTCACACTCCACTTTGGAACTACCCAGGAGCCAGCGCCCTCTCCCCTCTCCCGAGGGCTGGGCAGGGAGGCGCCG TGGACTCAGCCAGGCTGGGGGAGCCGGACATGGCTTGGCCTGGGGTCCCAGGGCCCTTCCTTGTTTCTCAGAGGCCC CTCAGCCACTGGAACCCCATCTTCAGCCCAGCCTGTCCGTCCCTGTCCCGGGCTGGGGAGGGGGGAGGGGAACTTTG TTGGGAATAAACTTCACTCTGTGGAAAAAAAAAAAAAAAAAAAA >gi|149158715|ref|NM_016475.3| Homo sapiens chromosome 14 open reading frame 100 (C14orf100), transcript variant 1, mRNA (SEQ ID NO: 13) CTAAACCCGGAAGCGAGGGAGGAACTTCGGAGCTGTCGCCCGGGTTACCGGGAGGCGGAGCCGCCGAGCTCGCTGTG GCCCGGATGTTCGGTGCAGCTGCCAGATCCGCTGATCTAGTGCTTCTCGAAAAAAACCTTCAGGCGGCCCATGGCTG TCGATATTCAACCAGCATGCCTTGGACTTTATTGTGGGAAGACCCTATTATTTAAAAATGGCTCAACTGAAATATAT GGAGAATGTGGGGTATGCCCAAGAGGACAGAGAACGAATGCACAGAAATATTGTCAGCCTTGCACAGAATCTCCTGA ACTTTATGATTGGCTCTATCTTGGATTTATGGCAATGCTTCCTCTGGTTTTACATTGGTTCTTCATTGAATGGTACT CGGGGAAAAAGAGTTCCAGCGCACTTTTCCAACACATCACTGCATTATTTGAATGCAGCATGGCAGCTATTATCACC TTACTTGTGAGTGATCCAGTTGGTGTTCTTTATATTCGTTCATGTCGAGTATTGATGCTTTCTGACTGGTACACGAT GCTTTACAACCCAAGTCCAGATTACGTTACCACAGTACACTGTACTCATGAAGCCGTCTACCCACTATATACCATTG TATTTATCTATTACGCATTCTGCTTGGTATTAATGATGCTGCTCCGACCTCTTCTGGTGAAGAAGATTGCATGTGGG TTAGGGAAATCTGATCGATTTAAAAGTATTTATGCTGCACTTTACTTCTTCCCAATTTTAACCGTGCTTCAGGCAGT TGGTGGAGGCCTTTTATATTACGCCTTCCCATACATTATATTAGTGTTATCTTTGGTTACTCTGGCTGTGTACATGT CTGCTTCTGAAATAGAGAACTGCTATGATCTTCTGGTCAGAAAGAAAPGACTTATTGTTCTCTTCAGCCACTGGTTA CTTCATGCCTATGGAATAATCTCCATTTCCAGAGTGGATAAACTTGAGCAAGATTTGCCCCTTTTGGCTTTGGTACC TACACCAGCCCTTTTTTACTTGTTCACTGCAAAATTTACCGAACCTTCAAGGATACTCTCAGAAGGAGCCAATGGAC ACTGAGTGTAGACATGTGAAATGCCAAAAACCTGAGAAGTGCTCCTAATAAAAAAGTAAATCAATCTTAACAGTGTA TGAGAACTATTCTATCATATATGGGAACAAGATTGTCAGTATATCTTAATGTTTGGGTTTGTCTTTGTTTTGTTTAT GGTTAGACTTACAGACTTGGAAAATGCAAAACTCTGTAATACTCTGTTACACAGGGTAATATTATCTGCTACACTGG AAGGCCGCTAGGAAGCCCTTGCTTCTCTCAACAGTTCAGCTGTTCTTTAGGGCAAAATCATGTTTCTGTGTACCTAG CAATGTGTTCCCATTTTATTAAGAAAAGCTTTAACACGTGTAATCTGCAGTCCTTAACAGTGGCGTAATTGTACGTA CCTGTTGTGTTTCAGTTTGTTTTTCACCTATAATGAATTGTAAAAACAAACATACTTGTGGGGTCTGATAGCAAACA TAGAAATGATGTATATTGTTTTTTGTTATCTATTTATTTTCATCAATACAGTATTTTGATGTATTGCAAAAATAGAT AATAATTTATATAACAGGTTTTCTGTTTATAGATTGGTTCAAGATTTGTTTGGATTATTGTTCCTGTAAAGAAAACA ATAATAAAAAGCTTACCTACATAAAATTTCAATGTTTTGACACTTAATTGTTGTTTGGCACAATAGTATGGAAGTAA TTCAAACTGGTAAATAGTTTCCTCTCATATCTCGGGTATATATACATACCATATTTTATTGATCCAGAGATACTTAT TTCACTTTGTGACATCTCTGAATTAGGATGCATCTTACAACTGATGGCTTATTAGATTTAATGAAATACAGAAGATA CACAGAATAAAAAGGGTTTTCCTGTGGTTGGTTTGTGGTTTGTGATAGGTGTTCTGTGATGTTTATGCTTTGAAGGC CTTAAGACTCATGGTTGCAACCATGGAAGCAAAATGAAATTTTTAGCTCTTAACCTAACAACCTGACCATGTTTATC CATTTTTATTGTTTAGAAGTTTATTTACTGATACTTGGTGGAGGTTGTGTGAATTAGTTAAATTTTAAATGTTTAAG ACTTCTATTAACAGCTGCAAAATATGAAAGTAAGTGCACTCACTTTTCCTGTAGTAGTCTGTCTTTTGAATTCACAG CAGTTGTATCCTTGAGTTACTTTGTTAATGTATTTTTCTCAGTACATTTAACCACTGGGAAATGAACCCTTGTACGA ATGTGTTTCTTCTTCTCTGTAGGAATAAAAATAAATATAAAAATTTTATTTGTATTGCACACAAAA >gi|145580589|ref|NM_022495.5| Homo sapiens chromosome 14 open reading frame 135 (C14orf135), mRNA (SEQ ID NO: 14) AACGACGCTCTTGCGTAAAGGCCCGGCCCAAGGGAACGTTCAGGGCGTCTCGGCTTTCCCCGCTGCTGCTTCTGCTA GGCCCAGTGCGAGACCAGAGCACGAGCGACTCCCGTCGTCCCCGGCCAGGCAGATGTTGGCCTAGTCCTGGCGCGAA CGAAGCGCGCTATTTCCCTGCTTCCTCTAGGCCAAGCCTGCTTTACGGCAGGGCCCGCCTCGGGAGCGAGCACAGAC CGGGGCAGCGAGGCCAGCCAGGCGCCGACGAGGTCCCCGAACGCGCACGCGCTCCGTTCAGCTCCGGGTGGCGGCCG CCGGAGTAGACGTTAGCCATGGAAACCGAGAGCTGGCCCGGGCGGGGCCGCGGTGAGCTCGTTATTCGGCCGCCGCA GCTTTTCTGCCTCCGCATTCGGGCACTAACCAACCTCCCGGCGGGAGCGCCCAGCCCGAGTTTACCTGCAAAAATGC GGTCCCTGGGATGCCTTCGCGTCTTCTCTTCCCTCGGGTGACTTGAGGTTTGTGGTAAATATGCCAGCTCTAGAACA CATGAATCAGATTTTACACATCTTGTTTGTATTTTTACCCTTTCTGTGGGCACTTGGGACTCTGCCCCCACCCGATG CACTTCTCTTATGGGCAATGGAGCAGGTTTTAGAGTTCGGCCTTGGAGGCTCATCTATGTCAACCCACTTACGGTTA TTAGTAATGTTCATCATGTCTGCTGGAACAGCTATAGCATCATATTTCATTCCAAGCACTGTTGGTGTGGTTCTTTT CATGACTGGATTTGGTTTCTTGCTGAGTCTGAACTTAAGTGATATGGGTCACAAAATTGGAACCAAATCTAAGGATT TACCCAGTGGTCCGGAAAAACATTTTTCATGGAAGGAATGCCTTTTCTACATCATTATATTAGTCTTGGCTCTTTTA GAAACTAGCTTGCTTCATCACTTTGCTGGCTTCTCACAGATTTCTAAAAGCAATTCCCAGGCTATTGTGGGCTATGG TTTGATGATATTACTTATAATACTGTGGATACTTAGAGAAATTCAAAGCGTATATATCATTGGAATTTTCCGAAATC CCTTTTATCCGAAGGATGTGCAAACTGTGACTGTATTCTTTGAGAAGCAAACTAGGCTCATGAAGATTGGTATTGTC AGACGGATTTTGCTAACTTTAGTATCACCTTTTGCCATGATAGCATTTCTTTCATTGGACAGTTCCTTACAAGGGCT CCACTCAGTGTCTGTCTGTATTGGATTCACAAGAGCCTTTAGAATGGTATGGCAGAATACAGAAAATGCTTTATTGG AGACAGTCATTGTATCAACAGTACACTTGATCTCCAGTACAGACATATGGTGGAACAGAAGCCTGGATACAGGACTC AGACTCTTACTGGTTGGTATCATACGTGATCGTTTGATTCAGTTCATCTCTAAATTGCAGTTTGCCGTGACTGTGCT TTTGACATCATGGACAGAGAAAAAACAACGTCGAAAAACAACTGCCACTTTATGTATACTCAACATTGTCTTTTCTC CATTCGTGTTGGTCATCATAGTTTTTTCTACACTACTCTCTTCTCCCTTACTCCCTCTTTTCACCCTTCCTGTGTTC TTGGTGGGGTTTCCCCGACCTATTCAGAGTTGGCCAGGAGCAGCAGGCACCACAGCCTGTGTGTGTGCAGATACAGT GTACTACTACCAAATGGTGCCCAGGTTGACTGCTGTACTGCAGACTGCAATGGCAGCTGGAAGTTTAGGTCTCCTCC TACCTGGATCTCATTACTTGGGCCGTTTTCAGGATCGTTTAATGTGGATAATGATTCTGGAATGTGGCTATACTTAC TGCTCTATTAACATTAAGGGGTTAGAATTGCAGGAAACATCCTGTCATACTGCAGAAGCTCGCAGAGTTGATGAAGT TTTTGAAGATGCTTTTGAGCAAGAATACACAAGAGTATGTTCCCTTAATGAACACTTTGGAAATGTCTTGACACCCT GTACTGTTTTGCCTGTGAAATTGTATTCTGATGCCAGGAATGTTCTATCAGGCATAATTGATTCTCATGAAAACTTA AAAGAATTTAAAGGTGACCTCATTAAAGTACTTGTGTGGATACTTGTTCAATACTGCTCCAAAAGGCCTGGCATGAA AGAGAATGTTCACAACACTGAAAATAAAGGGAAAGCACCTCTAATGTTGCCTGCTTTGAACACTTTGCCACCTCCCA AATCCCCAGAAGACATAGACAGTTTAAATTCAGAAACTTTTAATGACTGGTCTGATGATAATATTTTTGATGATGAG CCAACTATCAAAAAAGTAATAGAAGAAAAACATCAGTTGAAAGATTTGCCAGGTACAAATTTGTTTATTCCAGGATC AGTAGAATCACAGAGGGTTGGTGATCATTCTACAGGCACTGTTCCTGAAAACGATCTTTACAAAGCAGTTCTATTAG GATACCCTGCTGTTGACAAAGGAAAACAAGAGGACATGCCATATATTCCTCTCATGGAGTTCAGTTGTTCACATTCT CACTTAGTATGCTTACCCGCAGAGTGGAGGACTAGCTGTATGCCCAGTTCCAAAATGAAGGAGATGAGCTCGTTATT TCCAGAAGACTGGTACCAATTTGTTCTAAGGCAGTTGGAATGTTATCATTCAGAAGAGAAGGCCTCAAATGTACTGG AAGAAATTGCCAAGGACAAAGTTTTAAAAGACTTTTATGTTCATACAGTAATGACTTGTTATTTTAGTTTATTTGGA ATAGACAATATGGCTCCTAGTCCTGGTCATATATTGAGAGTTTACGGTGGTGTTTTGCCTTGGTCTGTTGCTTTGGA CTGGCTCACAGAAAAGCCAGAACTGTTTCAACTAGCACTGAAAGCATTCAGGTATACTCTGAAACTAATGATTGATA AAGCAAGTTTAGGTCCAATAGAAGACTTTAGAGAACTGATTAAGTACCTTGAAGAATATGAACGTGACTGGTACATT GGTTTGGTATCTGATGAAAAGTGGAAGGAAGCAATTTTACAAGAAAAGCCATACTTGTTTTCTCTGGGGTATGATTC TAATATGGGAATTTACACTGGGAGAGTGCTTAGCCTTCAAGAATTATTGATCCAAGTGGGAAAGTTAAATCCTGAAG CTGTTAGAGGTCAGTGGGCCAATCTTTCATGGGAATTACTTTATGCCACAAACGATGATGAAGAACGTTATAGTATA CAAGCTCATCCACTACTTTTAAGAAATCTTACGGTACAAGCAGCAGAACCTCCCCTGGGATATCCGATTTATTCTTC AAAACCTCTCCACATACATTTGTATTAGAGCTCATTTTGACTGTAATGTCATCAAATGCAATGTTTTTATTTTTTCA TCCTAAAAAAGTAACTGTGATTCTTGTAACTTGAGGACTTCTCCACACCCCCATTCAGATGCCTGAGAACAGCTAAG CTCCGTAAAGTTGGTTCTCTTAGCCATCTTAATGGTTCTAAAAAACAGCAAAAACATCTTTATGTCTAAGATAAAAG AACTATTTGGCCAATATTTGTGCCCTCTGGACTTTAGTAGGCTTTGGTAAATGTGAGAAAACTTTTGTAGAATTATC ATATAATGAATTTTGTAATGCTTTCTTAAATGTGTTATAGGTGAATTGCCATACAAAGTTAACAGCTATGTAATTTT TACATACTTAAGAGATAAACATATCAGTGTTCTAAGTAGTGATAATGGATCCTGTTGAAGGTTAACATAATGTGTAT ATATTTGTTTGAAATATAATTTATAGTATTTTCAAATGTGCTGATTTATTTTGACATCTAATATCTGAATGTTTTTG TATCAAGTAGTTTGTTTTCATAGACTTCAATTCATAAACTTTAAAAAACTTTTAATAAAATATTTTCCTTCCTTTTC AAATAAAAAAAAAAAAAAAAAAAAA >gi|8922115|ref|NM_017586.1| Homo sapiens chromosome 9 open reading frame 7 (C9orf7), mRNA (SEQ ID NO: 15) ACGCGGCCGGCTACCGAGCCCTTTGTGAGGGCTGTGAGCTGCGCCTGACGGTGGCACCATGAGCAGCTCAGGTGGGG CGCCCGGGGCGTCCGCCAGCTCTGCGCCGCCCGCGCAGGAAGAGGGCATGACGTGGTGGTACCGCTGGCTGTGTCGC CTGTCTGGGGTGCTGGGGGCAGTCTCTTGCGCGATCTCTGGCCTCTTCAACTGCATCACCATCCACCCTCTGAACAT CGCGGCCGGCGTGTGGATGATCATGAATGCCTTCATCTTGTTGCTGTGTGAGGCGCCCTTCTGCTGCCAGTTCATCG AGTTTGCAAACACAGTGGCGGAGAAGGTGGACCGGCTGCGCTCCTGGCAGAAGGCTGTCTTCTACTGCGGGATGGCG GTCGTTCCCATCGTCATCAGCCTGACCCTGACCACGCTGCTGGGCAACGCCATCGCCTTTGCTACGGGGGTGCTGTA CGGACTCTCTGCTCTGGGCAAAAAGGGCGATGCGATCTCCTATGCCAGGATCCAGCAGCAGAGGCAGCAGGCGGATG AGGAGAAGCTCGCGGAGACCCTGGAGGGGGAGCTGTGAAGGGCTGGGCGCCCCTCCCTCCCTGTCCCCTCTTCTGGC TCTGTGTGGGTCCAAGTGAGGCCTGGACTGTCCACGCTGAGGCACAGCCTGGAGAGGGGCCTTTGCACGTGTCCCTA CACCTGGAGTCCTCTGCTCCTTTCTCCAGACTGGCTTAAGCCAGGAGCCACTGGCTGCTGGTGTGAGGGTCTGGGCT GCTGGACTTGAGGCAGAGCCTGCAGCAGCTGTGTGGACACTACCCAGCCCTACTCCTCTGCTGGGTGGGTCTGCAGA TCTCACACCACAGACAGGGCTGCCTGTGACCTGCTGTGACCTGGGAGCAGCTTCCCCTGGAGATGCTGGTCCTGGCT TGAGGGGAGGGGCAAGTGGGACCCTGCCACCTGGGCACTGAGCAGAGGGACCTCCCCCAGCTCTCTTAGCAGGTGGA GCCCCAGGGCCTGGGACAGCCTGCCGCTGCCAGCAACCTCCCACTGCTGCCTAGGGTGCAGCGCCCACTGTCACCCT GCCTTCTGAAGAAGCCCACAGGGCTCCTAAGGTGCACCCCGGTACCTGGAACTGCAGCCTTGGCAGTGACTGGACAG CTGGGTGGGGGATGCTCCCTGCTGGCCCTGGGAACCTTGGACAGGCCACCTCAAGGCCCCTCGGCTGCCCCTCCTCC CTGGGCCTGCTGGGGCCCCTAGGTTCTGCCCATCACCCCCCGCCCCTGCTGGCCTTGGTGCTAAGGAAGTGGGGAGA GCAGGCTCTCCCTGGCACCGAGGGTGCCCACCCTCTCCCTGGTGTGGCCCCGTCAACATCAGCCACAGCCCAGCCCC ATTAGTGGGTTAGCGGGTCTGACCTCAGCCCCACTCAGGTGCTCCTGCTGGCCTGCCCAAGCCCTGCCCTCAGGGAG CTTCTGCCTTTTAAGAACTGGGCAGAGGCCACAGTCACCTCCCCACACAGAGCTGTCCCCACTGCCCTGGGTGCCAG GCTGTCCGGAGCCAGGCCTACCCAGGGAGGATGCAGAGAGCTGGTGCCCAGGATGTGCACCCCCATATTCCCTCTGC CCTGTGGCCTCAGCCCGCTGGCCTCTCTGACCGTGAGGCTGGCTCTCAGCCATCGGGCAGGTGCCTGGTCGGGCCTG GCTTAGCCCAGGTGGGGCTTGGCAGAAGCGGGCGGGTGTGGAAGATATTCCATCTGGGGCCAACCCCAGGCTGGGCC TGCGCTGAGCTTCTGGAGCGCAGGTACTGGGTCTTGCTAAGTGAACTGTTTCCCAGGAACACCTCTCGGGCCCATCT GCGTCTGAGGCTGGGAGTGGCATCTGAGGCCGGGAGTGGCATCTGAGGCCAGGAGTGGCAGGCTGGTGGGCTGGGCG TGGGGTTTTCTGGGCCCTGCCCAGTACTGCCCTGGGGACTTGGTGGGCTCCTGGGTCAGCAGCATCCCACCCCTGGG AGTCTGGCCAGCTGAGCCCCAGGGTGGCAGGGGCATTATAGCCTGGTGGACATGTGCCTTCAGGGTTCCTCCGGGGC CACCTTCCTCAGGCCAGTGCTGGGTTCAAAGGGCTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTATATGTGTGTGG GTGCACACATCTGTCCCATGTATGCAGTGAGACCTGTCTACCTCCCACAAGGAGCAAGGGCTCTGCCCGCCCTCTGC TCATTCCTACCCAGGTAGTGGGACCCCGGGCCCCCTTCTGCCTGGCTTGCCTGCTTCTGCCCTTTCCAGAGGGGTCT CACTGACAGCCAGAGACAGCAGGAGAAGGGTTGGCTGTGGATCAAGGAAGGCTGCCCCTGTACCCTGTGGGGAAATG GTGGGTGCATGGCTGGATGCAGAGGTGGAAGGCCCTGGGCCACAGGCGAGAGTGGGCGTGTCACCTGTCCCAGGTTC CCAGCAAGTCTGCAGCTGTGCAGTCCTGGGGTCCCTGACCCTGTCGCCCAGGGGGCGTGCTGTCCAGCAGGGGCCCT GCCTTGCAAGGAACGTCTCTTCCGGCGGCTGGGCCGCTCCTGCCTGGTCTGGGCTGTGTGTGGCGCCCTTTCCTTCT TGTTTGTTCCTCTGTGTTCTGTGTGCGTCTTAAGCAATAAAGCGTGGCCGTGGCTCGCGAAAAAAAAAAAAAAAAAA >gi|169188371|ref|XM_001725818.1| PREDICTED: Homo sapiens family with sequence similarity 26, member A (FAM26A), mRNA (SEQ ID NO: 16) CCCTGCCTTAAGTGCCTACTGGATCCCGGGAGCCTGGGCTGGGGCCTGGGCACTGCTTCCTCCTTGGCCCCTCAGGC CCTTGGAAGCAGAGAGAGAACCTCTTGCAGATCCCAGGCTCGTCCCCAGCACAGCAGACACCAGGAAGGTGGCCAGA GCCTCACTGAGCCGAACCGACGGCCGCCCACCCACCCAGGCTGGAGCCATGGATAAATTCCGCATGCTCTTCCAGCA CTTCCAGTCAAGCTCGGAGTCGGTGATGAATGGCATCTGCCTGCTGCTGGCTGCGGTCACCGTCAAGCTGTACTCCT CCTTTGACTTCAACTGTCCCTGCCTGGTGCACTACAATGCACTCTACGGCCTGGGCCTGCTGCTGACGCCCCCGCTC GCCCTGTTTCTCTGCGGCCTCCTCGCCAACCGGCAGTCTGTGGTGATGGTCGAGGAGTGGCGCCGGCCCGCAGGGCA CCGGAGGAAGGACCCAGGCATCATCAGGTACATGTGCTCCTCTGTGCTGCAGAGGGCGCTGGCCGCCCCCCTGGTCT GGATCCTGCTGGCCCTCCTTGACGGGAAGTGCTTCGTGTGTGCCTTCAGCAGCTCTGTGGACCCTGAGAAGTTTCTG GACTTTGCCAACATGACCCCCAGCCAGGTACAGCTCTTCCTGGCCAAGGTTCCCTGCAAGGAGGATGAGCTGGTCAG GGATAGCCCTGCTCGGAAGGCAGTGTCTCGCTACCTGCGGTGCCTGTCACAGGCCATCGGCTGGAGCGTCACCCTGC TGCTGATCATCGCGGCCTTCCTGGCCCGCTGCCTGAGGCCCTGCTTCGACCAGACAGTCTTCCTGCAGCGCAGATAC TGGAGCAACTACGTGGACCTGGAGCAGAAGCTCTTCGACGAGACCTGCTGTGAGCATGCGCGGGACTTCGCGCACCG CTGCGTGCTGCACTTCTTTGCCAGCATGCGGAGTGAGCTGCAGGCGCGGGGGCTGCGCCGGGGCAATGCAGGCAGGA GACTCGAGCTCCCCGCAGTGCCTGAGCCCCCAGAAGGCCTGGATAGTGGAAGTGGGAAGGCCCACCTGCGCGCAATC TCCAGCCGGGAGCAGGTGGACCGCCTCCTAAGCACGTGGTACTCCAGCAAGCCGCCGCTGGACCTGGCTGCATCCCC CGGGCTCTGCGGGGGTGGCCTTAGCCACCGCGCCCCTACCTTGGCACTGGGCACGAGGCTGTCACAACACACCGACG TGTAGGGTCCTGGCCAGGCTTGAAGCGGCAGTGTTCGCAGGTGAAATGCCGCGCTGACAAAGTTCTGGAGTCTTTCC AGGCCGTGGGGACCCCACGGCAGGCACCCTAAGTCTTGTTAGCCTCCTTTTTAAAGTAGCCCAATCTCTGCCTAGTT TCTGGGTGTGGCCTCCAGCGCGCTTCACAAACTTTAATGTGGACTCGGTTCACCGAGGGCCTTGTTAAATACAGGTT CAGACAGTGTAGCCAGGACCGAGTCTGAGATTCTGCATTTTAAACAAGCTCCTGGAGGCTGATGTGCTTTTGGTCAG TGAACCAAACTTTGAGTAGCAAGAATCTAAGTAAATCTGCCATGGGTTCTGGGTTCTAGATGTCAATTCTAAATAAT AATAATGACCTTAGTCTGCTGCCTCGATA >gi|47777332|ref|NM_001001412.1| Homo sapiens family with sequence similarity 26, member C (FAM26C), mRNA (SEQ ID NO: 17) CTCTGCTCTGAGCTCTGTTGGTCCCAGCCAGGAGAGCCCGAGTCATGAGGTGGGCACCCAGTGGGCAGGGTGGGCAG CAGGGGCCCTCTTGGAGGCAGCAGTGAGTTGGGAAGAGGAGGCCGGGCCCCACAGCGGGCATGATGGACAAGTTCCG GATGATCTTCCAGTTCCTGCAGTCCAACCAGGAGTCCTTCATGAATGGCATCTGTGGCATCATGGCCCTGGCCAGTG CCCAGATGTACTCGGCCTTCGACTTCAACTGCCCCTGCCTGCCGGGCTACAATGCGGCCTACAGCGCGGGCATCCTG CTGGCGCCACCCCTGGTGCTCTTTCTGCTTGGCCTGGTCATGAACAACAACGTGTCCATGCTGGCCGAAGAGTGGAA GCGGCCACCGGGCCGCCGGGCCAAGGACCCCGCTGTGTTGCGCTACATGTTCTGCTCCATGGCCCAGCGCGCCCTCA TCGCGCCTGTCGTCTGGGTGGCCGTCACGCTACTCGACGGCAAATGCTTCCTCTGTGCCTTCTGCACTGCCGTGCCC GTGAGCGCACTGGGCAACGGCAGCCTGGCACCCGGCCTTCCTGCCCCCGAGCTCGCCCGCCTGCTGGCCCGGGTGCC CTGCCCTGAGATCTACGATGGCGACTGGCTGTTGGCCCGAGAGGTGGCCGTGCGTTACCTCCGCTGCATCTCCCAGG CGCTGGGCTGGTCCTTCGTGCTGCTGACCACTCTGCTGGCATTCGTGGTGCGCTCTGTGCGGCCCTGCTTCACGCAG GCCGCCTTCCTCAAGAGCAAGTACTGGTCCCACTATATCGACATCGAGCGCAAGCTCTTCGACGAGACGTGCACGGA GCACGCCAAAGCCTTTGCCAAGGTCTGCATCCAGCAGTTCTTCGAGGCCATGAACCATGACCTGGAGCTGGGTCACA CCAACGGGACACTGGCCACGGCCCCTGCTTCCGCAGCTGCCCCCACGACCCCCGATGGTGCGGAGGAGGAAAGGGAG AAGCTGCGTGGCATCACGGATCAAGGCACCATGAACAGGCTGCTCACGAGCTGGCACAAATGCAAACCGCCTCTGCG GCTGGGCCAGGAGGAGCCACCGCTGATGGGCAACGGCTGGGCTGGGGGTGGGCCCCGGCCTCCGCGTAAGGAGGTGG CCACCTACTTCAGCAAAGTGTGAGGCGTGGCCAGCTGAAGAGGCAGGAACGGGGATCTGAGCCCACAGCCCCTCCAA CCCCCAAACCAGGTGGAAAAAGGAAGGGTTTCGGTGCTGGGCAGTACTCCCCTAGGCAGATCCACACTCCGTAGCAC TCGCCTGCCCATTGGAGGCAGGAAATTTGGAGCTGGAAGGGGATCTGATGCCTTCAGGTGTGACACTGCCCTGGATG GCCCTAGGGCAGTGGGCCCATGAGCAGTATTAGTCTAAAGGGGTCGGAACTGTCATGGCAGGTACAGGGACCAATGG CTCCCCTCTGCCCAGCCCTTCCCAGGCTGATGTTCACTGTCTCCTCCCAGGTTCAACAGACATCCCTGCACCAGGGT CCACCCTCGTCTGTGGCTGTTCAGTACCTCTCTTCCTTTATGCTCCGGGCTCGGGGAGTGGGAATCATCAGGCGTCT CATGAAGTGGGAGCCCTCTGATTTGGGCAAGCGTGTCGTAGGTGAGACTGGGTGTGCCGGGGCAGGTCCATAAGGAC ATGACACACAGCCTACATGGTGTGACACACCTGGGGTGACAGGCGATGAGACAAGATGTCAGAAGCTAGGTTCACAT GGAAGAGGTCAGAGTGTGTGGTCACCATGGGGGTCATGTGACAATTGTCCAGGTGGACTGCATGTTTATTTAGCACA AACCAAGCACAAAAGTCCTCCTGTAGAGGGGTCTTTGAAAAACCACCTTAATACCCACGTCACATCCAGGTCTCCAG GGGAAATCAGACCATCCCCAAGGCTTGAGAAGTTAGACACAGAAGCTGAAGTCTCTCCATTTTTCTCAAAGACCCCA CCTCTTGGGGATGGAGTTCTAAGAGGCTAAGAGGAGCTCCAAGGCTCTAGCCCAGGTGGGATGAGGGTGGAGGAGAG CAGTGTAAAGAGAAAGCAGCTCAGATTCCAGAGTGAGACAGAACTGGGTCAAATGGTGTCTCTACCACTCACAAACC CTGTCCCTGGGCCAGCTGCATCACTGCCTGTGCCTTCGTTTCTTCATCTATACAATGAGGATGAGGCCCCCCCGGCC CGCCATCATGGGGTTGCTGTGTGTAAAAGCACATGGCACATAGTAGGCACCCAGCACAGGGTGGCTAATGTATTTGT TGATTTCTGAACCTAAGGACTTCCTTCCTCCTCCCCTGGGCAGGGATGAGACAGCAACACAAACACTCGAGCTTCCA TCTTGTTGAGGAGGAAACAGAGGTACAGATAGGTTTCTCAGCACCGCCCTCAGCTCTGAGACATAAGTCCCAAGCAT CTAAGGATTCATTTTGATCTTGGCATGATTCCATCCTTTTTTATCCATCCTTCCCTCTATTCCCACTTCTGGGGTCC AGTTTCCCTCCTCTTAATTATTTGGGAGGAGTTGCTCAGATCTTTGTGGGCCAAGGTGGGCTGGGAGGGCTCTTCCA GGAGGTAGGAGTTGGTATGGGCCCTGAAGTCAGGGAGGATTAGGATGAGCAAAAAACAAGGTGTATGTTGGTGGGTG GCAGCACTTCCAGTGGGAAGAGAAGGCCCGGAGGTATCAGGAGGTACAAATGTGATGAAGAGCAAAGCTTTGGGTCA GGCACACCTGAGTTCAAATACCAGCACTGCAGGACTTGTGGCCAGTCACCCAGCCACTCTAAGCCTCAGTGTGTCTG TCTATAAAATGGATATTAGAAGACCTGCTTGGCCAGGCGGAGTGGCTCATGCCTGTAATCCCAGCACTTGGGAGGCC AAGGAGGGAGGATCACTTGAGCCTGGGAGTTGGAGACCAGCCTGGGCAACATAGCAAGACTCTGTCTCTGTAAAGTA ATAATAATAATAATAAGAAGAAGAAGAAGAATAAAGAGAAGATTTATAATTTTAAAAAAAAAAAAAAAAAAAAAAAA AAGAAAAAAAAAAAAAAAA >gi|46048468|ref|NM_152599.2| Homo sapiens hypothetical protein FLJ35773 (FLJ35773), mRNA (SEQ ID NO: 18) GATCGCGGCGCCGCCCCAGACCGGGGGCGCAGTCCCACTCGCTCCGAGCCCCGGTCCCCCAAGCCTCCCTCCCGGGT ACCTGGGGCCGCGCCCGCCCTGCGCCCAGCTCCGCCCTCCGTCGGCCCAGGCCTGACAGAGCCCGGCAGCCATGAGT GCCAACCCCCGGTGGGACATCAGCAGGGCGCTGGGGGTGGCCAAGCTCTTCCACCTGGTGTGCGGGGTGCGGGAAGC CTGCGTGACCCCGTTCCTGACCCTTTACCTGAGGCAGCTGGGCTTGGCCGCGCCCTGGGTGGGCACCCTAATGGGAA CCAAGCACCTAATCGCTGCCTTCTGGGCTCCCGTCTGTGCCTTCCTGGCCAAAAGCTACCGGAAAAGGAGAGCGCTT CTGATCGGCTCCCTGCTCGGCTCGGTGGGGGCCAGCCTGCTGATGGTCCTGGTCCCACCGGTAGACAAAAATCGGGT GCACTTCCCTTGTAATGGAAGCAGCGGCCTGACCAGCACAGACGCACTCCCGGGGGTCACGCTACCTGTGAACATCA CCTCGGCCCAAGAGTCTGCCTCCAGCCACCCAGCCAAGAGGACTGCAGAGGTGGAAATGCCTGGCTTCAGAAACCCA CCTGGTGAAAGTGACCGAGAAACTTTCCGTGATCTGCACGTCTACTTAGCGCCCTCCGTTGAAGGAGCTAGGACCAC ATCCCAAGCTCTCCTCCATCCTGTCACTTCGGGGCTGAAAGATCATCCCTGGGAAGTTACTTTTGAGGTGGTCAAGA CAGCCCTCCCCTTGCTTACTGGGGGGAAAGGGCCCGGGAATCCAGCCAATTTGTCAGGGACCAAGGGGAAAGCCTGG GCTTTTGACCTGTCCTTGGAGGCGTTGCGGCGGACTTTTATCCTCTCCTTGGGGTCCGTGGCGTTCTGGGAGCTGCT GACAGCGCCTCTGGAGCAGGTGGCAGATGACAGCCTTTATGAGTTCCTGGATTTTGTGGATGCCACTGACCGATACA GAAGCCTGTGGGTCTGGAGGTTGCTGGGCATGTCGGCAGGCGTGTGTGGCATCACAGCCTTGGTGGGGCAGCTGGAC TGCTTCCTGATGACCAGTGGCCCCCGAGGTGTGGTCCACTTCTATGGGTACTCGGTGGTCAGCACCCTGGCCTTACT GGTGAGCATTGCCTTTCCCATTCCCATCTGTCAGCAGTGGGAGCCCAGCTACAAAAGGGTCAAAGCACTGTCCATTG TGGGGGGTGACCCCCACCTCATTCTCCTCGCCTCCACCACTGTTTTGGTAGGAGCCATCGTCAGTACTGTCCAGAAC TTTCTGTTCTGGCACATGAAGGACCATGGGAGCGGCGAGCTGGTCATGGGTTTCTCGGTCGCCCTCAGCTTGCTGGG GGAAATTCTGCTTCATCCGTTCAAAGCTACATTGCTTAGGAAACTGTCCAGGACGGGCCTGGTGGGGCTGGGGCTGA GCTGCCTCGCTGGGCAGCTGCTGTACTACTCTTTCCTCTGGAGCTGGTGGTCCGTCCTCCCCATTCAGATCTTGAGT GCCATTAGCAACAGAGCTTTGTGGTGGGCTGTGGGGGCCTCAGTAGAGGACCTGGCCACTCCCCGCATGGAGAGGGC TCTGAGTGCCTTGTTCCGAGGCCACTTTTACGGGAGTGGCTGTAGCCTGGGCAGCTTTGTCGGGGGCTTCGTGGTGA TGCGCTTCAGCCTGGCTGTGCTCTACCAGGCCTGCTGTGTGGCCCTGTTGCTCTGGTTGGCCTTGCTCCTGTCCATA CAGCGGAGGCTGCCCCGAGAGCGGAAAATCAAGTACTCGAAGCTGCTGTCCATGGAGGTGAGTGACACCAGTGACTC TGAGCAGGGGACAGAACAGGACTGGCTTGTGAAGGCCATGAGGGAGGAACACTCAGACTGAAAGGGCTGAGAAATCC AGAGTGTGCTGATCCAGCAAGGAACGAATGGACTGAACAAAACTCAGCCTGCTGAGGACAGAAACCTGCCCTGGACT GCTGGGAGCCGGGGAAGAGAGGATGGGTCTGTGCTGAAGGCCCAACAGGATCATCTCATTGCATGATTTTCTTTACT TTTGAAGTAAAAGGAGATTTAACTTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAAAAAAAAAAAAAAA >gi|148230774|ref|NM_153835.3| Homo sapiens G protein-coupled receptor 113 (GPR113), mRNA (SEQ ID NO: 19) CTCCCTTTCATCTGGTGGCCCTAGCGCCACAAGCTGCCGCTTAGGAAGTCCCTGCCGGGAGCAGAAGTGGAGACATC AGCAGGATGGCATCGGCAAGTCGCTCCCCTCCCGGGCCTCATCTGCCAAACGATCATCTCCTCCTCCGAAGTTGTAT GCATGACAGGCGAGTGGAAACTTCACTAAAATGAAGGCGATTGACACAACAGAAGGAACTCCATCCTTTCGGGGGCT TACGAAAATAATAAGTTTAAAAAAAATAGGAAGGGAATTCCCTCGCTCCATGATCACTGAGCGCTCTCCTAAGGAAA AGGAAATCTCCCGGGGGGTGCCGACTACGGGCGGCGGGCTTAGGATGCTCCCACGCTCCCCGACCCCCAATCCCCAG GACCCGCAGGACCTCCGGAGGAACGCCCGCCAGCCCGCCCGGAGCCACGCGGCACAAGGTGACACGGACCGCGCCGC GCGGGCCCCTCAGCCGCCTGGGCGAGGCCGGGAGCAGGGAGAGGGGCATCCGCCGGCCCGCGGTACCTTGTACTTAT CAAAGCCAGCCAGCTGCTCCGGGCTCACGTATTCGTAGCCAGCCATGACGACCCGAAAACTGAGCGCCCACTCGGCA GCGACTCCCGGCTACAAGGCTGTGACACACAAGCACCACACCGGCTGGGCAAGGATGGCAAAGACTGGGCTGCCCGA GAAGGGACAGAGTCAGGCTGGAGGGGAATCTGGATCTGGGCAGCTCCTGGACCAAGAGAATGGAGCAGGGGAATCAG CGCTGGTCTCCGTCTATGTACATCTGGACTTTCCAGATAAGACCTGGCCCCCTGAACTCTCCAGGACACTGACTCTC CCTGCTGCCTCAGCTTCCTCTTCCCCAAGGCCTCTTCTCACTGGCCTCAGACTCACAACAGGTGAGTACATGAGCTG CTTCGAGGCCCAGGGCTTCAAGTGGAACCTGTATGAGGTGGTGAGGGTGCCCTTGAAGGCGACAGATGTGGCTCGAC TTCCATACCAGCTGTCCATCTCCTGTGCCACCTCCCCTGGCTTCCAGCTGAGCTGCTGCATCCCCAGCACAAACCTG GCCTACACCGCGGCCTGGAGCCCTGGAGAGGGCAGCAAAGCTTCCTCCTTCAACGAGTCAGGCTCTCAGTGCTTTGT GCTGGCTGTTCAGCGCTGCCCGATGGCTGACACCACGTACGCTTGTGACCTGCAGAGCCTGGGCCTGGCTCCACTCA GGGTCCCCATCTCCATCACCATCATCCAGGATGGAGACATCACCTGCCCTGAGGACGCCTCGGTGCTCACCTGGAAT GTCACCAAGGCTGGCCACGTGGCACAGGCCCCATGTCCTGAGAGCAAGAGGGGCATAGTGAGGAGGCTCTGTGGGGC TGACGGAGTCTGGGGGCCGGTCCACAGCAGCTGCACAGATGCGAGGCTCCTGGCCTTGTTCACTAGAACCAAGCTGC TGCAGGCAGGCCAGGGCAGTCCTGCTGAGGAGGTGCCACAGATCCTGGCACAGCTGCCAGGGCAGGCGGCAGAGGCA AGTTCACCCTCCGACTTACTGACCCTGCTGAGCACCATGAAATACGTGGCCAAGGTGGTGGCAGAGGCCAGAATACA GCTTGACCGCAGAGCCCTGAAGAATCTCCTGATTGCCACAGACAAGGTCCTAGATATGGACACCAGGTCTCTGTGGA CCCTGGCCCAAGCCCGGAAGCCCTGGGCAGGCTCGACTCTCCTGCTGGCTGTGGAGACCCTGGCATGCAGCCTGTGC CCACAGGACCACCCCTTCGCCTTCAGCTTACCCAATGTGCTGCTGCAGAGCCAGCTGTTTGGACCCACGTTTCCTGC TGACTACAGCATCTCCTTCCCTACTCGGCCCCCACTGCAGGCTCAGATTCCCAGGCACTCACTGGCCCCATTGGTCC GTAATGGAACTGAAATAAGTATTACTAGCCTGGTGCTGCGAAAACTGGACCACCTTCTGCCCTCAAACTATGGACAA GGGCTGGGGGATTCCCTCTATGCCACTCCTGGCCTGGTCCTTGTCATTTCCATCATGGCAGGTGACCGGGCCTTCAG CCAGGGAGAGGTCATCATGGACTTTGGGAACACAGATGGTTCCCCTCACTGTGTCTTCTGGGATCACAGTCTCTTCC AGGGCAGGGGGGGTTGGTCCAAAGAAGGGTGCCAGGCACAGGTGGCCAGTGCCAGCCCCACTGCTCAGTGCCTCTGC CAGCACCTCACTGCCTTCTCCGTCCTCATGTCCCCACACACTGTTCCGGAAGAACCCGCTCTGGCGCTGCTGACTCA AGTGGGCTTGGGAGCTTCCATACTGGCGCTGCTTGTGTGCCTGGGTGTGTACTGGCTGGTGTGGAGAGTCGTGGTGC GGAACAAGATCTCCTATTTCCGCCACGCCGCCCTGCTCAACATGGTGTTCTGCTTGCTGGCCGCAGACACTTGCTTC CTGGGCGCCCCATTCCTCTCTCCAGGGCCCCGAAGCCCGCTCTGCCTTGCTGCCGCCTTCCTCTGTCATTTCCTCTA CCTGGCCACCTTTTTCTGGATGCTGGCGCAGGCCCTGGTGTTGGCCCACCAGCTGCTCTTTGTCTTTCACCAGCTGG CAAAGCACCGAGTTCTCCCCCTCATGGTGCTCCTGGGCTACCTGTGCCCACTGGGGTTGGCAGGTGTCACCCTGGGG CTCTACCTACCTCAAGGGCAATACCTGAGGGAGGGGGAATGCTGGTTGGATGGGAAGGGAGGGGCGTTATACACCTT CGTGGGGCCAGTGCTGGCCATCATAGGCGTGAATGGGCTGGTACTAGCCATGGCCATGCTGAAGTTGCTGAGACCTT CGCTGTCAGAGGGACCCCCAGCAGAGAAGCGCCAAGCTCTGCTGGGGGTGATCAAAGCCCTGCTCATTCTTACACCC ATCTTTGGCCTCACCTGGGGGCTGGGCCTGGCCACTCTGTTAGAGGAAGTCTCCACGGTCCCTCATTACATCTTCAC CATTCTCAACACCCTCCAGGGCGTCTTCATCCTATTGTTTGGTTGCCTCATGGACAGGAAGATACAAGAAGCTTTGC GCAAACGCTTCTGCCGCGCCCAAGCCCCCAGCTCCACCATCTCCCTGGCCACAAATGAAGGCTGCATCTTGGAACAC AGCAAAGGAGGAAGCGACACTGCCAGGAAGACAGATGCTTCAGAGTGAACCACACACGGACCCATGTTCCTGCAAGG GAGTTGAGGCTGTGTGCTTGAACCCACCAGATGAGCCCTGGCCCAATGCTCTGAACTCTTCCCGCCTCCCGGAGCTC AGCCCTTGAGAAAGGCAGGCTTATATTTCCCTTAGTGACACTCATTTATCTTACAGCTCACCCCTTCTCATTTCTAA AGTATCCAGCAAGAATAGCAGGAAAAATTAGCTAAAGGCACCTAATGAATAAGCCTGCCTTTGCTCCAGAAATAATC GACAGATATCAAAGTGCGGAATAATTACAAGTAAACTTTCTCAACCAGTTTTTAACTACAACAATACATGTTGTGAA TGAATATATTTGATAAAAATGGTTTTAATTGACCTATTCAGCGATTTCTGATTATTTCTTTTTCAATAGTTATGAAG AAAGGATGACTTACTTGACAGGAACCTCTGATCTTTCAAACATTGGAGATGAAGGGCAGAATTTGGTTTGTCTTTTC AAGTTTAGGAAAAGGTGAAGTTAATTGGTCCCTCTTTCTTTAACCTTTAAAAAATCAATATAAAATGTAAGTTTCTT AACCATATCCATGTATAGAGGCATTGATTGATATGAGCACGTTGTAAGAATAGGTTATAAAAATTTAAAGTTTAATA TAAATTTATATCAATTAATAAAGTTTAATTTATATTTAAAAATGAATACTAGAAGAAAATCTTTTTGAAGACACCAA GATATCTATCTGGCTGAATTAACTTATGGAATTCACAAGAGGAAGATGACAGGATTCTGAGAAATTTTTAAACTAGA TACGTGAAAAAAGTCTGATGAATCGGTCTTTGTTAATTATGCAATTCATGGATATTTTTTATAAAATGGGACGGGGG CATTTTCTGTTAAAATAAAAATGGTTATGCTATCACGAAAAAAAAAAAAAAA >gi|74315998|ref|NM_152529.5| Homo sapiens G protein-coupled receptor 155 (GPR155), transcript variant 10, mRNA (SEQ ID NO: 20) CTCGCGGCCGGCGAGGGGCTGAGCTGACAGGGCCGCATCGGCTTACCCCACCTTACTTTATCGGAACGTGCCTAAGC TGCTGCAGCTGGCACCCGGTTGCGCTCGGCGAAGAGGGCTGGGGGCGGGAGATGACGGTGGTCTTCTCCCTGCTTGG CACCCTGCGAGCACCAGCTCCCTTCTCCTCGCCACTCCAAGGTTGCAGACGAAGCAGAGATCTGGTTGGAGTTGGAG GGTGAGAGAAAATGAATTCTAATTTACCTGCAGAGAACTTAACCATTGCAGTCAATATGACCAAGACTTTGCCTACA GCAGTAACGCATGGATTTAATTCCACTAATGACCCACCTTCAATGTCAATTACAAGGCTTTTTCCAGCCTTACTGGA ATGCTTTGGCATTGTCCTTTGTGGCTACATAGCAGGAAGGGCCAATGTCATAACATCAACCCAGGCCAAAGGACTAG GAAATTTTGTCTCCAGATTTGCACTTCCAGCTTTATTATTCAAAAACATGGTTGTACTTAATTTTTCCAATGTGGAC TGGTCCTTCCTATATAGTATCTTAATTGCCAAAGCTTCTGTATTTTTCATTGTATGTGTATTAACCTTATTGGTTGC CAGTCCTGATAGTCGATTTAGCAAAGCTGGACTATTCCCTATTTTTGCTACACAAAGTAATGACTTTGCATTGGGAT ACCCTATAGTTGAAGCTTTATATCAAACTACATACCCAGAATATCTCCAGTACATTTATTTGGTGGCACCAATATCT CTTATGATGTTAAACCCTATAGGGTTTATTTTCTGTGAAATCCAAAAGTGGAAAGACACTCAAAATGCTTCTCAAAA TAAAATAAAAATTGTGGGACTCGGACTCCTGCGTGTATTACAGAACCCAATAGTATTTATGGTCTTCATTGGCATCG CCTTCAATTTTATTCTTGATCGAAAGGTACCTGTATATGTCGAAAATTTTCTTGATGGACTTGGAAATTCTTTTTCT GGATCAGCCCTATTTTATCTTGGTCTCACGATGGTGGGAAAAATAAAGAGACTGAAGAAGTCGGCATTTGTAGTACT AATTCTTCTCATCACAGCTAAACTTCTGGTGCTGCCACTTCTGTGCAGAGAAATGGTGGAACTCTTGGACAAGGGCG ACAGTGTGGTGAACCATACAAGTTTATCAAATTATGCATTTCTGTATGGTGTATTTCCTGTAGCACCAGGAGTGGCT ATCTTTGCAACACAATTCAACATGGAAGTAGAAATTATAACCTCAGGGATGGTGATAAGCACATTTGTGTCTGCTCC CATCATGTACGTTTCTGCCTGGTTACTGACCTTTCCCACTATGGACCCTAAGCCATTGGCATATGCCATCCAGAATG TTAGTTTTGATATAAGTATTGTCAGCCTGATCTCCTTGATCTGGTCTCTGGCTATTCTTCTTTTGAGTAAGAAATAT AAACAGCTTCCTCATATGCTTACAACTAATTTACTCATTGCTCAGTCTATTGTCTGTGCTGGAATGATGATATGGAA TTTTGTTAAAGAAAAAAATTTTGTTGGACAAATTTTGGTGTTTGTTCTATTGTACAGCTCCCTCTATAGCACCTACC TGTGGACAGGCCTTCTAGCAATTTCTTTGTTTCTTTTGAAAAAGCGAGAGAGGGTACAAATTCCTGTTGGAATAATC ATAATATCTGGCTGGGGAATTCCTGCTCTCCTTGTTGGTGTTCTTTTGATAACTGGAAAACACAATGGAGATAGCAT TGACTCAGCCTTCTTTTATGGAAAAGAACAGATGATCACCACAGCAGTCACCCTGTTCTGCAGCATCCTGATAGCTG GCATATCCCTCATGTGCATGAACCAGACTGCCCAAGCAGGAAGCTATGAAGGTTTCGATCAGTCTCAGAGCCACAAA GTGGTGGAGCCTGGAAATACTGCTTTTGAGGAGAGTCCAGCACCAGTAAATGAACCAGAACTTTTTACAAGCTCTAT TCCAGAAACAAGTTGCTGCTCCTGCTCCATGGGAAATGGTGAATTACACTGCCCATCAATAGAGCCAATAGCAAACA CAAGCACCAGTGAGCCTGTGATTCCTTCGTTTGAGAAAAACAATCATTGTGTGAGTCGCTGTAACTCCCAGAGCTGC ATATTAGCCCAGGAAGAAGAACAGTATCTACAGAGTGGAGACCAGCAACTGACCCGACATGTGTTGCTGTGTTTACT TCTCATCATTGGCCTGTTCGCTAATCTTTCCAGTTGTTTATGGTGGCTATTCAACCAAGAGCCTGGAAGACTTTATG TTGAGTTACAGTTTTTCTGTGCCGTGTTTAACTTTGGTCAGGGATTTATTTCCTTTGGAATCTTTGGATTAGATAAA CATTTAATCATCCTGCCTTTCAAAAGAAGACTTGAATTCCTATGGAACAATAAAGACACAGCAGAAAACAGGGATTC TCCTGTTTCAGAGGAAATAAAAATGACCTGTCAACAATTTATCCATTATCACCGTGACCTCTGTATCCGAAACATTG TCAAAGAAAGAAGGTGTGGTGCAAAGACTTCTGCTGGAACTTTCTGTGGCTGTGACCTGGTGAGCTGGCTAATTGAA GTCGGCCTTGCCTCCGACCGTGGTGAAGCTGTGATATACGGAGACAGGCTGGTACAAGGGGGAGTCATCCAACATAT TACCAACGAGTATGAATTCCGGGATGAGTACTTGTTTTACAGATTTCTTCAAAAGAGTCCTGAACAGAGTCCTCCTG CTATTAATGCAAACACTCTCCAACAGGAAAGATATAAAGAAATTGAGCATTCATCCCCACCCTCACATTCCCCTAAG ACCTAAATTATGCAGGGGAGAACCCTACATGGAATCATATTCTAGCCGCGTATTCATTAGTTTTTAGCTGGGTGACC TTGGGCAAGTTAACAGAGGCAACCTCTCTGAGCCTCAGTTGTCTCTTCTGTAAAATGTGAAAAGATGTGCTCCCACC ACATGCGCAGGGTCTGTGATTTTACATGTATGTAAAACACATAGGAAGCTGACTTAGGAAAAAGAGAAAACCAAATT AAAGTTCTGATAATGAATATAATATAGTCATCCTTTAGTATCCAAGGGGATTGGTTCCAGGACTCCTGAAGATCCCA AAATCTGAGGATACTCAAGTCCCTTATATAAAATGGTGTAGGCCGGGCATGGTGGCTCACGCCTGTAATCCCAGTAC TTTGGGAGGCCGAGTCAGGTGGATCACCTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACATGGCGAAACCCCGTC TCTACTATAAAATACAAAAAATTAGTTGGGTGTGGTGGCGGGTGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCA GGAGAATCGCTTGAATCTGGGAGGCAGAGGTTGCTGTGAGCCGAGATCGTGCCACTGCACTCCAGCCTGAGCAACAG AGCAAGACTCTATCTCAAAAATAAAATAAAATAAAATAAAATAATTAATAAAATGGTGTAGTATTTGCATATAACCT ATGCACATTCTCCCATATAGTTTAATCATCTTTAGATACTTATAATGCCTAATACAATGTAAATGCTATGTAAATAG TTGTTGTTATACTGTATTGTTTAGGGAATAACAATAAGAAAAACAGTCTGTACATGTTCACTACAGATGCAACCATT GTTAAGCCTGACTACATCTTTTTATCTGCGGTTGATTGAATCTATGGATGTGGAACCTGTGCATATGGAGGGTCAAC TGTACTATAAATAATACGAATATGCCAACATTATATAATCATTGCTTTCTGCAACTGTTTACTATAATTTCAAAATT AATATCCTATTAACTGTTCCTATAAATTATCAAATTTGGCAAGTGTATTACTAGCAGGAGATGGACCTTAAATTATG ACAACTTTATATTTTTTGATAGCATCTCTTGAAAAAGAATTTTAATGATTCTAATAAGAGGTTCTTTTTCTTTTTTC CATTTCCTTGACAAATAGTACTCATTTAAAAACTAGAGGGCTAGGCTTAGTGGCTCACGCCTGTAATCTCAGCACTT TGGGAGGCTGAGGCGGGCAGATCGCTTGAGGTCAGGAGTTCAAGACCAGCCCGGGCAACGTGGTGAAACCCGGTCTG TACTAAAAAAAAAAAAAAAGAAAAAGAAAAAGAAAAAAGAATACCCAGGTGTGGTAGTGCATGCCTGTAGTCCCAGC TACTTTGGAGACTGAGGTGGGAGTACCCCTTGAGCCTGGGAGGCGCAGGTTGCAGTGAACCAAGATCACATCACTGC ACTTCAACCTGGGTGACAGAGCAAGACCCTGTCTCAAAAACAAAAAACAAGCAAAAAAAACCTAGAGGCACTATTTT TTTTTAAAGTTTGTCTTTTCTTTTCTACCCAAATTACTAATCTATGCCATTAAGGAAAGGAATAAGAACCTCCATAT GTATTATTATCTCCACAGTCCTGCAGAAGTACAATCTGATCTTTAACTTTCATGCTACAAATAATAATTTGAGTAGA TTAATTTGAATTTTATCAACAAAATTATTGCCATATGATGTATCATTTCTGTGTTTGAACAAAGCATCGTAATGCAG GATAACTTCTACTTTATTCCCTGTAGTTAAAAAAAAAAAAACTATATAGTTCAAGCCAATATTTAAAAATTCTAAAC CTAGGCTGGGCATGGTGACTCATACCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGTGAATTGCTTCAGCCCAG GAGTTCGAGACCAGCCTGGCCAATGTGGTGAAACCCCATCTCTACTAAAAAAAAAAAAAAAAAAAAAAATTAGCCAG GTGTGGTGGTGTGCACCTGTAATCCCAGCTACCCAGGAGGCTGAGGCAGGAAAATTGCTTGAAACCAGGAGGCAGAG GTTGCAGTGAGCTGAGATCGTGCCACTGCACTCCAGCCTGAGTGTCAGAGTGAGACTCTGTCTCAGAAAAAAAAAAA AAAATTCTAAAGATTACATTTAGAATTTAGTCTTTTTAAAGTGTCCATGTATAAAAATATATAATTTTTAAAATTAC TAAATGTTGCCTTTTCTCTTAGTCTAATATTTTAGCTACTAAAACAAAATATAAACTGGATAGCTTATAAACAACAT AAACTTATTTCTCACAGTTTTGGAGGCTGTGAAGTCCAAGATTAAGGCACTAACAGATCTAGTGTCTGGTAAGGCAA ATTTCTGGCTCATAGATGGTACCTTCTTGCTGTGTCCCCACATGGTAGATGGGAAGAACTGGTCTCATTGGCCCCTT ATAAGGACATTAATTCCACTCAATAGGCTCCACCCTCATGATCTAATAACCTCTCAAAGGCCCTACCTCCTAATACT AACACATTGAGGATGTGACTTCAACTTTACATTTCTACAGGCAGAGAAGTGGGGCTGTGTAAATTCTTCCCATCAGT ACTTGAATGTTCATTTAACAAATAACTTATCGAGCATCTAGCATGTTCCAGACACAATCTGAACACTGAGCACACAA CAGTTGGAACAAATATGATTCCTATCCTCATGGAGCTTCTATTCTCCTGTGAAAAACAGATGTTAAACATGATTGAG GATTAGGTTTCAACATAAGAATTCTAGGAGGACACAGACATTTAGACCATAGCATCTTCAGGTAAACTTTATCTTCA GTAAATTAAAGAGATCTATTTAGATGACCTTTGAGCATCTTAATTATTAGATGTCAGTGCTAGTTTAACTTATTTTA AACGTTTCAGATATTTATTTAATTATACTTTAAGTGTCTCATGTAAAAAAGTTATTTATAAAATAATTTATAGGGTT AGAGTCATTGCCCTTTTAATGCAACAAATAAACAGTTTTTTAAAAACCTGCATGGGGGCCAGGCGCGGTGGTTCATA CCTGCAATCCCAGCACTTTGGGAGGTCGAGGCTGGCGGATCACGAGGTCAGGAGATCGAGACCACCCTGATTAATGC GGTGAAATCCCGTCTCTACTAAAAATACAAAAAATTAGCCAGACGTGGTGGTGGGCACCTATAGTCCCAGCTACTCG GGAGGCTGAGGCAGGAGAATGGCATGAACCCGGAAGGCGGAGCTTGCAGTGAACCAAGATCGCGCCACTGCACTCCA GCCTGGGCGACAGAGTGAGACTCCATCGCAAAAAAAAAAAAAAAAAAACCTGCATGGAAGCCTAGTATATTTATTAA TAACAAATAAATTATACTTTAGTGTACTATTAACCTATACCAATTTTAAGTTGTGATTAGGGAATGGGGATGTTTTT AAGCTGAATTGTCTTGCTGCGGAACTTTCCTTTTTTAATAAGACCATATTATGACTCTGAATGCTCAAGGGTAAGTC TAAGGCCTCATTGCTGTTACCAGGAGATTTTTCTAGTTACAGTAATAAAGATGTTAATTCACATGCATGCAGACAAC TGAAACTCAAGTGGAGAATTTGTTTGTGAACAAGTCATACTACTTCTGTTATTTGCATGAATGGAATCTGCAATATC TTTTTCCATGGGAGACCCTAAAAGAAAACCCTGGATCAGAATGATCTGCAGTTTCAGATAATAAAGGCTTTTAAGAG ACATTTTTAGAATTAAAAATATGCTAATTTTATTAAATGAAAATATTTGTAACTGTTAACTTTCTCACTGACAAAGC AAGTTTCTCAATAAAATACCTATTTTAACTTGCATTACTGACATCTTTTCTTTGAGTAATCTGAATAATGCAGAAGC CATCATAGAGGTCTTTTCTATACATTCTCAATGTTTTCTTAAATGGGTTTCCTGAGTTCTGTTCTTCATGACTCTGG GCTCTGCAAACAGGGTTTCCCAATTACGCATTCTATAAACACTTTTATGAATGAGTCAATATGACATTGAGTCCTTT TCATACATTTCATCATTTCCAATATGTAGAGTGACAGCTAGAAAAATGATAAAATTTTGATTAAAACCTATCTCTTT TTCTTCAGCATAGTCAATTGTTTTCTTAACTCTCAATGAGTAACTCCATGCCTAGCTTGTGCTTAGCTTTCAATATT TTTAGACTAAGACAAAGTGTATTTGGCATTTTGAGAACAACAATTAATGGTCAGTAAATTTCTAAAGCAAGAAAAAT GTGAAACTAGTGTTTTATATGTTTGTTACGCAGCAGAATGCGGCTCTTAGTGTTTGCCCCTTCATATCTCATCATGT AAAATATTAAATTACTTTAGGCCACTGCACATAGGTAGTCCTGTCATGAGTGATGGCTGGAGAAAAGTTCAGGATCA TAAATGTTA >gi|142356892|ref|NM_080817.3| Homo sapiens G protein-coupled receptor 82 (GPR82), mRNA (SEQ ID NO: 21) AGTTGGTGTCATGCAAGAATCTATTCACACTGACTAAAGATATTGGAAGAGTGAAGATCAGAGAATTTTAAGTCTGA AATTTGGCATCACTGCCCTGAACAATATAACCTTAGTTGGCATAAACTACTCATACAGACAAAGGCATTATCCATCA CAATAAGTAACTTTTTGTCTTTATTTCAACCGGACAATCGTGATTAGAAAAGCTCCTGTGACAAAATTCAAGAAAAC CTGACATAAATGAACAACAATACAACATGTATTCAACCATCTATGATCTCTTCCATGGCTTTACCAATCATTTACAT CCTCCTTTGTATTGTTGGTGTTTTTGGAAACACTCTCTCTCAATGGATATTTTTAACAAAAATAGGTAAAAAAACAT CAACGCACATCTACCTGTCACACCTTGTGACTGCAAACTTACTTGTGTGCAGTGCCATGCCTTTCATGAGTATCTAT TTCCTGAAAGGTTTCCAATGGGAATATCAATCTGCTCAATGCAGAGTGGTCAATTTTCTGGGAACTCTATCCATGCA TGCAAGTATGTTTGTCAGTCTCTTAATTTTAAGTTGGATTGCCATAAGCCGCTATGCTACCTTAATGCAAAAGGATT CCTCGCAAGAGACTACTTCATGCTATGAGAAAATATTTTATGGCCATTTACTGAAAAAATTTCGCCAGCCCAACTTT GCTAGAAAACTATGCATTTACATATGGGGAGTTGTACTGGGCATAATCATTCCAGTTACCGTATACTACTCAGTCAT AGAGGCTACAGAAGGAGAAGAGAGCCTATGCTACAATCGGCAGATGGAACTAGGAGCCATGATCTCTCAGATTGCAG GTCTCATTGGAACCACATTTATTGGATTTTCCTTTTTAGTAGTACTAACATCATACTACTCTTTTGTAAGCCATCTG AGAAAAATAAGAACCTGTACGTCCATTATGGAGAAAGATTTGACTTACAGTTCTGTGAAAAGACATCTTTTGGTCAT CCAGATTCTACTAATAGTTTGCTTCCTTCCTTATAGTATTTTTAAACCCATTTTTTATGTTCTACACCAAAGAGATA ACTGTCAGCAATTGAATTATTTAATAGAAACAAAAAACATTCTCACCTGTCTTGCTTCGGCCAGAAGTAGCACAGAC CCCATTATATTTCTTTTATTAGACAAAACATTCAAGAAGACACTATATAATCTCTTTACAAAGTCTAATTCAGCACA TATGCAATCATATGGTTGACTTTTGAATGGAAAACCCCACAATATTAAGAAAAGCATTCATGTGACTTTATTAGGGA CACTAAACTACATCATTAACATGTCACAGCTTGGTTGACAATAATCACCAAGAAAATCTCTTTGGTTTTTAAAAATA AATAAACATATATTCATAAAACTCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA >gi|153266935|ref|NM_018970.5| Homo sapiens G protein-coupled receptor 85 (GPR85), mRNA (SEQ ID NO: 22) AATCTCACCACCCAGCAATGAGGTATTTTACTGCTGTCTCAAGATCAGATTATTACTGTAGAGAAGATTTTTATTTT TTGTTTCATTAACAGATTATTATAAAGCAAAAAGCATGCAGAAAAAGAAGCAGACGTTTTACATTGGGAATTAATGA AAGCGTGTCTGCTAGTTTTGGGTAGGAGAACTGGGAAGTTGTTGCTTAAAATTTTATATCACCTCCACAAACAAAAC TCTTCGGAAATGGTAAAATAAGAAAATGCATGATTCTAGAGGCATTCCTAAGCACCCACGTGTCAGGCTTTGTGGTG TCTGTGGTATCATCCGACCGTTTGGACTGGTGGCTTACTGAGAGCTCCATTTCTGGAAAGCCTTACAAGACTGAGGA ATATCAGACTGCGAATCACCGGGAACGGTTCCTTTGCAGCACAGAAGCAATCTCTCTCCCCATCTTCGCATATTCTG ATGGCAAAACAAGTGGAAGAAAAGAGGAAGCATGACTGCAGATCAGATCAGTTCTCTTTGTGGATTATATTTTCAGT AAAATGTATGGATCTATCTTTTCCTTGTTCTTATATCTAGATCATGAGACTTGACTGAGGCTGTATCCTTATCCTCC ATCCATCTATGGCGAACTATAGCCATGCAGCTGACAACATTTTGCAAAATCTCTCGCCTCTAACAGCCTTTCTGAAA CTGACTTCCTTGGGTTTCATAATAGGAGTCAGCGTGGTGGGCAACCTCCTGATCTCCATTTTGCTAGTGAAAGATAA GACCTTGCATAGAGCACCTTACTACTTCCTGTTGGATCTTTGCTGTTCAGATATCCTCAGATCTGCAATTTGTTTCC CATTTGTGTTCAACTCTGTCAAAAATGGTTCTACCTGGACTTATGGGACTCTGACTTGCAAAGTGATTGCCTTTCTG GGGGTTTTGTCCTGTTTCCACACTGCTTTCATGCTCTTCTGCATCAGTGTCACCAGATACTTAGCTATCGCCCATCA CCGCTTCTATACAAAGAGGCTGACCTTTTGGACGTGTCTGGCTGTGATCTGTATGGTGTGGACTCTGTCTGTGGCCA TGGCATTTCCCCCGGTTTTAGACGTGGGCACTTACTCATTCATTAGGGAGGAAGATCAATGCACCTTCCAACACCGC TCCTTCAGGGCTAATGATTCCTTAGGATTTATGCTGCTTCTTGCTCTCATCCTCCTAGCCACACAGCTTGTCTACCT CAAGCTGATATTTTTCGTCCACGATCGAAGAAAAATGAAGCCAGTCCAGTTTGTAGCAGCAGTCAGCCAGAACTGGA CTTTTCATGGTCCTGGAGCCAGTGGCCAGGCAGCTGCCAATTGGCTAGCAGGATTTGGAAGGGGTCCCACACCACCC ACCTTGCTGGGCATCAGGCAAAATGCAAACACCACAGGCAGAAGAAGGCTATTGGTCTTAGACGAGTTCAAAATGGA GAAAAGAATCAGCAGAATGTTCTATATAATGACTTTTCTGTTTCTAACCTTGTGGGGCCCCTACCTGGTGGCCTGTT ATTGGAGAGTTTTTGCAAGAGGGCCTGTAGTACCAGGGGGATTTCTAACAGCTGCTGTCTGGATGAGTTTTGCCCAA GCAGGAATCAATCCTTTTGTCTGCATTTTCTCAAACAGGGAGCTGAGGCGCTGTTTCAGCACAACCCTTCTTTACTG CAGAAAATCCAGGTTACCAAGGGAACCTTACTGTGTTATATGAGGGAGCATCTGTAAATCTTTAGCCTTGTGAAAAC TAACCTTCTCTGCTGAGCAATTGTGGCCCATAGCCATATTTTGAGAAGAAATTCAAGAATGGAATCAGCAGTTTTAA GGATTTGGGCAACATTCTGCAGTCTTTGCAATAGTTCACCTATAATCCTATTTTAAATCTCAGAGTGATCCTGCTGA CTGCCAGCAAAGGTTTGTAATTAAGAAGGGACTGAACCACTGCCCTAAGTTTCTTTATGTGGTCAAAAACTAGATAA TGAAAGTAGCAGGTGCTAAGTATCAGTGCTAAATGCTCTGTATGTCACTACATATGAAAAAACATCAAAAAACAATT AGCATTGGACATCTTAATAAATTAAGTTGACATGAGGTAAATGTGTTGATAAAAACTAATTTTAGAAGTTTGAAGAC TTTAAAACATTTCATACTACTATTGTTTTGCAAAGACTAAAATATTTGGGGACTTAAAGTACTGTAATCCACTAAAG ACGTGCCAATGAATTATTGGAATATCACACTTTAAAAACCGCCTTGTAAGTTCTGGGGAGCATTCCAAAGCAGTATA TTGGTTCCAATTAGAGTTTACTTTTTTTGTATTAATACATTGCTATTTCTAAATACCACTTTCCTCATCTACTAGTA AGATTGCTAGCATTGAACTGTATTATGTGGTTTTTGTTGATTTGGTATAAAGTTTTTCCAATTCATTTATATTTTAC AAATGCTAGATATTGGTCTGGGAGGCAACATTAATGGTACCAGCCTGTCACAACTGAGCAGTTCTAATAATGCAGAA TAAATACATGTTGCCTTAAAGGGTTATCTAGTATCCTTCATCTTATTTAGCACTGGAGCAAATAGCCAAGGGAAATC AAATCAGTAACTGGTCATGGTCATGCATCTAAAAGTGCATGGAAGATCATTTATTACTTTTTCCTTTTTTCTCACAT GGTTTGAAACTTAAAGTGCACATCACTGAAATAATGAGATTTTCTTCTACGGTGTGCTACCCTTTCTAAACTGTTCT AAGAAGCAGGCAGTTGATGTATGTTTATATTTTAAGTCAGCTGTCAAGGGGAGACCACAGCCTTAGTATGACATCCT GCACAATTTGTGAAGCATTTATTCTACTGAAGGCACAGTCTTGTTTATACTTTCTGCACATTCAGTGTATTGGTAAT TTAAATTATTTCAGTTTTAACTTGTGAAAGCTTATATTATGATTTCTGGTATTTTAGAAATACATTAGAGTCTGTGA GTCTCATTCTTTAAGATACAGATGTGTGAACTTCAATATAAAGTTGCATTTGCCAAAATTTACCCGTGTAGCCTGTT AATTTTCTTGAAATAAGTTTTACATTTTTGGCACATAACAACTTTTTTTTTAATTTGGGAGGCAAGCACAAACTAGG AAGACTAGCTTTATTATGGTTTTGCTTTTTGATTCTTGTAGCTACTACATTCCAGACTGGAAATGTATGAATGATAA TCAACATAATGCTGATAAACTGACATAATATTATCTGTAAAAGCATTATTTGGTAGTTTATTATAATCATCCCTCTA TTATTCTTAAATGCCAGTAGTATTTAGAGATGTGTACCTGCTTAGTTAATTGGCTCAGAATTTTAATATAAACATCA CACTTTAATTTGGAGCATAGTACCATAGAAATTTGGGGTTCTAAATATACAACTTGTAAGAAGAATGGTTTACACTA ACATTATGACAAAACTAGAAAAAGTTATTATTTTTGTTTGCTTTCTGTTGTTTTGTTTATTGGTTGGTTTTTGTGAA GTTTATTTTTTTTTGGTATTTGATAATTAAGATTAGGAATCTAATAACACAGAATTCCATATTGCTATAGTACTTCT GTAAAGAGAATATCAATATAAATAAGGAAAATAAATCAATGAAATGTTTCAATGATATATGCAACTATTCAGTTTTG CTCTTATAAGGACAGCTCAAGCCATGAATTAGTGAGCATTCTGACCTCATTTTTACTTTACACCAAAGTTGATTAGA TCTGAGACAAAATTTAATGCACAACAGTGAGTTGGATCTAGCAATAAAGTCTCCTTGGTACTGAAATCATTATCTAA AATAAAGGAAATGTTATCAAAAGATGTTCTGATAACATTGTGATTGTAACTCAAAAAAATTTATAGTAGAAACGTAA TTGCAATGATGATAATAACTAACTCTGCTTAGAGGTTCAAATATCACCAGCAATCAGTAAAAAATTCAGCAATAATC TTAAGGCCAGAGAGAACAGGTTCACCATTGCATAGACAAGAAAACAGATATGGGTTAAGAGTTGGGGACTGAGGAGT CAAGAGCAACGGCCACGTGAAGCTGCCTGACTCCACCTAGCTATTTGGAATAACCGATTCCCACAGTTTTGGTAAGA AACCAGCCCCAGTAATCAGTAAGTCAGGCTGAACTGCAGTGACTTTTATTTAAGCCTACTCCTGACTAACTTGGCAT TTGCAGGTCAAGCAGGAAGCAGTTGACAAGACACATCCTCAGTGAATCAATGCCATTTGTAACTCAACTGGTAACAG TAGTAATCATACAAAATAAAAACCTGCTTCAGTGTCTTAATGACCAAATCACATTATCTATTTTAGCACTCATTCCA AAATTCAGTATTTAATGTAATTAATCTTTAATCCATAAAAATACATCCCCACTGTAGCGGGGCAGGGGGTGTCCAAC TTCCCTGTGAGACTGATTATCAATAATAATGTGTCTCCCTCTTGGACTGAGCACACATCTGAGCTGAACGGCCTTTA AATTGTTTTTCATAATAGTGGTGATATGTTTGCGTGGATACGTCTGTACTATTTCATCTGGTTCATTTTGCATGTAA TAGATTTATCTGTGAGATGCCTGGCTGAAGCTAGGCATTCAGTCTGTGACTGTGGAATCCTATGCAGGTATTAACCA AGGCAGAAAGAGGTGAGTAACTTGCCCATTTCTCCACAGAGACCCCATTTAAATAACACAAAATTGACCACAGTGAT TAGATGAAAAAATTATTTGTAGATAGGATAATCTATTGACTGAATTATCTTTTGCAGATATCAGCTGGTTGGATTTC TCACCAGGATTGTCTATAGAAGTTAACTGATTTATGATTGTTAACACATAAATATGGCCACTTATCCATTTGCCTCA ACTTCAAAAAAAAAAAAAAAGAAAAAAAAAAAAAAAA >gi|32479526|ref|NM_000218.2| Homo sapiens potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1), transcript variant 1, mRNA (SEQ ID NO: 23) GCGGCGGGGCTGGCAGCAGTGGCTGCCCGCACTGCGCCCGGGCGCTCGCCTTCGCTGCAGCTCCCGGTGCCGCCGCT CGGGCCGGCCCCCCGGCAGGCCCTCCTCGTTATGGCCGCGGCCTCCTCCCCGCCCAGGGCCGAGAGGAAGCGCTGGG GTTGGGGCCGCCTGCCAGGCGCCCGGCGGGGCAGCGCGGGCCTGGCCAAGAAGTGCCCCTTCTCGCTGGAGCTGGCG GAGGGCGGCCCGGCGGGCGGCGCGCTCTACGCGCCCATCGCGCCCGGCGCCCCAGGTCCCGCGCCCCCTGCGTCCCC GGCCGCGCCCGCCGCGCCCCCAGTTGCCTCCGACCTTGGCCCGCGGCCGCCGGTGAGCCTAGACCCGCGCGTCTCCA TCTACAGCACGCGCCGCCCGGTGTTGGCGCGCACCCACGTCCAGGGCCGCGTCTACAACTTCCTCGAGCGTCCCACC GGCTGGAAATGCTTCGTTTACCACTTCGCCGTCTTCCTCATCGTCCTGGTCTGCCTCATCTTCAGCGTGCTGTCCAC CATCGAGCAGTATGCCGCCCTGGCCACGGGGACTCTCTTCTGGATGGAGATCGTGCTGGTGGTGTTCTTCGGGACGG AGTACGTGGTCCGCCTCTGGTCCGCCGGCTGCCGCAGCAAGTACGTGGGCCTCTGGGGGCGGCTGCGCTTTGCCCGG AAGCCCATTTCCATCATCGACCTCATCGTGGTCGTGGCCTCCATGGTGGTCCTCTGCGTGGGCTCCAAGGGGCAGGT GTTTGCCACGTCGGCCATCAGGGGCATCCGCTTCCTGCAGATCCTGAGGATGCTACACGTCGACCGCCAGGGAGGCA CCTGGAGGCTCCTGGGCTCCGTGGTCTTCATCCACCGCCAGGAGCTGATAACCACCCTGTACATCGGCTTCCTGGGC CTCATCTTCTCCTCGTACTTTGTGTACCTGGCTGAGAAGGACGCGGTGAACGAGTCAGGCCGCGTGGAGTTCGGCAG CTACGCAGATGCGCTGTGGTGGGGGGTGGTCACAGTCACCACCATCGGCTATGGGGACAAGGTGCCCCAGACGTGGG TCGGGAAGACCATCGCCTCCTGCTTCTCTGTCTTTGCCATCTCCTTCTTTGCGCTCCCAGCGGGGATTCTTGGCTCG GGGTTTGCCCTGAAGGTGCAGCAGAAGCAGAGGCAGAAGCACTTCAACCGGCAGATCCCGGCGGCAGCCTCACTCAT TCAGACCGCATGGAGGTGCTATGCTGCCGAGAACCCCGACTCCTCCACCTGGAAGATCTACATCCGGAAGGCCCCCC GGAGCCACACTCTGCTGTCACCCAGCCCCAAACCCAAGAAGTCTGTGGTGGTAAAGAAAAAAAAGTTCAAGCTGGAC AAAGACAATGGGGTGACTCCTGGAGAGAAGATGCTCACAGTCCCCCATATCACGTGCGACCCCCCAGAAGAGCGGCG GCTGGACCACTTCTCTGTCGACGGCTATGACAGTTCTGTAAGGAAGAGCCCAACACTGCTGGAAGTGAGCATGCCCC ATTTCATGAGAACCAACAGCTTCGCCGAGGACCTGGACCTGGAAGGGGAGACTCTGCTGACACCCATCACCCACATC TCACAGCTGCGGGAACACCATCGGGCCACCATTAAGGTCATTCGACGCATGCAGTACTTTGTGGCCAAGAAGAAATT CCAGCAAGCGCGGAAGCCTTACGATGTGCGGGACGTCATTGAGCAGTACTCGCAGGGCCACCTCAACCTCATGGTGC GCATCAAGGAGCTGCAGAGGAGGCTGGACCAGTCCATTGGGAAGCCCTCACTGTTCATCTCCGTCTCAGAAAAGAGC AAGGATCGCGGCAGCAACACGATCGGCGCCCGCCTGAACCGAGTAGAAGACAAGGTGACGCAGCTGGACCAGAGGCT GGCACTCATCACCGACATGCTTCACCAGCTGCTCTCCTTGCACGGTGGCAGCACCCCCGGCAGCGGCGGCCCCCCCA GAGAGGGCGGGGCCCACATCACCCAGCCCTGCGGCAGTGGCGGCTCCGTCGACCCTGAGCTCTTCCTGCCCAGCAAC ACCCTGCCCACCTACGAGCAGCTGACCGTGCCCAGGAGGGGCCCCGATGAGGGGTCCTGAGGAGGGGATGGGGCTGG GGGATGGGCCTGAGTGAGAGGGGAGGCCAAGAGTGGCCCCACCTGGCCCTCTCTGAAGGAGGCCACCTCCTAAAAGG CCCAGAGAGAAGAGCCCCACTCTCAGAGGCCCCAATACCCCATGGACCATGCTGTCTGGCACAGCCTGCACTTGGGG GCTCAGCAAGGCCACCTCTTCCTGGCCGGTGTGGGGGCCCCGTCTCAGGTCTGAGTTGTTACCCCAAGCGCCCTGGC CCCCACATGGTGATGTTGACATCACTGGCATGGTGGTTGGGACCCAGTGGCAGGGCACAGGGCCTGGCCCATGTATG GCCAGGAAGTAGCACAGGCTGAGTGCAGGCCCACCCTGCTTGGCCCAGGGGGCTTCCTGAGGGGAGACAGAGCAACC CCTGGACCCCAGCCTCAAATCCAGGACCCTGCCAGGCACAGGCAGGGCAGGACCAGCCCACGCTGACTACAGGGCCG CCGGCAATAAAAGCCCAGGAGCCCATTTGGAGGGCCTGGGCCTGGCTCCCTCACTCTCAGGAAATGCTGACCCATGG GCAGGAGACTGTGGAGACTGCTCCTGAGCCCCCAGCTTCCAGCAGGAGGGACAGTCTCACCATTTCCCCAGGGCACG TGGTTGAGTGGGGGGAACGCCCACTTCCCTGGGTTAGACTGCCAGCTCTTCCTAGCTGGAGAGGAGCCCTGCCTCTC CGCCCCTGAGCCCACTGTGCGTGGGGCTCCCGCCTCCAACCCCTCGCCCAGTCCCAGCAGCCAGCCAAACACACAGA AGGGGACTGCCACCTCCCCTTGCCAGCTGCTGAGCCGCAGAGAAGTGACGGTTCCTACACAGGACAGGGGTTCCTTC TGGGCATTACATCGCATAGAAATCAATAATTTGTGGTGATTTGGATCTGTGTTTTAATGAGTTTCACAGTGTGATTT TGATTATTAATTGTGCAAGCTTTTCCTAATAAACGTGGAGAATCACAGGCTGGGCTGGGCACTGCTCTCACCTTGGT TCCTGGGGCATCCATGGGGTCTCTCACAGACAGGACCCCTGCAGTTCCCCTGGAAGCAGTGCCCAGGTGGCTGTGGA ATAGGAACGCTAAAAAAAAAAAAAAAAA >gi|41349442|ref|NM_198503.2| Homo sapiens potassium channel, subfamily T, member 2 (KCNT2), mRNA (SEQ ID NO: 24) CTTTCTTTCTCCCTCCTCTCCTCCATTTGTTGTTTGATGTTTCCCACTCTTTGAGGAAGGATGGTTGATTTGGAGAG CGAAGTGCCCCCTCTGCCTCCCAGGTACAGGTTTCGAGATTTGCTGCTAGGGGACCAAGGATGGCAAAACGACGACA GGGTACAAGTTGAATTCTATATGAATGAAAATACATTTAAAGAAAGACTAAAATTATTTTTCATAAAAAACCAGAGA TCAAGTCTAAGGATACGCCTGTTCAATTTTTCTCTCAAATTACTAAGCTGCTTATTATACATAATCCGAGTACTACT AGAAAACCCTTCACAAGGAAATGAATGGTCTCATATCTTTTGGGTGAACAGAAGTCTACCTTTGTGGGGCTTACAGG TTTCAGTGGCATTGATAAGTCTGTTTGAAACAATATTACTTGGTTATCTTAGTTATAAGGGAAACATCTGGGAACAG ATTTTACGAATACCCTTCATCTTGGAAATAATTAATGCAGTTCCCTTCATTATCTCAATATTCTGGCCTTCCTTAAG GAATCTATTTGTCCCAGTCTTTCTGAACTGTTGGCTTGCCAAACATGCCTTGGAAAATATGATTAATGATCTACACA GAGCCATTCAGCGTACACAGTCTGCAATGTTTAATCAAGTTTTGATTTTAATATCTACATTACTATGCCTTATCTTC ACCTGCATTTGTGGGATCCAACATCTGGAACGAATAGGAAAGAAGCTGAATCTCTTTGACTCCCTTTATTTCTGCAT TGTGACGTTTTCTACTGTGGGCTTCGGGGATGTCACTCCTGAAACATGGTCCTCCAAGCTTTTTGTAGTTGCTATGA TTTGTGTTGCTCTTGTGGTTCTACCCATACAGTTTGAACAGCTGGCTTATTTGTGGATGGAGAGACAAAAGTCAGGA GGAAACTATAGTCGACATAGAGCTCAAACTGAAAAGCATGTCGTCCTGTGTGTCAGCTCACTGAAGATTGATTTACT TATGGATTTTTTAAATGAATTCTATGCTCATCCTAGGCTCCAGGATTATTATGTGGTGATTTTGTGTCCTACTGAAA TGGATGTACAGGTTCGAAGGGTACTGCAGATTCCAATGTGGTCCCAACGAGTTATCTACCTTCAAGGTTCAGCCCTT AAAGATCAAGACCTATTGAGAGCAAAGATGGATGACGCTGAGGCCTGTTTTATTCTCAGTAGCCGTTGTGAAGTGGA TAGGACATCATCTGATCACCAAACAATTTTGAGAGCATGGGCTGTGAAAGATTTTGCTCCAAATTGTCCTTTGTATG TCCAGATATTAAAGCCTGAAAATAAATTTCACATCAAATTTGCTGATCATGTTGTTTGTGAAGAAGAGTTTAAATAC GCCATGTTAGCTTTAAACTGTATATGCCCAGCAACATCTACACTTATTACACTACTGGTTCATACCTCTAGAGGGCA AGAAGGCCAGCAATCGCCAGAACAATGGCAGAAGATGTACGGTAGATGCTCCGGGAATGAAGTCTACCACATTGTTT TGGAAGAAAGTACATTTTTTGCTGAATATGAAGGAAAGAGTTTTACATATGCCTCTTTCCATGCACACAAAAAGTTT GGCGTCTGCTTGATTGGTGTTAGGAGGGAGGATAATAAAAACATTTTGCTGAATCCAGGTCCTCGATACATTATGAA TTCTACAGACATATGCTTTTATATTAATATTACCAAAGAAGAGAATTCAGCATTTAAAAACCAAGACCAGCAGAGAA AAAGCAATGTGTCCAGGTCGTTTTATCATGGACCTTCCAGATTACCTGTACATAGCATAATTGCCAGCATGGGTACT GTGGCTATAGACTTGCAAGATACAAGCTGTAGATCAGCAAGTGGCCCTACCCTGTCTCTTCCTACAGAGGGAAGCAA AGAAATAAGAAGACCTAGCATTGCTCCTGTTTTAGAGGTTGCAGATACATCATCGATTCAAACATGTGATCTTCTAA GTGACCAATCAGAAGATGAAACTACACCAGATGAAGAAATGTCTTCAAACTTAGAGTATGCTAAAGGTTACCCACCT TATTCTCCATATATAGGAAGTTCACCCACTTTTTGTCATCTCCTTCATGAAAAAGTACCATTTTGCTGCTTAAGATT AGACAAGAGTTGCCAACATAACTACTATGAGGATGCAAAAGCCTATGGATTCAAAAATAAACTAATTATAGTTGCAG CTGAAACAGCTGGAAATGGATTATATAACTTTATTGTTCCTCTCAGGGCATATTATAGACCAAAGAAAGAACTTAAT CCCATAGTACTGCTATTGGATAACCCGCCAGATATGCATTTTCTGGATGCAATCTGTTGGTTTCCAATGGTTTACTA CATGGTGGGCTCTATTGACAACCTAGATGACTTACTCAGGTGTGGAGTGACTTTTGCTGCTAATATGGTGGTTGTGG ATAAAGAGAGCACCATGAGTGCCGAGGAAGACTACATGGCAGATGCCAAAACCATTGTGAACGTGCAGACACTCTTC AGGTTGTTTTCCAGTCTCAGTATTATCACAGAGCTAACTCACCCCGCCAACATGAGATTCATGCAATTCAGAGCCAA AGACTGTTACTCTCTTGCTCTTTCAAAACTGGAAAAGAAAGAACGGGAGAGAGGCTCTAACTTGGCCTTTATGTTTC GACTGCCTTTTGCTGCTGGGAGGGTGTTTAGCATCAGTATGTTGGACACTCTGCTGTATCAGTCATTTGTGAAGGAT TATATGATTTCTATCACGAGACTTCTGTTGGGACTGGACACTACACCAGGATCTGGGTTTCTTTGTTCTATGAAAAT CACTGCAGATGACTTATGGATCAGAACTTATGCCAGACTTTATCAGAAGTTGTGTTCTTCTACTGGAGATGTTCCCA TTGGAATCTACAGGACTGAGTCTCAGAAACTTACTACATCTGAGTCTCAAATATCTATCAGTGTAGAAGAGTGGGAA GACACCAAAGACTCCAAAGAACAAGGGCACCACCGCAGCAACCACCGCAACTCAACATCCAGTGACCAGTCGGACCA TCCCTTGCTGCGGAGAAAAAGCATGCAGTGGGCCCGAAGACTGAGCAGAAAAGGCCCAAAACACTCTGGTAAAACAG CTGAAAAAATAACCCAGCAGCGACTGAACCTCTACAGGAGGTCAGAAAGACAAGAGCTTGCTGAACTTGTGAAAAAT AGAATGAAACACTTGGGTCTTTCTACAGTGGGATATGATGAAATGAATGATCATCAAAGTACCCTCTCCTACATCCT GATTAACCCATCTCCAGATACCAGAATAGAGCTGAATGATGTTGTATACTTAATTCGACCAGATCCACTGGCCTACC TTCCAAACAGTGAGCCCAGTCGAAGAAACAGCATCTGCAATGTCACTGGTCAAGATTCTCGGGAGGAAACTCAACTT TGATAAAAATAAAATGAGAAACTTTTTTCCTACAAAGACCTTGCTTGAAACCACAAAAGTTTTGCTGGCACGAAAGA AACTAGATGGAAATATATGTAATTCTCTCATATTTAAAAACGTAATCTCTTCTCTTAGAAGTATAGATCATTTTGAA ACTTAATGTACTACTTACTGGTACTCTCCCTATTAATATTTGAAGGACCTCAATGGAATAAATTTGAAAAGCTAAAT TAAAATACAAAAATTTAAATCTGACATTTAATTGTTTTATAATAATCCAAACTCTATGAAAGCAATTTTAAAAATTA TTAAGGTTTTATGAAGTTGACAAAATCTAACTATATTTGGTGCATCACAATGGACACAGAATGCTGCTGCTCCTCTT AAAAATTAAATGTGTCATATTATATTCTTTAAACTTACTGTTTTACAAAATTGAGCTCATCGTAAATGTCTAGTCTT CTCACATAGAGATTAACCAACAAACTTGTGTGGCTGACTTTTGTGTAAGAATCATAGTTTGCTTTAGAATACAAATC TTTAAGTCATTTTAACTTTTTTTTCTGCCTTACGATATAAAAATATTTATCTTAGAATTTGAGATGTTCATAGCATG TTTTATTACATTGAAGAAACTAAAACATAAATGAAAAGAAACACTAGGTTCCTGCACTTTTTGGTAACTTTATGTCT AGCAAATATTTTATGCCAAGAAAAGCATACTATAAAGCAAATATCTATTATTCTCCTAAACGAATGCCTAGCATAGA GAAAATACTTAATACACATTTGTTGACTTAAATTTAATTCAAGGATTGAAAAATTAACTGGATATCTTGAAATATAC AGTAATGATTGTCCTTAGACTCTTGAACTTTACCATCTTTCCTATTCATATATCTATATAGTAAATTTCACTAGAAA AATTCTTTTAAAATTGACAGAAGATAATTTATACCTTTTATGGACTCTGAAGACACTTCAAAACATTAAAAGTCCTT ATGTCTTTGGTAATGAAACAATAACACTCAATGAAGGATGTATTAAAATTTTTGACTTAATTTTGAAATCGTATATA TGAGCTATACTTTAACATTATGAGAGAAAAGCATAAAACAAAAATAGGTAGTTCTTGGCTTTTAACATTAATGCAAA TCATGCAGAATTTGAGTTATAAATTTAAATATAAATTGACCATTGATGATATCCAGTTTTTCATTTTTTACCTGTAT TGCATTTTCCCCCTAGAGAAATAGATCAAAAGAGCACAAGAGTATGCGTACATAGTTTACCAGGTAGTAGAAGTGTG TTAAAATGTTCCTGTAAAAGAAACATTGGTAAATTTAAATACATACTGTTCTAATTTTGTATTTTTTAATTTTTGAA TTTGACATTGAGTTTAATTCAGCAACAACAAAAAATACATATAAAACTAGAAAGGGACTTTTTTTCCTTTCTTTTCA TAATGAAGCAGATCAACTTAAAGGATAATAAAATTTTTAAAGAAAAGATATTCTAATGTACTCTCAATAATTCTACA GAAATAAAACTGTAAAGTGCAATGTGAAATCAAAGATTATAGTCATTGTATAATTTGGCTTGGAGGCTATGAAATGT CTTTTTTTCTTTTTGGTATTTTACATTATTCACATTTTAGAATAACAAGAACACCAAGAATTACCCCTAAAACAGAG ACCCTGTATTTAATCTACTTTGATCAGAGAAGTAGAATTTATAACAGGTTAGCTAAAATTGGGAGCATGCCTTAAAA CTTAAAGATTGTATGCATATATGTGTATATGTTATAAACGTGAAATATATTTGACACACACATTCACATATAAATTG TTAAAAACTGAAGGCAGAATGGAACTAATATATGTAACAGAGAAAAACAATAAATTTTATGAACTTGTTTTATATTT GCATATCAAGAGTCAAGTATGATGTTTCTTTAAGTTGACTTTTTTTACTTCATTATTTTTAGGAATAAATGTAAGAT TTTACAAATCTTTTATTTCCCCACAAGATCTGAAGTTTGGTATTTTTGCATTATGACAGTTGTTGAGACTAGGATTT TAAGCTAGGATATGATTATATTTCCTATATAACTAAAAATTTTGTTTCATAAATTTTAAAATAATTATTTTTGACTA TGAACATTAGTCCAAATTTAATATTTGACACAGTTCATACCAGCTTGCTACAATAATGATAATTTATTAGTCTTTCT GTTATTTAAAGAATAAAAACATGCTTATAAAAGACTTTTAATGAAATGTTGCCTTTTTAAAATAATTATACTTGCAC ATGAAAATAAAATATAAAGTCAATAATAGTCCTTGTAGCCCAATGGGAATTGATTCTGTTTATTGTCTGTACCATTT TGCTACCAGTTACATTGAACTGCTTTAAAATAAATAATAAAATTATTTCTAATGATG >gi|157502196|ref|NM_014738.4| Homo sapiens KIAA0195 (KIAA0195), mRNA (SEQ ID NO: 25) CTGAACTTTAGCTCTCTGGCCGGCGCCTCTGTTGCCCGGAAGGGAGGCAAGCCCCCTTAGAGTTGCCAGTAACGGAC ATGGCTGCGGCCCCCGGAGGAGGGGACGTGAAGTGAGGAGGGGGTTGGGAGGGGAGAGGACGCGGGCGAGGAAGACC AGCCCCGGGGCCCCGATGTTGTGACTGTGACAGACTCACTGGGGTTTGTACATGCTGGGGAGGAGCCTTCCTTTCAG GGGTGACCACATTCATCTGGGCATGCCTGCAGTACTCTTGGCCCATGGACCTGAAGGAGAAGCACCTGGGCGAGCCT CCCTCAGCCCTGGGCCTGTCCACGCGGAAGGCCCTCAGCGTCCTGAAGGAGCAGCTGGAGGCAGTGCTGGAAGGACA TCTCAGGGAGCGGAAGAAGTGTCTGACGTGGAAGGAGGTGTGGAGAAGCAGCTTCCTCCACCACAGTAACCGCTGCT CCTGCTTCCACTGGCCGGGGGCCTCACTCATGCTACTGGCCGTGCTGCTGCTGCTGGGCTGCTGCGGGGGACAGCCA GCCGGGAGCCGTGGGGTGGGGCTGGTGAATGCCTCGGCCTTGTTCCTGTTACTGCTTCTCAACCTTGTGCTCATCGG GCGGCAAGACCGGCTGAAGCGTCGGGAGGTAGAGCGGAGGCTGCGAGGGATCATTGACCAAATCCAAGATGCCCTCA GGGATGGCAGGGAGATCCAGTGGCCCAGTGCCATGTATCCAGACCTCCACATGCCTTTTGCGCCATCCTGGTCCTTG CACTGGGCCTACAGAGACGGACACCTGGTCAACCTGCCAGTCAGCCTGCTGGTTGAAGGAGACATCATAGCTTTGAG GCCTGGCCAGGAATCGTTTGCTTCTCTGAGGGGGATCAAGGATGACGAGCACATCGTCCTGGAGCCGGGAGACCTCT TCCCCCCCTTCTCCCCTCCACCCTCACCCCGGGGAGAAGTGGAGAGAGGGCCACAGAGCCCCCAGCAGCACCGGCTT TTCCGTGTCCTTGAGACCCCTGTGATTGACAACATCAGATGGTGCCTGGACATGGCCCTGTCCCGACCAGTCACTGC CCTGGACAATGAGCGGTTCACAGTGCAGTCGGTGATGCTACACTATGCTGTGCCCGTGGTCCTGGCCGGCTTCCTCA TCACCAATGCCCTGCGCTTCATCTTCAGTGCCCCGGGGGTCACTTCCTGGCAGTACACCCTCCTCCAGCTCCAGGTG AATGGCGTCCTGCCCATCCTCCCCCTGCTCTTTCCAGTCCTCTGGGTTCTGGCAACTGCCTGTGGAGAGGCCCGTGT CCTGGCCCAGATGAGCAAGGCCTCACCCAGCTCCCTGCTGGCTAAGTTCTCAGAGGATACTCTCAGCAGCTATACGG AGGCTGTCTCCTCTCAGGAAATGCTGCGCTGCATTTGGGGCCACTTCCTGAGGGTGCTCGGGGGGACATCGCCAACG CTGAGCCACAGTTCCAGCCTGCTGCACAGCCTGGGCTCTGTCACGGTCCTGTGCTGTGTGGACAAACAGGGGATCCT GTCATGGCCAAATCCCAGCCCAGAGACTGTACTGTTCTTCAGCGGGAAGGTGGAGCCCCCTCACAGCAGCCATGAGG ACCTCACCGATGGCCTATCCACCCGCTCCTTCTGCCATCCCGAGCCCCATGAACGAGACGCCCTCCTGGCTGGCTCC CTGAACAACACCCTGCACCTTTCCAATGAGCAGGAGCGTGGCGACTGGCCTGGCGAGGCTCCCAAGCCCCCCGAGCC CTATTCACACCACAAAGCGCATGGCCGCAGCAAACACCCATCTGGCTCCAACGTGAGCTTCAGCAGGGACACCGAGG GTGGTGAAGAAGAGCCCAGCAAGACCCAGCCTGGGATGGAGAGCGACCCCTACGAAGCAGAGGACTTTGTGTGTGAC TACCACCTGGAGATGCTGAGCCTGTCCCAGGACCAGCAGAACCCCTCCTGCATCCAGTTTGATGACTCCAACTGGCA GCTGCACCTCACCTCCCTCAAACCCCTGGGCCTCAATGTGCTGCTGAACCTGTGTGATGCCAGCGTCACCGAGCGCC TGTGCCGATTCTCCGACCACCTGTGCAACATCGCCCTGCAAGAGAGCCACAGCGCCGTGCTGCCCGTCCATGTGCCC TGGGGCCTCTGCGAGCTTGCCCGCCTCATTGGCTTCACTCCTGGGGCCAAGGAGCTTTTCAAGCAGGAGAACCATCT GGCGCTGTACCGCCTCCCCAGTGCCGAGACAATGAAGGAGACATCGCTGGGGCGGCTCTCCTGTGTCACCAAGCGGC GGCCTCCCCTCAGCCACATGATCAGCCTCTTCATTAAAGACACCACCACCAGCACAGAGCAGATGCTGTCCCATGGC ACCGCTGATGTGGTCTTAGAGGCCTGCACAGACTTCTGGGACGGAGCTGACATCTACCCTCTCTCGGGATCTGACAG AAAGAAAGTGCTGGACTTCTACCAGCGAGCCTGCCTGTCTGGGTATTGCTCTGCCTTCGCCTACAAGCCCATGAACT GCGCCCTGTCCTCTCAGCTCAATGGCAAGTGCATCGAGCTGGTACAGGTGCCCGGCCAAAGCAGCATCTTCACCATG TGCGAGCTGCCCAGCACCATCCCCATCAAGCAGAACGCCCGCCGCAGCAGCTGGAGCTCTGACGAAGGGATCGGGGA GGTGCTGGAGAAGGAAGACTGCATGCAGGCCCTGAGCGGCCAGATCTTCATGGGCATGGTGTCCTCCCAGTACCAGG CCCGGCTGGACATCGTGCGCCTCATTGATGGGCTTGTCAACGCCTGCATCCGCTTTGTCTACTTCTCTTTGGAGGAT GAGCTCAAAAGCAAGGTGTTTGCAGAAAAAATGGGCCTGGAGACAGGCTGGAACTGCCACATCTCCCTCACACCCAA TGGTGACATGCCTGGCTCCGAGATCCCCCCCTCCAGCCCCAGCCACGCAGGCTCCCTGCATGATGACCTGAATCAGG TGTCCCGAGATGATGCAGAAGGGCTCCTCCTCATGGAGGAGGAGGGCCACTCGGACCTCATCAGCTTCCAGCCTACG GACAGCGACATCCCCAGCTTCCTGGAGGACTCCAACCGGGCCAAGCTGCCCCGGGGTATCCACCAAGTGCGGCCCCA CCTGCAGAACATTGACAACGTGCCCCTGCTAGTGCCCCTTTTCACCGACTGCACCCCAGAGACCATGTGTGAGATGA TAAAGATCATGCAAGAGTACGGGGAGGTGACCTGCTGCCTGGGCAGCTCTGCCAACCTGCGGAACAGCTGCCTCTTC CTCCAGAGCGACATCAGCATTGCCCTGGATCCCCTGTACCCATCCCGTTGCTCCTGGGAGACCTTTGGCTACGCCAC CAGCATCAGCATGGCCCAGGCCTCGGATGGCCTTTCTCCCCTGCAGCTGTCAGGGCAGCTCAACAGCCTGCCCTGTT CCCTGACCTTTCGCCAGGAGGAGACCATCAGCATCATCCGGCTTATCGAACAGGCTCGGCATGCCACCTATGGCATC CGTAAGTGCTTCCTCTTCCTGCTGCAGTGCCAGCTGACTCTTGTGGTCATCCAGTTCCTTTCTTGCCTGGTCCAGCT GCCGCCACTCCTGAGTACCACCGACATCCTGTGGCTGTCCTGCTTTTGCTACCCTCTGCTCAGCATCTCTCTGCTGG GGAAGCCCCCCCATAGCTCCATCATGTCTATGGCAACGGGGAAAAACCTCCAGTCCATTCCCAAGAAGACCCAGCAC TACTTCCTGCTCTGCTTCCTGCTCAAGTTCAGCCTCACCATCAGCTCCTGCCTCATCTGCTTTGGCTTCACACTGCA GAGCTTCTGTGACAGCTCCCGGGACCGCAACCTCACCAACTGCTCCTCCGTCATGCTGCCCAGCAACGACGACAGGG CTCCAGCCTGGTTTGAGGACTTTGCCAATGGACTGCTGTCGGCTCAGAAGCTCACGGCCGCCCTGATTGTCCTGCAC ACTGTCTTCATTTCCATCACCCATGTGCATCGCACCAAGCCCCTGTGGAGAAAGAGCCCCTTGACCAACCTCTGGTG GGCCGTGACAGTGCCTGTGGTGCTGCTGGGTCAGGTGGTCCAGACGGCTGTGGACCTGCAGCTGTGGACACACAGGG ACAGCCACGTCCACTTTGGCCTGGAGGACGTGCCCCTGCTGACATGGCTCCTGGGCTGCCTGTCCCTGGTCCTTGTG GTGGTGACCAATGAGATCGTGAAGCTACATGAGATTCGGGTCCGAGTCCGCTACCAGAAGCGACAGAAGCTGCAGTT TGAAACTAAGCTGGGCATGAACTCTCCCTTCTGAGCCACTGGCTGTGGTGGCTGTAGTTGCCCCCGTCCCTGGGGCT AAAGCCAGACCCATTTCTGAACAGGGGAGTTTGTATCATGAATGTTTCCAGGTTTGCTCCTGCACCCGTGGCACTGG AAACCCAGCTCCCCGTGTCAGACCCCGCTGTCTTCCTGAGCCCTGGGGCTCACTGTGGAGGAGCTGACGGCCTGGGC CCTTGGCCAGTCCTGGCTCTTCCCTGGGCCTCACCAGGGACACTCTTGAATGTATGGCCTCAGGCGCTCCCTAGAGG GGCCCTAAACCCCCTCACCTGTGAGCTACCCCCTTTAGGGATCCCTTGCCCCCTTGGAGATCCCTTGCCCCCCAGTG CCTCTGCTCGTGGGTCCCTGGACACGGCCTTGAAGCCAACCTTCTTTGGAGGAGCAACAGCAGCAGCCTTGGCCGAC GCGTCCAACTCCCAAGGCTGCCGTGGAGGGCAGGGGGGTGGTGCTTGCCTGGATGTGGCCCCGAGTGCCTCCCCTCC CTCCCTCTGTGGGGGAGTCTCCCGCCTGAACCTGAAGATGGAGCAGGGCCCCCGCTTCGCCCTGGAGCCTCTTCCTG TGCCTGGCTCAAGCTGGCTGCCTGTCAGTCTTGGGGAATCTGGCCCAGGTCTCCTCAGCCTCTGCCCCAGTTCTGGG AGAAGTTTCTACTGGTGTATATTTTTTACTGGAAATGAGCCTTTTAGGAATGAATGTAGACTGGTTTGTATTAAAAT GTGTCAATTGCTAAGAAATACCTGTGGCTGGTCTGTAAGGCCACTCCAGGGTCTGCCCACCCCCGGCGGTGGCTGGC AAAGGGAGGCCTAAACCTTCCTCCATCTACGCGGGTGGGTCCCTCAGGTCTGGCTCAGGCGAGACCCCTAGGGTCAG GGGTCCCCATGTCACAGAGGCAAACACACAGCCCAGTCACGTGGAATGGTGTTTTCATTGGTGTTAGTTGGGGGAAG AGGTTAATGGTTACAGAGCCAGGGCCTGGGCCAATGGGGTCAGGCTCTCCCTGCCCTCAGGTGGGCAGTCGGGGCTC CTGCTGTGGTCCGAAGCCCCTCCCCCATTGTGTCCTCTCAGGCAGTTGATAGAATAAATTCCATTTAAAATATAAAA AAAAA >gi|24475886|ref|NM_003667.2| Homo sapiens leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), mRNA (SEQ ID NO: 26) TGCTGCTCTCCGCCCGCGTCCGGCTCGTGGCCCCCTACTTCGGGCACCATGGACACCTCCCGGCTCGGTGTGCTCCT GTCCTTGCCTGTGCTGCTGCAGCTGGCGACCGGGGGCAGCTCTCCCAGGTCTGGTGTGTTGCTGAGGGGCTGCCCCA CACACTGTCATTGCGAGCCCGACGGCAGGATGTTGCTCAGGGTGGACTGCTCCGACCTGGGGCTCTCGGAGCTGCCT TCCAACCTCAGCGTCTTCACCTCCTACCTAGACCTCAGTATGAACAACATCAGTCAGCTGCTCCCGAATCCCCTGCC CAGTCTCCGCTTCCTGGAGGAGTTACGTCTTGCGGGAAACGCTCTGACATACATTCCCAAGGGAGCATTCACTGGCC TTTACAGTCTTAAAGTTCTTATGCTGCAGAATAATCAGCTAAGACACGTACCCACAGAAGCTCTGCAGAATTTGCGA AGCCTTCAATCCCTGCGTCTGGATGCTAACCACATCAGCTATGTGCCCCCAAGCTGTTTCAGTGGCCTGCATTCCCT GAGGCACCTGTGGCTGGATGACAATGCGTTAACAGAAATCCCCGTCCAGGCTTTTAGAAGTTTATCGGCATTGCAAG CCATGACCTTGGCCCTGAACAAAATACACCACATACCAGACTATGCCTTTGGAAACCTCTCCAGCTTGGTAGTTCTA CATCTCCATAACAATAGAATCCACTCCCTGGGAAAGAAATGCTTTGATGGGCTCCACAGCCTAGAGACTTTAGATTT AAATTACAATAACCTTGATGAATTCCCCACTGCAATTAGGACACTCTCCAACCTTAAAGAACTAGGATTTCATAGCA ACAATATCAGGTCGATACCTGAGAAAGCATTTGTAGGCAACCCTTCTCTTATTACAATACATTTCTATGACAATCCC ATCCAATTTGTTGGGAGATCTGCTTTTCAACATTTACCTGAACTAAGAACACTGACTCTGAATGGTGCCTCACAAAT AACTGAATTTCCTGATTTAACTGGAACTGCAAACCTGGAGAGTCTGACTTTAACTGGAGCACAGATCTCATCTCTTC CTCAAACCGTCTGCAATCAGTTACCTAATCTCCAAGTGCTAGATCTGTCTTACAACCTATTAGAAGATTTACCCAGT TTTTCAGTCTGCCAAAAGCTTCAGAAAATTGACCTAAGACATAATGAAATCTACGAAATTAAAGTTGACACTTTCCA GCAGTTGCTTAGCCTCCGATCGCTGAATTTGGCTTGGAACAAAATTGCTATTATTCACCCCAATGCATTTTCCACTT TGCCATCCCTAATAAAGCTGGACCTATCGTCCAACCTCCTGTCGTCTTTTCCTATAACTGGGTTACATGGTTTAACT CACTTAAAATTAACAGGAAATCATGCCTTACAGAGCTTGATATCATCTGAAAACTTTCCAGAACTCAAGGTTATAGA AATGCCTTATGCTTACCAGTGCTGTGCATTTGGAGTGTGTGAGAATGCCTATAAGATTTCTAATCAATGGAATAAAG GTGACAACAGCAGTATGGACGACCTTCATAAGAAAGATGCTGGAATGTTTCAGGCTCAAGATGAACGTGACCTTGAA GATTTCCTGCTTGACTTTGAGGAAGACCTGAAAGCCCTTCATTCAGTGCAGTGTTCACCTTCCCCAGGCCCCTTCAA ACCCTGTGAACACCTGCTTGATGGCTGGCTGATCAGAATTGGAGTGTGGACCATAGCAGTTCTGGCACTTACTTGTA ATGCTTTGGTGACTTCAACAGTTTTCAGATCCCCTCTGTACATTTCCCCCATTAAACTGTTAATTGGGGTCATCGCA GCAGTGAACATGCTCACGGGAGTCTCCAGTGCCGTGCTGGCTGGTGTGGATGCGTTCACTTTTGGCAGCTTTGCACG ACATGGTGCCTGGTGGGAGAATGGGGTTGGTTGCCATGTCATTGGTTTTTTGTCCATTTTTGCTTCAGAATCATCTG TTTTCCTGCTTACTCTGGCAGCCCTGGAGCGTGGGTTCTCTGTGAAATATTCTGCAAAATTTGAAACGAAAGCTCCA TTTTCTAGCCTGAAAGTAATCATTTTGCTCTGTGCCCTGCTGGCCTTGACCATGGCCGCAGTTCCCCTGCTGGGTGG CAGCAAGTATGGCGCCTCCCCTCTCTGCCTGCCTTTGCCTTTTGGGGAGCCCAGCACCATGGGCTACATGGTCGCTC TCATCTTGCTCAATTCCCTTTGCTTCCTCATGATGACCATTGCCTACACCAAGCTCTACTGCAATTTGGACAAGGGA GACCTGGAGAATATTTGGGACTGCTCTATGGTAAAACACATTGCCCTGTTGCTCTTCACCAACTGCATCCTAAACTG CCCTGTGGCTTTCTTGTCCTTCTCCTCTTTAATAAACCTTACATTTATCAGTCCTGAAGTAATTAAGTTTATCCTTC TGGTGGTAGTCCCACTTCCTGCATGTCTCAATCCCCTTCTCTACATCTTGTTCAATCCTCACTTTAAGGAGGATCTG GTGAGCCTGAGAAAGCAAACCTACGTCTGGACAAGATCAAAACACCCAAGCTTGATGTCAATTAACTCTGATGATGT CGAAAAACAGTCCTGTGACTCAACTCAAGCCTTGGTAACCTTTACCAGCTCCAGCATCACTTATGACCTGCCTCCCA GTTCCGTGCCATCACCAGCTTATCCAGTGACTGAGAGCTGCCATCTTTCCTCTGTGGCATTTGTCCCATGTCTCTAA TTAATATGTGAAGGAAAATGTTTTCAAAGGTTGAGAACCTGAAAATGTGAGATTGAGTATATCAGAGCAGTAATTAA TAAGAAGAGCTGAGGTGAAACTCGGTTTAAA >gi|62912469|ref|NM_001017403.1| Homo sapiens leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6), transcript variant 1, mRNA (SEQ ID NO: 27) ATGCCCAGCCCGCCGGGGCTCCGGGCGCTATGGCTTTGCGCCGCGCTGTGCGCTTCCCGGAGGGCCGGCGGCGCCCC CCAGCCCGGCCCGGGGCCCACCGCCTGCCCGGCCCCCTGCCACTGCCAGGAGGACGGCATCATGCTGTCTGCCGACT GCTCTGAGCTCGGGCTGTCCGCCGTTCCGGGGGACCTGGACCCCCTGACGGCTTACCTGGACCTCAGCATGAACAAC CTCACAGAGCTTCAGCCTGGCCTCTTCCACCACCTGCGCTTCTTGGAGGAGCTGCGTCTCTCTGGGAACCATCTCTC ACACATCCCAGGACAAGCATTCTCTGGTCTCTACAGCCTGAAAATCCTGATGCTGCAGAACAATCAGCTGGGAGGAA TCCCCGCAGAGGCGCTGTGGGAGCTGCCGAGCCTGCAGTCGCTGCGCCTAGATGCCAACCTCATCTCCCTGGTCCCG GAGAGGAGCTTTGAGGGGCTGTCCTCCCTCCGCCACCTCTGGCTGGACGACAATGCACTCACGGAGATCCCTGTCAG GGCCCTCAACAACCTCCCTGCCCTGCAGGCCATGACCCTGGCCCTCAACCGCATCAGCCACATCCCCGACTACGCGT TCCAGAATCTCACCAGCCTTGTGGTGCTGCATTTGCATAACAACCGCATCCAGCATCTGGGGACCCACAGCTTCGAG GGGCTGCACAATCTGGAGACACTAGACCTGAATTATAACAAGCTGCAGGAGTTCCCTGTGGCCATCCGGACCCTGGG CAGACTGCAGGAACTGGGGTTCCATAACAACAACATCAAGGCCATCCCAGAAAAGGCCTTCATGGGGAACCCTCTGC TACAGACGATACACTTTTATGATAACCCAATCCAGTTTGTGGGAAGATCGGCATTCCAGTACCTGCCTAAACTCCAC ACACTATCTCTGAATGGTGCCATGGACATCCAGGAGTTTCCAGATCTCAAAGGCACCACCAGCCTGGAGATCCTGAC CCTGACCCGCGCAGGCATCCGGCTGCTCCCATCGGGGATGTGCCAACAGCTGCCCAGGCTCCGAGTCCTGGAACTGT CTCACAATCAAATTGAGGAGCTGCCCAGCCTGCACAGGTGTCAGAAATTGGAGGAAATCGGCCTCCAACACAACCGC ATCTGGGAAATTGGAGCTGACACCTTCAGCCAGCTGAGCTCCCTGCAAGCCCTGGATCTTAGCTGGAACGCCATCCG GTCCATCCACCCCGAGGCCTTCTCCACCCTGCACTCCCTGGTCAAGCTGGACCTGACAGACAACCAGCTGACCACAC TGCCCCTGGCTGGACTTGGGGGCTTGATGCATCTGAAGCTCAAAGGGAACCTTGCTCTCTCCCAGGCCTTCTCCAAG GACAGTTTCCCAAAACTGAGGATCCTGGAGGTGCCTTATGCCTACCAGTGCTGTCCCTATGGGATGTGTGCCAGCTT CTTCAAGGCCTCTGGGCAGTGGGAGGCTGAAGACCTTCACCTTGATGATGAGGAGTCTTCAAAAAGGCCCCTGGGCC TCCTTGCCAGACAAGCAGAGAACCACTATGACCAGGACCTGGATGAGCTCCAGCTGGAGATGGAGGACTCAAAGCCA CACCCCAGTGTCCAGTGTAGCCCTACTCCAGGCCCCTTCAAGCCCTGTGAGTACCTCTTTGAAAGCTGGGGCATCCG CCTGGCCGTGTGGGCCATCGTGTTGCTCTCCGTGCTCTGCAATGGACTGGTGCTGCTGACCGTGTTCGCTGGCGGGC CTGTCCCCCTGCCCCCGGTCAAGTTTGTGGTAGGTGCGATTGCAGGCGCCAACACCTTGACTGGCATTTCCTGTGGC CTTCTAGCCTCAGTCGATGCCCTGACCTTTGGTCAGTTCTCTGAGTACGGAGCCCGCTGGGAGACGGGGCTAGGCTG CCGGGCCACTGGCTTCCTGGCAGTACTTGGGTCGGAGGCATCGGTGCTGCTGCTCACTCTGGCCGCAGTGCAGTGCA GCGTCTCCGTCTCCTGTGTCCGGGCCTATGGGAAGTCCCCCTCCCTGGGCAGCGTTCGAGCAGGGGTCCTAGGCTGC CTGGCACTGGCAGGGCTGGCCGCCGCGCTGCCCCTGGCCTCAGTGGGAGAATACGGGGCCTCCCCACTCTGCCTGCC CTACGCGCCACCTGAGGGTCAGCCAGCAGCCCTGGGCTTCACCGTGGCCCTGGTGATGATGAACTCCTTCTGTTTCC TGGTCGTGGCCGGTGCCTACATCAAACTGTACTGTGACCTGCCGCGGGGCGACTTTGAGGCCGTGTGGGACTGCGCC ATGGTGAGGCACGTGGCCTGGCTCATCTTCGCAGACGGGCTCCTCTACTGTCCCGTGGCCTTCCTCAGCTTTGCCTC CATGCTGGGCCTCTTCCCTGTCACGCCCGAGGCCGTCAAGTCTGTCCTGCTGGTGGTGCTGCCCCTGCCTGCCTGCC TCAACCCACTGCTGTACCTGCTCTTCAACCCCCACTTCCGGGATGACCTTCGGCGGCTTCGGCCCCGCGCAGGGGAC TCAGGGCCCCTAGCCTATGCTGCGGCCGGGGAGCTGGAGAAGAGCTCCTGTGATTCTACCCAGGCCCTGGTAGCCTT CTCTGATGTGGATCTCATTCTGGAAGCTTCTGAAGCTGGGCGGCCCCCTGGGCTGGAGACCTATGGCTTCCCCTCAG TGACCCTCATCTCCTGTCAGCAGCCAGGGGCCCCCAGGCTGGAGGGCAGCCATTGTGTAGAGCCAGAGGGGAACCAC TTTGGGAACCCCCAACCCTCCATGGATGGAGAACTGCTGCTGAGGGCAGAGGGATCTACGCCAGCAGGTGGAGGCTT GTCAGGGGGTGGCGGCTTTCAGCCCTCTGGCTTGGCCTTTGCTTCACACGTGTAAATATCCCTCCCCATTCTTCTCT TCCCCTCTCTTCCCTTTCCTCTCTCCCCCTCGGTGAATGATGGCTGCTTCTAAAACAAATACAACCAAAACTCAGCA GTGTGATCTATAGCAGGATGGCCCAGTCCCTGGCTCCACTGATCACCTCTCTCCTGTGACCATCACCAACGGGTGCC TCTTGGCCTGGCTTTCCCTTGGCCTTCCTCAGCTTCACCTTGATACTGGGCCTCTTCCTTGTCATGTCTGAAGCTGT GGACCAGAGACCTGGACTTTTGTCTGCTTAAGGGAAATGAGGGAAGTAAAGACAGTGAAGGGGTGGAGGGTTGATCA GGGCACAGTGGACAGGGAGACCTCACAGAGAAAGGCCTGGAAGGTGATTTCCCGTGTGACTCATGGATAGGATACAA AATGTGTTCCATGTACCATTAATCTTGACATATGCCATGCATAAAGACTTCCTATTAAAATAAGCTTTGGAAGAGAT TACACATGATGTCTTTTTCTTAGAGATTCACAGTGCATGTTAGTGTAATAAAGAGATAAGTCCTACAGTA >gi|40255209|ref|NM_177964.3| Homo sapiens hypothetical protein LOC130576 (LOC130576), mRNA (SEQ ID NO: 28) ACTTCCTGAGCCGGGCTGGCTGGGTGGGAACAGGCTCCTTGCCGCCTCCCCAGCGCTGGCCACTACCACACTGCCGC CCGCCTGGGCCTCCTTTCAACCTCGTGGTGGAGCCCTGCGGTTTCCCAGCGGAGCCGGGCCCGGGGCTGCTCCCTCG CGGGCGAGGCTCACCTGTCCCGGCCCGGCCCCCTCCCGCGCCCCAGGTGGTTCAGGGCGGGGAGGAGCCGCGCCCCG CCCCGCGCGGTAGCAGCCAACGCCGGCCCCAGGCGGGTGCGCTGGGAGCCTGGGCCGGGAGCCGGGTGAGGGCGCCG AGAGGCTCGGTGGGCGCGGGCGGCGAGATATGCCACACTTCTGCCTGCTGTTGGCAACCCTCCTGGACTAGGCTGCT CTTGTTAATCACATGGATGTTGCTGATTACTCTGAGTGCAAACCTTTTCACTGTTCCAGAGAGGAGCCTGACAACCA CATTCTCCTTCTCAAGATATAAGAGTTCGGACCGCCCAGCACACAAGGTCAGCATGCTGCTCCTCTGTCACGCTCTC GCTATAGCTGTTGTCCAGATCGTTATCTTCTCAGAAAGCTGGGCATTTGCCAAGAACATCAACTTCTATAATGTGAG GCCTCCTCTCGACCCTACACCATTTCCAAATAGCTTCAAGTGCTTTACTTGTGAAAACGCAGGGGATAATTATAACT GCAATCGATGGGCAGAAGACAAATGGTGTCCACAAAATACACAGTACTGTTTGACAGTTCATCACTTCACCAGCCAC GGAAGAAGCACATCCATCACCAAAAAGTGTGCCTCCAGAAGTGAATGTCATTTTGTCGGTTGCCACCACAGCCGAGA TTCTGAACATACGGAGTGTAGGTCTTGCTGTGAAGGATGATCTGCAATGTAGAATTACCCACCAATCACACTAATG CAGTGTTTGCCGTAATGCACGCTCAGAGAACATCTGGCAGCAGTGCCCCCACACTCTACCTACCAGTGCTTGCCTGG GTCTTTGTGCTTCCATTGCTGTGATGCCACCATTCCTAGGAGAGGCAGAGACCAGCCTCTAAAGCACAAGCCAAAAA CTGTGTGAACGGTGAACTTTGGAGTGAAGATCAATCTTGCACTTGGTGAAGAGTGCACATTGGACCTCAAGGCGAAA GCCAGTGGTTTGCTTGGATAAAATGTTCCCGCATGAGGCCACAGGACTGAGGATGGGAATTTGGCAGGGCCTGAGAA GATGGTCTGACTTCCAGGCTTCCTGGTCAAAGAGAGCTACGTTTGGGCAGTTCTGCAGAGAGGATCCTGGCAACTAG TCCCACCTGACTAGGCCTTTAGCTGAAAGGATTTCTTGACCTCCTTGACTGCCTCAGAGGCTGCCAGGTCAAACCCT CTTGTTTATGTGATTAGCTCAGAGCATCTCTATGAAATCTAACCCTTCCCCTCATGAGAAAGCAGTTTTCCCCACCA ACAGCATAGTCAATGAGAAAGGCGACTGTACGAAGAAAACTTCCAGTGGAACTAATATGAAATCTATTTGCAAATTA TGGGGGGAAATAAAGCTTTTAAATTATACAATGAAAAAAAAAAAAAAAAAAAAAAAAAAA >gi|157426880|ref|NM_001101387.1| Homo sapiens hCG1776018 (LOC644139), mRNA (SEQ ID NO: 29) AGTTGCTGGGATTCACAACACACTGACTTCTGGACGTGGTCAGGGTGGCTTTCTCTGGCTGGCATGGACTTGAGCAG AAACTCATTGCCGGCTTCCTCCTTGCACGAGCACCAAGTGATTCCCAGGTCCCCCATCCTCCCCTGGGACATCGAGG ACACACAAAAACCTTGTTCACCCTCCACTGAGAGCGGGGCTAGAGATGGATGCTGAGTACAGGAAGGGTGTGTGAGG ATTCCTTTGGCTCCACTCTTGTTTCCAACTATTGCTGGTCCTAGGCGCCCAGTCCTGAGCAACCATGACGATGGAGA CTCTCCCCAAGGTTCTAGAGGTCGATGAGAAGTCTCCAGAAGCCAAGGACCTGCTGCCCAGCCAGACCGCCAGCTCC CTGTGCATCAGCTCCAGGAGCGAGTCTGTCTGGACCACCACCCCCAGGAGTAACTGGGAAATCTACCGCAAGCCCAT CGTTATCATGTCAGTGGGCGGTGCCATCCTGCTTTTCGGCGTGGTCATCACCTGCTTGGCCTACACCTTGAAGCTGA GTGACAAGAGTCTCTCCATCCTCAAAATGGTAGGGCCTGGCTTCCTGTCCCTGGGACTCATGATGCTGGTGTGCGGG CTGGTGTGGGTGCCCATCATCAAAAAGAAACAGAAGCACAGACAGAAGTCGAATTTCTTACGCAGCCTCAAGTCCTT CTTCCTGACTCGCTGATGGTGGTTTCCGCATCTCCCTGCCACCTTGACTGGGAGAAGATCTGATGACCAACATCCGA CATCCCTGTCTCCTCTGTGGGGTGCCATAAAACTGATCCAGGAAAATGCTCTTCCTGACCCTGTGGGGAAGATAGAG CTTGGGGCTCCACCCTCCATGCAGCCGGGAATGTTGCCAGATGTATCCACTTGATCTCTATTCTGACTGATGCTTCC TTGGATCCCGGCTGTGGCCTTCCCTTTGGTCACTCTAACCCCCTGCCCCTGCATCCAGGCATCATTCATCCAACTCT CTCTGCCAAGTGCAATGCATGCTGGGAAATTCTTCGAAGGTGGGCTATGCCCAAGGGAGAACCTCATGTTTACATAT CTGAGTGCCAGAGCTGGATTCTTCATTTGCATACTTCTGGAACCAAAACTGACCCACGGAGGTCCTTTACAGAGGAG GGAGGGATGGCTGAGCTCTGACCCATTGGGTTTGACAGCCCTAGCTCCCTTAGCAGACTTTCAAGATCACAAGTATC AAACATTCCAAAGACTGAACAATGAAGGGAGGCCTGGGAAAAATACTCTCCAAGATGGCACGTGCCCCTGGACATGA CAACATGACTCTAGGGGTTAGTCAGCTGAAGAAGTTTAGTTCCTAATTATATAATATTTACATCAGAGGCAGTGGGG TAGGCTAGGGGATGTCACTGTTTCCGCTTGACCTTATCTTTCTCATTGACCACTGTCTTCTCTGAACTTGATCATTA GCCAAGGACAAAATGCATGTTGCCCTAATTTCTTTCCTACCCCTGCCTCTATCTCTGCATCTAGAACAGCTAAATGG AAAGATACAGAGGGATCCTGTAAGGTTGTTTTCCCTTTCACGTCCATCAAGATCAAAATTGAGAGAATCAAGTTCCA TATCTGAATGATCTGTAGGTTTCTAGAGATGGAATTCACGTCAGAAAATTCCAACTTCTGTTATCCCTGCCCCCACC CACCAAAAAAGCCAACATTTATTAAGTGTCGCATTCTGGGATAAGCCCTGGCTGGGGGCAAGACACGGTCCCTGATG TCTTCTTGCTTCCCGAGGTGAGAGAGGCAGCCAAGCCAACTGGCGAAATGTGGGTGGGTGTGGGAACACAGGCGGTG TCTACCCTAGACTTGATAGAGGACGGAGAAATTCCTGGAGGCCATGTCCTCCAACCCAAAAACAAAAGGAAAGATAA GAGTTACCAAAGAGGGGAAAGAATGGCATTGGAAGCAGCAGGAGCTGCTATGCGTGTGCAGGAGTAGCTTGGGGAAG GAGAAGCATGATGGAATTAGGAAACTGCACGGCCATTTGTCTGACCTCCCAGATGTTTTTACTTCATCCCTCTCTTT CCCGGCTTCCCACCTCTTCACCAAGTGCCTAGCGCAGCTTCTCCTGGAGGCACATTGAGGGCCTCCTGGTGTCTATG GTAGAGACGGGAAGTGGGTTTCCAGAGGGCCTGGCAAGCAAAGAGTCCCTGAGAAGTGCTTCTGTAACTCCCTGTGG CAACCAAGAGGCCCGTAGGTGAAAGAACAGAAGCAGTACCTGTGAGGGAGCCAGCCACGCTGCCCTAGGCCAAAGAC CCCTGGAGAGCATTTGGTAATGAGGTGTGAGAGGAGAGCATCCTGCACCAGAATCACCCTTGTCTTGAGCTAATTCT CTTCACTCCTCAGCCTTGTGGCCTTCCCAGTCACCATGGCCCTCCAGATATCCCCATCCTGCATGGCAGTTCCATAT GCAGAGCCAGAATCCATCCTTGTTCCTTCTGCATTGTGAGAAAATCCATGGAGGAAAGCACTTGTGTCATGGGGACC ACCCCTACCTGACCCACCCACGGAGTCAGAGTTTGGGGAACTCATGGCCGTTGAGGCTCACCCAGGATGGCCATAGC CTTCATGGAGACCCATGCCAGTGTGGCCATGTCTCTAGCTCACCTCTAGCCCTGCACACAGGTGGTCAGGACCAATC TTGGGAGTGTTGCAAGTGCTATGTCGTTAATTGTAGTTTTAGTGCCTCAGTGACAAACCTTGCAGATCATTTCCCTT CTTCTGAGATGAATGCAGATTTGATGGCCCTATAATATTACTCTTGCATTCCTCGATGCATTCTTAAATGGGAGCAA ATGGGATGGGCCCCAGATCACTCACTGGAAACCCACACTCCAGGTGCCTCATTTCCTCTGCCCAGGAGATTGTAGCC TGGGCACAGCTATATGAGGAGGGCCCATTTGGATACTGCTATCATGGATGTCTTAGTGGAAGGAAGTTTAGGGATAA CCACAACTCTAGAAGTCCAGGTTCTGGACTCACTTTGCAGACTCTAGCAGTACCTGCCTCCATTCCCTGCCCACTCA AGCTAGTTTCTCAGCAAAGAGAATATGAGGAAATATCCCCAAACATCGTCATCCCCACTGGGATCCTCCACATGAGT GTGGGCTGGAAAGGTTCCAGGGTCACACTGAGGCAGGACATTTTTTGCCAATGCCTGTTACCCCATGGAAGGCTGAG GTACGGATGCACCTGATCTGGAAATGCAGCCCAGGTCAGACTCCACATTTCTGCAACAAAGCATCACCTGCAATGAC TCTTTTCACGTCAGTGGGTCAAAGGACAGAACCAGCTTCCGTGTTTTAGGCTCACTAGATTGTCTCATGCTCCCCAT GGCTATTCTGTTTGGGAGAATTTGATCTAACCCGAAGCCTAAAGGAATCAATGTAATGTTGAATTGTATTCTATGTA A >gi|93277116|ref|NM_031484.2| Homo sapiens MARVEL domain containing 1 (MARVELD1), mRNA (SEQ ID NO: 30) GAAAGGAGGAGAGGAAGAGAGGACTAAGAGGGGAGCAAGGCGAGGAGGCCGCGGCGGGCGCAGCGGGCACCTGGGCC GTGCTGCCCCCGCGAGCAAGGCGCCGCCATTCCGCTGCTCGGGGCGCCGCCGCCGCCGCCACCGCGCCCAGGGGCCA TGCTCCCGCCGCCCCCGCGCCAGCCGCCGCCCCAGGCGCGTGCGGCCCGCGGCGCGGTGCGCCTGCAGCGGCCCTTC CTGCGCAGCCCGCTGGGCGTGTTGCGGCTGCTGCAGCTGCTGGCCGGCGCTGCCTTCTGGATCACTATCGCCACCAG CAAGTACCAGGGCCCCGTGCACTTCGCGCTCTTCGTGTCCGTGCTCTTCTGGCTGCTCACCCTGGGCCTCTACTTCC TCACGCTGCTGGGCAAGCACGAGCTGGTCCCCGTGCTGGGCTCGCGCTGGCTCATGGTCAACGTGGCGCACGATGTG CTGGCGGCCGCGCTCTACGGCGCCGCCACCGGCATCATGAGCGACCAGATGCAGCGCCACAGCTACTGCAACCTCAA GGATTACCCGCTCCCCTGCGCCTACCACGCCTTCCTGGCGGCCGCCGTCTGCGGCGGCGTCTGCCACGGCCTCTACC TGCTTTCGGCGCTCTATGGCTGCGGGCGTCGCTGCCAGGGCAAGCAGGAGGTGGCGTGAGGCCGCCCGCGCCCGCCG CGGCCCCGATCGGGGCGGGGGAATCCCCGGAGACCAGCCTCCTTAATCCCTTCCCCCGCCGCCGCCCCGCGCGGGTG CGCCCTGGCACCCTCTCCCTGCCCTCCAGCGTTTCCACTGTCGCCCGCGCCCGGGAACCCTGACGCTCAGCTCCCGC CCGACGGCAGCGCCGCCGCCGCCCAGAATCCCAGCCCAGAATCCCGACCGCCGCGCCGGACGCGCCGTCTCCCGGGA CAAGCGCAGGCTGCGATCCGAGGGGCTGACACACACTCGCAGACGAGCCGCCCCGAGGCGAAACCTCGCGGTTCCTC TTCCCTTCCCTGCTGAGACTAAGACGTGGACAGGGGCCGCGCAGATCCGGGGGAGGCTCCCAAATTGGAACCAGGCT TCTGGCTGCCCCCTTCCCTCCCGCCCCGTGGTCGGAAGAGCACTCCCTTCCCTGGCCCCTCATCCAGCCTCCGGTGC TGTAAAACGCAGGCGCTGGGCCGCGGGCGGAGCTGAGGACAGGCCTTGGCTGGTCCCAGGATGAGCGACGAGTTTGG TTTTAGCTGGGGATTGTGCTGGCATCCTGCGAAGCTCCTCCCAGCCGGTCTCTCTGTGCTCGGTTGTCTTGGGGTGG GGCCCATCCGCCGAGGTGGGGACCGATAGGAGAAGCCGGTGGGTTGTACCCTTACACTTGTGGAGTCTCCTCTTGCC TCTACCTACTCCGCCTTTGTCCTTAAGGTTTTTGCAGGCCAGTGCCAAACACACACTAACTGTCCTGGCCTCTCCGT GACACAAGTCTCTTCCCAGCCTTCCTCACAGGCTTCTGCCGCCCCCCTCATCTCCACCCTCCCCCATATCTGTTTGC ATTAGGAGTTCCACGACCATGGTGGAATGTTAAGGTGAACCCCACCCCTTCTTACAGATGGGGACCCAGAGCCTGCT CTTGGGAACAGCCAGAGTAAGATTGGAACCCAGACTTGCAGTCCAGCGCTGTTTGCATTAAAAGGGTGGGTGAGTCA GGACCCCTGGCTCAGGAGCCGCCTCTCCTAAAAGAGGGTTTCAAGGCCAAATGGGTTTGTCAACGGTGCTGTCTCCC TTTCTTGGAGATGCTCATTAGCTTATCAAAGACTGAGAAGTCCCGCTGTTACAGAAATAATTTAGTTTGCTGTATTA ACTGCTCCTGGGCCTGGAGCAGTATTCCCACCTTAAGATTCCCAGCATCCCTGTGCTGTCCCGGCTCTCATTCATGC CGAAGGGCCCAACCCATTGGCTGTGTTCTGTTTGAAGATTTGGGGGGCGCCTTCTCTTTCTTCCCCAGGGAATTCTC TAGCAGAGGGAGGGGACCCACCCCAGTGAGGAAGTAGATTGCTGCCTCTAGCCAGAGACCTGAACTGGGGAATTTGA ACATTCCTTTACATTGTTGGAGAAATGAAGCCAAAGTTATTCAGATGGTTTTCCCAGGCTAAAGGAAAGTCACCTGC AAGAGATCCCGGCACTGATCTGGAGCAGCTGACAGGGTGGGTCTCCCTTACCAAAGAGAAGAACCACTCTCTGGCGC TGGGGTGACCTGCTGGCTGGGCCTGTAAGGTTTCCATGTTGCTGAGGCCATGGAGATTCCCAGAGCTGGTCACACCG ACCGCTCTCAGGGCCCGCTGCCCTGGGCTGGCAACACCATTCTGGCCTTGGCCTGCAGAAGCTTTCAGAGTCTTCAC TGGCAGTAGGGGGAGATGGGGAGAGGAATGATCTCTGCCCAGCCCCTTCCTTTCCAAACCATGCAATGGAAGAGCCC AGATGGGTGAAGATTGATTTTGCCTTAACTCAAGAGAATTCCTGTTCTCCTTGTGCTATGATTTGGACACAAGATTC TGGATACCTGGAACTTAGCTGTGTACTCCTGTACCCTAAACAGTGGATTTGAGTTCCAGCGTTTATTCTTTTTTCCT TTTTTCAGATCACCATCTAAGTTACATCTTTAGCTCAGGTCCATCCTTCTCAAGATCTCCTTCTTAGCCCCCCAGCC CCTGGTGCTGTCTGTGGTCAGGTGACCTTACTCAGGAGCAGATATCTCCTTGGCCGCCATGGAGCCTCATCCATCCA CACGTGCCTGTAGCATTCCAGAGCTCACTGCCCTTCTAGATGTGCCTTCCCGCTTGGCTTCCAGCGGCTTGTGCTCA CTCTGTCTGCCAGGTATGAGAAGAACACGTAAGACCGCCACCACACTCACCCTCCCTCAAGGCCCTGTGCCATAGGG GTGGCCACCCGACCTGCCCCCAGAACTTTTGGATACTGGAGGCAGTTGCATAGGTCTCCCTCTCTGGGCACCAGGAC TCAGTCCAGCCCAAGACTACTCTGGGCAGCTCCCATCCCAGTCTGGGGCCATTTGCAGACTCAGGAAAGGATTTCTA CAGTGTTCTATAAAAGCCAAAAGAGAGAGTGGGTTTGGGAAGAGTGAGGGTGGTTGGGGAGAGGGGACCGATGTGCC TCATTGTTTAGTGGTGATTACAAATATGCTTTTCTGGATAAAGTTTGGTTGTTTGCTCTTAAAAAAAAAAAAAAAAA AAAA gi|50582984|ref|NM_024717.3| Homo sapiens multiple C2 domains, transmembrane 1 (MCTP1), transcript variant L, >gi|50582995|ref|NM_001002796.1| Homo sapiens multiple C2 domains, transmembrane 1 (MCTP1), transcript variant S, mRNA (SEQ ID NO: 31) ATGCTAGACAGCTGCAAGCTGAAAAGTGCCTGCAATTTGCCATTTATTTGTAATAAGAAAATAATAAACACTGCTGG AACCAGTAATGCAGAAGTCCCCTTGGCTGATCCCGGAATGTACCAGCTGGACATTACATTAAGAAGGGGTCAAAGTT TAGCTGCTCGAGATCGAGGAGGGACGAGTGATCCATATGTGAAGTTTAAAATCGGAGGAAAAGAAGTTTTTAGAAGT AAGATAATACACAAGAACCTCAACCCTGTGTGGGAAGAAAAAGCTTGTATTCTGGTTGATCATCTTAGGGAGCCATT GTATATAAAGGTATTTGACTATGATTTTGGACTACAGGATGACTTTATGGGCTCAGCCTTTCTGGATCTGACACAAT TGGAGTTAAACAGGCCCACAGATGTGACCCTTACTCTGAAAGATCCTCATTATCCTGACCATGATCTTGGAATCATT TTGCTCTCAGTCATCCTTACCCCTAAAGAAGGAGAGTCCAGGGATGTGACAATGCTAATGAGGAAGAGTTGGAAAAG ATCAAGTAAGGAACTTTCAGAAAATGAAGTGGTTGGATCTTATTTCTCTGTGAAGTCTCTCTTTTGGAGGACGTGCG GCAGGCCAGCTCTTCCTGTCCTGGGCTTCTGCAGAGCAGAGCTTCAGAATCCTTATTGCAAAAATGTACAATTTCAG ACCCAAAGTTTACGCCTATCAGACCTACACAGAAAATCGCATCTTTGGAGAGGAATAGTCAGCATCACCTTGATTGA AGGGAGAGACCTCAAGGCCATGGATTCCAACGGGTTGAGCGATCCCTACGTGAAGTTCCGGCTTGGGCATCAGAAGT ACAAGAGCAAGATTATGCCAAAAACGTTGAATCCTCAGTGGAGGGAACAATTTGATTTTCACCTTTATGAAGAAAGA GGAGGAGTCATTGATATCACTGCATGGGACAAAGATGCTGGGAAAAGGGATGATTTCATTGGCAGGTGCCAGGTCGA CCTGTCAGCCCTCAGTAGGGAACAGACGCACAAGCTGGAGTTGCAGCTGGAAGAGGGTGAGGGACACCTGGTGCTGC TGGTCACTCTGACAGCATCAGCCACAGTCAGCATCTCTGACCTGTCTGTCAACTCCCTGGAGGACCAGAAGGAACGA GAGGAGATATTAAAGAGATATAGCCCATTGAGGATATTTCACAACCTGAAAGATGTGGGATTTCTCCAGGTGAAAGT CATCAGAGCGGAAGGGTTAATGGCTGCCGACGTCACTGGAAAAAGTGACCCATTTTGTGTGGTAGAACTGAACAACG ATAGACTGCTAACACATACTGTCTACAAAAATCTCAATCCTGAGTGGAATAAAGTCTTCACGTTCAACATTAAAGAT ATCCATTCAGTTCTTGAAGTGACAGTTTATGATGAAGATCGGGATCGAAGTGCTGACTTTCTGGGCAAAGTTGCTAT ACCATTGCTGTCTATTCAAAATGGTGAACAGAAAGCCTACGTCTTGAAAAACAAGCAGCTGACAGGGCCAACAAAGG GGGTCATCTATCTTGAAATAGATGTGATTTTTAATGCTGTGAAAGCCAGCTTACGAACATTAATACCCAAAGAACAG AAGTACATTGAAGAGGAAAACAGACTCTCTAAACAGCTGCTACTAAGAAACTTTATCAGAATGAAACGTTGTGTCAT GGTGCTGGTAAATGCTGCATACTACGTTAATAGTTGCTTTGATTGGGATTCACCCCCAAGGAGTCTCGCTGCTTTTG TGCTCTTTCTCTTTGTTGTCTGGAACTTTGAGCTCTACATGATACCACTGGTTTTGTTGTTACTATTGACATGGAAC TACTTCTTGATAATATCAGGGAAAGATAACAGGCAACGTGATACAGTAGTGGAGGACATGCTAGAGGACGAGGAAGA AGAAGATGACAAAGATGACAAGGACAGTGAAAAAAAGGGATTTATAAATAAAATCTATGCCATCCAGGAGGTATGTG TCAGTGTCCAGAACATCCTAGATGAAGTGGCTTCCTTTGGCGAAAGGATTAAGAATACTTTCAACTGGACTGTCCCA TTCTTAAGCTGGCTGGCCATTGTAGCCCTCTGTGTGTTCACAGCCATCCTGTACTGCATTCCGCTGAGATACATTGT CCTTGTCTGGGGCATCAATAAATTTACAAAAAAGCTTCGGAGTCCATATGCAATTGATAACAATGAACTACTTGACT TCCTTTCCAGAGTCCCTTCAGATGTACAAGTGGTGCAATACCAAGAACTGAAACCAGATCCTTCTCATAGCCCATAT AAAAGAAAGAAAAACAATCTTGGCTAG >gi|141802338|ref|NM_181644.3| Homo sapiens major facilitator superfamily domain containing 4 (MFSD4), mRNA (SEQ ID NO: 32) GCAGGGACCAGATCCGCGAGCCCGTCAGCCTGCGCCATGGGCTGCGACGGCCGCGTGTCGGGGCTGCTCCGCCGCAA CCTGCAGCCCACGCTCACCTACTGGAGCGTCTTCTTCAGCTTCGGCCTGTGCATCGCCTTCCTGGGGCCCACGCTGC TGGACCTGCGCTGTCAGACGCACAGCTCGCTGCCCCAGATCTCCTGGGTCTTCTTCTCGCAGCAGCTCTGCCTCCTG CTGGGCAGCGCCCTCGGGGGCGTCTTCAAAAGGACCCTGGCCCAGTCACTATGGGCCCTGTTCACCTCCTCTCTGGC CATCTCCCTGGTGTTTGCCGTCATCCCCTTCTGCCGCGACGTGAAGGTGCTGGCCTCAGTCATGGCGCTGGCGGGCT TGGCCATGGGCTGCATCGACACCGTGGCCAACATGCAGCTGGTAAGGATGTACCAGAAGGACTCGGCCGTCTTCCTC CAGGTGCTCCATTTCTTCGTGGGCTTTGGTGCTCTGCTGAGCCCCCTTATTGCTGACCCTTTCCTGTCTGAGGCCAA CTGCTTGCCTGCCAATAGCACGGCCAACACCACCTCCCGAGGCCACCTGTTCCATGTCTCCAGGGTGCTGGGCCAGC ACCACGTAGATGCCAAGCCTTGGTCCAACCAGACGTTCCCAGGGCTGACTCCAAAGGACGGGGCAGGGACCCGAGTG TCCTATGCCTTCTGGATCATGGCCATCATCAATCTTCCAGTGCCCATGGCTGTGCTGATGCTGCTGTCCAAGGAGCG GCTGCTGACCTGCTGTCCCCAGAGGAGGCCCCTGCTTCTGTCTGCTGATGAGCTTGCCTTGGAGACACAGCCTCCTG AGAAGGAAGATGCCTCCTCACTGCCCCCAAAGTTTCAGTCACACCTAGGGCATGAGGACCTGTTCAGCTGCTGCCAA AGGAAGAACCTCAGAGGAGCCCCTTATTCCTTCTTTGCCATCCACATCACGGCCGCCCTGGTCCTGTTCATGACGGA TGGGTTGACGGGTGCCTATTCCGCCTTCGTGTACAGCTATGCTGTGGAGAAGCCCCTGTCTGTGGGACACAAGGTGG CTGGCTACCTCCCCAGCCTCTTCTGGGGCTTCATCACACTGGGCCGGCTCCTCTCCATTCCCATATCCTCAAGAATG AAGCCGGCCACCATGGTTTTCATCAACGTGGTTGGCGTGGTGGTGACGTTCCTGGTGCTGCTTATTTTCTCCTACAA CGTCGTCTTCCTGTTCGTGGGGACGGCAAGCCTGGGCCTGTTTCTCAGCAGCACCTTTCCCAGCATGCTGGCCTACA CGGAGGACTCGCTGCAGTACAAAGGCTGTGCAACCACAGTGCTGGTGACAGGGGCAGGAGTTGGCGAGATGGTGCTG CAGATGCTGGTTGGTTCGATATTCCAGGCTCAGGGCAGCTATAGTTTCCTGGTCTGTGGCGTGATCTTTGGTTGTCT GGCTTTTACCTTCTATATCTTGCTCCTGTTTTTCCACAGGATGCACCCTGGACTCCCATCAGTTCCTACCCAAGACA GATCAATTGGAATGGAAAACTCTGAGTGCTACCAGAGGTAAAACTGGGTGAAGAAGGCAAGAGAAGACTTTCAGCCT CTTGATCACCAGCACGACCATACTGTTTCAGAAAGCTGGGTGGTGGTGGAGGCGCTATCTCAATGGCTATTCAAGTC TTCTCCACTAAAACTTGGTTGGGTAGAGGAAATTAAATTGAGTCCTGGTACCTGGTCAAAATCATTAGAAGTTTACC TGGCTTCTCAAGTTATCTTCTTCCCTGGTTCAGACTGTTGGTAAGAGCTGTCCAGATACCCAGATGGGAAGGAAGGA GACAGCCGCGCGCTTCACTCCATTTGTCACCTCATGCATGGACCATACTCTGGGTTTGAGATCATTCTTCATTGAAG TTTGTAAAAATAGGTTGAAATTGTAAAGCTCCATGATCATTGCTATGTAGATATATTTCAATTTAAGCAAAACAAGC TGCAAGTTATTCCCTGGCATGCTCAAAGGATTTTCGTGCTTTTCACTTAATAGTCCAAAGTCTCTTAAATTCCTGCT GCAGACATCAATAGCTTATCTATATTCTCAAACACCAAAAGGAAAAGTTGAATCTTGCTCTCTTTGGTATACTAATG TAGTGGTATGCTAAGCTGGCTCATACCAACTTAGAAAAGCTGATTGTAAAATTTTCATTTTGACAGCTGGTTATTAA ATGCAGCCATTATTAAAAATCAAATCATACAAACTTATAATTAAATCAATTACATTTAAAACAAAGGTAATAAATAT TCAAAGCATATCACTTCCTAATTTGATCTTGATGCTCTTGAGGTAATTTACGTCCATGGTACCTGTGTGGTGGAATT ACTATATATGATGGTGTGCTACTGTGCACCTTGTCTCAACTCCACTCTTCGTGATAGCATGTTGGTAGCTTGAAATC AGCCTGGTGGGAGTATTACCATGGACACTGGCAAAAGCTACAGATCCCGGAGAGCCAGTGGTTAAACATTTACCAGC ATACCACTGCTAGTAATCAAGGCTAACTGGTCCAGAAATCGCCCAGGAGAATGAAATGGATGTTCCATTTTTTTCTA CTGACATTGACTAGCATATAAAAGGTATAGAAACAGCACTAAGACTTTCTGAAAATACCTAATGAAAATTTTACATC TTTTTTTGTTTTTGTTTTTGTTTTTGAGACAGAGTCTCACTCTGTTGCCAGGCTGGAATGCAGTGGCGTCATCTCGG CTCACTGCAACCTCCGCCTCCCAGTTTCAAGCGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGTGACTACAGGCGCA TGCCATCACGCACAGCTAATTTTTTGTATTTTTAGTAGAGACGGGATTTCACCGTGTTAGCCAGGATGGTCTTGATC TCCTGACCTCATGATCTGCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGCACCCAGCCAAA AATTTTACATCTTTTATAGAGGGAAAAAAACTCTTTATACCATGGCAAGGCCTTTTCTTTCACAAAAAGCTGGGCCT ACTGAACAATTCAAGCTGTGCAGTAGTAGACTGAAAGCAGGATTTGTTGAGGAGTTACAGCTCCTGTCCAGAGCAAA TCCTGTAGTGATACAAGGAGAATGTAAACTTGCCAGCTTAGACAGGGATCAGTCCTGAGACTGCTGGCAGTAGCAAA TGGCTATTAGAGTAACTGTATAATGGTTTTGCCTGCACTTTCTCTATGTATATACAAATGTACATGTATAAATATAA AAATTAAGTGATCATGAAAGAAAAAAAAAAAA >gi|115387119|ref|NM_016499.3| Homo sapiens HSPC244 (MGC13379), mRNA (SEQ ID NO: 33) CCAAGGTCCTCCCCCGCACCCCTGAGGTCCTGCAGACGACGGCGTCGTGGGTGGTCACCGTTATCCCTTAGGTCTGG AGAGGGGACATCCGAGCGAGGGCCACTTGCGGCCAGGCCCGAGCTCGTCCAGCTCCGGGTGACCACAGAGTGCCGCG GGCGGGCAGAGGGGCCGGAAACCCAGGCCGCTTCGTCCCTGTTTCCGGCAGCGCCGCGCTGCTCCGGGAGCCGCTGT GGCAGCGTATGCTGCCACGGGGACTGAAGATGGCGCCGCGAGGTGAGATTCCGGAGGTAAACGGTTGTCCTCCACCC CGCTGGAAATCCTGTTCTTTCTGAACGGGTGGTATAATGCTACCTATTTCCTGCTGGAACTTTTCATATTTCTGTAT AAAGGTGTCCTGCTACCATATCCAACAGCTAACCTAGTACTGGATGTGGTGATGCTCCTCCTTTATCTTGGAATTGA AGTAATTCGCCTGTTTTTTGGTACAAAGGGAAACCTCTGCCAGCGAAAGATGCCGCTCAGTATTAGCGTGGCCTTGA CCTTCCCATCTGCCATGATGGCCTCCTATTACCTGCTGCTGCAGACCTACGTACTCCGCCTGGAAGCCATCATGAAT GGCATCTTGCTCTTCTTCTGTGGCTCAGAGCTTTTACTTGAGGTGCTCACCTTGGCTGCTTTCTCCAGTATGGACAG GATTTGAAGTACAGAATTTCAGCCAGCAGCCCATCAGGCTGACACCACACATATTGCTTCTGGTACTTTAGCCACAC CAGTGAGAATTGGTGGGGCAAGTTGTCCTGAGAAAGGCTGTGTGGCTTTTCTTCAGCACAGACATTTGGGCAAGCAA CTCAGCATAAGGCCAGTGGGTACCATCTTCTAAACCAGGACCATCAGCCCAAGAGACTCTTCTACACTCCAGTATAG GGAGGGGCAAGGTTATTCCCATCCTGCCCCTTCTCAGAACCAGTCCCCTGCTGACCTCAAGTTCTCCTCCTTGATCA CCGTGGCCAGAGCATCTCGTGTGGACCATCTAGGCTCCTTGGGCTTCAAGCAGGACCTGAGCCACATGCTCCCTGTA CGAGCTGTGCTATACCTGTCCCACATGAGCACGGAGAGCCTCATGTTGGTGGGTTTCCAGAGTGATGTGAAAGCCTC TCACCCCAATCCTCGGAGACTGAGTTCCACAACTTTTTTAGTAGCTCATAGTGTTATTTTTCTACTCTCTTCATGAA ACTAACTTTATTTTATAATAAATATGTATTTTCTGTTGTGGGGAAAAAAAAAAAAAAAAAAAA >gi|13899294|ref|NM_031457.1| Homo sapiens membrane-spanning 4-domains, subfamily A, member 8B (MS4A8B), mRNA (SEQ ID NO: 34) AAACAGGAAATAAATACGAATGAAACTGAGCTCTAAGCAGCATGTAACCTGGCCTGCATCCAGGAAATAGAGGACTT CGGATCCTTCTAACCCTACCACCCAACTGGCCCCAGTACATTCATTCTCTCAGGAAAAAAAACAAGGTCCCCACAGC AAAGAAAAGGAATAGGATCAAGAGATACGTGGCTGCTGGCAGAGCAAGCATGAATTCGATGACTTCAGCAGTTCCGG TGGCCAATTCTGTGTTGGTGGTGGCACCCCACAATGGTTATCCTGTGACCCCAGGAATTATGTCTCACGTGCCCCTG TATCCAAACAGCCAGCCGCAAGTCCACCTAGTTCCTGGGAACCCACCTAGTTTGGTGTCGAATGTGAATGGGCAGCC TGTGCAGAAAGCTCTGAAAGAAGGCAAAACCTTGGGGGCCATCCAGATCATCATTGGCCTGGCTCACATCGGCCTCG GCTCCATCATGGCGACGGTTCTCGTAGGGGAATACCTGTCTATTTCATTCTACGGAGGCTTTCCCTTCTGGGGAGGC TTGTGGTTTATCATTTCAGGATCTCTCTCCGTGGCAGCAGAAAATCAGCCATATTCTTATTGCCTGCTGTCTGGCAG TTTGGGCTTGAACATCGTCAGTGCAATCTGCTCTGCAGTTGGAGTCATACTCTTCATCACAGATCTAAGTATTCCCC ACCCATATGCCTACCCCGACTATTATCCTTACGCCTGGGGTGTGAACCCTGGAATGGCGATTTCTGGCGTGCTGCTG GTCTTCTGCCTCCTGGAGTTTGGCATCGCATGCGCATCTTCCCACTTTGGCTGCCAGTTGGTCTGCTGTCAATCAAG CAATGTGAGTGTCATCTATCCAAACATCTATGCAGCAAACCCAGTGATCACCCCAGAACCGGTGACCTCACCACCAA GTTATTCCAGTGAGATCCAAGCAAATAAGTAAGGCTACAGATTCTGGAAGCATCTTTCACTGGGACCAAAAGAAGTC CTCCTCCCTTTCTGGGCTTCCATAACCCAGGTCGTTCCTGTTCTGACAGCTGAGGAAACGTCTCTCCCACTGTTTGT ACTCTCACCTTCATTCTTCAATTCAGTCTAGGAAACCATGCTGTTTCTCTATCAAGAAGAAGACAGAGATTTTAAAC AGATGTTAACCAAGAGGGACTCCCTAGGGCACATGCATCAGCACATATGTGGGCATCCAGCCTCTGGGGCCTTGGCA CACACACATTCGTGTGCTCTGCTGCATGTGAGCTTGTGGGTTAGAGGAACAAATATCTAGACATTCAATCTTCACTC TTTCAATTGTGCATTCATTTAATAAATAGATACTGAGCATTCAAAAAAAAAAAAAAAAAA >gi|6005793|ref|NM_007213.1| Homo sapiens PRA1 domain family, member 2 (PRAF2), mRNA (SEQ ID NO: 35) CACATTAACCGGCAGGATGTCGGAGGTGCGGCTGCCACCGCTACGCGCCCTGGACGACTTTGTTCTGGGGTCGGCGC GTCTGGCGGCTCCGGATCCATGCGACCCGCAGCGATGGTGCCACCGCGTCATCAACAACCTCCTCTACTACCAAACC AACTACCTTCTCTGCTTCGGCATCGGCCTCGCTCTCGCCGGGTACGTGCGGCCACTTCATACGCTCCTGAGCGCGCT GGTAGTGGCGGTGGCCCTCGGCGTGCTGGTGTGGGCAGCTGAGACCCGCGCAGCTGTGCGCCGCTGCCGCCGCAGCC ACCCTGCAGCCTGCCTGGCCGCAGTGCTTGCCGTCGGCCTCCTGGTGCTCTGGGTCGCGGGCGGCGCTTGCACCTTC CTGTTCAGCATCGCCGGGCCGGTGCTTCTGATCCTGGTGCACGCCTCGTTGCGCCTGCGCAACCTTAAGAACAAGAT TGAGAACAAGATCGAGAGCATTGGTCTCAAGCGGACGCCAATGGGCCTGCTACTAGAGGCACTGGGACAAGAGCAGG AGGCTGGATCCTAGGCCCCTGGGATCTGTACCCAGGACCTGGAGAATACCACCCCACCCCCAGCCCATAATTGGGAC CCAGAGCCCTTTCCCAGCACTTAAAACAGGAGCCTAGAGCCCCCTGCCCAAACAAAACAGGACATCTGTGACCGCCC TACCCCCACGCCAGCCCCAAACTAAGATATCCCTCACACCCAGCCCCCATTACCTAGGGACAAGAGTCTTCCCCAGC CTTGAACCTAGGACCAAGAGCCACCTACATCCAGCCCCAAAACTGGGGCTTCAGGCCAGAGCATCCATGGCCAATTT CAAATTGTGAACCCAGAGACACTCCCATCCACCCTTCTCCATGCTCATCCCCAAACTGGGGCCTGGAGCAAGGCACT CTCAAATCTTGAACCCTGGACCAAAGCTTTTCCAGACCCCACCCTACCTTCCAACCCAGGTCAAGACATTGCCAAAT CTTGAACTCAGAACCCAAGTGTTCCATGCCCCTGTGTGGATGGAGTCGGGTATCCTGACTGTTGGACCCCTGGTCCA GGTGATCCCGACCCTCACCAGTCCCATTTGCCTCCCTCCAGCTCTGCTTAGGCATTTTGCCCCTCACCCCAATGTTC CACACCATCGACAACCAAGGGGTGAGGTGGGGACAGGCCTCAGCAGGGAATGGGGCGTATATGTTAGTGTTGCTGCA ACAATAAAGCCTGTTGCATCTCTCATGCCAA >gi|158186613|ref|NM_001109903.1| Homo sapiens ring finger protein, transmembrane 2 (RNFT2), transcript variant 1, mRNA (SEQ ID NO: 36) ACATGCTGCCCAGGCTGCGCGGGTGATTGGCTTGGCTGGACCTGAATGATGCGGCTGTGATTGCTGAATTGTCTGGG CAGGTTTGGAGTCTCTGGCAAGCTCCCCTGACTGTGCATCCCTCTGGAGACGAAGAGGAGGGGGAGGCCTGTCCTCT CTGGGATCCATTGGTCACATCCCCCTGAGGATTCCCGAATGCCTACCTCCAGTGTCGTCAACATGGAGTTCTGAAGT CCATGTGGCTCTTCACAGTGAATCAGGTGTTAAGGAAGATGCAGAGACGCCACAGCAGCAACACGGATAACATTCCA CCTGAAAGAAACCGCAGCCAGGCGCTCAGCTCCGAGGCGAGTGTGGATGAAGGTGGCGTCTTTGAGAGTCTGAAGGC AGAGGCAGCCTCCCCACCAGCGCTCTTCTCGGGCTTATCAGGCAGCCTCCCCACCAGCTCGTTCCCCTCCAGCCTGG TGCTGGGCTCCTCGGCTGGCGGCGGGGACGTGTTCATCCAGATGCCCGCGTCCAGGGAGGAAGGAGGGGGCCGGGGC GAGGGGGGCGCCTACCACCACCGCCAGCCCCACCACCATTTCCACCATGGCGGCCACCGCGGGGGCTCCCTGCTGCA GCACGTGGGTGGGGACCACCGGGGGCACTCGGAGGAGGGAGGCGACGAGCAGCCTGGGACGCCCGCCCCCGCCCTGT CCGAGCTGAAGGCTGTGATCTGCTGGCTCCAGAAAGGACTCCCCTTCATCCTGATCCTCCTGGCCAAACTGTGCTTT CAGCATAAGCTCGGCATTGCTGTGTGCATCGGGATGGCCAGCACCTTCGCCTATGCCAACTCCACGCTTCGAGAACA GGTCTCACTGAAGGAGAAGAGGTCAGTGCTGGTCATCTTGTGGATCCTGGCCTTTCTGGCGGGGAACACCCTCTATG TGCTTTATACATTCAGCTCCCAGCAGCTGTACAACAGCCTCATATTCCTGAAGCCCAACCTGGAGATGCTGGACTTC TTTGACCTGCTATGGATTGTGGGGATCGCAGACTTTGTTCTGAAGTACATCACCATCGCCCTCAAGTGCCTCATCGT GGCCCTGCCCAAGATCATCCTGGCTGTCAAGTCCAAGGGAAAGTTCTATCTGGTCATCGAGGAGCTGAGCCAGCTGT TCCGATCCCTTGTCCCCATCCAGCTGTGGTACAAATACATCATGGGTGACGACTCCTCCAACAGCTACTTCCTGGGC GGGGTCCTGATCGTTCTCTACAGCCTCTGCAAGTCCTTCGACATCTGTGGACGTGTGGGCGGAGTTAGGAAAGCCCT GAAGCTTCTCTGTACCTCTCAGAACTATGGAGTCCGAGCCACCGGGCAGCAGTGCACAGAAGCTGGTGACATCTGCG CCATCTGTCAGGCCGAGTTCCGAGAGCCTCTGATTCTCCTGTGCCAGCACGTGTTCTGTGAGGAGTGCCTCTGCCTG TGGCTGGACCGTGAGCGCACCTGCCCGCTCTGCCGCTCGGTCGCCGTGGACACCCTGCGCTGCTGGAAGGACGGCGC CACGTCCGCACACTTCCAGGTGTACTAGGACCGAACACTGAGGACACCCAGAAGGACGCCAAGGATTCAGGACATTT GCCCCTGTGTGCCACCAAACCAGGACTTTCCCCTTGGCTTGGCATCCCTGGCTCTCTCCTGGTACCCAGCAAGACGT CTGTTCCAGGGCAGTGTAGCATCTTTCAAGCTCCGTTACTATGGCGATGGCCATGATGTTACAATCCCACTTGCCTG AATAATCAAGTGGGAAGGGGAAGCAGAGGGAAATGGGGCCATGTGAATGCAGCTGCTCTGTTCTCCCTACCCTGAGG AAAAACCAAAGGGAAGCAACAGGAACTTCTGCAACTGGTTTTTATCGGAAAGATCATCCTGCCTGCAGATGCTGTTG AAGGGGCACAAGAAATTGGAGCTGGAGAAGATTGATGAAAGTGCAGGTGTGTAAGGAAATAGAACAGTCTGCTGGGA GTCAGACCTGGAATTCTGATTCCAAACTCTTTATTACTTTGGGAAGTCACTCAGCCTCCCTGTAGCCATCTCCAGGG TGACGGAACCCAGTGTATTACCTGCTGGAACCAAGGAAACTAACAATGTAGGTTACTAGTGAATACCCCAATGGTTT CTCCAATTATGCCCATGCCACCAAAACAATAAAACAAAATTCTCTAACACTGCAAAGAGTGAGCCATGCCTGTTAAC ACTGTAAAGAATGTAACATGTGGGGGACACACAGGGGCAGATGGGATGGTTTAGTTTAGGATTTTATTAGTGCATGC CCTACCCTCTGGGGGAACGTCCCATCTGAGGTTTTCTTCTCGGTGGGGGGATTTAACTTCTGTCCTAGGGAAAACAG TGTCTGATGAGGAGTGTTTCCAACACAGGCTACATGAATTCCCCTATACCAGTGCGAAAGCAGCCAGGAGTCCCCGT TGGAAAAGAACAATGCCACTCTCTTTTATGTATCTTGGTTCTGCAACTCATTTGTTGTAAGTAGGGTTAATCGAGTA TCAGGTTCACAGTATCCTGCCCTTATTATTTTATGATTCACTGACTCAAGTTCCACGAAGTCCTTAGAAATGGACCT CTTCATGTAAAATATCTTGAGAATAATAAATGTGAGGGAATAAGAAAGGCAAGCTTTGGACACAGATATGATAGGTG CATCAGCTTCGGAAGAGAAGAATGATGTGCAGAGTGTTAGGAAGACATCCGGGCTGCTGAGACTCGGGATTAGAAGA AAGAGAGGTAAATAAAGTGGGTCCTGGAATCTTTTAGGACTTCTGCTGTAGGACAAACAGCTGCCTTTGGTGTTTTA ATGTCTCCCAAAGTACCCTTCAGCCAATAAATACCATCTGTTGGTGCAAAAAAAAAAAAAAAAAA >gi|116235461|ref|NM_182556.2| Homo sapiens solute carrier family 25, member 45 (SLC25A45), transcript variant 1, mRNA (SEQ ID NO: 37) AGATCCTTGAAAGGGTTTTGGTTTTGACTGAGCAGAATGGTGCCATTGCAGATCAACACGCACTTTAAATAATCAAA ACCCCTATCTTTCCCCTGGGAAGGAGGAAGCCGAGGAAGGCTGTGTTTCTGACTCACACGGGGGAGTCGGGGGAGTC GTAAACAACCCTGAAGAGAACAGCCAGGCCTGTTCCCGCAAGCCCAGACAATGCCGGTGGAGGAATTTGTGGCTGGC TGGATCTCTGGCGCTCTGGGCTTGGTCCTGGGACACCCGTTTGACACTGTAAAGGTGAGGCTGCAGACCCAGACCAC CTACCGGGGCATCGTTGATTGCATGGTCAAGATTTACCGCCATGAGTCCCTCCTGGGCTTCTTCAAGGGAATGAGCT TCCCCATTGCCAGCATAGCTGTGGTCAACTCTGTCCTGTTTGGGGTCTATAGCAACACCCTGCTGGTGCTCACGGCC ACCTCCCACCAGGAGCGGCGGGCCCAGCCGCCCAGCTACATGCACATCTTCCTAGCGGGCTGCACCGGGGGGTTCCT GCAGGCCTACTGTCTGGCTCCTTTTGACCTCATCAAAGTCCGGCTACAAAACCAGACAGAGCCAAGGGCCCAGCCAG GGAGCCCCCCACCCCGGTACCAGGGGCCCGTGCACTGTGCAGCCTCCATCTTCCGGGAGGAGGGGCCCCGGGGGCTG TTCCGAGGAGCCTGGGCCCTGACGCTGAGGGACACCCCCACGGTGGGGATCTACTTCATCACCTATGAAGGGCTCTG TCGCCAGTACACACCAGAAGGCCAGAATCCCAGCTCAGCCACGGTGCTGGTGGCAGGGGGCTTTGCAGGCATTGCTT CCTGGGTGGCAGCCACGCCCTTAGACATGATCAAGTCCCGGATGCAGATGGATGGACTGAGACGCAGAGTGTACCAG GGGATGCTGGACTGCATGGTGAGCAGCATCCGGCAGGAAGGACTGGGAGTCTTCTTCCGGGGGGTCACCATCAACAG TGCCCGCGCCTTTCCCGTCAATGCTGTCACCTTCCTCAGCTACGAATATCTCCTCCGCTGGTGGGGATGAGCCCTGC GGCAATGCCAGCAGCTCCCCATCAGGCCCACGGCCTGGAGGCCAGTTTGAGATTGGAGGCCAGGTTGAAAGCTTGCA AATCAGTGCAAGAGGCTCAGCCCTTCCTAACCAAGGTGCCTCCCACCCGCGCAGATCTGGGCTGGGCAGACACCTGT GGGAGCCGGAAGCCAGGGGGCCTGTGCAGCCTCCCTGTGTAGCTGGCCTTGACTCCTTTGCCTCCCACATCTGTGAA ACAGGGAGCATGAGGCACAAGTGAGCTGGCAAGTGGTGCTGGTGACATCCCAGCTCCTGTCCTGTGCCTTCACCTCT TTTTTTTTTTTTTTTTTTTTTTGAGATGGAGTCTTTCTCTGTCACCCAGGCTGGAATGCAGTGGCGTGATCTCGGCT CACTGCAACCTCCGCCTTTCCACCTTCCGGGTTCAAGCAACTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACTATA GGCGCCCGCCACCACACCCAGCTAAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTCAGCCAGGATGGTC TTGATCTCCTGACTTTGTGATCCGCCCGCGTCGGCCTCTCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCG GCTGCCTTCACCTCTTAAGGAGCTCTGAGACTCCACTTCTGAGAGTCCCTGCGGCCTCCCACCTCCCTGCCTTTCAA AGCTCTCTCCCCCATGACCCAGGATAACCCTATGTCTCCTCCCCCAGAATCCTTCAGTGGCTCTCATCACCTTCAGG AAAAGCCCAAACTCCTTCCACCCTCCAGGTTCCTCCCTCCCCACGAGGCTTTGTTCTCCTGGGGTTGCTTCCTGGAC CCTGAACAAGTTGTGCTCTCATTGGCCGGGCCTGGCCAGCAGTGCACAGTGCCTGGCAGGTTGACTCTACCATCCCC GGGGCTGGCCCCGCTCTCCTCCGAGACCCAGGCTGAGCCCAGTCCCCTCACCCTTCCTTGACTTACCTCCCCACCTG AGGCTGACTTTGGGGTTCCCAGACACCCTACCCACACACATGCCTTGATCATAGCACTTGCCTGCGCTTCTTCAGAG TCATTAATTTGCTTCTCGGCTTCCCCACTGGACTGTGAGCTGCCTGAGGTCAGGGATTGCGCTTTGGATGGTTTCCA GCCTGAGCCTGGTGCTTGAACAGACGTGTGCAATAAATGCTCGTTAAATGATG >gi|33469136|ref|NM_182838.1| Homo sapiens solute carrier family 35, member E2 (SLC35E2), mRNA (SEQ ID NO: 38) GGGGCACTGAGGAGCGGCGCCCGCGGGGCAGCGAGGAGCCCGATGCAGGGTTCTGCGCGTCATTTCCGGTCCCGCGG GCGCCCCGTGAAGCCCACCTGGATCCGCCAGCGCTGTGCCACTCCCCAGTGCCGAGCTCCGAGCTGTCTCCGCGGCC TCGCGCCCGGCCCCTCCACCGCGCACCTCTTAGGCCCCGCCCGCCAGCGTCCCTTTGTTGTGAAGGCGCCGGGGCCT AGCGCTATGCCTGCGGCGGAGACTGCATCAGGCTCTCGCGTCTGCTTCTACGCTTTGCCTGGGAGAGGCCCTGGTGG CCTCGTTCCTGGCGCCCGGAGTCCCTGCTGCGGCCCCACCCCCGGGCGGTCACGGTGACCCATGCTGCCCAGCCTGG AGGTAAAATCGTTCGTGGCTGTGGCTTCAGCATGTCGTCCTCGGTGAAAACCCCAGCACTGGAAGAGCTGGTTCCTG GCTCCGAAGAGAAGCCGAAAGGCAGGTCGCCTCTCAGCTGGGGCTCTCTGTTTGGTCACCGAAGTGAGAAGATTGTT TTTGCCAAGAGCGACGGCGGCACAGATGAGAACGTACTGACCGTCACCATCACGGAGACCACGGTCATCGAGTCAGA CTTGGGTGTGTGGAGCTCGCGGGCGCTGCTCTACCTCACGCTGTGGTTCTTCTTCAGCTTCTGCACGCTCTTCCTCA ACAAGTACATCCTGTCCCTGCTGGGAGGCGAGCCCAGCATGCTAGGTGCGGTGCAGATGCTGTCCACCACGGTTATC GGGTGTGTGAAAACCCTCGTTCCTTGCTGTTTATATCAGCACAAGGCCCGGCTTTCCTACCCACCCAACTTCCTTAT GACGATGCTGTTTGTGGGTCTGATGAGGTTTGCAACTGTGGTTTTGGGTTTGGTCAGCCTGAAAAATGTGGCGGTTT CGTTTGCTGAGACGGTGAAGAGCTCCGCCCCCATCTTCACGGTGATCATGTCTCGGATGATTCTGGGGGAGTACACA GGACGTCCCAGTGATCGGGAGGAGCGGGAAGAGCTTCAGCTACAACCAGGACGTGGTGCTGCTGCTTCTGACAGACG GAGTCCTGTTCCACCTTCAGAGCGTCACGGCGTACGCCCTCATGGGGAAAATCTCCCCGGTGACTTTCAGGTCCCGC AGGCCCTGCACCGAGTCGCCTTGTCCATGGCGCTGCCCTGCCCCATGCTTCCTGCGTCCTGAGTAGGAGGTATCTCC GAGACAGGAAAAGTGGCCGCTCTCTCTCACTTTTTCTGGAACTCATGGTGGTCTCCTGGGCTTGGTCACTGTCTCTC ACCAGCATGTTTCTTTGTGCGGTCAGGAATTATTTCCAAATGCTCCTGAAGCCTAGTGTTTTAGTGAACATTAGTGA TTGTTAGCAGTGGTTCAAAAAAAAAAAACTTTTTTTTTTTTTTT >gi|83921601|ref|NM_001037984.1| Homo sapiens solute carrier family 38, member 10 (SLC38A10), transcript variant 1, mRNA (SEQ ID NO: 39) CGCCGCGGCGGCAGCTGAGTTGGGCTGAGGTGTCCCTAGCTGGCTCTGCGGCTCTTCCGGGTCTGGGCTCGGAGATT CACAGGCGGCCCGCGAGGCCGAGCGAGGGACGCATGGCCCTGAGGCGGCCGCAGGGCTTGGCGGGGTCCGGAGGTTG ACCTCGCCCCCGCAGCCGGCCTTCGAGGCTGCCTCCTCCAGGCAGCCTCTGGGGCCCGCGCCCGCGCCTGCTCAGGC TCCCGTGTTCAGGCTGCCCATCCCCTCCCCACCGGCGTCCCGGACGTTGGGACCTGTGACCGTGGCCTCGGGCTGGG CTTCCAAAGCCGGCCGCAGCCCGGCGACCCCCGAGGCCTCTCGCCCCGGGCCCCTAGACCTCTCACTATGACCGCGG CCGCCGCCTCCAACTGGGGGCTGATCACGAACATCGTGAACAGCATCGTAGGGGTCAGTGTCCTCACCATGCCCTTC TGCTTCAAACAGTGCGGCATCGTCCTGGGGGCGCTGCTCTTGGTCTTCTGCTCATGGATGACGCACCAGTCGTGCAT GTTCTTGGTGAAGTCGGCCAGCCTGAGCAAGCGGAGGACCTACGCCGGCCTGGCATTCCACGCCTACGGGAAGGCAG GCAAGATGCTGGTGGAGACCAGCATGATCGGGCTGATGCTGGGCACCTGCATCGCCTTCTACGTCGTGATCGGCGAC TTGGGGTCCAACTTCTTTGCCCGGCTGTTCGGGTTTCAGGTGGGCGGCACCTTCCGCATGTTCCTGCTGTTCGCCGT GTCGCTGTGCATCGTGCTCCCGCTCAGCCTGCAGCGGAACATGATGGCCTCCATCCAGTCCTTCAGCGCCATGGCCC TCCTCTTCTACACCGTGTTCATGTTCGTGATCGTGCTCTCCTCTCTCAAGCACGGCCTCTTCAGTGGGCAGTGGCTG CGGCGGGTCAGCTACGTCCGCTGGGAGGGCGTCTTCCGCTGCATCCCCATCTTCGGCATGTCCTTCGCCTGCCAGTC CCAGGTGCTGCCCACCTACGACAGCCTGGATGAGCCGTCAGTGAAAACCATGAGCTCCATATTTGCTTCCTCCCTTA ATGTGGTCACCACCTTCTACGTCATGGTGGGGTTTTTCGGCTACGTCAGCTTCACCGAGGCCACGGCCGGCAACGTG CTCATGCACTTTCCCTCCAACCTGGTGACGGAGATGCTCCGTGTGGGCTTCATGATGTCAGTGGCTGTGGGCTTCCC CATGATGATCCTGCCATGCAGGCAGGCCCTGAGCACGCTGCTGTGTGAGCAGCAGCAAAAAGATGGCACCTTTGCAG CAGGGGGCTACATGCCCCCTCTCCGGTTTAAAGCACTTACCCTCTCTGTGGTGTTTGGAACCATGGTTGGTGGCATC CTTATCCCCAACGTGGAGACCATCCTGGGCCTCACAGGAGCGACCATGGGAAGCCTCATCTGCTTCATCTGCCCGGC GCTGATCTACAAGAAAATCCACAAGAACGCACTTTCCTCCCAGGTGGTGCTGTGGGTCGGCCTGGGCGTCCTGGTGG TGAGCACTGTCACCACACTGTCTGTGAGCGAGGAGGTCCCCGAGGACTTGGCAGAGGAAGCCCCTGGCGGCCGGCTT GGAGAGGCCGAGGGTTTGATGAAGGTGGAGGCAGCGCGGCTCTCAGCCCAGGATCCGGTTGTGGCCGTGGCTGAGGA TGGCCGGGAGAAGCCGAAGCTGCCGAAGGAGAGAGAGGAGCTGGAGCAGGCCCAGATCAAGGGGCCCGTGGATGTGC CTGGACGGGAAGATGGCAAGGAGGCACCGGAGGAGGCACAGCTCGATCGCCCTGGGCAAGGGATTGCTGTGCCTGTG GGCGAGGCCCACCGCCACGAGCCTCCTGTTCCTCACGACAAGGTGGTGGTAGATGAAGGCCAAGACCGAGAGGTGCC AGAAGAGAACAAACCTCCATCCAGACACGCGGGCGGAAAGGCTCCAGGGGTCCAGGGCCAGATGGCGCCGCCTCTGC CCGACTCAGAAAGAGAGAAACAAGAGCCGGAGCAGGGAGAGGTTGGGAAGAGGCCTGGACAGGCCCAGGCCTTGGAG GAGGCGGGTGATCTTCCTGAAGATCCCCAGAAAGTTCCAGAAGCAGATGGTCAGCCAGCTGTCCAGCCTGCAAAGGA GGACCTGGGGCCAGGAGACAGGGGCCTGCATCCTCGGCCCCAGGCAGTGCTGTCTGAGCAGCAGAACGGCCTGGCGG TGGGTGGAGGGGAAAAGGCCAAGGGGGGACCGCCGCCAGGCAACGCCGCCGGGGACACAGGGCAGCCCGCAGAGGAC AGCGACCACGGTGGGAAGCCTCCCCTCCCAGCGGAGAAGCCGGCTCCAGGGCCTGGGCTGCCGCCCGAGCCTCGCGA GCAGAGGGACGTGGAGCGAGCGGGTGGAAACCAGGCGGCCAGCCAGCTGGAGGAAGCTGGCAGGGCGGAGATGCTGG ACCACGCCGTCCTGCTTCAGGTGATCAAAGAACAGCAGGTGCAGCAAAAGCGCTTGCTGGACCAGCAGGAGAAGCTG CTGGCGGTGATCGAGGAGCAGCACAAGGAGATCCACCAGCAGAGGCAGGAGGACGAGGAGGATAAACCCAGGCAGGT GGAGGTGCATCAAGAGCCCGGGGCAGCGGTGCCCAGAGGCCAGGAGGCCCCTGAAGGCAAGGCCAGGGAGACGGTGG AGAATCTGCCTCCCCTGCCTTTGGACCCTGTCCTCAGAGCTCCTGGGGGCCGCCCTGCTCCATCCCAGGACCTTAAC CAGCGCTCCCTGGAGCACTCTGAGGGGCCTGTGGGCAGAGACCCTGCTGGCCCTCCTGACGGCGGCCCTGACACAGA GCCTCGGGCAGCCCAGGCCAAGCTGAGAGATGGCCAGAAGGATGCCGCCCCCAGGGCAGCTGGCACTGTGAAGGAGC TCCCCAAGGGCCCGGAGCAGGTGCCCGTGCCAGACCCCGCCAGGGAAGCCGGGGGCCCAGAGGAGCGCCTCGCAGAG GAATTCCCTGGGCAAAGTCAGGACGTTACTGGCGGTTCCCAAGACAGGAAAAAACCTGGGAAGGAGGTGGCAGCCAC TGGCACCAGCATTCTGAAGGAAGCCAACTGGCTCGTGGCAGGGCCAGGAGCAGAGACGGGGGACCCTCGCATGAAGC CCAAGCAAGTGAGCCGAGACCTGGGCCTTGCAGCGGACCTGCCCGGTGGGGCGGAAGGAGCAGCTGCACAGCCCCAG GCTGTGTTACGCCAGCCGGAACTGCGGGTCATCTCTGATGGCGAGCAGGGTGGACAGCAGGGCCACCGGCTGGACCA TGGCGGTCACCTGGAGATGAGAAAGGCCCGCGGGGGGGACCATGTGCCTGTGTCCCACGAGCAGCCGAGAGGCGGGG AGGACGCTGCTGTCCAGGAGCCCAGGCAGAGGCCAGAGCCAGAGCTGGGGCTCAAACGAGCTGTCCCGGGGGGCCAG AGGCCGGACAATGCCAAGCCCAACCGGGACCTGAAACTGCAGGCTGGCTCCGACCTCCGGAGGCGACGGCGGGACCT TGGCCCTCATGCAGAGGGTCAGCTGGCCCCGAGGGATGGGGTCATCATTGGCCTTAACCCCCTGCCTGATGTCCAGG TGAACGACCTCCGTGGCGCCCTGGATGCCCAGCTCCGCCAGGCTGCGGGGGGAGCTCTGCAGGTGGTCCACAGCCGG CAGCTTAGACAGGCGCCTGGGCCTCCAGAGGAGTCCTAGCACCTGCTGGCCATGAGGGCCACGCCAGCCACTGCCCT CCTCGGCCAGCAGCAGGTCTGTCTCAGCCGCATCCCAGCCAAACTCTGGAGGTCACACTCGCCTCTCCCCAGGGTTT CATGTCTGAGGCCCTCACCAAGTGTGAGTGACAGTATAAAAGATTCACTGTGGCATCGTTTCCAGAATGTTCTTGCT GTCGTTCTGTTGCAGCTCTTAGTCTGAGGTCCTCTGACCTCTAGACTCTGAGCTCACTCCAGCCTGTGAGGAGAAAC GGCCTCCGCTGCGAGCTGGCTGGTGCACTCCCAGGCTCAGGCTGGGGAGCTGCTGCGTCTGTGGTCAGGCCTCCTGC TCCTGCCAGGGAGCACGCGTGGTCTTCGGGTTGAGCTCGGCCGTGCGTGGAGGTGCGCATGGCTGCTCATGGTCCCA ACACAGGCTACTGTGAGAGCCAGCATCCAACCCCACGCTTGCAGTGACTCAGAATGATAATTATTATGACTGTTTAT CGATGCTTCCCACAGTGTGGTAGAAAGTCTTGAATAAACACTTTTGCCTTCACCCAGAAAAAAAAAAA >gi|27735136|ref|NM_173512.1| Homo sapiens solute carrier family 38, member 11 (SLC38A11), mRNA (SEQ ID NO: 40) AGAAACATCCTGCAGCATCTCCGTCTCCGGAGGAAAAATACATTTGTCTGGGCGAACTCCGGTGGAAAAGCGCCCCA GGCTGCCACAGCCTAGAGATCTTGGGGCTGCAGCCCTCGCGGCCTGCCGAGGGAGCAGGGGGCGCCCGTGGAACTGG CTCCCTGCAGCTCTGCGGCTACACGCGGACCTCGGCTGTGTGCGAGGTGGCGGAGGAGGCTGGCCGGGTGCGAATCC GTACCCAGCCCCAGCATCTTCCACCTGCTGAGGACCACCGCTCAGCCATGGGCTACCAGAGGCAGGAGCCTGTCATC CCGCCGCAGGATTGCCTTATTCAATGAAGCAAGCTGGGTTTCCTTTGGGAATATTGCTTTTATTCTGGGTTTCATAT GTTACAGACTTTTCCCTTGTTTTATTGATAAAAGGAGGGGCCCTCTCTGGAACAGATACCTACCAGTCTTTGGTCAA TAAAACTTTCGGCTTTCCAGGGTATCTGCTCCTCTCTGTTCTTCAGTTTTTGTATCCTTTTATAGTTGATCCTGAAA ACGTGTTTATCGGTCGCCACTTCATTATTGGACTTTCCACAGTTACCTTTACTCTGCCTTTATCCTTGTACCGAAAT ATAGCAAAGCTTGGAAAGGTCTCCCTCATCTCTACAGGTTTAACAACTCTGATTCTTGGAATTGTAATGGCAAGGGC AATTTCACTGGGTCCACACATACCAAAAACAGAAGACGCTTGGGTATTTGCAAAGCCCAATGCCATTCAAGCGGTCG GGGTTATGTCTTTTGCATTTATTTGCCACCATAACTCCTTCTTAGTTTACAGTTCTCTAGAAGAACCCACAGTAGCT AAGTGGTCCCGCCTTATCCATATGTCCATCGTGATTTCTGTATTTATCTGTATATTCTTTGCTACATGTGGATACTT GACATTTACTGGCTTCACCCAAGGGGACTTATTTGAAAATTACTGCAGAAATGATGACCTGGTAACATTTGGAAGAT TTTGTTATGGTGTCACTGTCATTTTGACATACCCTATGGAATGCTTTGTGACAAGAGAGGTAATTGCCAATGTGTTT TTTGGTGGGAATCTTTCATCGGTTTTCCACATTGTTGTAACAGTGATGGTCATCACTGTAGCCACGCTTGTGTCATT GCTGATTGATTGCCTCGGGATAGTTCTAGAACTCAATGGTGTGCTCTGTGCAACTCCCCTCATTTTTATCATTCCAT CAGCCTGTTATCTGAAACTGTCTGAAGAACCAAGGACACACTCCGATAAGATTATGTCTTGTGTCATGCTTCCCATT GGTGCTGTGGTGATGGTTTTTGGATTCGTCATGGCTATTACAAATACTCAAGACTGCACCCATGGGCAGGAAATGTT CTACTGCTTTCCTGACAATTTCTCTCTCACAAATACCTCAGAGTCTCATGTTCAGCAGACAACACAACTTTCTACTT TAAATATTAGTATCTTTCAATGAGTTGACTGCTTTAAAAATATGTATGTTTTCATAGACTTTAAAACACATAACATT TACGCTTGCTTTAGTCTGTATTTATGTTATATAAAATTATTATTTTGGCTTTTATCAAGACTTGGCTTTTATGAGTA GTGC >gi|56549672|ref|NM_001008485.1| Homo sapiens solute carrier family 41, member 3 (SLC41A3), transcript variant 1, mRNA (SEQ ID NO: 41) CCCGGGCCCCCGGCGGGGCTCTGCGCTGCCGGAGCTTGGGCGTCTGCTGCTGTCCCGGAGCGCCAAGTCGTCCGAGG TCCGGCCGCCCGGCCGGGGCGGGGCCAGGGAGGCCCGGCCTTCCCGCTTCCTGCCTGAGCCGCAGGCCCGCCCCTGC GTCCTCCGCCCGCCTCTTTCCCGCCGCCGCCTGGGAGGGGACCCGGGCTGCCAGGCGCCCAGCTGTGCCCAGATGGA TGGGACAGAGACCCGGCAGCGGAGGCTGGACAGCTGTGGCAAGCCAGGGGAGCTGGGGCTTCCTCACCCCCTCAGCA CAGGAGGACTCCCTGTAGCCTCAGAAGATGGAGCTCTCAGGGCCCCTGAGAGCCAAAGCGTGACCCCCAAGCCACTG GAGACTGAGCCTAGCAGGGAGACCGCCTGGTCCATAGGCCTTCAGGTGACCGTGCCCTTCATGTTTGCAGGCCTGGG ACTGTCCTGGGCCGGCATGCTTCTGGACTATTTCCAGCACTGGCCTGTGTTTGTGGAGGTGAAAGACCTTTTGACAT TGGTGCCGCCCCTGGTGGGCCTGAAGGGGAACCTGGAGATGACACTGGCATCCAGACTCTCCACAGCTGCCAACACT GGACAAATTGATGACCCCCAGGAGCAGCACAGAGTCATCAGCAGCAACCTGGCCCTCATCCAGGTGCAGGCCACTGT CGTGGGGCTCTTGGCTGCTGTGGCTGCGCTGCTGTTGGGCGTGGTGTCTCGAGAGGAAGTGGATGTCGCCAAGGTGG AGTTGCTGTGTGCCAGCAGTGTCCTCACTGCCTTCCTTGCAGCCTTTGCCCTGGGGGTGCTGATGGTCTGTATAGTG ATTGGTGCTCGAAAGCTCGGGGTCAACCCAGACAACATTGCCACGCCCATTGCAGCCAGCCTGGGAGACCTCATCAC ACTGTCCATTCTGGCTTTGGTTAGCAGCTTCTTCTACAGACACAAAGATAGTCGGTATCTGACGCCGCTGGTCTGCC TCAGCTTTGCGGCTCTGACCCCAGTGTGGGTCCTCATTGCCAAGCAGAGCCCACCCATCGTGAAGATCCTGAAGTTT GGCTGGTTCCCAATCATCCTGGCCATGGTCATCAGCAGTTTCGGAGGACTCATCTTGAGCAAAACCGTTTCTAAACA GCAGTACAAAGGCATGGCGATATTTACCCCCGTCATATGTGGTGTTGGTGGCAATCTGGTGGCCATTCAGACCAGCC GAATCTCAACCTACCTGCACATGTGGAGTGCACCTGGCGTCCTGCCCCTCCAGATGAAGAAATTCTGGCCCAACCCG TGTTCTACTTTCTGCACGTCAGAAATCAATTCCATGTCAGCTCGAGTCCTGCTCTTGCTGGTGGTCCCAGGCCATCT GATTTTCTTCTACATCATCTACCTGGTGGAGGGTCAGTCAGTCATAAACAGCCAGACCTTTGTGGTGCTCTACCTGC TGGCAGGCCTGATCCAGGTGACAATCCTGCTGTACCTCGCAGAAGTGATGGTTCGGCTGACTTGGCACCAGGCCCTG GATCCTGACAACCACTGCATCCCCTACCTTACAGGGCTGGGGGACCTGCTCGGTTCAAGCTCCGTGGGCCACACTGC TGCTGTGCCAAGAAGGTGTACAGCCTCCCCAGGATGGGGCCTCATACAACCCTTCATCTGCACTCAACATTTAATCG TGTCCTTGCTGTCTTTTTATTTTCCTTTTTGTTTGTTAGCAAAAACCTCTATTTAGATTTCAATAATCAGAGAAGTG TAAAATAAAACAGATTATATTGTACTTGAAAAAA >gi|148612886|ref|NM_025257.2| Homo sapiens solute carrier family 44, member 4 (SLC44A4), mRNA (SEQ ID NO: 42) AGGGCGGGGCGGGCAGCAGGTGAGACGCCAGGTCTCCAGGGCTCCAATCACTCCGGAGACTGAGCCATGGGGGGAAA GCAGCGGGACGAGGATGACGAGGCCTACGGGAAGCCAGTCAAATACGACCCCTCCTTTCGAGGCCCCATCAAGAACA GAAGCTGCACAGATGTCATCTGCTGCGTCCTCTTCCTGCTCTTCATTCTAGGTTACATCGTGGTGGGGATTGTGGCC TGGTTGTATGGAGACCCCCGGCAAGTCCTCTACCCCAGGAACTCTACTGGGGCCTACTGTGGCATGGGGGAGAACAA AGATAAGCCGTATCTCCTGTACTTCAACATCTTCAGCTGCATCCTGTCCAGCAACATCATCTCAGTTGCTGAGAACG GCCTACAGTGCCCCACACCCCAGGTGTGTGTGTCCTCCTGCCCGGAGGACCCATGGACTGTGGGAAAAAACGAGTTC TCACAGACTGTTGGGGAAGTCTTCTATACAAAAAACAGGAACTTTTGTCTGCCAGGGGTACCCTGGAATATGACGGT GATCACAAGCCTGCAACAGGAACTCTGCCCCAGTTTCCTCCTCCCCTCTGCTCCAGCTCTGGGGCGCTGCTTTCCAT GGACCAACGTTACTCCACCGGCGCTCCCAGGGATCACCAATGACACCACCATACAGCAGGGGATCAGCGGTCTTATT GACAGCCTCAATGCCCGAGACATCAGTGTTAAGATCTTTGAAGATTTTGCCCAGTCCTGGTATTGGATTCTTGTTGC CCTGGGGGTGGCTCTGGTCTTGAGCCTACTGTTTATCTTGCTTCTGCGCCTGGTGGCTGGGCCCCTGGTGCTGGTGC TGATCCTGGGAGTGCTGGGCGTGCTGGCATACGGCATCTACTACTGCTGGGAGGAGTACCGAGTGCTGCGGGACAAG GGCGCCTCCATCTCCCAGCTGGGTTTCACCACCAACCTCAGTGCCTACCAGAGCGTGCAGGAGACCTGGCTGGCCGC CCTGATCGTGTTGGCGGTGCTTGAAGCCATCCTGCTGCTGATGCTCATCTTCCTGCGGCAGCGGATTCGTATTGCCA TCGCCCTCCTGAAGGAGGCCAGCAAGGCTGTGGGACAGATGATGTCTACCATGTTCTACCCACTGGTCACCTTTGTC CTCCTCCTCATCTGCATTGCCTACTGGGCCATGACTGCTCTGTACCTGGCTACATCGGGGCAACCCCAGTATGTGCT CTGGGCATCCAACATCAGCTCCCCCGGCTGTGAGAAAGTGCCAATAAATACATCATGCAACCCCACGGCCCACCTTG TGAACTCCTCGTGCCCAGGGCTGATGTGCGTCTTCCAGGGCTACTCATCCAAAGGCCTAATCCAACGTTCTGTCTTC AATCTGCAAATCTATGGGGTCCTGGGGCTCTTCTGGACCCTTAACTGGGTACTGGCCCTGGGCCAATGCGTCCTCGC TGGAGCCTTTGCCTCCTTCTACTGGGCCTTCCACAAGCCCCAGGACATCCCTACCTTCCCCTTAATCTCTGCCTTCA TCCGCACACTCCGTTACCACACTGGGTCATTGGCATTTGGAGCCCTCATCCTGACCCTTGTGCAGATAGCCCGGGTC ATCTTGGAGTATATTGACCACAAGCTCAGAGGAGTGCAGAACCCTGTAGCCCGCTGCATCATGTGCTGTTTCAAGTG CTGCCTCTGGTGTCTGGAAAAATTTATCAAGTTCCTAAACCGCAATGCATACATCATGATCGCCATCTACGGGAAGA ATTTCTGTGTCTCAGCCAAAAATGCGTTCATGCTACTCATGCGAAACATTGTCAGGGTGGTCGTCCTGGACAAAGTC ACAGACCTGCTGCTGTTCTTTGGGAAGCTGCTGGTGGTCGGAGGCGTGGGGGTCCTGTCCTTCTTTTTTTTCTCCGG TCGCATCCCGGGGCTGGGTAAAGACTTTAAGAGCCCCCACCTCAACTATTACTGGCTGCCCATCATGACCTCCATCC TGGGGGCCTATGTCATCGCCAGCGGCTTCTTCAGCGTTTTCGGCATGTGTGTGGACACGCTCTTCCTCTGCTTCCTG GAAGACCTGGAGCGGAACAACGGCTCCCTGGACCGGCCCTACTACATGTCCAAGAGCCTTCTAAAGATTCTGGGCAA GAAGAACGAGGCGCCCCCGGACAACAAGAAGAGGAAGAAGTGACAGCTCCGGCCCTGATCCAGGACTGCACCCCACC CCCACCGTCCAGCCATCCAACCTCACTTCGCCTTACAGGTCTCCATTTTGTGGTAAAAAAAGGTTTTAGGCCAGGCG CCGTGGCTCACGCCTGTAATCCAACACTTTGAGAGGCTGAGGCGGGCGGATCACCTGAGTCAGGAGTTCGAGACCAG CCTGGCCAACATGGTGAAACCTCCGTCTCTATTAAAAATACAAAAATTAGCCGAGAGTGGTGGCATGCACCTGTCAT CCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCAGAGGTTGCAGTGAGCCGAGATCGCGC CACTGCACTCCAACCTGGGTGACAGACTCTGTCTCCAAAACAAAACAAACAAACAAAAAGATTTTATTAAAGATATT TTGTTAACTCAGTAAAAAAAAAAAA >gi|148536860|ref|NM_006933.4| Homo sapiens solute carrier family 5 (inositol transporters), member 3 (SLC5A3), mRNA (SEQ ID NO: 43) CGGACCGTGCTTTCGCCGCCTGGGAGCCGTCCGGCGCAGCAGTTTCTAGGTCCCCACTGTCCCCGCCGTCCCGCCCC TTCGCGTCCCGGGAACCGGCTGGCTTCCGAGCCGCACTCGCCGATCCTCCAGGCATGCCCCGCTACGAGCTGGCTTT AATCCTGAAAGCCATGCAGCGGGGTTGGTACAGTAGGCTTCACTAGACTTAGCTGCAACTCAGAATTTCTCCTCCAG CACCTGAGTAAATGCTGATGGTCTTGTGGAGAGTGGATTAAGAGTACGAGCTAAGTTCTCAATCCCAATTAAGAAGC GGAAAATTTAAACTGTCTTCTTCAAAGTTTATCACAACCACCACCATCAAGACAGCAAACCAAAGGACAAAGACTTT GACCCTGCTGTGTTGCTCTGTGTAGTCCAGTTCACGTATGGTTTACAGACTTGGCTGGGGTTACTAAAAATAAATAA AAAGTTGGACACTTCTGTCATTGGAGCGCTATTATTCACAAGTTACCAGAATGAGAGCTGTACTGGACACAGCAGAC ATTGCCATAGTGGCCCTGTATTTTATCCTGGTCATGTGCATTGGTTTTTTTGCCATGTGGAAATCTAATAGAAGCAC CGTGAGTGGATACTTCCTGGCGGGGCGCTCTATGACCTGGGTAACAATTGGTGCCTCTCTGTTTGTGAGCAATATTG GGAGTGAGCACTTCATTGGGCTGGCAGGATCTGGAGCTGCAAGTGGATTTGCAGTGGGCGCATGGGAATTCAATGCC TTACTGCTTTTACAACTTCTGGGATGGGTTTTCATCCCAATTTACATCCGGTCAGGGGTATATACCATGCCTGAATA CTTGTCCAAGCGATTTGGTGGCCATAGGATTCAGGTCTATTTTGCAGCCTTGTCTCTGATTCTCTATATTTTCACCA AGCTCTCGGTGGATCTGTATTCGGGTGCCCTTTTTATCCAGGAGTCTTTGGGTTGGAATCTTTATGTGTCTGTCATC CTGCTCATTGGCATGACTGCTTTGCTGACTGTCACCGGAGGCCTTGTTGCAGTGATCTACACAGACACTCTGCAGGC TCTGCTCATGATCATTGGGGCACTTACACTTATGATTATTAGCATAATGGAGATTGGCGGGTTTGAGGAAGTTAAGA GAAGGTACATGTTGGCCTCACCCGATGTCACTTCCATCTTATTGACATACAACCTTTCCAACACAAATTCTTGTAAT GTCTCCCCTAAGAAAGAAGCCCTGAAAATGCTGCGGAATCCAACAGATGAAGATGTTCCTTGGCCTGGATTCATTCT TGGGCAGACCCCAGCTTCAGTATGGTACTGGTGTGCTGACCAAGTCATCGTGCAGAGGGTCCTTGCAGCCAAAAACA TTGCTCATGCCAAAGGCTCTACTCTTATGGCTGGCTTCTTAAAGCTCCTGCCAATGTTTATCATAGTTGTCCCAGGA ATGATTTCCAGGATACTGTTTACTGATGATATAGCTTGCATCAACCCAGAGCACTGCATGCTGGTGTGTGGAAGCAG AGCTGGTTGCTCCAATATTGCTTACCCACGCCTGGTGATGAAGCTGGTTCCTGTGGGCCTTCGGGGTTTAATGATGG CAGTGATGATTGCAGCTCTGATGAGTGACTTAGACTCTATCTTTAACAGTGCCAGTACCATATTCACCCTCGATGTG TACAAACTTATCCGCAAGAGCGCAAGCTCCCGGGAGTTAATGATTGTGGGGAGGATATTTGTGGCATTTATGGTGGT GATCAGCATAGCATGGGTGCCAATCATCGTGGAGATGCAAGGAGGCCAGATGTACCTTTACATTCAGGAGGTAGCAG ATTACCTGACACCCCCAGTGGCAGCCTTGTTCCTGCTGGCAATTTTCTGGAAGCGCTGCAATGAACAAGGGGCTTTC TATGGTGGAATGGCTGGCTTTGTTCTTGGAGCAGTCCGTTTGATACTGGCCTTTGCCTACCGTGCCCCAGAATGTGA CCAACCTGATAATAGGCCGGGCTTCATCAAAGACATCCATTATATGTATGTGGCCACAGGATTGTTTTGGGTCACGG GACTCATTACTGTAATTGTGAGCCTTCTCACACCACCTCCCACAAAGGAACAGATTCGAACCACCACCTTTTGGTCT AAGAAGAACCTGGTGGTGAAGGAGAACTGCTCCCCAAAAGAGGAACCATACCAAATGCAAGAAAAGAGCATTCTGAG ATGCAGTGAGAATAATGAGACCATCAACCACATCATTCCCAACGGGAAATCTGAAGACAGCATTAAGGGCCTTCAGC CTGAAGATGTTAATCTGTTGGTAACCTGCAGAGAGGAGGGCAACCCAGTGGCATCCTTAGGTCATTCAGAGGCAGAA ACACCAGTTGACGCTTACTCCAATGGGCAAGCAGCTCTCATGGGTGAGAAAGAGAGAAAGAAAGAAACGGATGATGG AGGTCGGTACTGGAAGTTCATAGACTGGTTTTGTGGCTTTAAAAGTAAGAGCCTCAGCAAGAGGAGTCTCAGAGACC TGATGGAAGAGGAGGCTGTTTGTTTACAGATGCTAGAAGAGACTCGGCAAGTTAAAGTAATACTAAATATTGGACTT TTTGCTGTGTGTTCACTTGGAATTTTCATGTTTGTTTATTTCTCCTTATGAACTTAAGGATATGGTGAGACACTAAC TTAAGACAATACTGACTGGTCTTTGGGGAAAAAAGTTATGTAACTGTGCATCTCTCAGGCATTGTTTACGCTGTAGG TTTTAGCCAAATTTTACTTAGCAGAAAATCATCTAATTACAAGACTTTATTTTCCCAGAGATGGATTAAAGTAAATC TTCAACTTAAGTGAAGCCAAACCTAACAGACTGAATTGTGCAAATGTGGTTTTAAATTTTGCATACCAAAGTAAGAA GAGACCAATTATTCTCACAGAGCACTTAGAGCAGAATATATGTTAAGTTACCATGAATTAAGGTATACTGTCTGCAC TGCCAAGTCTTGGCAGACCTTACCCTGAAGTAGAAGATTTGCTCATTTCTAAAGTTTTTTTTCTGTCTCTGTAATCC CTCCTACCATTAAGAAAAACTTATTTCTTAGACATTGTACAATCAGTTATGTACTGAAAATCGAATGTGCTTGTGTG ATACTTGTTTCAGGACAAGTTCATTTGCCAGGTTCATTTTGTTAGCATGAGCCTACGGATTCTGATTTCCCAAAGAA AGAATGTTTTCCTGTAGGTATTTTTGTACCACCAGTATATGGAATGTTAGGGAAAAACTTTGTTCCAGTTCCTTTTT TTTTTTCTTTCTACTTTCAAGTTTAAGTGAACCATACTGAAATGACCAACAAGTCTGCCTGTAAAGTTACATGTCAT GATTGTGTTGTTAAATGATTATGGGGGAGAAAATGAAGTAAATGTTGCTGATGATCCCCATATTTATTGATCATATT AAGGTTGTTTATATAGTTTGGAAATGACCAGCCCCCTAAGCAGTGTTTGATTAACTTATGCTAATCAGATGATTACT CATATATTCTGCTAATTTTCTAGCTTTATTCTTGTTATTTGGAAAAATTATTAGCCAAATGCCTTCCTAGGTGGATC CAGTTGGAAGATATGTCCAGAAACCTGAAGAAAAATTGACGCTGCCTTTGTGTGCTGGATTGCTCTACTTGATTAGA TCATGATATATCAAGGTTGAATTTTTAGAGGGAAAATTTAATTCTGATATCTTATTGCATCCTTGATAAGTTTTTCC CTGATTTTTTTTTTCCTCAAAAGACTTTCCATCTGTACACAGCCTCTACATTTTTGTTGTAGTGACTTAGAGCATAA GGATGTTTCAGTGCAAACTGGCCGTCGGTAACAGAAAACTCAGTGCATACTTTGCTGTTGTTAGGTTGTCAATATAG TCTTTCTGTAGGATGGATAGCATGTTTGAGAGGTGCCAAACAAGAACTTTTGGGGTTAGTAGTGTGTCTTGTGGAGG GTATTACAGGACTGTGTAATTATAGGACTCTAACTTGACATGGCTTGGCACCCACTTGCAGCTAGTGGGTACAGGGT ACAAAAGATGTTAGAGAAAAGCTCTACAGATTACGTACTTCTGTGTCTTCGTATGCTCAACACTGTCCTTTGTCCTC CATGAAAGATGAAGGAAGCAAATTATGTATGTACTTTCTTTGACCTTCTTTAATCTCTGATACTTTTTAGATTGCAT GATTTTACTAGGCTTGTATTTAGGGAAATTACTTTCATAAATACTTTTGTAGATTTTGAATCAAAACTCAGTCTTTT TAATTTTTTTGTAGTCTATAAACTAGTTTCATTATGATGGACTTGATTAGTCCAAAGTTAATTTTAGAAATTGTCAG GTAGCATAGTGTCTTCCCATGATCAGGAGGCTTTCTGAAGGACTGAGTCTGTAAATGAAAAAATAATTTATGTATGA ATAGCATGTATTTCTGAAGAGCTTAGAGTGCCTTGTAGAATTTTTTTCTCAATTTTATTCTTGAGGTTTATAATTTG GGGGCCAAATAGATAGAGCTCATCATTTTCTTGTTTGGAAGTTGAGGCTGCGACATGTCCAAGGTTATGAAGTCTCT TTTGGGAAGAACAGAAACCAGGTCTCCAAATCTGGACTCATGGTTTGTTCAGATGTGTCTGGACAAATGGTTGTCAA TGTTTTGTCCTGTTTTTTCAAAGGAACTGTTCTTCCTTTGGGACAACCTTTTGGTGTTTGGGAAAGTAATAAGATCT TGGATTTTTCAAATTAACATTAAGTTGTAAGAACTAAAATTTTCTTTGAACCACATTACTGTGTAATTCACTGATAA TTGACATATTGGCTGGGCAGCCTATCTCTTCCATATCCAGCGTAAATGAATAGGAGGTGTTTGTGATTTTTTTTTTC TCCCTTTATTTAACATTGAGTCCTAGTAGTTTGGAGAATTAGGGTCCCTCTACCTTCTTTCTGCTCTTGTCTTAGTA AGATACATAAGGTACATCATCTTGTGTCTGTGTGTATATAGCAGTAGGTCAAGTTTAGAGTACTAAAGTCTGTAAAT AAGGAATGACTATTAGCATATTCATTAGAATTGTTTATTCTTGCCAGTATAAACATCATTTTATTTAGACTAAAGTC CCTGAAGCTTGTCTTTCTTATTGCTTCCCAGTAATAGATAATGTGCTCGAGTAAGTTTGTGAATTGCTGATTGCAAC TTAATTCAGGGACCAGTCTTCAATCTATATTTCATTAGAATGATTGTTCCTGGAATGATCATACATGGACTGTCTTA AGCTAGCAAAATGTTCATACTTTACACTGACTAAATGGGTCCTAAATGATGACATTGGTCTTTAGACATTAACATGT GTATATTTTTATATTAGCTCAAGCTAAGGTTCAGAATTGAAGCTTGATATTGACTAGAATAGCTAAAAGTCAAAATG AGGTGAGGACACTGGTCTTGGAAGGTAGAGAAAAATAAATGTCTTACCAGGTGTTAATGGTATCCCCAGTTCTTAGA CTTTTGTCTTCTCAGGCAATTTTCATCTCAAGATCTGATGAGAAGGGCATATTACATTGGTATGCAGGATGATTATT GCATATTTTGTGGGACCTCTAATTTCCCTGGTCATCTTTCAGAATATTCTGTTCTGCCACCCCCAGAGAGTAAACAC TTGAGCCGATTTCTTCTTCCCCAGCTATTCTTTCCTGGGGGTAATTATGCTTTGTCTTTAGATTAGAGAAGCATCAA GCAATAGCAATGGTGCTGTGTCCTTCGGCCTAAATTCAATAGATCTCATCTCCTAGGGCTTCCTTTTCACTTGGCTC AAAGGATCCATTGTATTTTGGCACAAAGAGCCTGGCCAGGGTCATGTAGCCATAGCTCTTAGGGATGATACCTCAAG AAATTAGCTGGGACCCATCACTCTGTGAAACTTCACATTTTAAGAACTGAGTTGAGGGGGTTGTTATGCACTTCTGT AACTTGAGGCTAAGCAAGGGGTTAACTCTTGTGAGAGCCAATAGAGTGTGTCTGTATTCGCAGTCCATGGCTCATTT TCTTTATAGTAGGCATATGGATCTTCCCCTCTGACTTTGAATATCATTTGGTGTGGCCTGTGGGTTATTTTCATTCT TTACCACCAAATAAAGCGGCTTATTAGCTACTCAGTTACTTGCTACTCAAAGGTTAGGTCTTCCCTGTTCCTGCTTG GCAGTGTTAAAGCTTACAGGGTTAACTTATGATGATTCTCCTGGCTCATTTTCATCAGAGGCATGATGACTGGAAAG GGATCACATGGGTCGTTGGTGGTGACACCTCACTGTTTCCTAGGTTTGGATAGAGAGATGTATACAAGACCTTTCCT GTTAAATTACGTGACTACAGAGACTTGCCAGGACAAAATTTTCCTAAGAAATCAGAAAAATGATTAAGTGAGATAAG TACCTGGGTGACACAGATATTAGCCCGTTGGTAAAAGACAACAAATATTAGCTTAAAATCTGCATATGTAGAATCAT TTTCATTAGATTTAGAGCTTGAAGCACCTTGGCTCTCAGCTACTTTAAACTCCTCCCCATATAAATCAGGGCACCAA TAAATAAGTTTCAGCTTTTTAAACCCTGGTTTGATGTTAAGCATTATAAAGTACGAAGTTTGTTACCACAGTAGAGA TAATTTAGTAGAAAAATGCTTTGAGGCTTCAGTATTTGTAAGATTTTGCATTAGCCAGATGCTAGGTTGTTGAAGGC ATTTCAGTGTTGATAATAGCCTGAGCAGACTTCTTTACAAATGGGATCTGTTTCTATATGTGTATATGCCCACTTAC CATTCAGAGAGACTGGTCTTTCTCTTTGTCTTCCTTCACATTGCTGTGTCAGTTCTACACCTAGTCTTTTCAGCACT TAGCAAATTCAAATTTTGATTTTTTTGTCAGCTTAGTTCACTTTAAGGCATATTGGCATGGTGTGTGAAAGTGATGT TTTGCCCCAGTATTGAGGACTTTTAGATCCAAATAATGACTCATTAAATATAATTATGTTTTAAGTATACTGAATTT CTGTTAGCTTAAAATGTTAATTCTCAGGAATGATTTTCTCACACTTTGTGTTGGCTAATAATAAAAGCACTGTTTTA TTCTCAAAACTCCTTTTTCAAAAATTAGGGAGAGAGCAGTAGTGATCATTTATGTGAGCCCCTTTGAAATGATGGTG TCAGAGTGCAGAGAAACAATGGAGTTTTGATGCCAAAAAGGTTTTTTTGCAGTAAAAGTAAAAATTTGGAATTAGTT GGCATATAGAGGAACCCTTTTGTACTGGAACGTATGAGGCTGGATTGTGAAAAGGTAATCTTTCGATTGCTAGACTT GGTTAACTTAGGGCTGCAAATCTTTTTCTTCTGTCAAGGTCACTTAATATGGAATGTTTTTGTCAGACTGTCCTTTG TTGGAATACTTTAGCTGTTCAGCTACTTTGACTCCTAGGAGAGAATTTAGTTAAGGTTCAAAGTAATTAACTGGCTT TGCCAGTGGTGAGTCCCACACCATTATTCACTTAGTAGTCATATAAATGTTTTTATTTAAACTTCTCTCTCTTCAAT GCTGAGAATAAGGCTTTAAATTACTGATTCACCTTTAAAGGAATGTTGTGAGAATTGATGTAATTTCTGTTTCTGTT TCCATCTAAACTTCTTTATAAAAAGAGGGATTAGTTTTTTTGTTTTGGGGTAAGCACCTAATTTATCCAGTAACCAA CAACCCTAACCATTGGCATATATAGTCTTTCACTCAGAAATAAACAAAAACTGTTTGGTATATCTGTATCATTGCTA ATCTTGTGCACTTTACTTTTTGGGCAGTACCATACATAGTCTGAGGCTATTGACTTAAACCAATAACTGTACTTTAT GTAATGACTCTTAAATTTGGTTACCTGGGTTCACAGCTTGCTTGAAGAGAAAGGATGCTAGAATAAAGTAAGCAGCT GAAGAGCGAGCAAATCAAGACAAAACACAGTGGTCTCAGATTTTTCGTAGTGTGGGAACAGTGGTTTTGCTCTATAC CACTGAAAAGCACTATAACATAATTGTTGTCCATGATACTGAAGCTTTTCCCCTCACTTCTAGGTTGTTTACATTCA GAGCTCTATCAATAAGAGGAATACATATTACAGTGAATTCGACAACCGCACAAGTTGGCAGTAGGTATCCCCAACCT AATTTATCTTGGTAAATTCACCCTGTTTCCTAGTGCTGCTGGATAAAAGAGTGTTTACTTTTTATTGCTCTTAGACA GAGTAGTCTAGATAAGTTTTCAATTTATCAACATAGCCTAGACTTCTGTAAGTGGAATGTTCATTAGTAACTCATCT TTTTGTTGTTATAATTGGAAACAGAAACGAGGCTTATTGCTATTGCAGAAATCCCAAACTGGCAAAGGCCAGTATAT ATGGTATTCCATAATATAACCAGCTTTTGAAATTTATGTGTTTGGATTAGTGCCTTCTGGTTACCAGTATTGACTCT GCTAGTTTGCACCTTTCCGTTCTTAACAGAAAATTTGTATTTGTTATTCCTCTTAAATTTTGTCGTAACTAGTGAAG GAAGTAAAAAAAAAAAAAAAACATGCATTACATTGACATACTTTATGTGCAGCCTTTATTTAGGTTCAGTGAAACCA GGTAGTTCTGTATTTGTGTTGTAGCCTAAATGTTGTTTCTTTTATATCCATTAAAAACTTAAAGTTACTTATGTTCT GTGATCTTAATTTTGTTGTGTTTCCATTGTAGGTTGATAGGTATATCGAGAACAGGTACGTGACAACAGTTTATATT CCATGATAGAAAGCTAAAGTCCATAGAAAGCACAAAATCGTGTTCACACATTAGTGTACCCACACATAGAAAGCACA AGACTAATAGTATTCTCTGTATCCCACAAGTGCCAGTCATAAAGGCCACCAGGTATTTGTCTCAGAGTTGCTATGAG CACTACAGTATTGATAAGCCCAAGACAATGCGGTATCTAAACTGGTCCTAATGGTAAGGGACCCAAAGGAATAATCT CAATAAGTTTGTACCACATTGATGGAGGGAGAGAATATAAATGTCAAGAATGCCAAAATTATATTTGGGGGTTACTA GCTAAAATGGGGTTTGAGGGCTTTTTACTGCAACTTGAAACTGGAGAAATAGGGACAGATGTCTAGGTTTTTGGTGG GTGGAACAGGTGACATATTTCTGTTTTAAGCTGTAGTGTGATTGGGGTTTTTTGTAAAAAATCTTAAATCTTTTAGG AAATATTACCTCTTAACAGTGCCCCCCCAAACATGCAGAAAGTCATACTTTAACAGGGCAAATACTACTTGTCTTTG ATTTTTTTTGTGTACGTTTGTATGTGAGAGATGAAGTTACCTTTATTTTTTTCCTATACTTGACTGTGCTTCATTTT AATAAAGGATAATTTGATCTGAGTGTTCTGAGCATCAGACTAATTCTGAAGCATATTTGCTAGAGGAGCTACTTTGC TTTTCACAATGGGGTGGAGAGGATTCTTTCACTTGTCCCATTAACCCTCTTCTAGTCTAGATGAGATGAAATCTGTT AATGTGTGTGTAGAAGAAAACGTATGTTCTTCTACTCAGCATTGCCCTTTTCCACCTCCTCACTTCACCTCCGAGTA GCTTGTTTATCAAGAATGAATGAATGTCTTTGTCTTAAATTTTGCCCATGTGTTAAAAGATGTAATTCTCAGAATGG GAGAGAAATGACTACCTTTGTTCCTACTCTTTTATATAATTATCCTTTTAGGGAAAGACTTGGTCAACTCTAATATA TCTAGAAGGAAGACTATATCTGGTGTAGACTAATATGAGATGTTTTAGAAGAGTTAACCTGAACACTTTGAGGGAGA GATTATTCTTGCCAGCAAAAAGCTAGCCAGGAATGAGCCTACCACATTATTTGAGAATATCAAACCTCAGGCCTGGG GGGATGAGGGGAAGAAGATTACCAGAAGTGCAGGAAAGAGAAGTTTGAGGAACACCCTTGGCTTAGCAACATGTGAT AATGCAAAGCTGTTATAACCTGTTAATCCTACGTACTATGTGTTCTGTACCTTTACATGTTTTTAAATTTAAGATAG TTTGTAAGAACTGTACAAAAAAATGCTTCTGGAGATTTCTTTGGCAGAAATGCCTTTCATCTATAATTTCATGGAGA ACTGCTTTAATTAGCCTAGGTGAAAAGTAGTCCTAGCAGTGTAAATATGTATAATTAGAGTTTTCTAATTTCACTGT GAGATCTCTAACTTTTGAGTGGCAAACAGATCAAGTCTTTTGCTCATAGACTTTTCTGTGGGGTTATTAAAATGCAA AAGCTTTATTTTTTTTAATAATGCCATACTCCATTAGTGTCAGATGATGGTATGGAATTTGTTCCCTTGCTTTCCCC CACTGTTACTGCTTCAGTTTATAGATTGCCAGCAGAGTTCAGAAATAGAGCAGGGATTTACCCGTTCTTTGCTTGGA CATCCCATTTTCTTTTGTCCAGACCCATGTTGGCAATCATGTATGAACTGTGTTATACTTCTCAGTGCTTTCTTTTT TCTTTTTGATAAGATGGATATCAAAAATAGTTGCTGTGCAAAAGTTAGTAGTCTTCTTCAAGAAGAAAACCAATTCT TTTTCTAATAATATCCTGTGAAATTGCTTCATTCATTCATTTATTTTTAAGCCAAATGTCAGCAGAGTGCTGCTGCT TTTATCTAGTAATTTTGATATGTAAGTATTAATGCATTTTTAAAAGATGTCTACATTGAAACATGTTCTTCCCAGTG TCCTGCTTATGATGCTTTGTTCAGATTTTTTGTAAGAGACCAGTTAGTACACTGGGGGTGTATATTGTGTACATGTG TCATTTTAGTTAGGCATTGTAGGCCAAATGTGATTATAAATGAAGTTGATGAACATTAATTTTGTTATTAGTGAGTT TTTTGAATTGTAAATGGATTTCCAGTTTACCTTCTGTTGTCTACAGCTTTTTTAATTTTAAGGTTTGACTAATTGTA TCCATCTCATTGTACAGTGTTTTAGTTGCAAGCAGAAAGTAGAATTTGGTATAAAGCAGGTTATTTCTATATTGAAA GGAGTACAGTTGAAATTGTAGATTTAAGATTGTTAAAATCATGACAATTCTAACTTGTCTATTCTAACCTATTGTGT ACAATCTGATTTTTTAAAATTGTAAACATGTATGATCTTGGTTTCATGTGTTTTTGAAAGTGTTATTGTTTAAAAAA TGAAAAAAGCATATCTGCTAAAGAGCTGTCAGTTTTCATTACTGACTCTGTAAAATACACTGTTCTTTGTGTACTGT GTGTTATTTTGCCAGCTGCTGCATTAGCCTTCAAAAGTATTTGGAAACTTAAGATGAACTACATTTCTTGCAAAGTA CATTCCTTTCTGTGGTATTTTGTCCTGTAACTGAAGTATAGTAATTATTTTATGGAAATGTTAGCAATTCTGTACCA ACTTTGAATAAAATGAAAAATTTATAAAA >gi|115529447|ref|NM_021097.2| Homo sapiens solute carrier family 8 (sodium/calcium exchanger), member 1 (SLC8A1), transcript variant A, mRNA (SEQ ID NO: 44) TAGGTTGTGACAGTTGGAAGTGTCATGTACAACATGCGGCGATTAAGTCTTTCACCCACCTTTTCAATGGGATTTCA TCTGTTAGTTACTGTGAGTCTCTTATTTTCCCATGTGGACCATGTAATTGCTGAGACAGAAATGGAAGGAGAAGGAA ATGAAACTGGTGAATGTACTGGATCATATTACTGTAAGAAAGGGGTGATTTTGCCCATTTGGGAACCCCAAGACCCT TCTTTTGGGGACAAAATTGCTAGAGCTACTGTGTATTTTGTGGCCATGGTCTACATGTTTCTTGGAGTCTCTATCAT AGCTGATCGGTTCATGTCCTCTATAGAAGTCATCACATCTCAAGAAAAAGAAATAACCATAAAGAAACCCAATGGAG AGACCACCAAGACAACTGTGAGGATCTGGAATGAAACAGTTTCTAACCTGACCTTGATGGCCCTGGGATCTTCTGCT CCTGAGATTCTCCTTTCAGTAATTGAAGTGTGTGGCCATAACTTCACTGCAGGAGACCTCGGTCCTAGCACCATCGT GGGAAGTGCTGCATTCAATATGTTCATCATTATTGCACTCTGTGTTTATGTGGTGCCTGACGGAGAGACAAGGAAGA TTAAGCATTTGCGTGTCTTCTTTGTGACAGCAGCCTGGAGCATCTTTGCCTACACCTGGCTTTACATTATTTTGTCT GTCATATCTCCTGGTGTTGTGGAGGTCTGGGAAGGTTTGCTTACTTTCTTCTTCTTTCCCATCTGTGTTGTGTTCGC TTGGGTAGCGGATAGGAGACTTCTGTTTTACAAGTATGTCTACAAGAGGTATCGAGCTGGCAAGCAGAGGGGGATGA TTATTGAACATGAAGGAGACAGGCCATCTTCTAAGACTGAAATTGAAATGGACGGGAAAGTGGTCAATTCTCATGTT GAAAATTTCTTAGATGGTGCTCTGGTTCTGGAGGTGGATGAGAGGGACCAAGATGATGAAGAAGCTAGGCGAGAAAT GGCTAGGATTCTGAAGGAACTTAAGCAGAAGCATCCAGATAAAGAAATAGAGCAATTAATAGAATTAGCTAACTACC AAGTCCTAAGTCAGCAGCAAAAAAGTAGAGCATTTTATCGCATTCAAGCTACTCGCCTCATGACTGGAGCTGGCAAC ATTTTAAAGAGGCATGCAGCTGACCAAGCAAGGAAGGCTGTCAGCATGCACGAGGTCAACACTGAAGTGACTGAAAA TGACCCTGTTAGTAAGATCTTCTTTGAACAAGGGACATATCAGTGTCTGGAGAACTGTGGTACTGTGGCCCTTACCA TTATCCGCAGAGGTGGTGATTTGACTAACACTGTGTTTGTTGACTTCAGAACAGAGGATGGCACAGCAAATGCTGGG TCTGATTATGAATTTACTGAAGGAACTGTGGTGTTTAAGCCTGGTGATACCCAGAAGGAAATCAGAGTGGGTATCAT AGATGATGATATCTTTGAGGAGGATGAAAATTTCCTTGTGCATCTCAGCAATGTCAAAGTATCTTCTGAAGCTTCAG AAGATGGCATACTGGAAGCCAATCATGTTTCTACACTTGCTTGCCTCGGATCTCCCTCCACTGCCACTGTAACTATT TTTGATGATGACCACGCAGGCATTTTTACTTTTGAGGAACCTGTGACTCATGTGAGTGAGAGCATTGGCATCATGGA GGTGAAAGTATTGAGAACATCTGGAGCTCGAGGAAATGTTATCGTTCCATATAAAACCATCGAAGGGACTGCCAGAG GTGGAGGGGAGGATTTTGAGGACACTTGTGGAGAGCTCGAATTCCAGAATGATGAAATTGTCAAAACAATATCAGTC AAGGTAATTGATGATGAGGAGTATGAGAAAAACAAGACCTTCTTCCTTGAGATTGGAGAGCCCCGCCTGGTGGAGAT GAGTGAGAAGAAAGCCCTGTTATTGAATGAGCTTGGTGGCTTCACAATAACAGGAAAATACCTGTTTGGCCAACCTG TCTTCAGGAAGGTTCATGCTAGAGAACATCCGATTCTCTCTACTGTAATCACCATTGCAGACGAATATGATGACAAG CAGCCACTGACCAGCAAAGAGGAAGAGGAGAGGCGCATTGCAGAAATGGGGCGCCCCATCCTGGGAGAGCACACCAA GTTGGAAGTGATCATTGAAGAATCCTATGAATTCAAGAGTACTGTGGACAAACTCATTAAGAAGACAAACCTGGCCC TTGTGGTTGGGACTAACAGCTGGAGAGAACAGTTCATTGAAGCTATCACTGTCAGTGCTGGGGAAGATGATGACGAC GATGAATGTGGGGAAGAGAAGCTGCCCTCCTGTTTCGATTACGTGATGCACTTTCTGACTGTGTTCTGGAAGGTCCT GTTTGCCTTCGTCCCCCCTACTGAATACTGGAATGGCTGGGCGTGTTTCATTGTCTCCATCCTCATGATTGGCCTAC TGACAGCTTTCATTGGAGACCTGGCTTCCCACTTTGGCTGCACCATTGGCCTGAAAGATTCTGTGACTGCAGTCGTG TTCGTCGCACTTGGAACATCAGTGCCAGACACATTTGCCAGCAAAGTGGCAGCCACCCAGGACCAGTATGCAGACGC CTCCATAGGTAACGTCACGGGCAGCAACGCGGTGAATGTCTTCCTGGGAATCGGTGTGGCCTGGTCCATCGCTGCCA TCTACCACGCAGCCAATGGGGAACAGTTCAAAGTGTCCCCTGGCACACTAGCTTTCTCTGTCACTCTCTTCACCATT TTTGCTTTCATCAATGTGGGGGTGCTGCTGTATCGGCGGAGGCCAGAAATCGGAGGTGAGCTGGGTGGGCCCCGGAC TGCCAAGCTCCTCACATCCTGCCTCTTTGTGCTCCTATGGCTCTTGTACATTTTCTTCTCCTCCCTGGAGGCCTACT GCCACATAAAAGGCTTCTAAAGGAACTATCAGATATAGTAAATTTATATATATACATATATATACATAAAAATTATG TATAATGGACAGAGGAAACTGACATTTGTCATGTTCACTTACCTGCTGATGGAATCCAGCTTCAAGAGCATACTCTG TACTAGGGCCGAAGTAAAAAACCATCACCTCCCATTCCCAGGGGCATCATCATGTTCAACAAGGCATGGAGGCAGGG CCATCTTTGCAGCTCAGTCTAGAAGGGCTGCACTCTCTCCAGGTTGATAAATCCTTAAGGCTTTGATTTGTTTTGTT TTTGGTTTTGTTTTCAGTGGAGCTGGGGAGGTAGTTAATGTTTGGCTTTATTTTTGTTATTTTGTTTTGTTTTGTTT TTTTGGGAGAGTCAGGGTTGTTGCTTTTCTTTGTGGAAAGTGAAACCATCCAAATGTAAATGGGTTTTGGTAAAAAT TTAAATCATTAGTATTCCCCCTCACCTCCCCCAATCACTTTAAAACTTATTTTGGATTAAGAAAAAATCTGGGCATG GAAGAAGAAAGAAGCATGTCTTCATCGTATTACCAAAGTTCATGCTTATCTCCGGAATGTGAGTGGAGGTGAAGCTG CCTCCAAGAAGAAGCATAAAAGTGGAATGGAGCCAGGAAATCCGATGGTTCTAGAAATAGTCTGATATTTAAACATG TGATACCTGGCAGTCTCGTTTAACAGGTACAAGGAAAACGTGCCTAGATTCCCAGGAACGTGCAAAATCCTTTCTTT CTTATCTCTTTAGCTCTGGACTGTGATTGGCAAGGTCCTTCTTCCAGCATTCAGCCCAGCTAAGCCCCCAGGTGCCC CATCCCAACCCTGTTCCTCCTGTCCACCTGCCATCCCCTATGCAAACAGTAAGAATAACCCCATTCAAAAAGCACAT CATCGTTTTCCATTTGCATTAACATGTGTCTCAGTCCCATGTTGCCGTTGCTTGGGATTGTCTGTCAGTTTTATTTT CAAAGGCATCCATGGCTTGCACAATCCTGTTCCAGTCATGACTGAACATTTGCTCCTTCTTCATGTGCCGTTCGGAA ATGTTGTTGTGATACCTGTTACACAGTGCATGGTGAAAAACAAATAAAACAAAACAAAGAGTATCTGTATATAGTAG AGTATAGTACATACTGTTCTCCCATTTGGCAATGTTGATTGGACATTGAAGACATAAGTGAGTTTTCTTTTCACCTG AGTTGTTACTTTTGTGCTGTTATTGAGTTTGATTAATTACTAGGGATAAAAGGAGAAAATGGATTATTGTTCACGGT TCTGCACATTCATTTCTAAGAAGCAATAACTGTCATGTGGGGAGAAGTTAAAGCTATTGAGAGGATAGCAGGCAAAC TACAAAGATCTTCATGGAAAATTAGCCATGTGGAACACATCAGAGGCCTCTAAAAATCACCCATTAATTCAGGAAGG CCAAGGAGAAAGGCCTTATAGAGACGTTGATATGTTGGATGTGCCTAGGCTTTCAGAGCCACCCTTTCCACAACACC CCTCCCTGCAAAGTATTTATTTCACATCTGCACTGTCTGGCACAGATGGTAGATAGTGCTGGTTTGTTCATTTTATT TTTTTACTTAAAAGGCTATTTTGAGCCCTGTTTCTTTCACTGTCCAGTCTAGTCCTCTTTGATTATATCAGTAGTTG CTGAGTAAGAAAGAAGCCAGGGTGACCAACGGGCCTTTAAAAGTGTTGTCTCCTCTACTTATGCTGAAAGAGAAGGC AATTAAATAAGACTAGTACCTCCCAGGAGGATTGGACTGGGATATTTTTAACCCTTTAAAAAGAATAGCTGTTTCTA TGTTAAAATACCAAAGAACATGGATAAACCCAACATTCCAAAGTAGTGAGTCCACTAATGAGAAAAATAATAGAATG ACTTTGGTCACCTCTCGGAGACTTCTGTGTCTATAAGGAATCCCAGGCTGGAGACATTCCTAGCCCTCTGTATTGAT TCAAAAATACTTAATAAATTAAAGCTGTTGAGACTTATTTTTTCTTCTGTCACTCAGTAACCATGATCCTTCCTCAT TTAATAAACATTTGGTGACTGAATGAGTAATTAAATGCTGGTTACCCACTTAATGTGCCAGGTAGTATGATACTTTC TGGGGACTAAGCCATGAACAAAACAGTCTAGATCCCTGCCCTCAGAAGGGTTACAGTTTATGTGATTACTATTTTCA TGAGTAAAAGTGAAGAAAGCCATATGGAAAGATTTTTATCTTGCAAGAAAAAACAATTATGAAACTCTTTTAACATA AACACACTGAAACTGTATCAAAGCAATTGTCCAAATTGTATTTATACCCAAGAATTTCTTTAACTAAGAGAGCATAA GGCATATGTTTGGAAAACCACCCTCTTTATCTTTGACCGACTTGCAGATAAATATATCTCTCCATTTTAAACCAAGA AGGGCAATCATGTTGGTGATCCAGATCACTGAGAAAGCCCAGTGTATCCCATCTTTTATCTTTGTTGGCAATGGAAC TTTTCTATGGCCCACACTTTACAATTCTTTGTCATTCTAACCCATCCTTCCCATCCTTATTTTTTTTTTTTTTGAGA ATTGCTAAATGGAAAGCTAGCCTAGAAGCACCAAGTAAATATATTCAAGGAATATAAGTTGTTTAAACATTAGAAAA ATTTTTGCACTCATTTTTTAGCTGTATTAGGAATGTCAATAATCCTGTAGCAAATTTTCACAGAGAACTTTAAGAAA TTCTTGCATTGGTCGATTTCAATTTGAAAGCTTTTTGGTTTGTTTGCTTTTTAAATTTTCATGTTCTAGGAAACTAT GATTCTGGTTGTTCAGGATTGTTATTATTATAGTTGTGTAAAATTATTTTATTTTGTGTGTATTGTGCACAGCTTGG GGGGGGGGCGGGAAATGCACTAATTGTGCTCTTCCTTATAAATGGTACATATTACTGACACAGACAAATAAAGTTTC TAATTGTTTCTGATTTAATCACTAGTGATACAGCATATTCTGTATGAAATGTTTTCTCCTTTCTCATTGTCATCTAC TTCATTTTTTGTTTTCATGTTTTGAAGAAATAAAAACCAAAATGGTA >gi|38569454|ref|NM_003048.3| Homo sapiens solute carrier family 9 (sodium/hydrogen exchanger), member 2 (SLC9A2), mRNA (SEQ ID NO: 45) CCGGTGCCGCAGCAGCGGCGGGTGGCTGTCGCTGCCCTGCCCTGCACGGGGCAGGGCGGAGCGGGCTGAGCAGCCCG GGCGCGATGCGTTGAGCGCTCGGAGGGCCAACCGCCGGTCCCCTTGGCGGCAACCGGCGGCACCCATGGAACCACTG GGCAACTGGAGGAGCCTGCGGGCGCCACTGCCTCCGATGCTGTTGCTGCTGCTCCTGCAGGTGGCGGGGCCCGTGGG CGCCCTGGCGGAGACCTTGCTGAACGCGCCGAGGGCCATGGGCACCAGTTCCAGCCCGCCTAGCCCTGCGAGCGTGG TGGCTCCCGGAACGACGCTGTTCGAGGAGAGCCGGCTGCCTGTGTTTACGCTGGATTACCCCCACGTGCAGATCCCC TTCGAGATCACCCTTTGGATCCTGCTGGCCTCCCTGGCCAAGATTGGCTTCCATCTGTATCACAAGTTGCCCACAAT AGTGCCTGAGAGCTGCCTTCTTATAATGGTTGGACTTCTACTAGGTGGGATTATTTTTGGTGTTGATGAGAAGTCTC CCCCTGCAATGAAGACTGATGTATTTTTCTTGTACCTCCTCCCACCCATCGTGCTGGATGCCGGCTATTTCATGCCC ACTCGCCCATTCTTTGAGAACATTGGCACGATTTTCTGGTATGCTGTGGTAGGGACACTTTGGAATTCCATTGGCAT TGGGGTGTCTTTGTTTGGTATCTGCCAGATCGAAGCATTCGGCCTCAGCGACATCACTTTGCTCCAGAACCTGCTCT TTGGCAGCTTAATCTCAGCTGTCGATCCTGTGGCTGTGCTTGCTGTCTTTGAGAACATTCACGTCAATGAGCAGCTC TACATCCTGGTCTTTGGAGAGTCCCTGCTGAATGATGCAGTAACAGTGGTCCTGTACAACTTGTTCAAGTCGTTTTG CCAGATGAAAACCATTGAGACCATTGATGTGTTTGCAGGAATCGCCAACTTCTTTGTTGTGGGAATCGGTGGGGTGC TGATTGGCATCTTCTTGGGCTTTATAGCGGCATTTACTACTCGATTCACCCATAATATCCGAGTGATCGAGCCACTG TTTGTTTTCCTGTACAGTTATTTGTCCTACATCACAGCTGAAATGTTTCACCTCTCAGGCATCATGGCAATCACTGC TTGTGCAATGACTATGAATAAGTACGTAGAAGAAAATGTATCTCAGAAATCCTACACGACCATCAAGTACTTCATGA AGATGCTGAGCAGTGTCAGCGAAACCTTGATCTTCATCTTCATGGGTGTGTCTACCGTGGGCAAGAACCACGAGTGG AACTGGGCCTTCGTCTGCTTCACCCTGGCCTTCTGCCTCATGTGGCGAGCCCTGGGTGTTTTTGTCCTGACTCAGGT CATTAATAGGTTCCGGACCATTCCCCTGACCTTTAAGGACCAGTTCATCATTGCCTATGGAGGACTTCGAGGTGCCA TCTGTTTTGCGTTAGTGTTTCTCCTTCCTGCTGCTGTGTTTCCTCGGAAAAAATTGTTTATTACGGCTGCCATTGTT GTCATATTCTTTACTGTCTTCATTCTGGGAATAACTATTCGACCACTGGTGGAGTTTCTTGATGTCAAGAGGTCCAA TAAGAAACAACAAGCTGTCAGTGAAGAAATCTATTGTCGGTTGTTTGATCATGTGAAGACTGGAATTGAAGATGTTT GTGGACATTGGGGTCACAACTTTTGGAGAGACAAGTTTAAGAAGTTTGATGATAAATATCTGCGGAAGCTTTTGATT CGGGAAAACCAACCAAAGTCAAGTATTGTATCTTTATATAAAAAGCTTGAAATAAAACATGCCATTGAGATGGCAGA GACTGGGATGATAAGTACTGTCCCTACATTTGCATCTCTAAATGATTGTCGTGAAGAAAAAATAAGGAAGGTCACGT CCAGTGAAACTGATGAAATTCGAGAACTCTTATCAAGAAATCTCTATCAAATCCGTCAGCGAACTTTATCCTACAAC AGACACAGTCTGACAGCCGACACAAGTGAGAGACAAGCCAAGGAGATTCTGATTCGCCGGCGACACAGTTTGCGAGA AAGCATTAGGAAGGACAGCAGCTTGAATCGAGAACACAGGGCTTCCACTTCAACCTCCCGATATTTATCCTTACCTA AAAATACGAAGCTTCCAGAAAAGCTACAAAAGAGGAGGACTATTTCTATTGCAGATGGCAATAGCAGCGACTCAGAC GCAGATGCCGGGACCACCGTGCTCAATTTGCAGCCCAGAGCCAGGCGCTTCTTGCCAGAACAGTTCTCCAAGAAATC CCCCCAGTCCTATAAAATGGAATGGAAGAATGAGGTAGATGTTGATTCTGGCCGAGATATGCCCAGCACCCCCCCAA CACCCCACAGCAGAGAAAAGGGCACCCAGACGTCAGGCTTACTACAGCAGCCCCTTCTCTCTAAAGACCAGTCTGGC TCAGAGAGGGAAGACAGTTTGACTGAAGGCATCCCGCCCAAGCCGCCACCACGGCTGGTCTGGAGGGCATCGGAACC TGGAAGCCGGAAAGCCCGATTTGGGAGTGAGAAGCCTTAAGAGAAGCAGCGAAAGCAGATCTGAGTGTCTGACCCAG GACAGCTGTGGTTTGTCACTCTGAAACCTGATGCAACAGTGGAATCCATGTAAAACTCTCTGTGCATCTAAATACTT CTGGAGGGCGACAGATTCATGCCACGGATAAATGAGGCAAATCCGAAGAAAAGGAAAATCGAATAAAAAATAGTCCC ACAAAATACCTTTTGTGACTAATGGGTAGCAATCGTATTATTTGCTGGCCTGAAGAGAAAAAATGGTAATGTGTGCC TTTATTGAACTTGAATGACAGAACTTGAAATTTTTAACACATCCTTCTTGGTGAAGATTTTAATATATTACTTATAT GCTTCAAATTTTATTTATGAAAAAATATGTATATCTGTAATCAGTTGTTAAGTGAATGGCACTAAAAGTATCGAGAA CAGCTTTCTTTCCCAGGGGTGAAGGATGGCGCTCGGGGGTGACTCCTAAGCTCAGCGTGGAAGCTTTTCCCTGTCCT GACCCGATGGAGCAGCCGGTAAGTGAAGAGCACAGCTGGAAGCAGAGACACCTTATGACTCAAACTGGGCAAACAAT CGGAACGTCATGCAGAAGGAATGGCCTGACTCCTGCAGTGCAGATTGGAGGCCCCAGAACTCCTATGAACTACTGAG AGTCTACTGGTTTTTAACTTGTTCCTCTGTCTACTGTGTGTTTGGGGGTGACATCTAAATTCCATTTCTTCTTCTTG TTTAAATGGTGCAGAGAGAAAGGTTGCCCAGACATCCACCAGCTTACTGTGTTGACAGATTTGGGAGCAGCTTTTGA TGAAGTTCCACCCATGAGGGTCCATGTGGCAAGTAGGGCCACAGGGCAGCACCTGGTTACAACTTGCTGGTGGGTTT TATGTTGTGCAATACTAGGAGGAGGAGGCAGGTGATCTATGCTGATCTATGATCACCTGCTTCAGTAGAATTTTTCT GTAGAGTGTTGTTTGAATTTTGAGCCTCCAGGTTAGAGGCTCCAAGCAGACAAAGAAGAAAGTTTGTAGACACAATA TTCTAACATTGCACAAGTTGATGAGATATCAAGTTTTGAATATTATTCAGGAAGCACTTTGGAGAATGTGGGAGTCC TACTGTTTTGCACTAGTCTGTAATTTGTTACCTCTCCCCATTCGATAATATAGTAACTCAGAATTTTCATATAAAAT TGAATTCTACTCATTAGAGTACTTTTTAAAAGTACAGCAGAAAGAAAAGAAGTGGAACATAAGCATTCAAGATTAAT ATTTGATTCTCTATCTCTTAACTGTAGATTTTATTGGCCTGTTTTTTTTTTCTAAATAATTCTTTAAAACTTGACTG GAACATGCCTCTGCATTTCTGAGTGTAGAAATTAAATGAAGCCACTCACAGTCCTTTGATTTCCCACTGAAGATACC CCAAAGGATGCAAGTGCCTACAGTATTATCAGGAGGAGAACATGAAAATATTAAGACAAAAATCCTCAGCAGTTGTT CTCCACCCCTTCTCCACCTCCACCAGCAAGGAGAAGTCAATCTACACTTTTTTCTCATGTTCTAAAGTCTTAGAATA CTGCTGGATTGTTGAGCATGAGACAGAGCAAAGGTTAGATACACAAGGTACAAGTTCATAGGAGCACAATTCCTTGA TTCAGGGAAAGTAGCACAGAATGCAATTTGAAAACTACAGGCTTAGGACTCTGTGCCAAAAATCTCTATTTTAAATG AAAATATTTATATAAAAATACATTTATTCTGCTTAACACAAATTAAAACTGACATAAAATTTTATGATAATAACATG ATTCAAGAAATGTGATGTAGATTTTTGAGAATGCCAAAAATCAGGTTTCAGAAAAGCTACAGTATGAAATCTGAAAA GCAACAGAAATTGAAAGTGACCTTAAAGAATAAATTTCCTAATTTTTCCCAGTTTCCTATGTTTATAACTATTATAA AGAGTTTAACTTTCTGGAACTGAAGGAGAAAACATGAAAATGTTTATATTGCTTCTTGTTAAGCAGGTAGACCAAAT TCCGCTTTCAGTAATTCATCCATACAGAATTTGGATGACTATGTATAAAGGAAAACTTAAATCTTAATTATTATCAG TTTAAATTTTTTTTGTTTGTTGAATGACAAAGGCAATAAAAATAAATTTGACTTTAGCTTTTTTTCTATACTTTCCT CTTTTTGTAATTCTTAAATTCTAGTCACTAGTCATTATGAGAGTATTGACTAAATATTTTCACAATCTAAATATTGT CACAATCTAAATTTCTGTAGTACAGAGAGCCGTAGCCCTTTGTAAAGGCTTTCGTTCGTCCAAACAACACTTGATCC AACCAAAGTTCCAATGTGACTGTGGATCTTTGATAGGTCTTTGGTGTTGGTTGTAACAAAATTTGATTTGAACTACC TATAAATGAAAAGTCGGGGTTTATTACTTTATATGTAATGCTGAGAGGAGACTGTTGGGAACAGTTATGTCAATGAG CAAACTAGAAATTGGCTTCAAAGTCTGATACTTTTAAAAGCATGTGTTTTGTGTATATGCTCACAAAATGTCTGTGA AGAGATTTCTTTCAGCTTTTGCTCAGCTTTATGGTGGGGTGTACTGTTTTATCTGGGCGGTGAGGGTATTGATTTAC ATAAAAACTGTAGACAAACACAGTACGAGTCTCAGCACGTTTTGCATTTATTGTACTGCCCAAATTGTTTTTATGTT AAAAGTCACGTTTCATAATCTGCAATATTTTTGTCAAAGTGCACACTGTACTTTCTTCTTAAAAACGTGATTAAAGA GATCACTTTGTCCGGATGAAGCAGCTGTTGGCATTATCCGCTGAGGCTTGAAAAAA > >gi|141803413|ref|NM_023003.2| Homo sapiens transmembrane 6 superfamily member 1 (TM6SF1), mRNA (SEQ ID NO: 46) GGGGCGGGGCGCCCAGCGGGATGCGGTGAAGGGCGAGCGGCGCGGCGGCTGCGATGAGTGCCTCTGCGGCCACCGGG GTCTTCGTGCTGTCCCTCTCGGCCATCCCGGTCACCTATGTCTTCAACCACCTGGCGGCCCAGCATGATTCCTGGAC TATTGTAGGGGTTGCTGCCCTCATCCTGTTCCTGGTAGCACTGCTGGCTCGTGTCCTCGTCAAAAGAAAACCACCCC GGGACCCACTGTTCTATGTGTATGCAGTTTTTGGATTTACCAGCGTGGTGAACCTCATCATAGGACTGGAGCAAGAT GGAATCATTGACGGGTTCATGACACACTACTTGAGAGAGGGTGAACCGTATCTGAACACCGCATATGGGCACATGAT CTGCTACTGGGATGGCTCTGCTCATTATCTGATGTACCTGGTGATGGTGGCAGCCATAGCATGGGAGGAAACTTATA GAACCATTGGCCTATATTGGGTTGGATCTATTATTATGAGTGTTGTTGTTTTTGTGCCAGGAAACATTGTAGGGAAG TATGGAACACGAATTTGCCCTGCTTTTTTCTTAAGCATACCATATACTTGTCTTCCTGTCTGGGCTGGTTTCAGAAT CTATAATCAGCCATCAGAAAATTATAATTACCCCTCAAAGGTTATTCAAGAAGCCCAAGCGAAAGACCTGCTGAGAA GACCATTTGATTTAATGTTGGTTGTGTGTCTCCTCCTGGCAACTGGATTTTGCCTGTTCAGAGGTTTGATTGCTTTG GATTGCCCATCTGAGCTCTGCCGATTATATACGCAATTTCAAGAGCCCTATCTAAAGGATCCTGCTGCTTATCCTAA AATTCAGATGCTGGCATATATGTTCTATTCTGTTCCTTACTTTGTGACTGCACTGTATGGCTTAGTGGTTCCTGGAT GTTCCTGGATGCCTGACATCACATTGATACATGCTGGAGGTCTGGCTCAGGCTCAGTTTTCTCACATTGGTGCATCT CTTCATGCTAGAACTGCTTATGTCTACAGAGTCCCTGAAGAAGCAAAAATCCTTTTTTTAGCATTAAACATAGTATA TGGAGTTCTTCCTCAGCTCTTGGCCTATCGTTGTATCTACAAACCAGAGTTCTTCATAAAAACAAAGGCAGAAGAAA AAGTGGAATAAAAATATTACTTCATGTTCCTCCTTTCTAAATTACTAACTTTTGTTATACTGGTACTGATATTTTGT CCCATTTCACTCTCTTCTCATACGTGAGTACTTAAGAATATGTACATTCTTGCTCTGCACTGTATGTGTGAGCTATA TGGTATTGTGTAAATTTTTTTTGAAGGAAAATGGAAATTCTTGAGAAACAGTTTGTTTAAAGAAATATATTCAAAAT CATTTGTGAATAAACTTGATCATCCATCTCAAAAAAAAAAAAAAAAAAAAAAAA >gi|45387950|ref|NM_023943.1| Homo sapiens transmembrane protein 108 (TMEM108), mRNA (SEQ ID NO: 47) GGAGGGAGCCGGAGCGCTTCTCCCGAGTTGGTGATAGATTGGTGGTCATCCAACATGCAGAAATGAATGAGCAGTGA AAAGCAGCAGAGCCGATGGGTCATGAGGATGTAAGTGCGTTTGAAGGCTTCCACACCCTCTACTCCAGGACAGAATC ATGAATAAACTGGAGGATAAGCAGGACCAGATGATACCATGAAGAGAAGTTTACAGGCCCTCTATTGCCAACTGTTA AGTTTCCTGCTGATCTTGGCACTGACCGAAGCGCTGGCATTTGCCATCCAGGAACCATCTCCCAGGGAATCTCTTCA GGTCCTCCCTTCAGGCACTCCCCCGGGAACCATGGTGACAGCACCCCACAGCTCTACCAGACATACTTCTGTGGTGA TGCTGACCCCCAATCCCGATGGACCCCCCTCACAGGCTGCAGCTCCCATGGCAACACCGACACCCCGTGCAGAGGGG CACCCTCCTACGCACACCATCTCCACCATCGCTGCGACAGTAACCGCCCCCCATTCTGAAAGCTCCCTGTCCACAGG GCCCGCTCCAGCAGCCATGGCAACCACATCCTCCAAGCCAGAGGGCCGCCCTCGAGGGCAGGCTGCCCCCACCATCC TGCTGACAAAGCCACCGGGGGCCACCAGCCGCCCCACCACAGCGCCCCCCCGCACTACCACACGCAGGCCCCCCAGG CCCCCAGGCTCTTCCCGAAAAGGGGCTGGTAATTCATCACGCCCTGTCCCGCCTGCACCTGGTGGCCACTCCAGGAG TAAAGAAGGACAGCGAGGACGAAATCCAAGCTCCACACCTCTGGGGCAGAAGCGGCCCCTGGGGAAAATCTTTCAGA TCTACAAGGGCAACTTCACAGGGTCTGTGGAACCGGAGCCCTCTACCCTCACCCCCAGGACCCCACTCTGGGGCTAC TCCTCTTCACCACAGCCCCAGACAGTGGCTGCGACCACAGTGCCCAGCAATACCTCATGGGCACCCACCACCACCTC CCTGGGGCCTGCAAAGGACAAGCCAGGCCTTCGCAGAGCAGCCCAGGGGGGTGGTTCTACCTTCACCAGCCAAGGAG GGACACCAGATGCCACAGCAGCCTCAGGTGCCCCTGTCAGTCCACAAGCTGCCCCAGTGCCTTCTCAGCGCCCCCAC CACGGTGACCCACAGGATGGCCCCAGCCATAGTGACTCTTGGCTTACTGTTACCCCTGGCACCAGCAGACCTCTGTC TACCAGCTCTGGGGTCTTCACGGCTGCCACGGGGCCCACCCCAGCTGCCTTCGATACCAGTGTCTCAGCCCCTTCCC AGGGGATTCCTCAGGGAGCATCCACAACCCCACAAGCTCCAACCCATCCCTCCAGGGTCTCAGAAAGCACTATTTCT GGAGCCAAGGAGGAGACTGTGGCCACCCTCACCATGACCGACCGGGTGCCCAGTCCTCTCTCCACAGTGGTATCCAC AGCCACAGGCAATTTCCTCAACCGCCTGGTCCCCGCCGGGACCTGGAAGCCTGGGACAGCAGGGAACATCTCCCATG TGGCCGAGGGGGACAAACCGCAGCACAGAGCCACCATCTGCCTGAGCAAGATGGATATCGCCTGGGTGATCCTGGCC ATCAGCGTGCCCATCTCCTCCTGCTCTGTCCTGCTGACGGTGTGCTGCATGAAGAGGAAGAAGAAGACCGCCAACCC GGAGAACAACCTGAGCTACTGGAACAACACCATCACCATGGACTACTTCAACAGGCATGCTGTGGAGCTGCCCAGGG AGATCCAGTCCCTTGAAACCTCTGAGGACCAGCTCTCAGAGCCCCGCTCCCCAGCCAATGGCGACTATAGAGACACT GGGATGGTCCTTGTTAACCCCTTCTGTCAAGAAACACTGTTTGTGGGAAACGATCAAGTATCTGAGATCTAACTACA GCAGGCATCACTTTGCCATTCCGTATTTTTCGTCTCTAAATTATAAATATACAAATATATATATTATAAATATAACC TTTGTGTAACCCTGACTTAATGAGAAACATTTTCAGCTTTTTTTCCTATGAATTGTCAACATCTTTTTTACAAGTGT GGTTTAAAAAAAAAAAAACTTTACAGAATGATCTGTGGCTTTATAAAATAAAGGTATTTCTAAGCAAAAAAAAAAAA AAAAAA >gi|39725660|ref|NM_032927.2| Homo sapiens transmembrane protein 128 (TMEM128), mRNA (SEQ ID NO: 48) CCAAGATGGACTCCTCGCGGGCCCGGCAGCAGCTCCGGCGGCGATTCCTCCTCCTGCCGGACGCCGAGGCCCAGCTG GACCGCGAGGGTGACGCCGGGCCGGGTGAGGCGCGCACCAAGCCGCCCCGAGGTTCTCAGAGGCGAGGCGTCGGAAA ACGGCCGGCCTCCGGCAGCCCTGGCCCAGTCTGGAAGGACTGAGTTTCGGCTTTGCAAGTCGAATATTTAATGTCAG GGAAGATCCTTAGAATCGCGGAGTGCTGTGCATCGTCATTTCAGCTGCGCTTCAGAATTCTCTGGAGAGCTGATTTG ACACCTATTTGGAAATAGCGATTAAAATTAAAAATACCCACCAGTTTTAAGTCTTAAGGATTTACCAGAAACATGCG TGTACCGCAGTGTACAATGATGTGCGCAGTGTTTCACTTCAGGATTGCTTGTAATAGCGAATTACTAGAAATATCTG CCTTGCCCGTCAGCAGAAAGCTGTTTAAGTAAATTTGGGTATATGTATACCTGACACATCAGGTCGACTCGTATGTA CCAATGGGGATGATTTTCAAAGGGAAGTGTGGAACACTATGGTATGCCGCCATTTGGGTACAAAACAGAAACCTCCA CAGCTGTTGAGAAAAAGGAGAAACCTCTTCCAAGACTTAATATCCATTCTGGATTCTGGATTTTGGCATCCATTGTT GTGACCTATTATGTTGACTTCTTTAAAACCCTTAAAGAAAACTTCCACACTAGCAGCTGGTTTCTCTGTGGCAGTGC CTTGTTGCTTGTCAGTTTATCAATTGCATTTTACTGCATAGTCTACCTGGAATGGTATTGTGGAATTGGAGAATATG ATGTCAAGTATCCAGCCTTGATACCCATTACCACTGCCTCCTTTATTGCAGCAGGAATTTGCTTCAACATTGCTTTA TGGCATGTGTGGTCGTTTTTCACTCCATTGTTGTTGTTTACCCAGTTTATGGGGGTTGTCATGTTTATCACACTCCT TGGATGATTTCCGAAGAGACAGGGTCTTCTATGTTGCCCAGGCTGTCTTTGAACTCCTGGGATCAAGTGATCCTCCT GCCTCAGCCTTCGAAGTAGTTGGGACTACAGGCCCACGCCACCGTGCCTGGCTGGACATGTAAATTTGAAGTGAATG GTTAAACATCCAGCTAGCTGAAAGCATGGCAGACCCTAACAGAAAAGCTACAGTGTGTTTTTGCAGCTATGAAGTGA ATGGTTTCCTGGGGAAAATTGTGACTTTGTATAACTGTTGTTGAAACCAGAATAAATTATATTTCACTTGCATATGC ATAAATTATTAAAATTTTCAGAAGTCAGTGATACAGAAGTACTATTTTGCAATGTTAATCTGTTTGAGTCTTTGGAG AAAGTGGTTTCATTGTAGGTACATAGTGCACTGTTAATATTTTAAACAAGTAGTTCACTCTTCCATTTAAGGGATAG CAGTTCCTTGTATAAAATGACTGGATGTGTATAAAGGAATTATGTTGTCATGTGCCTTTAACCAGCTTTAGTAATTA CTATAATCTCATATTTATGATAGTTTTGTTAGGTGACAGGACCAAATGAAAATATTTTATGTTTTCTCATCACTTTA GATTTTATCATTATGTACATTACTGGGTTTTTAGCATTTCCTAATGTGAAGTTTTAATCACTTTTAAGTATACATTT TTTTCTGTATCATTTAAATAAAATATTTTTATAACTTTAAAAAAAAAAAAAAAAAA >gi|141801971|ref|NM_030923.3| Homo sapiens transmembrane protein 163 (TMEM163), mRNA (SEQ ID NO: 49) GCATTTCTGACTCGAGTCCCCGCCGCGCTTGTCGTCGCCGCAGCCGGGATCCGCAGCCCCGCGCCATGGAGCCGGCC GCGGGCATCCAGCGCCGCAGCTCCCAGGGGCCCACCGTCCCGCCGCCGCCCCGGGGCCACGCGCCACCGGCTGCCGC CCCCGGCCCGGCCCCGCTGAGCTCCCCGGTGCGCGAGCCGCCCCAGCTGGAGGAGGAGCGGCAGGTGCGGATCAGCG AGAGCGGCCAGTTCAGCGACGGGCTGGAGGACCGAGGCTTACTAGAAAGCAGCACCCGCCTGAAACCTCACGAAGCC CAGAACTACAGGAAGAAGGCATTGTGGGTGTCCTGGTTCTCCATCATTGTCACCCTGGCCCTCGCGGTGGCTGCCTT TACTGTCTCCGTTATGAGGTACAGCGCCTCTGCTTTTGGGTTTGCATTTGATGCCATCCTGGACGTCCTGTCATCGG CGATTGTCCTGTGGCGTTACAGCAACGCGGCCGCTGTGCACTCTGCCCATAGGGAGTACATAGCCTGTGTCATCTTG GGGGTGATATTCCTTCTGTCATCCATATGTATAGTGGTCAAAGCCATCCATGACCTCTCAACTAGGCTGCTCCCAGA AGTGGACGATTTCCTGTTCAGTGTCTCCATTTTAAGTGGGATTCTTTGCAGCATCCTGGCCGTGTTGAAGTTCATGC TGGGGAAGGTTCTGACCAGTAGAGCACTCATAACAGATGGGTTTAACTCCCTCGTGGGTGGCGTGATGGGCTTCTCC ATTCTTCTGAGCGCGGAAGTGTTCAAGCATGACTCAGCGGTCTGGTACCTGGACGGCAGCATAGGCGTTCTGATCGG CCTCACCATATTTGCCTATGGGGTCAAACTCCTCATCGACATGGTGCCGAGGGTGAGGCAGACACGTCACTACGAGA TGTTTGAGTGAAGGGGGCCAGCATCCGCATGAGACCATTGAGATGAGGAGTTTCCACATAGGCAAAGGGTGCCAATA TTTAACTGAACATCTGGTTTCTTTTTGGAAGTTTTCTTTCACATGGTTTGTCATTACAAGACAAGGTCTGCCCAGCC AGGTGGATCTACCTTGCCCCCATCACCTGCCGCCCCCATCAAACATGTTGGGACAATGCCCATAGGAATGGACCTCC TTCCCCGTCTCCAGCTGGGACTGGTGTTTTTTTAGTCTCTGGAGTATGATGGTTCTCATGGGTAGGATGAGATCTTT GGCAGAAAGGTCTTCGGTGGTGCTCTGAGCCTGCGCTGCATAGGACTGAGCAGACCCACCTCCTCCAGCTTGGGTGG CCCTGCCACTCCTGGTTCCAAGTCTCTCCTTTCCTGGCAGGTCTTAAGGGAAGATTGTACCCCTCACCCTTTACATA CCCAGAATCATCAGTATGTCACTTCCTAATTTCTATCAGTGTATCTCATTATTTCATACTGTTTTACTAATCCTAAG TCTAAACAGATTTGCTCAAAAGGAGACCATTCTATTTTTTAAAGTACTTAGTGATACACGTATAAGCTTTGCATGGA CGAATTAAATAAGCACATTGACCTTTTCTTGTACATTCAGAACCTGAACATCCATGTGAAAACTGGGTCCATTTTTG AGAGATGTGAAACTACAGTTTATTTGTAATAAATAAATATAATCTAAAAAAAAAAAAAAAA >gi|145207957|ref|NM_001001891.3| Homo sapiens transmembrane protein 16G (TMEM16G), transcript variant NGEP-L, mRNA (SEQ ID NO: 50) AAAGATAGATCCTGCTCCAGGAGCCGGGAAGCCTTGCCCTGGCCAGCTGTGCTGGGCACCTCCCCTGCCTGCTTCCT GGCCCACTTGCAGGCAAGGTGAGGGCATGCGAATGGCTGCCACTGCCTGGGCGGGGCTCCAAGGGCCACCCCTCCCC ACCCTCTGTCCCGCAGTGAGGACGGGACTCTACTGCCGAGACCAGGCTCACGCTGAGAGGTGGGCCATGACCTCCGA GACCTCTTCCGGAAGCCACTGTGCCAGGAGCAGGATGCTGCGGCGACGGGCCCAGGAAGAGGACAGCACCGTCCTGA TCGATGTGAGCCCCCCTGAGGCAGAGAAGAGGGGCTCTTACGGGAGCACAGCCCACGCCTCGGAGCCAGGTGGACAG CAAGCGGCCGCCTGCAGAGCTGGGAGTCCTGCCAAGCCCCGGATCGCAGACTTCGTCCTCGTTTGGGAGGAGGACCT GAAGCTAGACAGGCAGCAGGACAGTGCCGCCCGGGACAGAACAGACATGCACAGGACCTGGCGGGAGACTTTTCTGG ATAATCTTCGTGCGGCTGGGCTGTGTGTAGACCAGCAGGACGTCCAGGACGGGAACACCACAGTGCACTACGCCCTC CTCAGCGCCTCCTGGGCTGTGCTCTGCTACTACGCCGAAGACCTGCGCCTGAAGCTGCCCTTGCAGGAGTTACCCAA CCAGGCCTCCAACTGGTCGGCCGGCCTGCTGGCATGGCTGGGCATCCCCAACGTCCTGCTGGAGGTTGTGCCAGACG TACCCCCCGAGTACTACTCCTGCCGGTTCAGAGTGAACAAGCTGCCACGCTTCCTCGGGAGTGACAACCAGGACACC TTCTTCACAAGCACCAAGAGGCACCAAATTCTGTTTGAGATCCTGGCCAAGACCCCGTATGGCCACGAGAAGAAAAA CCTGCTTGGGATCCACCAGCTGCTGGCAGAGGGTGTCCTCAGTGCCGCCTTCCCCCTGCATGACGGCCCCTTCAAGA CGCCCCCAGAGGGCCCGCAGGCTCCACGCCTCAACCAGCGCCAAGTCCTTTTCCAGCACTGGGCGCGCTGGGGCAAG TGGAACAAGTACCAGCCCCTGGACCACGTGCGCAGGTACTTCGGGGAGAAGGTGGCCCTCTACTTCGCCTGGCTCGG GTTTTACACAGGCTGGCTCCTGCCAGCGGCAGTGGTGGGCACACTGGTGTTCCTGGTGGGCTGCTTCCTGGTGTTCT CAGACATACCCACGCAGGAACTGTGTGGCAGCAAGGACAGCTTCGAGATGTGCCCACTTTGCCTCGACTGCCCTTTC TGGCTGCTCTCCAGCGCCTGTGCCCTGGCCCAGGCCGGCCGGCTGTTCGACCACGGCGGCACCGTGTTCTTCAGCTT GTTCATGGCACTGTGGGCCGTGCTGCTGCTGGAGTACTGGAAGCGGAAGAGCGCCACGCTGGCCTACCGCTGGGACT GCTCTGACTACGAGGACACTGAGGAGAGGCCTCGGCCCCAGTTTGCCGCCTCAGCCCCCATGACAGCCCCGAACCCC ATCACGGGTGAGGACGAGCCCTACTTCCCTGAGAGGAGCCGCGCGCGCCGCATGCTGGCCGGCTCTGTGGTGATCGT GGTGATGGTGGCCGTGGTGGTCATGTGCCTCGTGTCTATCATCCTGTACCGTGCCATCATGGCCATCGTGGTGTCCA GGTCGGGCAACACCCTTCTCGCAGCCTGGGCCTCTCGCATCGCCAGCCTCACGGGGTCTGTAGTGAACCTCGTCTTC ATCCTCATCCTCTCCAAGATCTATGTATCCCTGGCCCACGTCCTGACACGATGGGAAATGCACCGCACCCAGACCAA GTTCGAGGACGCCTTCACCCTCAAGGTGTTCATCTTCCAGTTCGTCAACTTCTACTCCTCACCCGTCTACATTGCCT TCTTCAAGGGCAGGTTTGTGGGATACCCAGGCAACTACCACACCTTGTTTGGAGTCCGCAATGAGGAGTGCGCGGCT GGAGGCTGCCTGATCGAGCTGGCACAGGAGCTCCTGGTCATCATGGTGGGCAAGCAGGTCATCAACAACATGCAGGA GGTCCTCATCCCGAAGCTAAAGGGCTGGTGGCAGAAGTTCCGGCTTCGCTCCAAGAAGAGGAAGGCGGGAGCTTCTG CAGGGGCTAGCCAGGGGCCCTGGGAGGACGACTATGAGCTTGTGCCCTGTGAGGGTCTGTTTGACGAGTACCTGGAA ATGGTGCTGCAGTTCGGCTTCGTCACCATCTTCGTGGCCGCCTGTCCGCTCGCGCCGCTCTTCGCCCTGCTCAACAA CTGGGTGGAGATCCGCTTGGACGCGCGCAAGTTCGTCTGCGAGTACCGGCGCCCGGTGGCCGAGCGCGCCCAGGACA TCGGCATCTGGTTCCACATCCTGGCGGGCCTCACGCACCTGGCGGTCATCAGCAACGCCTTCCTCCTGGCCTTCTCG TCCGACTTCCTGCCGCGCGCCTACTACCGGTGGACCCGCGCCCACGACCTGCGCGGCTTCCTCAACTTCACGCTGGC GCGAGCCCCGTCCTCCTTCGCCGCCGCGCACAACCGCACGTGCAGGTATCGGGCTTTCCGGGATGACGATGGACATT ATTCCCAGACCTACTGGAATCTTCTTGCCATCCGCCTGGCCTTCGTCATTGTGTTTGAGCATGTGGTTTTCTCCGTT GGCCGCCTCCTGGACCTCCTGGTGCCTGACATCCCAGAGTCTGTGGAGATCAAAGTGAAGCGGGAGTACTACCTGGC TAAGCAGGCACTGGCTGAGAATGAGGTTCTTTTTGGAACGAACGGAACAAAGGATGAGCAGCCCGAGGGCTCAGAGC TCAGCTCCCACTGGACACCCTTCACGGTTCCCAAGGCCAGCCAGCTGCAGCAGTGACGCCTGGAAGGACATCTGGTG GTCCTTAGGGGAGTGGCCCCTCCTGAGCCCTGCGAGCAGCGTCCTTTTCCTCTTCCCTCAGGCAGCGGCTGTGTGAA CCGCTGGCTGCTGTTGTGCCTCATCTCTGGGCACATTGCCTGCTTCCCCCCAGCGCCGGCTTCTCTCCTCAGAGCGC CTGTCACTCCATCCCCGGCAGGGAGGGACCGTCAGCTCACAAGGCCCTCTTTGTTTCCTGCTCCCAGACATAAGCCC AAGGGGCCCCTGCACCCAAGGGACCCTGTCCCTCGGTGGCCTCCCCAGGCCCCTGGACACGACAGTTCTCCTCAGGC AGGTGGGCTTTGTGGTCCTCGCCGCCCCTGGCCACATCGCCCTCTCCTCTTACACCTGGTGACCTTCGAATGTTTCA GAGCGCAGGGCCGTTCTCCCTCGTGTCCTCTGGACCCACCCGCCCCTTCCTGCCCTGTTTGCGCAGGGACATCACCC ACATGCCCCAGCTCTCGGACCCTGCAGCTCTGTGTCCCAGGCCACAGCAAAGGTCTGTTGAACCCCTCCCTCCATTC CCAGTTATCTGGGTCCTCTGGATTCTTCTGTTTCTTGAATCAGGCTCTGCTTTCCCCCTAGCCACTACAGGCAGCCT CTGACAGTGCCGCTTTACTTGCATTCTGCAGCAATTACATGTGTCCTTTTGATCCTTGCCCAACTTCCCTCCCTCTC CCAGCTCCTGGCCCCTGGCCCAGGGCCCCTCTTGCTGTTTTTACCTCTGTTCCTTGGGGCCTAGTACCCAGCAAGCA CCCAAATGGGGGAGGTTTTGGGATGAGAGGAGGAAACGTGTATACCTGTAACATCTGGTGGCTCTTCCCCCAGAAGT TTGTGTTCATACATAATTGTTTTCCACGCTGGATCATAATGTGACGTGCAGTTCTGCCCTGTGCTGGGGAGCCACAT GAAGCTTCCCCTGGCTAACTTGCTACCCCGCAGCAATCCCAGTGTGGCCGTCTGCTTGCTAAAAAATGGATCTGTGC TCATCTGTATTGATGTCCTTGGAGTTCTACAAGTGGAACTTAAGTGTCAAAAAGAATATGTGGTTTTTAGCTGAGCG TGGTGGCTCACACCTGTAATCCCAGGACTTTGGGAGGCTGAGGCAGGAGGATTACAAGGTCAGGAGTTCGGGACTAG CCTGTCCAACATGGTGAAACCCTGTCTTTACTAAAAATGCAAAAATT >gi|156416013|ref|NM_014020.3| Homo sapiens transmembrane protein 176B (TMEM176B), transcript variant 1, mRNA (SEQ ID NO: 51) GCTGACCATGCTGGAACTGCGGCGACTACAGAGCCTGCGGGAACCTCCCCTTTCGCCCAAGATCTGCTCTGTCCCCC TCATCCTCCTCCCAGGGCCCTGGCGTCTGGGTCAAGCAGCGCCCCACACCTCGACCCCTCACCCCCTCCTCCCGGGC TCTTCCTGCGGCCTCCCCTCCACAGTCCGCAGGCTCTGGGACAGGACCGAGTCCTTGGCTGCCTGTGGAGCTCCTGT GCCAGCAGCTGCGCCCCGGCTGCGCTCCGGATACCCCCATCCCCGCCACCGCCGACCTCCCGCTCCACCGACTGCTG CTCACGCCCGACGGGTTCACGCCGCCCCTGCCCCGTGAAGGACCGCGCTGCGGTGCGGAGGCAGGATGACGCAAAAC ACGGTGATTGTGAATGGAGTTGCTATGGCCTCTAGGCCATCCCAGCCCACCCACGTCAACGTCCACATCCACCAGGA GTCAGCTTTGACACAACTGCTGAAAGCTGGAGGTTCTCTGAAGAAGTTTCTTTTTCACCCTGGGGACACTGTGCCTT CCACAGCCAGGATTGGTTATGAGCAGCTGGCTCTAGGGGTGACTCAGATATTGCTGGGGGTTGTGAGTTGTGTTCTT GGAGTGTGTCTCAGCTTGGGGCCCTGGACTGTGCTGAGTGCCTCAGGCTGTGCCTTCTGGGCGGGGTCTGTGGTGAT CGCAGCAGGAGCTGGGGCCATTGTCCATGAGAAGCACCCGGGCAAACTTGCTGGCTATATATCCAGCCTGCTCACCC TGGCAGGCTTTGCTACAGCTATGGCTGCTGTTGTCCTCTGCGTGAATAGCTTCATCTGGCAAACTGAACCCTTTTTA TACATCGACACTGTGTGTGATCGCTCAGACCCTGTCTTCCCTACCACTGGGTACAGATGGATGCGGCGAAGTCAAGA GAACCAATGGCAGAAGGAGGAGTGTAGAGCTTACATGCAGATGCTGAGGAAGTTGTTCACAGCAATCCGTGCCCTGT TCCTGGCTGTCTGTGTCTTGAAGGTCATTGTGTCCTTGGTTTCCTTGGGAGTAGGTCTTCGAAACTTGTGTGGCCAG AGCTCCCAGCCCCTGAATGAGGAAGGATCAGAGAAGAGGCTACTGGGGGAGAATTCAGTGCCCCCTTCGCCCTCTAG GGAGCAGACCTCCACTGCCATTGTCCTGTGAGCTGCCAAAGACCCCACGGGGTGCCCGCATGTCCCTGTCTAGGGCA GCCCAGGGCCCCCACTCCTGGCTCCTCACACTTGCCTCCCCTATGGCCGCTCTCCAGACCCTCCTCCTTTCTTCTCC CCACATCCGCACCTGCTGTTCCCACTCTGGGGTTCTCAAGTCCATGAACAGATATTGTTGCATTTTCCACAATGCTG ATTAAACATAATAAACAATCCAGAAAAGCAGTTTTGCCCAGAAAAAAAAAAAAAAAAA >gi|153792041|ref|NM_020823.1| Homo sapiens transmembrane protein 181 (TMEM181), mRNA (SEQ ID NO: 52) CGCGGAGGCGGATGGGCGCGGCTCCCTCCCCCACTCAGGCCTCTTCACGGGGCGGGGGGCCGGGTCCCCCAGCCCCC ACCCGCGCCGTGTCCAGCTCCTCGCGTGCTCGCGGCGGAGCCCTGAGCGCACTGGGTCCGAGTCCTGCGCGCCCCCT CACCACCTCCCCCGCACCTGCTCCTCCTCCTCGGTCCCGCCCAGCGCGCCAGCAGCCCGATCCCCAGTGCTGGGAGA AGAGAGGGGGCGCAGGCGGCGACACAAAGGGTGGAGCGGCGGGACCGGGACCCGGGAGGCTGCGCGGCATGGACGCC GAGTACCCTGCCTTTGAGCCCCCGCTCTGCAGCGAGCTCAAGCACCTGTGCCGGCGGCTGCGGGAAGCGTACCGCGA GCTCAAGGAGGACCTCACGCCCTTCAAGGATGACCGCTACTACAGGCTGGCGCCCATGCGGCTCTACACGCTCTCCA AGCGCCACTTTGTCCTCGTGTTTGTCGTCTTCTTCATCTGCTTTGGCCTGACCATCTTCGTTGGGATCAGAGGACCT AAAGTGATCCAGACTTCTGCGGCTAATTTTTCACTAAATAATAGCAAAAAGCTAAAGCCAATTCAAATACTTTCAAA TCCACTGTCTACATACAATCAGCAACTATGGCTGACATGTGTTGTTGAGTTGGATCAATCAAAAGAAACTTCTATTA AGACAAGCTTTCCCATGACTGTTAAAGTCGATGGTGTAGCTCAAGATGGAACCACGATGTACATTCATAACAAAGTT CACAACCGGACAAGGACCCTCACATGTGCAGGGAAATGTGCGGAGATTATTGTGGCTCACCTTGGCTACCTGAACTA CACTCAGTATACAGTGATAGTGGGATTTGAACACCTGAAGCTCCCCATCAAGGGAATGAACTTCACATGGAAGACTT ATAACCCTGCCTTCTCCCGGTTGGAAATCTGGTTCCGGTTTTTCTTTGTGGTGCTCACCTTCATCGTCACTTGCCTG TTTGCGCATTCCCTCCGGAAATTTTCCATGAGAGACTGGGGCATCGAGCAGAAGTGGATGTCTGTTCTCCTGCCTCT GCTGCTACTTTACAATGATCCGTTCTTCCCCCTCTCCTTCCTGGTCAACAGCTGGCTCCCAGGGATGCTGGATGACC TCTTTCAGTCCATGTTCCTGTGCGCCCTGCTGCTCTTCTGGCTGTGCGTGTACCACGGGATTCGTGTCCAGGGAGAA AGAAAGTGTTTAACTTTCTATTTGCCTAAATTCTTCATTGTTGGACTATTGTGGTTGGCTTCTGTTACGCTAGGAAT ATGGCAAACAGTTAACGAATTACATGATCCAATGTACCAGTATCGAGTTGATACCGGAAATTTTCAGGGAATGAAGG TCTTCTTCATGGTGGTGGCAGCGGTGTACATTCTGTACCTCTTGTTCTTGATAGTGCGGGCGTGTTCCGAGCTACGT CACATGCCTTATGTGGATCTCAGGTTGAAATTTTTGACTGCATTGACTTTCGTAGTACTTGTCATTAGCATCGCCAT CCTTTATTTGAGATTTGGGGCGCAAGTACTACAAGACAATTTTGTAGCAGAGCTGTCAACTCACTACCAGAATTCAG CCGAGTTCTTATCTTTCTATGGCCTGTTGAACTTCTATCTCTACACCTTGGCCTTTGTATATTCTCCATCGAAGAAT GCCCTCTATGAGTCCCAGCTGAAAGACAATCCTGCCTTCTCCATGCTGAATGACTCGGATGATGATGTGATTTATGG GAGTGACTATGAGGAAATGCCGCTGCAGAACGGCCAGGCCATCCGGGCCAAGTACAAGGAGGAGTCAGATAGTGACT GAGCCCCGGCCAGCCCAGCGAGGCGACAAGATGCCTGGATGCTTTCCCCGGTGACCGTCTGCTGACCTTCCCCTGTT ATATTCAGATTTTTCTTACAAGCAGAGATTTCCTGTTCATTTGTTTACATATTTTTTTAAAGGAAAACCAAAACTGA GGGTAAATTTAAATGTTTAGCCAAATTTATTGTCATGGTGGCTACGAGAAGAGGCATTGATAACAAGTTTCAACAGC CAAATCCTTTTTTACAGAGATTTCAGATGAGCGTGTTTTCAGTGATGAGGAAATTTCACGTTTTTAGTACAGTGAAT TATGTACTTTTTTTTCCTGTAATCATTCACTGATTCCAAGTTCACGGGCAGCCTGTGACTAGGTCCTCAGCGTGACA GCATCACCCTCTTTCTTCCCTTTTCCATGGTACTGTTTTGTGACCCTTTAAACTCAAAGGGAAGCCTTATCTGTGGC TGCTTCAGGGCAGTCCTTCCTCGTTGAGTGGCCAGTGCCCTGGGTAACCAGGTGGCTGAAGTGATTGGTCAGTTATG TGGACTGCGTTTTGTGCAGTGTGTGAGTTATGACTCATCGGGAATGGGAGATGCTGGGGTTCCAACCCTTCACGTCA CCAAAGGGGAAGTAATAGTGTGGAGTTCTGAGGAGGGTTTGATAAGTTGAATAAGGAAAGGCTAAGATAATTTACAG GTTACCAACTCATGTGGGGAAGGTCTTACTGCCATGGTGCTTTTCAGGGGCCTGTGTGTACACACATGATTAAATGG ATTTGCCTGTGGGAGGTATGGGCAGGAGAGGAACCCTTACCATTCCAGTAAATAGCAGTTTCTGCAATTCTGTTGAA TATGAAATGCCATAGAGCTTTATTTATTTATGTAAGTAAAAGCTAAATGAGGGGCCAGGTGCAGTGGCTCACATCTG TAATCTCAACACTTTGGGAGGCCAAGGTGGGAGGATCACTTGAGCCCAGGAGTTTGAGACCAGCCTGGGCAACACAG GGAGACCCCGTCTCTATAAAACATTTAGAAAGTTGGCTGGGCATGCTGGGGCATGCCCATAGTCCCAGCTACTCAGG AGGCTGAGGTGGGAGGATTGCTTGAGCCCTGGAGGTCAAGGCTGCAGTGAGCCATGATTGCACCACTGCACTCCAGC CTGGGTGTCAGAGCGAGAACCCGTGTCATAAATAAATAAAGCTACATGAAAGATTGATAGAATATTTTAGATTATTT ATTGGCCAAAAGTTTTTAAAACTCATATTTGGAAGCAAAATGAAAAGCAAGTAAAATGTTTTAAATGGTTCATGGAA AACGTATTTGGGTAGAAGGCAACTCGTGCTTCCGGAAGGGGTTCCCTGTCCTCCATGTGTCCACATGGCGGTCAGGT AGGGACGACCTGTTCTGTAAAGTCCTTGGCACTGCTGAATCTGTGGCATCATAGAAGGCCCTGGAGCTTCCCCGTTC CTTTCAGTCAGGGACTCCATATAGAGTCTCATGTGGACGTCTCCCGTGCTTTCCTCTTGACCTCTACAGTCACACTT CTGTTAACATCTGGTAACTGTGGGCAACCTGACTGATGCCGTCTTGGCAATTGAGGTCCAGAAGATGATAGTTCCGC AACGCAAGCAGTACCTACTTTTTTTCTTCATCTATGCATTGACTCTCAGATTACCATGCAGAGCTTCACGTTATCAT CCACGTTAAGTAGTGCTAGGTAGGACCTTAGAGATGTTCATGAGAAACTATTTGTTATGACTTTCCTTTGTATCTTT CCTTTTAATTTAAACTTTAATGATAATGTACTTTTAATATGGATTCTATTCACATTTGTTTTAAAAACCTTGTAAAT ATGAATGTTTAAGACAACTTACTGCAAGGGTAATTCAAGTTTACATGATTTTTAAATTTGCAATGATGTTTTTTTTA TTCTGTGTATTGAAAAAAATTTTCTGTTACCAAATTTTACAACTTCTAATAAGACTACTATAACTTTATGTAAACTG ATGAAGATGTGCTGATTAACATATTCTGTGATATGGTTTACAACTTTTAATCATAATTGTCCATGATTTTGGAATGC TGTTATTTATCAGTAAATGTAAAATATTTGAGGCATTTAGCCATACACACACTAGAACTTTTTAAAACTTTGTCCTA TAGTGTAATTATAAACTGATGACTATTATCTTCATACATTGAGTCTTCATGCATCAATGAAATGAAAAATATAGGAT TATTTATTTACTTTTTGTAACTAAGTGGGAAATAAGAAAAAAAGTTAGAAAGTACTTAAGGGGAAAATCGTTCTTAC TAAGTCATGTATTTTCAACTTGTCTTCCCTGGTATATCATAAATACCGACATATTACATACCCCATGTAAAATTTTG CTTAAACTCTCTAGCACTTGGCATGTAGAATATGTACCATAGGTATCAGGTTAAAACACTAAAGTCTGCCAGAAACT TTTGACAGTAGCAAGAAAATTGTTGAAGAAAAAATAAATTATTTACTGAGGGTAGTTATGTTAAAGTTTTGCGAACT TAAAGGGCTGACTTTAGTTCCTTCATGGTAATGGCTTGAGTAACATCATCTTTGGGATTTTTTAAATACTGGTCCAG TCTAGGAGAACCTGGAAGATGACCAGAGGTATTTCAGTTTCCCTAGGGAGAGCTTCGTTATCCATGTGGATGATAAG TCTGCTTGATTTATTATTAAATCATTATAGCAGTGAAGTGGTGCCATTTTCTCTCTCTTAAGCCCCATTTGAAAGGC TAGAGAAGGGGATATATATACTATGTTCAAGGTTTGTAAGGTTGTTAATGTACATAATTGCAGATTGCAATAAAAGC TTAGATACATTTTGTAAACCCAACCCACTAAATGAGCAGGTTACAAGACAAATGTCACCAGCCTCAAGTATTTTATG AACTATTTACTGAGGGTAGTTATGTTAAATAGATTATAATGTGGTAAATTATTTCCTGAATCCTTTATCACAGGAAA AACACAGACCCTCATAAAAGGGATAATTAAAACGGATGTGTCTGAACATTTAGTGAAGATGAGACTTAAAACATGAA AGTGTATTTGTGTATTTTGAGGGTTTTAGAAACCGGTTGCCTTAGAGGTTAGACTTTTGAAGAAAAAAAAAAAAAGA TACAGATCTTTTCCCCTGGCCAAAGGGAAGTTGTATTAGTCTGTGACATCTTGTGATGCTGTTTATCTTGGTTTGAC ATTGGAGATACGCTAGTAACTGTGATACCATACTATAAAACAGAAGAATTTTCTGCTACTAAAAACTGCCTTTTTAC AAAATGACTGTAAATATTTGTAAAATAAAATAACACTAAACTTTAAGCCCAAAAGGAGAGATAGAGCCATGTGTTCA GTTGTGGACCTGTCCGTGGGGCACAGTGCCACCCCATCACAGTGTTGCTGTCATCAGGCAAAAGTGAATGTTTGTTT ATGGCAAATTCGTCTTTTGCGAATGGCTTAATTCTGACACTACCTTTCTGGGAAATGTTAATAAATTTTTAATATTC ACTTCTA >gi|58533180|ref|NM_138399.3| Homo sapiens transmembrane protein 44 (TMEM44), transcript variant 1, mRNA (SEQ ID NO: 53) CGCCCGGGAGCGCGCCCTTCTCTGCCCGCGGTCGGTGCGCTCGGCCGGAGGCGCCGCGGCGGAACGGAACCCAGAGA AGGGGACGCGGGGCGGCGGCGCTCGGGGCTTGCCCGCGGCGAGGGAGGCTGCGCCCAGGTCCCCGGCCCCGCGCCGC GCGCCCAGCCGCGCCATGGGGGAGGCGCCCAGCCCCGCGCCCGCGCTCTGGGACTGGGACTACCTGGACCGCTGCTT CGCCCGCCACCGCGTCTGCATCTCCTTCGGCCTGTGGATCTGCGCCTCCTCCTGCTGGATCGCCGCCCACGCGCTGC TTCTCTATCTGAGATGTGCACAGAAACCCAGACAGGACCAGTCGGCACTGTGTGCTGCGTGCTGCCTCCTGACCAGT CTGTGTGACACCGTCGGGGCTCTTCTGGCCAGACAGCTCACAATCCAGGTTTTCACTGGTGCCTACCTAGCAGCTAT TGACTTAGTGAACTTTATGTTCATTCTCTTCCCAGTCTGTGGATCCAAATTCAAGTCTAATTCAGATCGGGAAGCCC GAGAGAGGAAGAGGAGGCGGCAGCTCAGGGCCAGTGTGTTTGCCCTGGCCCTGCCGCTGAGCCTGGGCCCGTGCTGG GCTCTGTGGGTTGCTGTCCCGAAGGCTTCAGCCACCATCCGGGGGCCACAGCGGAGGCTGCTAGCGAGCCTGCTGCA GGAAAATACTGAGATCCTCGGCTACCTGCTGGGTAGCGTTGCTGCCTTTGGCTCCTGGGCTTCTCGGATCCCCCCTC TCTCCAGAATTTGCCGGGGGAAGACATTTCCCTCCATCCACCTGTGGACCCGGCTCCTGTCGGCCCTGGCTGGCCTC CTCTATGCCTCGGCCATTGTGGCCCACGACCAGCACCCTGAGTACCTGCTGCGGGCCACACCCTGGTTCCTGACCTC CCTCGGCCGTGCGGCACTGGACCTCGCTATTATTTTCCTTTCGTGTGTGATGAAGAGCAAGATGAGACAGGCCTTAG GATTTGCCAAGGAAGCCAGAGAGAGCCCTGACACCCAAGCCCTTTTGACCTGTGCAGAGAAAGAGGAAGAAAACCAG GAGAATTTGGATTGGGTGCCTCTCACCACACTGTCACACTGCAAGTCACTGAGGACAATGACAGCAATCAGTCGCTA CATGGAGCTGACCATCGAGCCTGTGCAGCAGGCAGGCTGCAGTGCCACCAGGCTGCCAGGTGACGGGCAGACGAGCG CCGGAGATGCGTCCCTGCAGGACCCCCCGTCGTACCCTCCCGTTCAGGTCATCCGGGCCCGGGTGTCTTCCGGCAGC TCCTCTGAGGTCTCCTCCATCAACTCCGACCTGGAGCAGAAGTATTGGGAGGCCCTAAACTCGGAGCAGTGGGACCC TGAAGATGTGAACCTCGAAGGCAGCAAAGAAAATGTGGAGCTACTGGGATCCCAGGTGCACCAGGACTCTGTGAGGA CAGCACACCTGAGTGATGATGATTAACACCTTCTGGAGCCAGCTCATCAGCTCAGAGCCCAGGGTCAGGAGTTCGTT CAGTAACGCAGCGGGAATCAATCTGCACTGACACCGCGGCAGGAACTGAAGCTGCCCTGGCAAGTGAGGAACCAGGA GCCGTCACTGAGTGTGGCTGGGCTACATCATAGCTCATCACGGAGCTACGACTTTGGGTACTGCGGACAGACCTGGA TAGGCCCAGCATTCGTTCTGAAGATCACAGTTCACAGAAGCTTTTGCTTCGTAAAGATAATCCAAAGGATCTCAGAC CCGCTCTTCCTTTTCCCTTCATTCCCTTGAGAGTCAGCCATGAACGGAATACCTGCTAGGTTCCAGGAATGAGCTCA CCTAACAGATAGCAAATGTGTCTGGTTAGATCTCAGCAGAGCCCATTCTGCAAGACCTGGCTGAGCCAGATGAGAGG GTGGGCCCTGTGCTGGGGGGCCTTGGGTCACACACAGGAACCGAGACCTGGCTTCCACCCCCCAGTCACCCACTTGG GTTATCTGCTGGAAGTTATCGATAGGACTGTGTGGCCAACCAAGTGCTTGTGAGATCACTGACACTGCAAAAACAAA GCAAACTGCTCCGGGTACCAGGACTTCCTCCAACCTGGCAAGGGTGTGCGCTGAGGCGGGGCTTGCAGGTGAGGGGG CTGTATGCTTCAGGAACTAACTAAATGCATGCAGAAGGTAAGAGGCATGATGGGAGGTGTTCAAGCACAGCAATCCC ATTTGGGAGTTATTTTGATACTGCGATGAGTAAGGGTAAGGGCGCATGGAATGGGGCTAAGGTGGGAGTGAACACTG GGGTGAATAAATTTTAAATCAATTCAAGTATCTCAAAAAAAAAAAAAA >gi|83415183|ref|NM_175861.2| Homo sapiens transmembrane and tetratricopeptide repeat containing 1 (TMTC1), mRNA (SEQ ID NO: 54) AGATAGAAAAAGTAGTTTGCTTGGCATCTCCCAAATTATCTTGAGCAAACAATAAAATAAGAAATGTTTCAGAAGAC AATTCGGCTCCCAGGCCCAAACCAAAACTCGAACCTGGTACTTTTTGTAAGTGCGGGCCAAGAAAGGGGCTGTAAAG TTAAAGAGCCGGTGGCGCCTCTGAACACACCCGGGCAGGGCGAGCAGGATGTCCTTGTCCAGGGAGACCCCTTCTCC TGGCTTTGAGGAAGGTGCTCCCTATCCCCGCGGGTTCCTCCGCCAAGCGGGACGCCGCGCCGGGCGGGTGAGAGAAA GCCCGGGCAGGAGAGCACAGAGCCGGCGACTGGACGCGAGCGCGGGGCGGGTGGAGAGCGTCTCTCCGGGCGCCGCT GCTGTTGTCCCGGGTGCTGAAAAGCCGGGAACTTCCCGGGAAGCAGCGGCACTTTTCTCCCTGGAAGGCTAAACATA TTTTTGACTGGTATGAACCCATTCTACTTTCATGCAGTAAATATAATTTTACACTGCTTAGTGACTCTTGTGCTGAT GTACACCTGTGATAAAACTGTCTTCAAGAATCGTGGACTTGCTTTTGTAACGGCATTGCTTTTTGCTGTACATCCTA TTCATACTGAGGCGGTGGCTGGGATCGTTGGCAGAGCGGACGTGTTAGCGTGTCTGCTGTTTCTATTGGCCTTTCTC TCGTACAACAGGAGTCTGGATCAGGGCTGTGTTGGGGGAAGTTTCCCTTCCACGGTGTCTCCCTTCTTCTTGCTGCT CAGTTTGTTTCTGGGGACCTGTGCGATGCTGGTGAAAGAGACAGGCATCACGGTGTTTGGAGTGTGCTTGGTTTATG ACCTCTTTTCCCTTTCCAACAAGCAAGACAAGTCGAGCAATGGGGCCCTCTGTCCACGCAGCCCACAGCAGCCCGGG AGCCCCCAGCCCTCCTCACTGCCAGGCCATCCTCACCGGGAGAATGGGAAGCAGCAGCGGTTCCCTCACAAAGGAGC TTGGGGTGGCTGCCACTCTCCACTGCCACCAGAACCCAAGAGCAGTGGATTCCCAGTGTCCCCACGAGCTGTGTGGT CCATGATGAGATTCCTCACCTATTCCTACCTCTTGGCCTTCAATGTGTGGCTTCTGCTTGCACCCGTGACCCTGTGC TATGACTGGCAGGTCGGCAGTATTCCTCTGGTAGAGACCATATGGGACATGCGGAACTTAGCCACCATCTTTCTGGC GGTTGTGATGGCCTTATTGAGCCTGCACTGCTTAGCAGCCTTTAAGAGACTGGAGCACAAGGAGGTTTTAGTCGGCT TGTTGTTCCTGGTGTTCCCGTTCATTCCAGCCAGCAACCTCTTCTTCAGGGTGGGTTTTGTGGTGGCGGAGAGAGTC CTTTACATGCCTAGCATGGGCTACTGCATCCTTTTTGTGCATGGACTGAGCAAGCTCTGCACTTGGCTGAATCGATG TGGGGCCACCACCCTGATTGTGTCCACTGTGTTGCTGCTGTTGCTTTTCTCTTGGAAAACTGTGAAACAGAATGAAA TTTGGCTGTCAAGAGAGTCCCTATTCAGGTCTGGAGTTCAAACTCTGCCCCACAATGCCAAGGTTCACTACAACTAT GCCAATTTCCTGAAGGACCAAGGTCGGAACAAGGAAGCGATCTACCACTACAGAACAGCTCTCAAGTTGTATCCACG CCATGCAAGTGCGCTCAACAACCTTGGAACACTGACGAGAGACACAGCAGAGGCAAAGATGTACTATCAGAGGGCTC TCCAGCTCCATCCACAGCATAACCGGGCTCTTTTCAATCTGGGGAATCTCCTCAAGTCCCAGGAGAAAAAGGAAGAA GCTATCACCTTACTGAAGGATTCCATCAAATATGGTCCAGAGTTTGCAGATGCATATTCAAGCTTAGCTTCGTTATT GGCTGAGCAGGAGCGGTTTAAAGAAGCTGAAGAAATATACCAAACTGGAATAAAGAACTGTCCAGACAGCTCAGATT TACACAACAACTATGGGGTTTTCTTAGTTGATACTGGCTTACCAGAAAAGGCAGTGGCCCATTACCAGCAGGCCATC AAACTTAGCCCCAGTCATCACGTGGCCATGGTGAACTTGGGAAGACTCTACAGGTCACTGGGAGAGAACAGCATGGC TGAAGAATGGTACAAGCGCGCCCTGCAGGTGGCACACAAAGCTGAGATATTGTCACCTTTGGGAGCACTGTATTACA ACACTGGCCGATACGAAGAGGCTTTGCAGATTTACCAGGAAGCTGCAGCACTTCAGCCTTCTCAGAGGGAGCTCCGC TTGGCACTGGCTCAGGTTTTGGCCGTGATGGGTCAGACAAAAGAAGCTGAAAAGATGACCAATCACATTGTGTCAGA GGAGACCGGATGCCTTGAATGCTATCGCCTCTTGTCAGCCATCTATAGCAAGCAGGAGAACCACGACAAGGCACTTG ATGCTATAGACAAGGCTCTCCAGCTGAAACCAAAGGACCCAAAAGTCATTTCTGAACTTTTTTTCACAAAAGGAAAC CAATTAAGAGAGCAGAACCTTCTCGACAAAGCTTTTGAGAGCTATAGAGTGGCTGTGCAACTAAACCCAGACCAAGC ACAGGCCTGGATGAACATGGGTGGCATCCAACACATCAAGGGAAAATATGTGTCTGCAAGAGCTTATTATGAGAGAG CCTTACAGCTGGTTCCAGACAGCAAACTGCTGAAGGAAAATCTTGCCAAATTGGATCGCCTAGAAAAACGATTACAA GAAGTTCGAGAAAAGGATCAAACATAGCACCACCGTCTGACCCAACCTCATAGGATAATGTGGTGCCTCTGAAAGGG GAGTGATGGAAGCCTTGCTTTCACATCAGCAGGGGCACAACTAATGAGATTTTCTCTCATTCCGAGTTCAGGGTGAC ACATTTTGGGACATCTGCTGGTAGCCCAGTGCTGAAGGACTTGCTTTTCCATGAAGAAGACGAAAACAGCAAACAAG GGCAAGAAGGTCTGAGAGGGAAGGAGAATGACATTTACACATTTTACAGATTTTTGTTTGGTTTAACTCCAGATTTC TCTTGATATATCTCTGTGCTTTTGAGACCTGGAGATCTAATTCTGTTTAGACATTTTTTGTCCCAGAAATACAGAAG CTTGAAATGCTATGAAGGCAGAGCTTCTATTCTTTATGGGATGAAATATTTCAAAAGAGGATAAATCCTCTGTGGTA AGCCATTTGGAAAATCCTACCAAGAATTGGCTTATTTAATTTTCCAGAACCAGGAATGAGTATCTAATAGCTTTTGT AGAACCTTCCAGAATATGTGGGGAAAAAGGGCTATTGCTAAGTGAGCTTTATCTAATATCCTCCTAAGAGTTTTACT AGTGCTTTTTTGAGGAATTACAGGGAAGCTCCTGGAATTGTACATGGATATCTTTATCCCTAGGGGGAAATCAAGGA GCTGGGCACCCCTAATTCTTTATGGAAGTGTTTAAAACTATTTTAATTTTATTACAAGTATTACTAGAGTGGTGGTT CTACTCTAAGATTTCAAAAGTGCATTTAAAATCATACATGTTCCCGCCTGCAAATATATTGTTATTTTGGTGGAGAA AAAAATAGTATATTCTACATAAAAAATTAAAGATATTAACTAAGAGAAATGTCCTACTTTATTATCTTAATGTTCAG ACATCATGAGATTTATTATTTTTTTGAAAAATATATTGAACCATTGAGGAACCTTTATGATGTATCACAGAAATCTT CATAGATTCTAACTAGATGGAAAAAGAGCTCTATTTATTTGTGTTCCTAGGCTTAATGAGAATTCTGGGCTTAGAAC ATCAACGATTAATACCCAGAATTCTTTGTTTTGAGAATATTATGGAGAATGCTCTAAAAATCTAGGGTAAAGATCTA AATTCAAATTTTAAATATATATTTATATTTAAGAAATAGGAAAGGCAAAGTTGAACTCACAATTTGACATTTATTTT TAGTGTTATTTATTTCATAACTTATAAAATATTTAATATATACATACACACTCTTCTTTTTTCTCTGTACAAAGTGG TTTTAATATCAGCTTTCAAAACTGATCTTATAAAATGTAAATCTAAATTGTAAAATAGTTAAGTTTTAACAGTCCCT CCCAAACTTTGTGTTGATTATTCACTTGCTAAAGAGATGTGAGGAATCAGCCTTCAGTTTTTTGGCAGTAGTATATT TTGGAAGTGAAGAAATTGGAACACCTGTTTCTAATTTGGTCTTCATCATTAGAGACAAAACCAAAACACTCCAGGCA GTACTGTTTATAGTGCTGAGCCAGGTAGCACACAGACATAGTAGCCTAAAGGCTCACATAATTCGCATGCTCAGGCC AGGGCAGGGTAAAAATAGCCTTCTGCTTCTTTCAACCCAGTATCAGGAAGCACTACCCCAGTGTTATTATTTGTTTT GTCAAGGTAAGTCTAAATAAACAAGAAAAACTTCTTCGGAAGGCATGGCGAAGGGAGTATTTTAAATGAAAATGATT ACAGAATTTGAATTAGCATGCATCTCTTTGTGTGCAACAGTAATCCAAGAATGTATATGTTACCACTACAACCATTT GTTTCTAATAGTTTTTTCATGTTATATAACATAAATGTATCCACAACCTTAATTAAGAACTATTCTTCCCCCAAAAT CATAGTCCTAGTGTCAAGAAACATACTCCAGTGTTTATTGTAAAATAACAACCACACCCTCAAATTGAAAAAAGTGA ATGTCTAGGACTTTATTACAACTTTTCAGAATAATCTGTAATGAAAACTCATGCTTAAAAATTTAATGGAAAAGACT GAGCCCCAAATTTTGAATAGTGATTACGCCTTACTTGAAGTGCTAATAAAGGTAGGAGAGTACATTTGTTGGAATAA CAGAAATGGTGATTTCAGCCTAAAAGTTTCTGAGGGTAAAGGATCACATGACCTTCAGGAAACTCTCTGCCTCCTGT AGGTGCTTTCCTATCTCCCCCATCCTTCCCTACCCCTTTTCCCTTTTCCTTCCTCTCTTTTTCTCTCACTGTCACTC TGTCTACACACACTGGCATCTTTTGAACACTAAAAGTAAGCACTGTTTTTTAAAAAAGTAATTATTTGTTGGATCAG ATACTTTTATCCCAAGTGAATACCTTCACTGAGATGTGGCCAATGCAATAGTTTCACAGTAAAAACAGTGCCTATAA GAAAATAGATCACATACTATTTTTCAATGATATTAAGTGTATTTTGTAACTATTTTCATTTGGTCCTTGTAACATGA AATAATACATGGAACTTACCTTTATAATAAAAATGGAGTGCCCTGGTTCATCATAGAGGTGCATCTAGTTTGCCCTT AATGGAAGTATACTTGCTGTGTGGATTGATAGCACCTTCTTGAAATGGAGGAGCTCAGCTGGCCTCATGGATGTGCA ATTTTTGCAGTCCCACAGGGCCTTGCATACAGAAGCACCCCGAGCTCAGTTGAATGTCTGTTTGATTTTTTCTTATT TATTTTTTTGAGACACAGTTCCACTTTGTCTTTTTGTCACCCAGGATGGAGTTCAGTGGCACAAACATGGCTCACTG TAGCCTCGACCTCCCTGGCTGAAGGGATCCTCCCACCTCAGCCTCCCAAGTAACCGAGACTACAGGCATATGCCAGC ATGTCCAGCTAATTTTTGTATTTTTTGTAGAGACAGGGTTTCACCATGTTGCCCAGGCTGGTCTCAAACTCCTGGGC TCAAGCGATCTGCCCACCTCTGCCTCCCAAAGTGCTGGGATTAAAGGCATAAGCCACCATGTCCAACTGAAATTCTT AATAATTAATAATTTTTGAGCAAGAGGTCCACACTTTCATTTTGCACTGGGTTCCCAAACAGGTCCTGGGTAGGAAG GATGGCTGAGGATAAAACAGGAGTTGCTTTGGCCTGGCTGAACATTTGAACCAATGATCAGAGTTTCATTTTATGAT TGTGTTACTCTGAACAGATTTGCTATTTTTTTCCAGCTACATTTAGAGTTCCTCATGTATATATCACCCCTCTTTTT CCAGTCCATCTAACCTCTCCTTTTTTTTGTGCCTAGAATCAGTTCTCCTTGCCTTCAAAATCCCTGATAAGTGTCCA TTTCTTTTTGTATCCTTTGATGTAGAAGCCACAAGAATGGCTTTAGCAGCTTATTTTAATCTTATGAATTATTCATT CAGGATTTTTTAAATGATTCAGATGCTTTCAATCTGTTAACAGTATTTATAAAACATGTTTCAGTGATACAACATAG GTGAACTAAACCAAAGATGCAAATGCCTTGGAGGAAAAGAAATTGTATTATAGAGAATCCTGAGATATATCCTTTTG GGTTGTTTAATTTAAAGCCTATCACAAAACAAAGAGAATTGTCGCACTTTAATTCCAACCTCCTGCAGTACTTCACA ACCCTTAGCATAAGATTCTGAAATTTGTAATAGGTGGTACCTAGTTTGATGCAGGGTTTTGCAGCAGTTGTGCGAAT GCCTCTGCGCAACGGCCTTTCAGTCAGACTAAATGAGAAAATCCAAACTGTCCTATCAAAACTGACCCACAATAACT GTACTCTGAGGCGAAACAGAGCAAATGTGGGTTTCCTGTTTTCATTGTAAAACATTCCAGGTTCTCAGATTGAAGAG CTACATTCAGCTGATAGTTGACATCTGTTCCCTCACACGTAGTGGCTCTCAACACGGGCTGCACTTTGGAATCACCT GAGGACCTTTCGGAATCTTCGGTTGAATCATCCTGGCTGTCCTGGTGATGCTTCTTATGTGCAGCTAGGCTGGAGAA CCACTACAGGGCTGACACCTGGAATGGGAGCTTGTAACTTTTACAAAATAATAGATGTTTATCATCTTTTGCAATTT TTACTTTTAAGTCTATACTAAAATGAGCCAAAGAAGTCTTAACAATGATGTATGGCACAATTGGTTGGTTGAGGCTA TCATTCCATGATTACAAATAGGTGGTTATGTGGGGTGGTTTTGCACTTGTGGCAATTGGACTGCAATTTGGCCTTAA AATGACACAATTCCTCGTTCTCAGATGGAGAGGAATTGCCTTGAAATTTGCATGTACCAGACTAAGTGCCAGTATAT ATATGACTGATATTTTCGTGACTCATAGAAGGTGTCCATGGTATAGAGTTTATGCCTACATCTCTATCTTTATTTTG GGCACACATGAGCTTTTGTTAATTATTTCTTTGTACTTGTTAGAATCTGTTTTTGAAAAAAAAAAAAACTTTTGCTT TGATTTGTGGTGGATTCACCTTCTTAAAATAATAAATTTAGAGGATATTAGGAATGACATTCAAAACAAATATAGTG AGAGGTGATTTTTTAAAAATTTTTGTTCCTGGTTTCCAAATTATGTTTACTTTGATTTGATTATATGTTGGTATCTC CCAAATATAGGTTAACTTAGCTATTTAAATGGTATCTTTTGACATTTAAAAAGAATTAAGTACCTGTCAAATCTAGC ATTGAGGTTGCAGTTGAATAAGATAAAAGCTTAGGATGTCAAAAAATAATATAGAGAAATATTATAAGATTTTATGA TTATTCTTGACGTTTTTGATGCAAAAGGAAAATATGCTGAATAGTTCTTCCAAAAAATATTATTTCCCTCAATATTT TATTTGTAGCCATGTAATTTAAAGAGAACAGAAAATAACTGCAATCAAAAGTATGGTTTAATATCAATCAAAGTGGC ACAACAGAATTGATAAGATCTTTATAACAATCAATTGGCTGATATTAAAATATTGATTTTAATTGATCTTTTCAATT AAAATCTTTAGGGCCTGTAACTCATAAAATCAGCATCCACCACAATATATGGTCATTATTGGTTTGTAAGCATAGAT CACCATTGACTCCTACCTGGAGAGACATGTCTATTTCTAAAAATCCAGTAGTTTCTTTGCATTCTCAGTAGTACACG TTGTATATATATATATGTAACAAATTTGGTAGTTTTCAGTATGTGTGATGTCCTTTGGGGGTTATTTATCTTGCTGG TCCATAGGAGGGGTACACTACCCCAAGAATCAAGACATCTGAGTTCTAGTTCTAGTTCTAGCTCTGCCACTGAAGAG CCACCTTACCTGGGGCAAGTTAGCCATTGTCTCCCAGTCATGTTTACCACCCATGAAAGGACTCGTCGGTTTGATGT TTCCATTAAGCTCAATGAGTAACTCTAATAGTTACTCTTGAATCTGGATTGAAAAACACCATGCATCTGATGAGATA ATTCATAAATGTTGCCCCTTTTTTAAATGATACAACCCTAAAAGTGACTGAATTGCCCAAGTGCTTGAACATGGCAG AGGTAGTTACTCCTATTTTGCAGTTTGTGCACTTAAAAATTCCTACAGTGATTGTTACTTTACTGGGGAAAAAAGAT GAGGTGAAACTTCCTCCCAAGGAATTAAAATATCTGTAGAAGCCATGGCTTGCTTTTATAATGTGGAAATCATTTGA TTTGCTGTAATTCACGCAGATCCCTCCTTTTGTCAGGGGGAAATGATTTGCATCATGTTCTTTTTTCATAATGCTTT TACTTCCTGTTTGGATCAGTTGTATGTAAATGTACATTTTTGTTACTTTGGCTGTGCCCGTTAGAATTTATCTTCCA TAAAGTATTTCTCCCATTGAGTCTAATGATGTATACTTTGCCTAGGTCTTTCCAAAATTAAATTTATGTAAATGTCT ATTTTATATAAAATATGATTAAAATAAGTATGTCTGGTTTCAA >gi|118766329|ref|NM_032813.2| Homo sapiens transmembrane and tetratricopeptide repeat containing 4 (TMTC4), transcript variant 1, mRNA (SEQ ID NO: 55) GCGCGGCGGGCGGCCCCTCCCCCTGCCAGGTCCGGGCGGGTGCCTGGAGCCGCCAGAGTTTCCGCACCCGGGAGGGA GATGCGGCCGGGGCTCAGGCTCCTTGCAGTTGTAATTTAGATTCGAGAAGTGGTTTATCCTTTGACTGGAAAAGAAA AGTAGCTGCAGTATTCCCCCAGCACTTGCTGAGAGCATGCCGTATGCCAGGCTGTGAGGCTCGAGAGACAAGCAGTG GAAGAGTTGCGGCCTGTTTCATCTCTGGATTGTAAATCTGAGCCTCCTTCTGGCCCCTGGAAGGGGACAGCATCACC ATGGAATGATTCCTAACCAGCATAATGCTGGAGCCGGGAGCCACCAACCTGCAGTTTTCAGAATGGCCGTGTTGGAC ACTGATTTGGATCACATTCTTCCATCTTCTGTTCTTCCTCCATTCTGGGCTAAGTTAGTAGTGGGATCGGTTGCCAT TGTGTGTTTTGCACGCAGCTATGATGGAGACTTTGTCTTTGATGACTCAGAAGCTATTGTTAACAATAAGGACCTCC AAGCAGAAACGCCCCTGGGGGACCTGTGGCATCATGACTTCTGGGGCAGTAGACTGAGCAGCAACACCAGCCACAAG TCCTACCGGCCTCTCACCGTCCTGACTTTCAGGATTAACTACTACCTCTCGGGAGGCTTCCACCCCGTGGGCTTTCA CGTGGTCAACATCCTCCTGCACAGTGGCATCTCTGTCCTCATGGTGGACGTCTTCTCGGTTCTGTTTGGCGGCCTGC AGTACACCAGTAAAGGCCGGAGGCTGCACCTCGCCCCCAGGGCGTCCCTGCTGGCCGCGCTGCTGTTTGCTGTCCAT CCTGTGCACACCGAGTGTGTTGCTGGTGTTGTCGGCCGTGCAGACCTCCTGTGTGCCCTGTTCTTCTTGTTATCTTT CCTTGGCTACTGTAAAGCATTTAGAGAAAGTAACAAGGAGGGAGCGCATTCTTCCACCTTCTGGGTGCTGCTGAGTA TCTTTCTGGGAGCAGTGGCCATGCTGTGCAAAGAGCAAGGGATCACTGTGCTGGGTTTAAATGCGGTATTTGACATC TTGGTGATAGGCAAATTCAATGTTCTGGAAATTGTCCAGAAGGTACTACATAAGGACAAGTCATTAGAGAATCTCGG CATGCTCAGGAACGGGGGCCTCCTCTTCAGAATGACCCTGCTCACCTCTGGAGGGGCTGGGATGCTCTACGTGCGCT GGAGGATCATGGGCACGGGCCCGCCGGCCTTCACCGAGGTGGACAACCCGGCCTCCTTTGCTGACAGCATGCTGGTG AGGGCCGTAAACTACAATTACTACTATTCATTGAATGCCTGGCTGCTGCTGTGTCCCTGGTGGCTGTGTTTTGATTG GTCAATGGGCTGCATCCCCCTCATTAAGTCCATCAGCGACTGGAGGGTAATTGCACTTGCAGCACTCTGGTTCTGCC TAATTGGCCTGATATGCCAAGCCCTGTGCTCTGAAGACGGCCACAAGAGAAGGATCCTTACTCTGGGCCTGGGATTT CTCGTTATCCCATTTCTCCCCGCGAGTAACCTGTTCTTCCGAGTGGGCTTCGTGGTCGCAGAGCGTGTCCTCTACCT CCCCAGCGTTGGGTACTGTGTGCTGCTGACTTTTGGATTCGGAGCCCTGAGCAAACATACCAAGAAAAAGAAACTCA TTGCCGCTGTCGTGCTGGGAATCTTATTCATCAACACGCTGAGATGTGTGCTGCGCAGCGGCGAGTGGCGGAGTGAG GAACAGCTTTTCAGAAGTGCTCTGTCTGTGTGTCCCCTCAATGCTAAGGTTCACTACAACATTGGCAAAAACCTGGC TGATAAAGGCAACCAGACAGCTGCCATCAGATACTACCGGGAAGCTGTAAGATTAAATCCCAAGTATGTTCATGCCA TGAATAATCTTGGAAATATCTTAAAAGAAAGGAATGAGCTACAGGAAGCTGAGGAGCTGCTGTCTTTGGCTGTTCAA ATACAGCCAGACTTTGCCGCTGCGTGGATGAATCTAGGCATAGTGCAGAATAGCCTGAAACGGTTTGAAGCAGCAGA GCAAAGTTACCGGACAGCAATTAAACACAGAAGGAAATACCCAGACTGTTACTACAACCTCGGGCGTCTGTATGCAG ATCTCAATCGCCACGTGGATGCCTTGAATGCGTGGAGAAATGCCACCGTGCTGAAACCAGAGCACAGCCTGGCCTGG AACAACATGATTATACTCCTCGACAATACAGGTAATTTAGCCCAAGCTGAAGCAGTTGGAAGAGAGGCACTGGAATT AATACCTAATGATCACTCTCTCATGTTCTCGTTGGCAAACGTGCTGGGGAAATCCCAGAAATACAAGGAATCTGAAG CTTTATTCCTCAAGGCAATTAAAGCAAATCCAAATGCTGCAAGTTACCATGGTAATTTGGCTGTGCTTTATCATCGT TGGGGACATCTAGACTTGGCCAAGAAACACTATGAAATCTCCTTGCAGCTTGACCCCACGGCATCAGGAACTAAGGA GAATTACGGTCTGCTGAGAAGAAAGCTAGAACTAATGCAAAAGAAAGCTGTCTGATCCTGTTTCCTTCATGTTTTGA GTTTGAGTGTGTGTGTGCATGAGGCATATCATTAATAGTATGTGGTTACATTTAACCATTTAAAAGTCTTAGACATG TTATTTTACTGATTTTTTTCTATGAAAACAAAGACATGCAAAAAGATTATAGCACCAGCAATATACTCTTGAATGCG TGATATGATTTTTCATTGAAATTGTATTTTTTCAGACAACTCAAATGTAATTCTAAAATTCCAAAAATGTCTTTTTT AATTAAACAGAAAAAGAGAAAAAATTATCTTGAGCAACTTTTAGTAGAATTGAGCTTACATTTGGGATCTGAGCCTT GTCGTGTATGGACTAGCACTATTAAACTTCAATTATGACCAAGAAAGGATACACTGGCCCCTACAATTTGTATAAAT ATTGAACATGTCTATATATTAGCATTTTTATTTAATGACAAAGCAAATTAAGTTTTTTTATCTCTTTTTTTTAAAAC AACATACTGTGAACTTTGTAAGGAAATATTTATTTGTATTTTTATGTTTTGAATAGGGCAAATAATCGAATGAGGAA TGGAAGTTTTAACATAGTATATCTATATGCTTTTCCCCATAGGAAGAAATTGACTCTTGCAGTTTTTGGATGCTCTG ACTTGTGCAATTTCAATACACAGGAGATTATGTAATGTAATATTTTACATAAGCGGTTACTATCAATTGAAAGTTCA AGCCATGCTTTAGGCAAGAGCAGGCAGCCTCACATCTTTATTTTTGTTACATCCAAGGTGAAGAGGGCAACACATCT GTGTAAGCTGCTTTTTAGTGTGTTTATCTGAAGGCCGTTTTCCATTTTGCTTAATGTAACTACAGACATTATCCAGA AAATGCAAAATTTTCTATCAAATGGAGCCACATTCGGGGAATTCGTGGTATTTTTAAGAATTGAGTTGTTCCTGCTG TTTTTTATTTGATCCAAACAATGTTTTGTTTTGTTCTTCTCTGTATGCTGTTGACCTAATGATTTATGCAATCTCTG TAATTTCTTATGCAGTAAAATTACTACACAAACTAGCATGAAAATGTCATATTGCCTTCTTAATCAATTATTTTCAA GTAGTGAACTTTGTATCCTCCTTTACCTTAAAATGAAATCAAACTGACCAAATCATCAAAAAAAAAAAAAAAAAA >gi|93141224|ref|NM_003304.4| Homo sapiens transient receptor potential cation channel, subfamily C, member 1 (TRPC1), mRNA (SEQ ID NO: 56) CGGGCCTCGAGCCGAGGCAGCAGTGGGAACGACTCATCCTTTTTCCAGCCCTGGGGCGTGGCTGGGGTCGGGGTCGG GGTCGGGGCCGGTGGGGGCCCCGCCCCCGTCTCCTGGCCTGCCCCCTTCATGGGCCGCGATGATGGCGGCCCTGTAC CCGAGCACGGACCTCTCGGGCGCCTCCTCCTCCTCCCTGCCTTCCTCTCCATCCTCTTCCTCGCCGAACGAGGTGAT GGCGCTGAAGGATGTGCGGGAGGTGAAGGAGGAGAATACGCTGAATGAGAAGCTTTTCTTGCTGGCGTGCGACAAGG GTGACTATTATATGGTTAAAAAGATTTTGGAGGAAAACAGTTCAGGTGACTTGAACATAAATTGCGTAGATGTGCTT GGGAGAAATGCTGTTACCATAACTATTGAAAACGAAAACTTGGATATACTGCAGCTTCTTTTGGACTACGGTTGTCA GAAACTAATGGAACGAATTCAGAATCCTGAGTATTCAACAACTATGGATGTTGCACCTGTCATTTTAGCTGCTCATC GTAACAACTATGAAATTCTTACAATGCTCTTAAAACAGGATGTATCTCTACCCAAGCCCCATGCAGTTGGCTGTGAA TGCACATTGTGTTCTGCAAAAAACAAAAAGGATAGCCTCCGGCATTCCAGGTTTCGTCTTGATATATATCGATGTTT GGCCAGTCCAGCTCTAATAATGTTAACAGAGGAGGATCCAATTCTGAGAGCATTTGAACTTAGTGCTGATTTAAAAG AACTAAGTCTTGTGGAGGTGGAATTCAGGAATGATTATGAGGAACTAGCCCGGCAATGTAAAATGTTTGCTAAGGAT TTACTTGCACAAGCCCGGAATTCTCGTGAATTGGAAGTTATTCTAAACCATACGTCTAGTGACGAGCCTCTTGACAA ACGGGGATTATTAGAAGAAAGAATGAATTTAAGTCGTCTAAAACTTGCTATCAAATATAACCAGAAAGAGTTTGTCT CCCAGTCTAACTGCCAGCAGTTCCTGAACACTGTTTGGTTTGGACAGATGTCGGGTTACCGACGCAAGCCCACCTGT AAGAAGATAATGACTGTTTTGACAGTAGGCATCTTTTGGCCAGTTTTGTCACTTTGTTATTTGATAGCTCCCAAATC TCAGTTTGGCAGAATCATTCACACACCTTTTATGAAATTTATCATTCATGGAGCATCATATTTCACATTTCTGCTGT TGCTTAATCTATACTCTCTTGTCTACAATGAGGATAAGAAAAACACAATGGGGCCAGCCCTTGAAAGAATAGACTAT CTTCTTATTCTGTGGATTATTGGGATGATTTGGTCAGACATTAAAAGACTCTGGTATGAAGGGTTGGAAGACTTTTT AGAAGAATCTCGTAATCAACTCAGTTTTGTCATGAATTCTCTTTATTTGGCAACCTTTGCCCTCAAAGTGGTTGCTC ACAACAAGTTTCATGATTTTGCTGATCGGAAGGATTGGGATGCATTCCATCCTACACTGGTGGCAGAAGGGCTTTTT GCATTTGCAAATGTTCTAAGTTATCTTCGTCTCTTTTTTATGTATACAACCAGCTCTATCTTGGGTCCATTACAGAT TTCAATGGGACAGATGTTACAAGATTTTGGAAAATTTCTTGGGATGTTTCTTCTTGTTTTGTTTTCTTTCACAATTG GACTGACACAACTGTATGATAAAGGATATACTTCAAAGGAGCAGAAGGACTGTGTAGGCATCTTCTGTGAACAGCAA AGCAATGATACCTTCCATTCGTTCATTGGCACCTGCTTTGCTTTGTTCTGGTATATTTTCTCCTTAGCGCATGTGGC AATCTTTGTCACAAGATTTAGCTATGGAGAAGAACTGCAGTCCTTTGTGGGAGCTGTCATTGTTGGTACATACAATG TCGTGGTTGTGATTGTGCTTACCAAACTGCTGGTGGCAATGCTTCATAAAAGCTTTCAGTTGATAGCAAATCATGAA GACAAAGAATGGAAGTTTGCTCGAGCAAAATTATGGCTTAGCTACTTTGATGACAAATGTACGTTACCTCCACCTTT CAACATCATTCCCTCACCAAAGACTATCTGCTATATGATTAGTAGCCTCAGTAAGTGGATTTGCTCTCATACATCAA AAGGCAAGGTCAAACGGCAAAACAGTTTAAAGGAATGGAGGAATTTGAAACAGAAGAGAGATGAAAACTATCAAAAA GTGATGTGCTGCCTAGTGCATCGTTACTTGACTTCCATGAGACAGAAGATGCAAAGTACAGATCAGGCAACTGTGGA AAATCTAAACGAACTGCGCCAAGATCTGTCAAAATTCCGAAATGAAATAAGGGATTTACTTGGCTTTCGGACTTCTA AATATGCTATGTTTTATCCAAGAAATTAACCATTTTCTAAATCATGGAGCGAATAATTTTCAATAACAGATCCAAAA GACTATATTGCATAACTTGCAATGAAATTAATGAGATATATATTGAAATAAAGAATTATGTAAAAGCCATTCTTTAA AATATTTATAGCATAAATATATGTTATGTAAAGTGTGTATATAGAATTAGTTTTTTAAACCTTCTGTTAGTGGCTTT TTGCAGAAGCAAAACAGATTAAGTAGATAGATTTTGTTAGCATGCTGCTTGGTTTTCTTACTTAGTGCTTTAAAATG TTTTTTTTTATGTTTAAGAGGGGCAGTTATAAATGGACACATTGCCCAGAATGTTTTGTAAAATGAAGACCAGCAAA TGTAGGCTGATCTCCTTCACAGGATACACTTGAAATATAGAAGTTATGTTTTAAATATCTCTGTTTTAGGAGTTCAC ATATAGTTCAGCATTTATTGTTTAGGAGTATAATTTTATTTTATCTAAAATAATAGTCTATTTTTTCTTTTGTATTT TGTTATAATCTTAAGCAACAAAGAAAAAACCCTAATATTTGAATCTATTTATGTCTTTCAATTTAAATTCACTTCAG TTTTTGTTATTGTAATATATTTACTTTTACATGGTTATAATCACTTTATATTTTTAATGTTTTTTTCACTTAATATT TTATATATACATTTCCATGTATTGATGTAGTTAGTCCACATTTAAATTTTTATAGAATTATATAGTTTTTGAAAAAT ACAGTCAGTAGATGTTTTATTTTTTAGCTATTCAGTTATGTTTATAAGTTTGCATAGCTACTTCTCGACATTTGGTT TGTTTTAATTTTTTTGTATCATAATAGTCCTATTTTTTTTTCAAGTTGGAGTGAATGTTTTTAGTTTTAAGATAGAT AGGAGACACTTTTTTATCACATGTAGTCACAACCTGTTTTGTTTTTGTAAAACATAGGAAGTCTCTTTAATGCAATG ATTTGTTTTATATTTGGACTAAGGTTCTTGAGCTTATCTCCCAAGGTACTTTCCATAATTTAACACAGCTTCTATAA AAGTGACTTCATGCTTACTTGTGGATCATTCTTGCTGCTTAAGATGAAAAGCATTGGTTTTTTAAAATTAGAGAATA AAATATGTATTTAAATTTTTGGTGTGTTCACATAAAGGGATGTAGCTAAAATGTTTTCATAGGCTATTATATATTCT CGCAGCATTTCCAGTTAAGAGGATATTAGGTATATAATTCTCTTCTTAACCGAATGTCAGATGGTCTTACGCCACAG GGTGCAGGTAACCCTTGGTCTGTAAGCACCACCGATCCAGGGATCATTGTCTAAATAGGTTACTATTGTTTGTTTCA TCTTGCTTTTGCATTTTTATTTTTTAATTTCCAAATTTTAAGTGTTCCCTCTTTGGGGCAAATTCTTATAAAAATGT TTATTGTAAAGTTATATATTTTGTCTACGATGGGATTATGCACTTCCCAATTGGGATTTTACATCTGGATTTTTAGT CATTCTAAAAAACACCTAATTATTAAAACATTTATAGAGTGCCTACTGTATGCATGAGTTGAGTTGCTTCTGAGGTA CATTTTGAATGACAGCATATTGTAAGAAAAAAAAAGGTGAATAAAATTTGACATTAGATTATAAAAAAAAAAA >gi|21264577|ref|NM_005727.2| Homo sapiens tetraspanin 1 (TSPAN1), mRNA (SEQ ID NO: 57) GTGAGAGCCAGGCGTCCCTCTGCCTGCCCACTCAGTGGCAACACCCGGGAGCTGTTTTGTCCTTTGTGGAGCCTCAG CAGTTCCCTCTTTCAGAACTCACTGCCAAGAGCCCTGAACAGGAGCCACCATGCAGTGCTTCAGCTTCATTAAGACC ATGATGATCCTCTTCAATTTGCTCATCTTTCTGTGTGGTGCAGCCCTGTTGGCAGTGGGCATCTGGGTGTCAATCGA TGGGGCATCCTTTCTGAAGATCTTCGGGCCACTGTCGTCCAGTGCCATGCAGTTTGTCAACGTGGGCTACTTCCTCA TCGCAGCCGGCGTTGTGGTCTTTGCTCTTGGTTTCCTGGGCTGCTATGGTGCTAAGACTGAGAGCAAGTGTGCCCTC GTGACGTTCTTCTTCATCCTCCTCCTCATCTTCATTGCTGAGGTTGCAGCTGCTGTGGTCGCCTTGGTGTACACCAC AATGGCTGAGCACTTCCTGACGTTGCTGGTAGTGCCTGCCATCAAGAAAGATTATGGTTCCCAGGAAGACTTCACTC AAGTGTGGAACACCACCATGAAAGGGCTCAAGTGCTGTGGCTTCACCAACTATACGGATTTTGAGGACTCACCCTAC TTCAAAGAGAACAGTGCCTTTCCCCCATTCTGTTGCAATGACAACGTCACCAACACAGCCAATGAAACCTGCACCAA GCAAAAGGCTCACGACCAAAAAGTAGAGGGTTGCTTCAATCAGCTTTTGTATGACATCCGAACTAATGCAGTCACCG TGGGTGGTGTGGCAGCTGGAATTGGGGGCCTCGAGCTGGCTGCCATGATTGTGTCCATGTATCTGTACTGCAATCTA CAATAAGTCCACTTCTGCCTCTGCCACTACTGCTGCCACATGGGAACTGTGAAGAGGCACCCTGGCAAGCAGCAGTG ATTGGGGGAGGGGACAGGATCTAACAATGTCACTTGGGCCAGAATGGACCTGCCCTTTCTGCTCCAGACTTGGGGCT AGATAGGGACCACTCCTTTTAGGCGATGCCTGACTTTCCTTCCATTGGTGGGTGGATGGGTGGGGGGCATTCCAGAG CCTCTAAGGTAGCCAGTTCTGTTGCCCATTCCCCCAGTCTATTAAACCCTTGATATGCCCCCTAGGCCTAGTGGTGA TCCCAGTGCTCTACTGGGGGATGAGAGAAAGGCATTTTATAGCCTGGGCATAAGTGAAATCAGCAGAGCCTCTGGGT GGATGTGTAGAAGGCACTTCAAAATGCATAAACCTGTTACAATGTTAAAAAAAAAAAAAAAAAAA >gi|122937465|ref|NM_001080509.1| Homo sapiens tetraspanin 11 (TSPAN11), mRNA (SEQ ID NO: 58) AGACTGTCCCGAGCTTCCCCCGGGCGGGCAGAGGGAAGCCGGCTGGGGATGAGGAGTGGAGGAGGCAGGAATGCCTG GGACACTCGCGGGGCATGTGAGCAGGCCCAGAAGCCATGGCCCACTATAAGACTGAGCAGGACGACTGGCTGATCAT CTACTTGAAGTATTTACTCTTTGTCTTCAACTTCTTCTTCTGGGTCGGGGGAGCAGCCGTCCTGGCTGTGGGCATCT GGACCCTGGTGGAGAAGAGTGGCTACCTCAGCGTCCTGGCCTCCAGCACCTTTGCCGCCTCCGCCTACATCCTCATC TTTGCGGGCGTACTTGTCATGGTGACCGGCTTCCTGGGCTTCGGTGCCATCCTCTGGGAGCGGAAGGGCTGCCTCTC CACGTATTTCTGCCTGTTGCTCGTCATCTTCCTGGTTGAGCTGGTGGCGGGAGTCCTGGCCCATGTGTATTACCAGA GGCTGAGTGATGAACTGAAGCAGCACTTGAACCGGACTCTGGCTGAGAACTACGGGCAGCCCGGAGCCACGCAGATC ACCGCCTCAGTGGACCGACTCCAGCAGGATTTCAAGTGCTGTGGAAGCAACAGCTCAGCCGACTGGCAGCACAGCAC GTACATCCTGTTGCGGGAGGCCGAGGGCCGCCAGGTGCCCGACAGCTGCTGCAAGACAGTGGTGGTGCGCTGCGGCC AGCGGGCCCACCCCTCCAACATCTATAAGGTGGAGGGAGGCTGCCTCACCAAGCTGGAGCAGTTCCTGGCCGACCAC CTGCTGCTTATGGGGGCAGTGGGCATCGGGGTGGCCTGCCTGCAGATCTGCGGGATGGTTCTCACCTGCTGCTTGCA CCAGAGGCTCCAGCGGCATTTTTACTAATGGCCAACCACCTCCTCTTCCAACTGCCCCTCAAGACAACATGTGGCCA CATGCCATCTGCAAGGCCTGCAGAGTTAGCACCAGCTCCACTAGGGCCATAGATGCCCCCTCCTTTGTGCCTAGCTC CTGCGAATCCACCGAGTGCCTGAGACCATAGCTTCTGTGCCCACCCAGGCAGAGACCCTCGGCCCCCTCTCCTCCAT TTCTGAGCCCCCATGGCCAGATCCTGGGCAGGGAAATGATCCTTTCAGGAGACAACCAGAGCCCCTCACCAGGAACG GGGGCACCCGTGGACTACGGGAGGGTGGCGGTTGGGTTCTCTGCTCCCTCCCAGCTCCTGAACCTGGAACAATCGGC AGAAAACCCAGGAACCCCGGCACTCCTGCATTCAGCACGGGATTCCCCCACCCATGCCCAGAAGCCCTGACCTTGCT GTTTCTGGAAAAAGCATGGGGTGGGGCAGGGAGGGCTGGCATTTCCCCCAGAAGACCTTGCCCTTTGACCTGCCCAC TCTCCACACTGCCTCACCTGGAAAGCCATGTCCTGCTGGCCTCATTCCTTCCTGAAGGGCCTAGGAGTGGGGAGGCC TGGGTAGGGCAGCCACA >gi|48255911|ref|NM_012338.3| Homo sapiens tetraspanin 12 (TSPAN12), mRNA (SEQ ID NO: 59) GGCCCTGGCTGCCGCCGCTGCCTCGTCCGGACTCGGAGAGGACTTGGGAGGGACAGCGGCGCTGGGAGGTGGCTTAG CAGAGACTTTCCAGCAACTGCTGCCCAGGACTTTTTTTTTTTTTTTTCTTTTTCCCAGGAGGCGGCGACGGCGGCGG CGGGGGGAGAGGAAGAGAAAGAAGCGTCTCCAGCTGAAGCCAATGCAGCCCTCCGGCTCTCCGCGAAGAAGTTCCCT GCCCCGATGAGCCCCCGCCGTGCGTCCCCGACTATCCCCAGGCGGGCGTGGGGCACCGGGCCCAGCGCCGACGATCG CTGCCGTTTTGCCCTTGGGAGTAGGATGTGGTGAAAGGATGGGGCTTCTCCCTTACGGGGCTCACAATGGCCAGAGA AGATTCCGTGAAGTGTCTGCGCTGCCTGCTCTACGCCCTCAATCTGCTCTTTTGGTTAATGTCCATCAGTGTGTTGG CAGTTTCTGCTTGGATGAGGGACTACCTAAATAATGTTCTCACTTTAACTGCAGAAACGAGGGTAGAGGAAGCAGTC ATTTTGACTTACTTTCCTGTGGTTCATCCGGTCATGATTGCTGTTTGCTGTTTCCTTATCATTGTGGGGATGTTAGG ATATTGTGGAACGGTGAAAAGAAATCTGTTGCTTCTTGCATGGTACTTTGGAAGTTTGCTTGTCATTTTCTGTGTAG AACTGGCTTGTGGCGTTTGGACATATGAACAGGAACTTATGGTTCCAGTACAATGGTCAGATATGGTCACTTTGAAA GCCAGGATGACAAATTATGGATTACCTAGATATCGGTGGCTTACTCATGCTTGGAATTTTTTTCAGAGAGAGTTTAA GTGCTGTGGAGTAGTATATTTCACTGACTGGTTGGAAATGACAGAGATGGACTGGCCCCCAGATTCCTGCTGTGTTA GAGAATTCCCAGGATGTTCCAAACAGGCCCACCAGGAAGATCTCAGTGACCTTTATCAAGAGGGTTGTGGGAAGAAA ATGTATTCCTTTTTGAGAGGAACCAAACAACTGCAGGTGCTGAGGTTTCTGGGAATCTCCATTGGGGTGACACAAAT CCTGGCCATGATTCTCACCATTACTCTGCTCTGGGCTCTGTATTATGATAGAAGGGAGCCGGGGACAGACCAAATGA TGTCCTTGAAGAATGACAACTCTCAGCACCTGTCATGTCCCTCAGTAGAACTGTTGAAACCAAGCCTGTCAAGAATC TTTGAACACACATCCATGGCAAACAGCTTTAATACACACTTTGAGATGGAGGAGTTATAAAAAGAAATGTCACAGAA GAAAACCACAAACTTGTTTTACTGGACTTGTGAATTTTTGAGTACATACTATGTGTTTCAGAAATATGTAGAAATAA AAATGTTGCCATAAAATAACACCTAAGCATATACTATTCTATGCTTTAAAATGAGGATGGAAAAGTTTCATGTCATA AGTCACCACCTGGACAATAATTGATGCCCTTAAAATGCTGAAGACAGATGTCATACCCACTGTGTAGCCTGTGTATG ACTTTTACTGAACACAGTTATGTTTTGAGGCAGCATGGTTTGATTAGCATTTCCGCATCCATGCAAACGAGTCACAT ATGGTGGGACTGGAGCCATAGTAAAGGTTGATTTACTTCTACCAACTAGTATATAAAGTACTAATTAAATGCTAACA TAGGAAGTTAGAAAATACTAATAACTTTTATTACTCAGCGATCTATTCTTCTGATGCTAAATAAATTATATATCAGA AAACTTTCAATATTGGTGACTACCTAAATGTGATTTTTGCTGGTTACTAAAATATTCTTACCACTTAAAAGAGCAAG CTAACACATTGTCTTAAGCTGATCAGGGATTTTTTGTATATAAGTCTGTGTTAAATCTGTATAATTCAGTCGATTTC AGTTCTGATAATGTTAAGAATAACCATTATGAAAAGGAAAATTTGTCCTGTATAGCATCATTATTTTTAGCCTTTCC TGTTAATAAAGCTTTACTATTCTGTCCTGGGCTTATATTACACATATAACTGTTATTTAAATACTTAACCACTAATT TTGAAAATTACCAGTGTGATACATAGGAATCATTATTCAGAATGTAGTCTGGTCTTTAGGAAGTATTAATAAGAAAA TTTGCACATAACTTAGTTGATTCAGAAAGGACTTGTATGCTGTTTTTCTCCCAAATGAAGACTCTTTTTGACACTAA ACACTTTTTAAAAAGCTTATCTTTGCCTTCTCCAAACAAGAAGCAATAGTCTCCAAGTCAATATAAATTCTACAGAA AATAGTGTTCTTTTTCTCCAGAAAAATGCTTGTGAGAATCATTAAAACATGTGACAATTTAGAGATTCTTTGTTTTA TTTCACTGATTAATATACTGTGGCAAATTACACAGATTATTAAATTTTTTTACAAGAGTATAGTATATTTATTTGAA ATGGGAAAAGTGCATTTTACTGTATTTTGTGTATTTTGTTTATTTCTCAGAATATGGAAAGAAAATTAAAATGTGTC AATAAATATTTTCTAGAGAGTAAAAAAAAAAAAAAAAA >gi|54859559|ref|NM_012171.1| Homo sapiens tetraspanin 17 (TSPAN17), transcript variant 1, mRNA (SEQ ID NO: 60) GGCGGGGCCCGGTCCAGAGGCGGGGACAGCAGGGCTCCGGGCAAGGAGGTCTGGATGCTGAGGGCGGTCCCTGAGGG GCGGGCGGGGCCCGACCGGCGCTCTGTGTGGCCGAGGCCATGAAGCCGCAGCCGCCCGGCTAGGCCCCGGGCGGCTC TAGCCCAGGGCGGCCCGCGGGGCGCTGGGCCTGGCTCCCGGCTCCGGTTTCCGGGCCGGCGGGTGGCCGCTCACCAT GCCCGGCAAGCACCAGCATTTCCAGGAACCTGAGGTCGGCTGCTGCGGGAAATACTTCCTGTTTGGCTTCAACATTG TCTTCTGGGTGCTGGGAGCCCTGTTCCTGGCTATCGGCCTCTGGGCCTGGGGTGAGAAGGGCGTTCTCTCGAACATC TCAGCGCTGACAGATCTGGGAGGCCTTGACCCCGTGTGGCTGTTTGTGGTAGTTGGAGGCGTCATGTCGGTGCTGGG CTTTGCTGGCTGCATTGGGGCCCTCCGGGAGAACACCTTCCTGCTCAAGTTTTTCTCCGTGTTCCTCGGTCTCATCT TCTTCCTGGAGCTGGCAACAGGGATCCTGGCCTTTGTCTTCAAGGACTGGATTCGAGACCAGCTCAACCTCTTCATC AACAACAACGTCAAGGCCTACCGGGACGACATTGACCTCCAGAACCTCATTGACTTTGCTCAGGAATACTGGTCTTG CTGCGGAGCCCGAGGCCCCAATGACTGGAACCTCAATATCTACTTCAACTGCACTGACTTGAACCCCAGCCGGGAGC GCTGCGGGGTGCCCTTCTCCTGCTGCGTCAGGGACCCTGCGGAGGATGTCCTCAACACCCAGTGTGGCTACGACGTC CGGCTCAAACTGGTGAGAGGGGAGCTGGAGCAGCAGGGCTTCATCCACACCAAAGGCTGCGTGGGCCAGTTTGAGAA GTGGCTGCAGGACAACCTGATTGTGGTGGCGGGAGTCTTCATGGGCATCGCCCTCCTCCAGATCTTTGGCATCTGCC TGGCCCAGAACCTCGTGAGTGACATCAAGGCAGTGAAAGCCAACTGGAGCAAATGGAATGATGACTTTGAAAACCAC TGGCTTACGCCCACCATTTCCGAGGTCCTGTCCACGGCGGGGCCTCAGCAGAACTCTCTGACTGGGGCCCCTGGCCC GGCCCCACCCAGCCGACATGTTTTCTTTGGCCTGGGTGGTTTATACCCTGAGCCAACCTTTAAAAATTGGTAGATTT CACATAAAAGTCCAGATCCACAGCTTCTCTTGAAGAATGACCACCTGGCTACGCCGGCTCTTCGGTGGCAACACTAC CTGGGACACTGCCTCCCCAGTCACCAAGGGCCCCAGCTGGCCCGTTCTACTCACCTAAGTGCCGCCTGACCCTTGTA CACTAGGAGCTGGCCTCCCACCTCTGCAGGGTTATTCCCTGCACCTCGAGGCCGCTGCGGGCCAATCTGGAGTGAAA CACGGGGACCTGAAGGATGGAGAGGCTGGACCCCGCTTTGAAGAGGGTGCAGCCTGGGAAGGGCGGCCTTGCTGGGG ACTGCGGTGGGAGTAGAGTGCCCAGGAGAGGGTCTGAGGGGTGGGATGGGGGTCAGGACAATTTTGCAAAAGAAGTA GCTGGAAGCCATGGGACTGGCGGGAGCCTGTTTGGGGGATCTGGATGGTTGACTCCTAGGAGTCAAGTTCAGCATCT TCACCGTGGCTGCAGAGCTGCCTGATGGGCACTAGAGGGCATGCCAGCCCCACACTCCCTGGGTCTGGCTTCCTCCC GCAACCTCACTCTAGTAGAGCCTGTGCCTGCCTACTAGCGCTCTGGGGTTCGGAGAGTTTGGGAATTTCTCAGAGCC AACTGGCTCAGGCTTGGGAAGGCTGGCTGCTGCCCTCAGCTCCGCCTCATCAGCTATGTGAAGGGGTGTGTGTGGAG TGATCCTGCCGCCCCCTCCCTGGGCTCGTCCAGAGATCTCAAACTCCGATGCCCCTGGGGCCACGTATGTTGTATAA ATGGATGAAACAGGCCCTTGAGTTGGGAGCCTGCTTCACTTTGACTTTCCCACTGTTGCTGGAGACAAAGACATCGT GATGAGAGAAAGTTCGCACAATCTAGTCGGTAACAGCCACTTTCCTTGAGACCAAGAGAGTGCGGTGGGGATGGGGG GGAGAGCACGGGTCCCCGTCTGACAGTGGCCGCTGCCATATTCAGGTGTAGCTAATTGCTCTGGTGTGGGAATGCAG GCCTAATGACAGAAATCTGGAGAAGCCAGAAATACAGATTTGTATGTGAGATGTCCTGATTTTTTAAGTTGTTGGCA GAAATTAATTCAGAAATCAAATCTGCAGGCCAAACAAGGTGCAGGACCCAGCTTTGGCCCCATGCCCCTGTAGGTCC CTCTGGGACAGTCACCGCTGGGGTCCTGGCTGCTCTGTCATTGAGGGATGCTGGGCACTGCTGCCGGGTGGCCAGGG TATGGGGCATGTGCCCAGCAATGTGGCTCCTTGGCCCCGCTGGCCAGTGTCCTGGGCCCCTGACAGGCGCTGGCTGT GAGTGGTTTGTACATGCTACAATAAATGCAGCTGGCAGCATTGTGCAAAAAAAAAAAAAAAAAA >gi|21265107|ref|NM_004616.2| Homo sapiens tetraspanin 8 (TSPAN8), mRNA (SEQ ID NO: 61) AGTGCCCCAGGAGCTATGACAAGCAAAGGAACATACTTGCCTGGAGATAGCCTTTGCGATATTTAAATGTCCGTGGA TACAGAAATCTCTGCAGGCAAGTTGCTCCAGAGCATATTGCAGGACAAGCCTGTAACGAATAGTTAAATTCACGGCA TCTGGATTCCTAATCCTTTTCCGAAATGGCAGGTGTGAGTGCCTGTATAAAATATTCTATGTTTACCTTCAACTTCT TGTTCTGGCTATGTGGTATCTTGATCCTAGCATTAGCAATATGGGTACGAGTAAGCAATGACTCTCAAGCAATTTTT GGTTCTGAAGATGTAGGCTCTAGCTCCTACGTTGCTGTGGACATATTGATTGCTGTAGGTGCCATCATCATGATTCT GGGCTTCCTGGGATGCTGCGGTGCTATAAAAGAAAGTCGCTGCATGCTTCTGTTGTTTTTCATAGGCTTGCTTCTGA TCCTGCTCCTGCAGGTGGCGACAGGTATCCTAGGAGCTGTTTTCAAATCTAAGTCTGATCGCATTGTGAATGAAACT CTCTATGAAAACACAAAGCTTTTGAGCGCCACAGGGGAAAGTGAAAAACAATTCCAGGAAGCCATAATTGTGTTTCA AGAAGAGTTTAAATGCTGCGGTTTGGTCAATGGAGCTGCTGATTGGGGAAATAATTTTCAACACTATCCTGAATTAT GTGCCTGTCTAGATAAGCAGAGACCATGCCAAAGCTATAATGGAAAACAAGTTTACAAAGAGACCTGTATTTCTTTC ATAAAAGACTTCTTGGCAAAAAATTTGATTATAGTTATTGGAATATCATTTGGACTGGCAGTTATTGAGATACTGGG TTTGGTGTTTTCTATGGTCCTGTATTGCCAGATCGGGAACAAATGAATCTGTGGATGCATCAACCTATCGTCAGTCA AACCCCTTTAAAATGTTGCTTTGGCTTTGTAAATTTAAATATGTAAGTGCTATATAAGTCAGGAGCAGCTGTCTTTT TAAAATGTCTCGGCTAGCTAGACCACAGATATCTTCTAGACATATTGAACACATTTAAGATTTGAGGGATATAAGGG AAAATGATATGAATGTGTATTTTTACTCAAAATAAAAGTAACTGTTTACGTTAAAAAAAAAAAAAAAAAAAAAAAAA AAAA >gi|24371240|ref|NM_024630.2| Homo sapiens zinc finger, DHHC-type containing 14 (ZDHHC14), transcript variant 1, mRNA (SEQ ID NO: 62) GAAGGAGTGGACCCAACCTGGCCGCGCCGCAGAAGTGGCTCCCGAGGAAGCCGGCGCCGGGGCCGCCGCCTCGTGTC CCCTCGGGGCGCAGTGCTCGGGGGTCGGCGGGCCAGAGCCGAGGCGCGGCCGGGGAGCCGGGGGCTGCGGGGCCGAG CGGGCAGCCGCGCGAGGGGGCGGGCGCTCGGCGACCCGGGGGCCGGCCGGGCTGAGCCCCGCGCCCCGGGACGCGGG CTGGAAGCGACGGAGGAGTGCTGCCGCGGGCTGCGGACCAGCGCCGTCCCCTCACGGAGCGGGGATTCTGCTATGAC AGTTGGGCTCCCCGGAGGGTTAACCTGGGTGTCCTCGGCAAAGTTGTCGCCGAGCCGGGAGCCCGTGTAGGGGCCGC GGCGCCGCGGCTCGGGGGGCGGCCGGGCGGCCGGCGGCGGTCGTGGCTCGGCGGGGCCCGCGCGGCCGGGGGGCTCC TGGGGGTGTGCGCCCCCAGCCGGCTGCCCTCGTGGATGCCTCCCGGCGGCGGCGGGCCCATGAAAGACTGCGAGTAC AGCCAGATCAGCACCCACAGCTCCTCCCCCATGGAGTCGCCCCACAAGAAGAAGAAAATCGCGGCCCGGAGGAAATG GGAGGTGTTCCCGGGAAGAAACAAGTTCTTCTGTAACGGGAGGATCATGATGGCCCGGCAGACGGGCGTCTTCTACC TGACGCTCGTCCTCATCCTGGTCACTAGCGGACTCTTCTTCGCCTTCGACTGTCCGTACCTGGCGGTGAAAATCACC CCTGCCATCCCTGCAGTCGCTGGCATCCTGTTCTTCTTTGTGATGGGGACCCTGCTCCGCACCAGCTTCAGCGACCC CGGAGTCCTCCCACGAGCCACGCCTGATGAAGCCGCCGATCTGGAAAGGCAAATAGATATCGCAAACGGCACCAGTT CAGGGGGGTACCGCCCGCCTCCCAGAACCAAAGAAGTCATCATCAATGGCCAGACCGTGAAACTTAAATACTGTTTC ACCTGCAAGATTTTCCGGCCCCCTCGCGCCTCCCATTGCAGCCTTTGTGATAACTGCGTAGAACGGTTTGATCACCA CTGTCCCTGGGTAGGCAACTGTGTGGGGAAAAGAAACTACAGATTTTTTTATATGTTTATTTTATCTCTGTCTTTTC TGACAGTCTTTATATTTGCATTCGTTATCACCCACGTCATTCTTCGTTCACAGCAAACAGGATTCCTAAATGCCCTT AAGGACAGTCCTGCAAGCGTCCTGGAGGCTGTGGTGTGCTTCTTCTCTGTCTGGTCCATCGTTGGCCTCTCAGGATT CCACACCTACTTGATCAGCTCCAACCAGACAACAAATGAGGACATTAAAGGATCCTGGTCAAATAAAAGAGGTAAAG AAAATTACAATCCCTACAGCTACGGAAATATCTTTACCAACTGCTGTGTTGCCCTGTGTGGGCCCATCTCACCAAGC CTGATCGACAGAAGAGGGTACATCCAGCCCGACACGCCGCAGCCAGCAGCACCCTCCAATGGCATCACCATGTACGG GGCCACGCAGTCACAGAGTGACATGTGCGACCAAGACCAGTGCATTCAGAGCACCAAATTCGTTTTGCAGGCTGCAG CCACGCCCCTGCTGCAGAGCGAGCCCAGCCTCACCAGCGACGAGCTGCACCTGCCCGGGAAGCCTGGCCTGGGCACG CCCTGCGCCAGCCTCACACTGGGCCCGCCCACACCGCCCGCCTCCATGCCCAACCTCGCCGAGGCCACGCTCGCGGA CGTGATGCCCCGGAAAGATGAGCACATGGGCCACCAGTTCCTGACGCCCGATGAGGCGCCCTCGCCCCCCAGGCTAC TGGCGGCGGGCAGCCCCCTGGCGCACAGCCGCACCATGCACGTGCTGGGCCTGGCCAGCCAGGACTCCCTGCATGAG GACTCTGTGCGCGGCCTGGTGAAGCTCAGCTCCGTGTGACCCACATGGCCCCAGGCCGGGGGACACCAGAGGCTCCT CCATGGGCAGCAGGAGTGAGCGGAGGGGTGTGTCCCACAGCGACTTTCCCAGCCAATGCCACGGTGGAGATGACAGC CCCAGGTCTGGGGTACAGAGACCACTTAGGATGGCACAGGGTGGCTGGCCCCGGATGCTGAGAGCTTGGTTTCATTT GAATTTTCTTCCCCAACCTGAGTGCTTTGACAACAATGGAAATAGAGAAGTGGCTGCTTTCTTTTGGTGACCCTCCA GGGGTGGAATCGGAGTGTGTCTGCCCGCCCTTGTGACAGACACACGGAAGGCTTCTGACGCTTGTGGCCAGACTGCA ATTGCACTTATGTGTTATGCTACTAATATTTGAAACAGACCTGCCATTCCATTTGTTAATTAAAAAAAAAAAAAATC CTAAAGGGAAAAAACCGACCAGGTGTGGATCTGCATGCCACGCTGCCGTCTGTGTTACAGTGGTGTTGCTATTTCCA AGGAAGTGCTGCTTTCTTTTTCTTTTTTTAATTTTGTGAATTTTCAAGTGCTGTTTTGTTGGAAGACAGTGCAACGA ACTGAGACTAATGGACAGTGTCATCACTCAGCTTACTGGGCTGAGGCGTCTGTGGAGAGGTGGCACCGGGGCTGCAG AGGGCGGCTGGGGTTCCGTCGTGTCGGGTGTCACTTCACCTTCTGTTTGGCCGCTCGATGAGGTCTCGTGTTGAGAT ATTGTGTGCCACAACCCCCACAGTCTTCACCTCCGTGTGTGATGAAACTTCCCGTGGACAGCCAATAAAATGACGTC CTCTGTTATTTTGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA >gi|148005048|ref|NM_000222.2| Homo sapiens v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), transcript variant 1, mRNA (SEQ ID NO: 63) TCTGGGGGCTCGGCTTTGCCGCGCTCGCTGCACTTGGGCGAGAGCTGGAACGTGGACCAGAGCTCGGATCCCATCGC AGCTACCGCGATGAGAGGCGCTCGCGGCGCCTGGGATTTTCTCTGCGTTCTGCTCCTACTGCTTCGCGTCCAGACAG GCTCTTCTCAACCATCTGTGAGTCCAGGGGAACCGTCTCCACCATCCATCCATCCAGGAAAATCAGACTTAATAGTC CGCGTGGGCGACGAGATTAGGCTGTTATGCACTGATCCGGGCTTTGTCAAATGGACTTTTGAGATCCTGGATGAAAC GAATGAGAATAAGCAGAATGAATGGATCACGGAAAAGGCAGAAGCCACCAACACCGGCAAATACACGTGCACCAACA AACACGGCTTAAGCAATTCCATTTATGTGTTTGTTAGAGATCCTGCCAAGCTTTTCCTTGTTGACCGCTCCTTGTAT GGGAAAGAAGACAACGACACGCTGGTCCGCTGTCCTCTCACAGACCCAGAAGTGACCAATTATTCCCTCAAGGGGTG CCAGGGGAAGCCTCTTCCCAAGGACTTGAGGTTTATTCCTGACCCCAAGGCGGGCATCATGATCAAAAGTGTGAAAC GCGCCTACCATCGGCTCTGTCTGCATTGTTCTGTGGACCAGGAGGGCAAGTCAGTGCTGTCGGAAAAATTCATCCTG AAAGTGAGGCCAGCCTTCAAAGCTGTGCCTGTTGTGTCTGTGTCCAAAGCAAGCTATCTTCTTAGGGAAGGGGAAGA ATTCACAGTGACGTGCACAATAAAAGATGTGTCTAGTTCTGTGTACTCAACGTGGAAAAGAGAAAACAGTCAGACTA AACTACAGGAGAAATATAATAGCTGGCATCACGGTGACTTCAATTATGAACGTCAGGCAACGTTGACTATCAGTTCA GCGAGAGTTAATGATTCTGGAGTGTTCATGTGTTATGCCAATAATACTTTTGGATCAGCAAATGTCACAACAACCTT GGAAGTAGTAGATAAAGGATTCATTAATATCTTCCCCATGATAAACACTACAGTATTTGTAAACGATGGAGAAAATG TAGATTTGATTGTTGAATATGAAGCATTCCCCAAACCTGAACACCAGCAGTGGATCTATATGAACAGAACCTTCACT GATAAATGGGAAGATTATCCCAAGTCTGAGAATGAAAGTAATATCAGATACGTAAGTGAACTTCATCTAACGAGATT AAAAGGCACCGAAGGAGGCACTTACACATTCCTAGTGTCCAATTCTGACGTCAATGCTGCCATAGCATTTAATGTTT ATGTGAATACAAAACCAGAAATCCTGACTTACGACAGGCTCGTGAATGGCATGCTCCAATGTGTGGCAGCAGGATTC CCAGAGCCCACAATAGATTGGTATTTTTGTCCAGGAACTGAGCAGAGATGCTCTGCTTCTGTACTGCCAGTGGATGT GCAGACACTAAACTCATCTGGGCCACCGTTTGGAAAGCTAGTGGTTCAGAGTTCTATAGATTCTAGTGCATTCAAGC ACAATGGCACGGTTGAATGTAAGGCTTACAACGATGTGGGCAAGACTTCTGCCTATTTTAACTTTGCATTTAAAGGT AACAACAAAGAGCAAATCCATCCCCACACCCTGTTCACTCCTTTGCTGATTGGTTTCGTAATCGTAGCTGGCATGAT GTGCATTATTGTGATGATTCTGACCTACAAATATTTACAGAAACCCATGTATGAAGTACAGTGGAAGGTTGTTGAGG AGATAAATGGAAACAATTATGTTTACATAGACCCAACACAACTTCCTTATGATCACAAATGGGAGTTTCCCAGAAAC AGGCTGAGTTTTGGGAAAACCCTGGGTGCTGGAGCTTTCGGGAAGGTTGTTGAGGCAACTGCTTATGGCTTAATTAA GTCAGATGCGGCCATGACTGTCGCTGTAAAGATGCTCAAGCCGAGTGCCCATTTGACAGAACGGGAAGCCCTCATGT CTGAACTCAAAGTCCTGAGTTACCTTGGTAATCACATGAATATTGTGAATCTACTTGGAGCCTGCACCATTGGAGGG CCCACCCTGGTCATTACAGAATATTGTTGCTATGGTGATCTTTTGAATTTTTTGAGAAGAAAACGTGATTCATTTAT TTGTTCAAAGCAGGAAGATCATGCAGAAGCTGCACTTTATAAGAATCTTCTGCATTCAAAGGAGTCTTCCTGCAGCG ATAGTACTAATGAGTACATGGACATGAAACCTGGAGTTTCTTATGTTGTCCCAACCAAGGCCGACAAAAGGAGATCT GTGAGAATAGGCTCATACATAGAAAGAGATGTGACTCCCGCCATCATGGAGGATGACGAGTTGGCCCTAGACTTAGA AGACTTGCTGAGCTTTTCTTACCAGGTGGCAAAGGGCATGGCTTTCCTCGCCTCCAAGAATTGTATTCACAGAGACT TGGCAGCCAGAAATATCCTCCTTACTCATGGTCGGATCACAAAGATTTGTGATTTTGGTCTAGCCAGAGACATCAAG AATGATTCTAATTATGTGGTTAAAGGAAACGCTCGACTACCTGTGAAGTGGATGGCACCTGAAAGCATTTTCAACTG TGTATACACGTTTGAAAGTGACGTCTGGTCCTATGGGATTTTTCTTTGGGAGCTGTTCTCTTTAGGAAGCAGCCCCT ATCCTGGAATGCCGGTCGATTCTAAGTTCTACAAGATGATCAAGGAAGGCTTCCGGATGCTCAGCCCTGAACACGCA CCTGCTGAAATGTATGACATAATGAAGACTTGCTGGGATGCAGATCCCCTAAAAAGACCAACATTCAAGCAAATTGT TCAGCTAATTGAGAAGCAGATTTCAGAGAGCACCAATCATATTTACTCCAACTTAGCAAACTGCAGCCCCAACCGAC AGAAGCCCGTGGTAGACCATTCTGTGCGGATCAATTCTGTCGGCAGCACCGCTTCCTCCTCCCAGCCTCTGCTTGTG CACGACGATGTCTGAGCAGAATCAGTGTTTGGGTCACCCCTCCAGGAATGATCTCTTCTTTTGGCTTCCATGATGGT TATTTTCTTTTCTTTCAACTTGCATCCAACTCCAGGATAGTGGGCACCCCACTGCAATCCTGTCTTTCTGAGCACAC TTTAGTGGCCGATGATTTTTGTCATCAGCCACCATCCTATTGCAAAGGTTCCAACTGTATATATTCCCAATAGCAAC GTAGCTTCTACCATGAACAGAAAACATTCTGATTTGGAAAAAGAGAGGGAGGTATGGACTGGGGGCCAGAGTCCTTT CCAAGGCTTCTCCAATTCTGCCCAAAAATATGGTTGATAGTTTACCTGAATAAATGGTAGTAATCACAGTTGGCCTT CAGAACCATCCATAGTAGTATGATGATACAAGATTAGAAGCTGAAAACCTAAGTCCTTTATGTGGAAAACAGAACAT CATTAGAACAAAGGACAGAGTATGAACACCTGGGCTTAAGAAATCTAGTATTTCATGCTGGGAATGAGACATAGGCC ATGAAAAAAATGATCCCCAAGTGTGAACAAAAGATGCTCTTCTGTGGACCACTGCATGAGCTTTTATACTACCGACC TGGTTTTTAAATAGAGTTTGCTATTAGAGCATTGAATTGGAGAGAAGGCCTCCCTAGCCAGCACTTGTATATACGCA TCTATAAATTGTCCGTGTTCATACATTTGAGGGGAAAACACCATAAGGTTTCGTTTCTGTATACAACCCTGGCATTA TGTCCACTGTGTATAGAAGTAGATTAAGAGCCATATAAGTTTGAAGGAAACAGTTAATACCATTTTTTAAGGAAACA ATATAACCACAAAGCACAGTTTGAACAAAATCTCCTCTTTTAGCTGATGAACTTATTCTGTAGATTCTGTGGAACAA GCCTATCAGCTTCAGAATGGCATTGTACTCAATGGATTTGATGCTGTTTGACAAAGTTACTGATTCACTGCATGGCT CCCACAGGAGTGGGAAAACACTGCCATCTTAGTTTGGATTCTTATGTAGCAGGAAATAAAGTATAGGTTTAGCCTCC TTCGCAGGCATGTCCTGGACACCGGGCCAGTATCTATATATGTGTATGTACGTTTGTATGTGTGTAGACAAATATTT GGAGGGGTATTTTTGCCCTGAGTCCAAGAGGGTCCTTTAGTACCTGAAAAGTAACTTGGCTTTCATTATTAGTACTG CTCTTGTTTCTTTTCACATAGCTGTCTAGAGTAGCTTACCAGAAGCTTCCATAGTGGTGCAGAGGAAGTGGAAGGCA TCAGTCCCTATGTATTTGCAGTTCACCTGCACTTAAGGCACTCTGTTATTTAGACTCATCTTACTGTACCTGTTCCT TAGACCTTCCATAATGCTACTGTCTCACTGAAACATTTAAATTTTACCCTTTAGACTGTAGCCTGGATATTATTCTT GTAGTTTACCTCTTTAAAAACAAAACAAAACAAAACAAAAAACTCCCCTTCCTCACTGCCCAATATAAAAGGCAAAT GTGTACATGGCAGAGTTTGTGTGTTGTCTTGAAAGATTCAGGTATGTTGCCTTTATGGTTTCCCCCTTCTACATTTC TTAGACTACATTTAGAGAACTGTGGCCGTTATCTGGAAGTAACCATTTGCACTGGAGTTCTATGCTCTCGCACCTTT CCAAAGTTAACAGATTTTGGGGTTGTGTTGTCACCCAAGAGATTGTTGTTTGCCATACTTTGTCTGAAAAATTCCTT TGTGTTTCTATTGACTTCAATGATAGTAAGAAAAGTGGTTGTTAGTTATAGATGTCTAGGTACTTCAGGGGCACTTC ATTGAGAGTTTTGTCTTGGATATTCTTGAAAGTTTATATTTTTATAATTTTTTCTTACATCAGATGTTTCTTTGCAG TGGCTTAATGTTTGAAATTATTTTGTGGCTTTTTTTGTAAATATTGAAATGTAGCAATAATGTCTTTTGAATATTCC CAAGCCCATGAGTCCTTGAAAATATTTTTTATATATACAGTAACTTTATGTGTAAATACATAAGCGGCGTAAGTTTA AAGGATGTTGGTGTTCCACGTGTTTTATTCCTGTATGTTGTCCAATTGTTGACAGTTCTGAAGAATTCTAATAAAAT GTACATATATAAATCAAAAAAAAAAAAAAAA Homo sapiens TRPML3 (NM_018298) (SEQ ID NO: 64) ATGGCAGATCCTGAGGTAGTTGTGAGTAGCTGCAGCTCTCATGAAGAGGAAAATCG CTGCAATTTTAACCAGCAAACATCTCCATCTGAGGAGCTTCTATTAGAAGACCAGATG AGGCGAAAACTCAAATTTTTTTTCATGAATCCCTGTGAGAAGTTCTGGGCTCGAGGT AGAAAACCATGGAAACTTGCCATACAAATTCTAAAAATTGCAATGGTGACTATCCAGC TGGTCTTATTTGGGCTAAGTAACCAGATGGTGGTAGCTTTCAAGGAAGAGAATACTA TAGCATTCAAACACCTTTTCCTAAAAGGATATATGGACCGAATGGATGACACATATGC AGTGTACACACAAAGTGACGTGTATGATCAGTTAATCTTCGCAGTAAACCAGTACTTG CAGCTATACAATGTCTCCGTTGGGAATCATGCTTATGAGAACAAAGGTACCAAGCAA TCTGCTATGGCAATCTGTCAGCACTTCTACAAGCGAGGAAACATCTACCCTGGAAATG ATACCTTTGACATCGATCCAGAAATTGAAACTGAGTGTTTCTTTGTGGAGCCAGATGA ACCTTTTCACATTGGGACACCAGCAGAAAATAAACTGAACTTAACACTGGACTTCCAC AGACTCCTAACAGTGGAGCTTCAGTTTAAACTGAAAGCCATTAATCTGCAGACAGTTC GTCATCAAGAACTCCCTGACTGTTATGACTTTACTCTGACTATAACATTTGACAACAAG GCCCATAGTGGAAGAATTAAAATAAGTTTAGATAATGACATTTCCATCAGAGAATGT AAAGACTGGCATGTATCTGGATCAATTCAGAAGAACACTCATTACATGATGATCTTTG ATGCCTTTGTCATTCTGACTTGCTTGGTTTCATTAATCCTCTGCATTAGATCTGTGATT AGAGGACTTCAGCTTCAGCAGGAGTTTGTCAATTTTTTCCTCCTCCATTATAAGAAGG AAGTTTCTGTTTCTGATCAAATGGAATTTGTCAATGGATGGTACATTATGATTATTAT TAGTGACATATTGACAATCATTGGATCAATTCTAAAAATGGAAATCCAAGCTAAGAGT CTAACTAGTTATGATGTCTGTAGCATACTTCTTGGGACTTCTACCATGCTCGTGTGGC TTGGAGTCATCCGATACCTCGGTTTCTTTGCAAAGTACAACCTCCTCATTTTGACCCTT CAGGCAGCGCTGCCCAATGTCATCAGGTTCTGCTGCTGTGCAGCTATGATTTACTTAG GTTACTGCTTCTGTGGATGGATCGTGCTGGGGCCTTACCATGACAAGTTTCGTTCTCT GAACATGGTCTCTGAGTGCCTTTTCTCTCTGATAAATGGAGATGATATGTTTGCCACG TTTGCAAAAATGCAGCAAAAAAGTTACTTAGTCTGGCTGTTTAGTAGAATTTACCTCT ACTCATTCATCAGCCTCTTTATATATATGATTTTAAGTCTTTTCATTGCACTGATCACT GATACATACGAAACAATTAAGCAATACCAACAAGATGGCTTCCCAGAGACTGAACTTC GTACATTTATATCAGAATGCAAAGATCTACCCAACTCTGGAAAATACAGATTAGAAGA TGACCCTCCAGTATCTTTATTCTGCTGTTGTAAAAAG(SEQ ID NO: 67) Homo sapiens TRPML3 (NM_018298) (SEQ ID NO: 65) MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYT QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIATGNDTFD IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVS LILCIRSVIRGLQLQQEFVNFFLLHYKKEVSVSDQMEFVNGWYIMIIISDILTIIGSILKMEIQ AKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMIYLG YCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYSFI SLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVSLFC CCKK (SEQ ID NO: 68) Homo sapiens TRPML3 A419P (SEQ ID NO: 66) ATGGCAGATCCTGAGGTAGTTGTGAGTAGCTGCAGCTCTCATGAAGAGGAAAATCG CTGCAATTTTAACCAGCAAACATCTCCATCTGAGGAGCTTCTATTAGAAGACCAGATG AGGCGAAAACTCAAATTTTTTTTCATGAATCCCTGTGAGAAGTTCTGGGCTCGAGGT AGAAAACCATGGAAACTTGCCATACAAATTCTAAAAATTGCAATGGTGACTATCCAGC TGGTCTTATTTGGGCTAAGTAACCAGATGGTGGTAGCTTTCAAGGAAGAGAATACTA TAGCATTCAAACACCTTTTCCTAAAAGGATATATGGACCGAATGGATGACACATATGC AGTGTACACACAAAGTGACGTGTATGATCAGTTAATCTTCGCAGTAAACCAGTACTTG CAGCTATACAATGTCTCCGTTGGGAATCATGCTTATGAGAACAAAGGTACCAAGCAA TCTGCTATGGCAATCTGTCAGCACTTCTACAAGCGAGGAAACATCTACCCTGGAAATG ATACCTTTGACATCGATCCAGAAATTGAAACTGAGTGTTTCTTTGTGGAGCCAGATGA ACCTTTTCACATTGGGACACCAGCAGAAAATAAACTGAACTTAACACTGGACTTCCAC AGACTCCTAACAGTGGAGCTTCAGTTTAAACTGAAAGCCATTAATCTGCAGACAGTTC GTCATCAAGAACTCCCTGACTGTTATGACTTTACTCTGACTATAACATTTGACAACAAG GCCCATAGTGGAAGAATTAAAATAAGTTTAGATAATGACATTTCCATCAGAGAATGT AAAGACTGGCATGTATCTGGATCAATTCAGAAGAACACTCATTACATGATGATCTTTG ATGCCTTTGTCATTCTGACTTGCTTGGTTTCATTAATCCTCTGCATTAGATCTGTGATT AGAGGACTTCAGCTTCAGCAGGAGTTTGTCAATTTTTTCCTCCTCCATTATAAGAAGG AAGTTTCTGTTTCTGATCAAATGGAATTTGTCAATGGATGGTACATTATGATTATTAT TAGTGACATATTGACAATCATTGGATCAATTCTAAAAATGGAAATCCAAGCTAAGAGT CTAACTAGTTATGATGTCTGTAGCATACTTCTTGGGACTTCTACCATGCTCGTGTGGC TTGGAGTCATCCGATACCTCGGTTTCTTTGCAAAGTACAACCTCCTCATTTTGACCCTT CAGGCAGCGCTGCCCAATGTCATCAGGTTCTGCTGCTGTCCAGCTATGATTTACTTAG GTTACTGCTTCTGTGGATGGATCGTGCTGGGGCCTTACCATGACAAGTTTCGTTCTCT GAACATGGTCTCTGAGTGCCTTTTCTCTCTGATAAATGGAGATGATATGTTTGCCACG TTTGCAAAAATGCAGCAAAAAAGTTACTTAGTCTGGCTGTTTAGTAGAATTTACCTCT ACTCATTCATCAGCCTCTTTATATATATGATTTTAAGTCTTTTCATTGCACTGATCACT GATACATACGAAACAATTAAGCAATACCAACAAGATGGCTTCCCAGAGACTGAACTTC GTACATTTATATCAGAATGCAAAGATCTACCCAACTCTGGAAAATACAGATTAGAAGA TGACCCTCCAGTATCTTTATTCTGCTGTTGTAAAAAG(SEQ ID NO: 66) Homo sapiens TRPML3 A419P (SEQ ID NO: 67) MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYT QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDTFD IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVS LILCIRSVIRGLQLQQEFVNFFLLHYKKEVSVSDQMEFVNGWYIMIIISDILTIIGSILKMEIQ AKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCPAMIYLG YCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYSFI SLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVSLFC CCKK (SEQ ID NO: 67) Homo sapiens TRPML1 (NM_020533) (SEQ ID NO: 68) ATGACAGCCCCGGCGGGTCCGCGCGGCTCAGAGACCGAGCGGCTTCTGACCCCCAAC CCCGGGTATGGGACCCAGGCGGGGCCTTCACCGGCCCCTCCGACACCCCCAGAAGAG GAAGACCTTCGCCGTCGTCTCAAATACTTTTTCATGAGTCCCTGCGACAAGTTTCGAG CCAAGGGCCGCAAGCCCTGCAAGCTGATGCTGCAAGTGGTCAAGATCCTGGTGGTCA CGGTGCAGCTCATCCTGTTTGGGCTCAGTAATCAGCTGGCTGTGACATTCCGGGAAG AGAACACCATCGCCTTCCGACACCTCTTCCTGCTGGGCTACTCGGACGGAGCGGATG ACACCTTCGCAGCCTACACGCGGGAGCAGCTGTACCAGGCCATCTTCCATGCTGTGG ACCAGTACCTGGCGTTGCCTGACGTGTCACTGGGCCGGTATGCGTATGTCCGTGGTG GGGGTGACCCTTGGACCAATGGCTCAGGGCTTGCTCTCTGCCAGCGGTACTACCACC GAGGCCACGTGGACCCGGCCAACGACACATTTGACATTGATCCGATGGTGGTTACTG ACTGCATCCAGGTGGATCCCCCCGAGCGGCCCCCTCCGCCCCCCAGCGACGATCTCAC CCTCTTGGAAAGCAGCTCCAGTTACAAGAACCTCACGCTCAAATTCCACAAGCTGGTC AATGTCACCATCCACTTCCGGCTGAAGACCATTAACCTCCAGAGCCTCATCAATAATG AGATCCCGGACTGCTATACCTTCAGCGTCCTGATCACGTTTGACAACAAAGCACACAG TGGGCGGATCCCCATCAGCCTGGAGACCCAGGCCCACATCCAGGAGTGTAAGCACCC CAGTGTCTTCCAGCACGGAGACAACAGCTTCCGGCTCCTGTTTGACGTGGTGGTCAT CCTCACCTGCTCCCTGTCCTTCCTCCTCTGCGCCCGCTCACTCCTTCGAGGCTTCCTGC TGCAGAACGAGTITGTGGGGTTCATGTGGCGGCAGCGGGGACGGGTCATCAGCCTG TGGGAGCGGCTGGAATTTGTCAATGGCTGGTACATCCTGCTCGTCACCAGCGATGTG CTCACCATCTCGGGCACCATCATGAAGATCGGCATCGAGGCCAAGAACTTGGCGAGC TACGACGTCTGCAGCATCCTCCTGGGCACCTCGACGCTGCTGGTGTGGGTGGGCGT GATCCGCTACCTGACCTTCTTCCACAACTACAATATCCTCATCGCCACACTGCGGGTG GCCCTGCCCAGCGTCATGCGCTTCTGCTGCTGCGTGGCTGTCATCTACCTGGGCTACT GCTTCTGTGGCTGGATCGTGCTGGGGCCCTATCATGTGAAGTTCCGCTCACTCTCCAT GGTGTCTGAGTGCCTGTTCTCGCTCATCAATGGGGACGACATGTTTGTGACGTTCGC CGCCATGCAGGCGCAGCAGGGCCGCAGCAGCCTGGTGTGGCTCTTCTCCCAGCTCTA CCTTTACTCCTTCATCAGCCTCTTCATCTACATGGTGCTCAGCCTCTTCATCGCGCTCA TCACCGGCGCCTACGACACCATCAAGCATCCCGGCGGCGCAGGCGCAGAGGAGAGC GAGCTGCAGGCCTACATCGCACAGTGCCAGGACAGCCCCACCTCCGGCAAGTTCCGC CGCGGGAGCGGCTCGGCCTGCAGCCTTCTCTGCTGCTGCGGAAGGGACCCCTCGGA GGAGCATTCGCTGCTGGTGAAT (SEQ ID NO: 68) Homo sapiens TRPML1 (NM_020533) (SEQ ID NO: 69) MTAPAGPRGSETERLLTPNPGYGTQAGPSPAPPTPPEEEDLRRRLKYFFMSPCDKFRAKG RKPCKLMLQVVKILVVTVQLILFGLSNQLAVTFREENTIAFRHLFLLGYSDGADDTFAAY TREQLYQAIFHAVDQYLALPDVSLGRYAYVRGGGDPWTNGSGLALCQRYYHRGHVDPA NDTFDIDPMVVTDCIQVDPPERPPPPPSDDLTLLESSSSYKNLTLKFHKLVNVTIHFRLKTI NLQSLINNEIPDCYTFSVLITFDNKAHSGRIPISLETQAHIQECKHPSVFQHGDNSFRLLFD VVVILTCSLSFLLCARSLLRGFLLQNEFVGFMWRQRGRVISLWERLEFVNGWYILLVTSDV LTISGTIMKIGIEAKNLASYDVCSILLGTSTLLVWVGVIRYLTFFHNYNILIATLRVALPSVM RFCCCVAVIYLGYCFCGWIVLGPYHVKFRSLSMVSECLFSLINGDDMFVTFAAMQAQQGR SSLVWLFSQLYLYSFISLFIYMVLSLFIALITGAYDTIKHPGGAGAEESELQAYIAQCQDSPT SGKFRRGSGSACSLLCCCGRDPSEEHSLLVN (SEQ ID NO: 69) Homo sapiens TRPML2 (NM_153259) (SEQ ID NO: 70) ATGGCCCGGCAGCCTTATCGTTTTCCCCAGGCAAGGATTCCGGAGAGAGGATCAGGT GTTTTCAGGTTAACCGTCAGAAACGCAATGGCACATCGTGATTCTGAGATGAAAGAA GAATGTCTAAGGGAAGACCTGAAGTTTTACTTCATGAGCCCTTGTGAAAAATACCGA GCCAGACGCCAGATTCCGTGGAAACTGGGTTTGCAGATTTTGAAGATAGTCATGGTC ACCACACAGCTTGTTCGTTTTGGTTTAAGTAACCAGCTGGTGGTTGCTTTCAAAGAAG ATAACACTGTTGCTTTTAAGCACTTGTTTTTGAAAGGATATTCTGGTACAGATGAAGA TGACTACAGCTGCAGTGTATATACTCAAGAGGATGCCTATGAGAGCATCTTTTTTGCT ATTAATCAGTATCATCAGCTAAAGGACATTACCCTGGGGACCCTTGGTTATGGAGAA AATGAAGACAATAGAATTGGCTTAAAAGTCTGTAAGCAGCATTACAAGAAAGGGACC ATGTTTCCTTCTAATGAGACACTGAATATTGACAACGACGTTGAGCTCGATTGTGTTC AATTAGACCTTCAGGACCTCTCCAAGAAGCCTCCGGACTGGAAGAACTCATCATTCTT CAGACTGGAATTTTATCGGCTCTTACAGGTTGAAATCTCCTTTCATCTTAAAGGCATT GACCTACAGACAATTCATTCCCGTGAGTTACCAGACTGTTATGTCTTTCAGAATACGA TTATCTTTGACAATAAAGCTCACAGTGGCAAAATCAAAATCTATTTTGACAGTGATGC CAAAATTGAAGAATGTAAAGACTTGAACATATTTGGATCTACTCAGAAAAATGCTCAG TATGTCCTGGTGTTTGATGCATTTGTCATTGTGATTTGCTTGGCATCTCTTATTCTGT GTACAAGATCCATTGTTCTTGCTCTAAGGTTACGGAAGAGATTTCTAAATTTCTTCCT GGAGAAGTACAAGCGGCCTGTGTGTGACACCGACCAGTGGGAGTTCATCAACGGCT GGTATGTCCTGGTGATTATCAGCGACCTAATGACAATCATTGGCTCCATATTAAAAAT GGAAATCAAAGCAAAGAATCTCACAAACTATGATCTCTGCAGCATTTTTCTTGGAACC TCTACGCTCTTGGTTTGGGTTGGAGTCATCAGATACCTGGGTTATTTCCAGGCATATA ATGTGCTGATTTTAACAATGCAGGCCTCACTGCCAAAAGTTCTTCGGTTTTGTGCTTG TGCTGGTATGATTTATCTGGGTTACACATTCTGTGGCTGGATTGTCTTAGGACCATAC CATGACAAGTTTGAAAATCTGAACACAGTTGCTGAGTGTCTGTTTTCTCTGGTCAACG GTGATGACATGTTTGCAACCTTTGCCCAAATCCAGCAGAAGAGCATCTTGGTGTGGC TGTTCAGTCGTCTGTATTTATATTCCTTCATCAGCCTTTTTATATATATGATTCTCAGTC TTTTTATTGCACTTATTACAGATTCTTATGACACCATTAAGAAATTCCAACAGAATGGG TTTCCTGAAACGGATTTGCAGGAATTCCTGAAGGAATGCAGTAGCAAAGAAGAGTAT CAGAAAGAGTCCTCAGCCTTCCTGTCCTGCATCTGCTGTCGGAGGAGGAAAAGAAGT GATGATCACTTGATACCTATTAGC (SEQ ID NO: 70) Homo sapiens TRPML2 (NM_153259) (SEQ ID NO: 71) MARQPYRFPQARIPERGSGVFRLTVRNAMAHRDSEMKEECLREDLKFYFMSPCEKYRAR RQIPWKLGLQILKIVMVTTQLVRFGLSNQLVVAFKEDNTVAFKHLFLKGYSGTDEDDYS CSVYTQEDAYESIFFAINQYHQLKDITLGTLGYGENEDNRIGLKVCKQHYKKGTMFPSN ETLNIDNDVELDCVQLDLQDLSKKPPDWKNSSFFRLEFYRLLQVEISFHLKGIDLQTIHSR ELPDCYVFQNTIIFDNKAHSGKIKIYFDSDAKIEECKDLNIFGSTQKNAQYVLVFDAFVIV ICLASLILCTRSIVLALRLRKRFLNFFLEKYKRPVCDTDQWEFINGVVYVLVIISDLMTIIGSIL KMEIKAKNLTNYDLCSIFLGTSTLLVWVGVIRYLGYFQAYNVLILTMQASLPKVLRFCACA GMIYLGYTFCGWIVLGPYHDKFENLNTVAECLFSLVNGDDMFATFAQIQQKSILVWLFS RLYLYSFISLFIYMILSLFIALITDSYDTIKKFQQNGFPETDLQEFLKECSSKEEYQKESSAFL SCICCRRRKRSDDHLIPIS (SEQ ID NO: 71) Mus musculus TRPML3 (NM_134160) (SEQ ID NO: 72) ATGGCAAATCCCGAGGTGCTGGTTAGCAGCTGCAGAGCTCGCCAAGATGAAAGCCCC TGCACTTTCCACCCGAGCTCGTCCCCGTCAGAGCAGCTTCTCTTAGAAGACCAGATGA GGCGGAAACTCAAGTTCTTTTTTATGAATCCTTGTGAGAAGTICTGGGCTCGGGGTA GGAAGCCATGGAAACTTGCCATACAGATTCTGAAAATCGCGATGGTGACTATCCAGC TGGTTCTGTTTGGACTAAGTAACCAGATGGTAGTAGCTTTCAAAGAGGAGAACACTA TAGCCTTCAAACACCTCTTCCTAAAGGGCTACATGGATCGAATGGACGACACCTATGC AGTGTACACTCAGAGTGAAGTGTATGACCAGATCATCTTTGCAGTGACCCAGTACTT GCAGCTTCAGAACATCTCCGTGGGCAATCACGCTTATGAGAACAAGGGGACTAAGCA GTCGGCGATGGCAATCTGTCAGCACTTCTACAGGCAAGGAACCATCTGCCCCGGGAA CGACACCTTTGACATCGATCCAGAAGTTGAAACAGAATGTTTCCTTGTAGAGCCAGAT GAAGCTTCCCACCTTGGAACGCCTGGAGAAAATAAACTCAACCTGAGCCTGGACTTCC ACAGACTTCTGACGGTGGAGCTCCAGTTTAAGCTCAAAGCCATCAATCTGCAGACAG TTCGACACCAGGAGCTTCCTGACTGTTACGACTTTACGCTGACTATAACATTCGACAA CAAGGCTCACAGTGGAAGAATCAAAATAAGCTTAGACAACGACATTTCTATCAAAGA ATGCAAAGACTGGCATGTGTCTGGATCAATTCAGAAGAACACACACTACATGATGAT CTTTGATGCCTTTGTCATTCTGACCTGCTTGGCCTCACTGGTGCTGTGTGCCAGGTCT GTGATTAGGGGTCTTCAGCTTCAGCAGGAGTTTGTCAACTTCTTCCTTCTTCACTACA AGAAGGAAGTTTCGGCCTCTGATCAGATGGAGTTCATCAACGGGTGGTACATTATGA TCATCATTAGTGACATATTGACAATCGTTGGATCAGTTCTGAAAATGGAAATCCAAGC CAAGAGTCTCACAAGCTATGATGTCTGCAGCATACTTCTCGGGACGTCAACTATGCTC GTGTGGCTTGGAGTTATCCGATACCTGGGTTTCTTTGCGAAGTACAATCTCCTTATTC TGACCCTCCAGGCAGCGCTGCCCAACGTCATGAGGTTCTGTTGCTGCGCTGCTATGA TCTATCTAGGCTATTGCTTTTGCGGATGGATTGTGCTGGGCCCTTACCATGAGAAGT TCCGTTCCCTGAACAGGGTCTCCGAGTGCCTGTTCTCGCTGATAAACGGAGACGATA TGTTTTCCACATTTGCGAAAATGCAGCAGAAGAGTTACCTGGTGTGGCTGTTCAGCC GAGTCTACCTGTACTCGTTCATCAGCCTCTTCATTTACATGATTCTGAGCCTTTTCATC GCGCTCATCACAGACACATACGAAACAATTAAGCACTACCAGCAAGATGGCTTCCCAG AGACGGAACTTCGAAAGTTTATAGCGGAATGCAAAGACCTCCCCAACTCCGGAAAAT ACAGATTAGAAGATGACCCTCCGGGTTCTTTACTCTGCTGCTGCAAAAAG (SEQ ID NO: 72) Mus musculus TRPML3 (NM_134160) (SEQ ID NO: 73) MANPEVLVSSCRARQDESPCTFHPSSSPSEQLLLEDQMRRKLKFFFMNPCEKFWARGRKP WKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYTQ SEVYDQIIFAVTQYLQLQNISVGNHAYENKGTKQSAMAICQHFYRQGTICPGNDTFDID PEVETECFLVEPDEASHLGTPGENKLNLSLDFHRLLTVELQFKLKAINLQTVRHQELPDC YDFTLTITFDNKAHSGRIKISLDNDISIKECKDWHVSGSIQKNTHYMMIFDAFVILTCLASL VLCARSVIRGLQLQQEFVNFFLLHYKKEVSASDQMEFINGWYIMIIISDILTIVGSVLKMEI QAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVMRFCCCAAMIY LGYCFCGWIVLGPYHEKFRSLNRVSECLFSLINGDDMFSTFAKMQQKSYLVWLFSRVYLY SFISLFIYMILSLFIALITDTYETIKHYQQDGFPETELRKFIAECKDLPNSGKYRLEDDPPGS LLCCCKK (SEQ ID NO: 73) Gallus gallus TRPML3 (XM_426647) (SEQ ID NO: 74) ATGATCACCCGTGGTTTCCGTTCAGGCTTTTACGGCTGTAGCAATCGATATAGTGGT GCTAAGTGCCAGTTAGTTGCTCAGACGTTTGTCATTTCAGCAATGGAGACTCCTGAA GTGGCTGTAAGCAGCTGCAGTGCTCGGGATGACGAAGGGCTCTGCAGCTACGGACA ACACCTATTGCTGCCACAAGAGCTGGTGGCGGAAGACCAGCTGAGGAGGAAGCTGA AGTTCTTCTTCATGAACCCATGTGAAAAATTCTGGGCTCGGGGCAGAAAACCTTGGA AACTTGGGATTCAGCTGCTCAAAATAGCAATGGTTACCATTCAGCTGGTGCTTTTTGG ATTGAGCAATCAAATGGTGGTTGCTTTCAAAGAAGAGAACACTATTGCATTCAAACAT CTCTTCTTGAAAGGGTACATGGACAGAATGGATGATACCTATGCGGTATACACACAG ACAGATGTCTATGACCAAATATTCTTTGCCATCAATCAGTACTTACAGTTGCCCAACAT TTCTGTTGGAAACCATGCTTATGAGAAGAAAGGAGCAGAAGAGACAGCTCTGGCTG TATGTCAACAGTTCTACAAGCAAGGAACCATCTGTCCTGGAAATGACACCTTTGATAT AGACCCAGAGATTGTGACTGACTGCTTGTACATTGAGCCGATGATGTCTTTAGACAA CAGAACAGTGGGAAAGCACAATTTGAATTTCACTCTGGATTTCCACAGGCTCGTGGC AGTGCAACTCATGTTCAATCTGAAGGCAATCAACCTCCAGACCGTCCGTCACCACGAG CTCCCTGACTGTTACGATTTCACCCTGACGATAGTGTTTGATAATAAAGCCCACAGTG GAAGAATCAAAATCAGTCTAGACAACGACATAGAGATCAGGGAATGTAAAGACTGGC ACGTTTCTGGATCAATACAGAAGAATACGCATTACATGATGATCTTCGATGCTTTTGT CATACTGATCTGTCTGAGCTGATTGATCCTTTGCACTCGATCAGTAGTCAAAGGAATT CGGCTCCAAAGAGAATTTGTAAGTTTTTTCCTATATTATTACAAGAAAGAGGTATCTT ACAATGATCAGATGGAATTTGTCAATGGCTGGTATATCCTCATTATGGTTAGTGATGT CCTCACTATCGTTGGATCAACTCTCAAAATGGAGATACAGGCCAAGAGTCTGACAAG TTACGACGTCTGTAGCATACTCTTAGGAACATCCACTATGCTGGTGTGGCTTGGAGT CATTCGCTACCTCGGTTTCTTTCAGAAGTATAATCTTCTCATTCTAACGCTGCGAGCAG CACTACCCAACGTCATGAGGTTCTGCTGTTGTGCTGCTATGATCTATCTAGGTTATTG TTTCTGCGGATGGATTGTACTGGGGCCATACCACGTGAAGTTCCGTTCTCTGAATGT GGTTTCTGAATGCCTCTTTTCATTGATAkATGGAGATGACATGTTTGCCACTTTTGCA AAAATGCAGCAGAAAAGTTACTTGGTTTGGTTATTCAGTAGAATCTACCTCTACTCCT TCATCAGCCTGTTCATCTACATGGTGCTAAGTCTCTTCATTGCACTCATTACAGATACA TATGAAACTATCAAGCACTACCAACAAGATGGCTTTCCAGAGACAGAACTTCAGAGAT TTATATCACAGTGCAAAGACTTACCAAACTCTGGAAGGTACAGATTAGAAGAGGAAG GTTCTGTATCTCTCTTCTGTTGTTGCAGTGGTCCTAGTGAACATATC (SEQ ID NO: 74) Gallus gallus TRPLM3 (XM_426647) (SEQ ID NO: 75) MITRGFRSGFYGCSNRYSGAKCQLVAQTFVISAMETPEVAVSSCSARDDEGLCSYGQHLLL PQELVAEDQLRRKLKFFFMNPCEKFWARGRKPWKLGIQLLKIAMVTIQLVLFGLSNQMV VAFKEENTIAFKHLFLKGYMDRMDDTYAVYTQTDVYDQIFFAINQYLQLPNISVGNHAY EKKGAEETALAVCQQFYKQGTICPGNDTFDIDPEIVTDCLYIEPMMSLDNRTVGKHNLN FTLDFHRLVAVQLMFNLKAINLQTVRHHELPDCYDFTLTIVFDNKAHSGRIKISLDNDIEI RECKDWHVSGSIQKNTHYMMIFDAFVILICLSSLILCTRSVVKGIRLQREFVSFFLYYYKKE VSYNDQMEFVNGWYILIMVSDVLTIVGSTLKMEIQAKSLTSYDVCSILLGTSTMLVWLGVI RYLGFFQKYNLLILTLRAALPNVMRFCCCAAMIYLGYCFCGWIVLGPYHVKFRSLNVVSE CLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYSFISLFIYMVLSLFIALITDTYETIKHYQ QDGFPETELQRFISQCKDLPNSGRYRLEEEGSVSLFCCCSGPSEHI (SEQ ID NO: 75) Canis familiaris TRPML3 (XM_547306) (SEQ ID NO: 76) ATGACCCCTTTTGGCAGCTTGGCTTCTGCAAAGGCTTCAAACTCAAGAGCTGCCTGGA AGATTGTGGTGGATTCATTCAGCTCGCAGCACACGCCCCAGGTGGGCACTGGTGGTC CCCAGGAATCAGACAAGGCCCTTACCTTCGGAGAGTTAACGTTCTCCCACTCATCTCC ATTCTTCATCTGCGCCAGCCCTTCTCTCCCACCGTTGCACAGCAGTGGGCTAGACGAT GAGCCATACTGCTGGACAGGTTTTCACTGCATCAAGTACCTCGCGGGCCCAGCGAGT GTCCCAAACTCCCTTGAAAGAGGGAGT,kAGATATTGGTTTCCCAAGCCTCCTTTCCCA TCCGGACCTCCCCTTACCTGACACTGCTAAGCCGAGGGGAAAAGAAGCCTCTCTGCA GTTCCGTGGAGAAAAGGCCTTTGGGGGTTTTGGAGATGGGAAGTCTGACTCTCCTCT CGGAAGAGCTCAAACGGCAGCTCCCCGGCACGCTGTTGCTAGGACAACCTCCGTTGC TAAGGGAAAGAGGCGGCTCCTCTGCTGAGATTGACAAGACGCCGCTACCAATAGGG CGTCTACTCTCCGGCCGCCTCTTCAAGGCCGCACTTGTGATTGGCTGCTGTCGTGCTG ACGTCACGCAACTCGAACCGCCGAGAGATCCTGGGTTTTCGCCCGCTCGGCAGGAGG TGTGCGGTTTGGGTTCCCGCGTGGAGGGTGCTGCTGGCTCGAATGTAAACAATCTTT TTTTTTTTCTCCCCCTAGAGATGGCAAATCCTACGGTTGTTATAAGTAGCTGCAGCTC TCATGAAGAGGAAAATCGTTGCACTTTTAGCCAGCACACATCGCCCTCTGAGGAGCTT CTGTTAGAAGACCAGATAAGGCGAAAACTCAAATTTTTTTTCATGAATCCTTGTGAAA AGTTCTGGGCTCGAGGTAGAAAACCATGGAAGCTTGCCATACAAATTCTAAAAATTG CAATGGTGACTATCCAGCTGGTCTTTTTTGGGCTAAGTAACCAGATGGTTGTAGCTTT CAAGGAAGAAAACACTATAGCATTCAAACACCTCTTCTTAAAAGGATATATGGACCGA ATGGATGACACATATGCAGTGTACACACAACGTGATGTATATGATCAGATCATCTTTG CAGTGAACCAGTACTTGCTTCTACGCAATACCTCGGTTGGGAATCATGCTTATGAGAA CAAGGGGACGGAACAGTCTGCTATGGCAATCTGTCAGCACTTCTACAAGCAGGGAAA CATCTGTCCTGGAAATGATACCTTCGACATTGATCCAGAGATTGAAACTGAGTGTTTC TCTGTAGAGCCAGCTGAGCCTTTCCACGTCGGAACACTGGAAGAAAATAAACTCAAC TTAACGCTGGACTTTCACAGACTCCTCACGGTGGACCTGCAGTTTAAGCTGAAGGCC ATTAATCTGCAGACCATTCGGCATCACGAGCTCCCTGACTGTTATGACTTTACTCTCAC TATAACATTTGACAATAAGGCCCATAGTGGAAGAATTAAGATAAGTTTAGATAATGA TATTTCCATCAGAGAATGTAAAGACTGGCATGTATCGGGATCAATTCAGAAGAACAC TCACTACATGATGATCTTTGATGCCTTTGTTATTCTGACATGCTTGGCTTCACTAACCC TGTGCCTTCGATCTGTAATTAGAGGACTTCAGCTTCAACAGGAATTTGTCAATTTTTT CCTCCTCCATTATAAGAAGGAAGTTTCTGTTTCTGATCGAATGGAATTTGTCAATGGA TGGTACATTATGATTATTATTAGTGACATGTTGACAATTATTGGATCAATTCTGAAAA TGGAAATTCAAGCTAAGAGTCTAACAAGTTATGATGTTTGTAGCATACTTCTTGGGAC TTCCACCATGCTTGTGTGGCTTGGAGTTATTCGATACCTCGGCTTCTTTCAGAAGTAC AATCTCCTTATTCTGACCCTGCAGGCAGCACTGCCCAGTGTCATCAGGTTCTGTTGCT GTGCCGCTATGATTTATTTAGGCTATTGCTTCTGTGGATGGATTGTGCTGGGGCCGT ACCATGATAAGTTCCGTTCTCTGAACATGGTCTCTGAGTGCCTTTTCTCTCTGATAAAT GGAGATGATATGTTTGCCACATTTGCAAAAATGCAACAAAAAAGTTACTTGGTCTGG CTGTTTAGCAGAATTTATCTCTACTCATTCATCAGCCTCTTTATATATATGATTTTAAG TCTTTTCATCGCACTGATCACTGATACGTATGAAACAATTAAGCATTACCAACAAGAT GGCTTTCCAGAGACTGAACTTCGTACATTTATATCAGAGTGCAAAGATCTACCCAATT CTGGAAAATACAGATTAGAAGATGACACTCCAATATCTATATTCTGCTGTTGTAAAAA G (SEQ ID NO: 76) Canis familiaris TRPML3 (XM_547306) (SEQ ID NO: 77) MTPFGSLASAKASNSRAAWKIVVDSFSSQHTPQVGTGGPQESDKALTFGELTFSHSSPFFI CASPSLPPLHSSGLDDEPYCWTGFHCIKYLAGPASVPNSLERGSKILVSQASFPIRTSPYLTL LSRGEKKPLCSSVEKRPLGVLEMGSLTLLSEELKRQLPGTLLLGQPPLLRERGGSSAEIDK TPLPIGRLLSGRLFKAALVIGCCRADVTQLEPPRDPGFSPARQEVCGLGSRVEGAAGSNVN NLFFFLPLEMANPTVVISSCSSHEEENRCTFSQHTSPSEELLLEDQIRRKLKFFFMNPCEKF WARGRKPWKLAIQILKIAMVTIQLVFFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMD DTYAVYTQRDVYDQIIFAVNQYLLLRNTSVGNHAYENKGTEQSAMAICQHFYKQGNIC PGNDTFDIDPEIETECFSVEPAEPFHVGTLEENKLNLTLDFHRLLTVDLQFKLKAINLQTI RHHELPDCYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDA FVILTCLASLTLCLRSVIRGLQLQQEFVNFFLLHYKKFVSVSDRMEFVNGWYIMIIISDMLTI IGSILKMEIQAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFQKYNLLILTLQAALPSVIRFC CCAAMIYLGYCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVW LFSRIYLYSFISLFIYMILSLFIALITDTYETIKHYQQDGFPETELRTFISECKDLPNSGKYRLE DDTPISIFCCCKK (SEQ ID NO: 77) Danio rerio TRPML3 (XM_688418) (SEQ ID NO: 78) ATGTCTGACCGAGCGTCACACACTCATGAAAGCGCAACACTTCTGGACCCGGAGTGT GTGGAAAGCTTAAGGAGAAAACTCAAGTATTTCTTCATGAGTCCGTGTCAGAAATAC AGCACTAGAGGACGGATACCATGGAAGATGATGCTTCAGATACTCAAGATTTGTTTA GTATTCATCTACCTGGTCTCTTTTGGATTGAGCAACGAGATGATGGTGACGTTCAAA GAGGAAAATCTCATCGCCTTCAAGCACTTCTTTCTGAAAAACTACAAGGACAGCAATA AACATTACGCCTTGTACACAAAACATGAAGTTCACGACCACATCCTCTACACCATCAGA CGGTATCTACAGCTACAAAACCTGACGATTGGCAATCAAGCGCTGGAGATGATCGAT GGTCTGGCGACTCCTCTGTCTCTCTGTCAGCAGTTGTATCGACATGCGCGCGTCGTG CCGTCTAATGAGACGTTTGAAATCGATCCACATGTAGAGACAGAGTGTGTTTCTGTG TATCCCCTTTCTCCCATCACGACTGACAGTCTGGAAAACTCCCTGAACTTGACTTTAGA TTTTCAAAGGTTGTTAGCGGTAAACATTTATCTGAAGATCAAGGCTATCAACATTCAG ACGGTTCGCCATCAAGAGTTACCAGACTGCTACGACTTCAGCATTAATATCATGTTTG ACAATCGTGCACACAGCGGACAGATCAAGATCTCTCTCAGCAGCGGCGTGCAGATAA ACGTCTGTAAGGACTGGAACATTTCTGGCTCAAGTAAGTTGAACAGCCACTTTGCGC TGATTGTGGTGTTTGACTGTTTGATCATCTGCTTCTGTCTGCTGTCACTCATCCTCTGC ACGCGCTCAGTCCACACAGGATTTCTCCTACAGACTGAATACAGAAGATTCATGTCCA GTCAGCACAGTAAAAGCGTCTCATGGTCTGAGAGGCTGGAGTTCATCAACGGCTGGT ACATCCTCATCATCATCAGCGATGCGCTGACTATTGCAGGCTCAATCCTCAAAATCTG CATACAGAGCAAAGAACTGACGAGCTATGACGTGTGCAGTATTCTGCTGGGCACTGC AACAATGCTGGTGTGGATTGGAGTAATGCGCTACCTCAGTTTCTTCCAGAAATATTAT ATCCTCATCCTCACCCTGAAGGCTGCACTTCCCAATGTGATTCGATTCTCCATCTGCGC TGTTATGATCTACCTGAGTTACTGCTTCTGCGGATGGATCGTTTTGGGGCCACACCAT GAAAATTTTCGCACATTCAGTAGGGTTGCTGGCTGTCTTTTCTCCATGATTAATGGGG ATGAAATCTACTCCACGTTCACCAAGCTCCGGGAATACAGCACTCTGGTGTGGCTGTT CAGCAGACTCTACGTCTACAGCTTCATCCCGGTCTTCACATACATGGTTCTGAGTGTC TTCATCGCCCTCATCACAGACACGTATGAAACCATCAGGGTGAGTTATTTCAGCTTCA GTGAGAGTAGCTGCAAA (SEQ ID NO: 78) Danio rerio TRPML3 (XM_688418) (SEQ ID NO: 79) MSDRASHTHESATLLDPECVESLRRKLKYFFMSPCQKYSTRGRIPWKMMLQILKICLVFIY LVSFGLSNEMMVTFKEENLIAFKHFFLKNYKDSNKHYALYTKHEVHDHILYTIRRYLQL QNLTIGNQALEMIDGLATPLSLCQQLYRHARVVPSNETFEIDPHVETECVSVYPLSPITTD SLENSLNLTLDFQRLLAVNIYLKIKAINIQTVRHQELPDCYDFSINIMFDNRAHSGQIKISLS SGVQINVCKDWNISGSSKLNSHFALIVVFDCLIICFCLLSLILCTRSVHTGFLLQTEYRRFMS SQHSKSVSWSERLEFINGWYILIIISDALTIAGSILKICIQSKELTSYDVCSILLGTATMLVWIG VMRYLSFFQKYYILILTLKAALPNVIRFSICAVMIYLSYCFCGWIVLGPHHENFRTFSRVAG CLFSMINGDEIYSTFTKLREYSTLVWLFSRLYVYSFIPVFTYMVLSVFIALITDTYETIRVSYFS FSESSCK (SEQ ID NO: 79) Homo sapiens TRPML3 Codon-optimized (SEQ ID NO: 80) ATGGCCGACCCTGAGGTGGTGGTGTCCTCCTGCTCTAGCCACGAGGAAGAGAACCG GTGCAACTTCAACCAGCAGACCAGCCCCAGCGAGGAACTGCTGCTGGAAGATCAGAT GCGGCGGAAGCTGAAGTTCTTCTTCATGAACCCCTGCGAGAAGTTCTGGGCCAGAG GCCGGAAGCCTTGGAAGCTGGCCATCCAGATCCTGAAGATCGCCATGGTGACCATCC AGCTGGTGCTGTTCGGCCTGAGCAACCAGATGGTGGTGGCCTTCAAAGAGGAAAAC ACAATCGCCTTCAAGCACCTGTTTCTGAAGGGCTACATGGACCGGATGGACGACACC TACGCCGTGTACACCCAGAGCGACGTGTACGACCAGCTGATCTTCGCCGTGAACCAG TACCTGCAGCTGTACAACGTGAGCGTGGGCAACCACGCCTACGAGAACAAGGGCACC AAGCAGAGCGCCATGGCCATCTGCCAGCACTTCTACAAGCGGGGCAACATCTACCCC GGCAACGACACCTTCGACATCGACCCCGAGATCGAGACAGAGTGCTTCTTCGTGGAG CCCGACGAGCCTTTCCACATCGGCACCCCTGCCGAGAACAAGCTGAACCTGACCCTGG ACTTCCACCGGCTGCTGACCGTGGAGCTGCAGTTCAAGCTGAAGGCCATCAACCTGC AGACCGTGCGGCACCAGGAACTGCCCGACTGCTACGACTTCACCCTGACCATCACCTT CGATAACAAGGCCCACAGCGGCCGGATCAAGATCAGCCTGGACAACGACATCAGCAT CCGGGAGTGCAAGGACTGGCACGTGAGCGGCAGCATCCAGAAAAACACCCACTACA TGATGATCTTCGACGCCTTCGTGATCCTGACCTGCCTGGTGTCCCTGATCCTGTGCAT CAGAAGCGTCATCAGGGGCCTGCAGCTCCAGCAGGAATTCGTCAACTTCTTCCTGCT GCACTACAAGAAAGAAGTGTCCGTCAGCGACCAGATGGAATTTGTGAACGGCTGGT ACATCATGATCATCATCAGCGACATCCTGACAATCATCGGCAGCATTCTGAAGATGGA AATCCAGGCCAAGAGCCTGACCAGCTACGACGTGTGCAGCATTCTGCTGGGAACCTC CACCATGCTGGTCTGGCTCGGCGTGATCAGATACCTGGGCTTCTTCGCCAAGTACAA CCTGCTGATTCTGACACTGCAGGCCGCCCTGCCCAACGTGATCCGGTTCTGCTGCTGC GCCGCCATGATCTACCTGGGCTACTGCTTCTGCGGCTGGATCGTGCTGGGCCCCTAC CACGACAAGTTCCGGTCCCTGAACATGGTGTCCGAGTGCCTGTTCAGCCTGATCAAC GGCGACGACATGTTCGCCACCTTCGCCAAGATGCAGCAGAAAAGCTACCTGGTCTGG CTGTTCAGCCGGATCTACCTGTACAGCTTCATCAGCCTGTTCATCTACATGATCCTGA GCCTGTTTATCGCCCTGATCACCGATACCTACGAGACAATCAAGCAGTACCAGCAGGA CGGCTTCCCCGAGACAGAGCTGCGGACCTTCATCAGCGAGTGTAAGGACCTGCCCAA CAGCGGCAAGTACCGGCTGGAAGATGACCCCCCCGTGTCCCTGTTCTGCTGTTGCAA GAAG (SEQ ID NO: 80) Homo sapiens TRPML3 CDS variant C1149T silent mutation (SEQ ID NO: 81) ATGGCAGATCCTGAGGTAGTTGTGAGTAGCTGCAGCTCTCATGAAGAGGAAAATCG CTGCAATTTTAACCAGCAAACATCTCCATCTGAGGAGCTTCTATTAGAAGACCAGATG AGGCGAAAACTCAAATTTTTTTTCATGAATCCCTGTGAGAAGTTCTGGGCTCGAGGT AGAAAACCATGGAAACTTGCCATACAAATTCTAAAAATTGCAATGGTGACTATCCAGC TGGTCTTATTTGGGCTAAGTAACCAGATGGTGGTAGCTTTCAAGGAAGAGAATACTA TAGCATTCAAACACCTTTTCCTAAAAGGATATATGGACCGAATGGATGACACATATGC AGTGTACACACAAAGTGACGTGTATGATCAGTTAATCTTCGCAGTAAACCAGTACTTG CAGCTATACAATGTCTCCGTTGGGAATCATGCTTATGAGAACAAAGGTACCAAGCAA TCTGCTATGGCAATCTGTCAGCACTTCTACAAGCGAGGAAACATCTACCCTGGAAATG ATACCTTTGACATCGATCCAGAAATTGAAACTGAGTGTTTCTTTGTGGAGCCAGATGA ACCTTTTCACATTGGGACACCAGCAGAAAATAAACTGAACTTAACACTGGACTTCCAC AGACTCCTAACAGTGGAGCTTCAGTTTAAACTGAAAGCCATTAATCTGCAGACAGTTC GTCATCAAGAACTCCCTGACTGTTATGACTTTACTCTGACTATAACATTTGACAACAAG GCCCATAGTGGAAGAATTAAAATAAGTTTAGATAATGACATTTCCATCAGAGAATGT AAAGACTGGCATGTATCTGGATCAATTCAGAAGAACACTCATTACATGATGATCTTTG ATGCCTTTGTCATTCTGACTTGCTTGGTTTCATTAATCCTCTGCATTAGATCTGTGATT AGAGGACTTCAGCTTCAGCAGGAGTTTGTCAATTTTTTCCTCCTCCATTATAAGAAGG AAGTTTCTGTTTCTGATCAAATGGAATTTGTCAATGGATGGTACATTATGATTATTAT TAGTGACATATTGACAATCATTGGATCAATTCTAAAAATGGAAATCCAAGCTAAGAGT CTAACTAGTTATGATGTCTGTAGCATACTTCTTGGGACTTCTACCATGCTTGTGTGGC TTGGAGTCATCCGATACCTCGGTTTCTTTGCAAAGTACAACCTCCTCATTTTGACCCTT CAGGCAGCGCTGCCCAATGTCATCAGGTTCTGCTGCTGTGCAGCTATGATTTACTTAG GTTACTGCTTCTGTGGATGGATCGTGCTGGGGCCTTACCATGACAAGTTTCGTTCTCT GAACATGGTCTCTGAGTGCCTTTTCTCTCTGATAAATGGAGATGATATGTTTGCCACG TTTGCAAAAATGCAGCAAAAAAGTTACTTAGTCTGGCTGTTTAGTAGAATTTACCTCT ACTCATTCATCAGCCTCTTTATATATATGATTTTAAGTCTTTTCATTGCACTGATCACT GATACATACGAAACAATTAAGCAATACCAACAAGATGGCTTCCCAGAGACTGAACTTC GTACATTTATATCAGAATGCAAAGATCTACCCAACTCTGGAAAATACAGATTAGAAGA TGACCCTCCAGTATCTTTATTCTGCTGTTGTAAAAAG (SEQ ID NO: 81) Rattus norevigus (NM_00102059.1)(GI: 58865683) (SEQ ID NO: 82) gttcgacaga agcttgtgat ttatggtcca aggaatccag tgtcagatca atagacaaaa 61 tgccccaggg aagttgtgtg tgcattctac tggacagatc agagactggt cagaacaggt 121 gcttggctgg cggtgcgtcc aaacctcaga gatggcaaat cctgaggtgg tggtaagcag 181 ctgcagttct caccaggatg aaagtccctg cactttctac ccgagctcat cccagtccga 241 gcagcttctc ttagaagatc agatgaggcg gaaactcaaa ttctttttta tgaatccttg 301 cgagaagttc tgggctcggg gtaggaagcc atggaaactt gccatacaga ttctgaaaat 361 cgctatggtg actatccagc tggttctgtt tggactaagt aaccagatgg tagtagcttt 421 caaggaagag aacacgatag ccttcaaaca cctcttcctg aaaggctaca tggaccgaat 481 ggacgacacc tacgcggtgt acactcagaa tgatgtgtac gaccagatca tctttgcagt 541 gacccggtac ttgcaacttc gaaacatctc cgtcggcaac catgcttatg agaacaaggg 601 gactaagcag tcagcaatgg cagtctgtca gcacttctac aggcaaggca ccatctgccc 661 cgggaacgat accttcgaca tcgatccaga agtcgaaaca gactgtttcc ttatagagcc 721 agaggaagct ttccacatgg gaacacctgg agaaaacaaa ctcaacctga ccctggactt 781 ccacagactt ctgacagtgg agctccaatt taagctcaaa gccatcaacc tgcagacagt 841 tcgccaccag gagcttcctg actgttacga ctttaccctg actataacat tcgacaacaa 901 ggcacacagt ggaagaatca aaataagttt agacaacgac atttctatca gagaatgcaa 961 agattggcac gtgtctggat caattcagaa gaacacccac tacatgatga tcttcgatgc 1021 ctttgttatc ctgacctgct tgtcctcgct ggtgctctgc gccaggtctg tgattcgggg 1081 tcttcagctt cagcaggagt ttgtcaactt tttccttctt cactacaaga aggaagtttc 1141 ggcctctgat cagatggagt tcatcaacgg gtggtacatt atgatcatcg ttagtgacat 1201 actgacgatc gttggatcga ttctgaaaat ggaaatccaa gccaagagtc ttacaagcta 1261 cgatgtctgt agcatacttc ttgggacttc caccatgctc gtgtggcttg gcgttatccg 1321 atacctgggt ttctttgcga agtacaatct ccttatcctg accctccagg cagcgctgcc 1381 caatgtcatc aggttctgtt gctgtgcggc tatgatctat cttgggtatt gcttttgcgg 1441 atggattgtg ctgggccctt accatgagaa gttccgctct ctgaacaagg tctctgagtg 1501 cctattctca ctgataaatg gagacgacat gttttccacg ttcgcgaaaa tgcagcagaa 1561 aagttacctg gtgtggctgt tcagccgcgt ctacctgtac tcgttcatca gcctcttcat 1621 ctacatgatc ttgagccttt tcatcgcgct catcacagac acgtacgaaa ccattaagca 1681 ctaccagcaa gatggcttcc cagagacgga acttcgaaag tttatcgctg aatgcaaaga 1741 cctccccaac tctggaaaat acagattgga agatgaccct ccaggttctt tattctgctg 1801 ctgcaaaaag taactgtcgg gtttctctgt gcctgggagg aaaatacagt gtgtggatga 1861 gtcagagaca atatggatta ttggtaatca cgcaacagtg tgttcagata ctagtgttct 1921 gagttaactc acagctatga ctttgcgggg cctgttaaat atatttttaa atattaaaaa 1981 aaaaaaaaaa aaaaaaaaaa Rattus norevigus (NP_00102059.1)(GI: 58865684) (SEQ ID NO: 83) MANPEVVVSSCSSHQDESPCTFYPSSSQSEQLLLEDQMRRKLKFFFMNPCEKFWARGRKP WKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYTQ NDVYDQIIFAVTRYLQLRNISVGNHAYENKGTKQSAMAVCQHFYRQGTICPGNDTFDID PEVETDCFLIEPEEAFHMGTPGENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPDC YDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLSSL VLCARSVIRGLQLQQEFVNFFLLHYKKEVSASDQMEFINGWYIMIIVSDILTIVGSILKMEI QAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMIYL GYCFCGWIVLGPYHEKFRSLNKVSECLFSLINGDDMFSTFAKMQQKSYLVWLFSRVYLYS FISLFIYMILSLFIALITDTYETIKHYQQDGFPETELRKFIAECKDLPNSGKYRLEDDPPGSL FCCCKK Sus scrofa (AB271930)(GI: 146741299)(Partial) (SEQ ID NO: 84)  1 gtgaaatggc agatcctgag cctgtcataa gtagctgcag ctctcgtgaa gaggaaaatc 61 gctgcacttt taaccagcac acatgtccct ctgaggagcg tctattagaa gaccagatga 121 ggcgaaaact caaatttttt ttcatgactc cttgtgagaa gttctggact cgaggtcgaa 181 aaccatggaa acttgccatg caagttctaa aaattgcgat ggtgactatc cagctgatct 241 ttttcgggct aagtaaccag atggtggtag ctttcaagga agagaacacg atagcattta 301 aacacctctt tctaaagggc tatgtggacc agatggatga cacatatgcc gtgtacaccc 361 aaagcgacgt atacgatcgg atcgtcttcg cagtgaacca gtacttgcag ctacgcagca 421 tctcggttgg gaaccacgct tacgagaaca agggcgcgga gcagtcggcc atggcgatct 481 gttggcactt ctacaagcaa ggaaacatct gtcctggaaa tgacaccttt gacgttgatc 541 cagaagtaaa aactgaatgt ttctttgttg agccggatga agctgttgac actggaacac 601 tggaggagaa taagctcaac ttaacccttg actttcacag actcctaacg gtggagctgc 661 agtttaaact caaggccatt aatctgcaga cgattcgcca tcacgaactc cctgactgtt 721 atgacttcac cctgaccata acatttgaca a Sus scrofa (BAF62305.1)(GI: 14671300)(Partial) (SEQ ID NO: 85) MADPEPVISSCSSREEENRCTFNQHTCPSEERLLEDQMRRKLKFFFMTPCEKFWTRGRKP WKLAMQVLKIAMVTIQLIFFGLSNQMVVAFKEENTIAFKHLFLKGYVDQMDDTYAVYT QSDVYDRIVFAVNQYLQLRSISVGNHAYENKGAEQSAMAICWHFYKQGNICPGNDTFD VDPEVKTECFFVEPDEAVDTGTLEENKLNLTLDFHRLLTVELQFKLKAINLQTIRHHELP DCYDFTLTITFD Pan troglytes TRPML3 (XM_001140555.1) (GI: 114557485) (SEQ ID NO: 86) 1 cttactccaa tcaagcctct gcccgccagg aataggtaac ctgtgtgtgt ccgtttgctc 61 cttctaagag catgcctgat agatacttcg gtagcctctc cggatggccc cttcgtcggg 121 tagcctctcc tgatggggtc cttcgcccac cctgcctccc gcgccggcgc tccgggtgaa 181 tgtcaagggt ggctggctgc gaatacctcc ttcagctgct ggggttcccg acagtttgca 241 gtttttaaaa gtgcaccctc ggaagggctt ttcagactgg gtaaagctga cttttccaag 301 agatggcaga tcctgaggta gttgtgagta gctgcagctc tcatgaagag gaaaatcgct 361 gcaattttaa ccagcaaaca tctccatctg aggagcttct attagaagac cagatgaggc 421 gaaaactcaa attttttttc atgaatccct gtgagaagtt ctgggctcga ggtagaaaac 481 catggaaact tgccatacaa attctaaaaa ttgcaatggt gactatccag ctggtcttat 541 ttgggctaag taaccagatg gtggtagctt tcaaggaaga gaatactata gcattcaaac 601 accttttcct aaaaggatat atggaccgaa tggatgacac atatgcagtg tacacacaaa 661 gtgacgtgta tgatcagtta atcttcgcag taaaccagta cttgcagcta tacaatgtct 721 ccgttgggaa tcatgcttat gagaacaaag gtaccaagca atctgctatg gcaatctgtc 781 agcacttcta caagcgagga aacatctacc ctggaaatga tacctttgac atcgatccag 841 aaattgaaac tgagtgtttc tttgtggagc cagatgaacc ttttcacatt gggacaccag 901 cagaaaataa actgaactta acactggact tccacagact cctaacagtg gagcttcagt 961 ttaaactgaa agccattaat ctgcagacag ttcgtcatca agaactccct gactgttatg 1021 actttactct gactataaca tttgacaaca aggcccatag tggaagaatt aaaataagtt 1081 tagataatga catttccatc agagaatgta aagactggca tgtatctgga tcaattcaga 1141 agaacactca ttacatgatg atctttgatg cctttgtcat tctgacttgc ttggtttcat 1201 taatcctctg cattagatct gtgattagag gacttcagct tcagcaggta gggaacgttg 1261 ctttctagga atgctactga cattttgatt gacagagaca ttcactgtgc ctcccctctt 1321 ttccctaaag gagtttgtca attttttcct cctccattat aagaagggag tttctgtttc 1381 tgatcaaatg gaatttgtca atggatggta cattatgatt attattagtg acatattgac 1441 aatcattgga tcaattctaa aaatggaaat ccaagctaag gtaatttttt tcctaatcat 1501 gctattgtta gtgtcagatt tgcactaatg gtaatgtatt tttccagaat gtaagaattt 1561 tcagaatgaa ttgtttcttc caaactgtat atcaagtaga cttgaaattg gtaatggtaa 1621 ttttcttaaa tctagtcagg aggtctctta ggcagagttt ttcaaagtgt gatccacaaa 1681 ccattgcatc agaatcattg ggtgcctggt aaagtgtacc atgttagacc tactgaattc 1741 agactcttcg gcggggcctg tgaattctta cacacaccaa aattcataca caaccaaggt 1801 aactaaggta agagtttttt ttttttttaa atcttacaag aaatgctcaa atctttaaca 1861 aaaatgagtg ggtctatagg ggaaagtgag gtcaaggcac tatggtgtgc atgcttgcat 1921 ttgtttcctc cgtccattca aagtgagaat gctcccattt tcttacttta ccattgatgt 1981 gctacaagct tatttatttt aagactaacc tagcctaaaa atcaactgtc cccacaaaat 2041 aaaaatcaca ttaaaaaaac taatagtgtt cagactaatc ttgctcaaac ttatgtttcc 2101 ctagtcttga tgcgactgat tgagtcacct ggggagttgg ttataaacct gggcagagac 2161 cccaaatgca atggctcaga gaagatagga gcttatttct gtcttatgca atagtcagaa 2221 tgggttttac agactggtga gtagctcaac atctcacagt cattcaggca cccatgttcc 2281 tcccattttg tttctctgcc atcccttaag gacttgccct gactgcatga ttattgctgt 2341 gttgcctcaa acaggttgca gcttatggga agcaaaaaca cggtatggtg gaagctctcc 2401 catagactga tggcttggct caagagtggc cgactttatt tctgtacata tcccactgga 2461 tagaatttag tcaatcctaa ctgcagaggg agccagggaa cacagcccag gcatgtgcct 2521 aggaagggga gaatgggttt aggttgacac ttagcagctg ccactatatg tggctatagt 2581 atgtatcatt ggaatagatg tttaacttta gggacaaata aacaaaaaac caaaacaaaa 2641 aaaggagtaa ggggagagat ttgcagcaaa tctttatttt taccaacctc aactatcatt 2701 aatttcagtg aaccctaaat ggtgtccaac aaaatatctt tctagaccat tcaccgtctc 2761 tgcctcatag atgatcatat catgttttct tctcttctga aacctctaat acccttgtcc 2821 tatcctcatt ctaagctgat gaccttactt cctatttcac aaaaataata gaaaaaaaaa Pan troglytes TRPML3 (XP_001140555.1)(GI: 469371) (SEQ ID NO: 87) MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYT QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDTFD IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVS LILCIRSVIRGLQLQQVGNVAF Pan troglytes TRPML3 (XM_001140401.1)(GI: 114557483) (SEQ ID NO: 88) 1 cctctagaga tggcagatcc tgaggtagtt gtgagtagct gcagctctca tgaagaggaa 61 aatcgctgca attttaacca gcaaacatct ccatctgagg agcttctatt agaagaccag 121 atgaggcgaa aactcaaatt ttttttcatg aatccctgtg agaagttctg ggctcgaggt 181 agaaaaccat ggaaacttgc catacaaatt ctaaaaattg caatggtgac tatccagctg 241 gtcttatttg ggctaagtaa ccagatggtg gtagctttca aggaagagaa tactatagca 301 ttcaaacacc ttttcctaaa aggatatatg gaccgaatgg atgacacata tgcagtgtac 361 acacaaagtg acgtgtatga tcagttaatc ttcgcagtaa accagtactt gcagctatac 421 aatgtctccg ttgggaatca tgcttatgag aacaaaggta ccaagcaatc tgctatggca 481 atctgtcagc acttctacaa gcgaggaaac atctaccctg gaaatgatac ctttgacatc 541 gatccagaaa ttgaaactga gtgtttcttt gtggagccag atgaaccttt tcacattggg 601 acaccagcag aaaataaact gaacttaaca ctggacttcc acagactcct aacagtggag 661 cttcagttta aactgaaagc cattaatctg cagacagttc gtcatcaaga actccctgac 721 tgttatgact ttactctgac tataacattt gacaacaagg cccatagtgg aagaattaaa 781 ataagtttag ataatgacat ttccatcaga gaatgtaaag actggcattc tccctccgtc 841 gcccagcctg gaaacactca ttacatgatg atctttgatg cctttgtcat tctgacttgc 901 ttggtttcat taatcctctg cattagatct gtgattagag gacttcagct tcagcaggag 961 tttgtcaatt ttttcctcct ccattataag aagggagttt ctgtttctga tcaaatggaa 1021 tttgtcaatg gatggtacat tatgattatt attagtgaca tattgacaat cattggatca 1081 attctaaaaa tggaaatcca agctaagagt ctaactagtt atgatgtctg tagcatactt 1141 cttgggactt ctaccatgct tgtgtggctt ggagtcatcc gatacctcgg tttctttgca 1201 aagtacaatc tcctcatttt gacccttcag gcagcactgc ccaatgtcat caggttctgc 1261 tgctgtgcag ctatgattta cttaggttac tgcttctgtg gatggatcgt gctggggcct 1321 taccatgaca agtttcgttc tctgaacatg gtctctgagt gccttttctc tctgataaat 1381 ggagatgata tgtttgccac gtttgcaaaa atgcagcaaa aaagttactt agtctggctg 1441 tttagtagaa tttacctcta ctcattcatc agcctcttta tatatatgat tttaagtctt 1501 ttcattgcac tgatcactga tacatacgaa acaattaagc aataccaaca agatggcttc 1561 ccagagactg aacttcgtac atttatatca gaatgcaaag atctacccaa ctctggaaaa 1621 tacagattag aagatgaccc tccagtatct ttattctgct gttgtaaaaa gtagctatca 1681 ggtttatctg tactttagag gaaaatataa tgtgtagctg agttagaaca ctgtggatat 1741 tctgagatca gatgtagtat gtttgaagac tgttattttg agctaattga gacctataat 1801 tcaccaataa ctgtttatat ttttaaaagc aatatttaat gtctttgcag ctttatgctg 1861 ggcttgtt Pan troglytes TRPML3 XP_001140401.1 (GI: 114557484) (SEQ ID NO: 89) MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKFENTIAFKHLFLKGYMDRMDDTYAVYT QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDTFD IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHSPSVAQPGNTHYMMIFDAFVILTCL VSLILCIRSVIRGLQLQQEFVNFFLLHYKKGVSVSDQMEFVNGWYIMIIISDILTIIGSILKM EIQAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMI YLGYCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYL YSFISLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVS LFCCCKK Pan troglytes TRPML3 (XM_524756.2) (GI: 114557481) (SEQ ID NO: 90) 1 tcctctagag atggcagatc ctgaggtagt tgtgagtagc tgcagctctc atgaagagga 61 aaatcgctgc aattttaacc agcaaacatc tccatctgag gagcttctat tagaagacca 121 gatgaggcga aaactcaaat tttttttcat gaatccctgt gagaagttct gggctcgagg 181 tagaaaacca tggaaacttg ccatacaaat tctaaaaatt gcaatggtga ctatccagta 241 cttgcagcta tacaatgtct ccgttgggaa tcatgcttat gagaacaaag gtaccaagca 301 atctgctatg gcaatctgtc agcacttcta caagcgagga aacatctacc ctggaaatga 361 tacctttgac atcgatccag aaattgaaac tgagtgtttc tttgtggagc cagatgaacc 421 ttttcacatt gggacaccag cagaaaataa actgaactta acactggact tccacagact 481 cctaacagtg gagcttcagt ttaaactgaa agccattaat ctgcagacag ttcgtcatca 541 agaactccct gactgttatg actttactct gactataaca tttgacaaca aggcccatag 601 tggaagaatt aaaataagtt tagataatga catttccatc agagaatgta aagactggca 661 tgtatctgga tcaattcaga agaacactca ttacatgatg atctttgatg cctttgtcat 721 tctgacttgc ttggtttcat taatcctctg cattagatct gtgattagag gacttcagct 781 tcagcaggag tttgtcaatt ttttcctcct ccattataag aagggagttt ctgtttctga 841 tcaaatggaa tttgtcaatg gatggtacat tatgattatt attagtgaca tattgacaat 901 cattggatca attctaaaaa tggaaatcca agctaagagt ctaactagtt atgatgtctg 961 tagcatactt cttgggactt ctaccatgct tgtgtggctt ggagtcatcc gatacctcgg 1021 tttctttgca aagtacaatc tcctcatttt gacccttcag gcagcactgc ccaatgtcat 1081 caggttctgc tgctgtgcag ctatgattta cttaggttac tgcttctgtg gatggatcgt 1141 gctggggcct taccatgaca agtttcgttc tctgaacatg gtctctgagt gccttttctc 1201 tctgataaat ggagatgata tgtttgccac gtttgcaaaa atgcagcaaa aaagttactt 1261 agtctggctg tttagtagaa tttacctcta ctcattcatc agcctcttta tatatatgat 1321 tttaagtctt ttcattgcac tgatcactga tacatacgaa acaattaagc aataccaaca 1381 agatggcttc ccagagactg aacttcgtac atttatatca gaatgcaaag atctacccaa 1441 ctctggaaaa tacagattag aagatgaccc tccagtatct ttattctgct gttgtaaaaa 1501 gtagctatca ggtttatctg tactttagag gaaaatataa tgtgtagctg agttagaaca 1561 ctgtggatat tctgagatca gatgtagtat gtttgaagac tgttattttg agctaattga 1621 gacctataat tcaccaataa ctgtttatat ttttaaaagc aatatttaat gtctttgcag 1681 ctttatgctg ggcttgtttt taaaacaact ttaatgagga aagctattgg attattatta 1741 tttcttgttt attttgccat ggctttagaa tgtattctgt atgcctctct tttgctctga 1801 tactcttgct tcctgctatt ctgattgtgc agactgtgta attagtggaa aacaatcctt 1861 ggtctgactg tgactttgga caactcagta accctggctt ggaccactct caggagtcca 1921 tccttgagag agtgggtgta gttaccattt atacagtaat cattgcattt taaaatctgc 1981 tcttgaaagg aagaataaga gtgcaccaga ataagagcgc accagaataa gagcgcacca 2041 gctaacaatg tgatacggcc atatgtcact taaggataga gatatgttct gagaaatgtg 2101 tcattaggcg attttgtcat taaacatcat agcatgtact tccacaaacc tagatggtat 2161 agcctactac acacctaggc tatttggtat agcctgttga tcctggggta caaatctgta 2221 caacatgtta ctgtattgaa tacagtaggc aattgtaaca caatggtaag tatctaaaca 2281 tagaaaaggg acagtaaaaa tatggtttta taatcttctg ggaccaccat tgtatatgcg 2341 gtacatcgtt gaccaaaaca tcgttatcca gcatatgact gtatttggtt atgaaagcca 2401 actgttactt gattctgctt ttagttctta agaggatcag gtttttaaat actcatttac 2461 aagttttcta tcctccttca gtgttaaagt agaaagtaaa aagagtatct tatacatgca 2521 tgaaattaaa gcatatacca aatgca Pan troglytes TRPML3 (XP_524756.2)(GI: 114557482) (SEQ ID NO: 91) MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK PWKLAIQILKIAMVTIQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDT FDIDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQEL PDCYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTC LVSLILCIRSVIRGLQLQQEFVNFFLLHYKKGVSVSDQMEFVNGWYIMIIISDILTIIGSILKM EIQAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMI YLGYCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYL YSFISLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVS LFCCCKK Pan troglytes TRPML3 (XM_00114082.1)(GI: 114557479) (SEQ ID NO: 92) 1 tcctctagag atggcagatc ctgaggtagt tgtgagtagc tgcagctctc atgaagagga 61 aaatcgctgc aattttaacc agcaaacatc tccatctgag gagcttctat tagaagacca 121 gatgaggcga aaactcaaat tttttttcat gaatccctgt gagaagttct gggctcgagg 181 tagaaaacca tggaaacttg ccatacaaat tctaaaaatt gcaatggtga ctatccagct 241 ggtcttattt gggctaagta accagatggt ggtagctttc aaggaagaga atactatagc 301 attcaaacac cttttcctaa aaggatatat ggaccgaatg gatgacacat atgcagtgta 361 cacacaaagt gacgtgtatg atcagttaat cttcgcagta aaccagtact tgcagctata 421 caatgtctcc gttgggaatc atgcttatga gaacaaaggt accaagcaat ctgctatggc 481 aatctgtcag cacttctaca agcgaggaaa catctaccct ggaaatgata cctttgacat 541 cgatccagaa attgaaactg agtgtttctt tgtggagcca gatgaacctt ttcacattgg 601 gacaccagca gaaaataaac tgaacttaac actggacttc cacagactcc taacagtgga 661 gcttcagttt aaactgaaag ccattaatct gcagacagtt cgtcatcaag aactccctga 721 ctgttatgac tttactctga ctataacatt tgacaacaag gcccatagtg gaagaattaa 781 aataagttta gataatgaca tttccatcag agaatgtaaa gactggcatg tatctggatc 841 aattcagaag aacactcatt acatgatgat ctttgatgcc tttgtcattc tgacttgctt 901 ggtttcatta atcctctgca ttagatctgt gattagagga cttcagcttc agcaggagtt 961 tgtcaatttt ttcctcctcc attataagaa gggagtttct gtttctgatc aaatggaatt 1021 tgtcaatgga tggtacatta tgattattat tagtgacata ttgacaatca ttggatcaat 1081 tctaaaaatg gaaatccaag ctaagagtct aactagttat gatgtctgta gcatacttct 1141 tgggacttct accatgcttg tgtggcttgg agtcatccga tacctcggtt tctttgcaaa 1201 gtacaatctc ctcattttga cccttcaggc agcactgccc aatgtcatca ggttctgctg 1261 ctgtgcagct atgatttact taggttactg cttctgtgga tggatcgtgc tggggcctta 1321 ccatgacaag tttcgttctc tgaacatggt ctctgagtgc cttttctctc tgataaatgg 1381 agatgatatg tttgccacgt ttgcaaaaat gcagcaaaaa agttacttag tctggctgtt 1441 tagtagaatt tacctctact cattcatcag cctctttata tatatgattt taagtctttt 1501 cattgcactg atcactgata catacgaaac aattaagcaa taccaacaag atggcttccc 1561 agagactgaa cttcgtacat ttatatcaga atgcaaagat ctacccaact ctggaaaata 1621 cagattagaa gatgaccctc cagtatcttt attctgctgt tgtaaaaagt agctatcagg 1681 tttatctgta ctttagagga aaatataatg tgtagctgag ttagaacact gtggatattc 1741 tgagatcaga tgtagtatgt ttgaagactg ttattttgag ctaattgaga cctataattc 1801 accaataact gtttatattt ttaaaagcaa tatttaatgt ctttgcagct ttatgctggg 1861 cttgttttta aaacaacttt aatgaggaaa gctattggat tattattatt tcttgtttat 1921 tttgccatgg ctttagaatg tattctgtat gcctctcttt tgctctgata ctcttgcttc 1981 ctgctattct gattgtgcag actgtgtaat tagtggaaaa caatccttgg tctgactgtg 2041 actttggaca actcagtaac cctggcttgg accactctca ggagtccatc cttgagagag 2101 tgggtgtagt taccatttat acagtaatca ttgcatttta aaatctgctc ttgaaaggaa 2161 gaataagagt gcaccagaat aagagcgcac cagaataaga gcgcaccagc taacaatgtg 2221 atacggccat atgtcactta aggatagaga tatgttctga gaaatgtgtc attaggcgat 2281 tttgtcatta aacatcatag catgtacttc cacaaaccta gatggtatag cctactacac 2341 acctaggcta tttggtatag cctgttgatc ctggggtaca aatctgtaca acatgttact 2401 gtattgaata cagtaggcaa ttgtaacaca atggtaagta tctaaacata gaaaagggac 2461 agtaaaaata tggttttata atcttctggg accaccattg tatatgcggt acatcgttga 2521 ccaaaacatc gttatccagc atatgactgt atttggttat gaaagccaac tgttacttga 2581 ttctgctttt agttcttaag aggatcaggt ttttaaatac tcatttacaa gttttctatc 2641 ctccttcagt gttaaagtag aaagtaaaaa gagtatctta tacatgcatg aaattaaagc 2701 atataccaaa tgca Pan troglytes TRPML3 (XP_00114082.1)(GI: 114557480) (SEQ ID NO: 93) MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYT QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDTFD IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVS LILCIRSVIRGLQLQQEFVNFFLLHYKKGVSVSDQMEFVNGWYIMIIISDILTIIGSILKMEI QAKSLTSYDVCSILLGTSTMLATWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMIYL GYCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYS FISLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVSLF CCCKK Xenopus tropicalis (Silurana tropicalis)(NM_001016804.2)(GI: 77682897) (SEQ ID NO: 94) 1 ttgcaactag gtctgacagt aggacaatgt ggcaggtcac gtgacagcag tgctgatggt 61 agagatgcgc cagcattcag gtctgagagc agaaagaaaa gctggccaaa acaaaggaca 121 ttctctttgc tgcttcgcta gctgagacgc tgctatagta tagcagacat ggaaaaccca 181 gagctaataa agacatgcaa ctctttggat gaacatgatg gtccctactg ctgcaagcag 241 tgccctatga ctgatgagct acttatggaa gaccagctac gaaggaaact taaattcttt 301 ttcatgaacc catgtgagaa gttccgtgcc cgtggacgaa agccttggaa gctttgtatt 361 caaattttaa aaattgcaat ggtgacaatc caattagttt tatttggact cagtaatgaa 421 atggtagtca cctttaaaga ggagaacact gtagctttta agcatctgtt tttgaaagga 481 tataaggatg gacatgatga cacatatgct atctacagtc aagaagatgt tcatgctcat 541 ataaacttta caattaaaag gtacctagag ctacaaaaca tatctgttgg aaatcatgca 601 tatgaaagta atggtaaagg tcaaactgga atgtcattat gtcaacatta ctataaacaa 661 gggagtatct ttcctggaaa tgaaacattt gaaattgacc cacaaataga tactgaatgt 721 ttccatattg atccatcaac tctgtgttct aatgacacac ctgcagaata ctactggtct 781 aatatgacac tagacttcta tagacttgtt tcagttgaaa ttatgtttaa gcttaaagca 841 attaatcttc aaaccattcg tcatcatgaa cttccagact gctatgactt catggttata 901 ataacatttg ataataaggc acacagtgga aggataaaaa tcagcttaga taatgatgtt 961 ggaatccagg aatgcaaaga ctggcatgtg tctggatcta ttcaaaaaaa tactcattac 1021 atgatgattt ttgatgctgc tgttattttg gtctgcttat cttccataac actctgcatt 1081 cgctccgtgg ttaaaggaat tcacctacaa aaagaatatg taaacttttt ccagcatcgt 1141 tttgcaagga ctgtgtcctc agctgatcgc atggaatttg tcaatggctg gtacattatg 1201 ataatcatca gtgatgtttt gtcaattatt ggctcaatct tgaagatgga gatccaagca 1261 aagagcctca ccagttatga tgtctgcagt attctcttgg gaacatccac cttattagtg 1321 tggcttggag ttattcgcta cttgggattt tttaagaaat acaatcttct gatcctgaca 1381 cttagggcag ccttacctaa tgtgatacga ttctgctgtt gtgctgctat gatctacctg 1441 ggctactgct tctgtggctg gattgttctg gggccttacc atgtaaagtt caggtccctg 1501 aacatggttt cagagtgcct gttctccctt attaatggag acgatatgtt tacaacgttt 1561 tcaatcatgc aggagaagag ctacttggtt tggctgttta gtcgcattta tttgtattcc 1621 tttataagtc tcttcatata catggttctg agtctcttca ttgcacttat tactgacaca 1681 tacgatacaa tcaagaatta ccagatcgat ggctttccag aatcagaact tcacacattt 1741 gtatccgagt gcaaagattt gccaacctct ggtcgatata gggaacaaga cgagacctcc 1801 tgtttgtcta tgctgtgttg taatcggtaa aaaagaatcc cagaagaagc actttatcca 1861 tggcctttaa aaatctgcaa aaaaaaaaaa aaaaaa Xenopus tropicalis (Silurana tropicalis)(NP_001016804.2)(GI: 62857333) (SEQ ID NO: 95) MENPELIKTCNSLDEHDGPYCCKQCPMTDELLMEDQLRRKLKFFFMNPCEKFRARGRK PWKLCIQILKIAMVTIQLVLFGLSNEMVVTFKEENTVAFKHLFLKGYKDGHDDTYAIYSQ EDVHAHINFTIKRYLELQNISVGNHAYESNGKGQTGMSLCQHYYKQGSIFPGNETFEID PQIDTECFHIDPSTLCSNDTPAEYYWSNMTLDFYRLVSVEIMFKLKAINLQTIRHHELPDC YDFMVIITFDNKAHSGRIKISLDNDVGIQECKDWHVSGSIQKNTHYMMIFDAAVILVCLS SITLCIRSVVKGIHLQKFYVNFFQHRFARTVSSADRMEFVNGWYIMIIISDVLSIIGSILKMEI QAKSLTSYDVCSILLGTSTLLVWLGVIRYLGFFKKYNLLILTLRAALPNVIRFCCCAAMIYL GYCFCGWIVLGPYHVKFRSLNMVSECLFSLINGDDMFTTFSIMQEKSYLVWLFSRIYLYSFI SLFIYMVLSLFIALITDTYDTIKNYQIDGFPESELHTFVSECKDLPTSGRYREQDETSCLSML CCNR Xenopus tropicalis (Silurana tropicalis)(CR855599.2)(GI: 77623768) (SEQ ID NO: 96) 1 ttgcaactag gtctgacagt aggacaatgt ggcaggtcac gtgacagcag tgctgatggt 61 agagatgcgc cagcattcag gtctgagagc agaaagaaaa gctggccaaa acaaaggaca 121 ttctctttgc tgcttcgcta gctgagacgc tgctatagta tagcagacat ggaaaaccca 181 gagctaataa agacatgcaa ctctttggat gaacatgatg gtccctactg ctgcaagcag 241 tgccctatga ctgatgagct acttatggaa gaccagctac gaaggaaact taaattcttt 301 ttcatgaacc catgtgagaa gttccgtgcc cgtggacgaa agccttggaa gctttgtatt 361 caaattttaa aaattgcaat ggtgacaatc caattagttt tatttggact cagtaatgaa 421 atggtagtca cctttaaaga ggagaacact gtagctttta agcatctgtt tttgaaagga 481 tataaggatg gacatgatga cacatatgct atctacagtc aagaagatgt tcatgctcat 541 ataaacttta caattaaaag gtacctagag ctacaaaaca tatctgttgg aaatcatgca 601 tatgaaagta atggtaaagg tcaaactgga atgtcattat gtcaacatta ctataaacaa 661 gggagtatct ttcctggaaa tgaaacattt gaaattgacc cacaaataga tactgaatgt 721 ttccatattg atccatcaac tctgtgttct aatgacacac ctgcagaata ctactggtct 781 aatatgacac tagacttcta tagacttgtt tcagttgaaa ttatgtttaa gcttaaagca 841 attaatcttc aaaccattcg tcatcatgaa cttccagact gctatgactt catggttata 901 ataacatttg ataataaggc acacagtgga aggataaaaa tcagcttaga taatgatgtt 961 ggaatccagg aatgcaaaga ctggcatgtg tctggatcta ttcaaaaaaa tactcattac 1021 atgatgattt ttgatgctgc tgttattttg gtctgcttat cttccataac actctgcatt 1081 cgctccgtgg ttaaaggaat tcacctacaa aaagaatatg taaacttttt ccagcatcgt 1141 tttgcaagga ctgtgtcctc agctgatcgc atggaatttg tcaatggctg gtacattatg 1201 ataatcatca gtgatgtttt gtcaattatt ggctcaatct tgaagatgga gatccaagca 1261 aagagcctca ccagttatga tgtctgcagt attctcttgg gaacatccac cttattagtg 1321 tggcttggag ttattcgcta cttgggattt tttaagaaat acaatcttct gatcctgaca 1381 cttagggcag ccttacctaa tgtgatacga ttctgctgtt gtgctgctat gatctacctg 1441 ggctactgct tctgtggctg gattgttctg gggccttacc atgtaaagtt caggtccctg 1501 aacatggttt cagagtgcct gttctccctt attaatggag acgatatgtt tacaacgttt 1561 tcaatcatgc aggagaagag ctacttggtt tggctgttta gtcgcattta tttgtattcc 1621 tttataagtc tcttcatata catggttctg agtctcttca ttgcacttat tactgacaca 1681 tacgatacaa tcaagaatta ccagatcgat ggctttccag aatcagaact tcacacattt 1741 gtatccgagt gcaaagattt gccaacctct ggtcgatata gggaacaaga cgagacctcc 1801 tgtttgtcta tgctgtgttg taatcggtaa aaaagaatcc cagaagaagc actttatcca 1861 tggcctttaa aaatctgcaa aaaaaaaaaa aaaaaa // Xenopus tropicalis (Silurana tropicalis)(CAJ83717.1)(GI: 89273945) (SEQ ID NO: 97) MENPELIKTCNSLDEHDGPYCCKQCPMTDELLMEDQLRRKLKFFFMNPCEKFRARGRK PWKLCIQILKIAMVTIQLVLFGLSNEMVVTFKFENTVAFKHLFLKGYKDGHDDTYAIYSQ EDVHAHINFTIKRYLELQNISVGNHAYESNGKGQTGMSLCQHYYKQGSIFPGNETFEID PQIDTECFHIDPSTLCSNDTPAEYYWSNMTLDFYRLVSVEIMFKLKAINLQTIRHHELPDC YDFMVIITFDNKAHSGRIKISLDNDVGIQECKDWHVSGSIQKNTHYMMIFDAAVILVCLS SITLCIRSVVKGIHLQKEYVNFFQHRFARTVSSADRMEFVNGWYIMIIISDVLSIIGSILKMEI QAKSLTSYDVCSILLGTSTLLVWLGVIRYLGFFKKYNLLILTLRAALPNVIRFCCCAAMIYL GYCFCGWIVLGPYHVKFRSLNMVSECLFSLINGDDMFTTFSIMQEKSYLVWLFSRIYLYSFI SLFIYMVLSLFIALITDTYDTIKNYQIDGFPESELHTFVSECKDLPTSGRYREQDETSCLSML CCNR Homo sapiens Sodium Leak Channel, Non-Selective (NALCN), mRNa (NM_052867.2) GI: 93277089 (SEQ ID NO: 98) gi|93277089|ref|NM_052867.2| Homo sapiens sodium leak channel, non-selective (NALCN), mRNA CGCGCTGCCTGAGCTGAGCCGCCGTAGGTGAGGGGCCCGCGTCCCCGCCCGCCCTG GGCGCCGCGCCTGGCACTGATCCTGCCGGTCGCCCACTGTCGCCGCCGCCGCCGCCC GCGGGCACCATGACAGCTCTGAGCGCTGGGGTTACAGACTGTGGTTTTGTGCTTGCT CACCAAAGCTAACCTCAGCATGCTCAAAAGGAAGCAGAGTTCCAGGGTGGAAGCCCA GCCAGTCACTGACTTTGGTCCTGATGAGTCTCTGTCGGATAATGCTGACATCCTCTGG ATTAACAAACCATGGGTTCACTCTTTGCTGCGCATCTGTGCCATCATCAGCGTCATTTC TGTTTGTATGAATACGCCAATGACCTTCGAGCACTATCCTCCACTTCAGTATGTGACC TTCACTTTGGATACATTATTGATGTTTCTCTACACGGCAGAGATGATAGCAAAAATGC ACATCCGGGGCATTGTCAAGGGGGATAGTTCCTATGTGAAAGATCGCTGGTGTGTTT TTGATGGATTTATGGTCTTTTGCCTTTGGGTTTCTTTGGTGCTACAGGTGTTTGAAAT TGCTGATATAGTTGATCAGATGTCACCTTGGGGCATGTTGCGGATTCCACGGCCACT GATTATGATCCGAGCATTCCGGATTTATTTCCGATTTGAACTGCCAAGGACCAGAATT ACAAATATTTTAAAGCGATCGGGAGAACAAATATGGAGTGTTTCCATTTTTCTACTTT TCTTTCTACTTCTTTATGGAATTTTAGGAGTTCAGATGTTTGGAACATTTACTTATCAC TGTGTTGTAAATGACACAAAGCCAGGGAATGTAACCTGGAATAGTTTAGCTATTCCA GACACACACTGCTCACCAGAGCTAGAAGAAGGCTACCAGTGCCCACCTGGATTTAAA TGCATGGACCTTGAAGATCTGGGACTTAGCAGGCAAGAGCTGGGCTACAGTGGCTT TAATGAGATAGGAACTAGTATATTCACCGTCTATGAGGCCGCCTCACAGGAAGGCTG GGTGTTCCTCATGTACAGAGCAATTGACAGCTTTCCCCGTTGGCGTTCCTACTTCTAT TTCATCACTCTCATTTTCTTCCTCGCCTGGCTTGTGAAGAACGTGTTTATTGCTGTTAT CATTGAAACATTTGCAGAAATCAGAGTACAGTTTCAACAAATGTGGGGATCGAGAAG CAGCACTACCTCAACAGCCACCACCCAGATGTTTCATGAAGATGCTGCTGGAGGTTG GCAGCTGGTAGCTGTGGATGTCAACAAGCCCCAGGGACGCGCCCCAGCCTGCCTCCA GAAAATGATGCGGTCATCCGTTTTCCACATGTTCATCCTGAGCATGGTGACCGTGGA CGTGATCGTGGCGGCTAGCAACTACTACAAAGGAGAAAACTTCAGGAGGCAGTACG ACGAGTTCTACCTGGCGGAGGTGGCTTTTACAGTACTTTTTGATTTGGAAGCACTTCT GAAGATATGGTGTTTGGGATTTACTGGATATATTAGCTCATCTCTCCACAAATTCGAA CTACTACTCGTAATTGGAACTACTCTTCATGTATACCCAGATCTTTATCATTCACAATT CACGTACTTTCAGGTTCTCCGAGTAGTTCGGCTGATTAAGATTTCACCTGCATTAGAA GACTTTGTGTACAAGATATTTGGTCCTGGAAAAAAGCTTGGGAGTTTGGTTGTATTT ACTGCCAGCCTCTTGATTGTTATGTCAGCAATTAGTTTGCAGATGTTCTGCTTTGTCG AAGAACTGGACAGATTTACTACGTTTCCGAGGGCATTTATGTCCATGTTCCAGATCCT CACCCAGGAAGGATGGGTGGACGTAATGGACCAAACTCTAAATGCTGTGGGACATA TGTGGGCACCCGTGGTTGCCATCTATTTCATTCTCTATCATCTTTTTGCCACTCTGATC CTCCTGAGTTTGTTTGTTGCTGTTATTTTGGACAACTTAGAACTTGATGAAGACCTAA AGAAGCTTAAACAATTAAAGCAAAGTGAAGCAAATGCGGACACCAAAGAAAAGCTCC CTTTACGCCTGCGAATCTTTGAAAAATTTCCAAACAGACCTCAAATGGTGAAAATCTC AAAGCTTCCTTCAGATTTTACAGTTCCTAAAATCAGGGAGAGTTTTATGAAGCAGTTT ATTGACCGCCAGCAACAGGACACATGTTGCCTCCTGAGAAGCCTCCCGACCACCTCTT CCTCCTCCTGCGACCACTCCAAACGCTCAGCAATTGAGGACAACAAATACATCGACCA AAAACTTCGCAAGTCTGTTTTCAGCATCAGGGCAAGGAACCTTCTGGAAAAGGAGAC CGCAGTCACTAAAATCTTAAGAGCTTGCACCCGACAGCGCATGCTGAGCGGATCATT TGAGGGGCAGCCCGCAAAGGAGAGGTCAATCCTCAGCGTGCAGCATCATATCCGCCA AGAGCGCAGGTCACTAAGACATGGATCAAACAGCCAGAGGATCAGCAGGGGAAAAT CTCTTGAAACTTTGACTCAAGATCATTCCAATACAGTGAGATATAGAAATGCACAAAG AGAAGACAGTGAAATAAAGATGATTCAGGAAAAAAAGGAGCAAGCAGAGATGAAAA GGAAAGTGCAAGAAGAGGAACTCAGAGAGAACCACCCATACTTCGATAAGCCACTGT TCATTGTCGGGCGAGAACACAGGTTCAGAAACTTTTGCCGGGTGGTGGTCCGAGCA CGCTTCAACGCATCTAAAACAGACCCTGTCACAGGAGCTGTGAAAAATACAAAGTACC ATCAACTTTATGATTTGCTGGGATTGGTCACTTACCTGGACTGGGTCATGATCATCGT AACCATCTGCTCTTGCATTTCCATGATGTTTGAGTCCCCGTTTCGAAGAGTCATGCAT GCACCTACTTTGCAGATTGCTGAGTATGTGTTTGTGATATTCATGAGCATTGAGCTTA ATCTGAAGATTATGGCAGATGGCTTATTTTTCACTCCAACTGCTGTCATCAGGGACTT CGGTGGAGTAATGGACATAITTATATATCTTGTGAGCTTGATATTTCTTTGTTGGATG CCTCAAAATGTACCTGCTGAATCGGGAGCTCAGCTTCTAATGGTCCTTCGGTGCCTGA GACCTCTGCGCATATTCAAACTGGTGCCCCAGATGAGGAAAGTIGTTCGAGAACTTT TCAGCGGCTTCAAGGAAATTTTTTTGGTCTCCATTCTTTTGCTGACATTAATGCTCGTT TTTGCAAGCTTTGGAGTTCAGCTTTTTGCTGGAAAACTGGCCAAGTGCAATGATCCCA ACATTATTAGAAGGGAAGATTGCAATGGCATATTCAGAATTAATGTCAGTGTGTCAA AGAACTTAAATTTAAAATTGAGGCCTGGAGAGAAAAAACCTGGATTTTGGGTGCCCC GTGTTTGGGCGAATCCTCGGAACTTTAATTTCGACAATGTGGGAAACGCTATGCTGG CGTTGTTTGAAGTTCTCTCCTTGAAAGGCTGGGTGGAAGTGAGAGATGTTATTATTC ATCGTGTGGGGCCGATCCATGGAATCTATATTCATGTTTTTGTATTCCTGGGTTGCAT GATTGGACTGACCCTTTTTGTTGGAGTAGTTATTGCTAATTTCAATGAAAACAAGGG GACGGCTTTGCTGACCGTCGATCAGAGAAGATGGGAAGACCTGAAGAGCCGACTGA AGATCGCACAGCCTCTTCATCTTCCGCCTCGCCCGGATAATGATGGTTTTAGAGCTAA AATGTATGACATAACCCAGCATCCATTTTTTAAGAGGACAATCGCATTACTCGTCCTG GCCCAGTCGGTGTTGCTCTCTGTCAAGTGGGACGTCGAGGACCCGGTGACCGTACCT TTGGCAACAATGTCAGTTGTTTTCACCTTCATCTTTGTTCTGGAGGTTACCATGAAGA TCATAGCAATGTCGCCTGCTGGCTTCTGGCAAAGCAGAAGAAACCGATACGATCTCC TGGTGACGTCGCTTGGCGTTGTATGGGTGGTGCTTCACTTTGCCCTCCTGAATGCAT ATACTTACATGATGGGCGCTTGTGTGATTGTATTTAGGTTTTTCTCCATCTGTGGAAA ACATGTAACGCTAAAGATGCTCCTCTTGACAGTGGTCGTCAGCATGTACAAGAGCTTC TTTATCATAGTAGGCATGTTTCTCTTGCTGCTGTGTTACGCTTTTGCTGGAGTTGTTT TATTTGGTACTGTGAAATATGGGGAGAATATTAACAGGCATGCAAATTTTTCTTCGG CTGGAAAAGCTATTACCGTACTGTTCCGAATTGTCACAGGTGAAGACTGGAACAAGA TTATGCATGACTGTATGGTTCAGCCTCCGTTTTGTACTCCAGATGAATTTACATACTG GGCAACAGACTGTGGAAATTATGCTGGGGCACTTATGTATTTCTGTTCATTTTATGTC ATCATTGCCTACATCATGCTAAATCTGCTTGTAGCCATAATTGTGGAGAATTTCTCCTT GTTTTATTCCACTGAGGAGGACCAGCTTTTAAGTTACAATGATCTTCGCCACTTTCAA ATAATATGGAACATGGTGGATGATAAAAGAGAGGGGGTGATCCCCACGTTCCGCGT CAAGTTCCTGCTGCGGCTACTGCGTGGGAGGCTGGAGGTGGACCTGGACAAGGACA AGCTCCTGTTTAAGCACATGTGCTACGAAATGGAGAGGCTCCACAATGGCGGCGACG TCACCTTCCATGATGTCCTGAGCATGCTTTCATACCGGTCCGTGGACATCCGGAAGAG CTTGCAGCTGGAGGAACTCCTGGCGAGGGAGCAGCTGGAGTACACCATAGAGGAGG AGGTGGCCAAGCAGACCATCCGCATGTGGCTCAAGAAGTGCCTGAAGCGCATCAGA GCTAAACAGCAGCAGTCGTGCAGTATCATCCACAGCCTGAGAGAGAGTCAGCAGCAA GAGCTGAGCCGGTTTCTGAACCCGCCCAGCATCGAGACCACCCAGCCCAGTGAGGAC ACGAATGCCAACAGTCAGGACAACAGCATGCAACCTGAGACAAGCAGCCAGCAGCAG CTCCTGAGCCCCACGCTGTCGGATCGAGGAGGAAGTCGGCAAGATGCAGCCGACGC AGGGAAACCCCAGAGGAAATTTGGGCAGTGGCGTCTGCCCTCAGCCCCAAAACCAAT AAGCCATTCAGTGTCCTCAGTCAACTTACGGTTTGGAGGAAGGACAACCATGAAATC TGTCGTGTGCAAkATGAACCCCATGACTGACGCGGCTTCCTGCGGTTCTGAAGTTAA GAAGTGGTGGACCCGGCAGCTGACTGTGGAGAGCGACGAAAGTGGGGATGACCTT CTGGATATTTAGGTGGATGTCAATGTAGATGAATTTCTAGTGGTGGAAACCGTTTTC TAATAATGTCCTTGATTGTCCAGTGAGCAATCTGTAATTGATCTATAACTGAATTCCA GCTTGTCACAAGATGTTTATAAATTGATTTTCATCCTGCCACAGAAAGGCATAAGCTG CATGTATGATGGGTTACTATCAATCATTGCTCAAAAAAATTTTTGTATAATGACAGTA CTGATAATATTAGAAATGATACCGCAAGCAAATGTATATCACTTAAAAATGTCATATA TTCTGTCTGCGTAAACTAAGGTATATATTCATATGTGCTCTAATGCAGTATTATCACC GCCCCGCAAAAGAGTGCTAAGCCCAAAGTGGCTGATATTTAGGGTACAGGGGTTATA GCTTTAGTTCACATCTTTCCCATTTCCACTAGAAATATTTCTCTTGAGAGAATTTATTA TTTATGATTGATCTGAAAAGGTCAGCACTGAACTTATGCTAAAATGATAGTAGTTTTA CAAACTACAGATTCTGAATTTTAAAAAGTATCTTCTTTTTCTCGTGTTATATTTTTAAA TATACACAAGACATTTGGTGACCAGAACAAGTTGATTTCTGTCCTCAGTTATGTTAAT GAAACTGTTGCCTCCTTCTAAGAAAATTGTGTGTGCAAGCACCAGGCAAAGAAATGG ACTCAGGATGCTTAGCGGTTTAAAACAAACCTGTAGATAAATCACTTGAGTGACATA GTTGCGCAAAGATGTTAAGTTTCTTAAGAAACCTTTTAATAACTGAGTTTAGCAAAAA GAATAAAACTATATAGCTCAATTTATTTAAAAAAATCTTTGCATGTGTGATGTTATCAT TGGCTTCATTTCTTACCCAAGGTATGTCTGTTTTGCCATAAATCAGCAGAGTCATTTCA TTCTGGGTGATCCTAACACACCATTGCTACGTTAGATTTGAAATGACATCTCTGTTAA AAGAATCTTCTATGGAAATAATGGTGCCCTGCAAAATCTTCCTTTGAACTCACAGGTT AGGGATCACACAACTTACTTAATCGTTTITTGTTTTTGTTTTTTTTCCTTATATGTCAAT GGCCCATGTCCTCCGGGAAAATTAGAAAAGCAAAATGATTACAAAGTGCTGTTAGAT TTCTTGTGCTGGGCCAGCCAAGTAGAAGTGGACTTGACTTGGACCTTTAACTATTTTA TTACAGATTGGACATTTGCTGTTCAGATGTTTTTTAACAGAGGGATTATCTCAGAATC CTGTGACCTCCAGGTTGTTTTATAATCTATTTTTCTCTATTTAACATTCCTCAGATAGA TAGGCAAATAGGACATTCCTTCTGTGTCACAGAAGTATCGTGGTAGTGGCAGTCTAC AGTTTATATGATTCATTGTAACTATGAGATAAAGAACAACCAGTCATGTGGCCAAAAG GATTAGATTTGATTTGATGTTCACTTGGAGTTTACTTTTTGTACATACAAGATAAAAT AAATATTGGATTTGTAAAAT Homo sapiens Sodium Leak Channel, Non-Selective (NALCN), Polypeptide (NP_443099.1) GI: 24119274 (SEQ ID NO: 99) MLKRKQSSRVEAQPVTDFGPDESLSDNADILWINKPWVHSLLRICAIISVISVCMNTPMTF EHYPPLQYVTFTLDTLLMFLYTAEMIAKMHIRGIVKGDSSYVKDRWCVFDGFMVFCLWV SLVLQVFEIADIVDQMSPWGMLRIPRPLIMIRAFRIYFRFELPRTRITNILKRSGEQIWSVSIF LLFFLLLYGILGVQMFGTFTYHCVVNDTKPGNVTWNSLAIPDTHCSPELEEGYQCPPGFK CMDLEDLGLSRQELGYSGFNEIGTSIFTVYEAASQEGWVFLMYRAIDSFPRWRSYFYFITLI FFLAWLVKNVFIAVIIETFAEIRVQFQQMWGSRSSTTSTATTQMFHEDAAGGWQLVAVD VNKPQGRAPACLQKMMRSSVFHMFILSMVTVDVIVAASNYYKGENFRRQYDEFYLAEVA FTVLFDLEALLKIWCLGFTGYISSSLHKFELLLVIGTTLHVYPDLYHSQFTYFQVLRVVRLI KISPALEDFVYKIFGPGKKLGSLVVFTASLLIVMSAISLQMFCFVEELDRFTTFPRAFMSMF QILTQEGWVDVMDQTLNAVGHMWAPVVAIYFILYHLFATLILLSLFVAVILDNLELDEDL KKLKQLKQSEANADTKEKLPLRLRIFEKFPNRPQMVKISKLPSDFTVPKIRESFMKQFIDR QQQDTCCLLRSLPTTSSSSCDHSKRSAIEDNKYIDQKLRKSVFSIRARNLLEKFTAVTKILR ACTRQRMLSGSFEGQPAKFRSILSVQHHIRQERRSLRHGSNSQRISRGKSLETLTQDHSNT VRYRNAQREDSEIKMIQEKKEQAEMKRKVQEEELRENHPYFDKPLFIVGREHRFRNFCR VVVRARFNASKTDPVTGAVKNTKYHQLYDLLGLVTYLDWVMIIVTICSCISMMFESPFRR VMHAPTLQIAEYVFVIFMSIELNLKIMADGLFFTPTAVIRDFGGVMDIFIYLVSLIFLCWMP QNVPAESGAQLLMVLRCLRPLRIFKLVPQMRKVVRELFSGFKEIFLVSILLLTLMLVFASFG VQLFAGKLAKCNDPNIIRREDCNGIFRINVSVSKNLNLKLRPGEKKPGFWVPRVWANPR NFNFDNVGNAMLALFEVLSLKGWVEVRDVIIHRVGPIHGIYIHVFVFLGCMIGLTLFVGV VIANFNENKGTALLTVDQRRWEDLKSRLKIAQPLHLPPRPDNDGFRAKMYDITQHPFFK RTIALLVLAQSVLLSVKWDVEDPVTVPLATMSVVFTFIFVLEVTMKIIAMSPAGFWQSRRN RYDLLVTSLGVVWVVLHFALLNAYTYMMGACVIVFRFFSICGKHVTLKMLLLTVVVSMY KSFFIIVGMFLLLLCYAFAGVVLFGTVKYGENINRHANFSSAGKAITVLFRIVTGEDWNKI MHDCMVQPPFCTPDEFTYWATDCGNYAGALMYFCSFYVIIAYIMLNLLVAIIVENFSLFYS TEEDQLLSYNDLRHFQIIWNMVDDKREGVIPTFRVKFLLRLLRGRLEVDLDKDKLLFKH MCYEMERLHNGGDVTFHDVLSMLSYRSVDIRKSLQLEELLAREQLEYTIEEEVAKQTIRM WLKKCLKRIRAKQQQSCSIIHSLRESQQQELSRFLNPPSIETTQPSEDTNANSQDNSMQPE TSSQQQLLSPTLSDRGGSRQDAADAGKPQRKFGQWRLPSAPKPISHSVSSVNLRFGGRTT MKSVVCKMNPMTDAASCGSEVKKWWTRQLTVESDESGDDLLDI Homo sapiens Sodium / Potassium Transporting ATPase Interacting 3 (NKAIN3) (NP_173688.2) GI: 14538007 (SEQ ID NO: 100) 1 agccgcgagc ggcggccgcg gggccgagga gcctgggccg ggccgggcgg ggactactcc 61 ggagtcagga ggcagcagcg gcggaggacg aggatctctg gcagtcagcg ccgctcggac 121 gccgccggca ccatgggctg ctgcaccgga cgctgctcgc tcatctgcct ctgcgcgctg 181 cagttggtct cagcattaga gaggcagatc tttgacttcc ttggtttcca gtgggcgcct 241 attcttggaa attttctaca cataatagtt gtcatattgg gtttgtttgg gaccattcag 301 tacagacctc gatacataat ggtgtataca gtgtggactg ccctctgggt cacctggaat 361 gtgttcatta tctgctttta tttggaagta ggtggactct caaaggacac cgatctaatg 421 acattcaata tctctgtaca tcggtcatgg tggagagaac atgggcctgg ttgtgtcaga 481 agagtgctgc ctccctcagc ccatggcatg atggacgatt acacgtacgt ctctgtcaca 541 ggctgcatcg ttgacttcca gtacctggag gtcatccaca gtgctgtcca aatactactc 601 tctttggtgg gttttgtgta tgcctgttat gtgatcagta tttccatgga agaagaagac 661 acatattcat gtgatctgca agtatgcaaa catcttttta tccagatgct gcaaattatt 721 gaataagcaa gaattagtaa gatattatca ccaaattgtc acatcagtca agcctcatgt 781 gcttcctaag aactgaggtg atgcattatt ttagagtgtc attctaaacc ccagattcaa 841 catcttccta atctttctag tgcagtctaa tatataaatt ttatgaaaag cataggtttt 901 tttttaacca gcagtgctct ttgagaattt acattgattc ctaaagattg ccattgcttt 961 gtataaaatg ttataaatta tcttagcatc ttacctggaa tttccactaa attcaccaat 1021 ttatgatttg tgaaatctga ttttactttt tgaaaatttt catgtgaatt tcccattttc 1081 agtgttgtag cacctctctc ttcctctaag atcctccaag ctcatcaaaa gccatgatct 1141 tattatacca gcagttttat ttattcaatc tttcaacaag tagttattga acttctataa 1201 tgtgccaggc tctggagctc gccttacacc aaacagacac aatcgatcca ttcgaagtgt 1261 cgtaattaca cattgaggga ccaactagac cttttctcat tgtaaacttg gagcaaaagt 1321 aaattcatta aaataaattt acattatagt gccacaaaaa aatgaacaga accagaaagc 1381 attttttaca aaaattaaca gaacagtgtg atagagggga aaaggatgtg agatcatggt 1441 gccctacctt caatagggtg gccagaaaac acctctctga agaagcagca tttgagctga 1501 gacctgaaga acgaggagtc agtgatgcag agaacctcag gagatgcctt ccaatctgag 1561 aaaaga Homo sapiens Sodium / Potassium Transporting ATPase Interacting 3 (NKAIN3) Polypeptide (NP_775959.1) GI: 27735000 (SEQ ID NO: 101) MGCCTGRCSLICLCALQLVSALERQIFDFLGFQWAPILGNFLHIIVVILGLFGTIQYRPRYIM VYTVWTALWVTWNVFIICFYLEVGGLSKDTDLMTFNISVHRSWWREHGPGCVRRVLPPS AHGMMDDYTYVSVTGCIVDFQYLEVIHSAVQILLSLVGFVYACYVISISMEEEDTYSCDLQ VCKHLFIQMLQIIE Homo sapiens Mucolipin 3, mRNA gi|38174237|gb|BC060765.1| (SEQ ID NO: 102) TGGAGTCGCTCGCTGACTCGCCCTGCGCCCTCGCCGCGGACACCGGAGCTGCGGCCG CTCCCCGCTGTCCCCCAGCTTACTCCAATCAAGCCTCTGCCCGCCAGGAACAGGTAAC CTGTGTGTGTCCGTTTGCTCCTTCTAAGAGCATGCCTGATAGATACTTCGGTAGCCTC TCCGGATGGCCCCTTCGTCGGGTAGCCTCTCCTGATGGGGTCCTTCGCCCACCCTGCC TCCCGCGCCGGCGCTCCGGGTGAATGTCAAGGGTGGCTGGCTGCGAATACCTCCTTC AGCTGCTGGGGTTCCCGACAGTTTGCAGTTTTTAAAAGTGCACCCTCGGAAGGGCTT TTCAGACTGGGTAAACCTGACTTTTCCAAGAGATGGCAGATCCTGAGGTAGTTGTGA GTAGCTGCAGCTCTCATGAAGAGGAAAATCGCTGCAATTTTAACCAGCAAACATCTCC ATCTGAGGAGCTTCTATTAGAAGACCAGATGAGGCGAAAACTCAAATTTTTTTTCATG AATCCCTGTGAGAAGTTCTGGGCTCGAGGTAGAAAACCATGGAAACTTGCCATACAA ATTCTAAAAATTGCAATGGTGACTATCCAGCTGGTCTTATTTGGGCTAAGTAACCAGA TGGTGGTAGCTTTCAAGGAAGAGAATACTATAGCATTCAAACACCTTTTCCTAAAAGG ATATATGGACCGAATGGATGACACATATGCAGTGTACACACAAAGTGACGTGTATGA TCAGTTAATCTTCGCAGTAAACCAGTACTTGCAGCTATACAATGTCTCCGTTGGGAAT CATGCTTATGAGAACAAAGGTACCAAGCAATCTGCTATGGCAATCTGTCAGCACTTAT ACAAGCGAGGAAACATCTACCCTGGAAATGATACCTTTGACATCGATCCAGAAATTG AAACTGAGTGTTTCTTTGTGGAGCCAGATGAACCTTTTCACATTGGGACACCAGCAG AAAATAAACTGAACTTAACACTGGACTTCCACAGACTCCTAACAGTGGAGCTTCAGTT TAAACTGAAAGCCATTAATCTGCAGACAGTTCGTCATCAAGAACTCCCTGACTGTTAT GACTTTACTCTGACTATAACATTTGACAACAAGGCCCATAGTGGAAGAATTAAAATAA GTTTAGATAATGACATTTCCATCAGAGAATGTAAAGACTGGCATGTATCTGGATCAAT TCAGAAGAACACTCATTACATGATGATCTTTGATGCCTTTGTCATTCTGACTTGCTTG GTTTCATTAATCCTCTGCATTAGATCTGTGATTAGAGGACTTCAGCTTCAGCAGGTAG GGAACGTTGCTTTCTAGGAATGCTACTGACATTTTGATTGACAGAGACATTCACTGTG CCTCCCCTCTTTTCCCTAAAGGAGTTTGTCAATTTTTTCCTCCTCCATTATAAGAAGGA AGTTTCTGTTTCTGATCAAATGGAATTTGTCAATGGATGGTACATTATGATTATTATT AGTGACATATTGACAATCATTGGATCAATTCTAAAAATGGAAATCCAAGCTAAGGTAA TTTTTTTCCTAATCATGCTATTGTTAGTGTCAGATTTGCACTAATGGTAATGTATTTTT CCAGAATGTAAGAATTTTCAGAATGAATTGTTTCTTCCAAACTGTATATCAAGTAGAC TTGAAATTGGTAATGGTAATTTTCTTAAATCTAGTCAGGAGGTCTCTTAGGCAGAGTT TTTCAAAGTGTGATCCACAAACCATTGCATCAGAATCATTGGGTGCCTGGTAAAGTGT ACCATGTTAGACCTACTGAATTCAGACTCTTCGGCGGGGCCTGTGAATTCTTACACAC ACCAAAATTCATACACAACCAAGGTAACTAAGGTAAGAGTTTTTTTTTTTTTTTAATCT TACAAGAAATGCTCGAATCTTTAACAAAAATGAGTGGGGCTATAGGGGAAAGTGAG GTCAAGGCACTATGGTGTGCATGCTTGCATTTGTTTCCTCCGTCCATTCAAAGTGAGA ATGCTCCCATTTTCTTACTTTACCATTGATGTGCTACAAGCTTATTTATTTTAAGACTA ACCTAGCCTAAAAATCAACTGTCCCCACAAAATAAAAATCACATTAAAAAAACTAATAG TGTTCAGACTAATCTTGCTCAAACTTATGTTTCCCTAGTCTTGATGCAACTGATTGAGT CACCTGGGGAGTTGGTTATAAACCTGGGCAGAGACCCCAAATGCAATGGCTCAGAG AAGATAGGAGCTTATTTCTGTCTTATGCAATAGTCAGAATGGGTTTTACAGACTGGT GAGTAGCTCAACATCTCACAGTCATTCAGGCACCCATGTTCCTCCCATTTTGTTTCTCT GCCACCCCTTAAGGACTTGCCCTGACTGCATGATTATTGCCGTGTTGCCTCAAACAGG TTGCAGCTTATGGGAAGCAAAAACACGGTATGGTAGAAGCTCTCCCATAGACTGATG GCTTGGCTCAAGAGTGGCCGACTTTATTTCTGTACATATCCCACTGGATAGAATTTAG TCAATCCTAACTGCAGAGGGAGCCAGGGAACACAGCCCAGGCATGTGCCTAGGAAG GGGAGAATGGGTTTAGGTTGACACTTAGCAGCTGCCACTATATGTGGCTATAGTATG TATCATTGGAATAGATGTTTAACTTTAGGGACAAATAAAAAACCAAAACAAAAAAAG GAGTAAGGGGAGAGATTTGCAGCAAATCTTTATTTTTACCAACCTCAACTATCATTAA TTTCAGTGAACCCTAAATGGTATCCAACAAAATATCTTTCTAGACCATTCACCGTCTCT GCCTCATAGATGATCATATCATGTTTTCTTCTCTTCTGAAACCTCTAATACCCTTGTCCT ATCCTCATTCTAAGCTGATGACCTTACTTCCTATTTCACAAAAATAATAGAAAAAAAAA AAAAAAA > > Homo sapiens Mucolipin 3, cDNA gi|21752911|dbj|AK093948.1| Homo sapiens cDNA FLJ36629 (SEQ ID NO: 103) ATAGCCTTTCAAATTTCGGTTAATGGTAACTCTCATCAGTTACTCAAGCCAAAAATCTT GGATTCATCACAGACTCCTCTCTTTCACTAATCTCTTCTTCCCCACATCTAATCCAAGA GGAAATCCTATTGTTCTACCTTCATTGGCCAGGCACTGTGACTCATATAATCCCAGCA CATTGGGAGGCTGAGGCGGGAGGATGGCTTGAGCCCAGGAGTTCCAGACCAGCCTG GGAAACATAGTGAGGCCCCATCTCTACAAAAAATTAAAAAAATTAGCAGTCAAGGTG GCATGTGTCTGTAATCCAAGCTACTTGGGGGGCTGAGGTGGGAGGATTTCTTGAGC CCGGGAAGTCGAGGCTGCATTGAGCCACGGTTGTGCCACGGCACTCCAGCCTGGGT GACAGAGTGAGACCCCTGTTTCCAAAAAAAAAAAAAAAAAAAAAGAATAAAAATCAC CTGGTCAACTCCACTATTACCAGCCTGGTCCAAGCTACTATCTCTCATTTATATTATTG CAATAGCCTCCTCACTCCTCCAACAACCTGCTGTCAACCACAGCAGCCAACATCTGATC ATATCACTTCTGTTTGTGGTTCTCAAATCTCCCCAATTGAGTTACAGTAAAAGACAAAC TTGGTGAGTGCCACCTTATCTCTATAACTGTATACCCTTTCTATTGCTCACTCCAGCCA GATGCAATATCCTTGCCAAGCACCCTCCTGTCTCAGGGCCTTTGCACTTGCCAGTCCC TGTGCCTGGAAGGCTTCTCCCCTAGATTTTTGCATGACTTCTCCCTCCCTCCCTTCAGA TCTTTGCTCAAATGCCTTCTTTTTAGTGTATGTAAAATGACAAACCCATACCCATTCCT TATCCCCTCCTCTGAATTTTCTCTTCAGCAATTATCAGCAGCAAGTGTCCCAAAGTTTC TATTAACTTATTTCTGTTGTCTCTTTCTTCCCTCCACTAGAATGTAAGCTTTATGAGAG CAGAGACTTTTGTTTGTTCACTGCTTTATCCTTAGCACCTAAAACAGTGCCTTACTCAT AGTTACCTCAATATTTATTGCCAAATGAATTTCTGCTTTATAATCTGATTATATTTTTCC ACTCTCTCTTAGAGTCTAACTAGTTATGATGTCTGTAGCATACTTCTTGGGACTTCTAC CATGCTTGTGTGGCTTGGAGTCATCCGATACCTCGGTTTCTTTGCAAAGTACAACCTC CTCATTTTGACCCTTCAGGCAGCGCTGCCCAATGTCATCAGGTTCTGCTGCTGTGCAG CTATGATTTACTTAGGTTACTGCTTCTGTGGATGGATCGTGCTGGGGCCTTACCATG ACAAGTTTCGTTCTCTGAACATGGTCTCTGAGTGCCTTTTCTCTCTGATAAATGGAGA TGATATGTTTGCCACGTTTGCAAAAATGCAGCAAAAAAGTTACTTAGTCTGGCTGTTT AGTAGAATTTACCTCTACTCATTCATCAGCCTCTTTATATATATGATTTTAAGTCTTTTC ATTGCACTGATCACTGATACATACGAAACAATTAAGCAATACCAACAAGATGGCTTCC CAGAGACTGAACTTCGTACATTTATATCAGAATGCAAAGATCTACCCAACTCTGGAAA ATACAGATTAGAAGATGACCCTCCAGTAACTTTATTCTGCTGTTGTAAAAAGTAGCTA TCAGGTTTATCTGTACTTTAGAGGAAAATATAATGTGTAGCTGAGTTGGAACACTGT GGATATTCTGAGATCAGATGTAGTATGTTTGAAGACTGTTATTTTGAGCTAATTGAG ACCTATAATTCACCAATAACTGTTTATATTTTTAAAAGCAATATTTAATGTCTTTGCAA CTTTATGCTGGGATTGTTTTTAAAAAAAACTTTAATGAGGAAAGCTATTGGATTATTA TTATTTCTTGTTTATTTTGCCATGGCTTTAGAATGTATTCTGTATGCCTCTCTTTTGCT CTGATACTGTTGCTCCTGCTATTCTGATTGTGCAGACTGTATAATTAGTGGAAAACAA TCCTTGGTCTGACTGTGACTTTGGACAACTCAGTAACCCTGGCTTGGACCACTCTCAG GAGTCCATCCTTGAGAGAGTGGGTGTAGTTACCATTTATACAGTAATCATTGCATTTT AAAATCTTCTCTTGAAAGGAAGAATAAGAGTGCACCAGAATAAGAGCGCACCAGAAT AAGAGCACACCAGCTAACAATGTGATACGGCCATATGTCACTTAAGGATGGAGATAT GTTCTGAGAAATGTGTCATTAGGCGATTTTGTCATTAAACATCATAGCATGTACTTCC ACAAACCTAGATGGTATAGCCTACTACACACCTAGGCTATTTGGTATAGCCTGTTGGT CCTGGGGTACAAATCTGTACAACATGTTACTGTATTGAATACAGTAGGCAATTGTAAC TCAATGGTAAGTATCTAAACATAGAAAAGGGACAGTAAAAATATGGTTTTATAATCTT CTGGGACCACCATTGTATATGCGGTACATCATTGACCAAAACATCGTTATCCAGCATA TGACTGTATTTGGTTATGAAAGCCAACTGTTACTTGATTCTGCTTTTAGTTCTTAAGA GGATCAGGCTTTTAAATACTCATTTACAAGCTTTCTATCCTCCTTCAGTGTTAAAGTAG AAAGTAAAAAGAGTATCTTATACATGCATGAAATTAAAGCATATACCAAATGC >HUMAN TRPML3 POLYPEPTIDE AK093948 open reading frame (SEQ ID NO: 104) MLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMIYLGYCFCGWIVLGPYHDKF RSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYSFISLFIYMILSLFIALITDTY ETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVTLFCCCKK. > HUMAN TRPML3 POLYPEPTIDE BC060765 open reading frame (SEQ ID NO: 105) MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYT QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHLYKRGNIYPGNDTFD IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVS LILCIRSVIRGLQLQQVGNVAF

p value Ratio Top Top verus versus Probe Set ID Gene Title Gene Symbol Bottom Bottom MmugDNA.12222.1.S1_at chloride channel, calcium activated, family member 1 CLCA1 28.26 0.0794 MmugDNA.18105.1.S1_at ST8 alpha-N-acetyl-neuraminide alpha-2, 8-sialyltransferase 1 ST8SIA1 25.30 0.0112 MmugDNA.11091.1.S1_at — — 14.48 0.0463 MmugDNA.15011.1.S1_at toll-like receptor 10 precursor LOC697980 14.47 0.0262 MmugDNA.41559.1.S1_at taste receptor, type 2, member 16 TAS2R16 13.96 0.0356 MmugDNA.24584.1.S1_at hypothetical protein LOC703243 LOC703243 13.55 0.0725 MmugDNA.15361.1.S1_at phosphatidylinositol glycan, class N LOC699219 12.99 0.0249 Mmu.10677.1.S1_at matrix metalloproteinase 7 MMP7 11.87 0.0181 MmuSTS.783.1.S1_at taste receptor T2R7 LOC717909 11.70 0.0671 MmugDNA.25181.1.S1_at 3-hydroxysteroid epimerase LOC713549 11.52 0.0396 MmugDNA.9747.1.S1_at — — 11.31 0.0934 MmugDNA.10468.1.S1_at hypothetical protein LOC709833 LOC709833 11.21 0.0379 MmugDNA.7746.1.S1_at Protein FAM3B precursor (Cytokine-like protein 2-21) LOC722516 11.10 0.0882 MmugDNA.11368.1.S1_at proprotein convertase subtilisin/kexin type 2 PCSK2 10.97 0.0486 MmugDNA.26966.1.S1_at — — 10.92 0.0376 MmugDNA.15380.1.S1_at taste receptor T2R13 LOC718046 10.82 0.0924 MmugDNA.32635.1.S1_at — — 10.78 0.0891 MmugDNA.37045.1.S1_at — — 10.61 0.0029 MmugDNA.36075.1.S1_at potassium voltage-gated channel, shaker-related subfamily, KCNA2 10.45 0.0060 member 2 MmugDNA.35060.1.S1_at kinesin-like motor protein C20orf23 LOC695167 10.35 0.0420 MmugDNA.13207.1.S1_at — — 10.20 0.0665 MmunewRS.875.1.S1_at neuroligin 4 NLGN4X 10.13 0.0053 MmugDNA.35863.1.S1_at zinc finger protein 533 LOC704204 10.10 0.0657 MmugDNA.121.1.S1_at golgi SNAP receptor complex member 2 isoform A LOC716841 10.09 0.0493 MmugDNA.38131.1.S1_at kelch-like 8 LOC700864 9.90 0.0023 MmugDNA.41159.1.S1_at interleukin 17B receptor IL17RB 9.77 0.0005 MmugDNA.11591.1.S1_s_at dipeptidase 2 LOC701570 9.73 0.0020 MmugDNA.5167.1.S1_at male sterility domain containing 1 LOC710740 9.37 0.0930 MmugDNA.656.1.S1_at — — 9.25 0.0001 MmugDNA.7006.1.S1_at sialyltransferase 7E LOC705908 9.24 0.0467 MmugDNA.3684.1.S1_at G protein-coupled receptor 85 GPR85 9.18 0.0664 MmugDNA.1571.1.S1_at — — 9.09 0.0263 MmugDNA.24639.1.S1_at — — 9.04 0.0042 MmuSTS.906.1.S1_at taste receptor, type 2, member 14 LOC718111 9.00 0.0288 MmugDNA.30874.1.S1_at transmembrane protein 45B LOC718735 9.00 0.0000 MmugDNA.34847.1.S1_at apoptosis inhibitor 5 API5 8.45 0.0755 MmuSTS.778.1.S1_at Taste receptor type 2 member 49 (T2R49) (T2R56) TAS2R49 8.44 0.0007 MmuSTS.2869.1.S1_at tachykinin 1 isoform alpha precursor TAC1 8.44 0.0726 MmugDNA.30525.1.S1_at FCH and double SH3 domains 1 — 8.37 0.0258 MmugDNA.42433.1.S1_at — — 8.36 0.0058 MmugDNA.10579.1.S1_at dopamine receptor interacting protein — 8.30 0.0060 MmugDNA.16546.1.S1_at CMP-N-acetylneuraminic acid hydroxylase LOC574186 8.25 0.0649 MmugDNA.29722.1.S1_at — — 8.18 0.0717 MmuSTS.4056.1.S1_at Cornifin B (Small proline-rich protein IB) (SPR-IB) (14.9 kDa LOC717850 7.96 0.0689 pancornulin) MmugDNA.30502.1.S1_at NIPA-like domain containing 2 LOC703585 7.94 0.0421 MmugDNA.6642.1.S1_at leprecan-like 1 LOC704118 7.86 0.0183 MmugDNA.23279.1.S1_at transmembrane protein 46 LOC702501 7.85 0.0427 MmugDNA.3909.1.S1_at CG2698-PA LOC710299 7.80 0.0116 MmugDNA.39327.1.S1_at — — 7.78 0.0960 MmugDNA.3544.1.S1_at solute carrier family 22 (organic cation transporter), member LOC710102 7.72 0.0869 15 MmugDNA.39807.1.S1_at protocadherin beta 13 precursor LOC700999 7.71 0.0311 MmugDNA.17676.1.S1_at PXR2b protein PEX5L 7.65 0.0969 MmugDNA.30327.1.S1_at — — 7.62 0.0341 MmugDNA.6455.1.S1_at F11 receptor F11R 7.58 0.0487 MmugDNA.3223.1.S1_at — — 7.57 0.0247 MmugDNA.11678.1.S1_at 3(2),5-bisphosphate nucleotidase 1 (Bisphosphate 3- — 7.57 0.0034 nucleotidase 1) (PAP-inositol-1,4-phosphatase) (PIP) MmugDNA.7247.1.S1_at nemo-like kinase NLK 7.56 0.0087 MmugDNA.10209.1.S1_at PHD finger protein 14 PHF14 7.51 0.0000 MmuSTS.3737.1.S1_at protein tyrosine phosphatase, receptor type, C isoform 1 LOC712657 7.42 0.0139 precursor MmuSTS.1381.1.S1_at basic helix-loop-helix domain containing, class B, 5 LOC701485 7.39 0.0378 MmugDNA.20444.1.S1_at formin 2 LOC708376 7.38 0.0999 MmuSTS.1175.1.S1_at Taste receptor type 2 member 10 (T2R10) (Taste receptor TAS2R10 7.36 0.0445 family B member 2) (TRB2) MmuSTS.2644.1.S1_s_at taste receptor T2R55 LOC695053 7.36 0.0182 MmuSTS.3441.1.S1_at annexin A9 ANXA9 7.32 0.0133 MmugDNA.9493.1.S1_at — — 7.30 0.0007 MmugDNA.4334.1.S1_at tyrosine aminotransferase TAT 7.18 0.0194 MmuSTS.1040.1.S1_at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 ST8SIA5 7.18 0.0759 MmugDNA.25088.1.S1_at GTP-binding protein Rit2 (Ras-like protein expressed in RIT2 7.14 0.0292 neurons) (Ras-like without CAAX protein 2) MmugDNA.689.1.S1_at hypothetical protein LOC707842 LOC707842 7.11 0.0615 MmugDNA.4223.1.S1_at echinoderm microtubule associated protein like 5 LOC718818 7.08 0.0053 MmugDNA.29749.1.S1_at — — 7.02 0.0598 MmugDNA.1798.1.S1_at doublecortin and CaM kinase-like 3 LOC699654 6.99 0.0589 MmuSTS.1232.1.S1_at copine IV LOC717868 /// 6.98 0.0579 LOC719231 MmuSTS.784.1.S1_at taste receptor, type 2, member 8 LOC717924 6.95 0.0189 MmugDNA.26125.1.S1_at — — 6.94 0.0509 MmuSTS.2013.1.S1_at protocadherin beta 10 PCDHB10 6.92 0.0000 MmugDNA.19056.1.S1_at somatostatin receptor 1 SSTR1 6.90 0.0040 MmugDNA.43165.1.S1_at — — 6.88 0.0378 MmugDNA.34029.1.S1_at secernin 1 SCRN1 6.83 0.0410 MmugDNA.40941.1.S1_at — — 6.81 0.0380 MmugDNA.21034.1.S1_at — — 6.68 0.0782 MmugDNA.31223.1.S1_at protocadherin beta 3 PCDHB3 6.68 0.0261 MmugDNA.10620.1.S1_at Rho GTPase activating protein 18 LOC711107 6.67 0.0000 MmugDNA.35495.1.S1_at — — 6.67 0.0569 MmugDNA.23300.1.S1_at KIAA0828 protein KIAA0828 6.65 0.0692 MmugDNA.20297.1.S1_at hypothetical protein LOC705695 LOC705695 6.64 0.0273 MmugDNA.43474.1.S1_at protection of telomeres 1 POT1 6.62 0.0587 MmuSTS.1939.1.S1_at Fibroblast growth factor 11 (FGF-11) (Fibroblast growth FGF11 6.61 0.0983 factor homologous factor 3) (FHF-3) MmugDNA.26964.1.S1_at calponin like transmembrane domain protein LOC709910 6.59 0.0179 MmugDNA.33339.1.S1_at — — 6.58 0.0179 MmugDNA.32991.1.S1_at ectonucleotide pyrophosphatase/phosphodiesterase 6 LOC693950 6.54 0.0834 MmugDNA.34284.1.S1_at Sodium channel beta-3 subunit precursor LOC714673 6.52 0.0945 MmugDNA.20971.1.S1_at — — 6.49 0.0462 MmugDNA.9521.1.S1_at glutaminyl-peptide cyclotransferase QPCT 6.49 0.0528 MmuSTS.1179.1.S1_s_at taste receptor, type 2, member 43 LOC694161 6.47 0.0060 MmugDNA.25858.1.S1_at — — 6.47 0.0087 MmugDNA.38257.1.S1_at hypothetical protein LOC701675 LOC701675 6.46 0.0506 MmugDNA.41639.1.S1_at phosphodiesterase 1C, calmodulin-dependent 70 kDa PDE1C 6.44 0.0007 MmugDNA.33151.1.S1_at — — 6.42 0.0253 MmugDNA.1887.1.S1_at zinc finger protein 395 LOC698947 6.41 0.0237 MmuSTS.1713.1.S1_at WNT1 inducible signaling pathway protein 3 WISP3 6.37 0.0601 MmugDNA.8585.1.S1_at — — 6.34 0.0451 MmugDNA.17339.1.S1_s_at leucine rich repeat neuronal 3 LOC701932 6.31 0.0171 MmuSTS.527.1.S1_at platelet-derived growth factor C precursor — 6.30 0.0362 MmugDNA.15109.1.S1_s_at — — 6.29 0.0096 MmugDNA.2733.1.S1_s_at Fatty acid-binding protein, epidermal (E-FABP) (Psoriasis- — 6.23 0.0651 associated fatty acid-binding protein homolog) (PA-FABP) MmugDNA.35813.1.S1_at — — 6.23 0.0411 MmugDNA.20157.1.S1_at nel-like 1 precursor LOC701438 6.21 0.0389 MmugDNA.39143.1.S1_at — — 6.20 0.0333 MmuSTS.2452.1.S1_at McLeod syndrome-associated, Kell blood group protein LOC696407 6.20 0.0099 MmugDNA.33888.1.S1_at egl nine homolog 1 LOC713410 6.18 0.0609 MmugDNA.7614.1.S1_at ADP-ribosylation factor-like 6 LOC696616 6.17 0.0002 MmuSTS.1330.1.S1_at dual-specificity tyrosine-(Y)-phosphorylation regulated DYRK2 6.16 0.0203 kinase 2 MmuSTS.3090.1.S1_at latrophilin 3 LPHN3 6.16 0.0063 MmugDNA.23556.1.S1_at — — 6.14 0.0144 MmuSTS.1177.1.S1_at taste receptor, type 2, member 39 TAS2R39 6.10 0.0094 MmugDNA.14803.1.S1_s_at Fibroblast growth factor 12 (FGF-12) (Fibroblast growth LOC705813 6.05 0.0344 factor homologous factor 1) (FHF-1) Mmu.3466.1.S1_at — — 6.03 0.0171 MmugDNA.35142.1.S1_at — — 6.01 0.0002 MmuSTS.3438.1.S1_at ankyrin 2 ANK2 6.01 0.0264 MmugDNA.16713.1.S1_at potassium channel tetramerisation domain containing 4 LOC701916 6.00 0.0289 MmugDNA.23811.1.S1_at sel-1 suppressor of lin-12-like LOC708651 5.97 0.0664 MmunewRS.311.1.S1_at — — 5.95 0.0419 MmugDNA.2511.1.S1_at — — 5.93 0.0561 MmugDNA.5134.1.S1_at thrombospondin 4 THBS4 5.90 0.0003 MmugDNA.27291.1.S1_at — — 5.90 0.0192 MmugDNA.35237.1.S1_at — — 5.89 0.0799 MmugDNA.29494.1.S1_at coagulation factor II receptor F2R 5.86 0.0249 MmugDNA.41193.1.S1_at phosducin-like 3 — 5.86 0.0302 MmugDNA.27343.1.S1_s_at DnaJ (Hsp40) homolog, subfamily C, member 3 LOC695757 5.83 0.0649 MmugDNA.8284.1.S1_at — — 5.77 0.0007 MmuSTS.909.1.S1_at taste receptor, type 2, member 50 LOC693513 5.76 0.0712 MmuSTS.2673.1.S1_at calmegin CLGN 5.76 0.0576 MmugDNA.37138.1.S1_at Discs large homolog 2 (Postynaptic density protein PSD-93) LOC704826 5.76 0.0582 (Channel-associated protein of synapse-110) (Chapsyn- 110) MmugDNA.15905.1.S1_at — — 5.68 0.0480 MmugDNA.32064.1.S1_at butyrophilin-like 8 BTNL8 5.67 0.0176 MmugDNA.34572.1.S1_at decay accelerating factor for complement LOC714370 5.65 0.0083 MmugDNA.22059.1.S1_at integrin alpha 2 ITGA2 5.64 0.0227 MmuSTS.861.1.S1_at CG7231-PB, isoform B LOC715256 5.62 0.0968 MmugDNA.29329.1.S1_at — — 5.61 0.0108 MmugDNA.14073.1.S1_at microtubule-associated protein 6 isoform 2 LOC696223 5.60 0.0103 MmugDNA.27825.1.S1_at alpha 4 type IV collagen COL4A4 5.59 0.0662 MmugDNA.34698.1.S1_at ankyrin repeat domain 43 LOC708755 5.57 0.0236 MmuSTS.2650.1.S1_at adenylate kinase 5 isoform 1 LOC706248 5.57 0.0477 MmugDNA.21615.1.S1_at — — 5.56 0.0504 MmugDNA.18178.1.S1_at autotaxin ENPP2 5.56 0.0036 MmuSTS.1143.1.S1_at Beta-synuclein SNCB 5.53 0.0727 MmugDNA.40607.1.S1_at hypothetical protein LOC717552 LOC717552 5.53 0.0701 MmugDNA.18538.1.S1_s_at serine (or cysteine) proteinase inhibitor, clade I SERPINI1 5.53 0.0790 (neuroserpin), member 1 MmugDNA.5368.1.S1_at — — 5.50 0.0256 MmugDNA.30317.1.S1_at Baculoviral IAP repeat-containing protein 4 (Inhibitor of LOC698057 5.49 0.0475 apoptosis protein 3) (X-linked inhibitor of apoptosis protein) (X-linked IAP) (IAP-like protein) (HILP) MmugDNA.35810.1.S1_at adenosine A2b receptor ADORA2B 5.48 0.0099 MmugDNA.22262.1.S1_at neurotrypsin precursor LOC704461 5.46 0.0150 Mmu.9266.1.S1_x_at alpha-defensin 3 precursor LOC574310 5.46 0.0796 MmugDNA.1819.1.S1_at chromodomain helicase DNA binding protein 5 — 5.44 0.0524 MmugDNA.37049.1.S1_at Dipeptidyl aminopeptidase-like protein 6 LOC718148 5.42 0.0278 (Dipeptidylpeptidase VI) (Dipeptidylpeptidase 6) (Dipeptidyl peptidase IV-like protein) (Dipeptidyl aminopeptidase- related protein) (DPPX) MmugDNA.26844.1.S1_at hypothetical protein LOC716906 LOC716906 5.40 0.0620 MmugDNA.40160.1.S1_at — — 5.34 0.0828 MmugDNA.13497.1.S1_at runt-related transcription factor 2 isoform b LOC703331 5.33 0.0463 MmugDNA.35702.1.S1_at ADAMTS-like 1 ADAMTSL1 5.33 0.0106 Mmu.335.1.S1_at carboxypeptidase E CPE 5.30 0.0493 MmugDNA.13656.1.S1_at — — 5.30 0.0030 MmugDNA.22297.1.S1_at lysozyme LOC718361 5.29 0.0804 MmugDNA.28583.1.S1_at — — 5.25 0.0006 MmugDNA.18724.1.S1_s_at UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase 6 B4GALT6 5.25 0.0461 MmugDNA.38162.1.S1_at — — 5.24 0.0001 MmugDNA.27108.1.S1_at matrix metalloproteinase 19 MMP19 5.21 0.0313 MmugDNA.24659.1.S1_at mesothelin isoform 1 preproprotein LOC698095 5.19 0.0431 Mmu.11741.1.S1_at N-ethylmaleimide-sensitive factor LOC715297 5.19 0.0035 MmugDNA.1267.1.S1_s_at cytochrome P450 3A64 /// Cytochrome P450 3A7 CYP3A64 /// 5.18 0.0847 (CYPIIIA7) (P450-HFLA) LOC718917 MmuSTS.3164.1.S1_at cathepsin C CTSC 5.16 0.0003 MmugDNA.2042.1.S1_at dual specificity phosphatase 10 DUSP10 5.16 0.0148 MmuSTS.4822.1.S1_at GATA binding protein 6 LOC699591 5.15 0.0204 MmugDNA.28021.1.S1_at zinc finger and BTB domain containing 10 LOC704721 5.15 0.0905 MmugDNA.32990.1.S1_at protocadherin beta 5 PCDHB5 5.14 0.0458 MmugDNA.27188.1.S1_at hypothetical protein LOC694387 LOC694387 5.11 0.0446 MmugDNA.18606.1.S1_at — — 5.10 0.0278 MmugDNA.36968.1.S1_at microsomal triglyceride transfer protein large subunit MTTP 5.07 0.0525 MmugDNA.12625.1.S1_at Ras protein-specific guanine nucleotide-releasing factor 2 LOC711350 5.07 0.0298 MmuSTS.597.1.S1_s_at Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) LOC709186 5.07 0.0051 (HGPRTase) MmugDNA.8387.1.S1_at S-acyl fatty acid synthase thioesterase, medium chain THEDC1 5.06 0.0290 (Thioesterase II) (Thioesterase domain-containing protein 1) MmugDNA.19071.1.S1_at — — 5.06 0.0453 MmugDNA.1497.1.S1_at vacuolar protein sorting 13A isoform A LOC705323 5.04 0.0367 MmugDNA.26354.1.S1_at GEM 1 protein GEM 1 5.04 0.0011 MmunewRS.58.1.S1_at — — 5.04 0.0241 MmuSTS.531.1.S1_at UDP-GlcNAc:betaGal beta-1,3-N- LOC693396 5.04 0.0968 acetylglucosaminyltransferase 1 MmugDNA.38025.1.S1_at glycoprotein M6B GPM6B 5.03 0.0248 MmuSTS.1448.1.S1_at v-yes-1 Yamaguchi sarcoma viral related oncogene LYN 5.03 0.0807 homolog MmugDNA.1649.1.S1_at DHHC-containing protein 20 LOC705802 5.02 0.0886 MmugDNA.38429.1.S1_at hypothetical protein LOC698744 LOC698744 5.00 0.0001 MmugDNA.3432.1.S1_at plexin C1 LOC711320 4.99 0.0000 MmugDNA.30924.1.S1_at mothers against decapentaplegic homolog 4 SMAD4 4.97 0.0151 MmugDNA.43332.1.S1_at — — 4.96 0.0931 MmuSTS.4050.1.S1_at diacylglycerol kinase, beta DGKB 4.95 0.0176 MmugDNA.31803.1.S1_at calcium binding protein 39-like CAB39L 4.88 0.0227 MmugDNA.42361.1.S1_at — — 4.87 0.0521 MmugDNA.36141.1.S1_at — — 4.87 0.0504 MmuSTS.2022.1.S1_at Glutathione-requiring prostaglandin D synthase PGDS 4.87 0.0504 (Glutathione-dependent PGD synthetase) (Prostaglandin-H2 D-isomerase) (Hematopoietic prostaglandin D synthase) (H- PGDS) MmugDNA.20560.1.S1_at tripartite motif protein 9 TRIM9 4.86 0.0363 MmuSTS.1776.1.S1_at SATB family member 2 SATB2 4.86 0.0000 MmugDNA.17660.1.S1_s_at ectonucleotide pyrophosphatase/phosphodiesterase 4 LOC703680 4.83 0.0657 (putative function) MmugDNA.8441.1.S1_s_at GalNAc-4-sulfotransferase 2 LOC703877 4.83 0.0984 MmugDNA.10568.1.S1_at — — 4.81 0.0080 MmugDNA.5130.1.S1_at neuropilin- and tolloid-like protein 2 precursor LOC716468 4.81 0.0436 MmugDNA.10470.1.S1_at cyclic nucleotide gated channel beta 1 LOC708851 4.80 0.0916 MmugDNA.25697.1.S1_at — — 4.80 0.0646 MmugDNA.2214.1.S1_at protocadherin beta 14 PCDHB14 4.79 0.0153 MmuSTS.1120.1.S1_s_at protocadherin alpha 9 PCDHA9 4.78 0.0373 MmugDNA.33308.1.S1_at tetratricopeptide repeat domain 7B LOC696029 4.76 0.0022 MmugDNA.9526.1.S1_at Kelch repeat and BTB domain-containing protein 11 (Kelch KBTBD11 4.75 0.0031 domain-containing protein 7B) MmugDNA.42933.1.S1_at hypothetical protein LOC712344 LOC712344 4.74 0.0099 MmugDNA.28339.1.S1_at c-myc promoter binding protein LOC709675 4.74 0.0345 MmugDNA.16977.1.S1_at — — 4.73 0.0001 MmugDNA.9216.1.S1_s_at tripartite motif protein 31 isoform alpha — 4.71 0.0045 MmugDNA.29917.1.S1_at — — 4.69 0.0000 MmugDNA.8704.1.S1_at stanniocalcin 2 precursor LOC703900 4.69 0.0960 MmugDNA.11746.1.S1_at hypothetical protein LOC716531 LOC716531 4.64 0.0001 MmugDNA.7242.1.S1_at ring finger protein 183 LOC705679 4.63 0.0183 MmugDNA.34448.1.S1_at — — 4.62 0.0856 MmugDNA.12226.1.S1_at KIAA1946 LOC712442 4.61 0.0021 MmugDNA.16242.1.S1_at — — 4.61 0.0284 MmugDNA.42287.1.S1_at Beta crystallin A2 (Beta-A2-crystallin) LOC701178 4.59 0.0674 MmugDNA.13689.1.S1_at acyl-Coenzyme A oxidase 3, pristanoyl ACOX3 4.58 0.0836 MmugDNA.35429.1.S1_at — — 4.58 0.0297 MmugDNA.42474.1.S1_at neural cell adhesion molecule 1 NCAM1 4.58 0.0986 MmugDNA.42278.1.S1_at — — 4.58 0.0006 MmugDNA.15856.1.S1_at — — 4.57 0.0006 MmugDNA.26231.1.S1_at protein phosphatase 1, regulatory (inhibitor) subunit 14B — 4.56 0.0040 MmuSTS.1471.1.S1_at guanylate cyclase activator 1A (retina) LOC695552 4.56 0.0712 MmugDNA.38210.1.S1_at — — 4.56 0.0013 MmugDNA.8341.1.S1_at potassium voltage-gated channel, subfamily H, member 7 LOC702259 4.55 0.0691 isoform 2 MmugDNA.40476.1.S1_at CG17660-PA LOC698581 4.55 0.0164 MmugDNA.21371.1.S1_at L1 cell adhesion molecule L1CAM 4.54 0.0016 MmugDNA.10362.1.S1_at — — 4.54 0.0247 MmugDNA.34200.1.S1_at solute carrier family 16, member 10 LOC696132 4.54 0.0008 MmugDNA.10673.1.S1_at — — 4.53 0.0098 MmugDNA.34348.1.S1_at — — 4.51 0.0776 MmugDNA.14801.1.S1_at — — 4.51 0.0800 MmugDNA.16806.1.S1_at — — 4.51 0.0104 MmugDNA.26715.1.S1_at hypothetical protein LOC705319 LOC705319 4.50 0.0377 MmugDNA.29516.1.S1_at Transcribed locus — 4.50 0.0131 MmugDNA.35871.1.S1_at alpha-fetoprotein AFP 4.49 0.0827 MmuSTS.3720.1.S1_at prostaglandin-endoperoxide synthase 1 PTGS1 4.49 0.0550 MmugDNA.13337.1.S1_at — — 4.48 0.0825 MmugDNA.42244.1.S1_at — — 4.48 0.0930 MmugDNA.21236.1.S1_at arginine/serine-rich coiled-coil 1 LOC704232 4.47 0.0144 MmugDNA.36820.1.S1_at 1-acylglycerol-3-phosphate O-acyltransferase 5 AGPAT5 4.47 0.0076 MmugDNA.37762.1.S1_at methylenetetrahydrofolate dehydrogenase (NADP+ LOC705222 4.47 0.0074 dependent) 1-like MmugDNA.3018.1.S1_at Corticotropin-lipotropin precursor (Pro-opiomelanocortin) POMC 4.46 0.0858 (POMC) MmugDNA.30526.1.S1_at breast cancer membrane protein 11 LOC714517 4.46 0.0302 MmuSTS.2215.1.S1_at carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 LOC713994 4.45 0.0820 MmuSTS.1144.1.S1_at Jun dimerization protein p21SNFT LOC710551 4.45 0.0023 MmugDNA.33092.1.S1_s_at alpha-2-glycoprotein 1, zinc LOC710136 4.44 0.0971 MmugDNA.34402.1.S1_at taste receptor, type 1, member 2 LOC714666 4.44 0.0587 MmugDNA.583.1.S1_at phosphatidylinositol transfer protein, cytoplasmic 1 isoform a LOC718773 4.43 0.0076 MmugDNA.10551.1.S1_at Alpha-1,6-mannosyl-glycoprotein 2-beta-N- MGAT2 4.42 0.0455 acetylglucosaminyltransferase (Mannoside acetylglucosaminyltransferase 2) (N-glycosyl- oligosaccharide-glycoprotein N- acetylglucosaminyltransferase II) (Beta-1,2-N- acetylglucosaminyltransferase II) . . . MmugDNA.10172.1.S1_at — — 4.42 0.0763 MmugDNA.7644.1.S1_at amyloid beta (A4) precursor-like protein 2 APLP2 4.42 0.0771 MmuSTS.4251.1.S1_at DnaJ (Hsp40) homolog, subfamily B, member 9 LOC701094 4.42 0.0012 MmugDNA.30872.1.S1_at Tescalcin (TSC) TESC 4.41 0.0018 MmugDNA.16779.1.S1_at solute carrier organic anion transporter family member 4A1 SLCO4A1 4.41 0.0008 MmugDNA.36628.1.S1_at — — 4.39 0.0293 MmugDNA.39982.1.S1_at hydrogen voltage-gated channel 1 LOC709745 4.39 0.0378 MmugDNA.12304.1.S1_at — — 4.39 0.0926 MmugDNA.22401.1.S1_at goosecoid LOC702308 4.39 0.0452 MmugDNA.3017.1.S1_at — — 4.39 0.0176 MmugDNA.40588.1.S1_at — — 4.38 0.0736 MmugDNA.9680.1.S1_at — — 4.38 0.0521 MmugDNA.27684.1.S1_at guanine nucleotide binding protein (G protein), alpha 14 LOC705448 4.38 0.0003 MmugDNA.24197.1.S1_at — — 4.37 0.0840 MmugDNA.28806.1.S1_at — — 4.37 0.0872 MmugDNA.21653.1.S1_at Y17G7B.10b LOC704285 4.37 0.0535 MmugDNA.26796.1.S1_at beta-galactoside alpha-2,6-sialyltransferase II LOC713552 4.37 0.0025 MmugDNA.41976.1.S1_s_at probable nucleolar complex protein 14 LOC720068 4.37 0.0973 MmuSTS.63.1.S1_at hemochromatosis protein HFE 4.37 0.0581 MmugDNA.17587.1.S1_at molybdenum cofactor synthesis 3 MOCS3 4.36 0.0773 MmugDNA.22799.1.S1_at — — 4.35 0.0910 MmugDNA.43244.1.S1_at — — 4.35 0.0287 MmugDNA.4726.1.S1_at — — 4.35 0.0236 MmugDNA.27474.1.S1_at NIF3 NGG1 interacting factor 3-like 1 — 4.34 0.0009 MmuSTS.113.1.S1_at monogenic, audiogenic seizure susceptibility 1 LOC697794 4.34 0.0120 MmugDNA.13225.1.S1_at — — 4.34 0.0230 MmugDNA.40434.1.S1_at ataxin-1 ubiquitin-like interacting protein LOC714928 4.34 0.0944 MmuSTS.3087.1.S1_at RAD50 homolog isoform 1 LOC710718 4.33 0.0858 MmugDNA.2856.1.S1_at — — 4.32 0.0586 MmugDNA.24690.1.S1_at — — 4.32 0.0188 MmugDNA.17638.1.S1_at — — 4.32 0.0420 Mmu.4140.1.S1_at peptidylglycine alpha-amidating monooxygenase isoform b, LOC707733 4.31 0.0208 preproprotein MmuSTS.1399.1.S1_at complement factor B CFB 4.31 0.0450 MmugDNA.28599.1.S1_at dedicator of cytokinesis 10 DOCK10 4.30 0.0532 MmugDNA.5642.1.S1_at — — 4.28 0.0091 MmugDNA.33945.1.S1_at — — 4.28 0.0090 MmugDNA.845.1.S1_at N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase precursor AGA 4.28 0.0049 (Glycosylasparaginase) (Aspartylglucosaminidase) (N4-(N- acetyl-beta-glucosaminyl)-L-asparagine amidase) (AGA) MmugDNA.14017.1.S1_at dedicator of cytokinesis 9 DOCK9 4.28 0.0381 MmugDNA.1746.1.S1_at — — 4.27 0.0148 MmugDNA.7878.1.S1_at — — 4.27 0.0396 MmugDNA.42983.1.S1_s_at tripeptidyl-peptidase I precursor LOC709838 4.27 0.0116 MmugDNA.17468.1.S1_at protocadherin beta 6 PCDHB6 4.27 0.0080 MmugDNA.27490.1.S1_at — — 4.26 0.0588 MmugDNA.25045.1.S1_at — — 4.26 0.0872 MmugDNA.21311.1.S1_at ankyrin repeat and SOCS box-containing protein 4 ASB4 4.26 0.0713 MmugDNA.12780.1.S1_at BMX non-receptor tyrosine kinase BMX 4.26 0.0018 MmugDNA.39574.1.S1_at RWD domain containing 2 RWDD2 4.25 0.0242 MmugDNA.23856.1.S1_at — — 4.24 0.0588 MmugDNA.10231.1.S1_at mannosidase, endo-alpha LOC716710 4.24 0.0469 MmugDNA.38293.1.S1_at quiescin Q6 isoform a LOC718589 4.23 0.0244 MmugDNA.32049.1.S1_at transmembrane protein 64 LOC695826 4.23 0.0216 MmugDNA.10078.1.S1_at allantoicase ALLC 4.22 0.0463 MmugDNA.34409.1.S1_at — — 4.22 0.0589 MmugDNA.3676.1.S1_at — — 4.22 0.0067 MmugDNA.27799.1.S1_at hypothetical protein LOC703244 LOC703244 4.20 0.0047 MmugDNA.35140.1.S1_at UDP-glucuronate decarboxylase 1 LOC718456 4.20 0.0026 MmugDNA.12308.1.S1_at — — 4.20 0.0676 MmugDNA.29177.1.S1_at DNA polymerase zeta catalytic subunit (Seizure-related LOC703920 4.19 0.0016 protein 4) MmugDNA.366.1.S1_at fucosyltransferase 11 (alpha (1,3) fucosyltransferase) LOC706552 4.19 0.0249 MmugDNA.31712.1.S1_at polypeptide N-acetylgalactosaminyltransferase 6 GALNT6 4.18 0.0496 MmuSTS.649.1.S1_at interleukin 25 isoform 1 precursor LOC713943 4.18 0.0789 MmugDNA.41214.1.S1_at — — 4.16 0.0827 MmugDNA.28831.1.S1_at G protein-regulated inducer of neurite outgrowth 1 LOC697365 4.16 0.0458 MmugDNA.8787.1.S1_at Protein C10orf70 — 4.15 0.0040 MmuSTS.3573.1.S1_at protocadherin 8 PCDH8 4.15 0.0273 MmugDNA.13403.1.S1_at complement component 5 receptor 1 (C5a ligand) C5AR1 4.14 0.0245 MmugDNA.21971.1.S1_at N-acylsphingosine amidohydrolase (acid ceramidase) 1 LOC703699 4.13 0.0000 preproprotein isoform a MmugDNA.17057.1.S1_at RECK protein precursor — 4.13 0.0061 MmugDNA.22311.1.S1_at — — 4.12 0.0879 MmugDNA.8200.1.S1_at transglutaminase 7 LOC712676 4.12 0.0472 MmugDNA.42341.1.S1_at rabconnectin-3 beta isoform 2 LOC695302 4.11 0.0175 MmugDNA.601.1.S1_at SPRY domain-containing SOCS box protein SSB-4 LOC715278 4.10 0.0041 MmugDNA.27605.1.S1_at Spir-1 protein isoform 1 LOC722155 4.09 0.0878 MmugDNA.17977.1.S1_at neurexin 1 NRXN1 4.09 0.0029 MmugDNA.9585.1.S1_at histone deacetylase 9 isoform 3 LOC708314 4.08 0.0429 MmugDNA.43369.1.S1_at T-cell immunomodulatory protein LOC716435 4.08 0.0209 MmuSTS.2480.1.S1_at zinc finger protein 287 LOC695524 4.08 0.0212 MmugDNA.37092.1.S1_at down-regulator of transcription 1 (predicted) DR1 4.08 0.0606 MmugDNA.30978.1.S1_at desmoglein 2 DSG2 4.06 0.0049 MmuSTS.3837.1.S1_at solute carrier organic anion transporter family, member 2A1 SLCO2A1 4.05 0.0641 MmugDNA.26101.1.S1_at — — 4.04 0.0842 MmugDNA.25428.1.S1_at zinc finger protein 382 LOC713048 4.04 0.0143 MmugDNA.4774.1.S1_at — — 4.04 0.0319 MmugDNA.30877.1.S1_at zyg-11 homolog B (C. elegans)-like LOC715671 4.04 0.0081 MmugDNA.24520.1.S1_at synapsin II isoform IIa LOC695412 4.04 0.0046 MmugDNA.11034.1.S1_at — — 4.04 0.0031 MmugDNA.21096.1.S1_at zinc finger protein 275 ZNF275 4.03 0.0093 MmugDNA.43413.1.S1_at immunoglobin superfamily, member 21 LOC701539 4.03 0.0227 MmugDNA.42897.1.S1_at hypothetical protein LOC701560 LOC701560 4.03 0.0379 MmugDNA.19620.1.S1_at — — 4.02 0.0364 MmugDNA.15063.1.S1_s_at phosphatidate cytidylyltransferase 1 LOC706649 4.02 0.0319 MmugDNA.21133.1.S1_at — — 4.01 0.0911 MmugDNA.12118.1.S1_at — — 4.00 0.0007 MmugDNA.20406.1.S1_at GLE1-like, RNA export mediator isoform 1 LOC717474 4.00 0.0184 MmugDNA.34611.1.S1_at — — 4.00 0.0155 MmugDNA.19800.1.S1_at vang-like 1 LOC709730 3.99 0.0971 MmugDNA.6828.1.S1_at zinc finger protein 233 LOC713398 3.99 0.0396 MmugDNA.32366.1.S1_at — — 3.99 0.0269 MmugDNA.13572.1.S1_at — — 3.99 0.0080 MmugDNA.23433.1.S1_at — — 3.98 0.0701 MmugDNA.22715.1.S1_s_at — — 3.98 0.0039 MmugDNA.334.1.S1_at serine (or cysteine) proteinase inhibitor, clade B SERPINB2 3.96 0.0921 (ovalbumin), member 2 MmuSTS.1861.1.S1_at cholinergic receptor, nicotinic, alpha polypeptide 10 LOC718133 3.96 0.0531 MmugDNA.28216.1.S1_at CDC42-binding protein kinase alpha isoform B LOC697811 3.95 0.0269 MmugDNA.33930.1.S1_at LIN-7 homolog A (LIN-7A) (mLin-7) (Mammalian LIN-seven LOC697557 3.95 0.0069 protein 1) (MALS-1) (Vertebrate LIN 7 homolog 1) (Veli-1 protein) MmugDNA.2196.1.S1_at — — 3.94 0.0044 MmuSTS.1116.1.S1_at — — 3.94 0.0137 MmugDNA.29351.1.S1_at alpha-synuclein isoform NACP140 LOC706985 3.94 0.0198 MmugDNA.12808.1.S1_at hypothetical protein LOC694824 LOC694824 3.94 0.0695 MmugDNA.9043.1.S1_at ADP-ribosylation factor-like 6 interacting protein 2 LOC710647 3.94 0.0582 Mmu.937.1.S1_at hypothetical protein LOC710176 LOC710176 3.94 0.0314 MmugDNA.13793.1.S1_at — — 3.93 0.0047 MmugDNA.22471.1.S1_at — — 3.93 0.0011 MmugDNA.13861.1.S1_at fatty acid 2-hydroxylase LOC710403 3.92 0.0262 MmugDNA.31129.1.S1_at G protein-coupled receptor, family C, group 5, member B GPRC5B 3.92 0.0025 MmugDNA.41489.1.S1_at — — 3.91 0.0302 MmugDNA.12173.1.S1_at hypothetical protein LOC695417 LOC695417 3.91 0.0320 MmugDNA.37274.1.S1_s_at secretin receptor SCTR 3.91 0.0497 MmugDNA.10795.1.S1_at SVH protein LOC695210 3.90 0.0590 MmugDNA.24744.1.S1_at homeodomain leucine zipper protein LOC713087 3.90 0.0347 MmugDNA.39071.1.S1_at — — 3.89 0.0087 MmugDNA.818.1.S1_at — — 3.89 0.0375 MmugDNA.4556.1.S1_at Sorting nexin-5 — 3.89 0.0175 MmugDNA.13966.1.S1_s_at regulator of G-protein signalling 8 RGS8 3.89 0.0312 MmunewRS.597.1.S1_at Ral GEF with PH domain and SH3 binding motif 2 isoform 2 LOC717165 3.89 0.0520 MmuSTS.4601.1.S1_at interleukin 19 isoform 1 precursor LOC694806 3.89 0.0032 MmugDNA.13652.1.S1_at — — 3.87 0.0550 MmugDNA.7329.1.S1_s_at — — 3.86 0.0750 MmugDNA.40738.1.S1_at — — 3.86 0.0007 MmugDNA.2633.1.S1_at small nuclear RNA activating complex, polypeptide 1, 43 kDa LOC704797 3.86 0.0327 MmugDNA.7168.1.S1_at — — 3.86 0.0832 MmugDNA.36780.1.S1_at — — 3.85 0.0778 Mmu.14893.1.S1_x_at cytochrome P450 3A64 CYP3A64 3.84 0.0771 MmugDNA.19443.1.S1_at ataxin 2-binding protein 1 isoform 1 LOC713147 3.84 0.0099 MmugDNA.30992.1.S1_at SH3 and multiple ankyrin repeat domains 2 isoform 1 LOC708192 3.84 0.0487 MmugDNA.33696.1.S1_at hyaluronan binding protein 4 LOC710213 3.82 0.0699 MmugDNA.20527.1.S1_at — — 3.82 0.0945 MmugDNA.9900.1.S1_at nuclear factor of activated T-cells, cytoplasmic, calcineurin- LOC710601 3.82 0.0643 dependent 2 isoform C MmuSTS.3411.1.S1_at Ribose-phosphate pyrophosphokinase I (Phosphoribosyl LOC702529 3.82 0.0608 pyrophosphate synthetase I) (PRS-I) MmugDNA.4816.1.S1_at hypothetical protein LOC719170 LOC719170 3.81 0.0018 MmugDNA.35136.1.S1_at transmembrane protein 35 LOC702205 3.81 0.0773 MmugDNA.25086.1.S1_at glucosidase, alpha; neutral C GANC 3.80 0.0077 MmugDNA.1845.1.S1_at — — 3.80 0.0967 MmugDNA.29812.1.S1_at adaptor-related protein complex 3, beta 2 subunit AP3B2 3.79 0.0056 MmuSTS.4436.1.S1_at — — 3.79 0.0006 MmuSTS.782.1.S1_at potassium voltage-gated channel, Shab-related subfamily, KCNB2 3.79 0.0129 member 2 MmugDNA.3088.1.S1_at WNK lysine deficient protein kinase 3 WNK3 3.79 0.0093 MmuSTS.3509.1.S1_at Complement component 6 C6 3.78 0.0826 MmugDNA.41339.1.S1_at GTP cyclohydrolase I (GTP-CH-I) GCH1 3.78 0.0160 MmugDNA.14784.1.S1_at — — 3.77 0.0005 MmugDNA.9742.1.S1_at — — 3.77 0.0120 MmugDNA.5664.1.S1_at — — 3.76 0.0445 MmugDNA.480.1.S1_at — — 3.75 0.0159 MmugDNA.34213.1.S1_at cDNA sequence BC021395 LOC709217 3.74 0.0930 MmugDNA.16508.1.S1_at — — 3.73 0.0079 MmugDNA.17649.1.S1_at Sp3 transcription factor SP3 3.73 0.0274 MmugDNA.41644.1.S1_at spermatogenesis associated 5-like 1 LOC713376 3.72 0.0074 MmugDNA.9202.1.S1_at — — 3.72 0.0472 MmugDNA.17057.1.S1_s_at tumor suppressor candidate 3 isoform a LOC701123 3.72 0.0011 MmuSTS.56.1.S1_at hypothetical protein LOC715723 LOC715723 3.72 0.0043 MmugDNA.39898.1.S1_at — — 3.71 0.0068 MmugDNA.40119.1.S1_s_at HIV-1 Tat interactive protein 2, 30 kDa LOC701908 3.71 0.0078 MmugDNA.27371.1.S1_at hypothetical protein LOC697751 LOC697751 3.71 0.0857 MmugDNA.16327.1.S1_at pad-1-like DOPEY2 3.70 0.0023 MmuSTS.3363.1.S1_at phosphodiesterase 2A, cGMP-stimulated PDE2A 3.70 0.0029 MmugDNA.14309.1.S1_at activated leukocyte cell adhesion molecule LOC703777 3.70 0.0030 MmugDNA.24681.1.S1_at CTAGE family, member 5 — 3.70 0.0392 MmuSTS.101.1.S1_at acyl-Coenzyme A oxidase isoform b LOC705197 3.69 0.0138 MmugDNA.27013.1.S1_at — — 3.69 0.0484 MmugDNA.29538.1.S1_at — — 3.69 0.0315 MmugDNA.43028.1.S1_at — — 3.68 0.0468 MmugDNA.34314.1.S1_at synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 3.67 0.0570 MmugDNA.33133.1.S1_at hypothetical protein LOC711218 LOC711218 3.67 0.0227 MmugDNA.11493.1.S1_at — — 3.67 0.0378 MmugDNA.16985.1.S1_at ets variant gene 1 ETV1 3.67 0.0532 MmuSTS.1797.1.S1_at — — 3.67 0.0668 MmuSTS.2054.1.S1_at protein (peptidyl-prolyl cis/trans isomerase) NIMA- LOC699273 3.67 0.0431 interacting, 4 (parvulin) MmugDNA.18533.1.S1_at phospholipase D family, member 5 LOC706256 3.66 0.0682 MmuSTS.1511.1.S1_at RNA binding motif protein 15B LOC700716 3.66 0.0181 MmugDNA.15936.1.S1_at — — 3.66 0.0183 MmugDNA.29618.1.S1_at K09A9.6 LOC712623 3.65 0.0282 MmugDNA.831.1.S1_at — — 3.65 0.0675 MmugDNA.22531.1.S1_s_at — — 3.65 0.0988 MmugDNA.6653.1.S1_at tudor repeat associator with PCTAIRE 2 PCTAIRE2BP 3.65 0.0018 MmugDNA.25839.1.S1_at RAD1 homolog isoform 1 LOC703720 3.64 0.0444 MmugDNA.6534.1.S1_at hypothetical protein LOC701296 LOC701296 3.64 0.0007 MmugDNA.30983.1.S1_at — — 3.64 0.0165 MmugDNA.18313.1.S1_at arrestin beta 1 isoform A LOC695250 3.64 0.0141 MmugDNA.25553.1.S1_at retinitis pigmentosa GTPase regulator interacting protein 1 LOC697345 3.63 0.0105 MmugDNA.31716.1.S1_s_at molybdenum cofactor sulfurase LOC715633 3.62 0.0761 MmugDNA.41201.1.S1_at — — 3.62 0.0012 MmugDNA.7740.1.S1_at — — 3.61 0.0206 MmugDNA.1555.1.S1_at C29E4.8 LOC714698 3.61 0.0795 MmugDNA.27957.1.S1_at ganglioside induced differentiation associated protein 2 LOC714615 3.59 0.0280 MmugDNA.2255.1.S1_at phosphatidylinositol-4-phosphate 5-kinase, type I, beta LOC700538 3.59 0.0003 isoform 2 MmugDNA.23037.1.S1_at Ephrin type-B receptor 2 precursor (Tyrosine-protein kinase LOC720107 3.59 0.0647 receptor EPH-3) (Neural kinase) (Nuk receptor tyrosine kinase) (SEK-3) MmugDNA.41938.1.S1_at proline-rich protein PRP2 LOC702863 3.59 0.0012 MmugDNA.7947.1.S1_at — — 3.59 0.0538 MmugDNA.4820.1.S1_at Rho GTPase activating protein 6 ARHGAP6 3.59 0.0726 MmugDNA.31476.1.S1_at Ras-related protein Rab-28 (Rab-26) LOC694111 3.58 0.0643 MmugDNA.16749.1.S1_at — — 3.58 0.0095 MmugDNA.39259.1.S1_at — — 3.57 0.0161 MmugDNA.3689.1.S1_at nuclear factor of kappa light polypeptide gene enhancer in LOC694844 3.57 0.0001 B-cells inhibitor, beta isoform a MmugDNA.17315.1.S1_at — — 3.57 0.0712 MmugDNA.23019.1.S1_at — — 3.56 0.0014 MmugDNA.37589.1.S1_at Ubiquitin-conjugating enzyme E2S (Ubiquitin-conjugating — 3.55 0.0112 enzyme E2-24 kDa) (Ubiquitin-protein ligase) (Ubiquitin carrier protein) (E2-EPF5) MmugDNA.17498.1.S1_at — — 3.55 0.0024 MmugDNA.13233.1.S1_at brain expressed X-linked 2 LOC696048 3.55 0.0065 MmugDNA.22053.1.S1_at gamma-glutamyl carboxylase GGCX 3.55 0.0254 MmugDNA.35529.1.S1_at PARK2 co-regulated PACRG 3.55 0.0412 MmugDNA.40108.1.S1_at hypothetical protein LOC698322 LOC698322 3.54 0.0882 Mmu.1639.1.S1_at solute carrier family 15 (H+/peptide transporter), member 2 SLC15A2 3.54 0.0400 MmugDNA.19566.1.S1_at Type I iodothyronine deiodinase (Type-I 5deiodinase) (DIOI) DIO1 3.54 0.0037 (Type 1 DI) (5DI) MmuSTS.106.1.S1_at Elongation factor 1-delta (EF-1-delta) (Antigen NY-CO-4) — 3.54 0.0407 MmugDNA.41451.1.S1_s_at F33H2.6 LOC710209 3.52 0.0008 MmugDNA.39857.1.S1_at hypothetical protein LOC703607 LOC703607 3.52 0.0070 MmuSTS.3342.1.S1_at SET and MYND domain containing 3 SMYD3 3.52 0.0919 MmugDNA.31877.1.S1_at calreticulin 3 LOC719532 3.52 0.0899 MmugDNA.13028.1.S1_at periaxin LOC707626 3.52 0.0013 MmugDNA.29176.1.S1_at MEGF11 protein LOC714198 3.51 0.0977 MmuSTS.4142.1.S1_at — — 3.51 0.0060 MmugDNA.17878.1.S1_at CG5359-PA LOC711098 3.51 0.0020 MmugDNA.41017.1.S1_at — — 3.50 0.0855 MmugDNA.12740.1.S1_at — — 3.49 0.0567 MmugDNA.2965.1.S1_at butyrate-induced transcript 1 LOC709590 3.49 0.0306 MmuSTS.4796.1.S1_at flavin containing monooxygenase 4 FMO4 3.49 0.0927 MmuSTS.4569.1.S1_at MAD, mothers against decapentaplegic homolog 9 SMAD9 3.48 0.0297 MmuSTS.3579.1.S1_at — — 3.48 0.0321 MmugDNA.29168.1.S1_at Collagen alpha-1(III) chain precursor LOC719369 3.47 0.0245 MmugDNA.24379.1.S1_at tissue factor pathway inhibitor TFPI 3.47 0.0251 MmugDNA.6495.1.S1_at hypothetical protein LOC701956 LOC701956 3.47 0.0063 MmugDNA.31684.1.S1_at Protein C6orf78 homolog LOC714815 3.47 0.0341 MmugDNA.8650.1.S1_at solute carrier family 6, member 17 LOC701162 3.47 0.0032 MmuSTS.2222.1.S1_at synaptic vesicle protein 2B homolog LOC710980 3.46 0.0052 MmuSTS.2708.1.S1_at ADAM metallopeptidase domain 10 ADAM10 3.46 0.0615 MmugDNA.4023.1.S1_at — — 3.46 0.0005 MmugDNA.3743.1.S1_at transmembrane and coiled-coil domains 3 LOC716185 3.46 0.0184 MmuSTS.3521.1.S1_at arginyltransferase 1 ATE1 3.45 0.0116 MmugDNA.35799.1.S1_at — — 3.45 0.0060 MmugDNA.3417.1.S1_at — — 3.45 0.0480 MmugDNA.14546.1.S1_at testis specific, 10 interacting protein LOC715217 3.45 0.0517 MmugDNA.41404.1.S1_at cytoplasmic polyadenylation element binding protein 3 LOC698133 3.45 0.0022 MmugDNA.40609.1.S1_at — — 3.45 0.0449 MmugDNA.15703.1.S1_at putative homeodomain transcription factor 1 PHTF1 3.44 0.0091 MmugDNA.6582.1.S1_at hypothetical protein LOC701911 LOC701911 3.44 0.0206 MmugDNA.28101.1.S1_at ST3 beta-galactoside alpha-2,3-sialyltransferase 5 ST3GAL5 3.44 0.0116 MmugDNA.41240.1.S1_at — — 3.44 0.0124 MmugDNA.8735.1.S1_at — — 3.44 0.0204 MmugDNA.14126.1.S1_at hypothetical protein LOC694536 LOC694536 3.44 0.0688 MmugDNA.31606.1.S1_at — — 3.43 0.0033 MmugDNA.34884.1.S1_at CUB and zona pellucida-like domains 1 LOC706861 3.43 0.0890 MmugDNA.23074.1.S1_at plexin A2 LOC713800 3.43 0.0004 MmuSTS.1012.1.S1_at USP6 N-terminal like USP6NL 3.43 0.0199 MmugDNA.40409.1.S1_at Y55F3AM.9 LOC703159 3.42 0.0256 MmuSTS.3876.1.S1_at solute carrier family 6 (amino acid transporter), member 14 SLC6A14 3.42 0.0305 MmugDNA.38177.1.S1_at F-box only protein 21 isoform 2 LOC693647 3.41 0.0637 MmugDNA.35235.1.S1_at hypothetical protein LOC710443 LOC710443 3.41 0.0899 MmugDNA.19514.1.S1_at — — 3.41 0.0487 MmugDNA.25771.1.S1_at Protein C20orf22 homolog LOC706758 3.41 0.0889 MmugDNA.3375.1.S1_at ankyrin repeat domain 28 LOC696592 3.41 0.0355 MmunewRS.255.1.S1_at — — 3.41 0.0055 MmugDNA.38350.1.S1_s_at Potassium channel, subfamily K, member 5 — 3.41 0.0273 MmugDNA.29156.1.S1_at cyclin T2 isoform b LOC708813 3.40 0.0315 MmugDNA.1804.1.S1_at — — 3.40 0.0046 MmugDNA.13727.1.S1_at beta-site APP-cleaving enzyme 1 BACE1 3.40 0.0104 MmugDNA.36294.1.S1_at dopa decarboxylase (aromatic L-amino acid decarboxylase) DDC 3.40 0.0052 MmugDNA.18015.1.S1_at HLA class II histocompatibility antigen, DM beta chain LOC717870 3.40 0.0951 precursor (MHC class II antigen DMB) MmugDNA.10946.1.S1_at — — 3.40 0.0129 MmugDNA.35307.1.S1_at IQ motif containing G LOC714807 3.39 0.0051 MmugDNA.40386.1.S1_at hypothetical protein LOC718008 LOC718008 3.39 0.0568 MmuSTS.1442.1.S1_at — — 3.39 0.0810 MmugDNA.30491.1.S1_at neurexin 3 LOC678699 3.39 0.0046 MmugDNA.40498.1.S1_at — — 3.38 0.0141 MmuSTS.3629.1.S1_at EMI domain containing 1 LOC717414 3.38 0.0283 MmugDNA.42049.1.S1_at synaptotagmin-like 5 LOC697915 3.38 0.0543 MmugDNA.33991.1.S1_at ELOVL family member 6, elongation of long chain fatty LOC698870 3.37 0.0453 acids (FEN1/Elo2, SUR4/Elo3-like, yeast) MmugDNA.30419.1.S1_at — — 3.37 0.0108 MmugDNA.38819.1.S1_at hypothetical protein LOC716712 LOC716712 3.37 0.0815 MmugDNA.11736.1.S1_at — — 3.37 0.0918 MmugDNA.8760.1.S1_at — — 3.37 0.0545 MmugDNA.21748.1.S1_at FXYD domain containing ion transport regulator 4 LOC717636 3.37 0.0147 MmugDNA.40624.1.S1_at — — 3.37 0.0144 MmugDNA.34981.1.S1_at CG17687-PA LOC716031 3.36 0.0598 MmugDNA.21769.1.S1_at transmembrane protein 141 LOC721687 3.36 0.0278 MmugDNA.12396.1.S1_at zinc finger protein 621 LOC717189 3.36 0.0150 MmugDNA.35827.1.S1_s_at glucosaminyl (N-acetyl) transferase 2, I-branching enzyme LOC697468 3.35 0.0492 isoform B MmugDNA.31910.1.S1_at — — 3.35 0.0987 MmugDNA.39573.1.S1_s_at — — 3.35 0.0001 MmugDNA.27074.1.S1_at hypothetical protein LOC707868 LOC707868 3.35 0.0014 MmugDNA.4152.1.S1_at esophageal cancer related gene 4 protein LOC713611 3.34 0.0126 MmugDNA.28574.1.S1_at zinc finger protein 483 ZNF483 3.34 0.0050 MmugDNA.14788.1.S1_at CG14868-PA LOC715968 3.34 0.0385 Mmu.2046.1.S1_at Hypothetical protein LOC693623 — 3.34 0.0130 MmugDNA.38470.1.S1_at hypothetical protein LOC704380 LOC704380 3.33 0.0041 MmugDNA.43475.1.S1_at inositol polyphosphate-4-phosphatase, type 1 INPP4A 3.33 0.0395 MmugDNA.11863.1.S1_at receptor expression enhancing protein 1 LOC697390 3.32 0.0807 MmugDNA.12356.1.S1_at peroxin1 LOC702392 3.32 0.0067 MmugDNA.34502.1.S1_at bactericidal/permeability-increasing protein-like 2 LOC717287 3.32 0.0813 MmugDNA.28096.1.S1_at KIAA1799 protein LOC696830 3.32 0.0034 MmugDNA.19117.1.S1_at — — 3.32 0.0948 MmugDNA.22544.1.S1_at lysosomal-associated membrane protein 2 LAMP2 3.32 0.0120 MmugDNA.2026.1.S1_at neuraminidase NEU1 3.32 0.0176 MmuSTS.2482.1.S1_at zinc finger protein 3 isoform 2 LOC719069 3.31 0.0772 MmugDNA.8202.1.S1_at — — 3.31 0.0236 MmugDNA.12374.1.S1_at 5-nucleotidase, cytosolic III isoform 1 LOC708743 3.31 0.0020 MmugDNA.18151.1.S1_at — — 3.31 0.0350 MmugDNA.40189.1.S1_at 3-hydroxy-3-methylglutaryl-Coenzyme A reductase HMGCR 3.31 0.0110 MmugDNA.43623.1.S1_s_at disabled homolog 2 DAB2 3.31 0.0650 MmugDNA.22195.1.S1_at prospero-related homeobox 1 LOC709465 3.31 0.0373 MmugDNA.12057.1.S1_at hypothetical protein LOC708157 LOC708157 3.31 0.0963 MmugDNA.29604.1.S1_at — — 3.30 0.0482 MmugDNA.36778.1.S1_at ADAMTS-like 3 LOC712844 3.30 0.0777 MmugDNA.43352.1.S1_at chromobox homolog 2 isoform 1 LOC717462 3.30 0.0674 MmugDNA.41900.1.S1_at nudix-type motif 10 LOC695921 3.30 0.0511 MmugDNA.5215.1.S1_at — — 3.30 0.0039 MmugDNA.3581.1.S1_at — — 3.29 0.0050 MmugDNA.42978.1.S1_at — — 3.29 0.0052 MmugDNA.11001.1.S1_at transcription factor-like nuclear regulator — 3.29 0.0396 MmugDNA.32117.1.S1_at — — 3.28 0.0977 MmugDNA.4792.1.S1_at — — 3.28 0.0123 MmugDNA.14682.1.S1_at — — 3.28 0.0017 MmuSTS.1437.1.S1_at L-plastin LCP1 3.27 0.0624 Mmu.1276.1.S1_at serine protease inhibitor, Kunitz type, 2 LOC714755 3.27 0.0799 MmugDNA.29558.1.S1_at leucine rich repeat containing 7 LOC702347 3.27 0.0047 MmugDNA.36803.1.S1_at — — 3.26 0.0986 MmugDNA.37994.1.S1_at — — 3.26 0.0694 MmugDNA.37151.1.S1_at — — 3.26 0.0730 MmuSTS.2193.1.S1_at acid sphingomyelinase-like phosphodiesterase 3A LOC713696 3.25 0.0359 MmugDNA.15609.1.S1_at — — 3.25 0.0134 MmugDNA.34021.1.S1_at ARP3 actin-related protein 3 homolog ACTR3 3.25 0.0910 MmugDNA.13552.1.S1_at — — 3.25 0.0538 MmugDNA.14095.1.S1_at calpain 9 CAPN9 3.25 0.0723 MmugDNA.20778.1.S1_at transcriptional regulator ATRX isoform 2 LOC705735 3.24 0.0808 MmuSTS.3264.1.S1_at norrin LOC702203 3.24 0.0996 MmugDNA.21014.1.S1_at — — 3.24 0.0033 MmugDNA.26007.1.S1_at — — 3.24 0.0467 Mmu.14792.1.S1_at solute carrier family 40 (iron-regulated transporter), member 1 SLC40A1 3.24 0.0230 MmugDNA.14237.1.S1_at Dynein heavy chain at 16F CG7092-PA LOC694115 3.24 0.0962 MmuSTS.4208.1.S1_at glucosaminyl (N-acetyl) transferase 3, mucin type LOC702754 3.22 0.0016 MmugDNA.19093.1.S1_at — — 3.22 0.0397 MmugDNA.8868.1.S1_at hypothetical protein LOC710705 LOC710705 3.21 0.0002 MmugDNA.16163.1.S1_at — — 3.21 0.0003 MmugDNA.30042.1.S1_at CG1 protein (F18) LOC703003 3.21 0.0622 MmugDNA.100.1.S1_at — — 3.20 0.0940 MmugDNA.10033.1.S1_at poliovirus receptor LOC714190 3.20 0.0577 MmugDNA.26257.1.S1_at echinoderm microtubule associated protein like 1 isoform b LOC705977 3.20 0.0866 MmugDNA.37272.1.S1_at zinc finger protein 467 LOC712106 3.20 0.0577 MmugDNA.30904.1.S1_at — — 3.19 0.0072 MmuSTS.772.1.S1_at cytosolic sialic acid 9-O-acetylesterase homolog LOC711816 3.19 0.0375 MmugDNA.1780.1.S1_at — — 3.19 0.0140 MmuSTS.1855.1.S1_at cadherin 2, type 1 preproprotein LOC711526 3.19 0.0108 MmugDNA.36726.1.S1_at NG22 protein SLC44A4 3.18 0.0184 MmugDNA.28522.1.S1_at — — 3.18 0.0106 MmugDNA.40772.1.S1_at — — 3.18 0.0538 MmugDNA.40592.1.S1_at reticulon 4 receptor-like 1 LOC720246 3.18 0.0448 MmugDNA.41621.1.S1_at F54C1.5a LOC702261 3.18 0.0527 MmugDNA.20138.1.S1_at CXXC finger 6 LOC707759 3.17 0.0697 MmugDNA.30196.1.S1_at — — 3.17 0.0365 Mmu.16247.1.S1_at EF hand domain family, member A1 LOC706065 3.17 0.0044 MmugDNA.24683.1.S1_at — — 3.17 0.0121 MmugDNA.21254.1.S1_at hypothetical protein LOC695666 LOC695666 3.16 0.0344 MmugDNA.30331.1.S1_at multiple C2-domains with two transmembrane regions 1 LOC697733 3.16 0.0017 isoform S MmugDNA.14053.1.S1_at — — 3.16 0.0862 MmuSTS.72.1.S1_at hephaestin isoform a LOC709879 3.15 0.0624 Mmu.12852.1.S1_at Nedd4 family interacting protein 1 LOC705716 3.15 0.0181 MmugDNA.21162.1.S1_at 1D-myo-inositol-trisphosphate 3-kinase B LOC698185 3.15 0.0210 MmugDNA.2522.1.S1_at gamma-aminobutyric acid (GABA) A receptor, beta 3 GABRB3 3.15 0.0383 isoform 2 precursor MmugDNA.1070.1.S1_at — — 3.15 0.0660 MmugDNA.11921.1.S1_at CG7071-PA, isoform A LOC708298 3.15 0.0754 MmuSTS.2765.1.S1_at class III alcohol dehydrogenase 5 chi subunit ADH5 3.14 0.0011 MmugDNA.40331.1.S1_at — — 3.14 0.0007 MmugDNA.25139.1.S1_at carboxypeptidase D precursor LOC712407 3.14 0.0055 MmugDNA.12314.1.S1_at — — 3.14 0.0034 MmugDNA.32572.1.S1_at Fibroblast growth factor 14 (FGF-14) (Fibroblast growth FGF14 3.14 0.0082 factor homologous factor 4) (FHF-4) MmugDNA.3590.1.S1_at — — 3.13 0.0150 MmugDNA.13879.1.S1_at mannosidase, alpha, class 2A, member 1 LOC705480 3.13 0.0429 MmugDNA.3209.1.S1_at microfibrillar-associated protein 3-like MFAP3L 3.12 0.0120 MmugDNA.7233.1.S1_at — — 3.12 0.0851 MmugDNA.15955.1.S1_at TAO kinase 2 TAOK2 3.12 0.0021 MmugDNA.38589.1.S1_at lethal (2) k00619 CG4775-PA LOC715015 3.12 0.0309 MmugDNA.546.1.S1_at alpha glucosidase II alpha subunit isoform 2 LOC718672 3.12 0.0262 MmugDNA.41951.1.S1_at LPS-responsive vesicle trafficking, beach and anchor LOC693823 3.12 0.0005 containing MmugDNA.1873.1.S1_at — — 3.11 0.0183 MmugDNA.18551.1.S1_at inositol polyphosphate-5-phosphatase, 75 kDa INPP5B 3.11 0.0058 MmugDNA.15348.1.S1_at ERO1-like ERO1L 3.10 0.0079 MmugDNA.20795.1.S1_at slit homolog 1 LOC697716 3.10 0.0012 MmugDNA.28842.1.S1_at CKLF-like MARVEL transmembrane domain containing 7 LOC704329 3.10 0.0648 isoform b MmugDNA.10278.1.S1_at slit and trk like 3 protein LOC700660 3.10 0.0457 MmugDNA.41181.1.S1_at — — 3.09 0.0747 MmugDNA.42278.1.S1_s_at — — 3.09 0.0003 Mmu.12401.1.S1_at SECIS binding protein 2 LOC697442 3.09 0.0551 MmugDNA.7049.1.S1_at — — 3.09 0.0652 MmugDNA.11735.1.S1_at — — 3.08 0.0835 MmugDNA.42396.1.S1_at germ cell-less LOC701545 3.08 0.0538 MmugDNA.26488.1.S1_at — — 3.08 0.0363 MmugDNA.2284.1.S1_at notch 2 preproprotein LOC713798 3.08 0.0619 MmugDNA.28250.1.S1_at — — 3.08 0.0459 MmugDNA.17056.1.S1_s_at reticulon 4 receptor precursor LOC694382 3.08 0.0373 MmunewRS.972.1.S1_at glutamate decarboxylase-like 1 LOC706457 3.08 0.0098 MmugDNA.11045.1.S1_s_at microtubule-associated protein 7 LOC705355 3.07 0.0015 MmuSTS.1473.1.S1_at mitogen-activated protein kinase 9 isoform 1 LOC699736 3.07 0.0243 MmugDNA.31498.1.S1_at — — 3.07 0.0225 MmuSTS.4269.1.S1_at glutamate receptor, metabotropic 8 GRM8 3.07 0.0386 MmugDNA.18449.1.S1_s_at zinc finger, ZZ type with EF hand domain 1 — 3.06 0.0534 MmugDNA.11192.1.S1_at CG8312-PA, isoform A LOC705659 3.06 0.0538 MmugDNA.1116.1.S1_at — — 3.06 0.0407 MmugDNA.30277.1.S1_at — — 3.06 0.0039 MmugDNA.14729.1.S1_at CD82 antigen isoform 2 CD82 3.06 0.0323 MmugDNA.27419.1.S1_at actin-related protein 3-beta isoform 1 LOC715965 3.06 0.0384 MmuSTS.3981.1.S1_at SH3-domain GRB2-like 2 SH3GL2 3.05 0.0871 MmugDNA.37217.1.S1_at — — 3.05 0.0935 MmugDNA.15075.1.S1_at hypothetical protein LOC716982 LOC716982 3.05 0.0080 MmugDNA.16118.1.S1_at hect domain and RLD 3 HERC3 3.05 0.0004 MmunewRS.326.1.S1_at hypothetical protein LOC717316 LOC717316 3.05 0.0589 MmugDNA.9126.1.S1_at lin-7 homolog C LIN7C 3.05 0.0998 MmugDNA.10794.1.S1_at — — 3.04 0.0857 MmugDNA.32230.1.S1_at nucleolar protein 1, 120 kDa — 3.04 0.0954 MmugDNA.37502.1.S1_at — — 3.04 0.0417 MmugDNA.17117.1.S1_at hypothetical protein LOC700172 LOC700172 3.04 0.0173 MmugDNA.9078.1.S1_at zinc finger protein 141 (clone pHZ-44) ZNF141 3.03 0.0537 MmugDNA.9853.1.S1_at arachidonate 5-lipoxygenase ALOX5 3.03 0.0808 MmugDNA.22211.1.S1_at PET112-like LOC694983 3.03 0.0437 MmugDNA.26554.1.S1_at UDP glycosyltransferase 3 family, polypeptide A1 LOC700115 3.03 0.0736 MmugDNA.3964.1.S1_at chromosome 2 open reading frame 30 LOC716460 3.03 0.0238 MmugDNA.36028.1.S1_at — — 3.03 0.0039 MmugDNA.19859.1.S1_at hypothetical protein LOC700866 LOC700866 3.03 0.0654 MmugDNA.15510.1.S1_s_at beta-amyloid binding protein precursor LOC694282 3.02 0.0002 MmugDNA.16151.1.S1_at zinc finger protein 567 LOC713173 3.02 0.0327 MmugDNA.43512.1.S1_at Transcribed locus — 3.02 0.0112 MmuSTS.1643.1.S1_at transient receptor potential cation channel, subfamily M, LOC705070 3.02 0.0082 member 5 MmugDNA.24619.1.S1_at WD repeat domain 56 LOC705146 3.01 0.0331 MmuSTS.3607.1.S1_at cadherin 11, type 2 preproprotein LOC708826 3.01 0.0107 MmugDNA.29541.1.S1_at — — 3.00 0.0050 MmugDNA.36083.1.S1_s_at — — 3.00 0.0042 MmugDNA.15113.1.S1_at endoplasmic reticulum oxidoreductin 1-Lbeta LOC710912 3.00 0.0927 MmuSTS.2617.1.S1_at — — 3.00 0.0676 Mmu.380.1.S1_at tetratricopeptide repeat domain 27 LOC707021 3.00 0.0738 MmuSTS.898.1.S1_at engulfment and cell motility 1 isoform 1 /// hypothetical LOC705818 /// 3.00 0.0255 protein LOC713462 LOC713462 MmugDNA.21372.1.S1_at formin binding protein 3 PRPF40A 3.00 0.0062 MmugDNA.6394.1.S1_at microtubule-associated protein tau MAPT 3.00 0.0052 MmugDNA.10807.1.S1_at HESB like domain containing 1 — 2.99 0.0965 MmugDNA.34681.1.S1_at sortilin-related receptor containing LDLR class A repeats LOC713011 2.99 0.0129 preproprotein MmugDNA.6380.1.S1_at ankylosis, progressive homolog LOC717689 2.99 0.0159 MmugDNA.4142.1.S1_at RAB3B, member RAS oncogene family LOC712683 2.99 0.0030 MmugDNA.20373.1.S1_at galactosylceramidase GALC 2.98 0.0973 MmugDNA.29366.1.S1_at Transitional endoplasmic reticulum ATPase (TER ATPase) LOC698707 2.98 0.0020 (15S Mg(2+)-ATPase p97 subunit) (Valosin-containing protein) (VCP) MmugDNA.33876.1.S1_s_at olfactomedin 2 LOC711336 2.98 0.0088 MmugDNA.7330.1.S1_at mannosidase, alpha, class 1C, member 1 MAN1C1 2.98 0.0027 MmuSTS.2879.1.S1_at transforming growth factor, beta receptor III (betaglycan, LOC705053 2.98 0.0240 300 kDa) MmugDNA.39004.1.S1_at sweet taste receptor T1r isoform b LOC720987 2.98 0.0973 MmugDNA.32903.1.S1_at Protein C9orf116 (Pierce 1) LOC720855 2.97 0.0828 MmugDNA.23567.1.S1_at HMT1 hnRNP methyltransferase-like 6 PRMT6 2.97 0.0334 MmugDNA.24770.1.S1_at hypothetical protein LOC696555 LOC696555 2.97 0.0271 MmugDNA.39298.1.S1_at EGF-like-domain, multiple 5 MEGF9 2.97 0.0006 MmugDNA.39357.1.S1_at — — 2.97 0.0237 MmugDNA.6683.1.S1_at — — 2.96 0.0069 MmugDNA.17131.1.S1_at — — 2.96 0.0290 MmuSTS.2496.1.S1_at zinc finger protein 618 LOC708866 2.95 0.0450 MmugDNA.17574.1.S1_at polycystic kidney disease 2-like 1 PKD2L1 2.95 0.0062 MmuSTS.4419.1.S1_at FXYD domain-containing ion transport regulator 6 LOC698456 2.95 0.0109 MmuSTS.546.1.S1_at membrane associated guanylate kinase, WW and PDZ LOC698092 2.95 0.0917 domain containing 1 isoform a MmugDNA.5553.1.S1_at hypothetical protein LOC695259 LOC695259 2.95 0.0337 MmugDNA.1170.1.S1_at — — 2.94 0.0216 MmugDNA.39293.1.S1_at — — 2.94 0.0220 MmugDNA.36751.1.S1_at — — 2.94 0.0034 MmugDNA.2580.1.S1_at adaptor-related protein complex 3, beta 1 subunit AP3B1 2.94 0.0353 MmugDNA.42089.1.S1_at ectonucleoside triphosphate diphosphohydrolase 3 ENTPD3 2.94 0.0140 MmugDNA.5339.1.S1_at transportin 1 LOC707195 2.94 0.0080 MmugDNA.37020.1.S1_at dedicator of cytokinesis 1 DOCK1 2.94 0.0400 MmuSTS.2157.1.S1_at Scm-like with four mbt domains 1 LOC694961 2.93 0.0548 MmuSTS.2057.1.S1_at phosphoinositide-specific phospholipase C beta 1 isoform a LOC718387 2.93 0.0630 MmugDNA.32391.1.S1_at hepatocellular carcinoma-associated antigen 112 LOC713786 2.93 0.0012 MmugDNA.15308.1.S1_s_at — — 2.93 0.0128 MmuSTS.1570.1.S1_at neurobeachin NBEA 2.93 0.0050 MmugDNA.22319.1.S1_at histidine triad nucleotide binding protein 3 LOC712779 2.93 0.0091 MmugDNA.32797.1.S1_at CTAGE family, member 5 isoform 1 LOC699511 2.93 0.0027 MmugDNA.9436.1.S1_at — — 2.92 0.0507 MmugDNA.28664.1.S1_at guanine nucleotide binding protein, alpha stimulating activity LOC694289 2.92 0.0333 polypeptide 1 isoform c MmugDNA.21110.1.S1_at zinc finger protein 398 isoform 1 LOC710358 2.92 0.0141 MmugDNA.5715.1.S1_at tissue inhibitor of matrix metalloproteinase-1 TIMP-1 2.92 0.0113 MmugDNA.13442.1.S1_at ATPase, aminophospholipid transporter (APLT), class I, LOC702630 2.92 0.0030 type 8A, member 1 Mmu.3604.1.S1_s_at synaptotagmin binding, cytoplasmic RNA interacting protein LOC700732 2.92 0.0255 MmugDNA.35867.1.S1_at fibronectin leucine rich transmembrane protein 3 FLRT3 2.92 0.0081 MmugDNA.27436.1.S1_at — — 2.92 0.0200 MmugDNA.9183.1.S1_at Protein NipSnap3B (SNAP1) NIPSNAP3B 2.91 0.0192 MmugDNA.39239.1.S1_at TMEM9 domain family, member B /// hypothetical protein LOC694700 /// 2.91 0.0009 LOC719509 LOC708447 /// LOC719509 MmugDNA.9888.1.S1_at Tetratricopeptide repeat protein 9 (TPR repeat protein 9) LOC693495 2.91 0.0121 MmugDNA.29679.1.S1_at — — 2.91 0.0380 MmugDNA.36914.1.S1_at — — 2.90 0.0254 MmugDNA.38533.1.S1_at — — 2.90 0.0802 MmugDNA.6837.1.S1_at sorting nexin 13 SNX13 2.89 0.0060 MmugDNA.3572.1.S1_at — — 2.89 0.0038 MmugDNA.27179.1.S1_at synapse-associated protein 102 LOC697179 2.89 0.0797 MmugDNA.37780.1.S1_at — — 2.89 0.0748 MmugDNA.31668.1.S1_at — — 2.89 0.0279 MmuSTS.4659.1.S1_at tumor necrosis factor, alpha-induced protein 3 TNFAIP3 2.89 0.0946 MmugDNA.25426.1.S1_at — — 2.89 0.0361 MmugDNA.24776.1.S1_at protein phosphatase 1, regulatory subunit 7 LOC700574 2.89 0.0728 MmugDNA.5386.1.S1_at zinc finger protein 354B LOC712885 2.89 0.0369 MmugDNA.21944.1.S1_s_at holocytochrome c synthase (cytochrome c heme-lyase) HCCS 2.89 0.0331 MmugDNA.2867.1.S1_at — — 2.88 0.0624 MmugDNA.21421.1.S1_at RAB3A interacting protein isoform alpha 2 LOC717215 2.88 0.0107 MmugDNA.3747.1.S1_at Transmembrane protein 51 LOC693771 2.88 0.0127 MmugDNA.26393.1.S1_at MOCO sulphurase C-terminal domain containing 2 LOC705543 2.88 0.0080 MmugDNA.22547.1.S1_at transcriptional adaptor 2-like TADA2L 2.87 0.0311 MmugDNA.7154.1.S1_at kelch repeat and BTB (POZ) domain containing 2 KBTBD2 2.87 0.0286 MmugDNA.14782.1.S1_at CG15120-PA LOC715522 2.87 0.0118 MmuSTS.3706.1.S1_at presenilin 2 PSEN2 2.87 0.0715 MmugDNA.15936.1.S1_s_at — — 2.87 0.0067 MmugDNA.39373.1.S1_at putative aminopeptidase Fxna LOC717415 2.87 0.0888 MmugDNA.34782.1.S1_at Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) — 2.87 0.0613 (Keratin-8) (K8) MmugDNA.8649.1.S1_at p300/CBP-associated factor LOC698283 2.87 0.0028 MmugDNA.29427.1.S1_at hypothetical protein LOC702110 LOC702110 2.86 0.0045 MmugDNA.26314.1.S1_at basigin isoform 1 LOC721068 2.86 0.0328 MmugDNA.2721.1.S1_s_at — — 2.86 0.0111 MmugDNA.27358.1.S1_at — — 2.86 0.0056 MmugDNA.15702.1.S1_at — — 2.86 0.0184 MmugDNA.43128.1.S1_at choline kinase alpha isoform a LOC710564 2.86 0.0726 MmuSTS.3669.1.S1_at eyes absent 1 isoform b LOC694364 2.86 0.0024 MmugDNA.31695.1.S1_at Alpha-parvin (Calponin-like integrin-linked kinase-binding LOC703481 2.85 0.0278 protein) (CH-ILKBP) MmugDNA.6693.1.S1_at CG3304-PA, isoform A LOC708497 2.85 0.0432 Mmu.3814.1.S1_at MGC15407-like LOC677698 2.85 0.0073 MmugDNA.8146.1.S1_at ELOVL family member 7, elongation of long chain fatty LOC709866 2.85 0.0008 acids MmugDNA.17821.1.S1_at Protein KIAA1434 LOC719117 2.85 0.0623 MmugDNA.34061.1.S1_s_at glycosyltransferase 28 domain containing 1 LOC706863 2.85 0.0030 MmugDNA.43525.1.S1_at — — 2.85 0.0870 MmugDNA.11817.1.S1_at — — 2.84 0.0015 MmugDNA.10536.1.S1_at — — 2.84 0.0255 MmugDNA.20224.1.S1_at cullin 4B CUL4B 2.84 0.0531 MmugDNA.21065.1.S1_at — — 2.84 0.0726 MmugDNA.11873.1.S1_s_at NEDD4 family-interacting protein 2 (NEDD4 WW domain- NDFIP2 2.84 0.0019 binding protein 5A) (Putative MAPK-activating protein PM04/PM05/PM06/PM07) (Putative NF-kappa-B-activating protein 413) MmugDNA.30250.1.S1_at multiple coiled-coil GABABR1-binding protein LOC722750 2.84 0.0046 MmugDNA.3547.1.S1_at nuclear receptor binding factor 2 LOC697756 2.84 0.0023 MmugDNA.39661.1.S1_at heparan sulfate 2-O-sulfotransferase 1 HS2ST1 2.84 0.0407 MmugDNA.23891.1.S1_at Derlin-3 (Degradation in endoplasmic reticulum protein 3) DERL3 2.84 0.0321 (Der1-like protein 3) (DERtrin-3) MmugDNA.35787.1.S1_at — — 2.83 0.0922 MmugDNA.15859.1.S1_at hypothetical protein LOC709702 LOC709702 2.83 0.0784 MmugDNA.906.1.S1_at tRNA nucleotidyl transferase, CCA-adding, 1 TRNT1 2.83 0.0724 MmugDNA.39895.1.S1_at — — 2.83 0.0492 MmugDNA.12342.1.S1_at — — 2.83 0.0679 MmugDNA.41431.1.S1_at — — 2.83 0.0252 MmugDNA.24761.1.S1_at — — 2.82 0.0013 MmugDNA.8211.1.S1_at — — 2.82 0.0781 MmugDNA.40614.1.S1_at — — 2.82 0.0136 MmugDNA.9573.1.S1_at — — 2.82 0.0541 MmugDNA.36144.1.S1_at G-protein coupled receptor 113 LOC696215 2.82 0.0137 MmugDNA.5429.1.S1_at RNA pseudouridylate synthase domain containing 4 LOC714162 2.82 0.0238 MmugDNA.390.1.S1_at — — 2.82 0.0224 MmuSTS.1860.1.S1_at Homeobox protein CDX-1 (Caudal-type homeobox protein CDX1 2.82 0.0302 1) MmugDNA.15649.1.S1_at — — 2.81 0.0524 MmugDNA.41609.1.S1_at golgi apparatus protein 1 LOC710037 2.81 0.0682 MmugDNA.39981.1.S1_at microtubule associated monoxygenase, calponin and LIM MICAL2 2.81 0.0354 domain containing 2 MmugDNA.41888.1.S1_at UDP glycosyltransferase 8 (UDP-galactose ceramide UGT8 2.81 0.0002 galactosyltransferase) Mmu.1028.1.S1_at Tetraspanin-8 (Tspan-8) (Transmembrane 4 superfamily TSPAN8 2.80 0.0037 member 3) (Tumor-associated antigen CO-029) MmugDNA.40411.1.S1_at — — 2.80 0.0431 MmugDNA.6270.1.S1_at — — 2.80 0.0207 MmugDNA.3465.1.S1_at — — 2.80 0.0758 MmugDNA.28869.1.S1_s_at follicular lymphoma variant translocation 1 LOC700476 2.80 0.0299 MmugDNA.17877.1.S1_at — — 2.80 0.0198 MmugDNA.43133.1.S1_at Nucleoside diphosphate kinase homolog 5 (NDK-H 5) (NDP LOC713837 2.80 0.0119 kinase homolog 5) (nm23-H5) (Testis-specific nm23 homolog) (Inhibitor of p53-induced apoptosis-beta) (IPIA- beta) MmugDNA.38316.1.S1_at family with sequence similarity 20, member A LOC718937 2.80 0.0064 MmugDNA.28033.1.S1_at SID1 transmembrane family, member 1 SIDT1 2.80 0.0014 MmugDNA.29959.1.S1_at transducin-like enhancer protein 4 TLE4 2.80 0.0125 MmugDNA.11210.1.S1_s_at protocadherin gamma subfamily A, 12 isoform 2 precursor LOC702071 2.79 0.0187 MmuSTS.1312.1.S1_at DnaJ (Hsp40) homolog, subfamily C, member 6 LOC698682 2.79 0.0716 MmugDNA.19131.1.S1_at BTB (POZ) domain containing 4 BTBD4 2.79 0.0448 MmugDNA.26541.1.S1_at fibronectin type III domain containing 4 LOC702098 2.79 0.0462 MmugDNA.11140.1.S1_at notch homolog 5 LOC694004 2.79 0.0549 MmugDNA.20304.1.S1_at modulator of apoptosis 1 LOC707922 /// 2.79 0.0003 LOC708231 MmugDNA.8309.1.S1_at — — 2.79 0.0744 MmugDNA.35571.1.S1_at transposon-derived Buster3 transposase-like LOC695905 2.79 0.0239 MmuSTS.3190.1.S1_at — — 2.78 0.0062 MmugDNA.31552.1.S1_at CG18769-PB, isoform B LOC698670 2.78 0.0044 MmugDNA.11968.1.S1_at — — 2.78 0.0831 MmugDNA.31850.1.S1_at START domain containing 4, sterol regulated LOC706654 2.78 0.0281 MmugDNA.26580.1.S1_at TGF beta receptor associated protein -1 LOC713102 2.78 0.0062 MmugDNA.39053.1.S1_at — — 2.78 0.0250 MmugDNA.13898.1.S1_at — — 2.78 0.0892 Mmu.15592.2.S1_at phosphatidylinositol glycan, class F isoform 1 LOC714844 2.78 0.0019 MmugDNA.29438.1.S1_at — — 2.78 0.0522 MmugDNA.13438.1.S1_at CG11670-PA LOC701685 2.77 0.0273 MmugDNA.33828.1.S1_at hypothetical protein LOC693883 LOC693883 2.77 0.0613 MmugDNA.12035.1.S1_at — — 2.77 0.0187 MmugDNA.28591.1.S1_s_at taspase 1 TASP1 2.77 0.0529 MmugDNA.29219.1.S1_at — — 2.77 0.0025 MmugDNA.17221.1.S1_at hypothetical protein LOC719100 LOC719100 2.77 0.0461 Mmu.2523.1.S1_at legumain LGMN 2.76 0.0855 MmugDNA.14436.1.S1_at — — 2.76 0.0851 MmugDNA.12446.1.S1_at — — 2.76 0.0162 MmugDNA.24601.1.S1_at — — 2.76 0.0027 MmugDNA.7915.1.S1_at — — 2.76 0.0117 MmugDNA.35603.1.S1_at Sortilin precursor (Neurotensin receptor 3) (NTR3) (NT3) SORT1 2.75 0.0309 (Glycoprotein 95) (Gp95) (100 kDa NT receptor) MmugDNA.36573.1.S1_at CTCL tumor antigen se57-1 LOC694841 2.75 0.0207 MmuSTS.2972.1.S1_at lipase A precursor LOC695240 2.75 0.0071 MmuSTS.3122.1.S1_at myosin VIIA and Rab interacting protein LOC717173 2.74 0.0042 MmugDNA.26602.1.S1_at nuclear factor of activated T-cells, cytosolic component 1 LOC698089 2.74 0.0049 isoform C MmuSTS.1119.1.S1_at secreted modular calcium-binding protein 2 LOC703155 2.74 0.0582 MmugDNA.38654.1.S1_at — — 2.74 0.0116 MmugDNA.24367.1.S1_at islet cell autoantigen 1 LOC695889 2.74 0.0417 MmugDNA.7470.1.S1_at — — 2.74 0.0823 MmugDNA.21317.1.S1_at spermatid perinuclear RNA-binding protein LOC695402 2.74 0.0240 MmugDNA.36894.1.S1_at dehydrogenase/reductase (SDR family) member 7 DHRS7 2.74 0.0004 MmuSTS.3892.1.S1_at sphingomyelin phosphodiesterase 1, acid lysosomal SMPD1 2.73 0.0291 MmuSTS.3004.1.S1_at mutS homolog 3 MSH3 2.73 0.0912 MmugDNA.18199.1.S1_at unc-13 homolog D LOC704431 2.73 0.0133 MmugDNA.32264.1.S1_at G protein-coupled receptor 126 alpha 2 LOC706017 2.73 0.0429 MmuSTS.2507.1.S1_at GTP binding protein 1 GTPBP1 2.73 0.0496 MmugDNA.22747.1.S1_at tripartite motif-containing 2 LOC696517 2.73 0.0162 MmuSTS.1188.1.S1_at phospholipid scramblase 1 LOC713232 2.73 0.0006 MmugDNA.2003.1.S1_at — — 2.73 0.0904 MmugDNA.6213.1.S1_at — — 2.73 0.0031 MmugDNA.27564.1.S1_at Guanine nucleotide-binding protein G(t), alpha-3 subunit LOC708828 2.73 0.0162 (Gustducin alpha-3 chain) MmugDNA.33552.1.S1_at — — 2.73 0.0364 MmuSTS.2414.1.S1_at Guanine nucleotide-binding protein alpha-12 subunit (G LOC699857 2.72 0.0319 alpha-12) MmugDNA.37242.1.S1_at serine/threonine kinase 32A LOC708524 2.72 0.0499 MmuSTS.2307.1.S1_at beta isoform of regulatory subunit B55, protein phosphatase 2 PPP2R2B 2.72 0.0797 MmugDNA.35445.1.S1_at PHD finger protein 7 isoform 1 LOC697103 2.72 0.0380 MmugDNA.31310.1.S1_at CG13902-PA LOC699197 2.72 0.0796 Mmu.13628.1.S1_x_at FGFR1 oncogene partner 2 LOC708905 2.72 0.0287 MmugDNA.34470.1.S1_s_at hypothetical protein LOC708552 LOC708552 2.71 0.0083 MmugDNA.27420.1.S1_at — — 2.71 0.0567 MmugDNA.15282.1.S1_at hypothetical protein LOC711477 LOC711477 2.71 0.0018 MmugDNA.12849.1.S1_at Eukaryotic translation initiation factor 6 (eIF-6) (B4 integrin ITGB4BP 2.71 0.0280 interactor) (CAB) (p27(BBP)) (B(2)GCN homolog) MmugDNA.14244.1.S1_at — — 2.71 0.0049 MmugDNA.25223.1.S1_at CG31803-PA LOC701263 2.71 0.0197 MmugDNA.22504.1.S1_at — — 2.71 0.0906 MmuSTS.3220.1.S1_at v-myb myeloblastosis viral oncogene homolog (avian)-like 1 MYBL1 2.71 0.0824 MmugDNA.13093.1.S1_at hypothetical protein LOC708259 LOC708259 2.71 0.0701 MmugDNA.13057.1.S1_at protease, serine, 36 LOC714626 2.70 0.0599 MmugDNA.9375.1.S1_at — — 2.70 0.0479 MmuSTS.1294.1.S1_at RAP1, GTPase activating protein 1 RAP1GAP 2.70 0.0278 MmugDNA.11685.1.S1_at poly (ADP-ribose) polymerase family, member 8 LOC702637 2.70 0.0995 Mmu.14396.1.S1_at Glutathione S-transferase A1 (GTH1) (HA subunit 1) (GST- — 2.70 0.0140 epsilon) (GSTA1-1) (GST class-alpha) MmugDNA.20427.1.S1_at inosine monophosphate dehydrogenase 1 isoform b LOC701039 2.70 0.0686 MmugDNA.26008.1.S1_at — — 2.70 0.0015 MmugDNA.24890.1.S1_at CG4341-PA LOC698022 2.70 0.0249 MmuSTS.1767.1.S1_at N-myc downstream regulated gene 3 LOC702452 2.70 0.0887 MmugDNA.28653.1.S1_at — — 2.70 0.0331 MmugDNA.11814.1.S1_at zinc finger protein 322A LOC701098 2.70 0.0466 MmugDNA.25299.1.S1_at Small nuclear ribonucleoprotein Sm D1 (snRNP core protein LOC698965 2.70 0.0816 D1) (Sm-D1) (Sm-D autoantigen) MmugDNA.41883.1.S1_at — — 2.70 0.0762 MmugDNA.31230.1.S1_at Fibronectin type-III domain-containing protein 3a LOC705570 2.69 0.0370 MmugDNA.42805.1.S1_at Kinesin-like protein KIF2 LOC696561 2.69 0.0624 MmugDNA.26243.1.S1_at — — 2.69 0.0404 MmugDNA.27058.1.S1_at phosphoribosyl pyrophosphate amidotransferase proprotein LOC694868 2.69 0.0094 MmugDNA.41943.1.S1_at — — 2.69 0.0346 MmugDNA.9762.1.S1_at — — 2.69 0.0721 MmugDNA.22290.1.S1_at brefeldin A-inhibited guanine nucleotide-exchange protein 1 LOC704359 2.69 0.0717 MmugDNA.41355.1.S1_at — — 2.68 0.0676 MmugDNA.37885.1.S1_at homer 1 HOMER1 2.68 0.0925 MmugDNA.38723.1.S1_at a disintegrin and metalloprotease domain 28 isoform 1 LOC710953 2.68 0.0741 MmugDNA.12874.1.S1_at — — 2.68 0.0745 MmugDNA.38436.1.S1_at hypothetical protein LOC695519 LOC695519 2.68 0.0060 MmugDNA.23725.1.S1_at stress 70 protein chaperone, microsome-associated, 60 kDa STCH 2.67 0.0479 MmugDNA.18237.1.S1_at peroxisomal short-chain alcohol dehydrogenase — 2.67 0.0492 Mmu.7752.1.S1_at hypothetical protein LOC704532 LOC704532 2.67 0.0265 Mmu.7453.1.S1_at rabaptin, RAB GTPase binding effector protein 1 LOC711646 2.67 0.0190 MmugDNA.13154.1.S1_at — — 2.67 0.0955 MmugDNA.12949.1.S1_at — — 2.67 0.0394 MmuSTS.2807.1.S1_at solute carrier family 38, member 1 LOC702135 2.67 0.0217 MmugDNA.28465.1.S1_at Transgelin-3 (Neuronal protein NP25) (Neuronal protein 22) TAGLN3 2.67 0.0651 (NP22) MmugDNA.29560.1.S1_at hypothetical protein LOC710681 LOC710681 2.67 0.0154 MmugDNA.16975.1.S1_at — — 2.67 0.0968 MmugDNA.30208.1.S1_at — — 2.66 0.0462 MmugDNA.33379.1.S1_at — — 2.66 0.0063 MmugDNA.29425.1.S1_at B0507.2 LOC704194 2.66 0.0105 MmugDNA.28288.1.S1_at Dual specificity protein phosphatase 3 (Dual specificity DUSP3 2.66 0.0224 protein phosphatase VHR) MmugDNA.15303.1.S1_s_at ninein isoform 5 LOC709532 2.65 0.0437 MmugDNA.29050.1.S1_at — — 2.65 0.0291 MmunewRS.265.1.S1_at kin of IRRE like 3 LOC714534 2.65 0.0267 MmugDNA.24675.1.S1_at — — 2.65 0.0414 MmugDNA.8597.1.S1_at — — 2.65 0.0379 MmugDNA.10005.1.S1_at pre-B-cell leukemia transcription factor interacting protein 1 LOC717036 2.65 0.0501 MmugDNA.951.1.S1_at — — 2.65 0.0297 MmugDNA.35108.1.S1_at secretory carrier membrane protein 5 LOC710454 2.64 0.0103 MmugDNA.13757.1.S1_at Placenta-specific gene 8 protein (C15 protein) PLAC8 2.64 0.0186 MmugDNA.30027.1.S1_at hypothetical protein LOC695033 LOC695033 2.64 0.0128 MmugDNA.7760.1.S1_at — — 2.64 0.0072 MmugDNA.21589.1.S1_at protocadherin beta 4 PCDHB4 2.64 0.0703 Mmu.9306.1.S1_at growth factor receptor-bound protein 2 isoform 2 LOC702041 2.63 0.0360 MmugDNA.11105.1.S1_at centaurin, gamma 2 isoform 2 LOC693652 2.63 0.0244 MmugDNA.26258.1.S1_at — — 2.63 0.0637 Mmu.14771.1.S1_at calcipressin 1 isoform c LOC697108 2.63 0.0245 MmugDNA.30706.1.S1_at — — 2.63 0.0016 MmugDNA.37595.1.S1_s_at mortality factor 4 like 1 isoform b LOC711357 2.63 0.0734 MmugDNA.42160.1.S1_at — — 2.63 0.0710 MmugDNA.34056.1.S1_at RAP1 interacting factor 1 LOC694817 2.63 0.0344 MmugDNA.40644.1.S1_at solute carrier family 41 member 1 LOC696944 2.62 0.0135 MmugDNA.43211.1.S1_at IBR domain containing 1 LOC716647 2.62 0.0077 MmugDNA.32694.1.S1_at tumor necrosis factor, alpha-induced protein 8 LOC700778 2.62 0.0399 MmugDNA.22014.1.S1_at golgi autoantigen, golgin subfamily a, 7 LOC709911 2.62 0.0044 MmugDNA.32609.1.S1_at — — 2.61 0.0756 MmugDNA.28006.1.S1_at minichromosome maintenance protein domain containing 1 LOC714711 2.61 0.0293 MmugDNA.21156.1.S1_at — — 2.61 0.0666 MmuSTS.2808.1.S1_s_at chromobox homolog 3 — 2.61 0.0714 MmugDNA.14756.1.S1_at hypothetical protein LOC694136 LOC694136 2.61 0.0658 MmuSTS.4364.1.S1_at sterol O-acyltransferase (acyl-Coenzyme A: cholesterol SOAT1 2.61 0.0632 acyltransferase) 1 MmugDNA.34121.1.S1_at pappalysin 2 PAPPA2 2.60 0.0655 MmugDNA.3334.1.S1_at sidekick homolog 1 LOC719431 2.60 0.0565 MmugDNA.14892.1.S1_at iduronate-2-sulfatase IDS 2.60 0.0535 MmugDNA.39834.1.S1_s_at — — 2.60 0.0269 MmugDNA.16052.1.S1_at SEC10 protein EXOC5 2.60 0.0882 MmugDNA.10569.1.S1_at Golgin subfamily A member 1 (Golgin-97) LOC693285 2.60 0.0126 MmugDNA.10679.1.S1_at vacuolar H+ ATPase G1 LOC699522 2.60 0.0027 MmugDNA.1854.1.S1_at ankyrin repeat domain 20 family, member A2 LOC707318 2.60 0.0773 MmugDNA.23815.1.S1_at — — 2.59 0.0204 Mmu.7599.1.S1_at smooth muscle cell associated protein 5 LOC706656 2.59 0.0065 MmugDNA.14931.1.S1_at syntaxin 7 LOC701269 2.59 0.0544 MmugDNA.13732.1.S1_at — — 2.59 0.0529 MmugDNA.4660.1.S1_at — — 2.59 0.0470 MmugDNA.23822.1.S1_s_at cell adhesion molecule 1 CADM1 2.59 0.0163 MmugDNA.37623.1.S1_at protein tyrosine phosphatase, receptor type, G precursor LOC703937 2.59 0.0246 MmugDNA.32519.1.S1_at — — 2.58 0.0279 MmugDNA.13687.1.S1_at — — 2.58 0.0779 MmuSTS.4721.1.S1_at thyroid hormone receptor interactor 11 LOC697489 2.58 0.0012 MmugDNA.21480.1.S1_at — — 2.58 0.0742 MmugDNA.13466.1.S1_at activating transcription factor 6 LOC720056 2.58 0.0029 MmuSTS.3905.1.S1_at recoverin LOC717807 2.57 0.0728 MmuSTS.1760.1.S1_at alpha-N-acetylgalactosaminidase NAGA 2.57 0.0040 MmugDNA.9095.1.S1_at — — 2.57 0.0102 MmugDNA.535.1.S1_at — — 2.57 0.0131 MmugDNA.22662.1.S1_at — — 2.57 0.0151 MmugDNA.42675.1.S1_at transforming growth factor, beta 2 LOC707540 2.57 0.0522 MmugDNA.6958.1.S1_at — — 2.57 0.0725 MmugDNA.2631.1.S1_at Tetraspanin-6 (Tspan-6) (Transmembrane 4 superfamily LOC703166 2.57 0.0170 member 6) (T245 protein) (Tetraspanin TM4-D) (A15 homolog) MmugDNA.13189.1.S1_at CG10233-PA, isoform A LOC706860 2.57 0.0238 Mmu.14100.1.S1_at hypothetical protein LOC716612 LOC716612 2.56 0.0589 MmugDNA.37486.1.S1_at — — 2.56 0.0030 MmugDNA.6803.1.S1_at — — 2.56 0.0676 MmugDNA.20096.1.S1_at tropomodulin 3 (ubiquitous) TMOD3 2.56 0.0158 MmugDNA.4732.1.S1_at — — 2.56 0.0239 MmugDNA.3551.1.S1_at Y73F8A.5 LOC697670 2.56 0.0018 MmugDNA.11777.1.S1_at — — 2.56 0.0022 MmugDNA.6129.1.S1_at solute carrier family 25, member 35 LOC721965 2.56 0.0343 MmuSTS.1392.1.S1_at — — 2.55 0.0039 MmugDNA.33992.1.S1_at PTPRF interacting protein alpha 1 PPFIA1 2.55 0.0925 MmuSTS.1581.1.S1_at IQ motif containing GTPase activating protein 2 IQGAP2 2.55 0.0393 MmugDNA.32972.1.S1_at — — 2.55 0.0061 MmuSTS.1848.1.S1_at resistance to inhibitors of cholinesterase 8B isoform 2 LOC703061 2.55 0.0576 MmugDNA.12186.1.S1_at protein tyrosine phosphatase-like (proline instead of — 2.55 0.0353 catalytic arginine), member b MmugDNA.10635.1.S1_at Hypothetical protein LOC717382 — 2.54 0.0303 MmugDNA.7743.1.S1_at hypothetical protein LOC694489 LOC694489 2.54 0.0909 MmugDNA.22818.1.S1_at LOC57821 LOC700803 2.54 0.0571 MmugDNA.28543.1.S1_at ubiquitin specific protease 46 LOC698618 2.54 0.0001 MmugDNA.7920.1.S1_at synaptosomal-associated protein 29 LOC696708 2.53 0.0316 MmugDNA.41817.1.S1_at — — 2.53 0.0047 MmugDNA.33998.1.S1_at CG9240-PA /// hypothetical protein LOC718215 LOC696105 /// 2.53 0.0613 LOC718215 MmuSTS.4005.1.S1_at thrombospondin 2 precursor LOC708165 2.53 0.0700 MmugDNA.7442.1.S1_at NAD(P) dependent steroid dehydrogenase-like LOC714229 2.53 0.0286 MmugDNA.37241.1.S1_at hypothetical protein LOC704834 LOC704834 2.53 0.0785 MmugDNA.18544.1.S1_at MAPK/MAK/MRK overlapping kinase RAGE 2.52 0.0619 MmugDNA.14567.1.S1_at CGI-01 protein isoform 1 LOC704943 2.52 0.0722 MmugDNA.39392.1.S1_at Tumor necrosis factor receptor superfamily member 19L LOC718143 2.52 0.0339 precursor (Receptor expressed in lymphoid tissues) MmugDNA.36135.1.S1_at — — 2.52 0.0009 MmugDNA.38008.1.S1_at asparaginase-like 1 protein LOC718871 2.52 0.0079 MmugDNA.894.1.S1_at — — 2.52 0.0553 MmugDNA.9940.1.S1_s_at — — 2.52 0.0117 MmugDNA.30902.1.S1_at zinc finger protein 452 LOC708122 2.52 0.0174 MmunewRS.671.1.S1_at — — 2.51 0.0611 MmugDNA.29345.1.S1_at Golgi-localized syntaphilin-related protein isoform C LOC699436 2.51 0.0454 MmuSTS.1714.1.S1_s_at muscle-type acylphosphatase 2 LOC716728 2.51 0.0007 MmugDNA.17463.1.S1_at hypothetical protein LOC696917 LOC696917 2.51 0.0447 MmuSTS.4655.1.S1_at 2′,5′-oligoadenylate synthetase 1 OAS1 2.51 0.0103 MmugDNA.2445.1.S1_at — — 2.51 0.0229 MmuSTS.2654.1.S1_at ATP-binding cassette, sub-family A member 3 LOC696496 2.51 0.0198 MmugDNA.10791.1.S1_at Coiled-coil domain-containing protein 11 LOC700084 2.50 0.0645 MmugDNA.30349.1.S1_at Transmembrane protein 33 (DB83 protein) TMEM33 2.50 0.0047 MmugDNA.8272.1.S1_at — — 2.50 0.0928 MmuSTS.3815.1.S1_at ATPase, H+ transporting, lysosomal accessory protein 1 ATP6AP1 2.50 0.0128 MmugDNA.16292.1.S1_at transmembrane protein 56 LOC709729 2.50 0.0116 MmugDNA.33608.1.S1_at jumonji domain containing 1B LOC716648 2.50 0.0832 MmugDNA.20325.1.S1_s_at Kruppel-like factor 3 (basic) KLF3 2.50 0.0533 MmugDNA.36544.1.S1_at — — 2.50 0.0239 MmugDNA.18568.1.S1_s_at coiled-coil domain containing 64 LOC698147 2.50 0.0156 MmuSTS.1282.1.S1_at retinoic acid induced 2 LOC693329 2.50 0.0020 MmugDNA.16604.1.S1_at — — 2.50 0.0753 MmugDNA.2019.1.S1_at — — 2.50 0.0009 MmugDNA.15319.1.S1_at EH-domain containing 3 LOC705316 2.49 0.0546 MmuSTS.3025.1.S1_at — — 2.49 0.0259 MmugDNA.4609.1.S1_at sparc/osteonectin, cwcv and kazal-like domains SPOCK1 2.49 0.0876 proteoglycan 1 MmugDNA.26967.1.S1_at ROD1 regulator of differentiation 1 LOC711210 2.49 0.0050 MmugDNA.37971.1.S1_at heat shock 70 kDa protein 4 isoform a LOC709585 2.49 0.0242 MmuSTS.3404.1.S1_at — — 2.49 0.0276 MmugDNA.2456.1.S1_at CG14185-PA LOC698952 2.49 0.0639 Mmu.4703.1.S1_at — — 2.49 0.0143 MmugDNA.16581.1.S1_at calponin 3 LOC709538 2.49 0.0128 MmugDNA.6.1.S1_at secretogranin III LOC694089 2.49 0.0059 MmuSTS.1273.1.S1_at doublecortin and CaM kinase-like 1 LOC722071 2.49 0.0570 MmugDNA.39606.1.S1_at DNAJ domain-containing LOC700339 2.48 0.0702 MmugDNA.32745.1.S1_at — — 2.48 0.0016 MmugDNA.5221.1.S1_at — — 2.48 0.0528 MmugDNA.13152.1.S1_at — — 2.48 0.0168 MmugDNA.27246.1.S1_s_at leucine rich repeat containing 16 LOC694909 2.48 0.0648 MmuSTS.3254.1.S1_at semaphorin 3A LOC708263 2.47 0.0730 MmugDNA.12122.1.S1_s_at — — 2.47 0.0389 MmugDNA.29872.1.S1_at GTPase activating Rap/RanGAP domain-like 1 isoform 1 LOC695674 2.47 0.0024 MmugDNA.34800.1.S1_at — — 2.47 0.0944 MmugDNA.25958.1.S1_at DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 57 LOC713523 2.47 0.0649 MmugDNA.32735.1.S1_at hypothetical protein LOC702345 LOC702345 2.47 0.0058 MmugDNA.17104.1.S1_at — — 2.47 0.0822 MmugDNA.15497.1.S1_at Hypothetical protein LOC708044 — 2.47 0.0563 MmugDNA.13708.1.S1_at — — 2.47 0.0398 MmugDNA.35844.1.S1_at Protein C10orf57 homolog LOC701130 2.47 0.0547 MmugDNA.3000.1.S1_at signal sequence receptor gamma subunit LOC706518 2.47 0.0144 MmugDNA.18159.1.S1_at bone morphogenetic protein receptor type II BMPR2 2.47 0.0575 Mmu.10229.1.S1_at CD46 molecule, complement regulatory protein CD46 2.47 0.0654 MmugDNA.13343.1.S1_at erythrocyte protein band 4.1-like 1 isoform L LOC710697 2.47 0.0020 MmugDNA.32527.1.S1_at mitogen-activated protein kinase kinase kinase 7 interacting LOC696875 2.46 0.0710 protein 2 MmugDNA.8354.1.S1_at HGFL protein LOC716694 2.46 0.0605 MmugDNA.32803.1.S1_at hypothetical protein LOC717255 LOC717255 2.46 0.0654 MmugDNA.25652.1.S1_at netrin-G1 ligand LOC698610 2.46 0.0244 MmugDNA.39872.1.S1_at parathyroid hormone-responsive B1 isoform 2 LOC708412 2.46 0.0721 MmugDNA.13779.1.S1_at protein kinase C and casein kinase substrate in neurons 3 LOC713919 2.46 0.0997 MmugDNA.11262.1.S1_at — — 2.46 0.0172 MmugDNA.11097.1.S1_at Ribonuclease K6 precursor (RNase K6) — 2.46 0.0658 MmugDNA.13830.1.S1_at — — 2.45 0.0381 MmugDNA.20861.1.S1_at spermatogenesis associated 13 LOC721468 2.45 0.0640 MmuSTS.2607.1.S1_at citrate synthase precursor, isoform a — 2.45 0.0385 MmugDNA.15111.1.S1_at — — 2.45 0.0528 MmuSTS.2246.1.S1_at phospholipase C, gamma 2 (phosphatidylinositol-specific) PLCG2 2.45 0.0006 MmugDNA.17805.1.S1_at solute carrier family 9 (sodium/hydrogen exchanger), LOC712199 2.45 0.0407 isoform 2 MmugDNA.19536.1.S1_at — — 2.45 0.0378 MmugDNA.17107.1.S1_at mitogen-activated protein kinase 1 MAPK1 2.44 0.0344 MmugDNA.24092.1.S1_at hypothetical protein LOC708570 LOC708570 2.44 0.0745 MmugDNA.14738.1.S1_at TRAF2 and NCK interacting kinase TNIK 2.44 0.0358 MmugDNA.5147.1.S1_s_at Kelch repeat and BTB domain-containing protein 4 (BTB LOC711452 2.44 0.0121 and kelch domain-containing protein 4) MmugDNA.6438.1.S1_at nudix (nucleoside diphosphate linked moiety X)-type motif LOC707828 2.44 0.0458 21 MmugDNA.17791.1.S1_at — — 2.44 0.0445 MmugDNA.19209.1.S1_s_at Neutrophil gelatinase-associated lipocalin precursor (NGAL) LOC697208 2.44 0.0703 (p25) (25 kDa alpha-2-microglobulin-related subunit of MMP-9) (Lipocalin-2) (Oncogene 24p3) MmugDNA.20574.1.S1_at v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene KIT 2.44 0.0258 homolog MmugDNA.35313.1.S1_at hypothetical protein LOC704554 /// adenylate cyclase 9 ADCY9 /// 2.44 0.0330 LOC704554 MmugDNA.20823.1.S1_at — — 2.43 0.0067 MmugDNA.42796.1.S1_at inositol 1,3,4,5,6-pentakisphosphate 2-kinase LOC705937 2.43 0.0129 MmugDNA.17764.1.S1_at CG6678-PA LOC715524 2.43 0.0114 MmugDNA.43422.1.S1_at postsynaptic protein CRIPT LOC714949 2.43 0.0240 MmugDNA.34136.1.S1_at Normal mucosa of esophagus-specific gene 1 protein LOC713440 2.43 0.0780 MmugDNA.30592.1.S1_at transmembrane 9 superfamily member 2 TM9SF2 2.43 0.0017 MmugDNA.27400.1.S1_at mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N- LOC708094 2.43 0.0393 acetylglucosaminyltransferase, isoenzyme A MmuSTS.4839.1.S1_at golgi phosphoprotein 2 LOC715029 2.43 0.0064 Mmu.8934.1.S1_at Alpha- and gamma-adaptin-binding protein p34 LOC711436 2.43 0.0144 MmugDNA.2329.1.S1_at — — 2.43 0.0587 MmugDNA.17344.1.S1_at neurotrophin 3 NTF3 2.42 0.0822 MmugDNA.36340.1.S1_at — — 2.42 0.0398 MmugDNA.21012.1.S1_at rabphilin 3A-like (without C2 domains) — 2.42 0.0932 MmugDNA.17438.1.S1_at — — 2.42 0.0767 MmuSTS.1305.1.S1_at disrupted in renal carcinoma 2 LOC715135 2.42 0.0004 MmuSTS.664.1.S1_at caspase 7 isoform delta LOC697633 2.42 0.0130 MmugDNA.26043.1.S1_at Ataxin-7-like protein 1 LOC698666 2.41 0.0286 MmugDNA.33509.1.S1_at CG11178-PB, isoform B LOC693868 2.41 0.0659 MmugDNA.6922.1.S1_at — — 2.41 0.0385 MmugDNA.31513.1.S1_at ubiquitin specific protease 38 LOC700235 2.41 0.0544 MmuSTS.1706.1.S1_at ATP binding cassette, sub-family A (ABC1), member 13 LOC695208 2.41 0.0215 MmuSTS.415.1.S1_at — — 2.41 0.0183 MmugDNA.5945.1.S1_at CG6729-PA LOC711172 2.41 0.0529 MmugDNA.16172.1.S1_at transmembrane protein 5 TMEM5 2.41 0.0000 MmugDNA.7215.1.S1_at uronyl-2-sulfotransferase LOC697355 2.41 0.0823 MmugDNA.20155.1.S1_at — — 2.41 0.0172 MmugDNA.39588.1.S1_at — — 2.41 0.0526 MmugDNA.1883.1.S1_at EGFR-coamplified and overexpressed protein LOC716151 2.41 0.0004 MmugDNA.2888.1.S1_at HMT1 hnRNP methyltransferase-like 1 PRMT2 2.41 0.0030 MmugDNA.36209.1.S1_at — — 2.40 0.0506 MmugDNA.5649.1.S1_at autocrine motility factor receptor LOC699972 2.40 0.0223 MmugDNA.33055.1.S1_at hypothetical protein LOC696384 LOC696384 2.40 0.0752 MmuSTS.2026.1.S1_at cAMP-dependent protein kinase inhibitor gamma LOC712474 2.40 0.0094 MmugDNA.14045.1.S1_at advillin LOC712581 2.40 0.0001 MmugDNA.35277.1.S1_s_at actin related protein 2/3 complex, subunit 5 LOC699657 2.40 0.0138 MmugDNA.30729.1.S1_s_at golgi reassembly stacking protein 2 LOC694170 2.40 0.0106 MmugDNA.36130.1.S1_at attractin ATRN 2.40 0.0097 MmugDNA.7819.1.S1_at mitogen-activated protein kinase 8 isoform 1 LOC711115 2.39 0.0438 MmugDNA.43615.1.S1_at — — 2.39 0.0695 MmugDNA.25611.1.S1_at phosphodiesterase 6D, cGMP-specific, rod, delta LOC712629 2.39 0.0100 MmugDNA.27560.1.S1_at Hypothetical protein LOC709178 — 2.39 0.0044 MmugDNA.13637.1.S1_at zinc finger protein 135 (clone pHZ-17) LOC706617 2.39 0.0734 MmugDNA.103.1.S1_at PDZ and LIM domain 7 isoform 2 LOC706581 2.39 0.0805 MmugDNA.41605.1.S1_s_at casein kinase II, alpha 1 polypeptide LOC714841 2.39 0.0647 MmuSTS.3945.1.S1_at synaptotagmin I SYT1 2.39 0.0424 MmugDNA.5481.1.S1_at — — 2.39 0.0011 MmugDNA.10940.1.S1_at — — 2.39 0.0516 MmugDNA.9600.1.S1_at regulating synaptic membrane exocytosis 2 isoform 1 LOC694366 2.39 0.0629 MmuSTS.2040.1.S1_at hypothetical protein LOC716045 LOC716045 2.38 0.0203 MmugDNA.5934.1.S1_at — — 2.38 0.0282 MmugDNA.7962.1.S1_at syntaphilin SNPH 2.38 0.0359 MmugDNA.13339.1.S1_at G protein-coupled receptor 178 LOC705039 2.38 0.0053 MmuSTS.1208.1.S1_at trimethyllysine hydroxylase, epsilon TMLHE 2.38 0.0921 MmugDNA.31636.1.S1_at HMT1 hnRNP methyltransferase-like 3 LOC701789 2.38 0.0213 MmugDNA.3222.1.S1_at — — 2.38 0.0317 MmugDNA.38925.1.S1_at CG15021-PA LOC699097 2.38 0.0200 MmugDNA.8848.1.S1_at transmembrane protein 37 LOC695060 2.38 0.0843 MmuSTS.168.1.S1_x_at isopentenyl-diphosphate delta isomerase LOC710052 2.38 0.0011 MmugDNA.10165.1.S1_at Hematological and neurological expressed 1 — 2.38 0.0381 MmugDNA.14296.1.S1_at — — 2.37 0.0118 MmugDNA.26530.1.S1_at hypothetical protein LOC721032 LOC721032 2.37 0.0873 MmugDNA.42344.1.S1_at ADP-ribosylarginine hydrolase ADPRH 2.37 0.0911 MmugDNA.31196.1.S1_at — — 2.37 0.0106 MmugDNA.6107.1.S1_at Juxtaposed with another zinc finger protein 1 LOC697973 2.37 0.0564 MmugDNA.12227.1.S1_at — — 2.37 0.0092 MmugDNA.6506.1.S1_at — — 2.37 0.0548 MmugDNA.33621.1.S1_at zinc finger protein 528 LOC720193 2.37 0.0807 MmugDNA.5483.1.S1_at cell death inducing protein LOC705579 2.37 0.0183 MmugDNA.4206.1.S1_at calcium-activated potassium channel beta 4 subunit LOC717360 2.37 0.0762 MmugDNA.27722.1.S1_at — — 2.37 0.0449 MmugDNA.37306.1.S1_at melanoma antigen family E, 1 LOC705379 2.36 0.0431 MmugDNA.38283.1.S1_at NADPH cytochrome B5 oxidoreductase LOC695553 2.36 0.0419 MmugDNA.9872.1.S1_at lysosomal-associated membrane protein 1 LAMP1 2.36 0.0380 MmugDNA.39305.1.S1_at Fc fragment of IgG binding protein LOC700539 2.36 0.0153 MmugDNA.19557.1.S1_at filamin-binding LIM protein-1 isoform a LOC695727 2.36 0.0284 Mmu.4737.1.S1_at riboflavin kinase LOC704540 2.36 0.0146 MmugDNA.3346.1.S1_at makorin, ring finger protein, 2 LOC697649 2.36 0.0193 MmuSTS.3988.1.S1_at Cathepsin S precursor LOC708080 2.36 0.0054 MmugDNA.38289.1.S1_at WD repeat domain 27 LOC695097 2.36 0.0583 MmugDNA.684.1.S1_at alpha 2 type IX collagen LOC694248 2.36 0.0316 MmugDNA.41344.1.S1_at solute carrier family 4 member 11 LOC718393 2.36 0.0120 MmugDNA.8324.1.S1_at — — 2.35 0.0096 MmugDNA.12588.1.S1_at — — 2.35 0.0199 MmugDNA.36202.1.S1_at — — 2.35 0.0482 MmugDNA.23185.1.S1_at TATA element modulatory factor 1 LOC696619 2.35 0.0108 MmugDNA.12313.1.S1_at CG2943-PA LOC702573 2.35 0.0270 MmugDNA.15670.1.S1_s_at insulysin IDE 2.35 0.0735 MmugDNA.30396.1.S1_at Corneodesmosin precursor (S protein) LOC714553 2.35 0.0729 MmugDNA.12626.1.S1_s_at SWI/SNF-related matrix-associated actin-dependent SMARCA4 2.35 0.0853 regulator of chromatin a4 MmugDNA.20551.1.S1_at discoidin, CUB and LCCL domain containing 1 DCBLD1 2.35 0.0001 MmugDNA.19751.1.S1_at ADP-ribosylhydrolase like 1 isoform 1 LOC697842 2.34 0.0761 MmugDNA.5198.1.S1_at uncharacterized protein family UPF0227 member LOC717757 2.34 0.0500 RGD1359682 MmugDNA.28177.1.S1_s_at hypothetical protein LOC712492 LOC712492 2.34 0.0330 MmugDNA.14571.1.S1_s_at phosphatidylinositol glycan, class T precursor LOC710556 2.34 0.0061 Mmu.15853.1.S1_x_at ADP-ribosylation-like factor 6 interacting protein 5 LOC696360 2.34 0.0344 MmuSTS.255.1.S1_at non-imprinted in Prader-Willi/Angelman syndrome 1 LOC710236 2.34 0.0619 MmugDNA.10012.1.S1_at transmembrane protein 16D LOC695973 2.34 0.0997 MmugDNA.19562.1.S1_at zinc finger protein 406 isoform ZFAT-1 LOC698512 2.34 0.0839 MmugDNA.22652.1.S1_s_at — — 2.34 0.0641 MmugDNA.29515.1.S1_at splicing factor, arginine/serine-rich 14 LOC719666 2.34 0.0382 MmugDNA.17884.1.S1_at Nuclear respiratory factor 1 (NRF-1) (Alpha palindromic- LOC701933 2.34 0.0353 binding protein) (Alpha-pal) MmugDNA.32746.1.S1_at — — 2.34 0.0282 MmuSTS.1396.1.S1_s_at zinc finger, MYND domain containing 11 ZMYND11 2.34 0.0128 MmugDNA.18506.1.S1_at basic beta 1 syntrophin LOC703245 2.33 0.0093 MmugDNA.26826.1.S1_s_at solute carrier family 11 (proton-coupled divalent metal ion SLC11A1 2.33 0.0675 transporters), member 1 MmugDNA.38731.1.S1_at steroid 5 alpha-reductase 2-like LOC696381 2.33 0.0646 MmugDNA.27590.1.S1_at — — 2.33 0.0789 MmugDNA.17575.1.S1_at — — 2.33 0.0623 MmugDNA.17935.1.S1_at — — 2.33 0.0075 MmugDNA.22419.1.S1_at — — 2.33 0.0972 MmugDNA.23057.1.S1_at — — 2.33 0.0060 MmugDNA.41434.1.S1_at gamma-glutamyl hydrolase precursor LOC700747 2.33 0.0384 MmugDNA.17895.1.S1_at — — 2.33 0.0135 MmugDNA.23827.1.S1_at hypothetical protein LOC699699 LOC699699 2.33 0.0944 MmugDNA.10050.1.S1_at — — 2.33 0.0710 Mmu.2224.1.A1_at — — 2.32 0.0001 Mmu.12870.1.S1_at thymic dendritic cell-derived factor 1 TMEM59 2.32 0.0246 MmugDNA.19523.1.S1_at CD164 antigen, sialomucin CD164 2.32 0.0019 MmugDNA.22579.1.S1_at Growth-arrest-specific protein 7 (GAS-7) LOC717827 2.32 0.0431 MmuSTS.2905.1.S1_at Pre-B lymphocyte protein 3 precursor (VpreB3 protein) VPREB3 2.32 0.0105 (N27C7-2) MmugDNA.41669.1.S1_at apolipoprotein B mRNA editing enzyme, catalytic LOC714993 2.32 0.0081 polypeptide-like 4 (putative) MmugDNA.11443.1.S1_at — — 2.32 0.0432 MmugDNA.18263.1.S1_at zinc finger, DHHC domain containing 9 ZDHHC9 2.32 0.0271 MmuAffx.1008.1.S1_at Glutathione peroxidase 3 precursor (GSHPx-3) (GPx-3) LOC713057 2.32 0.0926 (Plasma glutathione peroxidase) (GSHPx-P) (Extracellular glutathione peroxidase) (GPx-P) MmugDNA.22975.1.S1_at hydroxysteroid dehydrogenase like 1 LOC714962 2.31 0.0247 MmugDNA.35709.1.S1_at calsyntenin 2 LOC715514 2.31 0.0056 MmugDNA.14527.1.S1_at F-box only protein 2 LOC722738 2.31 0.0601 MmugDNA.35626.1.S1_s_at Ras association (RalGDS/AF-6) domain family 6 isoform a LOC704459 2.31 0.0137 MmuSTS.2492.1.S1_at zinc finger protein 509 LOC712422 2.31 0.0239 MmuSTS.3145.1.S1_at nodal modulator 2 isoform 2 LOC714226 2.31 0.0001 MmuSTS.3540.1.S1_at p21-activated kinase 3 PAK3 2.31 0.0898 MmugDNA.15593.1.S1_at lysosomal acid phosphatase 2 ACP2 2.31 0.0605 MmugDNA.18121.1.S1_at — — 2.31 0.0029 MmugDNA.39434.1.S1_at — — 2.31 0.0976 MmugDNA.25583.1.S1_at PDZ domain containing 8 LOC709084 2.31 0.0851 MmugDNA.38757.1.S1_at — — 2.31 0.0970 MmugDNA.10667.1.S1_at ribophorin II precursor LOC708971 2.30 0.0244 MmugDNA.22894.1.S1_at cellular modulator of immune recognition LOC708030 2.30 0.0097 MmuSTS.4136.1.S1_at enolase 2 ENO2 2.30 0.0000 MmunewRS.108.1.S1_at RNA binding motif protein 18 LOC698457 2.30 0.0318 MmugDNA.13579.1.S1_at — — 2.30 0.0823 MmugDNA.13215.1.S1_at myosin VB MYO5B 2.30 0.0008 MmuSTS.3395.1.S1_at T16G12.5 LOC704499 2.30 0.0158 MmugDNA.3907.1.S1_at — — 2.30 0.0862 MmugDNA.26180.1.S1_at — — 2.29 0.0769 MmugDNA.37638.1.S1_at Hypothetical protein LOC721042 — 2.29 0.0189 MmuSTS.4204.1.S1_at growth arrest-specific 8 GAS8 2.29 0.0119 MmuSTS.1320.1.S1_at Calcipressin-2 (Thyroid hormone-responsive protein ZAKI-4) DSCR1L1 2.29 0.0211 (Down syndrome candidate region 1-like 1) (Myocyte- enriched calcineurin-interacting protein 2) (MCIP2) MmuSTS.1142.1.S1_at pleiomorphic adenoma gene-like 1 isoform 2 LOC699985 2.29 0.0086 MmuSTS.1514.1.S1_at — — 2.29 0.0218 MmuSTS.629.1.S1_at insulin-like growth factor 2 receptor IGF2R 2.29 0.0358 MmugDNA.34704.1.S1_at pecanex homolog LOC694094 2.29 0.0679 MmuSTS.2468.1.S1_at DHHC1 protein ZDHHC3 2.29 0.0010 MmugDNA.39065.1.S1_at elongation factor Tu GTP binding domain containing 1 — 2.29 0.0258 MmugDNA.43592.1.S1_at — — 2.29 0.0291 MmugDNA.18594.1.S1_at DNA-directed RNA polymerases I, II, and III 7.0 kDa POLR2K 2.29 0.0182 polypeptide (ABC10-alpha) (RPB7.0) (RPB10alpha) (RPABC4) MmugDNA.22717.1.S1_at — — 2.29 0.0484 MmugDNA.11519.1.S1_at breakpoint cluster region isoform 1 LOC709258 2.28 0.0734 MmugDNA.14224.1.S1_at hypothetical protein LOC715184 LOC715184 2.28 0.0889 MmugDNA.2963.1.S1_at KIAA1900 LOC709276 2.28 0.0527 MmugDNA.41313.1.S1_at Oxytocin-neurophysin 1 precursor (OT-NPI) OXT 2.28 0.0512 MmugDNA.23270.1.S1_at archaemetzincins-2 isoform 1 LOC718462 2.28 0.0394 MmugDNA.7783.1.S1_at solute carrier organic anion transporter family, member 3A1 SLCO3A1 2.28 0.0616 MmugDNA.40350.1.S1_s_at glutamate dehydrogenase 1 GLUD1 2.28 0.0037 MmugDNA.9234.1.S1_at tau tubulin kinase 2 LOC712249 2.27 0.0807 MmugDNA.21304.1.S1_s_at MAX protein isoform c LOC708228 2.27 0.0165 MmuSTS.3238.1.S1_at raft-linking protein RAFTLIN 2.27 0.0108 MmuSTS.1238.1.S1_at serine/threonine protein phosphatase with EF-hand motifs 1 PPEF1 2.27 0.0956 MmugDNA.39116.1.S1_at CDW92 antigen isoform 2 LOC715816 2.27 0.0566 Mmu.924.1.S1_at anaphase promoting complex subunit 13 LOC717294 2.27 0.0128 MmugDNA.33266.1.S1_at — — 2.27 0.0418 MmuSTS.1309.1.S1_at Doublesex- and mab-3-related transcription factor 2 DMRT2 2.27 0.0682 (Doublesex-like 2 protein) (DSXL-2) MmugDNA.34994.1.S1_s_at — — 2.27 0.0940 MmugDNA.42427.1.S1_at — — 2.27 0.0034 MmugDNA.16606.1.S1_s_at synapse-associated protein 97 DLG1 2.27 0.0636 MmugDNA.16402.1.S1_at cyclin M4 LOC710164 2.27 0.0425 MmugDNA.42754.1.S1_at — — 2.27 0.0453 MmugDNA.29639.1.S1_at — — 2.27 0.0957 MmugDNA.4933.1.S1_at — — 2.27 0.0759 MmugDNA.30201.1.S1_at Transcription factor Ovo-like 2 (hOvo2) (Zinc finger protein LOC719066 2.27 0.0162 339) MmugDNA.13664.1.S1_at — — 2.26 0.0969 MmugDNA.11714.1.S1_at transmembrane 6 superfamily member 1 LOC700147 2.26 0.0935 MmuSTS.160.1.S1_at cancer susceptibility candidate 1 LOC707753 2.26 0.0756 MmugDNA.32421.1.S1_at Mediator complex subunit 4 (Mediator of RNA polymerase II LOC704644 2.26 0.0005 transcription subunit 4) (Vitamin D3 receptor-interacting protein complex 36 kDa component) (DRIP36) (Activator- recruited cofactor 36 kDa component) (ARC36) (TRAP/SMCC/PC2 subunit . . . MmugDNA.617.1.S1_at pleckstrin homology domain containing, family H (with LOC713855 2.26 0.0144 MyTH4 domain) member 1 MmugDNA.29286.1.S1_at hypothetical protein LOC708459 LOC708459 2.26 0.0585 MmugDNA.26513.1.S1_at — — 2.26 0.0079 MmugDNA.4207.1.S1_at hypothetical protein LOC695219 LOC695219 2.25 0.0404 Mmu.11792.1.S1_at syntaxin 12 LOC716455 2.25 0.0076 MmugDNA.3187.1.S1_at midline 1 LOC713037 2.25 0.0123 MmuSTS.2358.1.S1_at Reticulon-2 (Neuroendocrine-specific protein-like 1) (NSP- RTN2 2.25 0.0554 like protein 1) (NSPLI) MmugDNA.13865.1.S1_at — — 2.25 0.0808 MmuSTS.1169.1.S1_at carbohydrate (chondroitin 4) sulfotransferase 12 CHST12 2.25 0.0631 MmugDNA.7568.1.S1_at myotubularin related protein 6 MTMR6 2.25 0.0109 MmugDNA.42542.1.S1_at — — 2.25 0.0141 MmuSTS.2722.1.S1_at homer 2 HOMER2 2.25 0.0035 MmugDNA.10742.1.S1_at farnesyl-diphosphate farnesyltransferase 1 FDFT1 2.25 0.0008 MmugDNA.42437.1.S1_at N-ethylmaleimide-sensitive factor attachment protein, alpha LOC717355 2.25 0.0490 MmugDNA.23264.1.S1_at — — 2.25 0.0558 MmugDNA.33445.1.S1_at ring finger protein 180 LOC698166 2.25 0.0840 MmugDNA.31781.1.S1_at vacuolar protein sorting 37C LOC694898 2.25 0.0416 MmugDNA.15898.1.S1_s_at ATPase, H+ transporting, lysosomal 70 kD, V1 subunit A, LOC696878 /// 2.25 0.0009 isoform 1 LOC709958 MmugDNA.29220.1.S1_at mitogen-activated protein kinase kinase kinase 13 LOC701085 2.25 0.0665 MmugDNA.18194.1.S1_at mitogen-activated protein kinase kinase 6 LOC693914 2.25 0.0209 Mmu.10240.1.S1_at ubiquitin C-terminal hydrolase UCH37 LOC712473 2.25 0.0146 MmugDNA.2778.1.S1_at WW, C2 and coiled-coil domain containing 1 LOC720812 2.25 0.0619 MmugDNA.14327.1.S1_at lactamase, beta isoform a LOC705365 2.24 0.0027 MmugDNA.6356.1.S1_at CG14980-PB LOC718128 2.24 0.0083 MmugDNA.41963.1.S1_s_at calcium binding atopy-related autoantigen 1 LOC701131 /// 2.24 0.0120 LOC708654 MmuSTS.357.1.S1_s_at malin LOC704451 2.24 0.0520 MmugDNA.12984.1.S1_at influenza virus NS1A binding protein isoform a LOC714152 2.24 0.0122 MmugDNA.36042.1.S1_at myotubularin-related protein 2 MTMR2 2.24 0.0122 MmugDNA.32344.1.S1_at phosphatidylinositol glycan, class K PIGK 2.24 0.0015 MmuSTS.1829.1.S1_at shroom LOC699613 2.24 0.0312 Mmu.14177.1.S1_at unc-50 homolog UNC50 2.24 0.0511 MmugDNA.17303.1.S1_at — — 2.24 0.0816 MmuSTS.4053.1.S1_at diacylglycerol kinase, iota DGKI 2.24 0.0540 MmugDNA.31861.1.S1_at ADP-ribosylation factor interacting protein 1 isoform 2 LOC697533 2.24 0.0738 MmugDNA.32277.1.S1_at DNA methyltransferase 2 DNMT2 2.24 0.0117 MmugDNA.7347.1.S1_at — — 2.23 0.0783 MmuSTS.242.1.S1_x_at hypothetical protein LOC710534 LOC710534 2.23 0.0769 MmugDNA.29827.1.S1_at — — 2.23 0.0209 MmuSTS.2213.1.S1_at T03G11.3 — 2.23 0.0690 MmugDNA.37378.1.S1_at — — 2.23 0.0285 MmuSTS.3577.1.S1_at protocadherin beta 15 PCDHB15 2.23 0.0039 MmugDNA.39878.1.S1_at CG15528-PA LOC716271 2.23 0.0314 MmugDNA.21179.1.S1_at SEC22 vesicle trafficking protein homolog C isoform b LOC716351 2.23 0.0145 MmuSTS.3806.1.S1_at ADP-ribosylation factor GTPase activating protein 3 LOC711160 2.23 0.0530 MmugDNA.31478.1.S1_at Ras-related protein Rab-33A (Small GTP-binding protein RAB33A 2.23 0.0714 S10) MmugDNA.9384.1.S1_at — — 2.23 0.0215 MmuSTS.3704.1.S1_at protein kinase, X-linked PRKX 2.23 0.0502 MmugDNA.1624.1.S1_at F-box only protein 3 isoform 2 LOC693281 2.22 0.0611 MmugDNA.732.1.S1_at hexosaminidase B HEXB 2.22 0.0224 MmugDNA.12951.1.S1_at zinc finger protein 77 LOC712142 2.22 0.0290 MmugDNA.24637.1.S1_at zinc finger protein HIT-39 LOC710861 2.22 0.0274 MmuSTS.1852.1.S1_at cell division cycle 25A isoform a LOC710858 2.22 0.0331 MmugDNA.34293.1.S1_at UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase 5 B4GALT5 2.22 0.0063 MmuSTS.4187.1.S1_at NAD(P)H: quinone oxidoreductase type 3, polypeptide A2 LOC704519 2.22 0.0262 MmugDNA.42423.1.S1_at — — 2.22 0.0136 MmugDNA.34057.1.S1_at Protein C9orf46 LOC693286 2.22 0.0134 MmugDNA.35491.1.S1_at CG13624-PC, isoform C LOC703459 2.22 0.0168 MmugDNA.22976.1.S1_s_at CG2747-PB, isoform B — 2.22 0.0105 MmuSTS.1422.1.S1_at hypothetical protein LOC721211 LOC721211 2.22 0.0334 MmugDNA.22793.1.S1_at tribbles homolog 2 LOC710966 2.22 0.0901 MmugDNA.40572.1.S1_at fucosidase, alpha-L- 1, tissue FUCA1 2.22 0.0228 MmugDNA.817.1.S1_at proteasome (prosome, macropain) 26S subunit, ATPase 2 LOC722117 2.21 0.0637 MmugDNA.38292.1.S1_at SORCS receptor 1 isoform b LOC693969 2.21 0.0537 MmugDNA.35537.1.S1_at cathepsin L CTSL 2.21 0.0957 MmugDNA.8681.1.S1_at CG14967-PA LOC709307 2.21 0.0675 MmuSTS.3280.1.S1_at calcium channel, voltage-dependent, alpha 2/delta subunit 2 LOC702429 2.21 0.0789 isoform b MmugDNA.38348.1.S1_at adducin 1 (alpha) ADD1 2.21 0.0553 MmugDNA.8155.1.S1_at — — 2.21 0.0001 Mmu.394.1.S1_at — — 2.21 0.0019 Mmu.14589.1.A1_at Secretory carrier membrane protein 1 — 2.21 0.0253 MmugDNA.15428.1.S1_at acetoacetyl-CoA synthetase LOC707015 2.21 0.0296 MmugDNA.2672.1.S1_at — — 2.21 0.0718 Mmu.7319.1.S1_at hypothetical protein LOC698039 LOC698039 2.21 0.0978 Mmu.14167.1.S1_at DNA topoisomerase I LOC697300 2.21 0.0879 MmugDNA.26813.1.S1_at — — 2.20 0.0739 MmugDNA.18358.1.S1_at jumonji domain containing 2B JMJD2B 2.20 0.0264 MmugDNA.30037.1.S1_at hypothetical protein LOC700951 LOC700951 2.20 0.0539 MmugDNA.40481.1.S1_at dynamin binding protein LOC709334 2.20 0.0109 MmugDNA.25680.1.S1_at hypothetical protein LOC702485 LOC702485 2.20 0.0848 MmugDNA.20470.1.S1_at — — 2.20 0.0464 MmugDNA.7063.1.S1_at — — 2.20 0.0848 MmugDNA.37434.1.S1_at karyopherin alpha 1 KPNA1 2.20 0.0119 MmuSTS.2333.1.S1_at Peroxisome assembly factor 1 (PAF-1) (Peroxin-2) LOC701636 2.20 0.0939 (Peroxisomal membrane protein 3) (35 kDa peroxisomal membrane protein) (RING finger protein 72) MmugDNA.17606.1.S1_at BTB (POZ) domain containing 11 isoform 3 /// hypothetical LOC704916 /// 2.20 0.0238 protein LOC705027 LOC705027 MmugDNA.32862.1.S1_at zinc finger protein 174 ZNF174 2.20 0.0684 MmugDNA.2565.1.S1_at — — 2.20 0.0079 MmugDNA.35698.1.S1_at — — 2.20 0.0366 MmugDNA.23911.1.S1_at — — 2.19 0.0292 MmugDNA.21753.1.S1_at — — 2.19 0.0073 MmugDNA.8775.1.S1_at — — 2.19 0.0057 MmugDNA.22114.1.S1_at 5′-methylthioadenosine phosphorylase MTAP 2.19 0.0179 MmuSTS.3163.1.S1_at regulator of G-protein signalling 7 RGS7 2.19 0.0763 MmugDNA.10574.1.S1_at amyloid beta A4 precursor protein-binding, family B, LOC712585 2.19 0.0110 member 1 isoform delta E9 MmugDNA.11741.1.S1_at hypothetical protein LOC694910 LOC694910 2.19 0.0055 MmugDNA.25725.1.S1_at Potassium voltage-gated channel subfamily E member 1 KCNE1 2.19 0.0377 (IKs producing slow voltage-gated potassium channel beta subunit Mink) (Minimal potassium channel) (Delayed rectifier potassium channel subunit IsK) MmugDNA.39110.1.S1_at membrane component chromosome 11 surface marker 1 LOC717473 2.19 0.0812 isoform 1 MmugDNA.2250.1.S1_at hypothetical protein LOC716978 LOC716978 2.19 0.0969 MmugDNA.17877.1.S1_s_at — — 2.19 0.0717 MmugDNA.24132.1.S1_at F16A11.1 LOC703783 2.19 0.0504 MmugDNA.34793.1.S1_at — — 2.19 0.0542 MmugDNA.7971.1.S1_at hypothetical protein LOC719652 LOC719652 2.19 0.0475 MmugDNA.96.1.S1_at — — 2.18 0.0813 MmuSTS.2238.1.S1_at collapsin response mediator protein 1 CRMP1 2.18 0.0048 MmugDNA.17576.1.S1_at p21-activated kinase 1 LOC698585 2.18 0.0691 MmugDNA.42599.1.S1_at acyl-CoA synthetase long-chain family member 5 isoform a LOC696404 2.18 0.0180 MmuSTS.4809.1.S1_at fucosyltransferase 8 FUT8 2.18 0.0898 MmugDNA.33186.1.S1_at kelch-like 20 LOC708546 2.18 0.0022 MmugDNA.39650.1.S1_at multiple coagulation factor deficiency 2 LOC717900 2.18 0.0365 MmugDNA.12193.1.S1_at beta chimerin CHN2 2.18 0.0041 MmugDNA.35302.1.S1_at sterol regulatory element-binding transcription factor 2 LOC712307 2.18 0.0113 MmugDNA.327.1.S1_at — — 2.18 0.0722 MmugDNA.38687.1.S1_at hypothetical protein LOC698137 LOC698137 2.18 0.0558 MmugDNA.7208.1.S1_at seizure related 6 homolog (mouse)-like 2 isoform 2 LOC707244 2.18 0.0767 MmugDNA.16529.1.S1_at twisted gastrulation LOC705804 2.18 0.0004 Mmu.1309.1.S1_at BCL2-associated transcription factor 1 BCLAF1 2.18 0.0898 MmugDNA.42025.1.S1_at — — 2.17 0.0333 MmugDNA.20036.1.S1_at — — 2.17 0.0261 MmugDNA.36083.1.S1_at — — 2.17 0.0019 MmuSTS.4278.1.S1_at secretagogin precursor LOC694072 2.17 0.0504 MmuSTS.4293.1.S1_at CEGP1 protein LOC708152 2.17 0.0095 Mmu.12751.1.S1_at Grancalcin GCA 2.17 0.0079 MmuSTS.4137.1.S1_at ectonucleoside triphosphate diphosphohydrolase 6 ENTPD6 2.17 0.0582 MmugDNA.36157.1.S1_at — — 2.17 0.0466 MmugDNA.40937.1.S1_at hypothetical protein LOC699965 LOC699965 2.17 0.0264 MmugDNA.41687.1.S1_at — — 2.17 0.0243 MmugDNA.32233.1.S1_s_at Transmembrane protein 50B (HCV p7-transregulated TMEM50B 2.17 0.0009 protein 3) MmugDNA.38432.1.S1_at WD repeat and FYVE domain containing 3 isoform 1 LOC706535 2.17 0.0583 MmuSTS.2292.1.S1_at protein phosphatase 1, regulatory (inhibitor) subunit 3F LOC715950 2.17 0.0293 MmugDNA.28838.1.S1_at tumor necrosis factor receptor superfamily, member 25 TNFRSF25 2.17 0.0954 MmugDNA.43442.1.S1_at — — 2.17 0.0092 MmugDNA.40985.1.S1_at — — 2.17 0.0995 MmugDNA.1900.1.S1_s_at — — 2.16 0.0135 Mmu.11367.1.S1_at developmentally regulated protein TPO1 LOC710413 2.16 0.0661 MmugDNA.11644.1.S1_at CG5022-PA LOC711670 2.16 0.0671 MmugDNA.5070.1.S1_at hypothetical protein LOC709015 LOC709015 2.16 0.0456 MmugDNA.34622.1.S1_at B aggressive lymphoma gene PARP9 2.16 0.0894 MmugDNA.28503.1.S1_at — — 2.16 0.0168 MmugDNA.14771.1.S1_s_at — — 2.16 0.0146 MmugDNA.4305.1.S1_at — — 2.16 0.0396 MmugDNA.42501.1.S1_at Dmx-like 2 LOC693954 2.16 0.0536 Mmu.828.1.S1_at leucine rich repeat containing 40 LOC702565 2.16 0.0103 MmugDNA.26452.1.S1_at TRIO and F-actin-binding protein (Protein Tara) (Trio- LOC701241 2.16 0.0659 associated repeat on actin) MmugDNA.14006.1.S1_at methyltransferase 5 domain containing 1 LOC698208 2.16 0.0220 MmugDNA.16489.1.S1_at — — 2.16 0.0929 MmugDNA.33403.1.S1_at WD repeat and SOCS box-containing protein 2 (WSB-2) LOC695359 2.16 0.0010 (CS box-containing WD protein) MmuSTS.3848.1.S1_at Surfeit locus protein 5 LOC714097 2.16 0.0346 MmugDNA.28161.1.S1_at AMIGO protein AMIGO1 2.16 0.0117 Mmu.1020.1.S1_s_at cysteine-rich with EGF-like domains 1 isoform 2 LOC699345 2.15 0.0581 MmugDNA.23895.1.S1_at — — 2.15 0.0568 MmugDNA.34300.1.S1_at — — 2.15 0.0476 MmugDNA.25815.1.S1_at — — 2.15 0.0128 MmuSTS.2538.1.S1_at Interleukin-13 receptor alpha-1 chain precursor (IL-13R- LOC710986 2.15 0.0172 alpha-1) (IL-13RA-1) (CD213a1 antigen) MmugDNA.31245.1.S1_at butyrophilin, subfamily 2, member A2 isoform a LOC699861 2.15 0.0979 MmugDNA.36602.1.S1_at transducin-like enhancer protein 1 LOC707336 2.15 0.0343 MmugDNA.21781.1.S1_at Testis-specific Y-encoded-like protein 3 (TSPY-like 3) LOC712128 2.15 0.0723 Mmu.2576.1.S1_at RING1 and YY1 binding protein LOC694390 2.15 0.0893 MmugDNA.9098.1.S1_at SWI/SNF related, matrix associated, actin dependent SMARCA1 2.15 0.0737 regulator of chromatin, subfamily a, member 1 MmugDNA.14464.1.S1_at ornithine decarboxylase antizyme inhibitor LOC693581 2.15 0.0021 MmugDNA.6468.1.S1_at WD repeat domain 48 LOC695026 2.15 0.0807 MmugDNA.12543.1.S1_at R13A5.9 LOC710476 2.14 0.0209 MmugDNA.35647.1.S1_at BTB and kelch domain containing 3 LOC706382 2.14 0.0185 MmugDNA.18973.1.S1_at nucleobindin 1 LOC718380 2.14 0.0548 MmugDNA.7913.1.S1_at — — 2.14 0.0589 MmugDNA.9254.1.S1_at solute carrier family 35, member C1 SLC35C1 2.14 0.0474 MmuSTS.702.1.S1_at inhibin, beta B (activin AB beta polypeptide) INHBB 2.14 0.0076 MmugDNA.1591.1.S1_at — — 2.14 0.0915 Mmu.8048.1.S1_at protein phosphatase 3 (formerly 2B), catalytic subunit, alpha PPP3CA 2.13 0.0704 isoform (calcineurin A alpha) MmugDNA.19851.1.S1_at — — 2.13 0.0874 MmugDNA.5616.1.S1_at serine/threonine kinase 38 STK38 2.13 0.0148 MmugDNA.4789.1.S1_at TP53-regulating kinase (p53-related protein kinase) (Nori-2) LOC716636 2.13 0.0179 MmugDNA.38238.1.S1_at stearoyl-CoA desaturase (delta-9-desaturase) LOC694079 2.13 0.0088 MmugDNA.14345.1.S1_s_at — — 2.13 0.0164 MmugDNA.17444.1.S1_at nucleoplasmin 2 LOC715448 2.13 0.0571 MmuSTS.4377.1.S1_at — — 2.13 0.0948 MmugDNA.26500.1.S1_at KIAA0564 protein KIAA0564 2.13 0.0336 MmugDNA.4249.1.S1_at — — 2.13 0.0344 MmuSTS.935.1.S1_at talin 2 LOC705008 2.13 0.0652 MmugDNA.33197.1.S1_at — — 2.13 0.0665 MmugDNA.39459.1.S1_at Sec23 (S. cerevisiae) homolog B LOC698440 2.13 0.0020 MmuSTS.3997.1.S1_at — — 2.12 0.0188 Mmu.9557.1.S1_at OTU domain containing 4 protein isoform 1 LOC701837 2.12 0.0798 MmugDNA.14887.1.S1_at Protein NipSnap1 LOC717745 2.12 0.0225 MmugDNA.25767.1.S1_at like-glycosyltransferase LOC717403 2.12 0.0858 MmugDNA.30227.1.S1_at nitric oxide synthase trafficking isoform 1 LOC705063 2.12 0.0210 MmugDNA.29197.1.S1_at hypothetical protein LOC698413 LOC698413 2.12 0.0069 MmugDNA.35367.1.S1_at — — 2.12 0.0045 MmuSTS.1000.1.S1_at myoneurin LOC698094 2.12 0.0044 MmugDNA.27645.1.S1_at hypothetical protein LOC710801 LOC710801 2.12 0.0193 MmugDNA.32669.1.S1_at Sur-8 CG5407-PA, isoform A — 2.12 0.0319 MmugDNA.43367.1.S1_at genetic suppressor element 1 LOC693298 2.12 0.0210 MmugDNA.41452.1.S1_at sperm protein 17 LOC574157 2.12 0.0436 MmugDNA.37832.1.S1_at — — 2.12 0.0135 MmugDNA.33994.1.S1_at unc-5 homolog B LOC715786 2.12 0.0074 MmugDNA.31700.1.S1_at stromal membrane-associated protein 1-like LOC694502 2.12 0.0138 MmugDNA.12779.1.S1_at remodeling and spacing factor 1 LOC699078 2.12 0.0480 MmugDNA.20356.1.S1_at platelet-activating factor acetylhydrolase 2 LOC719750 2.11 0.0689 MmuSTS.1250.1.S1_at cAMP responsive element binding protein-like 2 LOC696952 2.11 0.0786 MmugDNA.1301.1.S1_at InaD-like protein isoform 1 LOC694408 2.11 0.0733 MmugDNA.38366.1.S1_at Eukaryotic translation initiation factor 3 subunit 1 (eIF-3 LOC712295 2.11 0.0343 alpha) MmugDNA.15094.1.S1_at hypothetical protein LOC699533 LOC699533 2.11 0.0073 MmugDNA.24933.1.S1_at hypothetical protein LOC701291 LOC701291 2.11 0.0405 MmugDNA.18451.1.S1_at Peroxiredoxin-4 (Prx-IV) (Thioredoxin peroxidase AO372) LOC697635 2.11 0.0133 (Thioredoxin-dependent peroxide reductase A0372) (Antioxidant enzyme AOE372) (AOE37-2) MmugDNA.30695.1.S1_at — — 2.11 0.0121 MmugDNA.21266.1.S1_s_at sorcin isoform b LOC705215 2.11 0.0255 MmugDNA.41706.1.S1_at — — 2.11 0.0059 MmuSTS.2300.1.S1_at — — 2.11 0.0732 MmuSTS.2136.1.S1_at AXIN1 up-regulated 1 LOC694328 2.10 0.0010 MmugDNA.34250.1.S1_at hypothetical protein LOC697587 LOC697587 2.10 0.0430 MmugDNA.30761.1.S1_at abhydrolase domain containing 10 — 2.10 0.0313 MmugDNA.25568.1.S1_at ligase III, DNA, ATP-dependent LIG3 2.10 0.0203 MmugDNA.41814.1.S1_at Meis1 homolog MEIS1 2.10 0.0730 MmugDNA.23946.1.S1_at — — 2.10 0.0824 MmugDNA.15939.1.S1_at — — 2.10 0.0599 MmuSTS.3941.1.S1_at cell cycle progression 1 isoform 2 LOC698918 2.09 0.0097 MmugDNA.31766.1.S1_at — — 2.09 0.0173 MmugDNA.34607.1.S1_at THAP domain containing 7 LOC693821 2.09 0.0838 Mmu.10002.1.S1_at methionine adenosyltransferase II, alpha MAT2A 2.09 0.0100 MmugDNA.8056.1.S1_at Uteroglobin precursor (Secretoglobin family 1A member 1) LOC718857 2.09 0.0677 (Clara cell phospholipid-binding protein) (CCPBP) (Clara cells 10 kDa secretory protein) (CC10) (Urinary protein 1) (Urine protein 1) (UP1) MmugDNA.8398.1.S1_at odd Oz/ten-m homolog 3 LOC700867 2.09 0.0151 MmugDNA.41504.1.S1_at SUMO1/sentrin/SMT3 specific protease 2 SENP2 2.09 0.0168 MmugDNA.25057.1.S1_s_at WW domain containing E3 ubiquitin protein ligase 2 WWP2 2.09 0.0899 MmugDNA.30167.1.S1_at tumor rejection antigen (gp96) 1 HSP90B1 2.09 0.0317 MmugDNA.23937.1.S1_at — — 2.09 0.0679 MmunewRS.900.1.S1_at — — 2.08 0.0913 Mmu.13707.1.S1_at Transcribed locus, moderately XP_001163736.1 — 2.08 0.0995 prostaglandin-D synthase [Pan troglodytes] MmugDNA.42106.1.S1_at — — 2.08 0.0031 MmugDNA.25377.1.S1_at — — 2.08 0.0867 MmugDNA.33263.1.S1_at amine oxidase, copper containing 2 isoform b LOC711900 2.08 0.0495 Mmu.10780.1.S1_at ATP-binding cassette, sub-family D, member 3 ABCD3 2.08 0.0668 MmugDNA.23614.1.S1_at DDHD domain containing 1 LOC694361 2.08 0.0695 MmugDNA.28356.1.S1_at hypothetical protein LOC715793 LOC715793 2.08 0.0799 MmugDNA.39375.1.S1_at oligonucleotide/oligosaccharide-binding fold containing 1 LOC714968 2.08 0.0397 MmugDNA.17230.1.S1_at ets homologous factor LOC717350 2.08 0.0092 MmugDNA.43483.1.S1_at ubiquitin specific protease 47 USP47 2.07 0.0354 MmuSTS.4574.1.S1_at Alpha-mannosidase IIx (Mannosyl-oligosaccharide 1,3-1,6- MAN2A2 2.07 0.0066 alpha-mannosidase) (MAN IIx) (Mannosidase alpha class 2A member 2) MmugDNA.42098.1.S1_at AP-1 complex subunit sigma-2 (Adapter-related protein LOC713244 2.07 0.0007 complex 1 sigma-1B subunit) (Sigma-adaptin 1B) (Adaptor protein complex AP-1 sigma-1B subunit) (Golgi adaptor HA1/AP1 adaptin sigma-1B subunit) (Clathrin assembly protein complex 1 si . . . MmugDNA.21632.1.S1_at KIAA0368 protein KIAA0368 2.07 0.0077 MmugDNA.8695.1.S1_at — — 2.07 0.0027 MmugDNA.3713.1.S1_at CG14535-PA LOC712374 2.07 0.0672 MmugDNA.32882.1.S1_at Hypothetical protein LOC718964 — 2.07 0.0156 MmugDNA.39148.1.S1_at — — 2.07 0.0379 MmuSTS.2882.1.S1_at TCDD-inducible poly(ADP-ribose) polymerase LOC706180 2.07 0.0051 MmugDNA.6389.1.S1_at — — 2.07 0.0452 MmugDNA.25050.1.S1_at restin RSN 2.07 0.0543 MmugDNA.28737.1.S1_at CG2843-PA LOC695474 2.07 0.0871 MmugDNA.39973.1.S1_at Jade1 protein long isoform LOC693690 2.06 0.0012 Mmu.14041.1.S1_at ubiquitin specific protease 15 USP15 2.06 0.0149 MmugDNA.30790.1.S1_at chromobox homolog 7 CBX7 2.06 0.0331 MmugDNA.35116.1.S1_at kelch-like 12 LOC694420 /// 2.06 0.0120 LOC694548 /// LOC705991 MmugDNA.9677.1.S1_at — — 2.06 0.0871 MmugDNA.16866.1.S1_at Rho guanine nucleotide exchange factor (GEF) 10-like LOC701164 2.06 0.0444 isoform 2 MmugDNA.12243.1.S1_at — — 2.06 0.0214 MmuSTS.1567.1.S1_at diphosphomevalonate decarboxylase MVD 2.06 0.0860 MmuSTS.4422.1.S1_at tripartite motif-containing 36 TRIM36 2.06 0.0017 MmuSTS.3089.1.S1_at latrophilin 1 LPHN1 2.06 0.0754 MmugDNA.3623.1.S1_at CG30497-PA, isoform A LOC714457 2.06 0.0085 MmuSTS.633.1.S1_at apical protein of Xenopus-like APXL 2.06 0.0169 MmuSTS.3572.1.S1_at coronin, actin binding protein, 2B CORO2B 2.06 0.0096 MmugDNA.8806.1.S1_at — — 2.06 0.0017 MmugDNA.15578.1.S1_at — — 2.06 0.0364 MmugDNA.25084.1.S1_at baculoviral IAP repeat-containing 6 BIRC6 2.05 0.0157 MmugDNA.1057.1.S1_at DnaJ (Hsp40) homolog, subfamily A, member 1 DNAJA1 2.05 0.0253 MmugDNA.28429.1.S1_at hypothetical protein LOC716268 LOC716268 2.05 0.0256 MmugDNA.25034.1.S1_at regulator of G-protein signalling 11 isoform 1 LOC694588 2.05 0.0266 MmugDNA.42945.1.S1_at — — 2.05 0.0548 MmugDNA.26306.1.S1_at — — 2.05 0.0580 MmugDNA.17707.1.S1_at — — 2.05 0.0141 MmugDNA.1190.1.S1_at dpy-19-like 1, like LOC699789 /// 2.05 0.0511 LOC707898 /// LOC709323 MmugDNA.32656.1.S1_at axonemal dynein light chain 1 LOC697410 2.05 0.0635 MmugDNA.20986.1.S1_s_at cytochrome P450, family 39, subfamily A, polypeptide 1 LOC704242 2.05 0.0860 MmugDNA.19048.1.S1_at SDA1 domain containing 1 LOC700863 2.05 0.0742 MmugDNA.39253.1.S1_at CDC42 effector protein 5 LOC718922 2.05 0.0045 MmugDNA.14544.1.S1_at — — 2.05 0.0125 MmugDNA.4740.1.S1_at chromosome 2 open reading frame 7 LOC706052 2.04 0.0714 MmugDNA.5141.1.S1_at hypothetical protein LOC715248 LOC715248 2.04 0.0755 MmugDNA.19626.1.S1_at tripartite motif protein 32 (predicted) LOC705563 2.04 0.0199 Mmu.2091.3.S1_x_at HLA class I histocompatibility antigen, A-74 alpha chain LOC699243 /// 2.04 0.0896 precursor (MHC class I antigen A*74) (Aw-74) (Aw-19) /// LOC699987 /// HLA class I histocompatibility antigen, B-38 alpha chain LOC715737 /// precursor (MHC class I antigen B*38) (Bw-4) /// major LOC721022 /// histocom LOC723284 /// LOC723552 /// MAMU-A MmugDNA.40849.1.S1_at 7-dehydrocholesterol reductase DHCR7 2.04 0.0437 MmugDNA.2414.1.S1_at plastin 1 PLS1 2.04 0.0023 MmugDNA.19830.1.S1_at glycoprotein hormone alpha 2 LOC717261 2.04 0.0977 MmugDNA.27493.1.S1_at Rho-guanine nucleotide exchange factor (Rho-interacting LOC703897 2.04 0.0532 protein 2) (RhoGEF) (RIP2) Mmu.1943.1.S1_at Tax1 (human T-cell leukemia virus type I) binding protein 1 LOC698103 2.04 0.0133 MmunewRS.977.1.S1_s_at hypothetical protein LOC719873 LOC719873 2.04 0.0805 MmugDNA.28230.1.S1_at intersex-like LOC698032 2.04 0.0031 MmugDNA.14009.1.S1_s_at 5T4 oncofetal trophoblast glycoprotein LOC693944 2.04 0.0005 MmugDNA.3795.1.S1_at dynactin 4 (p62) DCTN4 2.04 0.0039 MmugDNA.24691.1.S1_at selenoprotein I SELI 2.04 0.0078 MmugDNA.5288.1.S1_at pyridoxine 5′-phosphate oxidase PNPO 2.04 0.0025 MmuSTS.2059.1.S1_at phospholipase C beta 4 isoform a LOC718418 2.04 0.0043 MmugDNA.10284.1.S1_at MORC family CW-type zinc finger 2 MORC2 2.04 0.0531 MmugDNA.22142.1.S1_at — — 2.04 0.0858 MmuSTS.3730.1.S1_at SLIT-ROBO Rho GTPase activating protein 2 SRGAP2 2.04 0.0146 MmugDNA.21501.1.S1_at — — 2.03 0.0030 MmuSTS.4228.1.S1_at dehydrogenase/reductase (SDR family) member 8 DHRS8 2.03 0.0360 MmugDNA.14076.1.S1_s_at tripartite motif-containing 59 LOC704829 2.03 0.0593 MmuSTS.4498.1.S1_at LGP1 homolog LOC709656 2.03 0.0795 MmugDNA.37577.1.S1_at MAM domain containing glycosylphosphatidylinositol anchor 1 LOC719423 2.03 0.0884 MmugDNA.3734.1.S1_at eukaryotic translation initiation factor 5A2 LOC695647 2.03 0.0565 MmugDNA.1893.1.S1_at RNA guanylyltransferase and 5-phosphatase LOC721442 2.03 0.0469 MmugDNA.2395.1.S1_at — — 2.03 0.0090 MmugDNA.8455.1.S1_at tigger transposable element derived 2 LOC706461 2.03 0.0283 MmugDNA.20114.1.S1_at translocating chain-associating membrane protein TRAM1 2.03 0.0380 MmugDNA.442.1.S1_at UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase 4 B3GALT4 2.03 0.0668 MmugDNA.476.1.S1_s_at programmed cell death 6 interacting protein LOC706636 2.03 0.0387 MmugDNA.39070.1.S1_at androgen-induced 1 LOC700988 2.03 0.0113 MmugDNA.38882.1.S1_at hypothetical protein LOC712812 LOC712812 2.03 0.0123 Mmu.6318.1.S1_at family with sequence similarity 18, member B /// Protein FAM18B /// 2.03 0.0170 FAM18B LOC719298 /// LOC723697 Mmu.2050.1.S1_s_at HIG1 domain family member 1A (Hypoxia-inducible gene 1 HIGD1A 2.03 0.0066 protein) MmugDNA.8048.1.S1_at calcium/calmodulin-dependent protein kinase II inhibitor 1 LOC705302 2.02 0.0005 MmugDNA.10177.1.S1_at TNF receptor-associated factor 3 TRAF3 2.02 0.0434 MmuSTS.735.1.S1_at — — 2.02 0.0009 MmugDNA.1551.1.S1_s_at chloride channel 3 isoform c LOC694472 2.02 0.0414 Mmu.7639.1.S1_at signal transducer and activator of transcription 1 STAT1 2.02 0.0894 MmuSTS.2418.1.S1_at — — 2.02 0.0452 MmuSTS.88.1.S1_at — — 2.02 0.0434 MmugDNA.29466.1.S1_at phosphorylase kinase, beta PHKB 2.02 0.0634 MmugDNA.21556.1.S1_at DNA primase large subunit, 58 kDa LOC712921 2.02 0.0187 Mmu.4348.1.S1_at membrane interacting protein of RGS16 LOC694849 2.02 0.0243 MmugDNA.2374.1.S1_at — — 2.02 0.0321 MmugDNA.20015.1.S1_at — — 2.02 0.0683 MmuSTS.1350.1.S1_at — — 2.02 0.0712 MmugDNA.15232.1.S1_at — — 2.02 0.0376 MmugDNA.7589.1.S1_at F-box only protein 24 isoform 1 LOC719216 2.02 0.0212 MmugDNA.12745.1.S1_at integrin, alpha 8 ITGA8 2.02 0.0990 MmugDNA.20321.1.S1_at HIR (histone cell cycle regulation defective, S. cerevisiae) LOC719142 2.02 0.0441 homolog A MmuSTS.2829.1.S1_at — — 2.02 0.0906 MmugDNA.12571.1.S1_at Ras-associated protein Rap1 LOC694037 2.02 0.0243 MmugDNA.34707.1.S1_at slit and trk like 6 LOC699338 2.02 0.0231 MmugDNA.19770.1.S1_at tumor differentially expressed 2-like SERINC2 2.01 0.0493 MmugDNA.18541.1.S1_at RAB guanine nucleotide exchange factor (GEF) 1 LOC695887 2.01 0.0739 MmugDNA.8837.1.S1_at karyopherin alpha 4 KPNA4 2.01 0.0619 MmugDNA.22626.1.S1_at dihydrolipoamide S-acetyltransferase (E2 component of — 2.01 0.0061 pyruvate dehydrogenase complex) MmugDNA.6899.1.S1_at — — 2.01 0.0370 MmugDNA.40422.1.S1_at — — 2.01 0.0545 MmugDNA.12060.1.S1_at UDP-glucose:glycoprotein glucosyltransferase 2 LOC697784 2.01 0.0461 MmugDNA.23452.1.S1_at valosin containing protein (p97)/p47 complex interacting LOC703582 2.01 0.0501 protein 1 MmugDNA.6995.1.S1_at — — 2.01 0.0671 MmugDNA.599.1.S1_at dpy-19-like 3 LOC700921 2.01 0.0681 Mmu.2601.1.S1_at transmembrane emp24 protein transport domain containing 4 LOC699105 2.01 0.0032 MmuSTS.4174.1.S1_at Cathepsin F precursor (CATSF) LOC713743 2.01 0.0025 MmugDNA.26527.1.S1_at zinc finger protein 697 LOC715582 2.01 0.0171 MmunewRS.902.1.S1_at embigin homolog LOC702068 2.01 0.0964 MmugDNA.10114.1.S1_at odd Oz/ten-m homolog 4 LOC701138 2.01 0.0938 MmugDNA.37121.1.S1_at dishevelled-associated activator of morphogenesis 1 LOC701706 2.01 0.0282 MmugDNA.34099.1.S1_at — — 2.00 0.0953 MmugDNA.25664.1.S1_at zinc finger protein 710 LOC701358 2.00 0.0791 MmugDNA.33143.1.S1_at nuclear factor, interleukin 3 regulated LOC704757 2.00 0.0359 MmugDNA.4085.1.S1_at cyclin E1 isoform 1 LOC700589 2.00 0.0203 MmuSTS.749.1.S1_at LysM, putative peptidoglycan-binding, domain containing 1 LOC709539 2.00 0.0752 MmugDNA.24820.1.S1_at casein kinase 1, gamma 3 CSNK1G3 2.00 0.0461 MmugDNA.29470.1.S1_at — — 2.00 0.0098 MmugDNA.19512.1.S1_at tenascin C (hexabrachion) TNC 92.06 0.0005 MmugDNA.6877.1.S1_at ankyrin repeat and sterile alpha motif domain containing 1B LOC694033 37.28 0.0256 MmuSTS.2164.1.S1_s_at BUB1 budding uninhibited by benzimidazoles 1 homolog LOC696598 30.10 0.0998 MmuSTS.355.1.S1_at podoplanin PDPN 29.70 0.0578 MmugDNA.23448.1.S1_at Keratin, type I cytoskeletal 14 (Cytokeratin-14) (CK-14) LOC703932 26.57 0.0038 (Keratin-14) (K14) MmugDNA.1670.1.S1_at cysteine and tyrosine-rich 1 protein precursor LOC708008 25.38 0.0325 MmuSTS.4685.1.S1_at thymidylate synthetase TYMS 24.58 0.0475 MmugDNA.2975.1.S1_at DNA polymerase epsilon subunit 2 LOC707526 24.10 0.0653 MmugDNA.32729.1.S1_at antigen identified by monoclonal antibody Ki-67 MKI67 22.59 0.0758 MmugDNA.33387.1.S1_at T-LAK cell-originated protein kinase PBK 19.75 0.0623 MmuSTS.3275.1.S1_at Probable dimethyladenosine transferase (S- — 19.29 0.0213 adenosylmethionine-6-N,N-adenosyl(rRNA) dimethyltransferase) (18S rRNA dimethylase) MmugDNA.13802.1.S1_at decorin DCN 17.00 0.0183 MmuSTS.4094.1.S1_at endothelin receptor type B EDNRB 16.58 0.0867 MmugDNA.17329.1.S1_at cell division cycle associated 7 LOC696474 16.22 0.0389 MmugDNA.38956.1.S1_at nucleolar and spindle associated protein 1 NUSAP1 15.82 0.0583 MmugDNA.24653.1.S1_at hyaluronan-mediated motility receptor HMMR 14.87 0.0507 MmugDNA.12273.1.S1_at DNA topoisomerase II, alpha isozyme TOP2A 14.45 0.0012 MmugDNA.17571.1.S1_at Repetin LOC712894 14.37 0.0893 MmugDNA.40742.1.S1_at cyclin B2 LOC702184 14.17 0.0157 MmugDNA.36470.1.S1_at kinetochore associated 2 LOC696232 13.85 0.0725 MmugDNA.19272.1.S1_s_at sperm associated antigen 5 SPAG5 13.79 0.0181 MmuSTS.844.1.S1_at lymphocyte-specific protein 1 isoform 1 LOC721048 13.75 0.0307 MmugDNA.25384.1.S1_at Ubiquitin-conjugating enzyme E2 C (Ubiquitin-protein ligase UBE2C 13.38 0.0002 C) (Ubiquitin carrier protein C) (UbcH10) MmuSTS.2303.1.S1_s_at discs large homolog 7 LOC696772 13.04 0.0536 MmuSTS.1203.1.S1_at alpha 1 type XV collagen COL15A1 12.52 0.0022 MmugDNA.11364.1.S1_at forkhead box M1 isoform 3 LOC708805 12.31 0.0691 MmugDNA.18486.1.S1_s_at serine protease inhibitor, Kazal type 2 (acrosin-trypsin LOC693946 12.30 0.0374 inhibitor) MmuSTS.2672.1.S1_at centromere protein F (350/400 kD) LOC709000 12.11 0.0860 MmugDNA.41909.1.S1_at endomucin LOC709580 12.02 0.0215 MmugDNA.24707.1.S1_at Fibroblast growth factor 19 precursor (FGF-19) FGF19 11.99 0.0680 MmugDNA.19464.1.S1_at ubiquitin-like, containing PHD and RING finger domains, 1 LOC695531 11.73 0.0111 MmugDNA.28534.1.S1_at interleukin 1 receptor, type II IL1R2 11.11 0.0247 MmuSTS.3846.1.S1_at sulfotransferase, estrogen-preferring SULT1E1 11.06 0.0880 MmuSTS.1223.1.S1_at periostin, osteoblast specific factor POSTN 10.97 0.0077 MmugDNA.10977.1.S1_at DAZ interacting protein 1 isoform 2 LOC695529 10.94 0.0839 MmugDNA.33823.1.S1_s_at KIAA0101 KIAA0101 10.89 0.0363 MmugDNA.35172.1.S1_at hypothetical protein LOC701037 LOC701037 10.86 0.0896 MmuSTS.1955.1.S1_at baculoviral IAP repeat-containing protein 5 isoform 1 LOC709565 10.69 0.0838 MmugDNA.40509.1.S1_at basonuclin 2 BNC2 10.50 0.0020 MmugDNA.33427.1.S1_at — — 10.41 0.0428 MmuSTS.3136.1.S1_at Regulator of G-protein signaling 5 RGS5 10.29 0.0555 MmugDNA.4481.1.S1_at EGF-containing fibulin-like extracellular matrix protein 1 LOC718984 10.22 0.0021 precursor MmuSTS.2035.1.S1_at platelet-derived growth factor receptor alpha PDGFRA 10.01 0.0496 MmuSTS.3987.1.S1_at — SLC27A3 9.99 0.0105 MmugDNA.8100.1.S1_at polymerase (DNA directed), epsilon POLE 9.87 0.0244 MmugDNA.9037.1.S1_at Nasopharyngeal carcinoma-associated antigen NPC-A-5 — 9.87 0.0936 MmugDNA.33356.1.S1_at development and differentiation enhancing factor 1 LOC695681 9.84 0.0572 MmugDNA.33929.1.S1_at trophinin associated protein (tastin) LOC709931 9.71 0.0772 MmuSTS.4310.1.S1_at histone 1, H2ai (predicted) LOC695891 9.64 0.0566 MmuSTS.2700.1.S1_at E2F transcription factor 7 LOC694423 9.61 0.0927 MmugDNA.9851.1.S1_at arachidonate 15-lipoxygenase ALOX15 9.59 0.0773 MmugDNA.4983.1.S1_at collagen, type XXVII, alpha 1 LOC708451 9.38 0.0390 MmuSTS.2858.1.S1_at SRY (sex determining region Y)-box 15 SOX15 9.38 0.0147 MmunewRS.17.1.S1_at aurora kinase B AURKB 9.35 0.0340 MmuSTS.1534.1.S1_at — KIF20A 9.26 0.0827 MmugDNA.34877.1.S1_at melanoma-associated chondroitin sulfate proteoglycan 4 LOC713086 9.25 0.0703 MmuSTS.1125.1.S1_at snail 2 SNAI2 9.21 0.0089 MmugDNA.37680.1.S1_at WD repeat and HMG-box DNA binding protein 1 WDHD1 9.11 0.0234 MmugDNA.5089.1.S1_at growth factor receptor-bound protein 10 isoform a LOC694786 9.10 0.0634 MmugDNA.40702.1.S1_at enolase superfamily member 1 ENOSF1 9.03 0.0552 Mmu.11047.2.S1_s_at Ig gamma-1 chain C region LOC711303 8.99 0.0572 MmuSTS.4834.1.S1_at glioma-associated oncogene homolog 1 GLI1 8.98 0.0230 MmugDNA.32726.1.S1_at Antigen KI-67 LOC705021 8.97 0.0000 MmugDNA.25678.1.S1_at EGF-like-domain, multiple 9 LOC700106 8.94 0.0026 MmuSTS.3919.1.S1_s_at regulator of G-protein signaling 10 isoform a LOC703125 8.93 0.0254 MmugDNA.23023.1.S1_at hypothetical protein LOC702839 LOC702839 8.93 0.0988 MmugDNA.13565.1.S1_at kinesin family member 11 KIF11 8.83 0.0906 MmuSTS.1877.1.S1_at collagen, type XVIII, alpha 1 COL18A1 8.81 0.0147 MmugDNA.34601.1.S1_at Ribosomal protein S6 RPS6 8.79 0.0857 MmugDNA.33493.1.S1_at tumor protein p73-like LOC703997 8.70 0.0516 MmugDNA.13626.1.S1_at prostaglandin I2 (prostacyclin) synthase /// prostaglandin I2 PTGIS 8.67 0.0049 (prostacyclin) synthase MmugDNA.15250.1.S1_at centromere protein A, 17 kDa CENPA 8.66 0.0498 MmugDNA.32562.1.S1_s_at Hemoglobin theta-1 subunit (Hemoglobin theta-1 chain) HBQ1 /// 8.53 0.0646 (Theta-1-globin) /// alpha 2 globin LOC701930 MmugDNA.31059.1.S1_at Securin (Pituitary tumor-transforming protein 1) (Tumor PTTG1 8.52 0.0329 transforming protein 1) (Esp1-associated protein) (hPTTG) MmugDNA.24523.1.S1_at cell division cycle associated 2 LOC711581 8.46 0.0921 MmugDNA.33436.1.S1_at thymosin-like 8 LOC693501 8.40 0.0296 MmugDNA.978.1.S1_at CDNA FLJ41452 fis, clone BRSTN2010363 — 8.22 0.0795 MmugDNA.21584.1.S1_s_at — — 8.21 0.0000 MmuSTS.2916.1.S1_at iroquois homeobox protein 2 IRX2 8.18 0.0698 MmugDNA.7359.1.S1_s_at TYRO protein tyrosine kinase binding protein TYROBP 8.15 0.0468 MmugDNA.33098.1.S1_at homeobox A3 isoform a LOC699979 8.11 0.0577 MmugDNA.18373.1.S1_at hypothetical protein LOC697150 LOC697150 8.11 0.0360 MmugDNA.8851.1.S1_at E2F transcription factor 2 E2F2 8.10 0.0630 MmugDNA.21962.1.S1_at inhibin beta A INHBA 8.09 0.0493 MmuSTS.1592.1.S1_at neuritin LOC722968 8.08 0.0300 MmuSTS.4722.1.S1_at thyroid hormone receptor interactor 13 LOC709328 7.99 0.0914 MmugDNA.16663.1.S1_at alpha 1 type VII collagen COL7A1 7.91 0.0603 MmugDNA.5836.1.S1_at pregnancy-associated plasma protein A, pappalysin 1 PAPPA 7.58 0.0602 MmuSTS.2073.1.S1_at peripheral myelin protein 22 LOC693527 7.57 0.0237 MmugDNA.29315.1.S1_at DEP domain containing 1a LOC701888 7.46 0.0609 MmuSTS.4833.1.S1_at gap junction protein, beta 5 (connexin 31.1) LOC711078 7.46 0.0501 MmugDNA.36119.1.S1_at hypothetical protein FLJ10357 FLJ10357 7.46 0.0549 MmuSTS.4814.1.S1_at gamma-aminobutyric acid (GABA) A receptor, epsilon GABRE 7.35 0.0325 MmugDNA.29829.1.S1_at hypothetical protein LOC718022 LOC718022 7.26 0.0181 MmugDNA.10011.1.S1_at establishment of cohesion 1 homolog 2 LOC713186 7.23 0.0759 MmugDNA.15721.1.S1_at DNA polymerase theta POLQ 7.21 0.0495 MmugDNA.23132.1.S1_s_at muscleblind-like 1 LOC708735 7.18 0.0870 MmugDNA.16746.1.S1_at Transcribed locus — 7.13 0.0397 MmugDNA.9813.1.S1_at steroid-sensitive protein 1 LOC708504 7.09 0.0041 MmugDNA.42865.1.S1_at cell division cycle 2 protein CDC2 7.09 0.0944 MmuSTS.673.1.S1_s_at chromatin assembly factor 1, subunit A (p150) LOC721861 7.08 0.0407 MmugDNA.42327.1.S1_at fibulin 1 FBLN1 7.05 0.0157 MmuSTS.3146.1.S1_s_at minichromosome maintenance deficient protein 5 MCM5 7.02 0.0229 MmugDNA.9770.1.S1_at G-2 and S-phase expressed 1 LOC714207 7.02 0.0673 MmuSTS.4144.1.S1_at glutathione transferase A5 — 7.01 0.0016 MmugDNA.1499.1.S1_at Pigment epithelium-derived factor precursor (PEDF) (EPC- LOC721262 6.99 0.0750 1) MmuSTS.1535.1.S1_at kinesin family member 2C KIF2C 6.86 0.0738 MmuSTS.3642.1.S1_at fibroblast growth factor receptor 2 FGFR2 6.84 0.0157 MmugDNA.3959.1.S1_at hypothetical protein LOC701440 LOC701440 6.74 0.0674 MmugDNA.22744.1.S1_s_at — — 6.73 0.0581 MmugDNA.10643.1.S1_s_at Apolipoprotein D precursor (Apo-D) (ApoD) LOC709223 6.71 0.0197 MmugDNA.41251.1.S1_at hypothetical protein LOC712701 LOC712701 6.69 0.0805 MmugDNA.25121.1.S1_at pancreatic ribonuclease RNASE1 6.65 0.0350 MmugDNA.18755.1.S1_at hypothetical protein LOC200030 LOC200030 6.64 0.0332 MmuSTS.644.1.S1_at citron LOC695846 6.63 0.0190 MmugDNA.35559.1.S1_at Histone H1.2 (H1d) LOC698238 6.62 0.0050 MmugDNA.37528.1.S1_at — — 6.57 0.0211 MmugDNA.41268.1.S1_at cyclin B1 CCNB1 6.55 0.0927 MmugDNA.40366.1.S1_at solute carrier family 24, member 5 SLC24A5 6.55 0.0000 Mmu.5727.1.S1_at G1/S-specific cyclin-D2 CCND2 6.53 0.0003 MmugDNA.9497.1.S1_at kinesin family member C1 KIFC1 6.44 0.0172 MmuSTS.1904.1.S1_at dicer1 LOC702516 6.43 0.0387 MmugDNA.25436.1.S1_at minichromosome maintenance protein 3 MCM3 6.40 0.0000 MmuSTS.1881.1.S1_at alpha 3 type VI collagen isoform 5 precursor LOC694701 6.38 0.0086 MmuSTS.4021.1.S1_at cytochrome P450, family 4, subfamily B, polypeptide 1 LOC709290 6.35 0.0285 MmugDNA.35290.1.S1_at hypothetical protein LOC696863 LOC696863 6.33 0.0371 MmugDNA.32826.1.S1_at kallikrein 8 isoform 2 — 6.32 0.0948 MmugDNA.36260.1.S1_at EGF, latrophilin and seven transmembrane domain ELTD1 6.31 0.0018 containing 1 MmuSTS.4328.1.S1_at plasminogen activator inhibitor type 1, member 2 SERPINE2 6.28 0.0044 MmugDNA.41228.1.S1_at NADP-dependent leukotriene B4 12-hydroxydehydrogenase /// LTB4DH 6.27 0.0527 NADP-dependent leukotriene B4 12- hydroxydehydrogenase (15-oxoprostaglandin 13-reductase) MmugDNA.31506.1.S1_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 HMGCS2 6.25 0.0306 (mitochondrial) MmuSTS.3741.1.S1_at tyrosine phosphatase, receptor-type, Z polypeptide 1 PTPRZ1 6.23 0.0829 MmugDNA.20272.1.S1_at cysteine-rich, angiogenic inducer, 61 CYR61 6.21 0.0552 MmugDNA.14075.1.S1_at Restin — 6.21 0.0576 MmugDNA.35622.1.S1_at Kinesin family member 14 KIF14 6.21 0.0036 MmugDNA.19983.1.S1_s_at testis derived transcript CAV1 6.20 0.0330 MmuSTS.1023.1.S1_at — SCN4B 6.19 0.0994 MmugDNA.42793.1.S1_at calcium/calmodulin-dependent protein kinase kinase 1, CAMKK1 6.18 0.0467 alpha MmugDNA.23406.1.S1_at SH3 domain containing ring finger 2 SH3RF2 6.17 0.0135 MmugDNA.19771.1.S1_at Transcribed locus — 6.16 0.0821 MmuSTS.1779.1.S1_at NIMA (never in mitosis gene a)-related kinase 2 NEK2 6.16 0.0886 MmugDNA.7491.1.S1_at Biliverdin reductase A — 6.13 0.0066 MmugDNA.30433.1.S1_at SHC SH2-domain binding protein 1 LOC716009 6.05 0.0001 MmugDNA.13151.1.S1_at Probable G-protein coupled receptor 92 GPR92 6.04 0.0268 MmugDNA.39863.1.S1_at chromosome 18 open reading frame 24 C18orf24 5.99 0.0496 MmugDNA.34856.1.S1_at RNA binding motif protein 6 RBM6 5.96 0.0446 Mmu.16175.1.S1_at CK230007 — 5.95 0.0684 Mmu.11188.1.S1_at caldesmon 1 isoform 4 LOC707050 5.93 0.0513 MmuSTS.2639.1.S1_at FAT tumor suppressor 2 precursor LOC713698 5.91 0.0047 MmugDNA.22443.1.S1_at nuclear factor I/B NFIB 5.88 0.0187 MmugDNA.19397.1.S1_at Chromosome 2 open reading frame 17 C2orf17 5.88 0.0483 MmugDNA.26212.1.S1_at ephrin-B1 EFNB1 5.88 0.0634 MmugDNA.27687.1.S1_s_at guanine nucleotide binding protein gamma 11 LOC700606 5.87 0.0207 MmugDNA.42502.1.S1_at Activity-dependent neuroprotector ADNP 5.86 0.0016 MmugDNA.35031.1.S1_at Transcription factor COE1 (OE-1) (O/E-1) (Early B-cell LOC694086 5.82 0.0007 factor) (Olfactory neuronal transcription factor) (Olf-1) Mmu.1262.1.A1_at — MEF2C 5.82 0.0164 MmuSTS.2987.1.S1_at MADS box transcription enhancer factor 2, polypeptide C LOC694992 5.77 0.0370 (myocyte enhancer factor 2C) MmugDNA.24078.1.S1_at hypothetical protein LOC699417 LOC699417 5.76 0.0711 MmugDNA.40153.1.S1_at olfactomedin-like 2A OLFML2A 5.74 0.0254 MmugDNA.37742.1.S1_at oncostatin M receptor LOC693569 5.74 0.0716 MmugDNA.8988.1.S1_at hypothetical protein LOC143381 LOC143381 5.70 0.0738 MmugDNA.18189.1.S1_at Insulin-like growth factor-binding protein 4 precursor LOC700963 5.69 0.0440 (IGFBP-4) (IBP-4) (IGF-binding protein 4) MmugDNA.8529.1.S1_at Secretory granule proteoglycan core protein precursor PRG1 5.63 0.0001 (Platelet proteoglycan core protein) (P.PG) (Hematopoetic proteoglycan core protein) (Serglycin) MmugDNA.23178.1.S1_at Chromobox homolog 5 (HP1 alpha homolog, Drosophila) CBX5 5.59 0.0958 MmugDNA.36354.1.S1_at fibroblast growth factor receptor 3 FGFR3 5.59 0.0298 MmugDNA.39673.1.S1_at SRY (sex determining region Y)-box 6 SOX6 5.57 0.0064 MmuSTS.4420.1.S1_at TPX2, microtubule-associated protein homolog TPX2 5.54 0.0556 MmugDNA.12787.1.S1_at tensin /// tensin TNS 5.54 0.0009 MmugDNA.35052.1.S1_at Dermatopontin precursor (Tyrosine-rich acidic matrix LOC700181 5.51 0.0038 protein) (TRAMP) MmugDNA.27071.1.S1_at retinoic acid receptor responder (tazarotene induced) 2 LOC704993 5.50 0.0557 MmugDNA.21100.1.S1_at laminin alpha 3 subunit isoform 1 LOC701313 5.49 0.0087 MmugDNA.37305.1.S1_at FRA10AC1 protein LOC700389 5.48 0.0630 MmugDNA.17614.1.S1_at T-box 5 TBX5 5.48 0.0963 MmugDNA.23701.1.S1_at — — 5.46 0.0105 MmugDNA.6672.1.S1_at dystonin DST 5.46 0.0844 MmugDNA.40463.1.S1_at MRNA; cDNA DKFZp686B0610 (from clone — 5.44 0.0808 DKFZp686B0610) MmuSTS.2214.1.S1_at six transmembrane epithelial antigen of the prostate STEAP1 5.44 0.0063 MmuSTS.1928.1.S1_at myeloblastosis proto-oncogene product isoform 2 LOC712321 5.41 0.0003 MmugDNA.35645.1.S1_s_at Rho GTPase activating protein 9 ARHGAP9 5.40 0.0030 MmugDNA.14897.1.S1_at AXL receptor tyrosine kinase isoform 2 LOC706123 5.35 0.0181 MmugDNA.1117.1.S1_at Friend leukemia virus integration 1 FLI1 5.35 0.0975 MmuSTS.4424.1.S1_at frizzled 7 LOC703064 5.31 0.0161 MmugDNA.25887.1.S1_s_at filamin 1 (actin-binding protein-280) FLNA 5.29 0.0256 MmugDNA.40242.1.S1_at LOC441301 — 5.27 0.0914 MmugDNA.21548.1.S1_s_at anthrax toxin receptor 2 LOC696513 5.26 0.0654 MmugDNA.36182.1.S1_at aquaporin 1 AQP1 5.26 0.0435 MmugDNA.14767.1.S1_at FRAS1 related extracellular matrix protein 2 FREM2 5.25 0.0835 MmugDNA.33751.1.S1_at Dexamethasone-induced Ras-related protein 1 (Activator of RASD1 5.25 0.0984 G-protein signaling 1) MmugDNA.25691.1.S1_at solute carrier family 16 (monocarboxylic acid transporters), SLC16A6 5.25 0.0466 member 6 MmuSTS.1922.1.S1_at v-ets erythroblastosis virus E26 oncogene homolog 1 ETS1 5.23 0.0322 MmugDNA.3558.1.S1_at serine/threonine protein kinase 6 AURKA 5.22 0.0358 MmugDNA.4124.1.S1_at cell division cycle associated 5 LOC721995 5.21 0.0575 MmugDNA.2333.1.S1_at synaptopodin SYNPO 5.21 0.0006 MmuSTS.2701.1.S1_at epidermal growth factor-like protein 6 precursor LOC711280 5.20 0.0491 MmugDNA.40392.1.S1_at lumican LUM 5.19 0.0120 MmugDNA.21491.1.S1_at CDNA clone IMAGE: 6043059, partial cds — 5.19 0.0980 MmugDNA.22192.1.S1_at vitamin K-dependent protein S precursor LOC694845 5.18 0.0750 MmugDNA.28039.1.S1_at Chromosome 10 open reading frame 18 C10orf18 5.17 0.0535 MmugDNA.23945.1.S1_at mitochondrial ribosomal protein L54 LOC713878 5.16 0.0885 MmugDNA.28350.1.S1_at Heparin-binding growth factor 1 precursor (HBGF-1) (Acidic FGF1 5.16 0.0183 fibroblast growth factor) (aFGF) (Beta-endothelial cell growth factor) (ECGF-beta) MmugDNA.4851.1.S1_at angiotensin II receptor, type 1 LOC712773 5.15 0.0653 MmugDNA.34285.1.S1_at nitric oxide synthase trafficking isoform 1 — 5.14 0.0724 MmugDNA.19357.1.S1_at Transcribed locus, strongly similar to XP_496055.1 similar — 5.13 0.0676 to p40 [Homo sapiens] Mmu.14966.1.S1_at EH domain binding protein 1 LOC693902 5.12 0.0757 MmugDNA.42808.1.S1_at transcription factor 8 (represses interleukin 2 expression) TCF8 5.11 0.0254 MmugDNA.30007.1.S1_at coiled-coil domain containing 102A LOC704988 5.10 0.0846 MmugDNA.5184.1.S1_s_at beta globin LOC715559 5.10 0.0122 MmuSTS.2069.1.S1_at Rac GTPase activating protein 1 LOC711887 5.06 0.0587 MmugDNA.15651.1.S1_at steroid sulfatase (microsomal), arylsulfatase C, isozyme S STS 5.04 0.0307 MmugDNA.19465.1.S1_at Transcribed locus, weakly similar to NP_060190.1 signal- — 5.03 0.0125 transducing adaptor protein-2 [Homo sapiens] MmugDNA.27239.1.S1_s_at retinol-binding protein 4, plasma precursor LOC701270 5.03 0.0423 MmugDNA.43409.1.S1_at solute carrier family 27 member 3 LOC718424 5.02 0.0762 MmugDNA.13155.1.S1_at chondroitin sulfate proteoglycan 2 (versican) LOC712365 5.00 0.0576 MmugDNA.18099.1.S1_at complement component 3 C3 4.97 0.0146 MmuSTS.2151.1.S1_at branched chain aminotransferase 1, cytosolic LOC707321 4.96 0.0031 MmunewRS.412.1.S1_s_at solute carrier family 9 (sodiumhydrogen exchanger), isoform SLC9A4 4.95 0.0130 4 (SLC9A4), mRNA MmugDNA.9733.1.S1_at Muscleblind-like (Drosophila) MBNL1 4.95 0.0396 MmugDNA.20784.1.S1_at quaking homolog, KH domain RNA binding (mouse) QKI 4.95 0.0001 MmuSTS.2287.1.S1_at peroxisome proliferator-activated receptor gamma 1-b PPARGAMMA 4.93 0.0218 MmuSTS.1783.1.S1_at nuclear factor I/A LOC694022 4.92 0.0568 MmugDNA.5690.1.S1_at septin 4 isoform 3 LOC714724 4.92 0.0427 MmugDNA.23105.1.S1_s_at Ig lambda chain V-II region BUR /// Ig lambda chain V-II LOC706778 /// 4.91 0.0034 region MGC /// Immunoglobulin lambda-like polypeptide 1 LOC707940 /// precursor (Immunoglobulin-related protein 14.1) LOC708547 /// (Immunoglobulin omega polypeptide) (Ig lambda-5) LOC720711 (CD179b antigen) /// Ig lambda chain V-II region NIG-84 MmugDNA.39956.1.S1_at Hairless homolog (mouse) HR 4.90 0.0242 MmuSTS.2029.1.S1_at polo-like kinase PLK1 4.88 0.0403 MmuSTS.154.1.S1_x_at — BTN3A2 4.87 0.0977 MmugDNA.35115.1.S1_at heparan sulfate proteoglycan 2 HSPG2 4.85 0.0002 MmugDNA.964.1.S1_at SH3-domain binding protein 1 SH3BP1 4.83 0.0803 MmugDNA.9449.1.S1_at WD repeat domain 76 LOC711191 4.83 0.0376 MmuSTS.165.1.S1_at inhibitor of DNA binding 3 LOC710290 4.82 0.0001 MmugDNA.43567.1.S1_at Homo sapiens, Similar to hypothetical protein FLJ21936, — 4.82 0.0615 clone IMAGE: 4044084, mRNA MmugDNA.40816.1.S1_at tumor necrosis factor, alpha-induced protein 9 TNFAIP9 4.82 0.0196 MmugDNA.23454.1.S1_at 15-hydroxyprostaglandin dehydrogenase [NAD+] (PGDH) HPGD 4.82 0.0099 (Prostaglandin dehydrogenase 1) MmugDNA.38346.1.S1_at phosphoserine aminotransferase isoform 1 LOC706387 4.81 0.0646 MmugDNA.28728.1.S1_at KIAA0485 protein KIAA0485 4.80 0.0069 MmuSTS.4004.1.S1_at thrombospondin 1 precursor LOC705413 4.78 0.0185 MmugDNA.23996.1.S1_at alpha 2 type I collagen LOC700359 4.75 0.0161 MmugDNA.18235.1.S1_at TGFB-induced factor 2 (TALE family homeobox) TGIF2 4.72 0.0241 MmugDNA.30842.1.S1_s_at Transgelin (Smooth muscle protein 22-alpha) (SM22-alpha) TAGLN 4.71 0.0509 (WS3-10) (22 kDa actin-binding protein) MmugDNA.822.1.S1_at Transcribed locus, moderately similar to XP_517655.1 — 4.71 0.0218 similar to KIAA0825 protein [Pan troglodytes] MmugDNA.19564.1.S1_s_at melanoma cell adhesion molecule LOC708449 4.71 0.0221 MmugDNA.26005.1.S1_at thyroglobulin TG 4.71 0.0150 MmugDNA.9817.1.S1_at Likely ortholog of mouse TORC2-specific protein AVO3 AVO3 4.70 0.0316 (S. cerevisiae) MmugDNA.12099.1.S1_at transducer of ERBB2, 1 TOB1 4.70 0.0197 MmugDNA.20357.1.S1_at interleukin 1 receptor, type I IL1R1 4.69 0.0159 MmugDNA.38818.1.S1_at adipocyte enhancer binding protein 1 precursor LOC699977 4.67 0.0329 MmugDNA.34995.1.S1_s_at collagen, type I, alpha 1 COL1A1 4.66 0.0032 MmugDNA.4218.1.S1_at four and a half LIM domains 1 FHL1 4.65 0.0322 MmuSTS.869.1.S1_at dysferlin DYSF 4.64 0.0604 MmugDNA.31007.1.S1_s_at fibronectin 1 FN1 4.63 0.0000 MmugDNA.21203.1.S1_x_at amyloid beta (A4) precursor protein-binding, family B, LOC707383 4.61 0.0921 member 1 interacting protein MmugDNA.16224.1.S1_s_at hypothetical protein LOC704308 LOC704308 4.60 0.0117 MmugDNA.22096.1.S1_at Galectin-1 (Lectin galactoside-binding soluble 1) (Beta- LGALS1 4.59 0.0571 galactoside-binding lectin L-14-I) (Lactose-binding lectin 1) (S-Lac lectin 1) (Galaptin) (14 kDa lectin) (HPL) (HBL) (Putative MAPK-activating protein MP12) MmugDNA.26778.1.S1_at Hypothetical protein similar to KIAA0187 gene product LOC96610 4.58 0.0395 MmugDNA.16831.1.S1_s_at synuclein, gamma (breast cancer-specific protein 1) LOC696535 4.58 0.0058 MmugDNA.35261.1.S1_at Fc fragment of IgG, low affinity IIa, receptor (CD32) FCGR2A 4.58 0.0713 MmugDNA.31316.1.S1_at hypothetical protein LOC702054 /// hypothetical protein LOC702054 /// 4.57 0.0204 LOC702584 LOC702584 MmugDNA.30287.1.S1_at GTPase, IMAP family member 6 isoform 1 LOC713565 4.57 0.0897 MmugDNA.5299.1.S1_at Rho-related BTB domain containing 1 RHOBTB1 4.56 0.0702 MmugDNA.30627.1.S1_s_at jub, ajuba homolog isoform 1 LOC712865 4.55 0.0343 MmuSTS.220.1.S1_at SCL/TAL1 interrupting locus LOC710099 4.54 0.0619 MmugDNA.33541.1.S1_at calpain small subunit 2 LOC698721 4.54 0.0190 MmugDNA.10511.1.S1_at mucin 15 LOC700194 4.53 0.0419 MmuSTS.90.1.S1_at high mobility group AT-hook 2 HMGA2 4.53 0.0315 MmugDNA.22320.1.S1_s_at pregnancy specific beta-1-glycoprotein 4 PSG4 4.52 0.0011 MmugDNA.6347.1.S1_at runt-related transcription factor 3 RUNX3 4.51 0.0494 MmugDNA.21974.1.S1_at keratin 5 KRT3 4.50 0.0002 MmugDNA.21584.1.S1_at — — 4.49 0.0045 MmugDNA.19709.1.S1_x_at growth hormone 1 GH1 4.48 0.0372 MmuSTS.4832.1.S1_at connexin 31 LOC710834 4.48 0.0144 MmugDNA.24059.1.S1_at Transcribed locus — 4.47 0.0651 MmugDNA.32484.1.S1_s_at tissue inhibitor of metalloproteinase 3 (Sorsby fundus TIMP3 4.47 0.0150 dystrophy, pseudoinflammatory) MmugDNA.35122.1.S1_at Discoidin domain receptor family, member 2 DDR2 4.47 0.0050 MmugDNA.18271.1.S1_at CDNA FLJ44429 fis, clone UTERU2015653 — 4.46 0.0001 MmuSTS.2362.1.S1_at S100-B (S100 calcium-binding protein B) (S-100 protein S100B 4.45 0.0185 beta subunit) (S-100 protein beta chain) MmugDNA.41157.1.S1_at matrix Gla protein MGP 4.44 0.0252 MmuSTS.934.1.S1_at four jointed box 1 LOC717833 4.44 0.0328 MmugDNA.30788.1.S1_at COBL-like 1 LOC702934 4.41 0.0521 MmugDNA.1969.1.S1_at hypothetical protein LOC714686 LOC714686 4.40 0.0385 MmuSTS.112.1.S1_at Asporin precursor (Periodontal ligament-associated protein LOC718125 4.40 0.0318 1) (PLAP-1) MmugDNA.13768.1.S1_at CDNA: FLJ22256 fis, clone HRC02860 — 4.39 0.0198 MmugDNA.28759.1.S1_at — — 4.39 0.0482 MmugDNA.15862.1.S1_at CDC28 protein kinase 2 LOC697324 4.39 0.0028 MmugDNA.22453.1.S1_at keratin 13 isoform b LOC706830 4.38 0.0080 MmugDNA.34784.1.S1_at CDNA FLJ12091 fis, clone HEMBB1002582 — 4.38 0.0522 MmugDNA.41887.1.S1_at MYB-related protein B MYBL2 4.36 0.0821 MmugDNA.17000.1.S1_at Activating transcription factor 7 ATF7 4.36 0.0972 MmugDNA.29263.1.S1_at Glycoprotein hormones alpha chain precursor (Anterior LOC697859 4.34 0.0348 pituitary glycoprotein hormones common alpha subunit) (Follitropin alpha chain) (Follicle-stimulating hormone alpha chain) (FSH-alpha) (Lutropin alpha chain) (Luteinizing hormone alph . . . MmugDNA.21650.1.S1_at Epidermal growth factor receptor (erythroblastic leukemia EGFR 4.33 0.0164 viral (v-erb-b) oncogene homolog, avian) MmugDNA.24420.1.S1_at kidney predominant protein NCU-G1 LOC719468 4.33 0.0291 MmugDNA.26915.1.S1_at follistatin FST 4.32 0.0314 MmugDNA.35764.1.S1_s_at High affinity immunoglobulin epsilon receptor gamma- LOC720291 4.32 0.0456 subunit precursor (FceRI gamma) (IgE Fc receptor gamma- subunit) (Fc-epsilon RI-gamma) MmugDNA.23015.1.S1_at Y43E12A.2 LOC702083 4.32 0.0536 MmuSTS.3532.1.S1_at CD53 antigen LOC702350 4.31 0.0013 MmuSTS.1975.1.S1_at nuclear receptor subfamily 3, group C, member 1 NR3C1 4.31 0.0356 MmugDNA.30097.1.S1_at coronin, actin binding protein, 1C CORO1C 4.30 0.0925 MmugDNA.16359.1.S1_at deleted in liver cancer 1 DLC1 4.30 0.0527 MmugDNA.23180.1.S1_at cartilage associated protein CRTAP 4.29 0.0637 MmugDNA.11572.1.S1_at chemokine (C—X—C motif) ligand 12 (stromal cell-derived CXCL12 4.28 0.0367 factor 1) MmuSTS.3488.1.S1_at CD48 antigen precursor (B-lymphocyte activation marker CD48 4.28 0.0930 BLAST-1) (BCM1 surface antigen) (Leucocyte antigen MEM-102) (TCT.1) Mmu.9771.1.S1_at osteomodulin OMD 4.28 0.0946 MmugDNA.34344.1.S1_at Neuron navigator 1 NAV1 4.27 0.0395 MmugDNA.37179.1.S1_at CG10889-PA LOC714837 4.27 0.0079 MmugDNA.985.1.S1_at pyruvate dehydrogenase kinase 4 PDK4 4.25 0.0509 MmugDNA.19882.1.S1_at potassium channel tetramerisation domain containing 15 LOC704761 4.25 0.0224 MmuSTS.3690.1.S1_at collagen, type VI, alpha 1 COL6A1 4.23 0.0002 MmuSTS.3265.1.S1_at RGM domain family, member A LOC712949 4.23 0.0001 MmugDNA.7509.1.S1_at hypothetical protein LOC710962 LOC710962 4.22 0.0691 MmugDNA.15267.1.S1_at RNA binding protein with multiple splicing 2 LOC712536 4.22 0.0002 MmugDNA.15951.1.S1_at reticulon 4 RTN4 4.21 0.0366 MmugDNA.13995.1.S1_at — — 4.21 0.0348 MmugDNA.19825.1.S1_s_at phosducin-like 3 LOC696369 4.21 0.0667 MmugDNA.3461.1.S1_at similar to RIKEN cDNA 1200014N16 gene MGC14289 4.19 0.0308 MmugDNA.23968.1.S1_s_at ubiquitin specific protease 32 LOC716857 4.19 0.0249 MmuSTS.3891.1.S1_at smoothened LOC701334 4.19 0.0433 MmuSTS.3429.1.S1_at Collagen alpha-1(XII) chain precursor LOC717820 4.19 0.0386 MmuSTS.1967.1.S1_at FYN binding protein (FYB-120/130) isoform 1 LOC693951 4.18 0.0997 MmugDNA.27563.1.S1_at hypothetical protein FLJ13910 /// hypothetical protein FLJ13910 /// 4.16 0.0252 LOC285074 LOC285074 MmugDNA.15700.1.S1_s_at phosphoglycerate dehydrogenase PHGDH 4.15 0.0032 MmuSTS.3850.1.S1_at ABI gene family, member 3 (NESH) binding protein LOC701192 4.14 0.0817 MmugDNA.1158.1.S1_at CD36 antigen (collagen type I receptor, thrombospondin CD36 4.14 0.0397 receptor) MmugDNA.34925.1.S1_at secreted protein, acidic, cysteine-rich (osteonectin) SPARC 4.09 0.0078 MmugDNA.31894.1.S1_at thioredoxin interacting protein LOC698683 4.09 0.0028 MmugDNA.18794.1.S1_at cell division cycle 20 CDC20 4.09 0.0481 MmuSTS.1308.1.S1_at dystrophin (muscular dystrophy, Duchenne and Becker DMD 4.09 0.0098 types) MmugDNA.27355.1.S1_at low density lipoprotein-related protein 1 LRP1 4.08 0.0607 MmugDNA.7866.1.S1_at DNA replication factor LOC711530 4.07 0.0109 MmugDNA.31873.1.S1_at Fatty acid-binding protein, adipocyte (AFABP) (Adipocyte FABP4 4.07 0.0130 lipid-binding protein) (ALBP) (A-FABP) MmugDNA.36912.1.S1_at complement factor D preproprotein LOC721138 4.07 0.0237 MmugDNA.10186.1.S1_at AF15q14 protein AF15Q14 4.06 0.0211 MmugDNA.6192.1.S1_at Baculoviral IAP repeat-containing 6 (apollon) BIRC6 4.06 0.0861 MmugDNA.26073.1.S1_at RAB30, member RAS oncogene family LOC701550 4.03 0.0735 MmugDNA.21516.1.S1_at phospholipid transfer protein PLTP 4.03 0.0251 MmugDNA.36883.1.S1_at PDZ domain containing 3 PDZK3 4.02 0.0007 MmugDNA.16991.1.S1_at integrin alpha 7 precursor LOC707279 4.02 0.0319 MmugDNA.3447.1.S1_at diacylglycerol O-acyltransferase homolog 2 LOC696549 4.02 0.0054 MmugDNA.17919.1.S1_at arachidonate 15-lipoxygenase, second type ALOX15B 4.01 0.0499 MmugDNA.35103.1.S1_at actin, alpha 2, smooth muscle, aorta ACTA2 4.01 0.0296 Mmu.16433.2.S1_at collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, COL3A1 3.99 0.0332 autosomal dominant) MmugDNA.24230.1.S1_s_at chemokine-like factor superfamily 3 isoform a LOC695592 3.99 0.0604 MmugDNA.16772.1.S1_at immunoglobulin J chain LOC706650 3.98 0.0350 MmugDNA.34863.1.S1_at hypothetical protein LOC283445 LOC283445 3.98 0.0580 MmunewRS.431.1.S1_at tyrosine phosphatase, receptor type, S — 3.97 0.0140 MmuSTS.61.1.S1_at helicase, lymphoid-specific LOC701598 3.97 0.0034 MmugDNA.34155.1.S1_at nidogen (enactin) NID1 3.95 0.0965 MmugDNA.9153.1.S1_s_at angiopoietin 1 ANGPT1 3.94 0.0482 MmugDNA.36429.1.S1_at Phosphoglycerate dehydrogenase like 1 PHGDHL1 3.93 0.0965 MmugDNA.26560.1.S1_at Transcribed locus — 3.93 0.0251 MmugDNA.36525.1.S1_at junctional adhesion molecule 2 JAM2 3.91 0.0727 MmugDNA.43116.1.S1_at glycoprotein (transmembrane) nmb isoform b precursor LOC704990 3.91 0.0020 MmugDNA.14973.1.S1_at CDC45-like LOC711800 3.90 0.0056 MmuSTS.1523.1.S1_at mannose receptor C type 1 MRC1 3.90 0.0326 MmugDNA.39378.1.S1_at ribonuclease HI, large subunit RNASEH2A 3.90 0.0623 MmugDNA.27459.1.S1_at Transcribed locus — 3.89 0.0217 MmugDNA.17136.1.S1_at Sorbin and SH3 domain containing 1 SORBS1 3.89 0.0146 MmugDNA.15966.1.S1_at Bromodomain adjacent to zinc finger domain, 2A BAZ2A 3.88 0.0740 MmugDNA.20219.1.S1_at myc target 1 LOC711296 3.88 0.0363 MmugDNA.43499.1.S1_at — — 3.88 0.0557 MmugDNA.10801.1.S1_s_at — — 3.86 0.0121 Mmu.6201.1.S1_at Glycogen phosphorylase, liver PYGL 3.86 0.0383 MmuSTS.4157.1.S1_at Mitotic spindle assembly checkpoint protein MAD2A (MAD2- LOC708574 3.85 0.0975 like 1) (HsMAD2) MmugDNA.37083.1.S1_at pleckstrin homology-like domain, family B, member 2 LOC709353 3.84 0.0493 MmugDNA.2976.1.S1_at hypothetical protein LOC718180 LOC718180 3.83 0.0297 MmugDNA.34946.1.S1_at — — 3.82 0.0871 MmugDNA.2272.1.S1_at CDNA FLJ34664 fis, clone LIVER2000592 — 3.82 0.0256 MmugDNA.27284.1.S1_at endothelial differentiation, lysophosphatidic acid G-protein- LOC709208 3.81 0.0286 coupled receptor, 2 MmugDNA.29523.1.S1_at hypothetical protein LOC700994 LOC700994 3.81 0.0180 MmugDNA.33148.1.S1_at mitochondrial glycerol 3-phosphate acyltransferase GPAM 3.79 0.0111 MmugDNA.12151.1.S1_at chromosome 18 open reading frame 54 LOC694192 3.79 0.0342 MmugDNA.11637.1.S1_s_at nestin LOC718562 3.79 0.0391 Mmu.15601.1.S2_s_at Intestinal alkaline phosphatase — 3.79 0.0175 MmugDNA.27885.1.S1_at excision repair cross-complementing rodent repair LOC699138 3.78 0.0396 deficiency complementation group 6 - like MmugDNA.33913.1.S1_at Calmodulin-like 4 CALML4 3.77 0.0635 MmugDNA.42756.1.S1_at — — 3.77 0.0776 MmugDNA.33637.1.S1_s_at melanoma antigen family D, 4 isoform 1 LOC697293 3.76 0.0236 MmugDNA.32538.1.S1_at ecotropic viral integration site 2B LOC712972 3.76 0.0866 MmugDNA.7512.1.S1_at mediator of RNA polymerase II transcription, subunit 13 THRAP1 3.76 0.0009 homolog MmuSTS.4815.1.S1_at gamma-aminobutyric acid (GABA) A receptor, pi GABRP 3.76 0.0213 MmugDNA.42949.1.S1_at Kinectin 1 (kinesin receptor) KTN1 3.75 0.0642 MmugDNA.9357.1.S1_at Similar to ribosomal protein S12 — 3.75 0.0693 MmuSTS.1780.1.S1_at hypothetical protein LOC710960 LOC710960 3.75 0.0391 MmugDNA.40177.1.S1_at HRAS-like suppressor 5 (H-rev107-like protein 5) LOC718317 3.75 0.0439 MmugDNA.41855.1.S1_at chloride intracellular channel 4 CLIC4 3.75 0.0477 MmugDNA.39310.1.S1_at homeo box C4 HOXC4 3.75 0.0753 MmugDNA.33364.1.S1_at lysosomal-associated membrane protein 1 LAMP1 3.75 0.0891 MmuSTS.2956.1.S1_at Lysosomal-associated multispanning membrane protein-5 LAPTM5 3.74 0.0769 MmugDNA.15666.1.S1_at prostatic secretory protein (PSP-94) MSMB 3.74 0.0536 MmugDNA.37771.1.S1_at Ring finger protein 12 RNF12 3.73 0.0118 MmugDNA.25197.1.S1_at asp (abnormal spindle)-like, microcephaly associated LOC711153 3.73 0.0360 MmugDNA.35955.1.S1_at Ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, UBE2D3 3.73 0.0666 yeast) MmugDNA.39545.1.S1_at sialyltransferase 7 ST6GALNAC2 3.73 0.0048 MmugDNA.24940.1.S1_at SERTA domain containing 4 SERTAD4 3.73 0.0064 MmuSTS.2245.1.S1_at phospholipase C, delta 1 PLCD1 3.72 0.0012 MmugDNA.4054.1.S1_at solute carrier family 25 (mitochondrial carrier; Graves SLC25A16 3.72 0.0026 disease autoantigen), member 16 MmugDNA.38062.1.S1_at Very hypothetical protein — 3.71 0.0666 MmuSTS.1539.1.S1_at lamin B1 LMNB1 3.70 0.0425 MmugDNA.29710.1.S1_at mitogen-activated protein kinase kinase kinase 6 LOC715911 3.70 0.0525 MmugDNA.3079.1.S1_at START domain containing 7 STARD7 3.70 0.0054 MmuSTS.3358.1.S1_at Hematopoietic progenitor cell antigen CD34 precursor LOC713858 3.70 0.0201 MmugDNA.23709.1.S1_at Ras-related protein Rab-13 LOC695135 3.69 0.0042 MmugDNA.13640.1.S1_at Plunc precursor (Palate lung and nasal epithelium clone PLUNC 3.68 0.0341 protein) (Lung-specific protein X) (Nasopharyngeal carcinoma-related protein) (Tracheal epithelium-enriched protein) (Secretory protein in upper respiratory tracts) (Von Ebn . . . MmugDNA.19840.1.S1_at Flavin containing monooxygenase 2 FMO2 3.67 0.0200 MmugDNA.12797.1.S1_at early B-cell factor 3 LOC713536 3.67 0.0679 MmugDNA.43327.1.S1_at Alpha crystallin B chain (Alpha(B)-crystallin) (Rosenthal fiber CRYAB 3.66 0.0179 component) (Heat-shock protein beta-5) (HspB5) (NY-REN- 27 antigen) MmugDNA.26357.1.S1_at CG14299-PA, isoform A LOC700766 3.65 0.0974 Mmu.16242.1.S1_at Pallidin (Pallid protein homolog) (Syntaxin 13-interacting PLDN 3.65 0.0676 protein) MmugDNA.3343.1.S1_at suppressor of cytokine signaling 3 SOCS3 3.65 0.0146 MmunewRS.372.1.S1_at gi:39645656 Homo sapiens similar to Serinethreonine- MGC75495 3.64 0.0005 protein kinase Nek1 (NimA-related protein kinase 1), mRNA (cDNA clone MGC: 75495 IMAGE: 30383658), complete cds MmugDNA.4113.1.S1_at heat shock 22 kDa protein 8 HSPB8 3.64 0.0306 MmugDNA.42494.1.S1_at Transcribed locus — 3.64 0.0679 MmuSTS.4058.1.S1_at sushi-repeat-containing protein, X-linked SRPX 3.63 0.0619 MmugDNA.17872.1.S1_at Putative serum amyloid A-3 protein SAA3P 3.63 0.0242 MmugDNA.34659.1.S1_s_at hypothetical protein LOC705662 LOC705662 3.63 0.0100 MmugDNA.34077.1.S1_at WD repeat and FYVE domain containing 2 WDFY2 3.63 0.0201 MmugDNA.3557.1.S1_at WD40 repeat protein Interacting with phosphoInositides of WIPI49 3.62 0.0905 49 kDa MmugDNA.5835.1.S1_at hypothetical protein LOC700615 LOC700615 3.62 0.0021 MmunewRS.1055.1.S1_at Myosin regulatory light chain 2, smooth muscle isoform LOC709784 3.61 0.0184 (Myosin RLC) (LC20) (Myosin regulatory light chain 9) MmuSTS.4533.1.S1_at breast cancer 1, early onset isoform 1 LOC712634 3.61 0.0225 MmugDNA.37529.1.S1_at pleckstrin homology domain containing, family H (with LOC713488 3.61 0.0629 MyTH4 domain) member 2 MmugDNA.36745.1.S1_at tubulin, beta 8 — 3.61 0.0229 MmugDNA.21536.1.S1_at proline arginine-rich end leucine-rich repeat protein PRELP 3.61 0.0589 MmugDNA.29432.1.S1_at CDNA FLJ12246 fis, clone MAMMA1001343 — 3.61 0.0308 MmuSTS.911.1.S1_at enhancer of zeste 2 EZH2 3.60 0.0107 MmugDNA.17513.1.S1_at LIM and cysteine-rich domains 1 LMCD1 3.59 0.0642 MmunewRS.170.1.S1_at gi:34535503 Homo sapiens cDNA FLJ46364 fis, clone — 3.59 0.0005 TESTI4051015, weakly similar to Aquaporin 7 MmugDNA.37690.1.S1_at zinc finger protein 208 ZNF208 3.59 0.0722 MmugDNA.14830.1.S1_at thyroid hormone responsive (SPOT14 homolog, rat) THRSP 3.58 0.0198 MmugDNA.38914.1.S1_at Rap guanine nucleotide exchange factor (GEF)-like 1 LOC699843 3.57 0.0737 MmugDNA.15276.1.S1_at sushi, von Willebrand factor type A, EGF and pentraxin LOC709478 3.57 0.0542 domain containing 1 MmugDNA.9453.1.S1_at lysyl oxidase preproprotein LOC699997 3.57 0.0512 MmuSTS.417.1.S1_at alpha-2A-adrenergic receptor ADRA2A 3.56 0.0301 MmugDNA.328.1.S1_at Nuclear protein 1 (Protein p8) (Candidate of metastasis 1) P8 3.56 0.0178 MmugDNA.34766.1.S1_at Corticoliberin precursor (Corticotropin-releasing factor) LOC702877 3.55 0.0843 (CRF) (Corticotropin-releasing hormone) MmugDNA.7723.1.S1_at male-specific lethal 3-like 1 (Drosophila) MSL3L1 3.55 0.0630 MmugDNA.25407.1.S1_at carboxypeptidase M CPM 3.54 0.0593 MmuSTS.1530.1.S1_at Kv channel interacting protein 2 isoform 6 LOC712434 3.54 0.0273 MmugDNA.12610.1.S1_at OX-2 membrane glycoprotein precursor (MRC OX-2 CD200 3.54 0.0915 antigen) (CD200 antigen) MmuSTS.835.1.S1_at downregulated in ovarian cancer 1 isoform 2 LOC699594 3.54 0.0876 MmugDNA.21403.1.S1_at trigger of mitotic entry 1 LOC722088 3.53 0.0250 MmugDNA.2694.1.S1_at ZW10 interactor (ZW10-interacting protein 1) (Zwint-1) LOC702198 3.52 0.0095 MmugDNA.32957.1.S1_at CG15105-PA, isoform A LOC696852 3.51 0.0745 MmunewRS.730.1.S1_at cadherin 13 CDH13 3.50 0.0291 MmugDNA.28367.1.S1_at SPARC-like 1 SPARCL1 3.49 0.0017 MmugDNA.28270.1.S1_at Early B-cell factor EBF 3.48 0.0343 MmugDNA.30316.1.S1_at Protein inhibitor of activated STAT, 1 PIAS1 3.48 0.0646 MmuSTS.1363.1.S1_at annexin A8 ANXA8 3.48 0.0190 MmugDNA.6544.1.S1_at Triosephosphate isomerase (TIM) (Triose-phosphate TPI1 3.48 0.0290 isomerase) MmugDNA.15422.1.S1_at absent in melanoma 1 LOC697117 3.47 0.0217 MmugDNA.37873.1.S1_at kinase related protein, telokin MYLK 3.44 0.0740 MmugDNA.22106.1.S1_at sterile alpha motif domain containing 4 SAMD4 3.44 0.0269 MmugDNA.25115.1.S1_at delta-like 1 homolog isoform 1 LOC707595 3.43 0.0452 MmugDNA.25541.1.S1_at hypothetical protein LOC705360 LOC705360 3.43 0.0002 MmuSTS.3320.1.S1_at cyclin E2 isoform 1 LOC700382 3.43 0.0417 MmuSTS.4488.1.S1_at spectrin, beta, non-erythrocytic 1 SPTBN1 3.43 0.0416 MmugDNA.13714.1.S1_at kallikrein 11 isoform 2 precursor — 3.43 0.0019 MmugDNA.14368.1.S1_at lipidosin LOC709676 3.41 0.0245 MmugDNA.7128.1.S1_at triggering receptor expressed on myeloid cells 4 TREM4 3.41 0.0097 MmugDNA.15051.1.S1_at A kinase (PRKA) anchor protein 2 AKAP2 3.41 0.0145 MmugDNA.39271.1.S1_at Transcribed locus — 3.41 0.0712 MmugDNA.38296.1.S1_at KIAA1102 protein KIAA1102 3.40 0.0636 MmugDNA.12755.1.S1_s_at bone morphogenetic protein 1 BMP1 3.39 0.0254 MmugDNA.35196.1.S1_at Transcribed locus — 3.39 0.0878 MmugDNA.7507.1.S1_at ATP-binding cassette, sub-family A, member 9 LOC693411 3.39 0.0736 Mmu.15849.1.S1_at transcription elongation regulator 1 isoform 1 LOC707912 3.38 0.0370 MmugDNA.25155.1.S1_at Nuclear ubiquitous casein and cyclin-dependent kinases NUCKS1 3.38 0.0007 substrate (P1) MmuSTS.2361.1.S1_at S100-A2 (S100 calcium-binding protein A2) (Protein S- LOC715264 3.37 0.0014 100L) (CAN19) MmuAffx.23.12.S1_at Transcribed locus, strongly XP_001153513.1 hypothetical — 3.36 0.0459 protein [Pan troglodytes] MmugDNA.13395.1.S1_at interferon, gamma-inducible protein 16 LOC719253 3.34 0.0180 MmugDNA.34006.1.S1_at leucine rich repeat and death domain containing protein LOC700580 3.34 0.0246 isoform 1 MmugDNA.13401.1.S1_s_at metastasis associated lung adenocarcinoma transcript 1 MALAT1 3.34 0.0765 (non-coding RNA) MmuSTS.2405.1.S1_at growth differentiation factor 11 GDF11 3.34 0.0680 MmugDNA.22100.1.S1_at Baculoviral IAP repeat-containing protein 5 (Apoptosis BIRC5 3.34 0.0120 inhibitor survivin) (Apoptosis inhibitor 4) MmuSTS.2514.1.S1_at hematopoietically expressed homeobox LOC699012 3.33 0.0592 MmugDNA.29693.1.S1_at hypothetical protein FLJ21742 FLJ21742 3.33 0.0066 MmuSTS.1347.1.S1_at high-mobility group box 2 LOC697057 3.32 0.0266 MmuSTS.1397.1.S1_at Complement C1q subcomponent subunit B precursor LOC718307 3.31 0.0198 MmugDNA.42305.1.S1_at A kinase (PRKA) anchor protein 13 AKAP13 3.31 0.0571 MmugDNA.19389.1.S1_at Chromosome 21 open reading frame 34 C21orf34 3.30 0.0456 MmugDNA.12452.1.S1_at hypothetical protein LOC699186 LOC699186 3.30 0.0179 MmugDNA.26596.1.S1_at methyltransferase like 4 LOC696353 3.30 0.0082 MmuSTS.4306.1.S1_at glycogenin 2 LOC703955 3.30 0.0119 MmuSTS.1398.1.S1_at complement component 1, s subcomponent C1S 3.29 0.0531 MmugDNA.37738.1.S1_at GRAM domain containing 3 LOC697870 3.29 0.0849 MmugDNA.36423.1.S1_at angiomotin like 1 LOC698211 3.29 0.0435 MmugDNA.38698.1.S1_at complement component 1, q subcomponent, receptor 1 C1QR1 3.28 0.0036 MmugDNA.21696.1.S1_at hypothetical protein BC007901 LOC91461 3.28 0.0816 MmugDNA.20213.1.S1_at meningioma expressed antigens 5 (hyaluronidase) MGEA5 3.27 0.0067 MmugDNA.19007.1.S1_at catalase CAT 3.26 0.0419 MmugDNA.20699.1.S1_at hypothetical protein LOC694371 LOC694371 3.26 0.0587 MmugDNA.6381.1.S1_at cystatin F LOC704850 3.26 0.0825 MmugDNA.13610.1.S1_at Full length insert cDNA clone YT94E02 — 3.25 0.0318 MmuSTS.159.1.S1_at microfibrillar-associated protein 4 LOC709521 3.25 0.0567 MmugDNA.3114.1.S1_at Wee1-like protein kinase (WEE1hu) WEE1 3.25 0.0474 MmuSTS.2860.1.S1_at Neuroligin 4 — 3.24 0.0013 MmuSTS.3636.1.S1_at Ets2 repressor factor ERF 3.24 0.0422 MmugDNA.24307.1.S1_s_at Sarcospan (K-ras oncogene-associated protein) (Kirsten- SSPN 3.24 0.0853 ras-associated protein) MmugDNA.18122.1.S1_at RAP2B, member of RAS oncogene family RAP2B 3.24 0.0026 MmugDNA.13964.1.S1_at trophoblast-derived noncoding RNA TncRNA 3.23 0.0115 MmugDNA.7717.1.S1_at MCM10 minichromosome maintenance deficient 10 (S. cerevisiae) MCM10 3.23 0.0644 MmugDNA.10682.1.S1_at aquaporin 7 AQP7 3.22 0.0409 MmugDNA.9561.1.S1_at tissue inhibitor of matrix metalloproteinase-2 TIMP-2 3.22 0.0005 MmugDNA.9052.1.S1_at MAM domain containing 2 LOC700333 3.21 0.0581 MmugDNA.23764.1.S1_at cyclin A CCNA2 3.21 0.0284 MmugDNA.962.1.S1_at platelet-derived growth factor receptor beta /// hypothetical LOC711667 /// 3.20 0.0641 protein LOC711667 PDGFRB MmugDNA.30376.1.S1_at minichromosome maintenance protein 7 MCM7 3.20 0.0000 MmugDNA.40338.1.S1_s_at Collagen alpha-1(V) chain precursor LOC722009 3.20 0.0018 MmugDNA.43126.1.S1_at KIAA1909 protein KIAA1909 3.19 0.0678 MmugDNA.12886.1.S1_at hypothetical protein LOC283755 /// D15F37 (pseudogene) /// LOC283755 /// 3.19 0.0143 MGC57820 protein MN7 /// MGC57820 MmugDNA.33174.1.S1_at T-cell receptor beta chain V region C5 precursor — 3.18 0.0008 MmugDNA.20801.1.S1_at Transcribed locus, moderately similar to XP_515629.1 — 3.16 0.0121 similar to U5 snRNP-specific protein, 200 kDa; U5 snRNP- specific protein, 200 kDa (DEXH RNA helicase family) [Pan troglodytes] MmuSTS.249.1.S1_at integrin, beta 2 ITGB2 3.16 0.0580 MmugDNA.18032.1.S1_at desmoglein 3 (pemphigus vulgaris antigen) DSG3 3.16 0.0084 MmugDNA.32328.1.S1_at lipoma HMGIC fusion partner LOC696978 3.16 0.0243 MmugDNA.3768.1.S1_at Kruppel-like factor 8 KLF8 3.16 0.0772 MmugDNA.34645.1.S1_s_at hypothetical protein LOC714309 LOC714309 3.15 0.0439 MmugDNA.19768.1.S1_at proliferation associated nuclear element 1 isoform a LOC709006 3.15 0.0103 MmugDNA.19278.1.S1_at phosphatase and actin regulator 2 PHACTR2 3.15 0.0524 MmugDNA.26562.1.S1_s_at growth arrest-specific 5 GAS5 3.14 0.0006 MmugDNA.15046.1.S1_at hemicentin 1 LOC714026 3.14 0.0142 MmugDNA.32563.1.S1_at methionine sulfoxide reductase B3 isoform 2 LOC717617 3.13 0.0827 MmugDNA.3350.1.S1_at L-3-hydroxyacyl-Coenzyme A dehydrogenase HADHSC 3.13 0.0983 MmugDNA.27093.1.S1_at alpha-2-macroglobulin A2M 3.13 0.0027 MmugDNA.28905.1.S1_at testis/prostate/placenta-expressed protein, isoform 2 LOC706183 3.12 0.0596 isoform 1 MmunewRS.723.1.S1_at serine (or cysteine) proteinase inhibitor, clade H, member 1 SERPINH1 3.12 0.0967 MmugDNA.39240.1.S1_at acyl-CoA synthetase long-chain family member 1 LOC694871 3.12 0.0034 MmugDNA.36848.1.S1_at Tissue factor pathway inhibitor 2 precursor (TFPI-2) TFPI2 3.11 0.0431 (Placental protein 5) (PP5) MmugDNA.5658.1.S1_at Bcl-2-related protein A1 (BFL-1 protein) (Hemopoietic- BCL2A1 3.11 0.0888 specific early response protein) (GRS protein) MmugDNA.25040.1.S1_at clusterin CLU 3.11 0.0568 MmugDNA.15918.1.S1_at monocyte to macrophage differentiation-associated LOC706723 3.10 0.0191 precursor MmugDNA.5064.1.S1_at transforming growth factor, beta-induced, 68 kDa TGFBI 3.10 0.0079 MmuSTS.4112.1.S1_at early growth response 1 EGR1 3.10 0.0015 MmugDNA.37314.1.S1_at Zinc finger, CCHC domain containing 6 ZCCHC6 3.09 0.0274 MmugDNA.16942.1.S1_at CDNA FLJ34374 fis, clone FEBRA2017502 — 3.09 0.0999 MmugDNA.24636.1.S1_at RAB, member of RAS oncogene family-like 2B RABL2B 3.09 0.0696 MmugDNA.24841.1.S1_at hypothetical protein LOC709979 LOC709979 3.08 0.0018 MmuSTS.4753.1.S1_at Wnt inhibitory factor 1 WIF1 3.08 0.0124 MmugDNA.30671.1.S1_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 LOC718822 3.08 0.0898 MmugDNA.2069.1.S1_at Isocitrate dehydrogenase 1 (NADP+), soluble IDH1 3.08 0.0678 MmugDNA.37149.1.S1_at oxysterol binding protein-like 6 OSBPL6 3.08 0.0801 MmugDNA.1095.1.S1_at Mediator of RNA polymerase II transcription, subunit 28 MED28 3.07 0.0008 homolog (yeast) MmugDNA.41794.1.S1_at moesin MSN 3.07 0.0208 MmugDNA.1253.1.S1_at — — 3.07 0.0105 MmugDNA.17781.1.S1_at neuroepithelial cell transforming gene 1 NET1 3.07 0.0094 MmugDNA.18663.1.S1_at Slit homolog 2 (Drosophila) SLIT2 3.07 0.0607 MmugDNA.25811.1.S1_at Transcribed locus — 3.07 0.0033 MmugDNA.18485.1.S1_at GC-rich sequence DNA-binding factor candidate LOC700489 3.07 0.0819 MmugDNA.10654.1.S1_at X-ray repair complementing defective repair in Chinese XRCC5 3.06 0.0952 hamster cells 5 (double-strand-break rejoining; Ku autoantigen, 80 kDa) MmugDNA.42236.1.S1_at Ribosomal protein L10a RPL10A 3.05 0.0207 MmugDNA.35088.1.S1_at Fibroblast growth factor receptor 1 (fms-related tyrosine FGFR1 3.05 0.0419 kinase 2, Pfeiffer syndrome) MmugDNA.18922.1.S1_at Hypothetical protein AY099107 LOC152185 3.05 0.0748 MmugDNA.31239.1.S1_at Forkhead box O3A FOXO3A 3.03 0.0108 MmugDNA.5694.1.S1_at ADAM metallopeptidase with thrombospondin type 1 motif, 5 ADAMTS5 3.03 0.0946 MmugDNA.39840.1.S1_at coactosin-like 1 LOC715376 3.03 0.0023 MmuSTS.2604.1.S1_at zinc finger homeobox 1b ZFHX1B 3.02 0.0942 MmugDNA.21087.1.S1_at integrin, alpha 5 (fibronectin receptor, alpha polypeptide) ITGA5 3.02 0.0160 MmuSTS.3523.1.S1_at B-cell CLL/lymphoma 11B isoform 1 LOC705238 3.02 0.0082 Mmu.7842.1.S1_at alpha 1 type IV collagen COL4A1 3.02 0.0409 MmugDNA.8730.1.S1_at Homo sapiens, clone IMAGE: 4778480, mRNA — 3.02 0.0632 MmuSTS.4829.1.S1_at growth hormone receptor GHR 3.02 0.0012 MmugDNA.14593.1.S1_at frizzled 4 LOC704754 3.01 0.0106 MmugDNA.42280.1.S1_at — — 3.01 0.0740 MmugDNA.34063.1.S1_at lysophosphatidylglycerol acyltransferase 1 LPGAT1 3.01 0.0644 MmuSTS.124.1.S1_at Homeobox protein Hox-A10 (Hox-1H) (Hox-1.8) (PL) LOC704713 3.01 0.0416 MmuSTS.24.1.S1_at Glycoprotein Xg precursor (Protein PBDX) XG 3.01 0.0839 MmugDNA.10983.1.S1_at septin 10 10-Sep 2.99 0.0257 MmugDNA.10337.1.S1_at CG9047-PA, isoform A LOC704595 2.99 0.0300 MmugDNA.15798.1.S1_s_at HLA class II histocompatibility antigen, DQ(2) alpha chain LOC717623 2.99 0.0862 precursor MmugDNA.8592.1.S1_at fatty acid binding protein 3, muscle and heart (mammary- FABP3 2.99 0.0766 derived growth inhibitor) MmugDNA.31542.1.S1_at colon carcinoma related protein LOC719328 2.98 0.0021 MmuSTS.1998.1.S1_at estrogen receptor 1 ESR1 2.98 0.0868 MmugDNA.22982.1.S1_at hypothetical protein LOC708514 LOC708514 2.98 0.0729 MmugDNA.25545.1.S1_at Full length insert cDNA clone ZD69D05 — 2.98 0.0295 MmugDNA.8954.1.S1_at glycerol-3-phosphate dehydrogenase 1 (soluble) GPD1 2.97 0.0050 MmuSTS.1138.1.S1_at Phospholipase A2, membrane associated precursor PLA2G2A 2.97 0.0880 (Phosphatidylcholine 2-acylhydrolase) (Group IIA phospholipase A2) (GIIC sPLA2) (Non-pancreatic secretory phospholipase A2) (NPS-PLA2) MmugDNA.10778.1.S1_at cyclin-dependent kinase inhibitor 3 LOC694877 2.97 0.0442 MmugDNA.10040.1.S1_at p53-regulated DDA3 isoform a LOC698060 2.96 0.0854 Mmu.2305.1.S1_at bluestreak CG6451-PA — 2.96 0.0295 MmuSTS.2278.1.S1_at peroxidasin LOC721654 2.95 0.0127 MmugDNA.1496.1.S1_at fatty acid desaturase 3 LOC722337 2.95 0.0442 MmugDNA.29758.1.S1_at proline-rich cyclin A1-interacting protein LOC709846 2.94 0.0143 MmuSTS.3401.1.S1_s_at CCAAT/enhancer-binding protein alpha (C/EBP alpha) LOC717153 2.94 0.0015 MmugDNA.2393.1.S1_at perilipin PLIN 2.93 0.0008 MmugDNA.393.1.S1_at CDNA FLJ26120 fis, clone SYN00419 — 2.93 0.0092 MmugDNA.30771.1.S1_at spermatogenesis associated factor SPAF LOC708640 2.93 0.0712 MmugDNA.15387.1.S1_at NEDD8 ultimate buster-1 NYREN18 2.92 0.0520 MmugDNA.5488.1.S1_at dehydrogenase/reductase (SDR family) member 3 LOC715548 2.92 0.0258 MmugDNA.35654.1.S1_at minichromosome maintenance protein 6 MCM6 2.92 0.0680 MmugDNA.30962.1.S1_at advanced glycosylation end product-specific receptor LOC717296 2.92 0.0097 isoform 1 precursor MmugDNA.36279.1.S1_at P3ECSL LOC705660 2.91 0.0626 MmugDNA.30623.1.S1_at ephrin receptor EphA1 EPHA1 2.91 0.0185 MmugDNA.42862.1.S1_s_at Fasciculation and elongation protein zeta 2 (Zygin-2) (Zygin LOC708288 2.91 0.0388 II) (Zygin-related protein types I/II) MmuSTS.2298.1.S1_at deafness, autosomal dominant 5 protein DFNA5 2.91 0.0812 MmugDNA.18093.1.S1_at FERM domain containing 6 LOC707266 2.91 0.0939 MmugDNA.34261.1.S1_at PI-3-kinase-related kinase SMG-1 LOC693542 2.90 0.0022 MmugDNA.39398.1.S1_at hypothetical protein LOC699173 LOC699173 2.89 0.0182 MmugDNA.6471.1.S1_at Cerebellar degeneration-related antigen 1 (CDR34) LOC698431 2.89 0.0015 MmugDNA.38313.1.S1_at Serum amyloid A protein precursor (SAA) /// serum amyloid LOC694944 /// 2.89 0.0137 A1 isoform 2 SAA1 MmugDNA.4080.1.S1_at peptidylprolyl isomerase F (cyclophilin F) PPIF 2.88 0.0024 MmugDNA.26182.1.S1_at heterogeneous nuclear ribonucleoprotein A1 HNRPA1 2.87 0.0025 MmugDNA.27473.1.S1_at CASP8 and FADD-like apoptosis regulator CFLAR 2.87 0.0203 MmugDNA.35112.1.S1_at kleisin beta isoform 2 LOC716120 2.87 0.0321 MmugDNA.22473.1.S1_at PP2135 protein PP2135 2.86 0.0928 MmugDNA.37882.1.S1_at hypothetical protein LOC703464 /// hypothetical protein LOC703464 /// 2.86 0.0211 LOC705990 LOC705990 MmuAffx.52.1.A1_at chemokine (C-C motif) ligand 4 CCL4 2.84 0.0361 MmugDNA.31283.1.S1_at hypothetical protein LOC693798 LOC693798 2.84 0.0659 MmuSTS.2520.1.S1_at heterogeneous nuclear ribonucleoprotein H2 HNRPH2 2.84 0.0827 MmugDNA.28432.1.S1_at adipocyte-specific adhesion molecule LOC708098 2.84 0.0517 MmugDNA.13083.1.S1_at activating transcription factor 7 interacting protein LOC698815 2.84 0.0965 MmugDNA.8865.1.S1_at Visinin-like protein 1 (VILIP) (Neural visinin-like protein 1) LOC699459 2.83 0.0285 (NVL-1) (NVP-1) (21 kDa CABP) MmuSTS.2601.1.S1_at embryonal Fyn-associated substrate isoform 2 LOC713838 2.83 0.0000 MmugDNA.38045.1.S1_at Transcribed locus — 2.82 0.0094 MmugDNA.9654.1.S1_at Heterogeneous nuclear ribonucleoprotein D (AU-rich HNRPD 2.82 0.0440 element RNA binding protein 1, 37 kDa) MmugDNA.38313.1.S1_s_at serum amyloid A1 isoform 2 LOC694944 2.81 0.0253 MmugDNA.24597.1.S1_at carbonyl reductase 3 LOC695769 2.81 0.0598 MmugDNA.36863.1.S1_at vang-like 1 LOC709730 2.80 0.0744 MmugDNA.15427.1.S1_at sterile alpha motif and leucine zipper containing kinase AZK ZAK 2.80 0.0920 MmugDNA.19311.1.S1_at laminin, beta 2 LAMB2 2.80 0.0012 MmugDNA.22113.1.S1_at Transcribed locus, strongly similar to XP_510155.1 similar — 2.80 0.0719 to PAPOLA protein [Pan troglodytes] MmuSTS.3531.1.S1_s_at — CCL4L 2.80 0.0516 MmugDNA.21105.1.S1_at DNA ligase I LIG1 2.80 0.0904 MmugDNA.15362.1.S1_at HEG homolog HEG 2.77 0.0055 MmugDNA.6611.1.S1_at hypothetical protein LOC701646 LOC701646 2.77 0.0623 MmugDNA.10320.1.S1_at nicotinamide nucleotide adenylyltransferase 3 NMNAT3 2.77 0.0937 MmugDNA.5714.1.S1_at timeless homolog LOC712835 2.77 0.0737 MmugDNA.6879.1.S1_at SNF1-like kinase 2 LOC711453 2.77 0.0878 MmugDNA.40900.1.S1_at Host cell factor-binding transcription factor Zhangfei (HCF- LOC702942 2.76 0.0186 binding transcription factor Zhangfei) (Tyrosine kinase- associated leucine zipper protein LAZip) MmugDNA.5326.1.S1_at cyclin-dependent kinase 3 CDK3 2.76 0.0203 MmugDNA.42369.1.S1_s_at Josephin domain containing 3 LOC696602 2.76 0.0792 MmuSTS.607.1.S1_at Heat-shock protein beta-7 (HspB7) (Cardiovascular heat LOC696704 2.75 0.0029 shock protein) (cvHsp) MmugDNA.39315.1.S1_at Leukemia inhibitory factor receptor LIFR 2.75 0.0588 MmuSTS.631.1.S1_at angiomotin like 2 LOC718868 2.74 0.0095 MmuSTS.2866.1.S1_at Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18) LOC719733 2.74 0.0870 (Op18) (Leukemia-associated phosphoprotein p18) (pp17) (Prosolin) (Metablastin) (Protein Pr22) MmugDNA.41518.1.S1_s_at vimentin VIM 2.74 0.0725 MmugDNA.5148.1.S1_at Notchless gene homolog NLE1 2.74 0.0939 MmugDNA.34796.1.S1_at chromosome 10 open reading frame 99 C10orf99 2.73 0.0070 MmugDNA.27576.1.S1_at — — 2.73 0.0033 MmuSTS.2115.1.S1_at — ARHGEF6 2.72 0.0401 MmugDNA.27574.1.S1_at membrane-spanning 4-domains, subfamily A, member 6A LOC697689 2.72 0.0785 isoform 2 MmugDNA.12560.1.S1_at enoyl Coenzyme A hydratase domain containing 3 LOC693583 2.72 0.0499 MmugDNA.35275.1.S1_at transmembrane protease, serine 8 (intestinal) LOC697965 2.72 0.0064 MmugDNA.43094.1.S1_at procollagen C-endopeptidase enhancer 2 PCOLCE2 2.72 0.0769 Mmu.3054.2.S1_at upstream of NRAS CSDE1 2.72 0.0039 MmuSTS.2641.1.S1_at ATP synthase, H+ transporting, mitochondrial F1 complex, — 2.72 0.0461 alpha subunit MmugDNA.18980.1.S1_at neuromedin B NMB 2.71 0.0546 MmugDNA.23958.1.S1_at G protein-coupled receptor 37 GPR37 2.71 0.0888 MmugDNA.43305.1.S1_at — — 2.71 0.0499 MmugDNA.31834.1.S1_at Fanconi anemia group A protein (Protein FACA) LOC714932 2.71 0.0205 MmugDNA.36837.1.S1_at poly(rC) binding protein 2 (predicted) /// poly(rC) binding LOC694744 /// 2.70 0.0636 protein 2 LOC703175 MmugDNA.11099.1.S1_at Catenin (cadherin-associated protein), beta 1, 88 kDa CTNNB1 2.70 0.0381 MmugDNA.37576.1.S1_at PHD finger protein 20-like 1 isoform 1 LOC701406 2.70 0.0015 MmuSTS.541.1.S1_at oxysterol-binding protein-like protein 8 isoform a LOC693338 2.69 0.0396 MmugDNA.16521.1.S1_at hypothetical protein DKFZp761N09121 DKFZP761N09121 2.69 0.0319 MmugDNA.9406.1.S1_at Ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) UBE2H 2.69 0.0368 MmuSTS.3625.1.S1_at polycystin 2 LOC702179 2.68 0.0079 MmugDNA.41756.1.S1_at membrane protein, palmitoylated 3 (MAGUK p55 subfamily MPP3 2.68 0.0063 member 3) MmugDNA.7204.1.S1_at serum/glucocorticoid regulated kinase LOC713082 2.67 0.0050 MmugDNA.19300.1.S1_at Endothelial protein C receptor precursor (Endothelial cell LOC706040 2.67 0.0858 protein C receptor) (Activated protein C receptor) (APC receptor) (CD201 antigen) MmugDNA.7974.1.S1_at TRAF interacting protein TRAIP 2.67 0.0891 MmugDNA.14150.1.S1_at CG8745-PA LOC702302 2.67 0.0453 MmugDNA.24498.1.S1_at replication factor C (activator 1) 4, 37 kDa RFC4 2.67 0.0043 MmugDNA.31559.1.S1_at CTD small phosphatase-like protein (CTDSP-like) (Small C- LOC697898 2.67 0.0039 terminal domain phosphatase 3) (Small CTD phosphatase 3) (SCP3) (Nuclear LIM interactor-interacting factor 1) (NLI- interacting factor 1) (NIF-like protein) (RBSP3) (YA22 protein) (. . . MmugDNA.27755.1.S1_at Similar to KIAA0393 protein MGC57820 2.67 0.0755 MmuSTS.825.1.S1_x_at degenerative spermatocyte homolog 1, lipid desaturase LOC702128 2.67 0.0943 MmugDNA.32190.1.S1_at HRAS-like suppressor 3 HRASLS3 2.66 0.0205 MmugDNA.378.1.S1_at Syntaxin 7 STX7 2.66 0.0271 MmugDNA.7129.1.S1_at UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- LOC701790 2.66 0.0855 acetylgalactosaminyltransferase-like 4 MmugDNA.37173.1.S1_at methyltransferase like 7A LOC693894 2.66 0.0812 MmugDNA.15924.1.S1_at Eukaryotic translation initiation factor 4E member 2 EIF4E2 2.66 0.0777 MmugDNA.18344.1.S1_at Jagged 1 (Alagille syndrome) JAG1 2.66 0.0523 MmugDNA.18912.1.S1_at inter-alpha trypsin inhibitor heavy chain precursor 5 isoform 2 LOC722614 2.65 0.0437 MmugDNA.38963.1.S1_at inhibitor of DNA binding 1 isoform b LOC713160 2.65 0.0167 MmugDNA.38359.1.S1_at H2A histone family, member Y H2AFY 2.65 0.0069 MmuSTS.1880.1.S1_at collagen, type IV, alpha 2 COL4A2 2.65 0.0233 MmuSTS.999.1.S1_at myc proto-oncogene protein MYC 2.65 0.0644 MmugDNA.27587.1.S1_at Homo sapiens, clone IMAGE: 5170410, mRNA — 2.65 0.0784 MmugDNA.20660.1.S1_at tripartite motif-containing 33 protein TRIM33 2.64 0.0247 MmugDNA.7029.1.S1_at Receptor activity-modifying protein 3 precursor (CRLR LOC697349 2.64 0.0289 activity-modifying protein 3) (Calcitonin-receptor-like receptor activity-modifying protein 3) MmuSTS.3328.1.S1_at origin recognition complex, subunit 1 LOC713271 2.63 0.0374 MmugDNA.38420.1.S1_s_at Transmembrane BAX inhibitor motif-containing protein 4 (Z- TMBIM4 2.63 0.0011 protein) (S1R protein) MmugDNA.32616.1.S1_at XIAP associated factor-1 isoform 1 LOC713425 2.63 0.0099 MmugDNA.2794.1.S1_at Epithelial membrane protein 1 (EMP-1) (Tumor-associated EMP1 2.63 0.0386 membrane protein) (CL-20) (B4B protein) MmugDNA.28550.1.S1_at heat shock protein, alpha-crystallin-related, B6 LOC710760 2.62 0.0083 MmugDNA.19535.1.S1_at desmocollin 3 DSC3 2.62 0.0261 MmugDNA.14923.1.S1_at Adenomatosis polyposis coli 2 APC2 2.62 0.0847 MmugDNA.10555.1.S1_at CDNA FLJ36553 fis, clone TRACH2008478 — 2.61 0.0113 MmugDNA.35200.1.S1_at hypothetical protein FLJ13305 FLJ13305 2.61 0.0709 MmugDNA.10323.1.S1_s_at RNA binding motif protein 25 LOC695911 2.60 0.0340 MmugDNA.25448.1.S1_at CG13745-PA LOC699878 2.60 0.0499 MmugDNA.40326.1.S1_at MRNA; cDNA DKFZp686F1318 (from clone — 2.60 0.0643 DKFZp686F1318) MmugDNA.11833.1.S1_at Homo sapiens, clone IMAGE: 5278284, mRNA — 2.60 0.0515 MmugDNA.31867.1.S1_at golgi associated, gamma adaptin ear containing, ARF GGA2 2.59 0.0586 binding protein 2 MmugDNA.33539.1.S1_at Ankyrin 3, node of Ranvier (ankyrin G) ANK3 2.59 0.0204 MmugDNA.37283.1.S1_at Polypyrimidine tract binding protein 2 PTBP2 2.57 0.0946 MmugDNA.40388.1.S1_at lactotransferrin LOC713115 2.57 0.0012 MmunewRS.711.1.S1_at corticotropin releasing hormone binding protein LOC707589 2.56 0.0397 MmugDNA.20034.1.S1_at Full length insert cDNA clone ZD69D05 — 2.55 0.0473 MmugDNA.40606.1.S1_at Activin A receptor type II-like 1 ACVRL1 2.55 0.0529 MmugDNA.42565.1.S1_at H+ transporting F1 ATP synthase epsilon subunit — 2.55 0.0439 MmugDNA.16683.1.S1_at solute carrier family 24 (sodium/potassium/calcium SLC24A3 2.54 0.0562 exchanger), member 3 MmugDNA.864.1.S1_at Chromosome 16 open reading frame 28 C16orf28 2.54 0.0225 MmugDNA.41780.1.S1_at interleukin 6 signal transducer receptor IL-6 2.53 0.0980 MmugDNA.37515.1.S1_at Hypothetical protein FLJ13941 FLJ13941 2.53 0.0038 MmugDNA.25797.1.S1_at Hypothetical protein MGC10067 MGC10067 2.53 0.0315 MmugDNA.27004.1.S1_at follistatin-like 1 FSTL1 2.52 0.0172 MmugDNA.1644.1.S1_at eukaryotic translation initiation factor 5B EIF5B 2.52 0.0295 MmugDNA.23477.1.S1_at RAS and EF hand domain containing RASEF 2.52 0.0477 MmugDNA.40191.1.S1_at Ubiquinol-cytochrome c reductase complex 14 kDa protein UQCRB 2.52 0.0061 (Complex III subunit VI) (QP-C) MmugDNA.5276.1.S1_at two AAA domain containing protein LOC704478 2.51 0.0788 MmugDNA.9275.1.S1_at Acetyl-Coenzyme A synthetase 2 (ADP forming) ACAS2 2.51 0.0312 MmugDNA.23637.1.S1_at Rho GTPase activating protein 23 ARHGAP23 2.51 0.0377 MmugDNA.31862.1.S1_at Transcribed locus, moderately similar to XP_524454.1 — 2.51 0.0338 LOC469069 [Pan troglodytes] MmugDNA.39520.1.S1_at Rho GDP-dissociation inhibitor 2 (Rho GDI 2) (Rho-GDI ARHGDIB 2.50 0.0744 beta) (Ly-GDI) MmugDNA.22495.1.S1_at choline phosphotransferase 1 LOC696056 2.50 0.0276 MmugDNA.40534.1.S1_s_at S-phase kinase-associated protein 2 isoform 1 LOC700617 2.49 0.0640 MmugDNA.25179.1.S1_s_at hypothetical protein LOC707276 /// Acidic leucine-rich ANP32B /// 2.49 0.0301 nuclear phosphoprotein 32 family member B (PHAPI2 LOC707276 protein) (Silver-stainable protein SSP29) (Acidic protein rich in leucines) MmugDNA.20756.1.S1_at methionine aminopeptidase 1D MAP1D 2.49 0.0157 MmugDNA.10451.1.S1_at lipoprotein lipase LPL 2.48 0.0793 MmugDNA.37784.1.S1_at Microfibrillar-associated protein 5 precursor (MFAP-5) MFAP5 2.48 0.0288 (Microfibril-associated glycoprotein 2) (MAGP-2) (MP25) MmugDNA.11410.1.S1_at WW domain-containing adapter with a coiled-coil region LOC715828 2.48 0.0246 isoform 1 MmugDNA.16003.1.S1_at hypothetical protein LOC713457 LOC713457 2.48 0.0832 MmugDNA.7480.1.S1_at Glutaredoxin-1 (Thioltransferase-1) (TTase-1) GLRX 2.48 0.0177 MmugDNA.41094.1.S1_at cytochrome P450, family 2, subfamily E, polypeptide 2 LOC718303 2.47 0.0545 homolog MmuSTS.2498.1.S1_at zinc finger protein 8 ZNF8 2.47 0.0011 MmuSTS.3305.1.S1_at Oxysterols receptor LXR-alpha (Liver X receptor alpha) NR1H3 2.47 0.0882 (Nuclear orphan receptor LXR-alpha) MmugDNA.22116.1.S1_at Neurotensin/neuromedin N precursor NTS 2.47 0.0663 MmuSTS.1525.1.S1_at mitochondrial ribosomal protein L35 MRPL35 2.47 0.0431 MmugDNA.14539.1.S1_at KIAA1450 protein KIAA1450 2.46 0.0140 MmugDNA.2162.1.S1_at C20orf111 LOC693890 2.46 0.0194 MmugDNA.14181.1.S1_at CDNA: FLJ23006 fis, clone LNG00414 — 2.46 0.0527 MmugDNA.38899.1.S1_at alpha 2 type VI collagen isoform 2C2 precursor LOC709493 2.46 0.0950 MmugDNA.12419.1.S1_at sno, strawberry notch homolog 1 LOC709260 2.46 0.0741 Mmu.13956.1.S1_at mitochondrial aldehyde dehydrogenase 2 ALDH2 2.46 0.0559 MmugDNA.27955.1.S1_at thrombospondin 3 THBS3 2.45 0.0003 Mmu.12740.1.S1_at activating transcription factor 2 LOC699072 2.45 0.0690 MmugDNA.2942.1.S1_at Ras-related protein Rab-15 LOC708330 2.44 0.0561 MmugDNA.42705.1.S1_at SH3 multiple domains 1 LOC714868 2.44 0.0830 MmugDNA.2199.1.S1_at hypothetical protein LOC706003 LOC706003 2.44 0.0707 MmugDNA.31469.1.S1_at Mitochondrial 28S ribosomal protein S25 (S25mt) (MRP- LOC703261 2.44 0.0413 S25) MmugDNA.32362.1.S1_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog MAFB 2.43 0.0446 B (avian) MmugDNA.37182.1.S1_at C17G10.1 LOC700219 2.43 0.0349 MmugDNA.3948.1.S1_at B-cell lymphoma 6 protein LOC708736 2.43 0.0461 MmugDNA.29568.1.S1_at Hypothetical gene supported by BX640700 — 2.43 0.0882 MmugDNA.22001.1.S1_at mucin 7, salivary LOC707153 2.43 0.0161 MmugDNA.24814.1.S1_at RAS protein activator like 2 RASAL2 2.43 0.0553 MmugDNA.23518.1.S1_at Muscleblind-like 2 (Drosophila) MBNL2 2.42 0.0661 MmugDNA.10700.1.S1_at opioid growth factor receptor-like 1 LOC715189 2.42 0.0889 MmugDNA.13067.1.S1_at serine/threonine kinase 4 STK4 2.42 0.0978 MmugDNA.40225.1.S1_at LIM domain containing preferred translocation partner in LPP 2.42 0.0289 lipoma MmugDNA.31182.1.S1_at centrosome spindle pole associated protein LOC704476 2.42 0.0587 MmugDNA.19553.1.S1_at damage-specific DNA binding protein 2 (48 kD) DDB2 2.41 0.0098 MmugDNA.2267.1.S1_at Transcribed locus — 2.41 0.0491 MmugDNA.2874.1.S1_at DNA polymerase gamma subunit 2, mitochondrial precursor LOC720356 2.41 0.0413 (Mitochondrial DNA polymerase accessory subunit) (PolG- beta) (MtPolB) (DNA polymerase gamma accessory 55 kDa subunit) (p55) Mmu.11306.1.S1_at MYC binding protein 2 MYCBP2 2.41 0.0484 MmugDNA.27252.1.S1_at Transcribed locus — 2.41 0.0826 MmugDNA.4547.1.S1_at aarF domain containing kinase 5 ADCK5 2.41 0.0068 MmugDNA.29817.1.S1_at Ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, UBE2E2 2.41 0.0791 yeast) MmugDNA.22188.1.S1_at Rho guanine nucleotide exchange factor (GEF) 10 ARHGEF10 2.40 0.0882 MmugDNA.3376.1.S1_at caspase recruitment domain family, member 8 CARD8 2.40 0.0302 MmugDNA.43065.1.S1_at pregnancy-induced growth inhibitor isoform 1 LOC714549 2.40 0.0211 MmugDNA.40500.1.S1_at hypothetical protein LOC694075 LOC694075 2.40 0.0409 MmugDNA.11419.1.S1_at molecule interacting with Rab13 MICAL-L1 2.39 0.0963 MmugDNA.1847.1.S1_at tissue inhibitor of metalloproteinase 2 TIMP2 2.39 0.0030 MmugDNA.11882.1.S1_at hypothetical protein LOC721782 LOC721782 2.39 0.0452 MmuSTS.1231.1.S1_at copine II LOC703557 2.39 0.0061 MmugDNA.22620.1.S1_at Galectin-7 (Gal-7) (HKL-14) (PI7) (p53-induced protein 1) LGALS7 2.38 0.0861 Mmu.15973.14.S1_at growth hormone variant /// growth hormone 1 isoform 1 /// CSH-3 /// 2.38 0.0038 chorionic somatommamotropin hormone 3 /// growth CSH-4 /// GH1 /// hormone 1 /// chorionic somatommamotropin hormone 4 LOC700885 /// LOC718116 /// LOC718474 MmugDNA.40962.1.S1_at Patched homolog (Drosophila) PTCH 2.37 0.0228 MmugDNA.11810.1.S1_at chromatin-specific transcription elongation factor large LOC708066 2.37 0.0275 subunit MmuSTS.2967.1.S1_at alcohol dehydrogenase, iron containing, 1 LOC703118 2.37 0.0768 MmugDNA.3168.1.S1_at CDNA clone IMAGE: 5294683, partial cds — 2.37 0.0307 MmugDNA.4900.1.S1_s_at amylase, alpha 2A; pancreatic AMY2A 2.37 0.0873 MmuSTS.1626.1.S1_at thyroid hormone receptor interactor 10 LOC703934 2.36 0.0148 MmuSTS.3226.1.S1_at myosin IXA LOC701520 2.36 0.0256 MmugDNA.23835.1.S1_at RNA binding motif protein 5 RBM5 2.35 0.0695 MmuSTS.1925.1.S1_at Tissue factor precursor (TF) (Coagulation factor III) F3 2.35 0.0169 (Thromboplastin) (CD142 antigen) MmugDNA.23256.1.S1_at guanylate cyclase 1, soluble, alpha 3 LOC699365 2.35 0.0208 MmunewRS.334.1.S1_at gi:42657654 — 2.35 0.0278 MmugDNA.524.1.S1_at Full length insert cDNA clone YX74D05 — 2.34 0.0963 MmuSTS.891.1.S1_at Microfibrillar-associated protein 2 precursor (MFAP-2) MFAP2 2.34 0.0609 (Microfibril-associated glycoprotein) (MAGP) (MAGP-1) MmuSTS.4399.1.S1_at cell division cycle associated 8 LOC719808 2.34 0.0254 MmugDNA.36.1.S1_at Sorting nexin-10 SNX10 2.33 0.0528 MmugDNA.24165.1.S1_at ATP synthase lipid-binding protein, mitochondrial precursor — 2.33 0.0024 (ATP synthase proteolipid P1) (ATPase protein 9) (ATPase subunit C) MmugDNA.38800.1.S1_at connexin 43 GJA1 2.33 0.0658 MmugDNA.2930.1.S1_at Full length insert cDNA clone ZE03F06 — 2.33 0.0266 MmugDNA.42198.1.S1_at glycosyltransferase-like 1B LOC714846 2.33 0.0727 MmugDNA.782.1.S1_s_at adenine phosphoribosyltransferase isoform b APRT 2.33 0.0978 MmugDNA.40585.1.S1_at — — 2.32 0.0884 Mmu.13676.1.S1_s_at Transcribed locus — 2.32 0.0702 MmugDNA.38278.1.S1_at Solute carrier family 1 (glutamate/neutral amino acid SLC1A4 2.32 0.0846 transporter), member 4 MmugDNA.37513.1.S1_at Y-box-binding protein 2 (Germ cell-specific Y-box-binding LOC714750 2.32 0.0853 protein) (FRGY2 homolog) MmuSTS.699.1.S1_at calcium activated chloride channel 2 LOC711959 2.32 0.0311 MmugDNA.35545.1.S1_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 DDX17 2.32 0.0193 MmuSTS.4279.1.S1_at ephrin A4 isoform b LOC717315 2.31 0.0921 MmuSTS.4415.1.S1_at nuclear matrix protein p84 THOC1 2.31 0.0067 MmugDNA.20377.1.S1_at growth arrest-specific 6 LOC716066 2.31 0.0374 MmugDNA.9919.1.S1_at solute carrier family 25, member 36 LOC715375 2.30 0.0365 MmugDNA.41865.1.S1_at procollagen C-endopeptidase enhancer PCOLCE 2.30 0.0277 Mmu.2142.1.S1_at tripartite motif-containing 22 TRIM22 2.30 0.0336 MmugDNA.21471.1.S1_at butyrophilin-like 9 BTNL9 2.30 0.0203 MmugDNA.33142.1.S1_at Thyroid hormone receptor associated protein 2 THRAP2 2.30 0.0902 MmugDNA.911.1.S1_at tRNA splicing endonuclease 54 homolog (SEN54, S. cerevisiae) LOC702604 2.29 0.0159 MmugDNA.462.1.S1_at Chromobox homolog 3 (HP1 gamma homolog, Drosophila) CBX3 2.29 0.0325 MmugDNA.16130.1.S1_at hypothetical protein LOC90393 LOC90393 2.29 0.0237 MmugDNA.32185.1.S1_s_at Troponin T, fast skeletal muscle (TnTf) (Fast skeletal LOC704095 2.29 0.0954 muscle troponin T) (fTnT) (Beta TnTF) MmuSTS.268.1.S1_at U2-associated SR140 protein LOC716408 2.29 0.0066 MmugDNA.39036.1.S1_at Coatomer subunit zeta-2 (Zeta-2 coat protein) (Zeta-2 COP) COPZ2 2.28 0.0507 MmugDNA.21025.1.S1_at cold inducible RNA binding protein LOC706175 2.28 0.0249 MmugDNA.40486.1.S1_s_at Immortalization-up-regulated protein (Hepatocyte growth LOC714854 2.28 0.0153 factor activator inhibitor type 2-related small pprotein) (HAI- 2-related small protein) (H2RSP) MmugDNA.26396.1.S1_at proline rich 6 LOC700414 2.28 0.0073 MmuSTS.2009.1.S1_at protocadherin 18 precursor LOC698420 2.27 0.0824 MmugDNA.9315.1.S1_at kinesin light chain 3 LOC714331 2.27 0.0027 MmugDNA.31698.1.S1_at chromosome 10 open reading frame 86 LOC705375 2.27 0.0652 MmugDNA.30174.1.S1_at v-ets erythroblastosis virus E26 oncogene like ERG 2.27 0.0267 MmuSTS.7.1.S1_at GULP, engulfment adaptor PTB domain containing 1 LOC708601 2.27 0.0459 MmuSTS.4265.1.S1_at glypican 4 LOC706665 2.26 0.0874 MmugDNA.14551.1.S1_at cat eye syndrome critical region protein 1 isoform a LOC709295 2.26 0.0215 precursor MmugDNA.28933.1.S1_at septin 11 11-Sep 2.26 0.0320 MmugDNA.24711.1.S1_at rhomboid family 1 LOC693423 2.26 0.0985 MmugDNA.22992.1.S1_at zinc finger protein (C2H2 type) 277 ZNF277 2.26 0.0065 MmugDNA.24410.1.S1_at melanoma associated antigen (mutated) 1 MUM1 2.26 0.0947 MmugDNA.9906.1.S1_at Histone H1.5 (Histone H1a) LOC705100 2.26 0.0128 MmuSTS.3965.1.S1_at colony stimulating factor 1 receptor precursor LOC711512 2.26 0.0542 MmugDNA.1769.1.S1_at CG4699-PA, isoform A LOC713138 2.25 0.0713 MmugDNA.43306.1.S1_at cyclin I — 2.25 0.0498 MmugDNA.42603.1.S1_at ankyrin repeat domain 28 LOC696592 2.25 0.0775 MmugDNA.37006.1.S1_at B-cell translocation gene 1, anti-proliferative LOC710112 2.25 0.0352 MmugDNA.7428.1.S1_at Wolf-Hirschhorn syndrome candidate 1 protein isoform 1 LOC712618 2.25 0.0954 MmugDNA.37011.1.S1_at CXXC finger 6 LOC694137 2.25 0.0304 MmugDNA.35449.1.S1_at Sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta- SIAT7B 2.24 0.0030 galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6- sialyltransferase) B /// CDNA clone IMAGE: 3831740, partial cds MmuSTS.1106.1.S1_at platelet/endothelial cell adhesion molecule (CD31 antigen) LOC718302 2.24 0.0231 MmugDNA.12061.1.S1_at — — 2.24 0.0089 MmuSTS.4678.1.S1_at three prime repair exonuclease 1 isoform d LOC710035 2.24 0.0664 Mmu.4786.2.S1_at pyrophosphatase 1 LOC716720 2.24 0.0781 MmugDNA.38317.1.S1_at Transcribed locus — 2.23 0.0610 MmugDNA.26830.1.S1_at polymerase (DNA directed), eta LOC700772 2.23 0.0463 MmugDNA.18586.1.S1_at structural maintenance of chromosomes 2-like 1 SMC2L1 2.23 0.0554 MmugDNA.11249.1.S1_at potassium channel tetramerisation domain containing 12 LOC695756 2.23 0.0517 MmugDNA.8879.1.S1_at sestrin 3 SESN3 2.23 0.0195 MmugDNA.24687.1.S1_at SLIT-ROBO Rho GTPase activating protein 1 SRGAP1 2.22 0.0821 MmugDNA.37739.1.S1_at serine/threonine kinase 24 (STE20 homolog, yeast) STK24 2.22 0.0258 MmuSTS.1280.1.S1_at RAB39 LOC709951 2.21 0.0169 MmugDNA.24944.1.S1_at Cytochrome P450, family 4, subfamily F, polypeptide 3 — 2.21 0.0677 MmunewRS.254.1.S1_at putative ISG12(c) protein IFI27 2.21 0.0683 MmugDNA.34004.1.S1_s_at secretory carrier membrane protein 2 SCAMP2 2.21 0.0608 MmugDNA.12030.1.S1_at SEC8 protein — 2.20 0.0199 MmugDNA.21255.1.S1_at neutrophil cytosolic factor 1 NCF1 2.20 0.0161 MmugDNA.43588.1.S1_at hypothetical protein LOC712570 LOC712570 2.20 0.0824 MmugDNA.23296.1.S1_s_at thyroid receptor-interacting protein 6 TRIP6 2.20 0.0513 MmugDNA.14929.1.S1_at insulin-like growth factor 2 mRNA binding protein 2 isoform b LOC701536 2.20 0.0109 MmugDNA.39168.1.S1_at platelet-derived growth factor C precursor LOC700236 2.19 0.0284 MmuSTS.1102.1.S1_at poly(rC) binding protein 4 isoform b PCBP4 2.19 0.0477 MmugDNA.41718.1.S1_at CG12134-PA, isoform A LOC706314 2.19 0.0509 MmugDNA.36456.1.S1_at C1q and tumor necrosis factor related protein 2 LOC695783 2.18 0.0650 MmuSTS.4542.1.S1_at Glycophorin C (PAS-2) (Glycoprotein beta) (GLPC) LOC712092 2.18 0.0118 (Glycoconnectin) (Sialoglycoprotein D) (Glycophorin D) (GPD) (CD236 antigen) MmugDNA.10214.1.S1_at KIAA0792 gene product KIAA0792 2.18 0.0596 MmugDNA.7604.1.S1_at THO complex 2 THOC2 2.18 0.0947 MmugDNA.4607.1.S1_at zinc finger protein 326 isoform 2 LOC696575 2.18 0.0302 MmugDNA.26241.1.S1_at cytochrome b5 reductase LOC714058 2.18 0.0499 MmugDNA.24148.1.S1_at trafficking protein, kinesin binding 2 LOC701779 2.17 0.0404 MmugDNA.15712.1.S1_x_at Cathepsin B CTSB 2.17 0.0099 MmugDNA.34134.1.S1_at quaking homolog, KH domain RNA binding isoform HQK-5 LOC712600 2.17 0.0569 MmugDNA.20961.1.S1_at abhydrolase domain containing 1 (predicted) LOC711493 2.17 0.0641 MmugDNA.11400.1.S1_at Homo sapiens, clone IMAGE: 6152133, mRNA — 2.17 0.0985 MmugDNA.32260.1.S1_at — — 2.17 0.0854 MmugDNA.3224.1.S1_at beta adrenergic receptor kinase 2 LOC714510 2.17 0.0824 MmuSTS.144.1.S1_at minichromosome maintenance protein 2 LOC710888 2.16 0.0450 MmugDNA.8814.1.S1_at TBC1 domain family, member 4 LOC696915 2.15 0.0771 MmugDNA.31838.1.S1_s_at histamine N-methyltransferase HNMT 2.15 0.0984 MmuSTS.224.1.S1_at solute carrier family 25, member 27 SLC25A27 2.15 0.0161 MmugDNA.24609.1.S1_at hypothetical protein LOC707415 LOC707415 2.14 0.0692 MmugDNA.9218.1.S1_at RNA binding motif protein 30 RBM30 2.14 0.0450 MmugDNA.1986.1.S1_at type 1 tumor necrosis factor receptor shedding ARTS-1 2.14 0.0959 aminopeptidase regulator MmugDNA.21483.1.S1_at zinc finger protein 579 LOC701452 2.14 0.0953 MmugDNA.16054.1.S1_at TWIST neighbor LOC707781 2.14 0.0733 MmugDNA.7039.1.S1_at — — 2.14 0.0038 MmuSTS.3729.1.S1_at fibromodulin precursor LOC703048 2.14 0.0183 MmugDNA.10834.1.S1_at allograft inflammatory factor 1 AIF1 2.14 0.0300 MmugDNA.32311.1.S1_at hormone-sensitive lipase LOC707997 2.14 0.0209 MmugDNA.12478.1.S1_at pleckstrin homology domain containing, family C (with LOC693958 2.14 0.0232 FERM domain) member 1 MmugDNA.37583.1.S1_at Protein tyrosine phosphatase, receptor type, S PTPRS 2.13 0.0946 MmugDNA.19987.1.S1_s_at hypothetical protein LOC284454 LOC284454 2.13 0.0374 MmugDNA.7038.1.S1_at Fc fragment of IgG, low affinity IIIb, receptor (CD16b) FCGR3B 2.13 0.0550 MmugDNA.32358.1.S1_at lamin A/C LMNA 2.13 0.0347 MmugDNA.16962.1.S1_at establishment of cohesion 1 homolog 1 LOC698845 2.13 0.0556 MmugDNA.23571.1.S1_at Epithelial stromal interaction 1 (breast) EPSTI1 2.13 0.0778 MmuSTS.2627.1.S1_at exostoses (multiple)-like 1 EXTL1 2.13 0.0154 MmuSTS.1193.1.S1_at phorbol-12-myristate-13-acetate-induced protein 1 LOC702789 2.13 0.0133 MmugDNA.20278.1.S1_at Insulin-like growth factor-binding protein 7 precursor LOC693564 2.12 0.0219 (IGFBP-7) (IBP-7) (IGF-binding protein 7) (MAC25 protein) (Prostacyclin-stimulating factor) (PGI2-stimulating factor) (IGFBP-rP1) MmugDNA.22598.1.S1_at poliovirus receptor-related 1 (herpesvirus entry mediator C; PVRL1 2.12 0.0579 nectin) MmugDNA.3092.1.S1_at Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP HNRPA2B1 2.12 0.0077 A2/hnRNP B1) MmuSTS.8.1.S1_at Histone H2A.x (H2a/x) LOC703073 2.12 0.0010 MmuSTS.2363.1.S1_at squamous cell carcinoma antigen recognized by T cells 2 LOC716054 2.12 0.0083 MmuSTS.3798.1.S1_at scavenger receptor class A, member 3 isoform 1 LOC718263 2.12 0.0501 MmugDNA.22785.1.S1_at — — 2.11 0.0320 MmugDNA.38565.1.S1_at v-fos FBJ murine osteosarcoma viral oncogene homolog FOS 2.11 0.0239 MmugDNA.20885.1.S1_at chromosome 10 open reading frame 6 LOC710786 2.11 0.0526 MmugDNA.11836.1.S1_at — — 2.11 0.0069 MmugDNA.16849.1.S1_at NAD-dependent deacetylase sirtuin-4 (SIR2-like protein 4) LOC720498 2.11 0.0416 MmuSTS.4531.1.S1_at ankyrin repeat and SOCS box-containing protein 1 ASB1 2.11 0.0647 MmugDNA.607.1.S1_at ras-like protein TC10 LOC717769 2.11 0.0443 MmugDNA.33195.1.S1_at hypothetical protein LOC704974 /// G-protein coupled LOC704974 /// 2.11 0.0049 purinergic receptor P2Y5 LOC705081 MmugDNA.40999.1.S1_at DAB2 interacting protein DAB2IP 2.10 0.0008 MmugDNA.9833.1.S1_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog MAF 2.10 0.0082 (avian) MmugDNA.21011.1.S1_at hypothetical protein FLJ90396 FLJ90396 2.10 0.0507 MmugDNA.2101.1.S1_at stearoyl-CoA desaturase (delta-9-desaturase) SCD 2.10 0.0023 MmuSTS.822.1.S1_at drebrin 1 DBN1 2.10 0.0386 MmugDNA.41100.1.S1_at GPI-anchored metastasis-associated protein homolog LOC718197 2.10 0.0588 MmugDNA.38957.1.S1_at Cleavage stimulation factor, 3′ pre-RNA, subunit 2, 64 kDa, CSTF2T 2.10 0.0646 tau variant MmugDNA.34474.1.S1_at cysteine sulfinic acid decarboxylase-related protein 2 LOC701290 2.08 0.0698 MmugDNA.9802.1.S1_at aldehyde dehydrogenase 3 family, member A1 ALDH3A1 2.08 0.0132 MmugDNA.43169.1.S1_at CD109 antigen (Gov platelet alloantigens) CD109 2.08 0.0492 MmuSTS.698.1.S1_at CKLF-like MARVEL transmembrane domain-containing CMTM6 2.08 0.0065 protein 6 (Chemokine-like factor superfamily member 6) MmugDNA.34248.1.S1_at splicing factor, arginine/serine-rich 15 LOC701931 2.08 0.0239 MmugDNA.33686.1.S1_s_at hypothetical protein LOC722265 LOC722265 2.08 0.0776 MmugDNA.33032.1.S1_at K06A9.1b LOC710668 2.07 0.0082 MmugDNA.14765.1.S1_at polymerase I and transcript release factor PTRF 2.07 0.0288 MmugDNA.32283.1.S1_at ladinin 1 LOC707971 2.07 0.0106 MmuSTS.2113.1.S1_at — ARHGEF19 2.07 0.0016 MmugDNA.11281.1.S1_at proline-, glutamic acid-, leucine-rich protein 1 LOC709306 2.07 0.0128 MmugDNA.21716.1.S1_at CDNA FLJ36544 fis, clone TRACH2006378 — 2.07 0.0908 MmugDNA.33042.1.S1_at latent transforming growth factor beta binding protein 2 LOC699435 2.07 0.0762 MmugDNA.9373.1.S1_at metastasis-associated protein 2 — 2.06 0.0100 Mmu.13445.1.S1_at calumenin precursor LOC699730 2.06 0.0342 MmuSTS.4590.1.S1_at transglutaminase 2 TGM2 2.06 0.0817 MmugDNA.19480.1.S1_at KIAA1219 protein KIAA1219 2.06 0.0781 MmugDNA.10100.1.S1_at hypothetical protein LOC722637 LOC722637 2.06 0.0099 MmugDNA.16322.1.S1_at Transcribed locus, weakly similar to NP_055301.1 neuronal — 2.06 0.0989 thread protein AD7c-NTP [Homo sapiens] MmugDNA.4438.1.S1_at transmembrane protein 39B LOC706700 2.06 0.0916 MmugDNA.35973.1.S1_at agrin LOC693314 2.06 0.0197 MmugDNA.36549.1.S1_at Hypothetical protein FLJ14888 FLJ14888 2.06 0.0846 MmugDNA.15963.1.S1_at PABP1-dependent poly A-specific ribonuclease subunit PAN3 2.05 0.0740 PAN3 MmugDNA.18234.1.S1_at runt-related transcription factor 2 isoform b LOC703331 2.05 0.0228 MmugDNA.32119.1.S1_at cytosolic malic enzyme 1 ME1 2.05 0.0425 MmugDNA.18163.1.S1_at gamma-aminobutyric acid (GABA) B receptor 1 isoform a LOC708987 2.05 0.0129 precursor MmugDNA.18569.1.S1_at phospholipase A2, group IVB LOC707262 2.04 0.0116 MmugDNA.23773.1.S1_at alpha 1 type XVIII collagen isoform 1 precursor LOC721919 2.04 0.0444 Mmu.16285.1.A1_at — ANP32A 2.04 0.0274 MmuSTS.2061.1.S1_at phospholipase C gamma 1 isoform a LOC697069 2.04 0.0259 MmugDNA.25737.1.S1_at Abl-interactor 1 ABI1 2.04 0.0333 MmugDNA.37418.1.S1_at NMD3 homolog LOC701677 2.04 0.0354 MmugDNA.29644.1.S1_at RAN binding protein 2-like 1 RANBP2L1 2.04 0.0405 MmugDNA.22841.1.S1_at Karyopherin alpha 5 (importin alpha 6) KPNA5 2.04 0.0159 MmugDNA.40840.1.S1_at ring finger and KH domain containing 2 LOC719403 2.03 0.0970 MmugDNA.39873.1.S1_s_at solute carrier family 38, member 2 LOC702253 2.03 0.0018 MmugDNA.29688.1.S1_at G-protein coupled receptor 116 LOC704887 2.03 0.0715 MmugDNA.2555.1.S1_at CDNA FLJ37816 fis, clone BRSSN2003093 — 2.03 0.0765 MmugDNA.27712.1.S1_at golgi SNAP receptor complex member 1 GOSR1 2.03 0.0166 MmuSTS.3453.1.S1_at PYD and CARD domain containing isoform b LOC713563 2.03 0.0818 MmugDNA.38737.1.S1_s_at transcription factor B1, mitochondrial LOC701830 2.03 0.0574 MmugDNA.371.1.S1_at — — 2.03 0.0252 MmuSTS.2285.1.S1_at POU domain, class 5, transcription factor 1 POU5F1 2.02 0.0989 MmugDNA.11375.1.S1_at spartin LOC693663 2.02 0.0884 MmuSTS.3541.1.S1_at NOD2 protein LOC695542 2.02 0.0867 MmunewRS.886.1.S1_at gi:51465519 — 2.02 0.0891 MmugDNA.33688.1.S1_at ribosomal protein L17 RPL17 2.02 0.0384 MmugDNA.31199.1.S1_at ADP-ribosylation factor-like protein 4C (ADP-ribosylation ARL4C 2.02 0.0154 factor-like 7) MmugDNA.32540.1.S1_at centaurin-alpha 2 protein CENTA2 2.02 0.0939 MmugDNA.19746.1.S1_at solute carrier family 2 (facilitated glucose transporter), SLC2A3 2.02 0.0013 member 3 MmugDNA.30247.1.S1_at RNA-binding region containing protein 2 isoform b LOC704198 2.01 0.0297 MmugDNA.35944.1.S1_at CDNA FLJ13136 fis, clone NT2RP3003139 — 2.01 0.0963 MmugDNA.29822.1.S1_at carbonic anhydrase IV CA4 2.01 0.0637 MmugDNA.15283.1.S1_at Transcribed locus — 2.01 0.0424 MmuSTS.1380.1.S1_at basic helix-loop-helix domain containing, class B, 3 BHLHB3 2.01 0.0588 MmugDNA.19213.1.S1_at unconventional myosin class XV CG2174-PA LOC711013 2.01 0.0214 Mmu.2043.1.S1_at axonal transport of synaptic vesicles LOC722674 2.01 0.0295 MmugDNA.18297.1.S1_at COP9 (constitutive photomorphogenic) homolog, subunit 2 LOC714814 2.00 0.0897 MmuSTS.263.1.S1_at sprouty homolog 1, antagonist of FGF signaling LOC708752 2.00 0.0535 MmuSTS.542.1.S1_at osteopetrosis associated transmembrane protein 1 LOC701341 2.00 0.0249 MmugDNA.39776.1.S1_at hypothetical protein LOC696417 LOC696417 2.00 0.0224 MmuSTS.4423.1.S1_at frizzled homolog 2 FZD2 2.00 0.0679 MmugDNA.40363.1.S1_at Hypothetical protein FLJ10948 FLJ10948 2.00 0.0540 Mmu.3412.1.A1_at Transcribed locus — 2.00 0.0909 MmugDNA.31062.1.S1_at CDC42 binding protein kinase gamma (DMPK-like) CDC42BPG 2.00 0.0044 MmugDNA.36785.1.S1_a_at hypothetical protein MGC2780 MGC2780 107.99 0.2056 MmugDNA.11034.1.S1_at MRNA full length insert cDNA clone EUROIMAGE 994183 — 66.61 0.0016 MmugDNA.15521.1.S1_at helicase with zinc finger /// ovostatin 2 /// cDNA sequence HELZ /// OVOS2 /// 38.75 0.0810 BC048546 LOC440080 MmugDNA.6868.1.S1_at adenosine deaminase-like ADAL 29.88 0.0860 MmugDNA.3759.1.S1_at zinc finger protein 208 ZNF208 27.54 0.1523 MmugDNA.19225.1.S1_at hemochromatosis type 2 (juvenile) HFE2 27.11 0.1919 MmugDNA.19620.1.S1_at Transcribed locus — 26.88 0.0322 MmunewRS.411.1.S1_at T-cell lymphoma breakpoint-associated target 1 TCBA1 23.70 0.0159 MmugDNA.5507.1.S1_at — — 23.68 0.0045 MmuSTS.2342.1.S1_at receptor (calcitonin) activity modifying protein 2 RAMP2 22.81 0.0433 MmuSTS.4185.1.S1_at nidogen 2 NID2 22.41 0.0046 Mmu.12045.1.S1_at phosphatidylinositol glycan, class K PIGK 21.51 0.0191 Mmu.2196.1.A1_at APP-70 mRNA fragment for amyloid precursor protein X15985 21.32 0.0840 protease inhibitor domain. MmuSTS.1412.1.S1_at potassium intermediate/small conductance calcium-activated KCNN3 20.30 0.0082 chann, , subfamily N, member 3 MmugDNA.21052.1.S1_at Transcribed locus — 19.79 0.0089 MmugDNA.5232.1.S1_at CDNA clone IMAGE: 4811759 — 16.97 0.0006 MmugDNA.13275.1.S1_at solute carrier family 34 (sodium phosphate), member 2 LOC694217 16.22 0.1746 MmugDNA.33984.1.S1_at CDNA clone IMAGE: 4814828 — 16.07 0.1046 MmugDNA.31271.1.S1_at Replication protein A3, 14 kDa RPA3 15.96 0.0083 MmugDNA.19644.1.S1_at anterior pharynx defective 1 homolog B (C. elegans) /// APH1B 15.89 0.0141 anterior pharynx defective 1 homolog B (C. elegans) MmuSTS.4301.1.S1_at sema domain, seven thrombospondin repeats (type 1 and type SEMA5A 15.83 0.0613 1-lik, , transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A MmugDNA.39574.1.S1_at RWD domain containing 2 RWDD2 15.13 0.0179 MmuSTS.4181.1.S1_at cullin 2 CUL2 15.12 0.0079 MmugDNA.30525.1.S1_at Transcribed locus, weakly XP_489263.1 RIKEN cDNA 230450_at 15.07 0.0170 9130004C02 gene [Mus musculus] MmuSTS.2619.1.S1_at erythroblast membrane-associated protein (Scianna blood ERMAP 14.89 0.1814 group) MmugDNA.18007.1.S1_s_at family with sequence similarity 102, member B FAM102B 14.49 0.1119 MmuSTS.4534.1.S1_at Bruton agammaglobulinemia tyrosine kinase BTK 13.98 0.0369 MmuSTS.898.1.S1_at Engulfment and cell motility 1 ELMO1 13.94 0.0068 MmugDNA.1875.1.S1_at aldehyde dehydrogenase 1 family, member B1 ALDH1B1 13.77 0.1752 MmugDNA.8764.1.S1_at — — 13.77 0.0751 MmuSTS.2829.1.S1_at solute carrier family 7 (cationic amino acid transporter, y+ sys, SLC7A6 13.70 0.0036 m), member 6 MmugDNA.12524.1.S1_at response gene to complement 32 RGC32 13.37 0.0077 MmugDNA.24601.1.S1_at Chromosome 18 open reading frame 17 C18orf17 13.37 0.0025 MmugDNA.9600.1.S1_at regulating synaptic membrane exocytosis 2 RIMS2 13.30 0.0310 MmugDNA.14408.1.S1_at chromosome 12 open reading frame 24 C12orf24 12.75 0.1070 MmugDNA.37885.1.S1_at homer homolog 1 (Drosophila) HOMER1 12.68 0.0144 MmugDNA.15936.1.S1_s_at CDNA: FLJ21874 fis, clone HEP02488 — 12.38 0.0063 MmuSTS.3629.1.S1_at EMI domain containing 1 EMID1 12.26 0.0380 MmugDNA.10412.1.S1_x_at Hypothetical protein KIAA0187 gene product /// LOC96610 /// 12.20 0.2034 Immunoglobulin lambda locus IGL@ MmugDNA.21132.1.S1_at hypothetical locus FLJ30594 FLJ30594 12.08 0.1018 MmugDNA.16717.1.S1_s_at seizure related 6 homolog (mouse)-like 2 /// seizure related 6 SEZ6L2 /// 11.95 0.0313 homolog (mouse)-like 2 isoform 1 LOC652900 MmuSTS.721.1.S1_at N-acetylneuraminate pyruvate lyase (dihydrodipicolinate NPL 11.73 0.0624 synthase MmugDNA.23998.1.S1_at DKFZP434B0335 protein DKFZP434B0335 11.67 0.0140 Mmu.10472.1.S1_at acid sphingomyelinase-like phosphodiesterase 3A LOC713696 11.58 0.0004 MmugDNA.34582.1.S1_at limbic system-associated membrane protein LSAMP 11.56 0.1465 MmugDNA.27799.1.S1_at chromosome 8 open reading frame 47 C8orf47 11.54 0.0051 MmugDNA.35367.1.S1_at transmembrane emp24 protein transport domain containing 8 TMED8 11.54 0.0000 MmuSTS.4580.1.S1_at heparan sulfate (glucosamine) 3-O-sulfotransferase 5 HS3ST5 11.36 0.0340 MmugDNA.14099.1.S1_at protein disulfide isomerase family A, member 5 PDIA5 11.07 0.0354 MmunewRS.286.1.S1_at cDNA FLJ46082 fis, clone TESTI2005153. gi:34536371 10.92 0.1933 MmugDNA.13637.1.S1_at hypothetical protein LOC169834 LOC169834 10.91 0.0446 MmugDNA.21508.1.S1_at CDNA FLJ37235 fis, clone BRAMY2002525 — 10.58 0.2144 MmugDNA.26503.1.S1_at polyhomeotic-like 2 (Drosophila) PHC2 10.50 0.0002 MmugDNA.9977.1.S1_at ethanolamine kinase 1 ETNK1 10.43 0.0022 MmuSTS.629.1.S1_at insulin-like growth factor 2 receptor IGF2R 10.32 0.0115 MmugDNA.42459.1.S1_at nucleotide binding protein 1 (MinD homolog, E. coli) NUBP1 10.13 0.0076 MmugDNA.16304.1.S1_at paraoxonase 2 PON2 10.03 0.2019 MmugDNA.27226.1.S1_at chromosome 10 open reading frame 49 C10orf49 10.03 0.1874 MmugDNA.27601.1.S1_at — — 10.01 0.0801 MmugDNA.19069.1.S1_at transient receptor potential cation channel, subfamily M, TRPM7 9.84 0.0026 member 7 MmugDNA.12483.1.S1_at HLA complex group 27 HCG27 9.82 0.1032 MmugDNA.15012.1.S1_at Arylformamidase AFMID 9.78 0.0546 MmugDNA.689.1.S1_at hypothetical protein LOC707842 LOC707842 9.65 0.1426 MmugDNA.1511.1.S1_at Transcribed locus — 9.54 0.1466 MmugDNA.6078.1.S1_at Sp2 transcription factor SP2 9.47 0.1325 MmugDNA.34436.1.S1_at Hypothetical protein LOC152485 LOC152485 9.36 0.0053 Mmu.15003.1.S1_x_at activating signal cointegrator 1 complex subunit 3-like 1 LOC705184 9.28 0.0157 MmugDNA.24349.1.S1_at Transcribed locus — 9.26 0.0882 MmugDNA.21279.1.S1_at Leucine-rich repeat protein SHOC-2 (Ras-binding protein Sur- RP11-139H14.4 9.21 0.0670 8) MmugDNA.13732.1.S1_at PHD finger protein 20-like 1 PHF20L1 9.20 0.0626 MmugDNA.28092.1.S1_at breakpoint cluster region isoform 1 LOC644165 9.11 0.2063 MmugDNA.4326.1.S1_at Transcribed locus — 8.93 0.0080 Mmu.15748.1.S1_s_at Transcribed locus, weakly XP_933032.2 hypothetical protein — 8.88 0.0874 [Homo sapiens] MmugDNA.17676.1.S1_at peroxisomal biogenesis factor 5-like PEX5L 8.86 0.0737 MmugDNA.38590.1.S1_at ligand-gated ion channel, zinc activated 1 LGICZ1 8.81 0.0142 MmugDNA.33781.1.S1_at dynein, axonemal, heavy polypeptide 10 DNAH10 8.80 0.1157 MmugDNA.43623.1.S1_s_at disabled homolog 2, mitogen-responsive phosphoprotein DAB2 8.75 0.0103 (Drosophila) MmugDNA.20593.1.S1_at tripeptidyl peptidase II TPP2 8.68 0.2180 MmugDNA.24454.1.S1_at phosphatidic acid phosphatase type 2C PPAP2C 8.68 0.1046 MmugDNA.4150.1.S1_at hypothetical protein FLJ40298 FLJ40298 8.67 0.1356 MmugDNA.22927.1.S1_at — — 8.66 0.1089 MmugDNA.39321.1.S1_at CDNA FLJ41751 fis, clone HSYRA2008154 — 8.65 0.0090 MmugDNA.38636.1.S1_at hypothetical protein FLJ39653 FLJ39653 8.61 0.0384 MmugDNA.8681.1.S1_at KIAA0100 /// hypothetical protein FLJ22349 KIAA0100 /// 8.61 0.0075 FLJ22349 MmugDNA.27488.1.S1_at suppression of tumorigenicity 14 (colon carcinoma) ST14 8.58 0.0576 MmugDNA.29768.1.S1_at melanocortin 2 receptor accessory protein MRAP 8.56 0.0423 MmugDNA.42270.1.S1_at gremlin 1, cysteine knot superfamily, homolog (Xenopus GREM1 8.53 0.1415 laevis) MmugDNA.30894.1.S1_at Transcribed locus, strongly NP_067647.1 leucine-rich repeat- — 8.44 0.1092 containing G protein-coupled receptor 7 [Homo sapiens] MmugDNA.37925.1.S1_at plasma glutamate carboxypeptidase PGCP 8.43 0.0055 MmugDNA.7703.1.S1_s_at pyrroline-5-carboxylate reductase family, member 2 PYCR2 8.42 0.0481 MmugDNA.29962.1.S1_at procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4- P4HA3 8.41 0.0311 hydroxylase), alpha polypeptide III MmugDNA.29322.1.S1_at chromosome 6 open reading frame 159 C6orf159 8.37 0.1465 MmugDNA.32728.1.S1_at GLIS family zinc finger 2 LOC708454 8.33 0.0118 MmugDNA.39848.1.S1_at DIP2 disco-interacting protein 2 homolog C (Drosophila) DIP2C 8.32 0.0054 MmugDNA.9959.1.S1_at — — 8.31 0.2016 MmuSTS.2576.1.S1_at DnaJ (Hsp40) homolog, subfamily B, member 12 DNAJB12 8.25 0.0207 MmugDNA.3860.1.S1_at — — 8.16 0.0618 Mmu.4703.1.S1_at — CO774986 8.16 0.0134 MmugDNA.33155.1.S1_at likely ortholog of MEF2-activating SAP transcriptional regulator FLJ36070 8.15 0.0863 MmugDNA.20631.1.S1_at Transcribed locus, strongly XP_513258.1 LOC456687 [Pan 230613_at 8.08 0.2120 troglodytes] MmugDNA.39834.1.S1_s_at fragile histidine triad gene FHIT 8.00 0.0019 MmugDNA.26008.1.S1_at musashi homolog 2 (Drosophila) MSI2 7.97 0.0002 MmugDNA.36272.1.S1_s_at dCMP deaminase DCTD 7.87 0.0027 MmugDNA.21159.1.S1_at hypothetical protein FLJ31846 FLJ31846 7.84 0.1945 MmugDNA.7644.1.S1_at amyloid beta (A4) precursor-like protein 2 APLP2 7.82 0.0540 MmugDNA.26889.1.S1_at Transcribed locus — 7.82 0.1703 MmugDNA.35633.1.S1_at Transcribed locus, strongly NP_659486.1 hypothetical protein — 7.80 0.0389 MGC10067 [Homo sapiens] MmugDNA.11626.1.S1_at dynein, cytoplasmic 2, heavy chain 1 DYNC2H1 7.80 0.0014 MmugDNA.18533.1.S1_at phospholipase D family, member 5 PLD5 7.80 0.0512 MmugDNA.36604.1.S1_at Transcribed locus — 7.77 0.0005 MmugDNA.12098.1.S1_at Transcribed locus — 7.76 0.0954 MmugDNA.8791.1.S1_at KIAA0586 KIAA0586 7.72 0.0606 MmugDNA.25037.1.S1_at CDNA FLJ30090 fis, clone BNGH41000015 — 7.68 0.0828 MmugDNA.30003.1.S1_at BTB (POZ) domain containing 16 BTBD16 7.66 0.0893 MmugDNA.29464.1.S1_at inositol monophosphatase domain containing 1 IMPAD1 7.65 0.0204 MmugDNA.29130.1.S1_at adenylate cyclase 1 (brain) ADCY1 7.64 0.0222 MmugDNA.42065.1.S1_at distal-less homeobox 6 DLX6 7.64 0.2136 MmugDNA.3371.1.S1_at reticulon 1 RTN1 7.63 0.0730 MmugDNA.23995.1.S1_at zinc finger protein 501 ZNF501 7.62 0.1374 MmugDNA.5842.1.S1_at — — 7.59 0.1545 MmugDNA.21402.1.S1_at R3H domain and coiled-coil containing 1 R3HCC1 7.58 0.0122 MmugDNA.11091.1.S1_at Nuclear factor I/A NFIA 7.58 0.0395 MmuSTS.383.1.S1_at lipase, gastric LIPF 7.56 0.1613 MmugDNA.26814.1.S1_at chromosome 3 open reading frame 19 C3orf19 7.55 0.0189 MmugDNA.38434.1.S1_at WD repeat domain 5B WDR5B 7.50 0.1039 MmugDNA.5186.1.S1_at RNA binding motif protein 23 RBM23 7.45 0.0136 MmugDNA.22050.1.S1_at EID-2-like inhibitor of differentiation-3 EID-3 7.45 0.0340 MmugDNA.40688.1.S1_at zinc finger protein 235 ZNF235 7.43 0.0135 MmugDNA.30778.1.S1_at growth factor, augmenter of liver regeneration (ERV1 GFER 7.42 0.0002 homolog, S. cerevisiae) MmuSTS.2673.1.S1_at calmegin CLGN 7.41 0.0581 MmugDNA.9553.1.S1_at Mannosidase, alpha, class 1A, member 1 MAN1A1 7.38 0.0114 MmugDNA.16242.1.S1_at — — 7.37 0.0006 MmugDNA.23074.1.S1_at plexin A2 PLXNA2 7.36 0.0096 MmugDNA.31786.1.S1_at hypothetical protein LOC158402 LOC158402 7.36 0.0327 MmugDNA.9822.1.S1_at immunoglobulin superfamily containing leucine-rich repeat 2 ISLR2 7.34 0.1736 MmugDNA.5439.1.S1_at catechol-O-methyltransferase COMT 7.32 0.0094 MmugDNA.23942.1.S1_at — — 7.26 0.0768 MmugDNA.37455.1.S1_at Transcribed locus — 7.25 0.0155 MmugDNA.34284.1.S1_at sodium channel, voltage-gated, type III, beta SCN3B 7.25 0.0578 MmugDNA.19576.1.S1_at zinc finger protein 547 ZNF547 7.24 0.0782 MmugDNA.34395.1.S1_at zinc finger protein 230 ZNF230 7.23 0.0152 MmugDNA.6131.1.S1_at chromosome 16 open reading frame 35 C16orf35 7.20 0.1537 MmugDNA.6727.1.S1_at — — 7.20 0.0804 MmugDNA.24272.1.S1_at KIAA1922 protein KIAA1922 7.19 0.1247 MmugDNA.6286.1.S1_at zinc finger protein 599 ZNF599 7.14 0.0790 MmuSTS.3570.1.S1_at collagen, type IV, alpha 4 COL4A4 7.14 0.0006 MmugDNA.39056.1.S1_at chromodomain helicase DNA binding protein 4 CHD4 7.13 0.0047 MmugDNA.34250.1.S1_at hypothetical protein LOC645644 FLJ42627 7.13 0.0043 MmuSTS.1813.1.S1_at sterol O-acyltransferase 2 SOAT2 7.11 0.0279 MmugDNA.24694.1.S1_at Retinoblastoma binding protein 4 RBBP4 7.10 0.0185 MmugDNA.24480.1.S1_at splicing factor proline/glutamine-rich (polypyrimidine tract SFPQ 7.09 0.0095 binding protein associated) MmugDNA.33264.1.S1_at TIP41, TOR signalling pathway regulator-like (S. cerevisiae) TIPRL 7.08 0.1207 MmugDNA.31611.1.S1_at PRotein Associated with Tlr4 MGC40499 7.01 0.0583 MmugDNA.26071.1.S1_s_at RAB30, member RAS oncogene family RAB30 6.97 0.0043 MmugDNA.11685.1.S1_at poly (ADP-ribose) polymerase family, member 8 PARP8 6.94 0.0303 MmugDNA.38371.1.S1_at hexosaminidase A (alpha polypeptide) HEXA 6.94 0.0512 MmugDNA.5558.1.S1_at tRNA phosphotransferase 1 TRPT1 6.93 0.0013 MmugDNA.34597.1.S1_at tetraspanin 1 TSPAN1 6.86 0.0007 MmugDNA.18788.1.S1_at Capping protein (actin filament) muscle Z-line, alpha 2 CAPZA2 6.85 0.0915 MmugDNA.28272.1.S1_at molybdenum cofactor synthesis 1 MOCS1 6.83 0.0681 MmugDNA.14078.1.S1_at EBNA1 binding protein 2 EBNA1BP2 6.82 0.0463 MmuSTS.2123.1.S1_at retinal outer segment membrane protein 1 ROM1 6.81 0.0210 MmugDNA.9513.1.S1_at exostoses (multiple)-like 2 EXTL2 6.79 0.0112 Mmu.7528.1.S1_at Zygin 1 ZYG1 6.76 0.0713 MmugDNA.12416.1.S1_at coiled-coil domain containing 51 CCDC51 6.76 0.0052 MmuSTS.3946.1.S1_at T-cell activation kelch repeat protein TA-KRP 6.76 0.0172 MmugDNA.12522.1.S1_at Pyrophosphatase (inorganic) 2 PPA2 6.74 0.0061 MmugDNA.39796.1.S1_at DIRAS family, GTP-binding RAS-like 3 DIRAS3 6.72 0.0734 MmugDNA.1685.1.S1_at zinc finger protein 682 ZNF682 6.72 0.0142 MmuSTS.2157.1.S1_at Scm-like with four mbt domains 1 SFMBT1 6.71 0.0051 MmugDNA.2165.1.S1_at small nuclear ribonucleoprotein polypeptide E SNRPE 6.70 0.0389 MmugDNA.2643.1.S1_at chromosome 11 open reading frame 59 C11orf59 6.69 0.0306 MmugDNA.13192.1.S1_s_at peptidylprolyl isomerase E (cyclophilin E) PPIE 6.67 0.0336 MmugDNA.13901.1.S1_at KIAA0194 protein KIAA0194 6.65 0.0029 MmugDNA.9677.1.S1_at hypothetical protein MGC39606 /// hypothetical protein MGC39606 /// 6.64 0.0636 LOC644596 LOC644596 MmugDNA.21296.1.S1_at CDNA FLJ14188 fis, clone NT2RP2005980 — 6.64 0.0539 MmugDNA.36977.1.S1_at transmembrane protein 107 TMEM107 6.62 0.0537 MmuSTS.3859.1.S1_at solute carrier family 26, member 9 SLC26A9 6.62 0.0483 MmuSTS.514.1.S1_at ATPase, Class VI, type 11C ATP11C 6.62 0.0004 MmugDNA.18137.1.S1_at — — 6.60 0.0451 MmugDNA.36662.1.S1_at STAM binding protein-like 1 STAMBPL1 6.60 0.0041 MmugDNA.13357.1.S1_at KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein KDELR1 6.58 0.0618 retention receptor 1 MmugDNA.34884.1.S1_at CUB and zona pellucida-like domains 1 CUZD1 6.58 0.0561 MmugDNA.10426.1.S1_at neuron navigator 3 NAV3 6.56 0.0493 MmunewRS.777.1.S1_at This record was removed as a result of standard genome annotation 6.54 0.0904 processing. MmugDNA.32277.1.S1_at DNA (cytosine-5-)-methyltransferase 2 DNMT2 6.51 0.0001 MmunewRS.654.1.S1_at taste receptor, type 2, member 44 TAS2R44 6.51 0.1568 MmuSTS.3981.1.S1_at SH3-domain GRB2-like 2 SH3GL2 6.48 0.0289 MmugDNA.23979.1.S1_at tetratricopeptide repeat domain 8 TTC8 6.47 0.0227 MmugDNA.9202.1.S1_at PRO0633 — 6.45 0.0369 MmugDNA.19839.1.S1_at metallothionein 1G MT1G 6.44 0.0115 MmugDNA.11505.1.S1_at RNA (guanine-9-) methyltransferase domain containing 3 RG9MTD3 6.44 0.0224 MmugDNA.37839.1.S1_s_at Full length insert cDNA clone ZD82B02 — 6.41 0.0024 MmugDNA.26070.1.S1_at putatative 28 kDa protein LOC56902 6.39 0.0219 MmugDNA.4320.1.S1_at chromosome 14 open reading frame 93 C14orf93 6.39 0.0814 MmugDNA.42430.1.S1_at chromosome 5 open reading frame 28 C5orf28 6.39 0.0427 MmugDNA.13752.1.S1_at spermatogenesis associated 7 SPATA7 6.37 0.0117 MmugDNA.39646.1.S1_s_at chromosome 19 open reading frame 10 C19orf10 6.36 0.1162 MmugDNA.4241.1.S1_at FRAS1 related extracellular matrix 3 FREM3 6.34 0.0744 MmugDNA.5102.1.S1_at — — 6.33 0.0111 MmugDNA.23567.1.S1_at protein arginine methyltransferase 6 PRMT6 6.33 0.0382 MmugDNA.42806.1.S1_at — — 6.33 0.0980 MmugDNA.35790.1.S1_at solute carrier family 7 (cationic amino acid transporter, y+ SLC7A3 6.31 0.1159 system), member 3 MmugDNA.11215.1.S1_at — — 6.30 0.0526 MmugDNA.9057.1.S1_at transmembrane protein 107 /// transmembrane protein 107 TMEM107 6.28 0.0390 MmugDNA.37336.1.S1_at stathmin-like 2 STMN2 6.27 0.1549 MmugDNA.117.1.S1_at DPH5 homolog (S. cerevisiae) DPH5 6.27 0.0417 Mmu.15115.1.S1_at Ribonuclease UK114 (14.5 kDa translational inhibitor LOC705533 6.25 0.0280 protein) (p14.5) (UK114 antigen homolog) MmugDNA.21121.1.S1_at Insulin-like growth factor 1 receptor IGF1R 6.25 0.0700 MmugDNA.13304.1.S1_at Fukuyama type congenital muscular dystrophy (fukutin) FCMD 6.24 0.0342 MmugDNA.40836.1.S1_at chromosome 6 open reading frame 168 C6orf168 6.23 0.0000 MmugDNA.23421.1.S1_at FLJ16124 protein ELJ16124 6.23 0.1070 MmugDNA.29466.1.S1_at Transcribed locus — 6.22 0.0243 MmugDNA.41017.1.S1_at CDNA clone IMAGE: 4791585 — 6.20 0.0430 MmugDNA.18662.1.S1_at parathyroid hormone receptor 2 PTHR2 6.19 0.1555 MmugDNA.27914.1.S1_at family with sequence similarity 55, member D FAM55D 6.19 0.1240 MmugDNA.39981.1.S1_at microtubule associated monoxygenase, calponin and LIM MICAL2 6.17 0.0214 domain containing 2 MmugDNA.33630.1.S1_at apolipoprotein B mRNA editing enzyme, catalytic APOBEC3G 6.13 0.0918 polypeptide-like 3G MmugDNA.41272.1.S1_at KIAA0174 KIAA0174 6.12 0.0498 MmugDNA.4554.1.S1_at membrane-associated ring finger (C3HC4) 9 9-Mar 6.12 0.0006 MmuSTS.4598.1.S1_at hypoxia up-regulated 1 HYOU1 6.11 0.0224 MmugDNA.40815.1.S1_at Family with sequence similarity 77, member D FAM77D 6.11 0.0370 MmugDNA.10816.1.S1_at CDNA FLJ90571 fis, clone OVARC1001725, highly Homo — 6.09 0.0585 sapiens patched related protein TRC8 (TRC8) gene Mmu.15827.1.S1_at tafazzin TAZ 6.09 0.0279 MmugDNA.18337.1.S1_at neurofilament, heavy polypeptide 200 kDa NEFH 6.08 0.0788 MmuSTS.3411.1.S1_at phosphoribosyl pyrophosphate synthetase 1 PRPS1 6.08 0.0271 MmugDNA.4215.1.S1_at matrix-remodelling associated 8 MXRA8 6.07 0.0277 MmugDNA.2493.1.S1_at Full-length cDNA clone CS0DI054YK19 of Placenta Cot 25- — 6.07 0.0954 normalized of Homo sapiens (human) MmugDNA.29221.1.S1_at mannosidase, alpha, class 2A, member 1 MAN2A1 6.06 0.0356 MmuSTS.2268.1.S1_at polymerase (RNA) II (DNA directed) polypeptide C, 33 kDa POLR2C 6.06 0.0054 MmugDNA.16039.1.S1_at Transcribed locus — 6.05 0.1426 MmugDNA.23370.1.S1_at SH3 and PX domains 2A SH3PXD2A 6.02 0.1440 Mmu.5073.1.S1_at histone deacetylase 1 LOC708441 6.01 0.0636 MmugDNA.18754.1.S1_at hypothetical protein LOC134466 LOC134466 6.00 0.0506 MmugDNA.34454.1.S1_at — — 5.97 0.0048 MmugDNA.23057.1.S1_at hypothetical gene supported by AK125122 FLJ13137 5.97 0.0012 MmugDNA.27855.1.S1_at — — 5.97 0.0167 MmuSTS.3142.1.S1_at methyl-CpG binding domain protein 5 MBD5 5.95 0.0115 MmugDNA.23903.1.S1_at Protein inhibitor of activated STAT, 2 PIAS2 5.94 0.0193 MmugDNA.7631.1.S1_at CDNA FLJ11682 fis, clone HEMBA1004880 — 5.94 0.1697 MmugDNA.20356.1.S1_at platelet-activating factor acetylhydrolase 2, 40 kDa PAFAH2 5.94 0.0009 MmugDNA.2708.1.S1_at Son of sevenless homolog 1 (Drosophila) SOS1 5.91 0.0461 MmugDNA.10905.1.S1_at tectonic FLJ21127 5.89 0.0025 MmugDNA.28625.1.S1_at without children CG5965-PA LOC707028 5.89 0.0638 MmugDNA.11493.1.S1_at eukaryotic translation initiation factor 4A, isoform 2 EIF4A2 5.87 0.0421 MmugDNA.23572.1.S1_s_at glutamate-cysteine ligase, modifier subunit GCLM 5.86 0.0027 MmuSTS.2280.1.S1_at Dapper, antagonist of beta-catenin, homolog 1 (Xenopus DACT1 5.86 0.0752 laevis) MmugDNA.25697.1.S1_at Ubiguitin-conjugating enzyme E2W (putative) UBE2W 5.85 0.0579 MmugDNA.24422.1.S1_at glucosidase, beta, acid 3 (cytosolic) GBA3 5.84 0.1210 MmugDNA.26055.1.S1_at THAP domain containing 5 THAP5 5.82 0.1799 MmuSTS.1960.1.S1_at forkhead box D1 FOXD1 5.81 0.0736 MmugDNA.35294.1.S1_at protein tyrosine phosphatase-like A domain containing 1 PTPLAD1 5.80 0.0213 MmugDNA.15150.1.S1_at histone deacetylase 8 HDAC8 5.77 0.0384 MmugDNA.32612.1.S1_s_at prostaglandin D2 synthase 21 kDa (brain) /// prostaglandin PTGDS 5.77 0.1930 D2 synthase 21 kDa (brain) MmuSTS.1829.1.S1_at Shroom-related protein ShrmL 5.77 0.0060 MmuSTS.3849.1.S1_at Spectrin repeat containing, nuclear envelope 2 SYNE2 5.74 0.0000 Mmu.13961.1.S1_at Protein NipSnap3A (NipSnap4) (Target for Salmonella LOC716188 5.72 0.0252 secreted protein C) (TassC) MmugDNA.29451.1.S1_at Transcribed locus 241668_s_at 5.71 0.1366 MmugDNA.39448.1.S1_at Interferon regulatory factor 2 IRF2 5.71 0.0394 MmugDNA.13520.1.S1_at cytoplasmic linker associated protein 2 CLASP2 5.70 0.0457 MmugDNA.35274.1.S1_at Hypothetical protein FLJ30707 FLJ30707 5.69 0.0422 MmugDNA.1285.1.S1_at zinc finger protein-like 1 ZFPL1 5.67 0.1329 MmugDNA.31491.1.S1_at KIAA1333 KIAA1333 5.66 0.1185 MmuSTS.1032.1.S1_at nucleoporin 133 kDa NUP133 5.65 0.1949 MmugDNA.28191.1.S1_at Pleiotropic regulator 1 (PRL1homolog, Arabidopsis) PLRG1 5.64 0.0702 MmugDNA.42978.1.S1_at Transcribed locus, weakly XP_530800.1 PREDICTED: — 5.64 0.0280 hypothetical protein XP_530800 [Pan troglodytes] MmugDNA.11439.1.S1_at 5′-nucleotidase domain containing 1 NT5DC1 5.64 0.0577 MmuSTS.706.1.S1_at interleukin-1 receptor-associated kinase 4 IRAK4 5.64 0.0778 MmugDNA.37826.1.S1_at Hypothetical protein LOC285346 LOC285346 5.63 0.0874 MmuSTS.4259.1.S1_at dual specificity phosphatase 4 DUSP4 5.63 0.1028 MmunewRS.954.1.S1_at zinc finger protein 484 isoform a ZNF484 5.63 0.1344 MmugDNA.24846.1.S1_at vacuolar protein sorting 26 homolog B (S. cerevisiae) VPS26B 5.61 0.0039 MmugDNA.36142.1.S1_at chromosome 9 open reading frame 117 C9orf117 5.58 0.0052 MmugDNA.3197.1.S1_at RNA binding motif protein 25 RBM25 5.58 0.2066 MmugDNA.30489.1.S1_at neurolysin (metallopeptidase M3 family) NLN 5.56 0.0281 MmugDNA.15190.1.S1_at chromosome 1 open reading frame 151 C1orf151 5.55 0.0874 MmugDNA.21034.1.S1_at UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- GALNT1 5.54 0.0402 acetylgalactosaminyltransferase 1 (GalNAc-T1) MmugDNA.14671.1.S1_at dynein, cytoplasmic 2, light intermediate chain 1 DYNC2LI1 5.52 0.0052 MmugDNA.21379.1.S1_at SNF1-like kinase 2 SNF1LK2 5.52 0.0281 MmugDNA.5564.1.S1_at zinc finger protein 3 ZNF3 5.51 0.0061 MmugDNA.30983.1.S1_at Metallophosphoesterase 1 MPPE1 5.50 0.0158 MmuSTS.2242.1.S1_at TH1-like (Drosophila) TH1L 5.49 0.0001 MmugDNA.7470.1.S1_at hypothetical LOC400523 LOC400523 5.49 0.0366 MmugDNA.34874.1.S1_at casein kinase 2, alpha prime polypeptide CSNK2A2 5.47 0.0014 MmugDNA.43133.1.S1_at non-metastatic cells 5, protein expressed in (nucleoside- NME5 5.45 0.0009 diphosphate kinase) MmuSTS.3223.1.S1_at phospholipase D3, phophatidylcholine-specific PLD3 5.44 0.0358 Mmu.10002.1.S1_s_at methionine adenosyltransferase II, alpha MAT2A 5.44 0.0000 MmugDNA.32811.1.S1_at Transcribed locus — 5.44 0.0954 MmugDNA.284.1.S1_at hypothetical LOC149643 LOC149643 5.43 0.0564 MmuSTS.2289.1.S1_at protein phosphatase 1, regulatory subunit 10 PPP1R10 5.43 0.0004 MmugDNA.7541.1.S1_at coiled-coil domain containing 88 CCDC88 5.41 0.0296 MmugDNA.1662.1.S1_at PRP38 pre-mRNA processing factor 38 (yeast) domain PRPF38A 5.39 0.0054 containing A MmuSTS.4599.1.S1_at huntingtin interacting protein B HYPB 5.38 0.0000 MmugDNA.5606.1.S1_at 5′-nucleotidase, cytosolic III-like NT5C3L 5.38 0.0235 MmugDNA.12250.1.S1_at CDNA clone IMAGE: 3928921 — 5.37 0.0135 MmugDNA.25740.1.S1_at coenzyme Q9 homolog (S. cerevisiae) COQ9 5.37 0.0000 MmugDNA.34111.1.S1_s_at heat shock 105 kDa/110 kDa protein 1 HSPH1 5.37 0.0000 MmugDNA.21848.1.S1_at TSPY-like 1 TSPYL1 5.37 0.0105 MmugDNA.9756.1.S1_at HERPUD family member 2 HERPUD2 5.36 0.0453 Mmu.3466.1.S1_at — CN648872 5.36 0.0770 MmugDNA.23725.1.S1_at stress 70 protein chaperone, microsome-associated, 60 kDa STCH 5.34 0.0144 MmugDNA.38793.1.S1_at cholecystokinin CCK 5.33 0.2072 MmugDNA.41164.1.S1_at phosphonoformate immuno-associated protein 5 PFAAP5 5.32 0.0567 MmugDNA.35343.1.S1_s_at CDNA FLJ41946 fis, clone PLACE6019701 — 5.31 0.0490 MmugDNA.26593.1.S1_at armadillo repeat containing, X-linked 5 ARMCX5 5.31 0.0081 MmugDNA.14053.1.S1_at — — 5.29 0.0696 MmugDNA.9095.1.S1_at zinc finger protein 396 ZNF396 5.27 0.0141 MmugDNA.25958.1.S1_at DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 57 DHX57 5.27 0.0389 MmugDNA.21062.1.S1_at suppression of tumorigenicity 7 ST7 5.27 0.0326 MmugDNA.12969.1.S1_at ribonuclease H2, subunit C RNASEH2C 5.27 0.0527 MmugDNA.39661.1.S1_at heparan sulfate 2-O-sulfotransferase 1 HS2ST1 5.26 0.0062 MmugDNA.26250.1.S1_at zinc finger protein 111 LOC388565 5.25 0.0232 MmugDNA.39242.1.S1_at melanoma inhibitory activity family, member 3 MIA3 5.25 0.0014 MmugDNA.35720.1.S1_at zinc finger protein 306 /// zinc finger protein 306 ZNF306 5.25 0.0552 MmuSTS.4680.1.S1_at thymic stromal lymphopoietin TSLP 5.25 0.0113 MmugDNA.35830.1.S1_at — — 5.24 0.0523 MmuSTS.2253.1.S1_at polymerase (DNA directed), iota POLI 5.23 0.0000 MmugDNA.41690.1.S1_at Fibronectin type III domain containing 3 FNDC3 5.23 0.0908 MmugDNA.16026.1.S1_at — — 5.22 0.0871 MmugDNA.12860.1.S1_at hypothetical protein 284297 FLJ35258 5.21 0.0605 Mmu.6352.1.S1_at F16A11.1 LOC703783 5.21 0.0698 MmugDNA.28831.1.S1_at G protein-regulated inducer of neurite outgrowth 1 KIAA1893 5.21 0.0138 MmuSTS.4601.1.S1_at interleukin 19 IL19 5.20 0.0401 MmugDNA.25269.1.S1_at chitinase domain containing 1 CHID1 5.20 0.0280 MmuAffx.956.1.S1_at dolichyl-diphosphooligosaccharide-protein — 5.20 0.0203 glycosyltransferase MmugDNA.10359.1.S1_at DEAH (Asp-Glu-Ala-His) box polypeptide 30 DHX30 5.20 0.0654 MmugDNA.32727.1.S1_at — — 5.19 0.0109 MmugDNA.37069.1.S1_at dihydropyrimidinase DPYS 5.19 0.0266 MmugDNA.30075.1.S1_at chromosome 6 open reading frame 162 C6orf162 5.18 0.0316 MmugDNA.9073.1.S1_at — — 5.18 0.0376 MmugDNA.12316.1.S1_at KIAA0090 KIAA0090 5.18 0.0905 MmugDNA.39259.1.S1_at MRNA; cDNA DKFZp564E202 (from clone DKFZp564E202) /// — 5.17 0.0284 CDNA FLJ44257 fis, clone TKIDN2015263 MmugDNA.38606.1.S1_at chromosome 9 open reading frame 89 C9orf89 5.16 0.0215 MmugDNA.3686.1.S1_at intraflagellar transport 57 homolog (Chlamydomonas) IFT57 5.14 0.0000 MmugDNA.29286.1.S1_at zinc finger protein 320 /// hypothetical protein FLJ38482 ZNF320 /// 5.14 0.0252 FLJ38482 MmugDNA.31720.1.S1_at CUE domain containing 1 CUEDC1 5.14 0.0362 MmugDNA.22403.1.S1_at receptor accessory protein 5 REEP5 5.14 0.0303 MmugDNA.1116.1.S1_at Transcribed locus — 5.12 0.0056 MmugDNA.8918.1.S1_at WNT1 inducible signaling pathway protein 2 WISP2 5.12 0.1048 MmugDNA.17764.1.S1_at RCC1 domain containing 1 RCCD1 5.11 0.0040 MmugDNA.31260.1.S1_at chromosome 11 open reading frame 63 C11orf63 5.11 0.0246 Mmu.6716.1.S1_at Cathepsin S precursor LOC708080 5.09 0.0754 MmuSTS.299.1.S1_at potassium intermediate/small conductance calcium- KCNN2 5.09 0.0055 activated chann, , subfamily N, member 2 MmugDNA.31161.1.S1_at Homo sapiens, clone IMAGE: 4095671, mRNA — 5.09 0.0722 MmugDNA.34930.1.S1_at — — 5.08 0.1327 MmugDNA.19331.1.S1_at Full-length cDNA clone CS0DK012YA15 of HeLa cells Cot — 5.07 0.0161 25-normalized of Homo sapiens (human) MmugDNA.36727.1.S1_at zinc finger, MYM-type 4 ZMYM4 5.07 0.0456 MmugDNA.42518.1.S1_at nudE nuclear distribution gene E homolog like 1 (A. nidulans) NDEL1 5.05 0.0746 MmugDNA.14355.1.S1_at chromosome 21 open reading frame 6 C21orf6 5.05 0.0047 MmugDNA.4328.1.S1_at zinc finger protein 480 ZNF480 5.03 0.0101 MmuSTS.2927.1.S1_at potassium voltage-gated channel, subfamily H (eag- KCNH3 5.00 0.0509 related), memb, 3 MmuSTS.4230.1.S1_at discs, large (Drosophila) homolog-associated protein 4 DLGAP 4 5.00 0.0584 MmugDNA.27648.1.S1_at — — 4.98 0.0573 MmugDNA.41452.1.S1_at sperm autoantigenic protein 17 SPA17 4.98 0.0031 MmuSTS.3254.1.S1_at sema domain, immunoglobulin domain (Ig), short basic SEMA3A 4.98 0.0854 domain, sec ted, (semaphorin) 3A MmugDNA.3708.1.S1_at Full length insert cDNA clone YX81F03 — 4.97 0.0024 MmugDNA.3643.1.S1_at hypothetical protein LOC643749 LOC643749 4.97 0.0165 MmugDNA.7067.1.S1_at RNA binding motif protein 18 LOC698457 4.97 0.0025 MmugDNA.10033.1.S1_at poliovirus receptor PVR 4.96 0.0778 MmugDNA.16402.1.S1_at cyclin M4 CNNM4 4.96 0.0001 MmugDNA.42450.1.S1_at — — 4.96 0.1236 MmugDNA.7713.1.S1_at chromosome 4 open reading frame 17 C4orf17 4.96 0.0059 MmugDNA.11708.1.S1_at chloride channel CLIC-like 1 CLCC1 4.95 0.0038 MmugDNA.19659.1.S1_at Interleukin 17 receptor D IL17RD 4.95 0.0034 MmugDNA.11406.1.S1_at protein tyrosine phosphatase, receptor type, G PTPRG 4.95 0.0002 MmugDNA.3737.1.S1_at chromosome 13 open reading frame 23 C13orf23 4.95 0.0133 MmugDNA.1748.1.S1_at transmembrane protein 27 TMEM27 4.94 0.0726 MmugDNA.30715.1.S1_at armadillo repeat containing 8 ARMC8 4.94 0.0096 MmugDNA.31956.1.S1_at Transcribed locus — 4.94 0.0633 MmugDNA.2511.1.S1_at CDNA FLJ40061 fis, clone TESOP2000083 — 4.94 0.1619 MmugDNA.20090.1.S1_at TDP-glucose 4, 6-dehydratase TGDS 4.93 0.0336 MmugDNA.17318.1.S1_at Transcribed locus — 4.91 0.1084 MmugDNA.22124.1.S1_at transmembrane protein 138 TMEM138 4.90 0.1081 Mmu.6994.1.S1_at basic fibroblast growth factor mRNA, partial cds. AF251270 4.89 0.0539 MmugDNA.25717.1.S1_s_at retinoblastoma-like 2 (p130) RBL2 4.89 0.1029 MmugDNA.32584.1.S1_at zinc finger protein 571 ZNF571 4.88 0.0004 MmuSTS.32.1.S1_at zinc finger protein 32 ZNF32 4.87 0.0000 MmugDNA.30643.1.S1_at B9 protein EPPB9 4.86 0.1011 MmugDNA.14909.1.S1_at N-acetyltransferase 1 (arylamine N-acetyltransferase) NAT1 4.86 0.0099 MmuSTS.2239.1.S1_at testis expressed sequence 264 TEX264 4.85 0.0109 MmugDNA.28738.1.S1_at zinc finger protein 354C LOC713468 4.85 0.0244 MmuSTS.773.1.S1_at core 1 UDP-galactose:N-acetylgalactosamine-alpha-R beta C1GALT2 4.85 0.0022 1,3-gala, osyltransferase 2 MmugDNA.7405.1.S1_at multiple substrate lipid kinase MULK 4.84 0.0000 MmugDNA.8329.1.S1_at chromosome 10 open reading frame 72 C10orf72 4.83 0.1341 MmugDNA.33312.1.S1_at zinc finger, CCHC domain containing 9 ZCCHC9 4.83 0.0024 Mmu.11141.1.S1_at catenin (cadherin-associated protein), alpha 1, 102 kDa CTNNA1 4.83 0.0647 MmugDNA.3844.1.S1_at — — 4.82 0.0000 MmuSTS.1873.1.S1_at cornichon homolog CNIH 4.82 0.0001 Mmu.1020.1.S1_s_at cysteine-rich with EGF-like domains 1 isoform 2 LOC699345 4.82 0.0586 MmugDNA.24075.1.S1_at CG15828-PA 244889_at 4.81 0.0948 MmugDNA.30042.1.S1_at chromosome X open reading frame 6 CXorf6 4.81 0.0517 MmuSTS.351.1.S1_at synaptophysin SYP 4.81 0.0485 MmugDNA.38488.1.S1_s_at LSM10, U7 small nuclear RNA associated LSM10 4.80 0.0004 MmugDNA.1625.1.S1_at protein kinase, AMP-activated, alpha 1 catalytic subunit PRKAA1 4.80 0.0425 MmugDNA.25564.1.S1_at MRNA; cDNA DKFZp564G1162 (from clone — 4.79 0.0079 DKFZp564G1162) MmugDNA.29139.1.S1_at chromosome 14 open reading frame 50 C14orf50 4.79 0.1206 MmuSTS.1491.1.S1_at zinc finger protein 281 ZNF281 4.78 0.0190 MmugDNA.5201.1.S1_at chromosome 14 open reading frame 130 C14orf130 4.78 0.0074 MmunewRS.875.1.S1_at neuroligin 4, Y-linked NLGN4Y 4.78 0.0000 MmugDNA.6389.1.S1_at zinc finger, CCHC domain containing 12 ZCCHC12 4.76 0.0124 MmugDNA.12224.1.S1_at CDNA clone IMAGE: 4821804 — 4.76 0.0779 MmunewRS.335.1.S1_at full length insert cDNA clone YZ18B05. gi:3483412 4.75 0.0715 MmugDNA.21758.1.S1_at DNA cross-link repair 1C (PSO2 homolog, S. cerevisiae) DCLRE1C 4.75 0.1520 MmugDNA.4778.1.S1_at KIAA1505 protein KIAA1505 4.75 0.1070 MmugDNA.133.1.S1_at zinc finger protein 223 LOC711740 4.74 0.1432 MmugDNA.7270.1.S1_at zinc finger protein 641 ZNF641 4.74 0.0002 MmugDNA.20328.1.S1_s_at N-acetylglucosamine-1-phosphate transferase, gamma GNPTG 4.74 0.0000 subunit MmugDNA.40786.1.S1_at arylsulfatase family, member K ARSK 4.74 0.0631 Mmu.11997.1.S1_at calmodulin 1 LOC698552 4.73 0.0030 MmugDNA.1667.1.S1_at immunoglobulin superfamily, member 4D IGSF4D 4.73 0.1791 MmugDNA.20342.1.S1_at spindlin family, member 2 /// spindlin family, member 2 /// SPIN2 /// SPIN-2 4.72 0.0223 spindlin-like protein 2 /// spindlin-like protein 2 MmugDNA.3891.1.S1_at chromosome 2 open reading frame 15 C2orf15 4.72 0.0163 MmugDNA.32461.1.S1_at — — 4.72 0.0094 MmugDNA.14567.1.S1_at KIAA0859 KIAA0859 4.72 0.1058 MmugDNA.43246.1.S1_at neutral sphingomyelinase (N-SMase) activation associated NSMAF 4.72 0.0053 factor MmugDNA.2324.1.S1_at KIAA0895 protein KIAA0895 4.71 0.0648 MmugDNA.1640.1.S1_at Transcribed locus — 4.71 0.1101 MmugDNA.42549.1.S1_at galanin GAL 4.71 0.0951 MmugDNA.3017.1.S1_at LQK1 hypothetical protein short isoform LQK1 4.70 0.0226 MmugDNA.28661.1.S1_at coiled-coil domain containing 28B CCDC28B 4.69 0.1325 MmuSTS.4364.1.S1_at sterol O-acyltransferase 1 SOAT1 4.69 0.0729 MmugDNA.2668.1.S1_at mannose receptor-like LOC709768 4.69 0.0118 MmugDNA.8460.1.S1_at LAG1 longevity assurance homolog 6 (S. cerevisiae) LASS6 4.68 0.0041 MmugDNA.30211.1.S1_at ATPase, Ca++ transporting, type 2C, member 1 ATP2C1 4.67 0.0624 MmugDNA.22541.1.S1_at chromosome 1 open reading frame 89 /// chromosome 1 C1orf89 4.66 0.0231 open reading frame 89 MmugDNA.23541.1.S1_at coiled-coil domain containing 50 CCDC50 4.65 0.0487 MmugDNA.38008.1.S1_at asparaginase-like 1 protein LOC718871 4.65 0.0005 MmugDNA.34690.1.S1_at MAWD binding protein MAWBP 4.65 0.0787 MmugDNA.31478.1.S1_at RAB33A, member RAS oncogene family RAB33A 4.64 0.0430 MmugDNA.28356.1.S1_at hypothetical protein LOC715793 LOC715793 4.64 0.1301 MmugDNA.35760.1.S1_at receptor transporter protein 4 RTP4 4.63 0.1847 MmugDNA.1257.1.S1_at peptidylprolyl isomerase (cyclophilin)-like 1 PPIL1 4.63 0.0032 MmugDNA.38638.1.S1_at inhibitor of kappa light polypeptide gene enhancer in B- IKBKB /// NCSTN 4.61 0.0019 cells, kinase beta /// nicastrin MmugDNA.31887.1.S1_at hypothetical LOC402617 LOC402617 4.60 0.1114 MmugDNA.18767.1.S1_at MRNA full length insert cDNA clone EUROIMAGE 110216 — 4.57 0.1233 MmugDNA.40451.1.S1_at polycomb group ring finger 1 PCGF1 4.56 0.0175 MmugDNA.18456.1.S1_at CDNA FLJ33400 fis, clone BRACE2009828 — 4.55 0.1261 MmugDNA.31245.1.S1_at butyrophilin, subfamily 2, member A2 BTN2A2 4.55 0.0552 MmugDNA.43078.1.S1_at KIAA1838 KIAA1838 4.55 0.0050 MmugDNA.39763.1.S1_at ubiquitin specific peptidase 36 USP36 4.54 0.0836 MmugDNA.12921.1.S1_at hypothetical protein FLJ36208 FLJ36208 4.54 0.1669 MmugDNA.3000.1.S1_at signal sequence receptor, gamma (translocon-associated SSR3 4.54 0.0185 protein gamma) MmugDNA.31177.1.S1_at zinc finger protein 582 ZNF582 4.54 0.0129 MmuSTS.2548.1.S1_at thioredoxin domain containing 12 (endoplasmic reticulum) TXNDC12 4.54 0.0231 MmugDNA.32746.1.S1_at inositol 1,4,5-triphosphate receptor, type 2 ITPR2 4.54 0.0394 MmugDNA.14882.1.S1_s_at Huntingtin interacting protein K HYPK 4.53 0.0411 MmugDNA.2875.1.S1_at protein-O-mannosyltransferase 1 POMT1 4.53 0.0018 MmugDNA.13007.1.S1_at hypothetical protein LOC284669 LOC284669 4.52 0.0142 Mmu.3693.1.S1_at splicing factor p54 LOC702698 4.52 0.0572 MmugDNA.20453.1.S1_at heterogeneous nuclear ribonucleoprotein L HNRPL 4.51 0.0000 MmugDNA.14296.1.S1_at hypothetical protein FLJ37201 FLJ37201 4.51 0.0035 MmugDNA.9174.1.S1_at coiled-coil domain containing 129 CCDC129 4.51 0.0743 MmugDNA.17031.1.S1_at DTW domain containing 1 DTWD1 4.50 0.0000 MmugDNA.10168.1.S1_at trafficking protein particle complex 4 TRAPPC4 4.50 0.0069 MmugDNA.33621.1.S1_at zinc finger-like LOC400713 4.49 0.0368 MmugDNA.28329.1.S1_at Zinc finger protein 250 ZNF250 4.49 0.0001 MmugDNA.3693.1.S1_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 DDX17 4.49 0.0217 MmugDNA.5788.1.S1_s_at transmembrane 4 L six family member 5 TM4SF5 4.48 0.1028 MmugDNA.3666.1.S1_at glucose 6 phosphatase, catalytic, 3 G6PC3 4.47 0.0353 MmugDNA.4300.1.S1_at CDNA clone IMAGE: 4812643 — 4.47 0.0315 MmugDNA.13717.1.S1_at Type 1 tumor necrosis factor receptor shedding ARTS-1 4.46 0.0839 aminopeptidase regulator MmugDNA.31311.1.S1_at methyltransferase like 5 METTL5 4.46 0.0001 MmugDNA.19122.1.S1_at N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 NDST2 4.46 0.1122 MmugDNA.17470.1.S1_at translocase of inner mitochondrial membrane 9 homolog TIMM9 4.45 0.0749 (yeast) MmugDNA.36689.1.S1_at dihydroxyacetone kinase 2 homolog (S. cerevisiae) DAK 4.45 0.2128 MmugDNA.32341.1.S1_at UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- GALNT5 4.45 0.0515 acetylgalactosaminyltransferase 5 (GalNAc-T5) MmugDNA.29495.1.S1_at ankyrin and armadillo repeat containing ANKAR 4.45 0.0616 MmugDNA.9999.1.S1_at cytochrome b5 domain containing 2 CYB5D2 4.45 0.0104 MmugDNA.28421.1.S1_at Discs, large (Drosophila) homolog-associated protein 1 DLGAP1 4.45 0.0793 MmugDNA.38681.1.S1_at — — 4.44 0.1501 MmugDNA.28495.1.S1_at integrin beta 1 binding protein 1 ITGB1BP1 4.44 0.0060 MmugDNA.42735.1.S1_at hypothetical protein LOC144874 LOC144874 4.44 0.1195 MmugDNA.6818.1.S1_at armadillo repeat containing 2 ARMC2 4.43 0.0802 MmugDNA.40576.1.S1_at — — 4.43 0.1762 MmugDNA.8518.1.S1_at Hypothetical protein LOC645323 LOC645323 4.42 0.1298 MmugDNA.16049.1.S1_at Ubiquitin specific peptidase 30 USP30 4.42 0.0000 MmuSTS.4469.1.S1_s_at vasodilator-stimulated phosphoprotein VASP 4.42 0.0468 MmugDNA.38086.1.S1_at chromosome 10 open reading frame 137 C10orf137 4.41 0.0223 MmugDNA.31273.1.S1_at bobby sox homolog (Drosophila) BBX 4.41 0.0269 MmugDNA.39436.1.S1_at Transcribed locus — 4.41 0.0107 MmuSTS.2675.1.S1_s_at ATP-binding cassette, sub-family B (MDR/TAP), member 10 ABCB10 4.41 0.0156 Mmu.2243.1.S1_at eukaryotic translation initiation factor 3, subunit 2 beta, EIF3S2 4.40 0.0204 36 kDa MmugDNA.14154.1.S1_at ceroid-lipofuscinosis, neuronal 5 CLN5 4.40 0.0271 MmugDNA.8714.1.S1_s_at inosine triphosphatase (nucleoside triphosphate ITPA 4.40 0.0380 pyrophosphatase) Mmu.15592.2.S1_at phosphatidylinositol glycan, class F isoform 1 LOC714844 4.39 0.0098 MmugDNA.19980.1.S1_at tripartite motif-containing 5 TRIM5 4.39 0.1642 MmugDNA.3645.1.S1_at serine/threonine kinase receptor associated protein STRAP 4.39 0.0135 MmugDNA.29562.1.S1_at prohibitin PHB 4.37 0.0035 MmugDNA.2122.1.S1_at stomatin STOM 4.37 0.0263 MmugDNA.20601.1.S1_s_at prolyl endopeptidase-like PREPL 4.37 0.0512 MmugDNA.26227.1.S1_at RFT1 homolog (S. cerevisiae) RFT1 4.37 0.1974 MmugDNA.119.1.S1_at zinc finger protein 542 ZNF542 4.36 0.1250 MmugDNA.38257.1.S1_at chromosome 3 open reading frame 18 C3orf18 4.36 0.0391 MmugDNA.38303.1.S1_at TAF4b RNA polymerase II, TATA box binding protein TAF4B 4.35 0.0954 (TBP)-associated factor, 105 kDa Mmu.13799.1.S1_at hypothetical protein LOC696762 LOC696762 4.35 0.0294 MmugDNA.24015.1.S1_at LanC lantibiotic synthetase component C-like 2 (bacterial) LANCL2 4.35 0.0403 MmugDNA.38882.1.S1_at zinc finger protein 775 ZNF775 4.35 0.0238 MmugDNA.11471.1.S1_at ATPase family, AAA domain containing 1 ATAD1 4.35 0.0077 MmugDNA.6735.1.S1_at zinc finger protein 642 ZNF642 4.33 0.0727 MmugDNA.18469.1.S1_at zinc finger protein 588 ZNF588 4.33 0.1354 MmugDNA.11216.1.S1_at cancer susceptibility candidate 4 CASC4 4.33 0.0008 MmugDNA.28842.1.S1_at CKLF-like MARVEL transmembrane domain containing 7 CMTM7 4.32 0.0168 MmugDNA.19883.1.S1_at SECIS binding protein 2 SECISBP2 4.32 0.0191 MmugDNA.18544.1.S1_at renal tumor antigen RAGE 4.32 0.0365 MmugDNA.31414.1.S1_at SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae) SUMO1 4.32 0.0298 MmugDNA.30985.1.S1_at glucosidase, beta (bile acid) 2 GBA2 4.32 0.0080 MmugDNA.33696.1.S1_at hyaluronan binding protein 4 HABP4 4.32 0.0433 MmugDNA.24247.1.S1_at chromosome 10 open reading frame 11 C10orf11 4.31 0.1241 Mmu.11729.1.S1_s_at Translocon-associated protein beta subunit precursor LOC719383 4.31 0.0536 (TRAP-beta) (Signal sequence receptor beta subunit) (SSR- beta) MmugDNA.33158.1.S1_at coiled-coil domain containing 22 CCDC22 4.30 0.0689 MmugDNA.10111.1.S1_at chromosome 1 open reading frame 131 C1orf131 4.29 0.0196 MmugDNA.43034.1.S1_at HLA-B associated transcript 5 BAT5 4.29 0.0313 MmugDNA.10771.1.S1_at ligase IV, DNA, ATP-dependent LIG4 4.29 0.0048 MmugDNA.39663.1.S1_at Bernardinelli-Seip congenital lipodystrophy 2 (seipin) /// BSCL2 /// 4.28 0.0093 heterogeneous nuclear ribonucleoprotein U-like 2 HNRPUL2 MmugDNA.36927.1.S1_at DNA (cytosine-5-)-methyltransferase 3 alpha DNMT3A 4.28 0.0096 MmugDNA.24861.1.S1_s_at neuroguidin, EIF4E binding protein NGDN 4.27 0.0007 MmugDNA.24533.1.S1_at cathepsin S CTSS 4.27 0.0031 MmuSTS.1546.1.S1_at musashi homolog 2 MSI2 4.27 0.0014 MmugDNA.831.1.S1_at Chromosome 14 open reading frame 161 C14orf161 4.26 0.0165 MmugDNA.10644.1.S1_at Muscleblind-like 2 (Drosophila) MBNL2 4.25 0.0000 MmugDNA.33695.1.S1_at zinc finger protein 34 ZNF34 4.25 0.0030 MmugDNA.23792.1.S1_at thrombospondin, type I, domain containing 3 THSD3 4.24 0.1178 MmugDNA.12396.1.S1_at chromosome 3 open reading frame 41 C3orf41 4.24 0.0202 MmugDNA.21184.1.S1_at hypoxia inducible factor 3, alpha subunit HIF3A 4.24 0.1766 MmugDNA.6866.1.S1_at STEAP family member 3 STEAP3 4.24 0.1494 MmugDNA.15710.1.S1_at vacuolar protein sorting 39 (yeast) VPS39 4.23 0.0007 Mmu.586.1.S1_at Protein KIAA0143 LOC696036 4.23 0.0432 MmuSTS.2503.1.S1_at zinc finger, SWIM domain containing 5 ZSWIM5 4.23 0.0370 MmugDNA.21399.1.S1_at Transcribed locus — 4.22 0.0664 MmuSTS.2401.1.S1_s_at replication protein A1, 70 kDa RPA1 4.22 0.0162 Mmu.5491.1.S1_at prosaposin LOC709510 4.22 0.1033 MmugDNA.15874.1.S1_at Mitochondrial fission regulator 1 MTFR1 4.21 0.0570 MmugDNA.32637.1.S1_at nucleosomal binding protein 1 NSBP1 4.21 0.0038 MmugDNA.10551.1.S1_at mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N- MGAT2 4.21 0.0530 acetylglucosaminyltransferase /// mannosyl (alpha-1,6-)- glycoprotein beta-1,2-N-acetylglucosaminyltransferase MmugDNA.41398.1.S1_at chromosome 3 open reading frame 31 C3orf31 4.21 0.0943 MmugDNA.17617.1.S1_s_at trophinin /// trophinin TRO 4.21 0.0108 MmugDNA.39122.1.S1_at chromosome 3 open reading frame 1 C3orf1 4.21 0.0262 MmugDNA.18454.1.S1_at Transcribed locus — 4.20 0.0989 MmugDNA.39611.1.S1_at Dedicator of cytokinesis 2 DOCK2 4.19 0.1153 MmuSTS.2075.1.S1_at POU domain, class 2, transcription factor 3 POU2F3 4.19 0.0002 MmugDNA.28348.1.S1_s_at chaperonin containing TCP1, subunit 2 (beta) CCT2 4.18 0.0291 MmugDNA.26826.1.S1_s_at solute carrier family 11 (proton-coupled divalent metal ion SLC11A1 4.17 0.0308 transporters), member 1 Mmu.9862.2.S1_at F-box only protein 4 isoform 2 LOC697007 4.17 0.2109 Mmu.303.1.S1_at crystallin, zeta LOC704403 4.17 0.0292 MmugDNA.19380.1.S1_at chromosome 1 open reading frame 19 C1orf19 4.16 0.0000 MmugDNA.11030.1.S1_s_at chromosome 3 open reading frame 15 C3orf15 4.16 0.0146 MmugDNA.732.1.S1_at hexosaminidase B (beta polypeptide) HEXB 4.16 0.0013 MmugDNA.43014.1.S1_at hypothetical LOC389172 LOC389172 4.16 0.0052 MmugDNA.14429.1.S1_at chromosome X open reading frame 58 CXorf58 4.15 0.0672 MmugDNA.33820.1.S1_at KIAA0100 KIAA0100 4.15 0.0184 MmugDNA.1154.1.S1_at SNF1-like kinase /// SNF1-like kinase SNF1LK 4.15 0.0142 MmugDNA.9493.1.S1_at phosphodiesterase 4D, cAMP-specific (phosphodiesterase PDE4D 4.15 0.0016 E3 dunce homolog, Drosophila) MmugDNA.38138.1.S1_at zinc finger protein 267 ZNF267 4.14 0.0014 MmugDNA.37212.1.S1_at zinc finger, ZZ-type containing 3 ZZZ3 4.14 0.0098 MmugDNA.41461.1.S1_at zinc finger protein 333 ZNF333 4.14 0.1972 MmugDNA.19606.1.S1_at pseudouridylate synthase 7 homolog (S. cerevisiae)-like /// pseudouridylate synthase 7 homolog (S. cerevisiae)-like PUS7L 4.13 0.0653 MmugDNA.11456.1.S1_at ligatin LGTN 4.13 0.0557 MmugDNA.36143.1.S1_s_at choline dehydrogenase CHDH 4.13 0.2015 MmugDNA.7248.1.S1_s_at CCR4-NOT transcription complex, subunit 2 CNOT2 4.13 0.0005 MmugDNA.5833.1.S1_at phosphoinositide-3-kinase, regulatory subunit 4, p150 PIK3R4 4.13 0.0029 MmugDNA.39422.1.S1_at UDP-GlcNAc:betaGal beta-1,3-N- B3GNT1 4.12 0.0370 acetylglucosaminyltransferase 1 MmugDNA.1591.1.S1_at Homo sapiens, clone IMAGE: 3352913, mRNA — 4.12 0.0569 MmugDNA.34328.1.S1_at dyslexia susceptibility 1 candidate 1 DYX1C1 4.12 0.0834 MmugDNA.111.1.S1_at zinc finger protein 180 ZNF180 4.11 0.1267 MmugDNA.5762.1.S1_at vacuolar protein sorting 25 homolog (S. cerevisiae) VPS25 4.10 0.0377 MmugDNA.16868.1.S1_at hypothetical protein FLJ36665 FLJ36665 4.09 0.1171 MmugDNA.6114.1.S1_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 DDX18 4.09 0.0159 MmugDNA.33106.1.S1_at — — 4.09 0.0272 MmugDNA.24857.1.S1_at RAP2A, member of RAS oncogene family /// RAP2B, RAP2A /// RAP2B 4.07 0.1231 member of RAS oncogene family MmunewRS.1035.1.S1_s_at cDNA FLJ31653 fis, clone NT2RI2004190. gi:16551556 4.06 0.0241 MmugDNA.6270.1.S1_at synaptogyrin 1 SYNGR1 4.06 0.0066 MmugDNA.42267.1.S1_at Transcribed locus — 4.06 0.1725 MmugDNA.1721.1.S1_at zinc finger protein 442 /// zinc finger protein 442 ZNF442 4.06 0.0870 MmugDNA.1190.1.S1_at dpy-19-like 2 (C. elegans) DPY19L2 4.06 0.0340 MmugDNA.10350.1.S1_at DEAH (Asp-Glu-Ala-His) box polypeptide 16 DHX16 4.05 0.0105 MmuSTS.2597.1.S1_at eukaryotic translation elongation factor 1 epsilon 1 EEF1E1 4.05 0.0005 MmugDNA.13760.1.S1_at AHA1, activator of heat shock 90 kDa protein ATPase AHSA1 4.05 0.0000 homolog 1 (yeast) MmugDNA.27617.1.S1_at tektin 2 (testicular) TEKT2 4.04 0.0469 MmugDNA.29808.1.S1_at mannosidase, alpha, class 2C, member 1 MAN2C1 4.04 0.0015 MmugDNA.29621.1.S1_at bone morphogenetic protein 6 BMP6 4.04 0.0815 MmugDNA.26069.1.S1_at — — 4.04 0.0531 MmuSTS.3237.1.S1_at RAD54 homolog B (S. cerevisiae) RAD54B 4.04 0.0748 Mmu.9266.1.S1_x_at alpha-defensin 4 precursor, mRNA, complete cds. AY859406 4.02 0.0972 MmugDNA.35254.1.S1_at nudix (nucleoside diphosphate linked moiety X)-type motif NUDT16P 4.01 0.1650 16 pseudogene MmugDNA.40333.1.S1_at low density lipoprotein receptor-related protein associated LRPAP1 4.01 0.0177 protein 1 Mmu.4677.1.S1_s_at rabconnectin-3 beta isoform 2 LOC695302 4.01 0.0167 MmugDNA.15059.1.S1_at zinc finger protein 780B ZNF780B 4.01 0.1768 MmugDNA.2321.1.S1_at ELL associated factor 2 EAF2 4.00 0.0663 Mmu.14167.1.S1_at DNA topoisomerase I LOC697300 4.00 0.1952 MmugDNA.3213.1.S1_at single stranded DNA binding protein 4 SSBP4 4.00 0.0429 MmugDNA.42484.1.S1_at ARP6 actin-related protein 6 homolog (yeast) ACTR6 4.00 0.0252 MmugDNA.7865.1.S1_at PPAR binding protein PPARBP 4.00 0.0589 MmugDNA.18301.1.S1_at chromosome 18 open reading frame 10 C18orf10 4.00 0.0013 MmugDNA.40541.1.S1_at zinc finger protein 555 ZNF555 4.00 0.0028 MmugDNA.6772.1.S1_at ER degradation enhancer, mannosidase alpha-like 2 EDEM2 3.99 0.0411 MmugDNA.24353.1.S1_at retinoic acid receptor responder (tazarotene induced) 1 RARRES1 3.99 0.1529 MmugDNA.34452.1.S1_s_at — — 3.98 0.0067 MmugDNA.9814.1.S1_at Transcribed locus — 3.98 0.0111 MmugDNA.27740.1.S1_at U2-associated SR140 protein SR140 3.98 0.0286 MmuSTS.3952.1.S1_at SEC22 vesicle trafficking protein homolog C (S. cerevisiae) SEC22C 3.98 0.0001 MmugDNA.36936.1.S1_at deoxyguanosine kinase DGUOK 3.97 0.0061 MmugDNA.16551.1.S1_at hypothetical protein FLJ25770 FLJ25770 3.97 0.0789 MmugDNA.32988.1.S1_at ring finger protein 123 RNF123 3.97 0.0078 MmugDNA.40932.1.S1_at zinc finger protein 691 ZNF691 3.97 0.0191 MmugDNA.42528.1.S1_at cytochrome P450, family 4, subfamily F, polypeptide 2 CYP4F2 3.96 0.1843 MmugDNA.38754.1.S1_at Galactokinase 2 GALK2 3.96 0.0572 MmuSTS.2536.1.S1_at Interferon tau-1 IFNT1 3.96 0.1884 MmugDNA.21837.1.S1_at CDNA FLJ40810 fis, clone TRACH2009743 — 3.95 0.0554 Mmu.10030.1.S1_at syntenin isoform 3 LOC698381 3.95 0.0001 Mmu.5329.1.S1_at Phospholipid hydroperoxide glutathione peroxidase, GPX4 3.95 0.1220 mitochondrial precursor (PHGPx) (GPX-4) MmugDNA.36752.1.S1_at lymphocyte antigen 6 complex, locus G5C LY6G5C 3.93 0.1998 MmuSTS.897.1.S1_at sema domain, seven thrombospondin repeats (type 1 and SEMA5B 3.93 0.0637 type 1-lik, , transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B MmugDNA.40072.1.S1_at hypothetical protein DKFZp313A2432 DKFZp313A2432 3.93 0.1059 MmugDNA.19577.1.S1_at phosphatidylinositol glycan anchor biosynthesis, class M PIGM 3.93 0.2113 MmugDNA.11968.1.S1_at UBX domain containing 7 UBXD7 3.93 0.0163 MmugDNA.19665.1.S1_at hypothetical protein LOC196394 LOC196394 3.93 0.0165 MmugDNA.23833.1.S1_at chromosome 21 open reading frame 58 C21orf58 3.93 0.1718 MmugDNA.27456.1.S1_at polymerase (RNA) I polypeptide D, 16 kDa POLR1D 3.92 0.0000 MmugDNA.30349.1.S1_at Transcribed locus — 3.92 0.0066 MmugDNA.7253.1.S1_at — — 3.92 0.1111 MmugDNA.14931.1.S1_at t-SNARE domain containing 1 TSNARE1 3.91 0.0947 MmugDNA.30795.1.S1_at chromosome 10 open reading frame 81 C10orf81 3.91 0.0955 MmugDNA.17018.1.S1_s_at butyrophilin, subfamily 2, member A1 BTN2A1 3.91 0.0004 MmugDNA.26488.1.S1_at nischarin NISCH 3.90 0.0435 MmugDNA.1076.1.S1_at WD repeat domain 61 WDR61 3.89 0.0001 MmugDNA.19511.1.S1_at death inducer-obliterator 1 DIDO1 3.89 0.0638 MmugDNA.5147.1.S1_s_at kelch repeat and BTB (POZ) domain containing 4 KBTBD4 3.89 0.0043 MmugDNA.26429.1.S1_at AP2 associated kinase 1 AAK1 3.89 0.1855 MmugDNA.36463.1.S1_s_at tyrosine kinase, non-receptor, 1 TNK1 3.89 0.0001 MmuSTS.1060.1.S1_at Solute carrier family 25, member 29 SLC25A29 3.89 0.0804 MmugDNA.12692.1.S1_at quinolinate phosphoribosyltransferase (nicotinate- QPRT 3.88 0.0444 nucleotide pyrophosphorylase (carboxylating)) MmugDNA.19435.1.S1_s_at DnaJ (Hsp40) homolog, subfamily A, member 1 DNAJA1 3.88 0.0014 MmugDNA.1963.1.S1_at CDNA clone IMAGE: 5278089 — 3.88 0.1079 MmugDNA.40985.1.S1_at CDNA clone IMAGE: 4825288 — 3.88 0.0338 MmuSTS.3495.1.S1_at A kinase (PRKA) anchor protein 3 AKAP3 3.87 0.0508 MmuSTS.3737.1.S1_at protein tyrosine phosphatase, receptor type, C PTPRC 3.87 0.0186 MmugDNA.31476.1.S1_at RAB28, member RAS oncogene family RAB28 3.87 0.0939 MmugDNA.30719.1.S1_at dom-3 homolog Z (C. elegans) DOM3Z 3.87 0.0007 MmugDNA.3113.1.S1_at transient receptor potential cation channel, subfamily C, TRPC2 3.87 0.0121 member 2 MmuSTS.4117.1.S1_at transmembrane protein 15 TMEM15 3.87 0.0145 MmugDNA.41463.1.S1_at Vac14 homolog (S. cerevisiae) VAC14 3.86 0.0546 MmugDNA.26499.1.S1_at leupaxin LPXN 3.86 0.0090 MmugDNA.37595.1.S1_at mortality factor 4 like 1 MORF4L1 3.85 0.0059 MmugDNA.22504.1.S1_at — — 3.84 0.0508 MmugDNA.20249.1.S1_at RNA binding motif protein 26 RBM26 3.84 0.0198 MmugDNA.13483.1.S1_at — — 3.84 0.0604 MmugDNA.16424.1.S1_at gelsolin (amyloidosis, Finnish type) GSN 3.84 0.0118 MmugDNA.16896.1.S1_at stromal antigen 3 STAG3 3.82 0.0959 MmuSTS.2334.1.S1_at peroxisomal membrane protein 4, 24 kDa PXMP4 3.81 0.0013 MmugDNA.28442.1.S1_s_at chromosome 20 open reading frame 74 C20orf74 3.81 0.0043 MmugDNA.6811.1.S1_at smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans) SMU1 3.80 0.0001 MmugDNA.13860.1.S1_at — — 3.79 0.0387 MmugDNA.13463.1.S1_at COP9 constitutive photomorphogenic homolog subunit 6 COPS6 3.79 0.0192 (Arabidopsis) MmugDNA.4402.1.S1_s_at mago-nashi homolog FLJ10292 3.78 0.0492 MmugDNA.18844.1.S1_at cholinergic receptor, nicotinic, alpha 1 (muscle) CHRNA1 3.77 0.1879 MmugDNA.40143.1.S1_at transmembrane protein 67 TMEM67 3.77 0.0848 MmuSTS.2481.1.S1_at zinc finger protein 294 ZNF294 3.77 0.0304 MmugDNA.30140.1.S1_at thioredoxin-like 4B TXNL4B 3.77 0.0239 MmugDNA.38654.1.S1_at MORN repeat containing 2 MORN2 3.77 0.0047 MmuSTS.2773.1.S1_at solute carrier family 1 (neutral amino acid transporter), SLC1A5 3.76 0.0113 member MmugDNA.31203.1.S1_at THAP domain containing, apoptosis associated protein 2 THAP2 3.76 0.0136 MmugDNA.13298.1.S1_at zinc finger protein 473 ZNF473 3.76 0.0210 MmugDNA.19431.1.S1_at ZXD family zinc finger C ZXDC 3.76 0.1070 MmugDNA.33573.1.S1_s_at serine/threonine kinase 16 STK16 3.76 0.0507 MmugDNA.24286.1.S1_at coagulation factor II (thrombin) receptor-like 1 F2RL1 3.76 0.0055 MmugDNA.41306.1.S1_at zinc finger protein 650 ZNF650 3.76 0.0002 MmugDNA.8919.1.S1_at Transcribed locus — 3.75 0.0786 MmugDNA.4185.1.S1_at nicolin 1 NICN1 3.75 0.1272 MmugDNA.21236.1.S1_at arginine/serine-rich coiled-coil 1 LOC704232 3.75 0.0445 MmugDNA.32661.1.S1_at dihydropyrimidine dehydrogenase DPYD 3.75 0.0062 MmugDNA.20872.1.S1_at docking protein 1, 62 kDa (downstream of tyrosine kinase 1) DOK1 3.75 0.0846 MmugDNA.34300.1.S1_at nicotinamide nucleotide adenylyltransferase 1 NMNAT1 3.75 0.0851 MmuSTS.3697.1.S1_at COP9 constitutive photomorphogenic homolog subunit 4 COPS4 3.74 0.0000 MmuSTS.3649.1.S1_at chloride channel 4 CLCN4 3.74 0.1113 MmugDNA.40690.1.S1_at zinc finger protein 197 ZNF197 3.74 0.0025 MmugDNA.41072.1.S1_at chromosome X and Y open reading frame 10 CXYorf10 3.73 0.0146 MmugDNA.26793.1.S1_at hypothetical protein MGC40579 MGC40579 3.73 0.0030 MmugDNA.7453.1.S1_at integrator complex subunit 9 RC74 3.73 0.0020 MmugDNA.41810.1.S1_at KIAA1429 KIAA1429 3.72 0.0204 MmugDNA.42873.1.S1_at nuclear transcription factor, X-box binding 1 NFX1 3.72 0.1160 MmugDNA.13884.1.S1_at TNFAIP3 interacting protein 2 TNIP2 3.72 0.0166 MmugDNA.6002.1.S1_at apolipoprotein A-I binding protein APOA1BP 3.72 0.0046 MmugDNA.28839.1.S1_at Hypothetical protein LOC150384 LOC150384 3.72 0.0243 MmugDNA.11009.1.S1_at elongation factor Tu GTP binding domain containing 1 EFTUD1 3.72 0.0006 MmuSTS.2811.1.S1_s_at solute carrier family 39 (zinc transporter), member 7 SLC39A7 3.72 0.1074 MmugDNA.11298.1.S1_at RNA binding motif protein 12B RBM12B 3.72 0.1376 MmugDNA.38831.1.S1_at transient receptor potential cation channel, subfamily C, TRPC4AP 3.71 0.0751 member 4 associated protein MmuSTS.1121.1.S1_at single-strand-selective monofunctional uracil-DNA SMUG1 3.71 0.1049 glycosylase 1 MmugDNA.23627.1.S1_at caspase 2, apoptosis-related cysteine peptidase (neural CASP2 3.71 0.1012 precursor cell expressed, developmentally down-regulated 2) Mmu.14962.1.S1_at glycosyltransferase 8 domain containing 1 LOC695999 3.71 0.0060 MmugDNA.13631.1.S1_s_at CD320 molecule CD320 3.71 0.0663 MmugDNA.23982.1.S1_at phosphoprotein associated with glycosphingolipid PAG1 /// 3.71 0.0018 microdomains 1 /// phosphoprotein associated with LOC653745 glycosphingolipid microdomains 1 MmuSTS.2557.1.S1_at tumor necrosis factor (ligand) superfamily, member 19 TNFSF4 3.70 0.0375 MmugDNA.9215.1.S1_s_at REX2, RNA exonuclease 2 homolog (S. cerevisiae) REXO2 3.70 0.0235 MmugDNA.14634.1.S1_at alcohol dehydrogenase IB (class I), beta polypeptide ADH1B 3.70 0.2072 MmuSTS.2989.1.S1_at met proto-oncogene MET 3.69 0.0006 MmugDNA.6796.1.S1_at F-box and WD-40 domain protein 8 FBXW8 3.69 0.0022 MmugDNA.35611.1.S1_at — — 3.69 0.0476 MmunewRS.1092.1.S1_at F-box and WD-40 domain protein 12 FBXW12 3.69 0.1972 MmugDNA.37110.1.S1_at chromosome 1 open reading frame 34 C1orf34 3.69 0.0005 MmugDNA.8905.1.S1_at Transcribed locus, strongly XP_376888.2 PREDICTED: — 3.69 0.0321 Laminin receptor 1 [Homo sapiens] MmugDNA.24188.1.S1_s_at deleted in a mouse model of primary ciliary dyskinesia RP11-529I10.4 3.68 0.0323 MmugDNA.36794.1.S1_at zinc finger protein 593 ZNF593 3.68 0.0540 MmuSTS.4394.1.S1_at DENN/MADD domain containing 4A DENND4A 3.67 0.0345 MmugDNA.4893.1.S1_at hypothetical protein MGC16385 MGC16385 3.67 0.0054 MmunewRS.474.1.S1_at ras homolog gene family, member C RHOC 3.67 0.1242 MmugDNA.29861.1.S1_at carbonic anhydrase XI CA11 3.67 0.0227 MmugDNA.3791.1.S1_at sphingosine-1-phosphate phosphatase 1 SGPP1 3.67 0.0007 MmugDNA.10595.1.S1_at — — 3.67 0.1276 MmugDNA.34611.1.S1_at Hypothetical protein LOC643011 LOC643011 3.67 0.0005 MmugDNA.38962.1.S1_at acid phosphatase 6, lysophosphatidic ACP6 3.66 0.0113 MmugDNA.3351.1.S1_at DNA segment on chromosome 4 (unique) 234 expressed D4S234E 3.66 0.0658 sequence MmugDNA.2806.1.S1_s_at mitogen-activated protein kinase kinase kinase kinase 1 MAP4K1 3.66 0.0540 MmugDNA.1419.1.S1_at CDNA: FLJ23065 fis, clone LNG04894 — 3.65 0.1255 MmugDNA.24776.1.S1_at protein phosphatase 1, regulatory subunit 7 PPP1R7 3.65 0.0367 MmugDNA.35069.1.S1_at RAB6B, member RAS oncogene family RAB6B 3.65 0.0351 MmugDNA.29893.1.S1_at ankyrin repeat domain 28 ANKRD28 3.64 0.0027 MmugDNA.2018.1.S1_at RNA binding protein S1, serine-rich domain /// RNA binding RNPS1 3.64 0.0026 protein S1, serine-rich domain MmugDNA.31080.1.S1_at phosphatidylinositol glycan anchor biosynthesis, class O PIGO 3.64 0.0464 MmugDNA.24890.1.S1_at transmembrane and tetratricopeptide repeat containing 2 TMTC2 3.64 0.0230 MmugDNA.5735.1.S1_at — — 3.64 0.0557 MmugDNA.26841.1.S1_at estrogen-related receptor alpha ESRRA 3.63 0.0274 MmugDNA.27441.1.S1_at protein phosphatase 2 (formerly 2A), regulatory subunit A PPP2R1B 3.63 0.0345 (PR 65), beta isoform MmuSTS.1040.1.S1_at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 ST8SIA5 3.63 0.0623 MmugDNA.7493.1.S1_at intraflagellar transport 122 homolog (Chlamydomonas) IFT122 3.63 0.0020 MmuSTS.3957.1.S1_at splicing factor, arginine/serine-rich 6 SFRS6 3.62 0.0000 MmugDNA.29820.1.S1_at calcium and integrin binding 1 (calmyrin) CIB1 3.62 0.0323 MmugDNA.16149.1.S1_at Full-length cDNA clone CS0DC025YP03 of Neuroblastoma — 3.62 0.0491 Cot 25-normalized of Homo sapiens (human) MmugDNA.6842.1.S1_at proteasome maturation protein POMP 3.62 0.0204 MmuSTS.1527.1.S1_at mitochondrial ribosomal protein L49 MRPL49 3.62 0.0034 MmugDNA.19557.1.S1_at filamin binding LIM protein 1 FBLIM1 3.61 0.0016 MmugDNA.32221.1.S1_at family with sequence similarity 3, member C FAM3C 3.61 0.0022 MmuSTS.1501.1.S1_at membrane cofactor protein MCP 3.60 0.0015 MmugDNA.38325.1.S1_s_at chromosome 15 open reading frame 17 C15orf17 3.60 0.0580 MmugDNA.3200.1.S1_at Homo sapiens, clone IMAGE: 5768746, mRNA — 3.60 0.1685 MmugDNA.2659.1.S1_at coiled-coil domain containing 32 CCDC32 3.60 0.0505 MmugDNA.19268.1.S1_at mitochondrial ribosomal protein L2 MRPL2 3.60 0.0018 MmugDNA.24173.1.S1_at Mastermind-like 2 (Drosophila) MAML2 3.59 0.0493 MmugDNA.24843.1.S1_at zinc finger protein 226 ZNF226 3.59 0.0000 MmugDNA.35062.1.S1_s_at aconitase 2, mitochondrial ACO2 3.59 0.0031 MmugDNA.17481.1.S1_at tripartite motif-containing 36 TRIM36 3.58 0.0010 MmugDNA.3106.1.S1_at protective protein for beta-galactosidase (galactosialidosis) PPGB 3.58 0.0000 MmugDNA.38210.1.S1_at Full-length cDNA clone CS0DF025YA01 of Fetal brain of — 3.58 0.0127 Homo sapiens (human) MmugDNA.15726.1.S1_at corin, serine peptidase CORIN 3.58 0.2106 MmugDNA.24500.1.S1_at CGI-09 protein CGI-09 3.57 0.0000 MmugDNA.16131.1.S1_at penta-EF-hand domain containing 1 PEF1 3.57 0.0794 MmugDNA.9872.1.S1_at lysosomal-associated membrane protein 1 LAMP1 3.56 0.0236 Mmu.4348.1.S1_at membrane interacting protein of RGS16 LOC694849 3.56 0.0006 MmugDNA.5941.1.S1_at BTB (POZ) domain containing 9 BTBD9 3.56 0.1375 MmugDNA.10425.1.S1_at chondroitin polymerizing factor CHPF 3.56 0.0133 MmugDNA.845.1.S1_at aspartylglucosaminidase AGA 3.56 0.0019 MmugDNA.3137.1.S1_at protein phosphatase 1G (formerly 2C), magnesium- PPM1G 3.56 0.0107 dependent, gamma isoform MmugDNA.35064.1.S1_at acyl-Coenzyme A oxidase 2, branched chain ACOX2 3.55 0.0374 MmugDNA.33241.1.S1_at Impact homolog (mouse) IMPACT 3.55 0.0052 MmugDNA.18757.1.S1_at chromosome 3 open reading frame 39 C3orf39 3.55 0.0763 MmugDNA.4130.1.S1_at mitochondrial ribosomal protein L14 MRPL14 3.55 0.0210 MmugDNA.7996.1.S1_at zinc finger protein 536 ZNF536 3.55 0.1304 MmugDNA.34470.1.S1_s_at Hypothetical protein FLJ20309 FLJ20309 3.55 0.0078 MmugDNA.722.1.S1_at — — 3.54 0.0027 MmugDNA.26101.1.S1_at chromosome 10 open reading frame 25 C10orf25 3.54 0.1140 MmugDNA.10676.1.S1_s_at Dmx-like 1 DMXL1 3.54 0.0303 MmugDNA.16755.1.S1_at ureidopropionase, beta UPB1 3.54 0.1655 MmugDNA.22341.1.S1_at CDNA FLJ31513 fis, clone NT2RI1000127 — 3.54 0.0101 MmuSTS.4756.1.S1_at Fanconi anemia, complementation group A FANCA 3.54 0.0421 MmuSTS.149.1.S1_at MAM domain containing glycosylphosphatidylinositol MDGA1 3.54 0.0991 anchor 1 Mmu.9020.1.S1_at — CN802973 3.53 0.0706 MmugDNA.14464.1.S1_at antizyme inhibitor 1 AZIN1 3.53 0.0000 MmugDNA.3591.1.S1_at hematopoietic signal peptide-containing LOC284361 3.52 0.0013 MmugDNA.2520.1.S1_at gamma-aminobutyric acid (GABA) A receptor, beta 3 GABRB3 3.52 0.1177 MmugDNA.9838.1.S1_x_at protein disulfide isomerase family A, member 4 /// protein PDIA4 3.52 0.0436 disulfide isomerase family A, member 4 MmugDNA.961.1.S1_at hypothetical protein BC009862 LOC90113 3.52 0.0115 MmugDNA.11411.1.S1_at — — 3.52 0.0264 MmuSTS.3925.1.S1_at sal-like 2 (Drosophila) SALL2 3.51 0.0042 MmugDNA.32205.1.S1_s_at cytochrome b5 type A (microsomal) CYB5A 3.51 0.0112 MmugDNA.32647.1.S1_at KIAA0409 KIAA0409 3.51 0.0080 MmugDNA.11293.1.S1_at F-box protein 4 FBXO4 3.51 0.0376 MmugDNA.4391.1.S1_at secernin 2 SCRN2 3.51 0.0570 MmugDNA.15005.1.S1_at glutaminase GLS 3.50 0.1533 MmugDNA.28947.1.S1_at lactamase, beta 2 LACTB2 3.50 0.0364 MmugDNA.16632.1.S1_at Coenzyme Q10 homolog B (S. cerevisiae) COQ10B 3.50 0.0485 MmugDNA.8992.1.S1_at cytoplasmic beta-actin LOC709469 3.50 0.1131 MmugDNA.36746.1.S1_at FYVE, RhoGEF and PH domain containing 6 FGD6 3.50 0.0657 MmugDNA.24282.1.S1_at RIKEN cDNA 4921524J17 LOC388272 3.50 0.0156 MmugDNA.6398.1.S1_at 1-acylglycerol-3-phosphate O-acyltransferase 7 AGPAT7 3.50 0.0454 (lysophosphatidic acid acyltransferase, eta) MmugDNA.8757.1.S1_at chromosome 21 open reading frame 108 C21orf108 3.49 0.0797 MmugDNA.26500.1.S1_at KIAA0564 protein RP11-125A7.3 3.49 0.0000 MmugDNA.34273.1.S1_at Mitochondrial transcription termination factor MTERF 3.49 0.0856 MmuSTS.2708.1.S1_at a disintegrin and metalloproteinase domain 10 ADAM10 3.49 0.0131 MmugDNA.41055.1.S1_at chromosome 3 open reading frame 62 C3orf62 3.49 0.0726 MmugDNA.29251.1.S1_at guanine nucleotide binding protein (G protein), alpha GNAT2 3.49 0.0400 transducing activity polypeptide 2 MmugDNA.26180.1.S1_at Chromosome 9 open reading frame 42 C9orf42 3.49 0.0292 MmuSTS.1660.1.S1_at leucyl-tRNA synthetase 2, mitochondrial LARS2 3.49 0.0460 MmugDNA.43332.1.S1_at Transcribed locus — 3.49 0.0334 MmugDNA.20126.1.S1_at 5,10-methenyltetrahydrofolate synthetase (5- MTHFS 3.48 0.0071 formyltetrahydrofolate cyclo-ligase) MmuSTS.1987.1.S1_at death-associated protein DAP 3.48 0.0005 MmugDNA.40683.1.S1_at heterogeneous nuclear ribonucleoprotein K HNRPK 3.48 0.0301 MmugDNA.22114.1.S1_at methylthioadenosine phosphorylase MTAP 3.47 0.0264 MmugDNA.40281.1.S1_at Transcribed locus 237420_at 3.47 0.0200 MmugDNA.9668.1.S1_at PWP1 homolog (S. cerevisiae) PWP1 3.47 0.0124 MmugDNA.3432.1.S1_at plexin C1 PLXNC1 3.47 0.0162 MmugDNA.11221.1.S1_s_at catenin (cadherin-associated protein), beta 1, 88 kDa CTNNB1 3.47 0.0447 MmugDNA.32959.1.S1_at CDNA FLJ38419 fis, clone FEBRA2009846 — 3.47 0.1735 MmugDNA.19660.1.S1_s_at epoxide hydrolase 1, microsomal (xenobiotic) EPHX1 3.46 0.0000 MmuSTS.4149.1.S1_at lipoic acid synthetase LIAS 3.45 0.0166 MmugDNA.27400.1.S1_at mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N- MGAT4A 3.45 0.0004 acetylglucosaminyltransferase, isozyme A MmugDNA.3969.1.S1_at Transcribed locus, strongly XP_372416.1 PREDICTED: — 3.45 0.1619 leucine rich repeat containing 10 [Homo sapiens] MmunewRS.977.1.S1_s_at chromosome 10 open reading frame 125 C10orf125 3.45 0.0268 MmugDNA.336.1.S1_s_at SH3 and multiple ankyrin repeat domains 2 SHANK2 3.44 0.0424 MmugDNA.10656.1.S1_at GPI-anchored membrane protein 1 GPIAP1 3.44 0.0012 MmugDNA.38403.1.S1_at — — 3.44 0.0927 MmugDNA.28792.1.S1_at metallo-beta-lactamase superfamily protein LOC153364 3.43 0.0467 MmugDNA.15913.1.S1_at NudC domain containing 2 NUDCD2 3.43 0.0000 MmugDNA.10398.1.S1_s_at G protein-coupled receptor 172A GPR172A 3.43 0.0559 MmugDNA.15.1.S1_at Hypothetical protein FLJ30655 FLJ30655 3.43 0.0037 MmugDNA.39070.1.S1_at androgen-induced 1 AIG1 3.43 0.0025 MmugDNA.2721.1.S1_s_at Transcribed locus, weakly XP_864747.1 PREDICTED: — 3.43 0.0094 hypothetical protein XP_859654 [Canis familiaris] Mmu.12027.3.S1_at heterogeneous nuclear ribonucleoprotein K isoform a LOC709112 3.43 0.0681 MmugDNA.38984.1.S1_at uracil-DNA glycosylase 2 UNG2 3.43 0.0995 MmuSTS.4179.1.S1_at cathepsin O CTSO 3.43 0.0144 MmugDNA.26924.1.S1_at hypothetical protein LOC720691 LOC720691 3.42 0.1571 Mmu.1137.1.S1_at clone 2.32 T-cell receptor gamma chain mRNA, complete AY190025 3.42 0.0301 cds. MmuSTS.3149.1.S1_at nuclear receptor subfamily 2, group F, member 6 NR2F6 3.42 0.0585 MmugDNA.3922.1.S1_at CDNA clone IMAGE: 5266242 — 3.42 0.0051 MmugDNA.8473.1.S1_at KIAA1875 KIAA1875 3.42 0.0943 MmugDNA.38687.1.S1_at family with sequence similarity 121B /// NODAL modulator 3 FAM121B /// 3.42 0.1139 NOMO3 MmugDNA.21376.1.S1_s_at SMAD, mothers against DPP homolog 3 (Drosophila) /// SMAD3 /// UROD 3.42 0.0101 uroporphyrinogen decarboxylase MmugDNA.17400.1.S1_at UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- GALNT7 3.42 0.0000 acetylgalactosaminyltransferase 7 (GalNAc-T7) Mmu.4958.1.S1_at Rhesus monkey apolipoprotein(a) mRNA, 3 end. J04635 3.42 0.0785 MmugDNA.9546.1.S1_s_at succinate dehydrogenase complex, subunit B, iron sulfur SDHB 3.41 0.0242 (Ip) MmugDNA.8291.1.S1_at spectrin, beta, erythrocytic (includes spherocytosis, clinical SPTB /// 3.41 0.1210 type I) /// spectrin, beta, erythrocytic (includes LOC653716 spherocytosis, clinical type I) MmugDNA.5881.1.S1_at IQ motif containing C IQCC 3.40 0.0207 MmugDNA.2675.1.S1_at trimethyllysine hydroxylase, epsilon TMLHE 3.40 0.1204 MmugDNA.36751.1.S1_at ret finger protein 2 RFP2 3.40 0.0005 MmugDNA.32977.1.S1_at osmosis responsive factor OSRF 3.40 0.0100 MmugDNA.20463.1.S1_at EST from clone 27306, 5′ end — 3.40 0.0005 MmugDNA.14340.1.S1_s_at SEH1-like (S. cerevisiae) SEH1L 3.39 0.0258 MmugDNA.34005.1.S1_at CG8580-PA, isoform A LOC718520 3.39 0.0005 MmugDNA.767.1.S1_at hypothetical protein BC015395 LOC130940 3.39 0.1357 MmugDNA.10620.1.S1_at Rho GTPase activating protein 18 ARHGAP18 3.39 0.0000 Mmu.11667.1.S1_at Calcyclin-binding protein (CacyBP) (hCacyBP) (Siah- CACYBP /// 3.39 0.0000 interacting protein) (S100A6-binding protein) LOC709343 MmugDNA.8892.1.S1_at hypothetical protein LOC646482 LOC646482 3.38 0.1081 MmugDNA.26367.1.S1_at acyl-CoA synthetase short-chain family member 1 ACSS1 3.38 0.0380 MmugDNA.2176.1.S1_at interferon stimulated exonuclease gene 20 kDa ISG20 3.38 0.0000 MmugDNA.29483.1.S1_at UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- GALNT13 3.38 0.0534 acetylgalactosaminyltransferase 13 (GalNAc-T13) MmuSTS.3944.1.S1_at succinate-CoA ligase, GDP-forming, beta subunit SUCLG2 3.37 0.0043 MmugDNA.2878.1.S1_at IQ motif containing E IQCE 3.37 0.0575 MmugDNA.24079.1.S1_s_at coiled-coil domain containing 115 CCDC115 3.37 0.0018 MmugDNA.646.1.S1_at zinc finger protein 420 ZNF420 3.37 0.0215 MmuSTS.2567.1.S1_s_at Ubiquitin-like 4 UBL4 3.37 0.0006 MmunewRS.414.1.S1_at transcription elongation factor A (SII)-like 1 TCEAL1 3.37 0.0002 MmugDNA.18382.1.S1_at potassium channel tetramerisation domain containing 18 KCTD18 3.37 0.0036 MmugDNA.36367.1.S1_at replication factor C (activator 1) 1, 145 kDa RFC1 3.36 0.0093 MmuSTS.2408.1.S1_s_at splicing factor, arginine/serine-rich 15 SFRS15 3.36 0.0084 MmugDNA.38549.1.S1_at elongation protein 4 homolog (S. cerevisiae) ELP4 3.36 0.0279 MmugDNA.27232.1.S1_at RNA binding motif and ELMO/CED-12 domain 1 RBED1 3.36 0.0628 MmugDNA.30570.1.S1_at flightless I homolog (Drosophila) FLII 3.36 0.0522 MmugDNA.22711.1.S1_at arginyl-tRNA synthetase-like RARSL 3.36 0.0078 MmugDNA.40118.1.S1_at vitelliform macular dystrophy 2-like 2 VMD2L2 3.35 0.0953 MmuSTS.3727.1.S1_at protein tyrosine phosphatase, non-receptor type substrate 1 PTPNS1 3.35 0.0115 MmugDNA.16151.1.S1_at zinc finger protein 567 ZNF567 3.35 0.0104 MmugDNA.34207.1.S1_at Transcribed locus — 3.35 0.1488 MmugDNA.3005.1.S1_at polymerase (RNA) II (DNA directed) polypeptide B, 140 kDa POLR2B 3.34 0.0033 MmugDNA.26951.1.S1_at zinc finger protein 174 ZNF174 3.34 0.0446 MmugDNA.25836.1.S1_at SWI/SNF related, matrix associated, actin dependent SMARCA4 3.34 0.0394 regulator of chromatin, subfamily a, member 4 MmugDNA.40790.1.S1_at matrin 3 MATR3 3.34 0.0880 MmugDNA.15859.1.S1_s_at FAST kinase domains 2 FASTKD2 3.33 0.0003 MmugDNA.26707.1.S1_at aarF domain containing kinase 4 ADCK4 3.33 0.0000 MmuSTS.1553.1.S1_at Mitogen-activated protein kinase kinase kinase 7 interacting MAP3K7IP1 3.33 0.0067 protein 1 MmugDNA.27387.1.S1_s_at mannosidase, alpha, class 2B, member 1 MAN2B1 3.32 0.0175 MmugDNA.23626.1.S1_at — — 3.32 0.0842 MmugDNA.27590.1.S1_at — — 3.32 0.1370 MmugDNA.13842.1.S1_at ADP-ribosylation-like factor 6 interacting protein 4 ARL6IP4 3.31 0.0687 MmugDNA.36711.1.S1_at bolA-like 1 (E. coli) BOLA1 3.31 0.0000 MmugDNA.35351.1.S1_at round spermatid basic protein 1 RSBN1 3.31 0.0414 MmunewRS.884.1.S1_at zinc finger protein 29 MGC75360 3.31 0.1372 MmugDNA.21146.1.S1_at STT3, subunit of the oligosaccharyltransferase complex, STT3A 3.29 0.0106 homolog A (S. cerevisiae) MmugDNA.14126.1.S1_at chromosome 1 open reading frame 176 C1orf176 3.29 0.0492 MmugDNA.3522.1.S1_at KRIT1, ankyrin repeat containing KRIT1 3.29 0.0900 MmugDNA.1835.1.S1_at zinc finger protein 786 ZNF786 3.29 0.0065 MmugDNA.30488.1.S1_at isocitrate dehydrogenase 2 (NADP+), mitochondrial IDH2 3.29 0.0771 MmugDNA.35876.1.S1_at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 ST8SIA2 3.28 0.0593 MmugDNA.29769.1.S1_at Proteasome (prosome, macropain) subunit, beta type, 7 PSMB7 3.28 0.1130 MmuSTS.3141.1.S1_at methionine adenosyltransferase I, alpha MAT1A 3.28 0.0685 MmugDNA.28691.1.S1_at chromosome 4 open reading frame 30 C4orf30 3.28 0.0289 MmugDNA.27041.1.S1_at solute carrier family 25 (mitochondrial carrier; phosphate SLC25A23 3.27 0.0245 carrier), member 23 MmugDNA.1453.1.S1_at dysbindin (dystrobrevin binding protein 1) domain DBNDD2 3.27 0.0046 containing 2 MmuSTS.2928.1.S1_at potassium voltage-gated channel, subfamily H (eag- KCNH7 3.27 0.1254 related), memb, 7 Mmu.1184.1.S1_at endomembrane protein emp70 precursor isolog TM9SF3 3.27 0.1019 MmugDNA.17590.1.S1_at hypothetical gene supported by BC036588 LOC400657 3.27 0.0882 MmugDNA.4941.1.S1_at ring finger protein 14 RNF14 3.27 0.1095 MmugDNA.15613.1.S1_at glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) GNS 3.27 0.0730 MmugDNA.15594.1.S1_at gonadotropin-releasing hormone 2 GNRH2 3.27 0.0389 MmuSTS.1234.1.S1_at carnitine palmitoyltransferase II CPT2 3.26 0.0017 MmugDNA.1780.1.S1_at — — 3.26 0.0226 MmugDNA.36001.1.S1_at septin 3 3-Sep 3.26 0.1383 MmugDNA.18459.1.S1_at protease, serine, 15 PRSS15 3.26 0.1011 MmugDNA.31437.1.S1_at Glycosylphosphatidylinositol specific phospholipase D1 GPLD1 3.26 0.0097 MmugDNA.736.1.S1_at Full-length cDNA clone CS0DJ002YF02 of T cells (Jurkat — 3.25 0.0015 cell line) Cot 10-normalized of Homo sapiens (human) MmugDNA.27420.1.S1_at — — 3.25 0.0258 MmugDNA.16170.1.S1_s_at transmembrane protein 4 TMEM4 3.25 0.0005 MmugDNA.37197.1.S1_at cytochrome b5 domain containing 1 CYB5D1 3.25 0.0905 MmugDNA.3346.1.S1_at makorin, ring finger protein, 2 MKRN2 3.25 0.0000 MmugDNA.8231.1.S1_at triple functional domain (PTPRF interacting) TRIO 3.25 0.2126 MmugDNA.32917.1.S1_at G protein-coupled receptor 56 GPR56 3.24 0.0001 MmugDNA.34839.1.S1_at unc-5 homolog A (C. elegans) UNC5A 3.24 0.0215 MmugDNA.35448.1.S1_at phosphohistidine phosphatase 1 PHPT1 3.24 0.0749 MmugDNA.8574.1.S1_at tetraspanin 32 TSPAN32 3.24 0.0871 MmugDNA.33908.1.S1_at KIAA0141 KIAA0141 3.24 0.0050 MmuSTS.4810.1.S1_at follicular lymphoma variant translocation 1 FVT1 3.23 0.0006 MmugDNA.17221.1.S1_at chromosome 11 open reading frame 11 C11orf11 3.23 0.0529 MmugDNA.15445.1.S1_at chromosome 14 open reading frame 132 C14orf132 3.23 0.0629 MmugDNA.37901.1.S1_at COX4 neighbor COX4NB 3.23 0.0005 MmugDNA.9762.1.S1_at Hypothetical protein LOC643382 LOC643382 3.23 0.0376 MmuSTS.2544.1.S1_at translocase of inner mitochondrial membrane 23 homolog TIMM23 3.22 0.0000 (yeast) MmuSTS.3926.1.S1_at tetraspanin 31 TSPAN31 3.22 0.0303 MmugDNA.23914.1.S1_at hypothetical gene supported by AF064843; AK025716 /// LOC439994 /// 3.21 0.1319 hypothetical protein LOC642361 /// hypothetical protein LOC642361 /// LOC646509 LOC646509 MmugDNA.25504.1.S1_at tubulin, gamma complex associated protein 5 TUBGCP5 3.21 0.0027 MmugDNA.19562.1.S1_at zinc finger protein 406 /// Zinc finger protein 406 ZNF406 /// 3.21 0.0468 LOC654252 MmugDNA.11799.1.S1_at CAS1 domain containing 1 CASD1 3.21 0.0679 MmugDNA.22745.1.S1_at oxidoreductase NAD-binding domain containing 1 OXNAD1 3.21 0.0025 MmugDNA.29698.1.S1_at transmembrane protein 128 TMEM128 3.21 0.0063 MmugDNA.21404.1.S1_at high-mobility group 20B HMG20B 3.20 0.0295 MmugDNA.37311.1.S1_at F-box and leucine-rich repeat protein 20 FBXL20 3.20 0.1599 MmugDNA.26098.1.S1_at Yip1 domain family, member 4 YIPF4 3.20 0.0937 MmunewRS.416.1.S1_at ATPase, H+ transporting, lysosomal 5658 kDa, V1 subunit gi:39645818 3.20 0.0716 B, isoform 1 (Renal tubular acidosis with deafness), mRNA (cDNA clone MGC: 74733 IMAGE: 5208385), complete cds. /GEN = ATP6V1B1 /PROD = ATPase, H+ transporting, lysosomal 5658 kD, V1subunit B, isoform 1 MmugDNA.24420.1.S1_s_at Chromosome 1 open reading frame 85 C1orf85 3.19 0.0399 MmugDNA.1438.1.S1_at mitochondrial ribosomal protein 63 MRP63 3.19 0.0838 MmugDNA.25245.1.S1_at cSH-PTP2 LOC441868 3.18 0.0771 MmugDNA.20570.1.S1_at WW domain binding protein 1 WBP1 3.18 0.0001 MmugDNA.37020.1.S1_at dedicator of cytokinesis 1 DOCK1 3.18 0.0728 MmuSTS.1407.1.S1_at potassium channel, subfamily K, member 3 KCNK3 3.18 0.0806 MmugDNA.11054.1.S1_at transmembrane protein 53 TMEM53 3.18 0.1004 MmugDNA.25885.1.S1_at ATP/GTP binding protein-like 3 AGBL3 3.18 0.0755 MmugDNA.38701.1.S1_at glucosidase, alpha; acid (Pompe disease, glycogen storage GAA 3.18 0.0184 disease type II) MmugDNA.43423.1.S1_s_at Nuclear respiratory factor 1 NRF1 3.18 0.0933 MmugDNA.3251.1.S1_at KIAA1183 protein KIAA1183 3.18 0.2092 MmugDNA.30199.1.S1_at transmembrane protein 70 TMEM70 3.18 0.0021 MmugDNA.15760.1.S1_at peroxiredoxin 5 PRDX5 3.17 0.1334 MmugDNA.30636.1.S1_at eukaryotic translation initiation factor 2-alpha kinase 3 EIF2AK3 3.17 0.0171 MmugDNA.36645.1.S1_at isochorismatase domain containing 1 ISOC1 3.17 0.0099 Mmu.3814.1.S1_at MGC15407-like LOC677698 3.17 0.0744 MmugDNA.16486.1.S1_at coiled-coil domain containing 66 CCDC66 3.16 0.0054 MmugDNA.12087.1.S1_at peptidyl-tRNA hydrolase 1 homolog (S. cerevisiae) PTRH1 3.16 0.0024 MmugDNA.33464.1.S1_at PHD finger protein 6 /// PHD finger protein 6 PHF6 3.16 0.0667 MmuSTS.238.1.S1_at 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase HMGCL 3.16 0.0027 (hydroxymethyl, utaricaciduria) MmunewRS.64.1.S1_at mitochondrial ribosomal protein L13 MRPL13 3.16 0.0003 MmugDNA.15050.1.S1_x_at chromosome 5 open reading frame 31 C5orf31 3.16 0.0390 Mmu.3280.1.S1_at retinoblastoma-associated protein 140 LOC722528 3.16 0.0136 MmugDNA.28942.1.S1_at — — 3.16 0.0067 MmugDNA.43211.1.S1_at IBR domain containing 1 IBRDC1 3.15 0.0006 MmuSTS.1528.1.S1_at mitochondrial ribosomal protein L50 MRPL50 3.15 0.0206 MmuSTS.3308.1.S1_at SATB family member 1 SATB1 3.15 0.0007 MmugDNA.8392.1.S1_s_at SWI/SNF related, matrix associated, actin dependent SMARCA5 3.15 0.0053 regulator of chromatin, subfamily a, member 5 MmugDNA.11966.1.S1_at ribonuclease T2 RNASET2 3.15 0.0025 MmugDNA.19079.1.S1_s_at karyopherin alpha 1 (importin alpha 5) KPNA1 3.14 0.0136 MmuSTS.2957.1.S1_at LIM domain binding 1 LDB1 3.14 0.0697 MmuSTS.1291.1.S1_at de-etiolated 1 DET1 3.14 0.0395 MmugDNA.9689.1.S1_at chromosome 20 open reading frame 82 C20orf82 3.14 0.0503 MmugDNA.4538.1.S1_at dynein, light chain, roadblock-type 2 DYNLRB2 3.14 0.0037 MmugDNA.10006.1.S1_at activating signal cointegrator 1 complex subunit 3-like 1 /// ASCC3L1 3.14 0.0043 activating signal cointegrator 1 complex subunit 3-like 1 MmugDNA.35020.1.S1_at PHD finger protein 20 PHF20 3.14 0.0000 MmugDNA.18760.1.S1_at integrin alpha FG-GAP repeat containing 3 ITFG3 3.14 0.0000 MmuSTS.4243.1.S1_s_at protein phosphatase 1F (PP2C domain containing) PPM1F 3.14 0.0303 MmugDNA.21710.1.S1_at CDNA FLJ38498 fis, clone FELNG2000241 — 3.14 0.0038 MmugDNA.18438.1.S1_at Rho guanine nucleotide exchange factor (GEF) 12 ARHGEF12 3.13 0.1368 MmugDNA.27794.1.S1_at Transcribed locus, strongly NP_079090.1 Cas-Br-M — 3.13 0.0004 (murine) ecotropic retroviral transforming sequence-like 1; E-cadherin binding protein E7 [Homo sapiens] MmugDNA.36386.1.S1_at hypothetical protein LOC283680 LOC283680 3.13 0.0048 MmugDNA.13015.1.S1_at echinoderm microtubule associated protein like 4 EML4 3.13 0.0093 MmugDNA.7282.1.S1_at hypothetical protein MGC5242 MGC5242 3.13 0.0008 MmugDNA.36432.1.S1_at smoothelin SMTN 3.13 0.0273 MmugDNA.21419.1.S1_at hypothetical protein LOC644096 LOC644096 3.13 0.0006 Mmu.2231.1.S1_at F-actin capping protein alpha-1 subunit CAPZA1 3.13 0.1124 MmugDNA.30086.1.S1_at CG13876-PA LOC693668 3.13 0.0672 MmugDNA.8672.1.S1_at syndecan 3 (N-syndecan) SDC3 3.13 0.0201 MmugDNA.1837.1.S1_at radial spokehead-like 1 /// radial spokehead-like 1 RSHL1 3.13 0.2159 MmugDNA.40109.1.S1_at ubiquitin-like 7 (bone marrow stromal cell-derived) UBL7 3.13 0.0040 MmuSTS.3145.1.S1_at NODAL modulator 1 NOMO1 3.12 0.0003 MmugDNA.1608.1.S1_at F-box and leucine-rich repeat protein 2 FBXL2 3.12 0.0301 MmugDNA.7343.1.S1_at CDNA clone IMAGE: 4797878 — 3.12 0.1962 MmugDNA.20535.1.S1_at chromosome 1 open reading frame 50 C1orf50 3.12 0.0081 MmuSTS.2562.1.S1_s_at tumor suppressing subtransferable candidate 1 TSSC1 3.12 0.0010 MmugDNA.19650.1.S1_at deoxyhypusine hydroxylase/monooxygenase /// DOHH 3.12 0.0831 deoxyhypusine hydroxylase/monooxygenase MmugDNA.3700.1.S1_at transmembrane protein 39A TMEM39A 3.12 0.0384 MmugDNA.41216.1.S1_at AF034176 Human mRNA (Tripodis and Ragoussis) Homo — 3.11 0.1344 sapiens cDNA clone ntcon5 contig MmugDNA.24685.1.S1_at retinitis pigmentosa 2 (X-linked recessive) RP2 3.11 0.0605 MmuSTS.507.1.S1_s_at N-acylsphingosine amidohydrolase 3-like ASAH3L 3.11 0.0119 MmugDNA.988.1.S1_at 3-phosphoinositide dependent protein kinase-1 PDPK1 3.11 0.0509 MmugDNA.3400.1.S1_at Doublecortin domain-containing protein 2 LOC642926 3.11 0.0189 MmugDNA.15806.1.S1_at CDNA clone IMAGE: 4813920 — 3.11 0.1892 MmugDNA.41923.1.S1_at eukaryotic translation initiation factor 2 alpha kinase 4 EIF2AK4 3.11 0.0696 MmugDNA.7995.1.S1_at cysteine-rich PAK1inhibitor CRIPAK 3.11 0.1785 MmugDNA.5163.1.S1_at Transcribed locus — 3.10 0.0566 MmugDNA.23909.1.S1_at acyl-Coenzyme A dehydrogenase family, member 8 ACAD8 3.10 0.1817 MmugDNA.28412.1.S1_at KIAA1370 KIAA1370 3.10 0.0000 MmugDNA.11861.1.S1_at salvador homolog 1 (Drosophila) SAV1 3.10 0.0059 MmugDNA.7288.1.S1_s_at KIAA0280 KIAA0280 3.09 0.0105 MmugDNA.15715.1.S1_at HCLS1 associated protein X-1 HAX1 3.09 0.0106 MmugDNA.38581.1.S1_at excision repair cross-complementing rodent repair ERCC1 3.09 0.0102 deficiency, complementation group 1 (includes overlapping antisense sequence) MmugDNA.9603.1.S1_at KIAA0753 KIAA0753 3.09 0.0595 MmugDNA.22362.1.S1_at proteasome (prosome, macropain) subunit, beta type, 1 PSMB1 3.09 0.0108 MmugDNA.6764.1.S1_at ATPase type 13A1 ATP13A1 3.08 0.0244 MmunewRS.184.1.S1_at hypothetical protein LOC701867 LOC701867 3.08 0.1983 MmugDNA.23270.1.S1_at hypothetical protein FLJ32065 FLJ32065 3.08 0.0304 MmugDNA.41792.1.S1_at keratinocyte associated protein 3 KRTCAP3 3.08 0.0277 MmugDNA.28683.1.S1_at chromosome 9 open reading frame 39 C9orf39 3.08 0.0154 MmuSTS.4748.1.S1_at ubiquitin specific protease 18 USP18 3.08 0.1155 MmugDNA.13548.1.S1_at cytochrome c oxidase subunit Va COX5A 3.07 0.0790 MmugDNA.30189.1.S1_at hypothetical protein LOC283481 LOC283481 3.07 0.2062 MmugDNA.35491.1.S1_at adult retina protein LOC153222 3.07 0.0001 MmugDNA.37253.1.S1_s_at heterogeneous nuclear ribonucleoprotein D-like HNRPDL 3.07 0.0577 MmugDNA.31553.1.S1_at cofactor of BRCA1 COBRA1 3.07 0.0232 MmugDNA.25401.1.S1_at abhydrolase domain containing 14B ABHD14B 3.07 0.0170 MmuSTS.4318.1.S1_at solute carrier family 36 (proton/amino acid symporter), SLC36A4 3.07 0.1274 member 4 MmuSTS.4037.1.S1_at solute carrier family 41, member 2 SLC41A2 3.07 0.1483 MmugDNA.41507.1.S1_at ATP-binding cassette, sub-family B (MDR/TAP), member 6 ABCB6 3.06 0.0126 MmugDNA.14233.1.S1_at sperm specific antigen 2 SSFA2 3.06 0.0120 MmugDNA.34695.1.S1_at Leucine rich repeat neuronal 6C LRRN6C 3.06 0.1945 MmugDNA.39744.1.S1_at zinc finger protein 609 ZNF609 3.06 0.0160 MmugDNA.4156.1.S1_at ATPase, H+ transporting V0 subunit E2-like (rat) ATP6V0E2L 3.06 0.0340 MmugDNA.29456.1.S1_at Breakpoint cluster region protein, uterine leiomyoma, 2 WDR22 3.06 0.0131 MmugDNA.4944.1.S1_at tau tubulin kinase 1 TTBK1 3.05 0.0548 MmugDNA.22968.1.S1_at — — 3.05 0.0531 MmugDNA.42434.1.S1_at N-acetylglucosaminidase, alpha- (Sanfilippo disease IIIB) NAGLU 3.05 0.0982 MmugDNA.42291.1.S1_at G protein-coupled receptor kinase 6 GRK6 3.05 0.0293 MmugDNA.121.1.S1_at golgi SNAP receptor complex member 2 GOSR2 3.05 0.0435 MmugDNA.17630.1.S1_at cell division cycle 40 homolog (S. cerevisiae) CDC40 3.05 0.0398 MmugDNA.30084.1.S1_at — — 3.05 0.0012 MmugDNA.33923.1.S1_at chromosome 1 open reading frame 79 C1orf79 3.05 0.0664 MmugDNA.37503.1.S1_at ets variant gene 7 (TEL2 oncogene) ETV7 3.05 0.0228 MmugDNA.15871.1.S1_at BSD domain containing 1 BSDC1 3.04 0.0107 MmugDNA.32390.1.S1_at dipeptidyl-peptidase 7 DPP7 3.04 0.1328 MmugDNA.41073.1.S1_at Transcribed locus — 3.04 0.0000 MmuSTS.2834.1.S1_at solute carrier family 8 (sodium/calcium exchanger), member 3 SLC8A3 3.04 0.0879 MmugDNA.20734.1.S1_at zinc finger and BTB domain containing 11 ZBTB11 3.04 0.0326 MmuSTS.247.1.S1_at inositol polyphosphate-1-phosphatase INPP1 3.04 0.0049 MmugDNA.22134.1.S1_at SIN3 homolog A, transcription regulator (yeast) SIN3A 3.04 0.0000 MmugDNA.17708.1.S1_at torsin A interacting protein 1 TOR1AIP1 3.03 0.0001 MmugDNA.42050.1.S1_at — — 3.03 0.0980 MmugDNA.30213.1.S1_at zinc finger, MYM-type 5 ZMYM5 3.03 0.0036 MmugDNA.43311.1.S1_at LDLR-FUT fusion protein (LDLR-FUT) — 3.02 0.1029 MmugDNA.26409.1.S1_at hypothetical protein LOC644242 /// hypothetical protein LOC644242 /// 3.02 0.0510 LOC650429 /// hypothetical protein LOC650446 LOC650429 /// LOC650446 MmuSTS.59.1.S1_at histone deacetylase 5 HDAC5 3.02 0.0063 MmugDNA.34663.1.S1_at flavin containing monooxygenase 3 FMO3 3.02 0.1292 MmugDNA.40441.1.S1_at CDNA clone IMAGE: 5270500 — 3.02 0.1493 MmuSTS.1202.1.S1_at component of oligomeric golgi complex 7 COG7 3.01 0.0056 MmugDNA.33076.1.S1_at Transcribed locus — 3.01 0.0492 MmuSTS.658.1.S1_at putative T1/ST2 receptor binding protein IL1RL1LG 3.01 0.0153 MmugDNA.26960.1.S1_at WD repeats and SOF1 domain containing WDSOF1 3.01 0.0000 MmugDNA.24887.1.S1_at tripartite motif-containing 2 TRIM2 3.01 0.0073 MmugDNA.26072.1.S1_at active BCR-related gene ABR 3.01 0.0038 MmugDNA.28188.1.S1_at hypothetical gene supported by AK124342 FLJ42351 3.01 0.0975 MmugDNA.40888.1.S1_at taurine upregulated gene 1 TUG1 3.00 0.0221 MmugDNA.39101.1.S1_at — — 3.00 0.1428 MmuSTS.4591.1.S1_at thyroid hormone receptor, alpha THRA 3.00 0.0270 MmugDNA.16168.1.S1_s_at structural maintenance of chromosomes 3 SMC3 3.00 0.0000 MmugDNA.40670.1.S1_at 3′(2′), 5′-bisphosphate nucleotidase 1 BPNT1 3.00 0.0221 MmuSTS.1100.1.S1_at PAX transcription activation domain interacting protein 1 like PAXIP1L 3.00 0.0160 MmugDNA.4318.1.S1_at FLJ12716 protein FLJ12716 3.00 0.0565 MmugDNA.28833.1.S1_at CDNA FLJ41690 fis, clone HCASM2009405 — 2.99 0.0293 MmugDNA.28320.1.S1_at CDNA clone IMAGE: 5259419 — 2.99 0.2149 MmugDNA.19977.1.S1_at KIAA1217 KIAA1217 2.99 0.0595 MmunewRS.283.1.S1_at NAD(P) dependent steroid dehydrogenase-like HSPC105 2.99 0.1709 MmuSTS.4337.1.S1_at F-box only protein 25 FBXO25 2.99 0.0969 MmugDNA.42396.1.S1_at germ cell-less LOC701545 2.99 0.0783 MmugDNA.23292.1.S1_at Ras suppressor protein 1 RSU1 2.99 0.0016 MmugDNA.17188.1.S1_at acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain ACADS 2.99 0.0453 MmugDNA.8639.1.S1_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 DDX21 2.99 0.0027 MmugDNA.6559.1.S1_at chromosome 9 open reading frame 119 C9orf119 2.99 0.0393 MmugDNA.41506.1.S1_at ankyrin repeat and SOCS box-containing 6 ASB6 2.99 0.0077 MmugDNA.13579.1.S1_at KIAA1712 KIAA1712 2.99 0.0879 MmugDNA.19830.1.S1_at glycoprotein hormone alpha 2 GPHA2 2.99 0.0280 Mmu.3556.1.S1_s_at family with sequence similarity 96, member A isoform a LOC714217 2.98 0.0000 MmugDNA.10102.1.S1_s_at heat shock 70 kDa protein 8 HSPA8 2.98 0.0043 MmugDNA.4343.1.S1_at hypothetical protein FLJ10241 FLJ10241 2.98 0.0015 MmugDNA.6426.1.S1_at CD151 molecule (Raph blood group) CD151 2.98 0.0338 MmugDNA.27731.1.S1_at MRNA from chromosome 5q21-22, clone: 843Ex — 2.98 0.0000 MmugDNA.33252.1.S1_at protease, serine, 16 (thymus) PRSS16 2.98 0.0020 MmugDNA.20450.1.S1_at chromosome 19 open reading frame 2 C19orf2 2.97 0.0001 MmuSTS.3421.1.S1_at claudin 3 CLDN3 2.97 0.0204 MmugDNA.26818.1.S1_at methyltransferase like 4 METTL4 2.97 0.0076 MmugDNA.33099.1.S1_at KIAA0423 KIAA0423 2.97 0.0005 MmuAffx.1252.1.A1_at protocadherin alpha (PCDH) mRNA, 3 prime UTR. AY598414 2.96 0.1373 MmugDNA.9975.1.S1_at zinc finger protein 331 ZNF331 2.95 0.0596 MmugDNA.41468.1.S1_at necdin-like 2 NDNL2 2.95 0.0006 MmugDNA.17362.1.S1_at PTD016 protein LOC51136 2.95 0.0267 MmugDNA.43033.1.S1_at HemK methyltransferase family member 2 HEMK2 2.95 0.1934 MmugDNA.29141.1.S1_at UDP-glucose ceramide glucosyltransferase-like 1 UGCGL1 2.95 0.0396 MmugDNA.13178.1.S1_at CDC14 cell division cycle 14 homolog B (S. cerevisiae) CDC14B 2.95 0.0382 MmugDNA.26142.1.S1_at coiled-coil domain containing 95 CCDC95 2.95 0.0654 MmugDNA.2882.1.S1_at zinc finger CCCH-type containing 7B ZC3H7B 2.95 0.0351 MmugDNA.22445.1.S1_at Ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) UBE2I 2.95 0.0079 MmugDNA.5279.1.S1_at transmembrane protein 33 TMEM33 2.95 0.0097 Mmu.1276.1.S1_at serine protease inhibitor, Kunitz type, 2 LOC714755 2.94 0.0663 MmugDNA.43012.1.S1_at chromosome 17 open reading frame 28 C17orf28 2.94 0.0440 MmuSTS.1982.1.S1_at CD14 antigen CD14 2.94 0.0049 MmugDNA.41964.1.S1_at hypothetical protein LOC646870 LOC646870 2.94 0.0728 MmugDNA.37306.1.S1_at melanoma antigen family E, 1 MAGEE1 2.94 0.0035 MmugDNA.36805.1.S1_at CDNA clone IMAGE: 5265020 — 2.93 0.0047 MmugDNA.23752.1.S1_at Hypothetical gene supported by AK126569 230404_at 2.93 0.0014 MmugDNA.7176.1.S1_at zinc finger protein 508 ZNF508 2.93 0.1404 MmugDNA.15639.1.S1_s_at nuclear distribution gene C homolog (A. nidulans) NUDC 2.93 0.1171 MmugDNA.23645.1.S1_at kinase insert domain receptor (a type III receptor tyrosine KDR 2.93 0.0526 kinase) MmugDNA.28242.1.S1_at G protein-coupled receptor 82 GPR82 2.92 0.0520 MmugDNA.26896.1.S1_at hypothetical protein LOC285847 LOC285847 2.92 0.1348 MmugDNA.33291.1.S1_at E74-like factor 2 (ets domain transcription factor) ELF2 2.92 0.0090 MmugDNA.1352.1.S1_at 3-hydroxyisobutyryl-Coenzyme A hydrolase HIBCH 2.92 0.0317 Mmu.14583.1.S1_at Transcribed locus — 2.92 0.0000 MmugDNA.23757.1.S1_at high-mobility group protein 2-like 1 HMG2L1 2.92 0.0821 MmugDNA.3973.1.S1_at TBP-interacting protein TIP120A 2.92 0.0295 MmugDNA.20292.1.S1_at breast cancer metastasis suppressor 1 BRMS1 2.92 0.0411 MmugDNA.28666.1.S1_at palmdelphin PALMD 2.91 0.0451 MmuSTS.2571.1.S1_at ubiquitin specific peptidase 20 USP20 2.91 0.0475 MmugDNA.26331.1.S1_at Mitogen-activated protein kinase kinase kinase 13 MAP3K13 2.91 0.0470 MmugDNA.10238.1.S1_at testis expressed sequence 9 TEX9 2.91 0.1328 MmunewRS.102.1.S1_at mRNA for KIAA1979 protein. gi:18916872 2.90 0.1195 MmuSTS.3241.1.S1_at BCL2/adenovirus E1B 19 kDa interacting protein 1 BNIP1 2.90 0.0091 MmugDNA.1167.1.S1_at pyrophosphatase (inorganic) 2 /// ring finger protein 36 PPA2 /// RNF36 2.90 0.0008 MmugDNA.2679.1.S1_at small nuclear ribonucleoprotein polypeptide A′ SNRPA1 2.90 0.0215 MmugDNA.29871.1.S1_at NADH dehydrogenase (ubiquinone) Fe—S protein 2, 49 kDa NDUFS2 2.89 0.0192 (NADH-coenzyme Q reductase) Mmu.4717.1.S1_at ankyrin repeat and BTB (POZ) domain containing 1 isoform 2 LOC710603 2.89 0.0439 MmugDNA.20718.1.S1_at heterogeneous nuclear ribonucleoprotein A3 pseudogene 1 /// HNRPA3P1 /// 2.89 0.0013 heterogeneous nuclear ribonucleoprotein A3 HNRPA3 MmugDNA.28284.1.S1_at GA binding protein transcription factor, alpha subunit 60 kDa GABPA 2.89 0.0000 MmuSTS.4752.1.S1_at vacuolar protein sorting 45 homolog (S. cerevisiae) VPS45 2.89 0.0020 MmugDNA.7814.1.S1_at family with sequence similarity 120A FAM120A 2.89 0.0377 MmugDNA.43320.1.S1_at UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, B3GALT4 2.89 0.0379 polypeptide 4 MmugDNA.38533.1.S1_at CDNA FLJ11692 fis, clone HEMBA1004983 — 2.89 0.1672 MmugDNA.37108.1.S1_at Ribosomal protein L7-like 1 RPL7L1 2.89 0.0294 MmugDNA.43087.1.S1_at choroideremia (Rab escort protein 1) /// hypothetical protein CHM /// 2.89 0.0003 LOC642090 LOC642090 MmugDNA.37619.1.S1_at serine/threonine/tyrosine interacting protein /// STYX /// 2.89 0.0039 serine/threonine/tyrosine interacting protein LOC653890 MmugDNA.6995.1.S1_at Heterogeneous nuclear ribonucleoprotein A0 HNRPA0 2.89 0.0419 MmugDNA.33286.1.S1_at centrosomal protein 57 kDa CEP57 2.88 0.0039 MmugDNA.7613.1.S1_at vitelliform macular dystrophy 2 (Best disease, bestrophin) VMD2 2.88 0.0211 MmugDNA.41643.1.S1_at TPTE and PTEN homologous inositol lipid phosphatase LOC374491 /// 2.88 0.1625 pseudogene /// TPTE and PTEN homologous inositol lipid LOC642904 /// phosphatase isoform gamma /// TPTE and PTEN LOC649370 homologous inositol lipid phosphatase isoform gamma MmugDNA.17851.1.S1_at NADH dehydrogenase (ubiquinone) 1, alpha/beta NDUFAB1 2.88 0.0718 subcomplex, 1, 8 kDa MmugDNA.35659.1.S1_at chromosome 9 open reading frame 84 C9orf84 2.88 0.1866 MmuSTS.1608.1.S1_at kelch-like 7 (Drosophila) KLHL7 2.88 0.0008 MmugDNA.20882.1.S1_at hypothetical protein MGC61571 MGC61571 2.88 0.0025 MmugDNA.7201.1.S1_at carboxypeptidase D CPD 2.87 0.0239 MmugDNA.22156.1.S1_at LOC166075 LOC401097 2.87 0.0185 MmugDNA.18427.1.S1_at Keratin associated protein 5-11 KRTAP5-11 2.87 0.0621 MmugDNA.10502.1.S1_at dehydrogenase/reductase (SDR family) member 13 DHRS13 2.87 0.0613 MmuSTS.2492.1.S1_at zinc finger protein 509 ZNF509 2.87 0.0312 MmugDNA.33371.1.S1_at chymotrypsin-like CTRL 2.87 0.0277 MmugDNA.24978.1.S1_at neuronal PAS domain protein 1 NPAS1 2.87 0.1278 MmugDNA.37408.1.S1_at tyrosyl-tRNA synthetase 2 (mitochondrial) YARS2 2.86 0.0023 MmugDNA.27947.1.S1_at FLJ45244 protein FLJ45244 2.86 0.2182 MmugDNA.38426.1.S1_at KIAA0892 KIAA0892 2.86 0.0020 Mmu.12307.1.S1_at KIAA1008 KIAA1008 2.86 0.1271 MmuSTS.534.1.S1_at UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, B4GALT2 2.86 0.1428 polypeptide MmugDNA.21102.1.S1_at hypothetical protein LOC651803 LOC651803 2.86 0.0893 MmugDNA.25674.1.S1_at potassium channel tetramerisation domain containing 14 KCTD14 2.86 0.0286 MmugDNA.11321.1.S1_at FUN14 domain containing 1 FUNDC1 2.86 0.0497 MmugDNA.27909.1.S1_at hypothetical protein FLJ20125 FLJ20125 2.86 0.0288 MmugDNA.41621.1.S1_at tetratricopeptide repeat domain 30B TTC30B 2.85 0.0837 MmugDNA.22964.1 S1_at Transcribed locus — 2.85 0.1242 MmugDNA.32172.1.S1_at haloacid dehalogenase-like hydrolase domain containing 2 HDHD2 2.85 0.0025 MmugDNA.33685.1.S1_at chromosome X open reading frame 26 CXorf26 2.85 0.0000 MmuSTS.2187.1.S1_at solute carrier family 41, member 3 SLC41A3 2.85 0.0794 MmuSTS.3436.1.S1_at alpha-methylacyl-CoA racemase AMACR 2.85 0.0891 MmuSTS.1512.1.S1_at isoprenylcysteine carboxyl methyltransferase ICMT 2.84 0.0002 MmuSTS.234.1.S1_at chromosome 15 open reading frame 40 C15orf40 2.84 0.0002 MmunewRS.872.1.S1_at otopetrin 1 OTOP1 2.84 0.0322 MmugDNA.28434.1.S1_at TROVE domain family, member 2 TROVE2 2.84 0.0136 MmugDNA.18405.1.S1_s_at Suppression of tumorigenicity 7 like ST7L 2.84 0.0768 MmugDNA.32265.1.S1_at chromosome 19 open reading frame 52 C19orf52 2.84 0.0659 MmugDNA.11590.1.S1_at chromosome 1 open reading frame 165 C1orf165 2.83 0.0087 MmugDNA.12017.1.S1_at fibronectin type III and ankyrin repeat domains 1 FANK1 2.82 0.0001 MmugDNA.8492.1.S1_at chromosome 6 open reading frame 153 C6orf153 2.82 0.0193 MmugDNA.22105.1.S1_at dynein, axonemal, light intermediate polypeptide 1 DNALI1 2.82 0.0264 Mmu.16365.1.S1_at PRP4 pre-mRNA processing factor 4 homolog B (yeast) LOC709497 /// 2.82 0.0238 (predicted) LOC710193 MmugDNA.42362.1.S1_at ornithine decarboxylase antizyme 2 OAZ2 2.82 0.0858 MmugDNA.2230.1.S1_at phosphatidylinositol 4-kinase, catalytic, alpha polypeptide PIK4CA 2.82 0.0002 MmugDNA.23113.1.S1_at Midline 2 MID2 2.81 0.0018 MmugDNA.9055.1.S1_at multiple C2 domains, transmembrane 2 MCTP2 2.81 0.1229 MmugDNA.28806.1.S1_at Zinc finger protein 284 ZNF284 2.81 0.0754 MmugDNA.6963.1.S1_at tweety homolog 2 (Drosophila) TTYH2 2.81 0.0997 MmugDNA.24592.1.S1_at CTD (carboxy-terminal domain, RNA polymerase II, CTDSP2 2.81 0.1065 polypeptide A) small phosphatase 2 MmugDNA.18857.1.S1_at KIAA0467 KIAA0467 2.81 0.0008 MmugDNA.40098.1.S1_at hypothetical protein LOC144363 LOC144363 2.81 0.1331 MmugDNA.23612.1.S1_at Transcribed locus — 2.81 0.0728 MmuSTS.1461.1.S1_at mitogen-activated protein kinase kinase kinase kinase 3 MAP4K3 2.81 0.0000 MmuSTS.2022.1.S1_at prostaglandin D2 synthase, hematopoietic PGDS 2.80 0.1324 MmugDNA.21008.1.S1_at ubiquitin specific peptidase 14 (tRNA-guanine USP14 2.80 0.0026 transglycosylase) MmugDNA.5481.1.S1_at Full-length cDNA clone CS0DF012YD09 of Fetal brain of — 2.80 0.0074 Homo sapiens (human) MmuSTS.4011.1.S1_at solute carrier family 35, member B3 SLC35B3 2.80 0.0186 MmugDNA.12978.1.S1_at phosphoinositide-3-kinase, class 2, alpha polypeptide PIK3C2A 2.80 0.0138 MmugDNA.25990.1.S1_at coiled-coil domain containing 123 CCDC123 2.79 0.1079 MmugDNA.21323.1.S1_at CDNA FLJ14181 fis, clone NT2RP2004300 — 2.79 0.1179 MmugDNA.34194.1.S1_at chromosome 6 open reading frame 120 C6orf120 2.79 0.1196 MmugDNA.1311.1.S1_at hypothetical protein MGC26733 MGC26733 2.79 0.0076 MmugDNA.10629.1.S1_at translocase of inner mitochondrial membrane 17 homolog A TIMM17A 2.79 0.0004 (yeast) MmugDNA.33991.1.S1_at CDNA: FLJ22539 fis, clone HRC13227 — 2.78 0.0066 MmugDNA.20536.1.S1_at transmembrane and tetratricopeptide repeat containing 3 TMTC3 2.78 0.0230 MmugDNA.6356.1.S1_at chromosome 7 open reading frame 28A /// chromosome 7 C7orf28A /// 2.78 0.0024 open reading frame 28B C7orf28B MmugDNA.6519.1.S1_at WD repeat domain 39 WDR39 2.78 0.0098 MmugDNA.36685.1.S1_at SET domain, bifurcated 2 SETDB2 2.78 0.0199 MmugDNA.22793.1.S1_s_at tribbles homolog 2 (Drosophila) TRIB2 2.78 0.1659 MmugDNA.2623.1.S1_at prefoldin subunit 4 PFDN4 2.77 0.0015 MmuSTS.421.1.S1_at ORM1-like 3 (S. cerevisiae) ORMDL3 2.77 0.0697 MmugDNA.36435.1 S1_s_at histidyl-tRNA synthetase HARS 2.77 0.0220 MmugDNA.39696.1.S1_at UTP15, U3 small nucleolar ribonucleoprotein, homolog UTP15 2.77 0.1158 (S. cerevisiae) MmugDNA.13739.1.S1_at sorting nexin 14 SNX14 2.77 0.0059 MmuSTS.1965.1.S1_at frequently rearranged in advanced T-cell lymphomas 2 FRAT2 2.77 0.0258 MmugDNA.18514.1.S1_at RNA (guanine-9-) methyltransferase domain containing 2 RG9MTD2 2.77 0.0616 MmugDNA.26813.1.S1_at MRNA; cDNA DKFZp762M127 (from clone — 2.77 0.0023 DKFZp762M127) MmunewRS.1000.1.S1_s_at zinc finger protein 432 ZNF432 2.76 0.1958 MmugDNA.22282.1.S1_at WD repeat and FYVE domain containing 1 WDFY1 2.76 0.1120 MmuSTS.4631.1.S1_at vascular endothelial growth factor B VEGFB 2.76 0.0010 MmugDNA.14574.1.S1_at dedicator of cytokinesis 5 DOCK5 2.76 0.0832 MmugDNA.32208.1.S1_at katanin p80 (WD repeat containing) subunit B 1 KATNB1 2.76 0.0202 MmugDNA.7187.1.S1_at splicing factor, arginine/serine-rich 4 SFRS4 2.76 0.0061 MmuSTS.1088.1.S1_at Solute carrier family 43, member 2 SLC43A1 2.76 0.0585 MmugDNA.4698.1.S1_at calcium binding and coiled-coil domain 2 CALCOCO2 2.76 0.0099 MmugDNA.11372.1.S1_at Cysteine rich BMP regulator 2 (chordin-like) CRIM2 2.76 0.1851 MmugDNA.18070.1.S1_at Kruppel-like factor 9 KLF9 2.76 0.0804 MmugDNA.14499.1.S1_at zinc finger protein 596 ZNF596 2.76 0.0833 MmugDNA.40758.1.S1_at galactokinase 2 /// retinoblastoma binding protein 8 GALK2 /// RBBP8 2.76 0.0046 MmugDNA.33141.1.S1_at nitrilase 1 NIT1 2.75 0.0000 MmugDNA.42186.1.S1_at hippocampus abundant transcript 1 HIAT1 2.75 0.0086 MmugDNA.4834.1.S1_at aarF domain containing kinase 2 ADCK2 2.75 0.0220 MmugDNA.26458.1.S1_at Activating transcription factor 6 ATF6 2.74 0.0017 MmugDNA.2646.1 S1_at atrophin 1 ATN1 2.74 0.0001 MmugDNA.40233.1.S1_at X-ray repair complementing defective repair in Chinese XRCC1 2.74 0.1076 hamster cells 1 MmugDNA.20861.1.S1_at spermatogenesis associated 13 LOC721468 2.74 0.0177 MmugDNA.12752.1.S1_s_at spastic paraplegia 20, spartin (Troyer syndrome) SPG20 2.74 0.0000 MmugDNA.41135.1.S1_at Colorectal cancer-related mRNA sequence — 2.74 0.1356 MmuSTS.4719.1.S1_at tripartite motif-containing 6 TRIM6 2.74 0.0029 MmugDNA.4017.1.S1_at — — 2.74 0.1313 MmugDNA.27784.1.S1_at — — 2.74 0.1942 MmuSTS.4614.1.S1_at tripartite motif-containing 4 TRIM4 2.74 0.0305 MmugDNA.8727.1.S1_at t-complex 1 TCP1 2.74 0.0457 MmugDNA.638.1.S1_at cytoskeleton associated protein 1 CKAP1 2.74 0.1205 MmugDNA.6338.1.S1_at hypothetical protein FLJ20152 FLJ20152 2.73 0.0006 MmuSTS.2636.1.S1_at family with sequence similarity 3, member A FAM3A 2.73 0.0019 MmugDNA.33300.1.S1_at WWC family member 3 WWC3 2.73 0.1279 MmugDNA.18996.1.S1_at elongation factor Tu GTP binding domain containing 2 EFTUD2 2.73 0.0230 MmugDNA.24045.1.S1_s_at zinc finger protein 292 ZNF292 2.73 0.1182 MmugDNA.1299.1.S1_at CLPTM1-like CLPTM1L 2.73 0.0121 MmugDNA.22429.1.S1_at family with sequence similarity 120B FAM120B 2.73 0.0002 MmugDNA.13037.1.S1_at chromosome 21 open reading frame 119 C21orf119 2.72 0.0357 MmugDNA.20321.1.S1_at HIR histone cell cycle regulation defective homolog A (S. cerevisiae) HIRA 2.72 0.0018 MmugDNA.42547.1.S1_at histidyl-tRNA synthetase-like HARSL 2.72 0.0116 MmugDNA.1760.1.S1_s_at COP9 constitutive photomorphogenic homolog subunit 8 COPS8 2.72 0.0761 (Arabidopsis) MmugDNA.13758.1.S1_at COMM domain containing 3 COMMD3 2.72 0.0140 MmuSTS.304.1.S1_at single stranded DNA binding protein 3 SSBP3 2.71 0.0862 MmuSTS.2591.1.S1_at Xenotropic and polytropic retrovirus receptor XPR1 2.71 0.0029 MmugDNA.33009.1.S1_at zinc finger protein 700 ZNF700 2.71 0.0451 MmugDNA.1463.1.S1_s_at proline rich 14 PRR14 2.71 0.0339 MmugDNA.35741.1.S1_at coiled-coil-helix-coiled-coil-helix domain containing 6 /// CHCHD6 2.71 0.0482 coiled-coil-helix-coiled-coil-helix domain containing 6 MmugDNA.4692.1.S1_at zinc finger RNA binding protein ZFR 2.71 0.0332 MmugDNA.36934.1.S1_at zinc finger protein 643 ZNF643 2.71 0.1950 MmugDNA.16923.1.S1_at tumor necrosis factor receptor superfamily, member 13B TNFRSF13B 2.71 0.1291 MmugDNA.15223.1.S1_at hypothetical protein FLJ39061 FLJ39061 2.70 0.0031 MmuSTS.350.1.S1_at spectrin repeat containing, nuclear envelope 1 SYNE1 2.70 0.1061 MmuSTS.246.1.S1_at leucine rich repeat containing 42 LRRC42 2.70 0.0007 MmuSTS.2186.1.S1_at zinc finger protein 354B ZNF354B 2.70 0.0677 Mmu.12802.2.S1_at chaperonin containing TCP1, subunit 2 LOC717182 2.70 0.1220 MmugDNA.6418.1.S1_at zinc finger protein 83 ZNF83 2.70 0.0013 MmuSTS.528.1.S1_at ATPase, Cu++ transporting, beta polypeptide (Wilson ATP7B 2.70 0.0280 disease) MmuSTS.727.1.S1_at cyclin M2 CNNM2 2.70 0.1167 MmugDNA.15549.1.S1_s_at GDP-mannose 4,6-dehydratase GMDS 2.70 0.0006 MmugDNA.8210.1.S1_at PR domain containing 16 PRDM16 2.70 0.1783 MmuSTS.3743.1.S1_at RAB26, member RAS onocogene family RAB26 2.69 0.0289 MmugDNA.6865.1.S1_at Transcribed locus, moderately NP_689672.2 hypothetical — 2.69 0.0231 protein MGC45438 [Homo sapiens] MmuSTS.2292.1.S1_at protein phosphatase 1, regulatory (inhibitor) subunit 3F PPP1R3F 2.69 0.0001 MmugDNA.34280.1.S1_at KIAA0683 gene product KIAA0683 2.69 0.0352 MmugDNA.13838.1.S1_at zinc finger protein 502 ZNF502 2.69 0.0750 MmuSTS.1404.1.S1_at potassium inwardly-rectifying channel, subfamily J, member 6 KCNJ6 2.69 0.1718 MmugDNA.19168.1.S1_at enhancer of mRNA decapping 4 EDC4 2.69 0.0220 MmugDNA.34757.1.S1_s_at dynactin 6 DCTN6 2.69 0.0000 MmugDNA.8435.1.S1_at proline synthetase co-transcribed homolog (bacterial) PROSC 2.69 0.0000 MmugDNA.6197.1.S1_at chromosome 4 open reading frame 24 C4orf24 2.69 0.2130 MmugDNA.3702.1.S1_at CDNA FLJ46881 fis, clone UTERU3015647, moderately — 2.69 0.0653 Embigin precursor MmugDNA.12591.1.S1_s_at dendritic cell-derived ubiquitin-like protein DC-UbP 2.68 0.0503 MmugDNA.11985.1.S1_at asparagine-linked glycosylation 2 homolog (S. cerevisiae, ALG2 2.68 0.0105 alpha-1,3-mannosyltransferase) MmugDNA.25835.1.S1_at Homo sapiens, clone IMAGE: 4133122, mRNA — 2.68 0.0342 MmuSTS.3979.1.S1_at serum/glucocorticoid regulated kinase family, member 3 SGK3 2.68 0.0238 MmugDNA.9043.1.S1_at ADP-ribosylation factor-like 6 interacting protein 2 ARL6IP2 2.68 0.0814 Mmu.7150.1.S1_at Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP HNRPA2B1 2.68 0.0223 A2/hnRNP B1) MmugDNA.33865.1.S1_s_at chromosome 20 open reading frame 7 /// chromosome 20 C20orf7 /// 2.67 0.0426 open reading frame 7 /// transmembrane protein 14B /// TMEM14B transmembrane protein 14B MmugDNA.3820.1.S1_at clathrin, light polypeptide (Lcb) CLTB 2.67 0.2188 MmugDNA.30567.1.S1_at hypothetical protein BC014011 LOC116349 2.67 0.0466 MmugDNA.40707.1.S1_at zinc finger, X-linked, duplicated B ZXDB 2.66 0.0300 MmugDNA.43058.1.S1_at kinesin family member 13A KIF13A 2.66 0.1629 MmuSTS.4168.1.S1_at M-phase phosphoprotein 6 MPHOSPH9 2.66 0.0283 MmugDNA.3585.1.S1_at — — 2.66 0.1649 MmugDNA.37285.1.S1_at mitochondrial GTPase 1 homolog (S. cerevisiae) MTG1 2.66 0.0492 MmugDNA.25292.1.S1_at jagunal homolog 1 (Drosophila) JAGN1 2.66 0.0199 MmugDNA.9421.1.S1_at mannose-6-phosphate receptor (cation dependent) M6PR 2.66 0.0305 MmugDNA.18308.1.S1_at poliovirus receptor-related 2 (herpesvirus entry mediator B) PVRL2 2.65 0.1122 MmugDNA.20905.1.S1_at Chromosome 13 open reading frame 10 C13orf10 2.65 0.0168 MmugDNA.34704.1.S1_at pecanex homolog (Drosophila) PCNX 2.65 0.1063 MmugDNA.12760.1.S1_at Fibroblast growth factor 14 FGF14 2.65 0.0872 MmugDNA.43498.1.S1_at NmrA-like family domain containing 1 NMRAL1 2.65 0.0479 MmugDNA.21653.1.S1_at hypothetical protein FLJ30596 FLJ30596 2.65 0.0681 MmugDNA.14752.1.S1_at MRNA; cDNA DKFZp547E193 (from clone DKFZp547E193) — 2.65 0.1773 MmuSTS.4276.1.S1_at SREBF chaperone SCAP 2.64 0.0005 MmugDNA.8363.1.S1_at tyrosyl-DNA phosphodiesterase 1 TDP1 2.64 0.1058 MmugDNA.34065.1.S1_at uncharacterized hematopoietic stem/progenitor cells protein MDS032 2.64 0.0254 MDS032 MmunewRS.641.1.S1_at selenoprotein S SELS 2.64 0.0693 MmugDNA.7596.1.S1_at — — 2.64 0.2105 MmugDNA.3465.1.S1_at Full-length cDNA clone CS0DI027YJ20 of Placenta Cot 25- — 2.64 0.1052 normalized of Homo sapiens (human) MmugDNA.13992.1.S1_at Leo1, Paf1/RNA polymerase II complex component, LEO1 2.64 0.0000 homolog (S. cerevisiae) MmugDNA.14603.1.S1_at bicaudal D homolog 1 (Drosophila) BICD1 2.64 0.0314 Mmu.2724.1.S1_at glutamate dehydrogenase 1 GLUD1 2.63 0.0345 MmugDNA.26006.1.S1_at hypothetical protein MGC16169 MGC16169 2.63 0.1844 MmugDNA.34293.1.S1_at UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, B4GALT5 2.63 0.0018 polypeptide 5 MmugDNA.5213.1.S1_at Spleen tyrosine kinase SYK 2.63 0.0169 MmugDNA.26186.1.S1_at ankyrin repeat and IBR domain containing 1 ANKIB1 2.63 0.0499 MmugDNA.30722.1.S1_at tetratricopeptide repeat domain 12 TTC12 2.63 0.1383 MmugDNA.20572.1.S1_at trafficking protein particle complex 6A TRAPPC6A 2.63 0.1754 MmuSTS.645.1.S1_at Charcot-Marie-Tooth neuropathy 4B2 (autosomal recessive, CMT4B2 2.63 0.0754 with my, in outfolding) MmugDNA.12020.1.S1_at YTH domain family, member 3 YTHDF3 2.63 0.1578 MmugDNA.23364.1.S1_at Transcribed locus, strongly XP_515572.1 PREDICTED: — 2.63 0.1417 hypothetical protein XP_515572 [Pan troglodytes] MmugDNA.3150.1.S1_s_at Cdc42 guanine nucleotide exchange factor (GEF) 9 ARHGEF9 2.63 0.0380 MmugDNA.26131.1.S1_at Nuclear transcription factor, X-box binding-like 1 NFXL1 2.62 0.0005 MmugDNA.23082.1.S1_at nudix (nucleoside diphosphate linked moiety X)-type motif NUDT14 2.62 0.0487 14 MmugDNA.33074.1.S1_at Transcribed locus, strongly XP_068632.2 PREDICTED: — 2.62 0.0003 hypothetical protein XP_068632 [Homo sapiens] MmugDNA.30447.1.S1_at Hermansky-Pudlak syndrome 6 HPS6 2.62 0.0431 MmugDNA.37520.1.S1_at chromosome 1 open reading frame 66 C1orf66 2.62 0.0280 MmuSTS.4696.1.S1_at alanyl-tRNA synthetase AARS 2.62 0.0110 Mmu.1900.1.S1_s_at H3 histone, family 3B LOC693887 /// 2.62 0.0092 LOC693939 /// LOC694152 /// LOC695663 /// LOC699443 /// LOC702881 /// LOC707040 /// LOC708847 /// LOC708899 /// LOC709296 /// LOC710748 /// LOC718673 MmugDNA.3450.1.S1_at signal recognition particle receptor (‘docking protein’) SRPR 2.62 0.0000 MmugDNA.20613.1.S1_at CSL-type zinc finger-containing protein 2 (DelGEF- ZCSL2 2.61 0.0000 interacting protein 1) (DelGIP1) MmugDNA.26173.1.S1_at LOC440133 LOC440133 2.61 0.1688 MmugDNA.15693.1.S1_at acyl-Coenzyme A dehydrogenase family, member 11 ACAD11 2.61 0.1017 Mmu.14509.2.S1_at cytosolic malate dehydrogenase MDH1 2.61 0.0408 Mmu.967.1.S1_s_at N-acetylated alpha-linked acidic dipeptidase 2 — 2.61 0.0338 MmugDNA.33096.1.S1_s_at coiled-coil domain containing 47 CCDC47 2.61 0.0002 MmugDNA.43345.1.S1_at Family with sequence similarity 98, member B FAM98B 2.61 0.0000 MmugDNA.20494.1.S1_at Ewing sarcoma breakpoint region 1 EWSR1 2.61 0.0040 MmugDNA.901.1.S1_at — — 2.61 0.1627 MmugDNA.18015.1.S1_at major histocompatibility complex, class II, DM beta /// major HLA-DMB 2.61 0.1120 histocompatibility complex, class II, DM beta MmugDNA.18688.1.S1_at FLJ32363 protein FLJ32363 2.61 0.1221 MmugDNA.40426.1.S1_at chromosome 20 open reading frame 42 C20orf42 2.61 0.0017 MmugDNA.17109.1.S1_at zinc finger protein 570 ZNF570 2.61 0.0031 MmuSTS.448.1.S1_at piggyBac transposable element derived 2 PGBD2 2.60 0.0847 MmuSTS.2213.1.S1_at lysosomal trafficking regulator LYST 2.60 0.0532 MmugDNA.41077.1.S1_at chromosome 11 open reading frame 10 C11orf10 2.60 0.0723 MmugDNA.7760.1.S1_at Transcribed locus, strongly XP_498525.1 PREDICTED: — 2.60 0.0044 hypothetical protein XP_498525 [Homo sapiens] MmuDNA.14575.1.S1_at hypothetical protein FLJ32810 FLJ32810 2.60 0.0347 

The invention claimed is:
 1. A composition consisting of (i) a purified primate taste cell population, wherein the purified taste cells co-express KIT, T1R1 and T1R3 and (ii) a probe that provides for the specific detection of nucleic acids encoding KIT nucleic acid or KIT polypeptides.
 2. The composition containing purified taste cell population of claim 1, wherein the probe comprises at least one nucleic acid which hybridizes to KIT.
 3. The composition containing purified taste cell population of claim 1, wherein the probe comprises at least antibody which specifically binds to KIT polypeptides.
 4. The composition containing purified taste cell population of claim 1, wherein the purified taste cells further express TRPM5.
 5. The composition containing purified taste cell population of claim 1, wherein the purified taste cells are macaque taste cells.
 6. The composition containing purified taste cell population of claim 1, wherein the purified taste cells are human taste cells.
 7. A method of isolating taste cells that express KIT, comprising: (i) contacting an impure population of cells containing taste cells with a probe that specifically detects taste cells which express KIT; (ii) separating the detected KIT-expressing taste cells from the impure cell population and (iii) identifying in the resultant KIT-expressing taste cells those taste cells which further co-express T1R1 and T1R3.
 8. The method of claim 7, wherein the probe comprises at least one nucleic acid which hybridizes to KIT.
 9. The method of claim 7, wherein the probe comprises at least antibody which specifically binds to KIT polypeptides.
 10. The method of claim 7, further comprising separating those KIT expressing cells which are detected to further express T1R1 and T1R3.
 11. The method of claim 7, wherein the KIT-expressing taste cells and/or KIT/T1R1 and/or T1R3 co-expressing cells taste cells are separated by FACS or magnetic bead cell separation.
 12. The method of claim 7, wherein the purified taste cells are macaque taste cells.
 13. The method of claim 7, wherein the purified taste cells are human taste cells. 